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Dedication
Richard H. Morrow (1932–2013)
We dedicate this book to the memory of Dick Morrow who died after a short illness in 
the final stages of editing the book (Figure D.1). Dick Morrow had a profound influence 
on the careers and development of the very many students and colleagues he mentored, 
including my own. It was an enormous privilege to have worked with him in various 
locations over a period in excess of 40 years. We first met in 1970 when he was teaching 
epidemiology at Makerere University in Uganda, and I was a newly arrived lecturer. It 
was my great good fortune to be allocated an office next to Dick at the top of Mulago 
Hill. He guided me through writing my first grant application to the Wellcome Trust, 
for a trial to assess whether BCG vaccination protected against Buruli ulcer and, with 
his ever present optimism, persuaded me to start the study with my own funds, antici-
pating a positive outcome from the Trust! The short time we overlapped in Kampala 
cemented what was to become a lifelong friendship.
We both worked in Uganda on the ambitious cohort study designed to evaluate 
whether prior infection with the Epstein–Barr virus was the trigger for causing the Af-
rican childhood cancer Burkitt’s lymphoma. This study involved many players and was 
executed by the World Health Organization (WHO) International Agency for Research 
on Cancer, but what has been lost in the history of that research is the key role that Dick 
had in the genesis of the study and the enormous intellectual contribution he made to 
its design. However, one of the most endearing features of the man was his indifference 
to personal credit, believing that what was important was that the right things were 
done and what was key were the scientific insights, rather than who had them.
In the 1970s, Dick returned to Ghana to work in the newly formed Health Planning 
Unit, and, in extended visits, I worked with him and Ghanaian colleagues to pursue 
his idea of a new way of measuring the burden of different diseases in Ghana through 
the concept of ‘years of healthy life lost’, a combination measure of years lost due to 
premature mortality and time spent in different states of morbidity, each of which was 
accorded a weight according to severity. We published the method and data for Ghana, 
and Dick’s insights were later taken up by others in developing the Global Burden of 
Disease exercise. The origination of this methodology from Dick has never been prop-
erly acknowledged, but this never really bothered Dick whose pleasure came from see-
ing the idea being taken forward and built upon.
In 1979, Dick became the epidemiologist for the then recently formed Tropical Dis-
ease Research (TDR) Programme at WHO in Geneva, first working under the director-
ship of Ade Lucas and then Tore Godal. Dick’s emphasis of the fundamental importance 
of epidemiology and rigorous design in field research on tropical diseases did much to 
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Figure D.1 Richard H. Morrow (1932–2013).
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DEDICATION vii
lay the foundations of the TDR programme. The joy that Dick always had in helping 
and seeing others develop and succeed suited him ideally for work in a programme in 
which capacity development was a major part. I had the pleasure of accompanying him 
on a large number of field trips, promoting epidemiology and epidemiological meth-
ods in many low- and middle-income countries. In 1987, I was able to work with Dick 
for a year in Geneva with TDR, and it was then we devised the idea of producing a book 
on the aspects of field research methods that are rarely detailed in published papers. 
This was very much a labour of love on both our parts, and we were able to persuade 
numerous colleagues, with a wealth of field research experience, to contribute to the 
venture. The first edition of what came to be known as ‘The toolbox’ was published in 
1990, and we revised it in 1996. Sections of the book have become dated, and, a couple 
of years ago, we decided that a complete revision was required, taking on David Ross as 
a co-editor. We worked on this on a regular basis, again enlisting the help of numerous 
colleagues, during meetings and conference calls, every few weeks, between the three 
of us. We were revising the manuscript right up to the time of Dick’s untimely short 
final illness, and he was able to complete his review and revisions of all of the chapters.
Dick’s passing has left an enormous hole in my life and in that of all those who en-
joyed his friendship and mentorship in a life devoted to improving the health and well-
being of those in the most deprived communities. His legendary rock-like calmness, 
intellectual curiosity, and warm kindness were an inspiration. Appreciation of Dick’s 
many qualities was shared by many friends and colleagues, including contributors to 
The toolbox—his intellect, integrity, sense of humour, creativity, willingness to give oth-
ers credit for what he started, and making himself available and giving of himself to 
his colleagues and students, often to the detriment of his own work. He believed in the 
goodness of mankind, always saw the best in people, never spoke badly of anyone, and 
truly treated all equally, with respect and kindness, whether this was a first-year student 
or the Director General of WHO.
Peter G. Smith
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The organizations that we represent have a long-standing commitment to the develop-
ment of capacity to conduct high-quality field research to evaluate the impact of inter-
ventions against diseases prevalent in low- and middle-income countries (LMICs). The 
idea of producing a book detailing the methods used to conduct intervention trials of 
health interventions in LMICs was conceived in the 1980s when one of us (T. G.) was 
the TDR Director. Since it was first published, the ‘Toolbox’ has been very widely used, 
both by those undertaking intervention trials and epidemiological research in LMICs 
and in teaching courses. Since the 1980s, significant progress has been made in devel-
oping interventions that have reduced the burden of many diseases in impoverished 
communities, and much of this progress has been through the rigorous evaluation of in-
terventions in randomized controlled trials before their adoption into public health use. 
Notable examples have been the evaluation and deployment of insecticide-impregnated 
bed-nets for malaria control and the development, testing, and introduction into public 
health programmes of vaccines against diseases which are major killers of infants and 
children, such as diarrhoeal diseases and respiratory infections.
The standards to which field trials of health interventions have been conducted have 
undoubtedly improved markedly over the last three decades, and dissemination and 
use of the Toolbox has contributed to this. In parallel, over this period, there has been 
a substantial increase in oversight and regulatory requirements related to clinical and 
field trials, and it was timely therefore for the authors of the Toolbox to produce a re-
vised version, taking account not only of these regulatory changes, but also of the revo-
lution in data collecting, processing, and computing methods.
Although the Toolbox is aimed at those conducting health intervention trials in 
LMICs, it is likely to be valuable for anyone undertaking field research or surveys in 
those countries, as many of the issues that arise in trials also arise in other kinds of 
investigation. We are confident that the Toolbox will continue to make an important 
contribution to building up epidemiological capacity in LMICs.
We congratulate the authors on their labours. We believe that this new edition of the 
Toolbox is likely to enhance the quality and quantity of field research that is being con-
ducted on the health conditions afflicting those in LMICs, and this can only speed the 
control of these diseases that cause so much suffering to so much of mankind.
Tore Godal, Director (1986–98) of TDR, the Special Programme for Research and Training in 
Tropical Diseases
John Reeder, Present Director of TDR, the Special Programme for Research and Training in 
Tropical Diseases
Cesar Victora, President of the International Epidemiological Association
Jimmy Whitworth, Head of Department of Population Health, the Wellcome Trust
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Field trials of interventions against disease in LMICs may be complex and expensive 
undertakings, requiring the follow-up of hundreds, or thousands, of individuals for 
long periods. The conduct of such trials requires careful planning, in order to assure 
their timely and successful completion. Over the last several decades, an increasing 
number of large field trials have been conducted successfully in LMICs and have pro-
vided information critical to the assessment of the likely health impact of potential 
interventions. With a few exceptions, descriptions of the detailed procedures and 
methods that were essential for the conduct of successful trials are not published. A 
consequence of this is that those planning field trials have few practical guidelines 
available to them, and investigators have to design a study, often with little access to the 
knowledge and experience that has been accumulated previously. Personal experience 
is a good teacher, but, all too often, investigators have learned by repeating the mistakes 
of previous field researchers, at considerable cost and inconvenience.
Problems arise in the design, conduct, or analysis of many trials that may be unique 
to the particular study, but most potential problems have been faced by many investi-
gators previously, some of whom devised good solutions and some not so good ones. 
Few publications exist which document this wealth of experience, and it is very difficult 
for potential field investigators to learn the practical issues in trial design and conduct.
The intention of this manual is to go some way towards filling this gap in the literature. 
It builds on the first two editions and has been comprehensively revised to take account 
of the evolution of methods that has taken place since the first edition in 1990. It has been 
compiled by contributors with extensive direct experience in the design, conduct, and 
analysis of field trials, and it attempts to document their accumulated experience for the 
guidance of those who might undertake field trials of health interventions in LMICs. It 
can be read in its entirety as an introduction to the field and/or can serve as a reference vol-
ume during each of the different stages of planning, conducting, and analysing a field trial.
The first edition had the title Methods for field trials of interventions against tropical 
diseases: a toolbox. We changed the title for the second edition to Field trials of health 
interventions in developing countries: a toolbox, recognizing that many issues discussed 
in the manual will be relevant to the conduct of field epidemiological studies on dis-
eases that would not necessarily be classed as ‘tropical’. For the third edition, we have 
changed the title again to Field trials of health interventions: a toolbox, as the ‘develop-
ing country’ terminology has been generally replaced by ‘LMICs’, but this would have 
made for a rather tortuous title! The focus of the book nonetheless is on field research 
in LMICs. Though some sections have wider relevance, we have preserved trials in the 
title because they are the main orientation of the book.
For the third edition, we have comprehensively reviewed the content of all the chap-
ters that were included in the second edition. In addition, we have added chapters on 
Preface to the third edition
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PREfACE TO THE THIRD EDITIONx
topics or issues that were incompletely covered previously. Specifically, there are new 
chapters on conducting systematic literature reviews, trial governance, preliminary 
studies and pilot testing, budgeting and accounting, intervention costing and eco-
nomic analysis, and Phase IV studies. Most of the other chapters have been rewritten, 
taking into account the substantial developments in trial methodology that have taken 
place since the second edition was published in 1996.
The Toolbox will always be a work in progress, and our intention is to continue to re-
fine and improve it, as experience is gained with its practical use. We encourage those 
who use the manual to write to the editors if there are aspects of the manual that they 
think are in need of improvement.
Responsibility for producing initial drafts of the different chapters of the manual was 
assigned among the participants listed at the front of the book. The editors reviewed 
each of the contributions, and input was also sought from contributors other than those 
who had drafted the specific chapter. In this way, many different persons contributed to 
each chapter, and it seemed inappropriate therefore to attribute responsibility for any 
one chapter to individuals, as each chapter owes its final form to the collective contri-
butions of those listed.
The text was discussed extensively and edited by the three of us to try to maintain a uni-
form style. The manual was also circulated to other field research scientists for their sug-
gestions for any changes. We gratefully acknowledge valuable contributions from: Salim 
Abdulla, Martin Adjuik, Chris Grundy, Claudia Hanson, Adnan Hyder, Maria Merritt, 
Honorati Masanja, Luke Mullany, Hassan Mshinda, Annabelle South, and Susanne Wedner.
We are also very grateful to those who authored the first and second editions of the 
book, upon whose contributions the third edition is built. These are: Jackie Cattani, John 
Cleland, Nick Day, Joel Gittelsohn, Andy Hall, Birthe Høgh, Betty Kirkwood, Lindlwe 
Makubalo, Tom Marshall, Louis Molineaux, Jorg Pönnighaus, S. Radhakrishna, Ian 
Riley, Bob Snow, Harrison Spencer, Marcel Tanner, Carol Vlassoff, and Fred Wurapa. 
In addition, we are grateful to the following field research scientists who commented 
on chapters in the first two editions: Astier Almedon, Steve Bennett, Boachie Boatin, 
Loretta Brabin, David Brandling-Bennett, Gilbert Burnham, Peter Byass, Andreas de 
Francisco, Tony Degrement, Aime de Muynck, Isabelle de Zoysa, Anne Dick, Nicola 
Dollimore, Herbert Gillies, Brian Greenwood, Hazel Inskip, Japhet Killewo, Sarah 
Macfarlane, Bruce Macleod, Gilly Maude, Daan Mulder, Andrzej Radalowicz, Brian 
Southgate, Malcolm Pike, Roger Webber, Jimmy Whitworth, and Andrew Wilkins.
From the above, it is apparent that the Toolbox benefited from the wisdom of a large 
number of field research scientists. We apologize to those whose suggestions we have 
incorporated, but whose contribution we have inadvertently omitted to acknowledge!
We have been very keen to ensure that the Toolbox is made available as widely as pos-
sible, especially to those in LMICs. We are delighted therefore that, in addition to a paper-
back version, it has been possible to make the book available online and in open access 
through generous financial support from the UNDP/World Bank/WHO Special Pro-
gramme for Research and Training in Tropical Diseases and from the Wellcome Trust.
London and Baltimore P. G. S.
2015 R. H. M.
 D. A. R.
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Chapter 1
Introduction to field trials 
of health interventions
1 Scope of the book 1
2 Outline of contents 2
1 Scope of the book
In this book, we aim to provide a practical and comprehensive guide to the design and 
conduct of field trials of health interventions directed against disease problems in low- 
and middle-income countries (LMICs). Our main emphasis is on randomized con-
trolled trials (RCTs), but many of the issues discussed are of relevance to other kinds 
of field research in LMICs. Published papers reporting the results of intervention trials 
rarely include details of the practical aspects of preparation for a trial and its conduct, 
yet these are crucial to the execution of a successful trial. Those conducting trials for the 
first time often do not have access to references detailing the many practical issues that 
have to be addressed in the organization and conduct of a trial. New investigators gen-
erally have to learn by experience and, as a consequence, often repeat mistakes that oth-
ers have learned not to make. While ‘learning by doing’ can be a valuable educational 
method, it is usually inefficient and wasteful. We have tried to synthesize the experience 
of investigators with substantial experience of conducting field trials in LMICs and de-
scribe procedures and practices found to work well in LMIC settings. Thereby, we hope 
that new investigators will build on and extend the experience of others, rather than 
repeat the same mistakes.
Trials of health interventions involve the implementation of a specific health inter-
vention and comparison of the effects of that intervention with the effects of the cur-
rently available ‘best’ intervention or, if there is none, comparison with what happens 
with no intervention (or with a placebo). In order to avoid bias in the allocation of par-
ticipants to the intervention or comparison group, assignment of individuals or groups 
to a particular intervention should be done by randomization. The ‘trial’ approach is 
in contrast to observational studies such as cross-sectional surveys, cohort studies, and 
case-control studies. But many of the methods and techniques described in this book 
may also be usefully deployed in observational studies.
We use the term ‘field trial’ for trials conducted outside clinical settings, in contrast 
to ‘clinical trial’ that is used for studies carried out in health facilities. Thus, field trials 
generally involve participants who are living at home in their normal environment, 
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2 CHAPTER 1: INTRODUCTION TO fIELD TRIALS Of HEALTH INTERVENTIONS
rather than being ‘captive’ in hospitals or outpatient clinics. Most trials of preventive 
measures, such as immunizations or health education, are ‘field’ trials. Important dif-
ferences in field and clinical trials include inclusion and exclusion criteria that may be 
less stringent in field trials than criteria often imposed in clinical trials, in which it may 
be important to have a clearly defined disease condition for treatment. To the extent 
that there are less stringent inclusion and exclusion criteria, there may be fewer prob-
lems with the external validity of trial conclusions than there often are for clinical trials 
that limit the generalizability of conclusions. Another difference is that randomization 
of intervention by groups (clusters), rather than by individuals, is more often necessary 
or useful in field trials than in clinical trials (see Chapter 4, Section 4).
Clinical trials of drugs and vaccines are commonly carried out in successive phases, 
as described in Chapter 2, Section 3. Phase I trials are early studies conducted in a few 
human volunteers to test the safety of a promising new drug or vaccine. Thereafter, Phase 
II trials are carried out on larger numbers of volunteers, often to gauge immunogenicity 
(of a vaccine) and the effect of different doses or number of doses and to monitor for 
any adverse reactions. When these phases are successfully completed, Phase III trials are 
conducted on much larger numbers of volunteers who are randomized to receive either 
the new product or the comparison product, in order to establish the efficacy of the new 
intervention. The main focus of the book will be large-scale randomized field trials. For 
pharmaceuticals and vaccines, these will usually be Phase III trials, though this designa-
tion by phase does not fit so well with some other important types of interventions such 
as behaviour change interventions or environmental modification.
We do not envisage that many readers will sit down and read the book from begin-
ning to end! We have called it a ‘toolbox’, because we think this reflects how it might 
be used, i.e. to consult different chapters and sections to guide different stages in the 
planning and execution of a trial.
2 Outline of contents
The chapters of this book can be considered in three main groupings. Chapters 2 
through to 13 review issues to consider and steps to be taken before starting a trial. 
Chapters 14 through to 20 detail the tasks to be carried out during the conduct of a 
trial, with a focus on data collection. Chapters 21 and 23 discuss the analysis, interpre-
tation, and reporting of trial results. We have also included a short chapter on Phase 
IV studies (Chapter 22), that are usually conducted after a product has been licensed 
and is in, or is about to go into, public health use. Phase IV studies are usually not ran-
domized designs, because of the ethical issues in withholding a licensed intervention 
from participants, and such studies are not a main focus of this book. However, we 
have included this chapter because many of the design, conduct, and analysis issues 
discussed in other chapters have relevance for Phase IV studies and also because it will 
often be desirable for Phase III trials, which usually measure the efficacy of an interven-
tion delivered in a highly controlled manner, to be followed by Phase IV evaluations in 
‘real-life’ programmes.
Before embarking on a trial, the first steps are to define the goals, objectives, and key 
questions for the study. As background to this, the broad array of potential types of 
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interventions is catalogued in Chapter 2. The importance of critically reviewing essen-
tial background information relevant to a trial, including trials of similar interventions, 
through a systematic review of literature is emphasized in Chapter 3. The heart of the 
book is concerned with the design of the trial, as outlined in Chapter 4, and making it of 
appropriate size (Chapter 5). Many of the design details are guided by ethical concerns 
(Chapter 6), regulatory requirements, and governance issues (Chapter 7). A major 
issue in planning a trial is generating the resources to carry it out, and guidance is given 
in Chapter 8 on the preparation of grant applications for trials to funding agencies.
Field trials are generally based in communities, and their successful conduct is 
highly dependent on investigators engaging appropriately with community members 
at all stages in the planning and execution of a trial (Chapter 9). Before a trial starts, 
the target population has to be defined and registered (Chapter 10), and then the inter-
ventions under test must be allocated to individuals or communities, in an unbiased 
way, by randomization, with the intervention allocations being kept ‘blind’, if possible, 
to investigators and participants. Ways of achieving this are discussed in Chapter 11. 
Evaluation of the impact of an intervention depends upon appropriate definition of the 
outcomes that the intervention is expected to affect. Choice of appropriate outcome 
measures and unambiguous definition of these is considered in Chapter 12.
Undertaking a trial is often a major activity, involving a large trial team for several 
years. It is rarely possible to start a trial immediately the protocol has been written and 
the funding obtained. Almost always, it is necessary to have collected preliminary data 
to facilitate the planning of the trial and to conduct studies to test out the procedures 
that are proposed for use in the trial, and modifying them appropriately if they are not 
found to be fit for purpose. Such preliminary studies and pilot testing of procedures 
are covered in Chapter 13. Information about trial participants is commonly collected 
through the administration of questionnaires. The various forms that these might take 
and different methods of administering them are summarized in Chapter 14.
Most intervention trials involve some element of behaviour change, both on the parts 
of those administering the intervention (for example, workers in the health service) 
and of those taking it up—the trial participants. The extent of behaviour change re-
quired will vary, according to the intervention under test. Evaluating a new vaccine 
which is administered at the same time as routine vaccinations in the childhood im-
munization programme may require relatively little behaviour change, but implement-
ing an intervention to reduce high-risk sexual behaviour to lower the risk of human 
immunodeficiency virus (HIV) infection, or promoting hand-washing to reduce the 
risk of diarrhoeal diseases, will involve substantial behaviour changes. Undertaking 
social and behavioural research to facilitate the design and implementation of inter-
ventions is reviewed in Chapter 15.
Quality control of all aspects of conducting a trial is crucial if the findings from the 
trial are to be used to make important public health decisions about the use, or other-
wise, of an intervention, based on the trial results. These issues are discussed in Chapter 
16, while Chapter 17 specifically focuses on methods and quality control in field labo-
ratories, which are an important component of most trials.
Nothing can be done without financial support for the trial. The essentials for the 
preparation of budgets for grant applications are given in Chapter 8. The efficient 
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planning and management of finances during a trial are also key to success, and a re-
quirement of funding agencies. The necessary budgeting and accounting methods are 
outlined in Chapter 18. Chapter 19 affords an overview of the main methods used to 
assess the costs of health interventions and summarizes the types of economic ana-
lyses that can be conducted to assist decisions concerning resource allocation to health 
interventions.
In all but the smallest trials, substantial amounts of data are collected and have to be 
efficiently processed, both during the conduct of the trial and for the analysis of the re-
sults during, and at the end of, the trial. Methods of data management are summarized in 
Chapter 20, and an outline of methods of statistical analysis of trials is given in Chapter 21. 
In most trials it will be necessary to employ a statistician to oversee the analysis of the data 
from the trial, but the relatively simple methods summarized in this chapter should be suf-
ficient to elucidate the main results from most trials.
Finally, Chapter 23 stresses the importance of communication at all stages of the 
trial, how best to communicate to the many different audiences who should be in-
formed about the trial, and the necessary steps to translate research findings into policy 
and public health action.
We have deliberately not included large numbers of references, as the book is in-
tended to stand largely on its own, without readers needing access to a well-stocked 
library. Referencing has been reserved for where a particular study has been described, 
or as a guide for readers who may require a more detailed explanation of a concept than 
can be included in this text. Whenever possible, we have favoured open access or rela-
tively low-cost resources.
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1 Introduction to types of intervention  
and their development
This book is about the evaluation of the effectiveness of health-related interventions. 
We use the term ‘intervention’ to apply to any activity undertaken with the objective of 
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improving human health by preventing disease, by curing or reducing the severity or 
duration of an existing disease, or by restoring function lost through disease or injury. 
There are a wide variety of new interventions, and new strategies for the use of inter-
ventions, that are being developed against the major diseases common in LMICs. These 
include both public health and clinical care measures, and include drugs for acute and 
chronic conditions, vaccines, vector control, health education, behaviour change strat-
egies, injury prevention, and better health planning and management methods that 
improve a spectrum of health-related activities. Research involving a wide range of 
disciplines is needed to develop, deploy, and assess these interventions, ranging from 
molecular biology and immunology to social sciences, epidemiology, and statistics. 
The focus of this book is on the evaluation of interventions through field trials. Field 
trials are required to assess how interventions, both old and new, may be best applied in 
populations and to determine their impact on improving the health of the population.
In this chapter, the characteristics of different kinds of intervention that may be 
used in disease control programmes are reviewed. How each type of intervention is 
implemented is outlined, and the implications of these implementation strategies for 
the design, conduct, and interpretation of field trials are discussed. The nature of an 
intervention will determine the way in which it can be evaluated in a field trial. Some 
interventions which are applied to individuals can be evaluated through the random 
allocation of individuals to the intervention or the ‘control’ arms. Other interventions 
are applied to groups of individuals, such as households or whole communities, and the 
group should therefore be the unit of randomization.
2 Types of intervention
Interventions can be classified into two broad categories: (1) preventive interventions 
are those that prevent disease from occurring and thus reduce the incidence (new 
cases) of disease, and (2) therapeutic interventions are those that treat, mitigate, or 
postpone the effects of disease, once it is under way, and thus reduce the case fatality 
rate or reduce the disability or morbidity associated with a disease. Some interventions 
may have both effects.
2.1 Preventive interventions
2.1.1 Vaccines
Vaccines are administered to individuals, usually before they have encountered the 
infectious agent against which the vaccine is targeted, in order to protect them when 
they are naturally exposed to the agent. Many are among the most cost-effective inter-
ventions, because, after a single dose or a series of doses of the vaccine, an individual 
may acquire long-term protection against the agent. They work by inducing a variety 
of immune mechanisms, through the humoral and/or cellular immune systems. The 
immunological responses and associated immunological memory induced by vacci-
nation confer protection from later infections, though a booster vaccination may be 
necessary if the interval between the original vaccination and exposure to the agent is 
long. Most vaccines have to be administered before the infectious agent is encountered 
naturally, and thus field trials of such vaccines will involve the enrolment of healthy 
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individuals and often involve infants or very young children—though the vaccine may 
be given at a later age if the age of natural infection is at later ages, for example, for most 
sexually transmitted infections (STIs), or if a new infectious agent, to which no one has 
been previously exposed, enters a community such as a new strain of influenza.
Not all vaccines are targeted at persons without previous exposure to the infectious 
agent. For example, there is substantial research to develop vaccines against parasitic 
diseases. The mode of action of some of these vaccines is to prevent parasitic prolifera-
tion within the host after invasion (and hence curtailment of disease), and some vac-
cines against vector-borne diseases are even targeted to prevent replication of the forms 
of the infection in the vector, so that onward transmission to humans is prevented.
For infectious diseases that affect both high-income countries (HICs) and LMICs, 
the first trials of new vaccines are usually conducted in HICs. This is because currently 
most new vaccines are developed and produced in HICs (though this situation is chang-
ing), and it is generally accepted that at least early clinical studies should be conducted 
in the country of vaccine manufacture. However, the results of trials in HICs may not 
be directly applicable to LMICs for a variety of reasons such as differing prevalences of 
other infections or of nutritional deficiencies, which might interfere with the mode of 
action of the vaccine. Thus, there will often be a need for further trials of the vaccine 
in LMICs, even if efficacy has been established in HICs. In addition, there has been in-
creased focus in recent years on the development of vaccines against infectious agents 
that only, or almost only, occur in LMICs, such as malaria or visceral leishmaniasis, or 
where the overwhelming disease burden is in such countries, such as tuberculosis (TB) 
or HIV infection. For vaccines against these agents, the first major field trials to assess 
efficacy are likely to be conducted in LMICs.
2.1.2 Nutritional interventions
Food and nutrition are major determinants of human health and disease. Particu-
larly in low-income countries and deprived populations in middle-income countries, 
 under-nutrition remains a major cause of disease. Severe malnutrition, such as kwashi-
orkor or marasmus, is life-threatening, but milder forms of malnutrition are major risk 
factors that adversely influence the susceptibility to, and the outcome of, many infec-
tious and other diseases, as well as cognitive development. In addition to calorie and 
protein deficiencies, specific deficiencies in micronutrients, such as iron, folate, zinc, 
iodine, and vitamin A, may be important determinants of severe diseases. Trials to ad-
dress these problems may involve the regular provision of high-protein/calorie diets or 
supplementation to individuals with specific micronutrients, involving repeated visits 
to the same persons over several years, the frequency of administration depending on 
the nature of the supplement(s). Other trials, often with the intervention being applied 
at a community level, may involve food fortification (for example, iron, iodine, vitamin 
D) and experiments to change agricultural practices or eating or food preparation hab-
its to increase the intake of particular micronutrients.
2.1.3 Maternal and neonatal interventions
A mother’s health and well-being during pregnancy and around the time of delivery, in-
cluding access to appropriate care, are critical determinants of maternal mortality and 
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neonatal and child health in the early years of life, and possibly for much longer. Pre-
ventive interventions before or during pregnancy include family planning, treatment 
of infections, such as syphilis and malaria, good nutrition, including micronutrients, 
good antenatal monitoring and care, and access to skilled care at the time of delivery 
and post-partum. Trials of maternal interventions may involve both community-based 
studies, with the early identification of pregnancies and the instigation of preventive 
interventions to avoid pregnancy complications, or may be hospital- or health centre-
based, directed at improving the performance of the health system in caring for women 
during and after pregnancy and at the time of birth.
Interventions directed to the neonate are also important, such as exclusive breast-
feeding and care practices, such as ‘kangaroo mother care’, a method of care of pre-
term infants, involving infants being carried, usually by the mother, with skin-to-skin 
contact.
2.1.4 Education and behaviour change
Some interventions directed at preventing disease are based solely upon changing 
human behaviour (for example, anti-smoking campaigns or campaigns to promote 
breastfeeding). Nearly all health interventions must have an associated educational 
component for their effective deployment, but the extent of educational effort required 
ranges from the provision of simple information (for example, when and where a clinic 
for immunization will be held) to efforts at increasing understanding (for example, of 
the importance of male circumcision for the prevention of HIV) and to attempts to 
change lifestyles (for example, diet or sexual habits). Education to increase knowledge 
and impart new skills may be necessary but is rarely sufficient to induce behaviour 
change. Individuals must also have the capacity, willingness, and motivation to act on 
the knowledge and to use the skills. The design and implementation of an educational 
intervention, and other ‘complex’ interventions (Craig et al., 2008), will usually need 
to be researched through careful investigations in the community, using the kinds of 
methods discussed in Chapters 9 and 15.
Examples of educational components of disease control programmes include:
◆	 educating children or mothers about the causes of the disease, such as diarrhoea, 
and how to prevent it
◆	 promoting adherence to long-term treatment such as for HIV infection or TB
◆	 developing effective participation in programmes that:
●	 need broad coverage to maximize the effects of immunization or drug 
distribution
●	 require people to recognize disease symptoms for early treatment
●	 necessitate active co-operation in home improvements or insecticide 
programmes
●	 involve direct action and responsibility in deploying vector, or intermediate 
host, traps
●	 need community efforts for environmental improvements such as developing 
and maintaining improved water supplies or better disposal methods for faeces.
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Organizing trials of behaviour change interventions are among the most challeng-
ing, and there are few examples illustrating the design of replicable interventions that 
achieve lasting behavioural change in the context of a trial. For example, changing to-
bacco smoking behaviour at a population level required decades of concerted, multi-
faceted campaigns. However, attempts to reduce diarrhoeal diseases and respiratory 
infections through the promotion of hand-washing with soap have produced encour-
aging results.
2.1.5 Environmental alterations
Alterations to the environment directed at reducing the transmission of infections are 
central to the control of many infectious diseases, particularly those that are trans-
mitted through water, such as cholera, or through the faecal–oral route such as many 
gastrointestinal infections. Environmental interventions to reduce human faecal and 
urine contamination include latrine construction, provision of sewage systems, clean 
water supplies, and protected food storage. Other environmental interventions tackle 
indoor or outdoor air pollution or involve the disposal of contaminants such as pesti-
cides or heavy metals. Many of these interventions require substantial educational ef-
forts and lifestyle changes. They are also interventions that typically have to be applied 
to whole communities, rather than to individuals in a community, so that, in trials, the 
unit of randomization is the community or, in some instances, the household.
2.1.6 Vector and intermediate host control
Some major communicable diseases in developing countries depend on vector and 
intermediate hosts for their transmission. For different infections, the vectors include 
mosquitoes, tsetse flies, triatomine bugs, sandflies, ticks, and snails. There are a wide 
variety of control measures to reduce transmission of these infections through attack-
ing the vectors or the reservoirs of infection. Most interventions require a good un-
derstanding of the vector or intermediate host, its life cycle, and the environmental 
conditions that it requires to propagate infections. Control measures may include the 
application of insecticides or larvicides, new or improved selective biological agents 
against disease vectors, engineering techniques for reducing vector habitats, commu-
nity involvement in eliminating vector breeding sites and in deploying traps, housing 
and screening improvement for reducing human–vector contact, and strategies involv-
ing combinations of methods with, for example, the objective of reducing or delaying 
insecticide resistance. For many of these methods, intermediate process indicators, 
such as reduction in vector density, can be used for the assessment of impact, but it 
is often also necessary to determine the impact of the measures on the health status 
of the population. For example, for malaria, many different approaches to vector con-
trol have been used, based upon attacking the mosquito in various stages of its life 
cycle. These include control of breeding sites to reduce vector density by drainage and 
waterway engineering and application of specific larvicides and biological agents; the 
use of mosquito netting, screens, and repellents for personal protection from bites; 
aerosol distribution of insecticides to reduce adult mosquito densities; and different 
approaches to killing adult mosquitoes, through either spraying residual insecticides, 
such as with dichlorodiphenyltrichloroethane (DDT), on the internal walls of houses 
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where mosquitoes rest after a blood meal or through the use of insecticide-treated bed-
nets (ITNs) that kill and/or repel mosquitoes seeking a blood meal. These different 
approaches require quite different study designs. Residual insecticide on the walls of 
houses offers relatively little direct protection to those in the treated household, as the 
mosquitoes take up the insecticide while resting after a blood meal. The protection is 
to those in other households whom these mosquitoes would have bitten for their next 
blood meal. To reduce transmission in high transmission areas, virtually all households 
in the neighbourhood must be sprayed. The higher the intensity of transmission, the 
more difficult it is to achieve sufficient coverage. The use of ITNs, developed as an inter-
vention against malaria over the last two decades, leads to reductions in transmission, 
clinical disease, and overall childhood mortality. Trials of these kinds of intervention 
often involve communities, rather than individuals, as the unit of randomization. These 
trials are especially challenging to design, because some vectors, such as mosquitoes, 
may have a flight range that may lead to the ‘contamination’ of intervention communi-
ties, with vectors coming in from outside of the community.
2.1.7 Drugs for the prevention of disease
Drugs or other interventions may be used for the prevention of infection (prophy-
laxis) or disease consequent on infection. An example of the former would be isoniazid 
prophylaxis to HIV-infected individuals to reduce their risk of TB, and of the latter, the 
treatment of HIV-infected individuals with antiretroviral drugs to slow the progression 
of their disease. Sometimes, the use of drugs for prophylaxis or to reduce disease pro-
gression does not involve individual diagnosis, but community or group diagnosis is 
needed to identify groups that should receive the treatment. For example, mass admin-
istration of anti-helminthic treatment to schoolchildren is sometimes administered in 
this way. Whether requiring specific diagnosis or not, therapeutic or preventive agents 
are usually taken on an individual basis, though sometimes agents can be distributed 
to everyone in a community through the water supply (for example, fluoride against 
dental caries) or in food (for example, historically, diethylcarbamazine for filariasis and 
chloroquine for malaria in medicated salt). Mass treatment of school-age children in 
areas highly endemic for the infection with an anti-schistosomal drug every year or two 
may be sufficient to virtually eliminate serious disease consequences of infection with 
Schistosoma mansoni.
Prophylaxis may be aimed at preventing or limiting infection, particularly in those at 
high risk for a limited period of time (for example, anti-malarials taken by those who 
are temporarily visiting malaria-endemic areas). The value of such an approach is lim-
ited by the duration of action of the agent (which determines the frequency with which 
it must be taken), by adverse reactions, and sometimes by the role of the intervention in 
stimulating the development of drug-resistant organisms. For some purposes, prophy-
laxis may be used by permanent residents of endemic areas (for example, anti-malarials 
in pregnancy).
Drugs also may be used prophylactically for treatment of preclinical infection (for 
example, during the incubation period before the onset of symptoms, as for the gam-
biense type of trypanosomiasis) or for treatment of subclinical infection (for example, 
ivermectin against onchocerciasis, and praziquantel against schistosomiasis).
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Strategies for the use of such interventions include the mass treatment of entire popula-
tions or the targeted treatment of identifiable subgroups (such as school-age children) in 
areas where the infection is highly prevalent. Generally, such treatment is applied for the 
benefit of the individuals treated, but the objective may also be to reduce the transmission 
of the agent in the community more generally. When the prevalence is very high and the 
treatment is cheap, treating all those in a defined population may be more cost-effective 
than screening the whole population and then treating only those found infected.
2.1.8 Injury prevention
Injuries are major causes of death and disability, especially in LMICs. They dispropor-
tionately affect the young and have a large economic impact on society. For children 
and young people, road traffic accidents, drowning, fires, poisoning, interpersonal vio-
lence, and war are leading global causes of serious injuries, but often these are not con-
sidered ‘health problems’ and are not sufficiently integrated into public health thinking. 
Yet there are many potential interventions that might lead to reductions in deaths and 
disabilities from injuries, such as traffic calming or infrastructural changes to separate 
pedestrians from fast-moving vehicles to reduce motor vehicle injuries, and improving 
the security of water sources to reduce drowning accidents; there is great need for more 
trials of interventions directed at reducing injuries.
2.2 Therapeutic interventions
2.2.1 Treatment of infectious diseases
The mechanism of action of a drug used for disease control will influence the design of 
field trials to evaluate its impact. Most drugs employed against infectious disease are 
used to kill or inhibit the replication or spread of the pathogen in the host. Strategies 
for disease control that use such agents may involve case detection (which requires an 
appropriate case definition and a diagnostic method), followed by treatment that is 
designed to reduce morbidity and mortality. Often, the public health success of this ap-
proach depends critically upon case finding, and, for diseases such as TB and leprosy, it 
depends also on case holding, i.e. being able to follow and treat each patient at regular 
intervals over sufficient time to eliminate the agent from the individual. Case finding 
and treatment may also reduce transmission of an agent if cases are the main reservoirs 
of infection, if case detection methods locate a high proportion of prevalent cases, and 
if the treatment is sufficiently effective.
2.2.2 Surgical and radiation treatment
RCTs of surgical and radiation treatments are usually done as clinical trials; field trials 
of these interventions are relatively uncommon. However, procedures, such as cata-
ract extraction or simple inguinal hernia repair, are examples of where field trials have 
been usefully undertaken. In general, the only distinctive feature that may set these 
apart, in terms of study design, from other field trials is the issue of ‘blinding’ (see 
Chapter 11, Section 4). For some forms of surgery, ‘sham’ operations have been used 
in clinical studies and perhaps could be considered in field trials. In general, however, 
randomized trials of these procedures will have to be conducted without blinding.
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2.2.3 Diagnostics to guide therapy
The efficient treatment of most diseases requires first that they be accurately diagnosed. 
Often the diagnosis is made on the basis of clinical symptoms and signs, but the impre-
cision of this method for many conditions is increasingly recognized. There is an urgent 
need for new, or improved, sensitive and specific diagnostic tests for many infectious 
and chronic diseases, that are both simple to use and cheap. For example, intervention 
strategies that depend upon case finding and treatment usually require suitable diag-
nostic tests. Specific studies may be necessary to measure the specificity, sensitivity, 
and predictive values of different diagnostic tests, as these properties will impact on the 
likely effectiveness of a case finding and treatment intervention. For example, the de-
velopment and widespread introduction of rapid diagnostic tests for malaria, to replace 
microscopy or the presumptive treatment of fever, has been an important innovation 
in malaria control and has also focused attention on the need for improved diagnostic 
methods and appropriate treatment of non-malarial fevers.
Field trials to evaluate the performance characteristics of diagnostics are not dis-
cussed specifically in this book, other than in the context that they may be incorporated 
as part of an intervention strategy to improve the control of a specific disease. The 
design of studies to evaluate the properties of diagnostics has been discussed elsewhere 
(Peeling et al., 2010).
2.2.4 Control of chronic diseases
Chronic conditions may have an infectious aetiology (for example, HIV, TB) or may 
have environmental or other causes (for example, cardiovascular diseases and many 
cancers). Many chronic diseases, once diagnosed, may not be curable, but they can be 
controlled by a combination of education/behaviour change interventions, plus regu-
lar, often daily, use of pharmaceuticals. The nature of the clinical care required is often 
more complicated than required for acute conditions, such as diarrhoea and pneumo-
nia, which, once diagnosed, usually require a single course of treatment. Interventions 
for chronic disease often must include screening of communities to identify cases; as-
sessment of each case for the stage of the disease and possible attendant complications 
that are likely to require a variety of laboratory tests; and developing a long-term treat-
ment and assessment plan. The treatment of such conditions often requires long-term 
monitoring, with a dependence on reliable laboratory results and a system to track the 
clinical and laboratory findings within a single individual over time. Trials of such in-
terventions must often be conducted over several years, or even decades, to completely 
assess treatment efficacy.
2.3 Other forms of intervention
2.3.1 Legislation, legal action, taxation, and subsidies
Enforcement of anti-pollution laws, food labelling, and legal restrictions have an im-
portant role to play in public health. Behaviour may be strongly influenced by legal 
restrictions, and increasing prices through taxation have been shown to be effective 
in reducing tobacco and alcohol consumption, for example. However, it is difficult to 
design randomized trials of such interventions, because the interventions usually have 
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to be implemented at the national level, making it very difficult to identify a suitable 
control group.
There has been increasing interest recently in providing various types of subsidies to 
individuals to change their health-related behaviour (often known as conditional cash 
transfers). Examples include incentives for children to remain in school, or to health 
care providers to provide services of at least a certain minimum quality (performance 
incentives). Some of these interventions have been evaluated through RCTs, and there 
is further scope for using such approaches.
2.3.2 Health systems interventions
Increasing recognition of the importance of interventions that operate at health sys-
tems level, such as policy implementation, financing, educational reform, and strength-
ening of leadership, management, and governance, has led to a variety of health sector 
training programmes, organization changes, decentralization and devolution, and 
various incentives and personnel policies. Most of these efforts have been introduced 
on a system-wide basis, with little thought about the value of rigorous assessment. But, 
with adequate planning, rigorous evaluation of these kinds of interventions should be 
possible through randomized trials, especially by making use of the ‘stepped wedge’ ap-
proach of a phased introduction of measures in different communities over a period of 
time (Brown and Lilford, 2006). Many health systems research studies may be consid-
ered as implementation research, and most could be considered as complex interven-
tions, as discussed in Sections 2.3.3 and 2.3.4.
2.3.3 Implementation research
Within the context of field trials, implementation research does not aim to develop 
new interventions but focuses on optimizing the delivery of existing interventions that 
have previously been shown to be efficacious when implemented well. Implementation 
research explores the challenges of how best to implement research findings in the real 
world and how to contextualize interventions for specific settings. Hence, an example 
of an implementation research trial was one where a comparison was made of the costs 
and effectiveness of health workers delivering antiretroviral therapy to patients who 
attend a central clinic or hospital, compared with lay workers delivering the antiretro-
virals to patients in their homes and only referring them to the clinic if they reported 
problems on a screening questionnaire (Jaffar et al., 2009).
A general reference on implementation research is Werner (2004).
2.3.4 Complex interventions
The design of a trial to evaluate the efficacy of a new vaccine or drug is relatively straight-
forward, in the sense that there are many past examples of such evaluations to draw 
upon when planning a new study. However, the evaluation of some interventions, such 
as the deployment of a new procedure in the health service or in public health practice, 
may involve consideration of several interacting components, including, for example, 
educational components and behavioural change. Such interventions pose special prob-
lems for evaluation, and these kinds of intervention have been called ‘complex’. Many 
of the extra problems relate to the difficulty of standardizing the design and delivery 
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of the interventions, their sensitivity to features of the local context, the organizational 
and logistical difficulty of applying experimental methods to service or policy change, 
and the length and complexity of the causal chains linking intervention with outcome.
In 2000, the UK Medical Research Council published a Framework for development 
and evaluation of RCTs for complex interventions to improve health to help research-
ers and research funders to recognize and adopt appropriate methods. These guide-
lines were updated and revised subsequently and can be downloaded from the Internet 
(<http://www.mrc.ac.uk/documents/pdf/complex-interventions-guidance>).
Box 2.1 is reproduced from the guidelines and summarizes the steps in developing 
and evaluating trials involving complex interventions.
Developing, piloting, evaluating, reporting, and implementing a complex inter-
vention can be a lengthy process. All of the stages are important, and too strong a 
focus on the main evaluation, to the neglect of adequate development and piloting 
work, or proper consideration of the practical issues of implementation, will result 
in weaker interventions that are harder to evaluate, less likely to be implemented, 
and less likely to be worth implementing.
Developing an intervention
Questions to ask yourself include: Are you clear about what you are trying to do—
what outcome you are aiming for, and how you will bring about change? Does your 
intervention have a coherent theoretical basis? Have you used this theory systemati-
cally to develop the intervention? Can you describe the intervention fully, so that it 
can be implemented properly for the purposes of your evaluation and replicated by 
others? Does the existing evidence—ideally collated in a systematic review—suggest 
that it is likely to be effective or cost-effective? Can it be implemented in a research 
setting, and is it likely to be widely implementable if the results are favourable?
If you are unclear about the answers to these questions, further development 
work is needed, before you begin your evaluation. If you are evaluating a policy or a 
service change as it is being implemented, rather than carrying out an experimental 
intervention study, you still need to be clear about the rationale for the change and 
the likely size and type of effects, in order to design the evaluation appropriately.
Piloting and feasibility
Questions to ask yourself include: Have you done enough piloting and feasibility 
work to be confident that the intervention can be delivered as intended? Can you 
make safe assumptions about effect sizes and variability, and rates of recruitment 
and retention in the main evaluation study?
Box 2.1 The development–evaluation–implementation 
process
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Evaluating the intervention
Questions to ask yourself include: What design are you going to use, and why? Is an 
experimental design preferable, and, if so, is it feasible? If a conventional parallel 
group RCT is not possible, have you considered alternatives such as cluster rand-
omization or a stepped wedge design? If the effects of the intervention are expected 
to be large or too rapid to be confused with secular trends, and selection biases are 
likely to be weak or absent, then an observational design may be appropriate. Have 
you set up procedures for monitoring the delivery of the intervention and oversee-
ing the conduct of the evaluation?
Including a process evaluation is a good investment to explain discrepancies be-
tween expected and observed outcomes, to understand how the context influences 
outcomes, and to provide insights to aid implementation. Including an economic 
evaluation will likewise make the results of the evaluation much more useful for 
decision makers.
Reporting
Questions to ask yourself include: Have you reported your evaluation appropriately, 
and have you updated your systematic review? It is important to provide a detailed 
account of the intervention, as well as a standard report of the evaluation methods 
and findings, to enable replication studies or wider-scale implementation. The re-
sults should ideally be presented in the context of an updated systematic review of 
similar interventions.
Implementation
Questions to ask yourself include: Are your results accessible to decision makers, and 
have you presented them in a persuasive way? Are your recommendations detailed 
and explicit?
Strategies to encourage implementation of evaluation findings should be based 
on a scientific understanding of the behaviours that need to change, the relevant 
decision-making processes, and the barriers and facilitators of change. If the in-
tervention is translated into routine practice, monitoring should be undertaken to 
detect adverse events or long-term outcomes that could not be observed directly 
in the original evaluation, or to assess whether the effects observed in the study are 
replicated in routine practice.
Reproduced with permission from Medical Research Council, Developing and evaluating com-
plex interventions: new guidance, Copyright © MRC, available from <http://www.mrc.ac.uk/ 
complexinterventionsguidance>. This box is distributed under the terms of the Creative Commons 
Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is available at 
http://creativecommons.org/licenses/by-nc/.
Box 2.1 The development–evaluation–implementation process (continued)
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3 Evolution of new intervention products and sequence 
of study phases
Many intervention products, and especially drugs and vaccines, are likely to originate 
from basic research in laboratories. Such products must go through a long series of 
tests, before they can be considered for use in the kinds of field trials that are the focus 
of this book. Before any human use, a new product will be tested in the laboratory for its 
activity and toxicity in various in vitro and animal test systems. If it successfully passes 
through these stages, studies of safety, toxicity, and activity may be conducted in a small 
number of human volunteers, with careful clinical monitoring. A series of further stud-
ies, each including increasing numbers of subjects, must be carried out before a new 
product can be introduced for widespread use. Trials in humans usually go through a 
series of sequential ‘phases’ of progressively increasing size to establish first the safety 
and mode of action and then, in later phases, the efficacy against the target disease(s) 
and safety in a larger number of subjects.
3.1 Clinical studies: Phases I to IV
Phase I studies are exploratory first-in-human trials and may involve the adminis-
tration of small, then larger, doses of the study product to a small number of healthy 
human subjects (ten to 50) to gather preliminary data on the product’s pharma-
cokinetics (where the product and its metabolites go within the body and in what 
concentrations) and pharmacodynamics (what the drug does in the body). These 
studies can help to establish the dosage and frequency that are safe and necessary 
to have an effect. These trials are designed to make an initial assessment of the 
safety and tolerability of the drug or vaccine in a small number of, usually healthy, 
volunteers.
Phase II trials are conducted for products that have shown no significant safety 
problems in Phase I trials. They involve progressively larger numbers of participants 
(for example, initially tens of subjects, but later studies may involve 100s) and are 
designed to assess how well the intervention works (therapeutic drugs would in-
volve studies in patients, whereas vaccines would be assessed for immunogenicity 
in healthy volunteers), as well as to check for safety in a larger number of healthy 
volunteers (vaccines) or in patients (therapeutic drugs). Phase II trials may also be 
designed to evaluate what doses and the number of doses of the intervention should 
be given, and what the intervals should be between doses. Usually, a product will be 
evaluated in a number of different Phase II trials, evaluating its performance under 
different circumstances, for example, a malaria vaccine might be initially trialled in 
adults but then tested in progressively younger groups until tested in the final target 
population of infants.
Phase III trials aim to provide a definitive assessment of the efficacy of the inter-
vention against the primary outcome(s) of interest. They also provide safety data in a 
larger group of subjects. These trials usually involve large numbers of individuals (e.g. 
1000–3000 or more) and are studies that are conducted to produce the evidence of ef-
ficacy and safety required to submit a product to a licensing authority. For this reason, 
they are sometimes called ‘pivotal’ trials.
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Phase IV studies are conducted after the intervention has been shown to be effica-
cious in Phase III trials and are conducted to assess the safety and effectiveness of an 
intervention when used under routine health service conditions, or close to these con-
ditions (rather than in the special circumstances of a controlled trial). Where they in-
volve a regulated product, such as a drug or vaccine, they are usually post-registration 
or post-licensure studies. Safety issues that are important, but which arise in a relatively 
small proportion of individuals, may only become apparent through Phase IV studies, 
once there is widespread use of an intervention. Phase IV studies sometimes take the 
form of randomized trials where the safety and effectiveness are assessed by compar-
ing the results of administering the product to some individuals or communities, but 
not to others (allocated at random). However, such trials may be difficult to conduct, 
once a product has been licensed by the national regulatory authority, and then non-
randomized assessments must be made, such as through ‘before versus after studies’ 
or case-control investigations. Many trials of strategies of how best to use drugs or 
vaccines can also be considered as Phase IV studies, such as a comparison of intermit-
tent preventive therapy (IPT) using anti-malarial drugs given to all young children, 
compared to teaching their mothers to recognize and treat their children if they have 
possible falciparum malaria.
The main focus of the book will be on large-scale Phase III trials conducted ‘in the 
field’ (i.e. outside clinical facilities), but there is also a specific chapter on Phase IV stud-
ies (see Chapter 22).
Although similar terms are often used for the ‘phase’ of trials conducted to test the ef-
fectiveness or efficacy of interventions that do not use an investigational product, such 
as behaviour change interventions or incentives, these have much less well-defined, or 
universally agreed, phases, and it is not uncommon for the first RCT of such an inter-
vention to be the equivalent of a Phase III trial of a drug or vaccine.
3.2 Registration of new interventions
Legal registration procedures are mandated in most countries before a drug or vaccine 
can be put into general use, and these procedures normally require documentation of 
the safety and efficacy of the intervention, based on RCTs involving many hundreds of 
subjects. Further guidance on the rules and regulations for assessing the safety and ef-
ficacy of products for use in human beings can be found at the website of the US Food 
and Drug Administration (<http://www.fda.gov>).
3.3 ‘Proof of principle’ trials
The purposes of field trials may change as experience with an intervention accumu-
lates. Sometimes, particularly in early trials of a new intervention, the purpose of the 
study is analytic to demonstrate an effect or to establish a principle, with little consid-
eration as to whether the intervention is practicable at the population level for disease 
control. An example might be the use of a malaria vaccine that must be administered 
monthly to be effective. Such studies are sometimes called ‘explanatory’ or ‘proof of 
principle’ trials (Schwartz and Lellouch, 1967). Once an effect against the disease under 
study has been demonstrated, there might then be greater impetus to develop new 
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formulations of the intervention or different schedules that would be more practicable 
for application in a disease control programme. Subsequent, and generally larger, trials 
are conducted, in which the purpose is to establish the benefit of an intervention ap-
plied under the circumstances of general use. These studies are often called ‘pragmatic’ 
trials (Schwartz and Lellouch, 1967).
3.4 Trials of intervention delivery strategies
Although new products developed through basic science research may serve as the 
impetus for field trials, some interventions or intervention strategies are developed 
directly as a result of field studies and experience such as a vaccine strategy for smallpox 
eradication and the use of tsetse fly traps for the control of trypanosomiasis transmis-
sion. Thus, trials may be needed not only of the product itself, but also of the way that 
product is used or delivered. Trials like these would involve intervention ‘packages’ 
which might include, for example, the same drug or vaccine, but provided with differ-
ent educational approaches or delivery methods. Sometimes, an intervention that has 
been shown to be effective must be added into an ongoing disease control programme 
that involves other kinds of interventions. For example, it is expected that, when ef-
fective malaria vaccines become available, they will be added to other malaria control 
methods, based on a combination of vector control, case finding, and treatment strate-
gies. Further studies of how best to integrate these interventions into an overall strategy 
will have to be worked out. In addition, policy and planning decisions about disease 
control will have to be guided by appropriate cost-effectiveness analyses.
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1 Introduction to reviewing the literature
Systematic reviews are increasingly recognized as an essential step in health care re-
search. They are a method designed to produce an objective, unbiased, up-to-date sum-
mary of available evidence. In this chapter, an outline is given of the methods used to 
systematically review the medical literature and to assess the risk of bias in the identi-
fied studies. Results from a systematic review may be summarized as a narrative or a 
summary estimate produced from a quantitative meta-analysis. In either case, system-
atic reviews are usually a necessary step in preparing to conduct intervention trials and 
in setting the results of trials into context.
Before embarking on an intervention trial, it is essential to review what is already 
known about the questions to be addressed in the trial. The most objective way to do 
this is to conduct a systematic review of all similar studies that have been published pre-
viously on the topic. Such a review should enable an assessment to be made of whether 
(1) sufficient evidence for the effect of the intervention already exists, or (2) there is a 
clear scientific rationale for an effect of the intervention, but there is insufficient evi-
dence that the intervention works in practice, or (3) there is an insufficient rationale for 
an intervention effect. If the review of the published evidence supports (1) or (3), then 
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there may be little justification for conducting a (further) trial. Furthermore, funding 
agencies may require a systematic review to provide evidence that a new trial is justi-
fied, and some journals (including, for example,  the Lancet (Clark and Horton, 2010)) 
now require authors to include, in papers reporting the results of a trial, a summary of 
the findings from a recent systematic review, in order to put their trial into context, or 
to report their own up-to-date systematic review. For example, before proposing a trial 
of a new school-based behaviour change intervention to reduce the incidence of HIV 
infection, it would be essential to review the literature on the effectiveness of previous 
school-based interventions, and also to review the literature on the rationale underpin-
ning the mechanism by which such an intervention might be expected to be effective.
A proposed trial is worthwhile if the conclusions from a systematic search of the lit-
erature provide a strong rationale that the proposed intervention will work, but there 
is currently insufficient evidence to know how effective, if at all, it is likely to be in the 
target population for the trial. In addition to wasting time and resources, a trial of an in-
tervention which has already been proven effective may be considered unethical, as par-
ticipants in the control arm would not receive a beneficial intervention, and conducting 
a further trial may delay scale-up of the intervention to those who would benefit from it.
In this chapter, we describe methods for conducting systematic reviews of epidemio-
logical studies (including observational studies as well as intervention trials) to judge 
whether a new intervention trial is justified. We also include sections on assessing the risk 
of bias in studies and on providing a narrative and quantitative summary of the findings.
Systematic reviews are not trivial undertakings, and not all investigators will have the 
time or resources to conduct the kind of review that we outline in this chapter. Ideally, 
other investigators will have conducted a recent review, and it will be possible to utilize 
their findings. For example, an agency such as the World Health Organization (WHO) 
might have commissioned a review in order to assist them in setting priorities for dis-
ease control or to highlight important areas for research. Those planning to conduct a 
trial might not need to conduct their own systematic review but could build on the pre-
vious work. However, even if an investigator is not going to undertake their own review, 
it is important that they understand how such reviews are conducted and indeed can 
assess the quality of published systematic reviews. This chapter should facilitate this.
The insights that a systematic review can give to the reviewers on the effects of an in-
tervention and the quality of previous studies are invaluable. It is highly recommended 
that all those conducting trials participate in at least one systematic review fairly early 
in their careers!
2 Systematic reviews
Reviewing the literature can be a daunting task. The volume of information available 
through published papers, or the Internet, is vast and constantly expanding. Given the 
volume of literature available, an ‘ad hoc’ review of the literature is subject to substantial 
biases if only some studies are included, since the studies that are found this way may 
well not be representative of all the relevant studies. The best way to ensure an objective 
and unbiased review of the literature is to conduct a review that follows strict guidelines 
to minimize bias in selecting and interpreting reported studies.
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The basic steps in a systematic review are shown in Box 3.1.
In this chapter, we provide a brief overview of each of these steps. Further details are 
given in published guidelines, such as the Cochrane handbook for systematic reviews of in-
terventions (Higgins and Green, 2008) and the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines (<http://www.prisma-statement.org>) 
(Liberati et al., 2009), and books on systematic reviews in health research (Egger et al., 
2001, Glasziou, 2001, Khan, 2003).
2.1 Defining the question
The first step in a systematic review is to define the research question. A structured ap-
proach for framing the question is useful—the PICOS approach (Population; Interven-
tions (or Exposure); Comparison; Outcomes; Study design) (Higgins and Green, 2008) 
is used by both Cochrane and PRISMA.
For example, a systematic review summarized the evidence of the effectiveness of be-
havioural interventions to prevent HIV infection among young people in sub-Saharan 
Africa (Napierala Mavedzenge et al., 2011). The review question was structured, using 
the PICOS approach, as follows:
Population: Among young people aged 10–24 years in sub-Saharan Africa . . .
Intervention/exposure/comparison: . . . does exposure to an intervention focusing on 
reducing HIV risk behaviours, relative to no or minimal intervention, . . .
Outcomes: . . . reduce the risk of HIV, STIs, or pregnancy . . .
Study design: . . . when evaluated through experimental or quasi-experimental study 
designs?
A second example, used in this chapter, is a systematic review of the evidence that the 
use of chewing substances (such as smokeless tobacco or betel nuts) is associated with 
cardiovascular disease (CVD) in Asia (Zhang et al., 2010). In this case, the question was 
structured as follows:
Population: Among people in Asian countries . . .
Intervention/exposure/comparison: . . . does exposure to chewing substances, relative 
to not chewing them, . . .
Outcomes: . . . increase the risk of CVD . . .
Study design: . . . when evaluated through observational epidemiological studies?
1 Defining the question.
2 Identifying relevant studies in a predefined, systematic way.
3 Assessing the quality of each relevant study.
4 Summarizing the evidence.
5 Interpreting the findings.
Box 3.1 The five basic steps in a systematic review
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Previous systematic reviews had examined this question in the United States of 
America (USA) and Sweden, but there was no synthesis of the evidence from Asia. 
If strong evidence for an association was found, this could lead to the develop-
ment and evaluation of an intervention directed at reducing betel chewing in these 
populations.
Once the research question is identified, a detailed protocol should be prepared for 
the review. This will include definition of the search strategy and the planned analy-
ses. There are plans to develop an international register of systematic reviews, led by 
the Centre for Reviews and Dissemination (<http://www.york.ac.uk/inst/crd/index.
htm>), which will enable researchers to register their review protocol. This will extend 
the register developed by the Cochrane Collaboration (<http://www.cochrane.org>), 
which was established in 1993 to promote systematic reviews of health care interven-
tions. Researchers undertaking reviews under the Cochrane Collaboration are required 
to register the protocol for their review in advance, and the review is  peer-reviewed 
before publication. However, many systematic reviews are undertaken outside of the 
Collaboration and may not currently be registered.
2.2 Identifying relevant literature
The most time-consuming step of a systematic review is to identify studies which 
address the defined review question. The aim is to have a search strategy which is 
highly sensitive (i.e. there is a very high probability of including relevant studies), 
specific (i.e. there is a high probability of excluding non-relevant studies), and pre-
cise (i.e. the proportion of studies retrieved which are relevant is high) (Jenkins, 
2004).
The first step in defining the search strategy to identify published papers is to set in-
clusion and exclusion criteria, based on the review question (Table 3.1). Ideally, searches 
should include papers published in any language (to be fully inclusive and to avoid pos-
sible publication bias of those with positive findings being more likely than those with 
negative findings to be published in English language journals). RCTs are generally 
regarded as the gold standard for providing evidence of the impact of an intervention, 
and it is essential to review previous RCTs of similar interventions. However, if there 
have been few relevant RCTs, non-randomized trials and observational studies should 
also be reviewed. The initial search may be limited to published papers, but sometimes 
it is important to include the ‘grey’ literature (conference abstracts, technical reports, 
and discussion papers). This is because some completed studies are never published in 
peer-reviewed journals, and studies are often less likely to be published there if they do 
not find an effect of the intervention. Inclusion of unpublished studies may therefore 
reduce bias. However, unpublished studies are difficult to identify and have not under-
gone peer review, so they may be of poorer quality and insufficient information may be 
provided to contribute usefully to a review.
2.2.1 Electronic searching
Three commonly used electronic medical databases are MEDLINE (available freely via 
PubMed at <http://www.ncbi.nlm.nih.gov/PubMed>), Embase (<http://www.embase.
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Table 3.1 Inclusion criteria: example for the systematic review of behavioural 
interventions to prevent HIV infection among young people in sub-Saharan Africa
PICOS component (see text) Inclusion criteria Exclusion criteria
Population Young people aged 10–24 
years. In studies with a wider 
age range, there must be an 
analysis of the impact of the 
intervention in young people 
(10–24 years) or, at least, in 
part of that age range.
In sub-Saharan Africa.
Based in a school, and/or  
health facility, and/or 
geographically defined 
community.
Study population not 
representative of a general 
population of young people 
(for example, young sex 
workers).
fewer than 100 people in the 
study.
Intervention/exposure Behavioural intervention 
focused on one or more of  
the following:
(i)  improving sexual and 
reproductive health skills  
and behaviour
(ii)  reducing the risk of  
sexually transmitted  
diseases (STDs)
(iii)  reducing unintended 
pregnancies
(iv)  increasing utilization 
of health services for 
treatment of STIs and/
or behaviours related to 
more appropriate service 
utilization.
Comparison No or minimal behavioural 
intervention.
No suitable comparison group 
(for example, non-randomized 
study with post-intervention 
data only).
No adjustment for differences 
between groups that might 
bias the findings.
continued
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com>), and CENTRAL (Cochrane Central Register of Controlled Trials, <http://www.
cochrane-handbook.org>). A comprehensive search strategy requires each of these 
databases to be searched (Higgins and Green, 2008). However, these databases have a 
North American/European bias, and, for studies in LMICs, it is worth also searching 
other relevant databases such as LILACS (Latin American Caribbean Health Sciences 
Literature), African Healthline, GlobalHealth, and Popline. In addition, there are many 
subject-specific databases, such as PsychInfo (for psychology and related behavioural and 
social sciences), as well as Internet search engines such as Google Scholar. It may also be 
useful to search conference databases and trial registries to identify additional papers.
Strategies can be used to identify both free-text words in the database and controlled 
terms (called MeSH in MEDLINE, i.e. medical subject headings) that are used as key-
words. Search strategies need to include the key terms in the review question and use 
the Boolean operators (such as ‘AND’, ‘OR’, ‘NOT’) to produce a search that is both 
sensitive and specific to the research question. The search strategy used for the example 
of chewing substances and CVD in Asia is given in Box 3.2.
Table 3.1 (continued) Inclusion criteria: example for the systematic review of behavioural 
interventions to prevent HIV infection among young people in sub-Saharan Africa
PICOS component (see text) Inclusion criteria Exclusion criteria
Outcome At least one of the following 
measured:
   (i)  prevalence or incidence of 
HIV infection
  (ii)  prevalence or incidence of 
another STI
(iii)  prevalence or incidence of 
pregnancy (measured by 
laboratory test or clinically 
observed)
(iv)  reported sexual and 
reproductive health 
behaviour (including 
treatment-seeking 
behaviour).
Measured less than 3 months 
after the intervention starts.
Study design Published in 2005–2008 
(because an earlier systematic 
review had covered the period 
up to the end of 2004).
Randomized and non-
randomized epidemiological 
studies which included a 
contemporaneous comparison 
group or a before–after/
time series analysis in the 
intervention group only.
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Often the reviewers will already know about some key published studies. It is useful 
to check that all of these have been identified by the electronic database search. If not, 
a careful review of the search strategy may establish the reason for this, and the search 
can be amended accordingly.
2.2.2 Reviewing abstracts
The search strategy commonly identifies several thousands of potentially relevant pa-
pers. The next step is for two reviewers to independently read through the abstract of 
each paper and define it as being potentially relevant or not. At this stage, it is recom-
mended to err on the side of caution, i.e. include as ‘potentially relevant’ if the relevance 
is unclear from the abstract. The two reviewers should then compare their results and 
We searched PubMed (up to July 2010), using the terms: (‘cardiovascular diseases’ 
[MeSH] OR (‘cardiovascular’ [All Fields] AND ‘diseases’ [All Fields]) OR ‘cardiovas-
cular diseases’ [All Fields] OR ‘cerebrovascular disorders’ [MeSH] OR (‘cerebrovas-
cular’ [All Fields] AND ‘disorders’ [All Fields]) OR ‘cerebrovascular disorders' [All 
Fields] OR ‘stroke’ [MeSH] OR ‘stroke’ [All Fields] OR 'mortality' OR death*) AND 
(‘betel quid’ OR ‘betel-quid’ OR ‘betel nut’ OR ‘betel nuts’ OR ‘areca nut’ OR ‘areca 
nuts’ OR ‘paan’ OR ‘pan’ OR 'snuff ' OR 'snus' OR ‘gul’ OR ‘gutka’ OR ‘khaini’ OR 
‘loose leaf ’ OR ‘maras’ OR ‘mawa’ OR ‘mishri’ OR ‘naswar’ OR ‘Areca catechu’ OR 
‘tooth powder’ OR ‘shammah’ OR ‘tobacco chewing gum’ OR ‘zarda’ OR ‘tobacco, 
smokeless’ [MeSH] OR ‘smokeless tobacco’ OR ‘chewing tobacco’ OR ‘non-smoking 
tobacco’) AND (‘cohort studies’ [MeSH] OR ‘cross-sectional studies’ [MeSH] OR 
‘case control studies’ [MeSH] OR (‘cohort’ [TI] AND stud* [TI]) OR (case* [TI] 
AND control* [TI]) OR 'prospective' OR 'retrospective' OR ' cross-sectional' OR 
‘cross sectional’), which yielded 1006 potentially relevant references. We adapted 
the searching strategy for a second search in ISI Web of Science (updated 19 July 
2010) and found another 739 references. We identified all observational studies, 
including cohorts, case-control studies, and cross-sectional studies, provided that 
they explored the association between ever using chewing substances and the oc-
currence (incidence or mortality) of CVD and reported the strength of the asso-
ciations with a quantitative risk estimate. There was no limitation on the language, 
study year, or publication status.
Text extract reproduced from Zhang, L. N. et al., Chewing substances with or without tobacco and 
risk of cardiovascular disease in Asia: a meta-analysis, Journal of Zhejiang University Science B, 
Volume 11, Issue 9, pp.681–9, Copyright © Zhejiang University and Springer-Verlag Berlin Heidel-
berg 2010. This box is not covered by the Creative Commons licence terms of this publication. For 
permission to reuse please contact the rights holder.
Box 3.2 Example of a search strategy for evidence  
of an association between chewing substances and 
CVD, ischaemic heart disease, or cerebrovascular 
disease in Asia
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reconcile any differences by discussion, further reference to the abstracts, or a third 
reviewer independently reading the abstract.
2.2.3 Reviewing full articles
Full copies of all papers, the abstracts of which were considered to be potentially rel-
evant, should be obtained (electronically, from libraries, or by emailing the author). 
They should be reviewed by the two reviewers who independently assess whether or 
not each paper meets each of the inclusion/exclusion criteria. Discrepancies should be 
resolved as for the abstracts.
2.2.4 Hand searching
The next step in the search strategy is usually to review the reference lists of all the eli-
gible studies identified from the electronic database search, to identify any studies that 
were missed by that search but have been referenced in the eligible papers.
Previous review papers should also be read to check that no known papers have 
been omitted. Finally, it is legitimate, though sometimes time-consuming, to include 
unpublished studies which can be identified through colleagues or contact with the in-
vestigators of unpublished studies, for example, identified through Internet searches or 
trial registers. It is also important to identify ongoing studies, where possible, as these 
may be included in updates of the review.
2.2.5 Flow chart of search strategy
The template for a flow chart summarizing the search results is given in Figure 3.1. In 
the example of behavioural interventions among young people in sub-Saharan Africa, 
a total of 1173 papers were identified from the electronic databases, of which 137 were 
deemed potentially relevant after review of their titles and abstracts, and full-text arti-
cles were obtained. After excluding those not meeting the inclusion criteria, the final 
review included 40 papers, representing 23 studies (as sometimes the results of one 
study were reported in more than one paper) (Napierala Mavedzenge et al., 2011). For 
the example of chewing substances and CVD in Asia, 1756 publications were identified 
from electronic databases, of which only six were eligible for inclusion in the analysis 
of CVD (Zhang et al., 2010).
2.3 Descriptive synthesis of studies
When the eligible papers have been identified, a data extraction form should be com-
pleted for each study, which contains fields enabling a detailed description of the study 
design and of the results. For example, descriptive elements would include the PICOS 
components, as discussed in Section 2.1. The results should focus on the pre-specified 
outcomes in the review protocol and would include outcome measures, definition 
of exposures/interventions, measures of effect, and 95% confidence intervals (CIs). 
The form should be pilot-tested on a few sample papers and revised, as appropriate. 
Two reviewers then read each paper in detail independently, summarize the paper 
on to the data extraction form, and appraise the risk of biases. A common shortcut, 
which is permissible, is that one reviewer completes the data extraction form and the 
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other then checks and edits it, with the final version based on a discussion of any 
discrepancies.
The next step is to begin to summarize the evidence from the eligible studies as a 
whole. All reviews should include a descriptive table of the included studies, which 
summarize the study population, intervention, comparison, outcome, and study de-
sign. One of the 23 studies that were identified in the review of behavioural interven-
tions among young people is summarized in Table 3.2.
In the table that summarizes the results of each study, all the primary and second-
ary outcome measures should be included. For a binary outcome, this would include 
the proportion with the outcome among the exposed and unexposed groups, the ap-
propriate measure of effect (e.g. risk ratio (RR), rate ratio (RR), or odds ratio (OR)), 
and 95% CI. For continuous outcomes, the mean, standard deviation in the exposed 
and unexposed, plus the effect measure (e.g. standardized mean difference) should 
be given.
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Figure 3.1 flow diagram of study selection process.
from Moher et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA 
statement, PLoS Medicine, Volume 6, Issue 7, e1000097, Copyright © Moher et al. 2009. This  
figure is reproduced from an open-access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited.
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Table 3.2 Description of one of the studies included in the systematic review of youth interventions against HIV infection in sub-Saharan Africa
Study, location, 
and programme
Type of intervention and setting Target population, primary objectives, 
comparison, and study outcomes
Intervention description Study design
United Republic  
of Tanzania, 
MEMA kwa  
Vijana
Schools:
Teacher-led.
Curriculum-based sexual and 
reproductive health education.
Health facility:
Interventions to facilitate youth 
friendliness of service providers,  
linked to interventions in the 
community and in other sectors 
(schools), to promote acceptance  
and utilization
Target population:
Persons aged 12–19 years in rural areas.
Primary objectives:
Delayed sexual initiation, increased condom use, 
decreased number of sexual partners, and  
increased use of health services, especially  
for sexual and reproductive health services.
Comparison arm:
Current (very limited) sexual and reproductive 
health education in schools, and no additional 
interventions within health facilities or in the  
wider community.
Study outcomes:
Primary: HIV incidence; HSV2 prevalence.
Secondary: pregnancy (by test and self-reported); 
prevalence of other STIs (by test and self-reported); 
knowledge and attitudes related to sexual and 
reproductive health issues; self-reported sexual 
risk behaviours, including sexual debut during trial 
follow-up, use of condoms, number of sexual  
partners, use of health services if reported a  
potential STI.
In-school teacher-led and  
peer-assisted programme.
Covered refusal, self-efficacy, 
self-esteem, STI/HIV, sexuality, 
contraception, social values, 
respect, gender.
Used drama, stories, and 
games.
Also included interventions 
to make government health 
services more youth-friendly, 
youth condom promotion 
and distribution, and limited 
community-wide  
interventions.
Ten to 15 lessons per year  
over 3 years.
Cluster 
randomized trial.
Ten intervention 
clusters, ten 
control clusters.
Adapted with permission from Journal of Adolescent Health, Volume 49, Issue 6, Napierala Mavedzenge et al., HIV prevention in young people in sub-Saharan Africa: a system-
atic review, pp. 568–86, Copyright © 2011 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved. <http://www.sciencedirect.com/science/
journal/1054139X>. This table is not covered by the Creative Commons licence terms of this publication. for permission to reuse please contact the rights holder.
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2.4 Assessing risk of bias in the studies
Once the description of each study is completed, an evaluation should be con-
ducted of the extent of potential bias and error that may have arisen, either from 
the design or the analysis of each of the original studies. The main aim of this is to 
guide interpretation of the findings of the review. In some cases, it may be decided 
to exclude a study which is flawed to the extent that the results are considered likely 
not to be valid. Alternatively, a sensitivity analysis might be conducted to evaluate 
how the summary results differ if results from more flawed studies are included or 
excluded.
There are several methods for assessing the risk of bias, including checklists or ‘qual-
ity score’ scales. The recommendation of the Cochrane Collaboration and the PRISMA 
guidelines is to use a ‘domain-based evaluation’, in which critical assessments are made 
for domains such as blinding of participants and generation of the random sequence 
(for randomized studies) (Higgins and Green, 2008). For observational studies, there 
are additional possible sources of bias. For example, in case-control studies, check 
should be made on the external validity of case selection, the choice of control group, 
and adjustment for confounding factors.
Table 3.3 summarizes some of the sources of potential bias in RCTs and observa-
tional studies.
The assessment of potential biases should be tailored to the research question. For 
each review, there should be consideration of whether one potential bias is more im-
portant to the interpretation of findings than others. For example, if an outcome is 
Table 3.3 Methods for assessing risk of bias in RCTs and observational studies
Source of bias Definition Assessment for RCTs Assessment for 
observational 
studies
Selection bias Systematic differences 
between the comparison 
groups
Generation of  
random allocation
Allocation  
concealment
Selection of exposed/
unexposed
Selection of cases/
controls
Performance bias Systematic differences in 
the care provided (apart 
from intervention)
Blinding of participant 
and provider
Misclassification of 
exposure
Systematic differences 
in those exposed and 
unexposed
Misclassification of 
exposure
Attrition bias Systematic differences 
between the comparison 
groups in withdrawals 
from the study
Intention-to-treat 
analysis
Outcome data not 
available for all 
participants
Differing follow-up 
rates between 
exposed and 
unexposed (or 
participation rates in 
cases and controls)
Detection bias Systematic difference  
in outcome assessment
Blinding of those evaluating outcome
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measured objectively (for example, mortality), then blinding of those evaluating the 
outcome is not going to be very important. In contrast, if loss to follow-up is high and 
associated with the outcome, then this could cause substantial bias.
A table summarizing the risk of bias in each study should be completed indepen-
dently by two reviewers, and any differences reconciled by discussion or reference to a 
third reviewer. Summarizing the results can be done in different ways—some authors 
rank the studies in order of quality; others divide them into those with low, medium, 
or high risk of bias. These decisions should be taken independently of the results of 
the studies, if possible, before examining the results, and the reviewers need to decide 
which studies (if any) will be taken forward to a quantitative meta-analysis of findings.
2.5 Quantitative synthesis of results
2.5.1 Forest plots
Following the descriptive analysis and assessment of risk of bias, it may or may not be 
appropriate to conduct a formal meta-analysis that quantifies the overall effect of the 
intervention. If, for example, the study populations, interventions, and reported out-
comes differed substantially, the authors may decide to focus on describing the studies, 
their results, applicability, and limitations in a narrative review, rather than produce a 
quantitative summary. This was the case for the systematic review of interventions in 
young people in sub-Saharan Africa (Napierala Mavedzenge et al., 2011).
In other cases, it might be useful to summarize the data quantitatively. A first step for 
this is to produce a graph, called a forest plot, which displays the measure of effect (e.g. 
OR) for each study, together with a horizontal line denoting the CI. Before constructing 
such a graph, it is important to consider whether the results from the different studies 
are indeed measuring the same effect and are comparable to each other. For example, 
a smoking cessation intervention may have a different effect in pregnant women than 
among teenage girls. In such cases, it would be beneficial to present results stratified by 
subgroups, in whom effects might be expected to differ. As with all analyses, these sub-
groups should be defined in advance and included in the review protocol. For example, 
in the review of chewing substances in Asia, it was decided a priori to stratify by geo-
graphical region, to minimize confounding due to the presence or absence of tobacco 
in chewing substances, as this was thought to differ between regions.
In this example, the six eligible studies included five cohort studies and one case-
control study. The forest plot is shown in Figure 3.2. The solid vertical line indicates a 
relative risk (RR) of one, representing no association between the exposure and out-
come. In this example, all six studies had a RR greater than one, indicating an increased 
risk of CVD among individuals who used chewing substances, and the 95% CI did not 
include one for four of these studies, indicating strong evidence of an association. The 
forest plot also includes an overall (summary) estimate of the RR. This is a weighted 
average of the effects from each of the studies.
There are two main methods of obtaining the summary measure of an intervention 
effect. In a ‘fixed-effects’ model, it is assumed that the true effect of exposure (or the 
intervention) is the same in each study, any variation between studies being solely 
due to chance. In contrast, a ‘random-effects’ model may be used, in which the true 
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effect of exposure for the individual studies are assumed to inherently vary (e.g. due 
to differences in the populations or residual confounding factors). In a random-ef-
fects model, the weights allow for this between-study variation, as well as the random 
variation.
In Figure 3.2, a random-effects model was used, and the weights for each study 
are given on the right-hand side of the forest plot. The overall (summary) estimate is 
RR = 1.26, with a 95% CI of 1.12–1.40. Note that this summary estimate is more pre-
cise (i.e. has a narrower CI) than any one of the individual studies. By undertaking a 
systematic review and meta-analysis, the reviewers can now report that there is strong 
evidence that, in these populations, exposure to chewing substances was associated 
with an increased risk of CVD of around 26%, compared with non-users.
2.5.2 Examining heterogeneity
The effect sizes of individual studies will inevitably be different from each other, but it 
is important to assess whether this difference is likely to be due to random variation 
(i.e. the true underlying effect will be the same) or to real differences in underlying ef-
fect sizes in the individual studies. It is therefore essential to examine the consistency 
of the effects and to quantify the heterogeneity (or difference) in effect sizes between 
studies. Several measures are available for this, one of which is the I2 statistic (Higgins 
et al., 2003). This statistic is the percentage of total variation across studies that is due 
to heterogeneity, rather than chance. A value of I2 of 0% indicates no observed hetero-
geneity, and larger values indicate increasing heterogeneity. The principal advantage 
of the I2 statistic is that it does not depend on the number of studies included in the 
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Figure 3.2 forest plot for the association of exposure to chewing substances and risk of 
CVD in Asia.
Reproduced from Zhang, L. N. et al., Chewing substances with or without tobacco and risk of car-
diovascular disease in Asia: a meta-analysis, Journal of Zhejiang University Science B, Volume 11, 
Issue 9, pp. 681–9, Copyright © Zhejiang University and Springer-Verlag Berlin Heidelberg 2010, 
with permission from Springer and Springer Science and Business Media. This image is not covered 
by the Creative Commons licence terms of this publication. for permission to reuse please contact 
the rights holder.
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meta-analysis and so can be used even for meta-analyses containing relatively few 
studies, which typically have low power to detect heterogeneity using other measures.
In our example, the value of I2 is 35.9%, with a p-value of 0.17, indicating little 
evidence of heterogeneity. The reviewers were therefore justified in presenting the 
summary estimate. If, in contrast, the I2 statistic suggests evidence of heterogeneity, 
for example if I2 was 70%, further exploration of the causes of heterogeneity would 
be needed, for example by undertaking (pre-specified) subgroup analyses. If there 
was no longer evidence of heterogeneity within subgroups, this would indicate that 
the stratifying characteristics were an important source of heterogeneity, and re-
sults should be presented within subgroups, rather than overall.
3 Software available for systematic reviews  
and meta-analyses
Systematic reviews involve managing large quantities of information. There are vari-
ous software packages available which can be used to prepare systematic reviews. 
For example, the Cochrane Collaboration produces a freely available program called 
RevMan which is a Windows-based software package designed to enter reviews in 
the Cochrane format. This includes an analysis module (MetaView) for quantitative 
summaries.
Results of searches from electronic databases can also be automatically down-
loaded into a reference manager software package, such as EndNote, and, from 
there, exported into database packages, such as Excel, for review and assessment 
of abstracts. Standard statistical packages, such as Stata, include modules for 
meta-analyses.
4 Reporting findings from systematic reviews
There are several guidelines for reporting results of a systematic review. The most re-
cent are the PRISMA guidelines (<http://www.prisma-statement.org>) which are given 
in Table 3.4 (Moher et al., 2009). These include a full description of the rationale for the 
review, the research question, methods used, and analyses. Reviewers will then need to 
summarize their main findings, including the strengths and limitations of the review, 
the strength of the evidence for each main outcome, and the relevance to different 
population groups.
Finally, the results of the systematic review need to be assessed for their implica-
tions for policy and future research. One system to assist with interpreting results of 
systematic reviews is the GRADE system (Grading of Recommendations Assessment, 
Development, and Evaluation) (Guyatt et al., 2008). This gives guidelines as to whether 
results from a systematic review provide ‘strong’ or ‘weak’ evidence. This includes not 
only results of a systematic review, but also an evaluation of the balance between de-
sirable and undesirable effects, and whether the intervention represents a wise use of 
resources.
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Table 3.4 PRISMA guidelines for systematic reviews and meta-analyses
Section/topic # Checklist item Reported on page #
TITLE
Title 1 Identify the report as a systematic 
review, meta-analysis, or both
ABSTRACT
Structured summary 2 Provide a structured summary, 
including, as applicable:  
background; objectives; data  
sources; study eligibility criteria, 
participants, and interventions;  
study appraisal and synthesis  
methods; results; limitations; 
conclusions and implications  
of key findings; systematic review 
registration number
INTRODUCTION
Rationale 3 Describe the rationale for the  
review in the context of what is  
already known
Objectives 4 Provide an explicit statement of 
questions being addressed with 
reference to participants,  
interventions, comparisons, outcomes, 
and study design (PICOS)
METHODS
Protocol and 
registration
5 Indicate if a review protocol exists, 
if and where it can be accessed 
(for example, Web address), and, 
if available, provide registration 
information, including registration 
number
Eligibility criteria 6 Specify study characteristics (for 
example, PICOS, length of  
follow-up) and report characteristics 
(for example, years considered, 
language, publication status)  
used as criteria for eligibility, giving 
rationale
Information sources 7 Describe all information sources  
(for example, databases with  
dates of coverage, contact with  
study authors to identify additional  
studies) in the search and date last 
searched
continued
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
34 CHAPTER 3: REVIEWING THE LITERATURE
Section/topic # Checklist item Reported on page #
Search 8 Present full electronic search  
strategy for at least one database, 
including any limits used, such  
that it could be repeated
Study selection 9 State the process for selecting  
studies (i.e. screening, eligibility, 
included in systematic review, 
and, if applicable, included in the 
meta-analysis)
Data collection  
process
10 Describe method of data extraction 
from reports (for example, piloted 
forms, independently, in duplicate) 
and any processes for obtaining and 
confirming data from investigators
Data items 11 List and define all variables for  
which data were sought (for example, 
PICOS, funding sources) and any 
assumptions and simplifications  
made
Risk of bias in  
individual studies
12 Describe methods used for assessing 
risk of bias of individual studies 
(including specification of whether  
this was done at the study or  
outcome level) and how this 
information is to be used in any  
data synthesis
Summary measures 13 State the principal summary  
measures (for example, risk ratio, 
difference in means)
Synthesis of results 14 Describe the methods of handling 
data and combining results of studies, 
if done, including measures of 
consistency (for example, I2) for each 
meta-analysis
Risk of bias across 
studies
15 Specify any assessment of risk of 
bias that may affect the cumulative 
evidence (for example, publication  
bias, selective reporting within  
studies)
Additional analyses 16 Describe methods of additional 
analyses (for example, sensitivity or 
subgroup analyses, meta-regression), 
if done, indicating which were 
pre-specified
Table 3.4 (continued) PRISMA guidelines for systematic reviews and meta-analyses
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Section/topic # Checklist item Reported on page #
RESULTS
Study selection 17 Give numbers of studies screened, 
assessed for eligibility, and included  
in the review, with reasons for  
exclusions at each stage, ideally  
with a flow diagram
Study characteristics 18 for each study, present characteristics 
for which data were extracted (for 
example, study size, PICOS, follow-up 
period), and provide the citations
Risk of bias within 
studies
19 Present data on risk of bias of each  
study and, if available, any outcome l 
evel assessment (see item 12)
Results of individual 
studies
20 for all outcomes considered  
(benefits or harms), present, for  
each study: (a) simple summary data  
for each intervention group,  
(b) effect estimates and confidence 
intervals, ideally with a forest plot
Synthesis of results 21 Present results of each meta-analysis 
done, including confidence  
intervals and measures of  
consistency
Risk of bias across 
studies
22 Present results of any assessment  
of risk of bias across studies  
(see item 15)
Additional analysis 23 Give results of additional analyses, 
if done (for example, sensitivity or 
subgroup analyses, meta-regression) 
(see item 16)
DISCUSSION
Summary of evidence 24 Summarize the main findings,  
including the strength of evidence  
for each main outcome; consider their 
relevance to key groups (for example, 
health care providers, users, and  
policy makers)
Limitations 25 Discuss limitations at study and 
outcome level (for example, risk of 
bias) and at review level (for example, 
incomplete retrieval of identified 
research, reporting bias)
Table 3.4 (continued) PRISMA guidelines for systematic reviews and meta-analyses
continued
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1 Introduction to trial design
Trials should be designed to produce unambiguous estimates of the effects of inter-
ventions, which are precise enough for public health planning. A common goal of all 
intervention studies, including trials, is to evaluate the effect of a specific intervention 
(or a specific package of interventions) applied in a specific manner to a well-defined 
population. In the trial design, the major issues will be: (1) the nature of the interven-
tion, the strategy for its implementation, and the natural size of the unit at which the 
intervention is applied (for example, individual, household, school, village, district); 
(2) the likely effects, including possible adverse effects, and how they should be meas-
ured; and (3) the comparisons that need to be made with other interventions.
In most LMICs, disease control is the responsibility of the Ministry of Health (MOH). 
Therefore, wherever possible, the Ministry should be involved in the planning and moni-
toring of trials, and the results must be made available in such a way that they are of direct 
relevance to national disease control activities (see Chapter 23). As the Ministry is often 
the implementing agency for interventions in public health programmes, it is generally 
desirable that independent investigators actually conduct the trials of interventions.
This chapter gives an overview of the main factors to consider in the development 
and implementation of health intervention trials in LMICs.
1.1 Planning a trial
The trial planning process is a major exercise which starts, and which should be largely 
completed, before any field activities have taken place, other than initial feasibility stud-
ies and small-scale pilot investigations (see Chapter 13). The planning process should 
encompass all aspects of the trial, from formulation of detailed objectives, based on the 
initial idea, through preparation for all field activities, collection of data, and analysis 
of results, to their publication, dissemination, and potential use in disease control. The 
plan should also try to anticipate the form of any studies that will follow, depending on 
the possible different outcomes of the trial.
Detailed planning is necessary for several purposes. First, information on the trial will 
be required by local and national administrations for them to review as part of the trial 
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approval process. A similar description will be required by any agency that is going to 
review the proposal for funding. The detail required in such grant applications varies 
greatly from agency to agency. Some require a comprehensive document with full details 
of all trial procedures, while others put quite a small upper limit on the size of any applica-
tion they are prepared to review. It is usually more time-consuming to prepare the former 
kind of application, but the latter kind may present a more formidable challenge, because, 
in relatively few words, the investigators have to present convincing evidence that they 
have considered and worked out all issues that would have been included in the longer 
type of application. Advice on the preparation of grant applications is given in Chapter 8.
A second reason for detailed planning at the start of an investigation is that pos-
sible problems must be anticipated in advance and solutions thought through, in order 
to reduce the likelihood of the trial falling behind schedule or having to be radically 
changed or abandoned, due to problems that could have been foreseen and avoided. 
Commonly, funding agencies require a section on potential risks to the trial, in which 
the investigators are asked to specify what could go wrong and the consequences this 
would have for the trial. It is rare to be able to predict all potential problems, but the 
more that have been considered in advance, the smaller the chance of catastrophe.
Realistic estimates must be made of the resources needed (for example, for transport, 
staff salaries, allowances, items of equipment) and the likely trial duration, including 
the time to analyse and report the trial, in order to be able to calculate the required 
budget for the trial. Underestimating the support needed may jeopardize some of 
the objectives, which may have to be revised or abandoned in the middle of the trial, 
whereas overestimating the cost may prejudice the funding agency against agreeing 
to support the trial. It is tempting to underestimate costs in the hope of increasing the 
chance of funding, but this may be self-defeating and, in any case, will often be picked 
up by the experienced investigators asked to review the trial proposal by the funding 
agency. The time it will take to conduct and analyse a trial is also often underestimated, 
particularly for trials where implementation of the intervention, or package of inter-
ventions, is not directly under the control of the evaluators but depends instead on the 
MOH or other partners. Advice on the preparation of budgets is given in Chapter 18.
In the present chapter, the steps to be included in the trial plan are discussed in the 
approximate order that they would arise, from the formulation of objectives through 
to the eventual publication, dissemination, and use of the findings. In the remaining 
chapters, specific issues relevant to the planning process are reviewed in greater detail, 
and cross-references are given in this chapter, where appropriate.
1.2 Ethical considerations in designing a trial
Ethical considerations impinge on many aspects of the design and conduct of trials 
and are discussed fully in Chapter 6. Briefly, any research investigation that involves 
human subjects should be submitted for ethics committee review. Intervention trials 
in some communities in LMICs may pose specific ethical dilemmas. The dogma that 
an investigator ‘should treat everyone in the trial as though they were a member of his 
or her own family’ is both difficult to apply and often inappropriate in situations of 
extreme poverty, in which some trials in LMICs will take place. Related issues concern 
the responsibility that an investigator has to those who live in the same community as 
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the trial subjects but who, for whatever reason, are not included in the trial, and what 
happens regarding the public health use of an intervention after a trial has shown an 
intervention to be efficacious. Very commonly, an investigator must walk a tightrope, 
balancing his or her responsibilities to the individuals in the trial with those related to 
the potential of the interventions being evaluated to improve public health. The MOH 
knows these problems well, as they are implicit in any allocation of the health budget 
between the various potential preventive and curative services, but, commonly, the of-
ficials allocating the routine health budget are several steps removed from the individu-
als and communities that their decisions will affect. The field trial researcher usually 
has to face these issues directly. There are no simple solutions to these problems. It is 
important that each research study is subject to strict ethical review, with due attention 
to the specific conditions in and under which it will be conducted.
1.3 Trial governance
Since the first edition of this book was published, there has been a much greater em-
phasis on trial governance and quality control (QC) in trials. There are now extensive 
international guidelines on the governance of clinical trials, in which the roles of bod-
ies, such as the trial ‘sponsor’, the principal investigator (PI), the trial Steering Com-
mittee, and the Data and Safety Monitoring Committee (DSMC), are discussed and 
defined. These aspects are considered in more detail in Chapter 7.
2 Definition of trial objectives
Once an idea for a trial has been formulated, it will be necessary to detail the specific 
objectives of the trial. To do this, the researcher will need to find out what has already 
been done regarding the evaluation of the intervention or interventions of a similar 
kind. This may involve meeting or corresponding with those undertaking similar stud-
ies, and it will almost invariably involve conducting a systematic literature review to 
find out what has been published that is relevant (see Chapter 3).
With this background information, the objectives of the trial can be formulated. 
These should include the overall aim or purpose of the trial, such as ‘to evaluate the 
efficacy of a specific microbicide gel for the prevention of HIV infection in women’ or 
‘to measure the impact of a breastfeeding promotion strategy on the incidence of diar-
rhoeal diseases in infants’. The specific objectives give more detailed statements of the 
particular questions that the trial is designed to answer, or the hypotheses that it will 
test. Finally, a list of subsidiary objectives may be given which relate to issues which are 
not central to the overall objectives but about which information will also be gathered 
while the trial is in progress.
2.1 The idea for a trial
One of the most creative phases of the planning of a trial is the selection of the subject 
area of the research and the formulation of the specific questions that will be addressed. 
A major motivation for most successful researchers is that they are doing something that 
they really enjoy and are researching questions about which they feel passionate. Their 
motivation may come from scientific curiosity about the causes or treatment or control 
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of a particular disease, or about the effects of a specific intervention, or their concern may 
be to explore different ways that health or social systems can improve the public health. 
The field researcher may be motivated by working directly with people in their commu-
nities and be stimulated by the challenges posed by working in remote or difficult situ-
ations, outside of the hierarchy that may exist, for example, in a hospital environment.
The development or refinement of an idea for a field trial should take place in inter-
action with others at local, national, and possibly international levels. The research ac-
tivity must not only be acceptable to the population in which it will be undertaken, but 
also to those who will authorize it nationally and to those who will fund it. Most good 
ideas for field research on the control of a disease that is of public health importance 
are likely to attract support.
Field research likely to receive the highest priority, both nationally and internation-
ally, is that directed at control of diseases of greatest public health importance. An im-
portant preliminary to the development of a research proposal on a specific disease or 
condition may be a survey in the local community to determine the importance of the 
disease of interest. Such local data might be presented side by side with estimates of the 
global burden of disease attributable to the condition being studied.
The progress of science (and of public health) is not only dependent on ground-
breaking first trials that show that a new intervention can be effective in one context. 
Progress also requires the replication of such trials in different settings to determine 
whether the findings from the original trial may be generally applicable. Replications 
of trials of bacille Calmette–Guérin (BCG) vaccination against TB and leprosy and of 
rotavirus vaccines, for example, have shown substantial variations in the efficacy of the 
vaccines in different parts of the world. This is even more important for effectiveness 
trials of interventions that are delivered through routine services where results may 
show important variations from one location to another, due to contextual differences. 
Although sometimes disparagingly called ‘me too!’ trials, such confirmatory (or other-
wise!) trials are very important for the assessment of the public health usefulness of an 
intervention in a specific context.
A trial may either test for superiority or for equivalence. The choice will depend on 
the nature and effectiveness of the comparison intervention and has important im-
plications for the choice of trial size (see Chapter 5). For example, if the aim is to test 
whether a new drug for the treatment of visceral leishmaniasis is more effective than 
the standard drug treatment, this will require what is called a ‘superiority’ trial. How-
ever, it could be that the new drug is much cheaper or is thought to have fewer side 
effects. If this was confirmed in a field trial, it would be likely to be adopted even if it 
was no more effective than the standard drug, so a trial that is designed to test for ‘non-
inferiority’ or ‘equivalence’ would be appropriate.
2.2 Trial purpose
The statement of the purpose of a trial (termed ‘goal’ by some agencies) should convey 
to the reader the type of intervention, or package of interventions, to be evaluated (with-
out details of how it will be applied, dose, and so on) and the endpoints against which 
the impact will be measured, without necessarily specifying the magnitude or precise 
nature of the impact expected or which the trial will be designed to detect. It may also 
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include a description of the ways in which the results of the trial may influence public 
health policy and contribute to scientific knowledge. For example, in a trial of the use of 
the drug ivermectin against onchocerciasis, the statement of the purpose might be ‘to 
assess the impact of mass treatment with ivermectin on the transmission of onchocer-
ciasis and to measure any side effects in those treated with the drug’. For a trial of a new 
vaccine against the blood stages of the malaria parasite, the purpose may be ‘to meas-
ure whether a Plasmodium falciparum asexual blood stage vaccine reduces episodes of 
clinical malaria’. For a trial to test the effect of cash payments conditional on girls either 
staying in, or returning to, secondary school on their risk of HIV infection, the purpose 
might be ‘to assess whether educational conditional cash transfers reduce acquisition 
of HIV infection in girls’. Finally, for the example of the equivalence trial of a new drug 
for visceral leishmaniasis treatment, the purpose might be ‘to test whether the new drug 
is at least as effective as the standard treatment for treatment of visceral leishmaniasis’.
2.3 Specific objectives of the trial
In the specific objectives (called specific aims by some agencies), a quantitative state-
ment should be made regarding the size of the effect of an intervention that a trial is 
designed to detect and the precision with which the effect will be measured. Such specifi-
cations are necessary in order to calculate how large a trial should be, using the methods 
described in Chapter 5. The nature of the intervention should be given in more detail 
than in the statement of purpose (for example, dose and frequency of administration), 
and the endpoints of the trial clearly stated. They should also include a specification of 
the size of the trial and detail the population in which the intervention will be applied. 
For the example of the trial of ivermectin against onchocerciasis, the specific objectives 
would include a statement of the size of the impact on transmission which the trial would 
have a reasonable chance of detecting and the frequency with which adverse reactions 
of different kinds would have to occur to be detected in the trial, while, for a malaria 
vaccine, a more detailed description of the formulation of the vaccine would be required 
and statements included on the magnitude of the true effects on the incidence of malaria 
that the trial would be very likely to detect as being statistically significant. Finally, for the 
conditional cash transfer trial (see Section 2.2), the specific objectives should state the 
size of payment, to whom it will be given (for example, to the girl herself, her parents, or 
some combination of the two), the age range of the girls in the trial, and the size of effect 
on HIV incidence that the trial would have a reasonable chance of detecting.
The proper specification of the specific objectives is crucial to a successful trial. They 
should include a concise, but detailed, description of the intervention to be evaluated, 
the outcome(s) of interest, and the population in which the trial will be conducted. The 
more specific and detailed the objectives are, the clearer it will be how to design a study 
to meet them. It is crucial to set appropriate objectives, and it is worth spending time to 
get these both correct and unambiguous.
2.4 Subsidiary objectives of the trial
In the context of many trials, there will be secondary endpoints which will be meas-
ured in the trial but which are not the prime purpose for which the trial is conducted. 
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Also substudies may be included, having subsidiary objectives, such as the comparison 
of various serological tests or the analysis of genetic markers and their correlation with 
disease. It may be decided to add other objectives on to an intervention trial which do 
not relate to the main objectives. In the trial of ivermectin against onchocerciasis, for 
example, the impact on some other parasitic diseases might be assessed.
To increase the plausibility of trial findings, it is important to document changes 
in intermediate outcomes, which are directly related to the outcomes of principal in-
terest, whenever this is possible. This requires laying out an ‘impact model’ (see also 
Chapter 15), describing how the intervention is expected to lead to the major outcome 
being studied. For stand-alone biological interventions, these models tend to be quite 
simple. For example, a trial of the effect of periodic vitamin A supplementation on child 
mortality should document that the vitamin A status improved in children receiving 
the supplement, but not in the comparison group. Impact models for non-biological in-
terventions are often more complex. For example, in the conditional cash transfer trial, 
the impact on retention in secondary school and school achievement grades or the 
impact on reported sexual risk behaviours or on the incidence of other STDs or of preg-
nancy could also be studied, as well as the primary endpoint of HIV incidence. Impact 
models are essential for deciding which intermediate indicators must be measured.
The introduction of an intervention may also provide a special opportunity for de-
termining particular key factors in the pathogenesis of disease. For example, trials of 
ivermectin, a microfiliaricide, against Wuchereria bancrofti may provide evidence for 
the role of microfilaria, as compared to that of adult worms, in the pathogenesis of 
lymphatic filariasis disease. Decisions to add on studies of this kind should not be taken 
lightly, as they will invariably need additional commitment of resources and may in-
volve the trial population in additional inconvenience. They may thus have a negative 
impact on the primary objectives, perhaps by overstretching the trial team’s technical 
or managerial resources, and the final ‘cost’ to the trial may be much greater than it ap-
peared to be in purely monetary terms.
Once a large field trial is successfully under way, it is not unusual for the trial organizers 
to be approached by other investigators who wish to graft on additional procedures to an-
swer questions of interest to them. There may be considerable value in utilizing the same 
trial for multiple purposes, but full consideration should be given to the extra work that this 
will entail, especially for key members of the research team, and to other possible harmful 
effects such as upsetting the rapport between the trial team and the trial population.
3 Selection of interventions
3.1 Intervention characteristics required
Several criteria should guide the suitability of candidate interventions to be evaluated 
in a large-scale field trial. The intervention, or package of interventions, should usu-
ally be one that could be introduced into a national or regional disease control pro-
gramme (though this criterion might not apply for ‘explanatory’ or ‘proof of principle’ 
trials—see Chapter 2, Section 3.3). The dose (when applicable) should be ‘optimal’. Evi-
dence would usually be required from smaller preliminary studies (sometimes called 
Phase I and II trials, particularly with respect to trials of drugs and vaccines) that the 
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intervention is relatively safe and produces a convincing intermediate response, such 
as a good antibody response to a vaccine or a change in self-reported sexual behaviour 
for an intervention to prevent unwanted pregnancies.
When an intervention has to be repeated several times to be effective (for example, 
micronutrient supplements), there should be evidence that the interval between each 
intervention is appropriate. For some interventions, the concept of dose is meaning-
less, such as the application of a diagnostic or screening test. Corresponding relevant 
evidence would then be required that the test is adequate (for example, previous studies 
indicating that it had good sensitivity, specificity, and predictive values). For continu-
ous or repeated treatments, similar considerations apply to the duration of treatment. 
For example, with vitamin supplementation, the duration required will depend on 
whether the outcome of interest is the reversal of the acute effects of severe deficiency 
or of the chronic effects of more moderate deficiency. In addition to being safe and giv-
ing promise of being efficacious, the intervention must be acceptable to those to whom 
it is directed, relatively easy to deliver, and, at least eventually, of sufficiently low cost 
that it could be incorporated into the national disease control strategy if it is proved to 
be effective within the field trial.
3.2 Number of interventions compared
The choice of the number of different interventions to compare in a field trial is likely 
to be determined not only by the number of competing alternatives, but also by the 
implications the choice has on the size of the trial. This, in turn, is dependent on the fre-
quency with which the outcome of interest occurs. ‘Rare’ outcomes require large trials 
(as discussed in Chapter 5). For example, in a trial of leprosy vaccines in South India, it 
was planned that each ‘arm’ (one of the alternative intervention assignments) included 
in the trial would require around 65 000 trial participants, in order for the trial to have 
the desired statistical power to detect effects that would be of public health importance 
(Gupte et al., 1998). Clearly, in this situation, a decision to add another arm would have 
had enormous cost and logistic consequences.
If the outcome is common, however, trials to compare more than two interventions 
may be undertaken more readily. For example, if seroconversion following vaccination 
is the outcome of interest, it may be straightforward to compare multiple vaccines or 
vaccination strategies in a single trial.
It is important to note, however, that many researchers try to build too many com-
parisons into a trial. There is often a tendency to divide groups after the sample size 
has been calculated or to plan comparisons within groups, without going through the 
appropriate computations (as given in Chapter 5).
Comparisons within a single trial can always be made with much greater confidence 
than those between trials. Thus, if drug A is found to be 50% more effective than a 
placebo in one trial and drug B is found to be 50% more effective than a placebo in 
another trial, it will not necessarily be possible to conclude that A and B are equally 
effective, as the circumstances in which the two trials were conducted will not have 
been identical. A further trial may be necessary for a direct comparison of A and B. If 
the need for this trial could have been anticipated in advance, it would have been more 
efficient to conduct one trial involving both drugs A and B and a placebo. A trial like 
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this may be more complex to organize and would probably have to be substantially 
larger than either of the ‘2-arm’ trials but would still tend to be smaller than the sum 
of the two trials.
When two interventions are being compared to a control intervention, and in situ-
ations where it would be possibly appropriate to apply both interventions to the same 
individual (or community), an efficient way of comparing both interventions with the 
control arm in the same trial is to design it as a ‘factorial’ trial. In such trials, some 
individuals receive the control intervention, others receive one or other of the new in-
terventions, and some receive both interventions (typically 25% in each of four groups) 
(Montgomery et al., 2003). Although not commonly used, this design is very efficient, 
unless there is ‘interaction’ between the two interventions, i.e. the effect of both inter-
ventions applied at the same time is different from the simple sum of the separate effects 
of each of the interventions. Ayles et al. (2008), Awasthi et al. (2013a), and Awasthi et al. 
(2013b) are examples of the design of such trials.
3.3 Combined interventions
For some diseases, there are several possible interventions that may reduce the disease 
impact on a population. For example, interventions against malaria include destruc-
tion of mosquito breeding sites, spraying of residual insecticide, personal protection 
measures (for example, use of bed-nets and repellents), drug prophylaxis, and drug 
treatment, and trials might be designed to evaluate each of these interventions indi-
vidually. A malaria control programme may choose to use more than one intervention 
at the same time and may wish to evaluate the impact of the ‘package’ of interventions, 
rather than the individual components of it. In such a case, the trial might compare 
an integrated strategy incorporating several different interventions applied simultan-
eously with a control group in which only the routine interventions that were previ-
ously available would be applied.
Several trials of this kind have been conducted for the prevention of HIV. For ex-
ample, a recent trial in Tanzania tested the effectiveness of a package of interventions 
targeted to young people. Those in the intervention group received HIV prevention 
education in school; health workers in their local health facilities were given special 
training and support to try to make their facilities more ‘youth friendly’; new sup-
pliers who were thought to be particularly attractive to young people were trained 
and supported to sell condoms, and annual ‘youth health weeks’ were organized in 
their local communities (Ross et al., 2007). The advantage of this kind of trial is that 
it allows the testing of a package on interventions that might reasonably be expected 
to have a greater impact than any single component of the package. However, if no 
effect is seen, then although it may be reasonable to conclude that no one of the 
components of the intervention (at least, as applied in the trial) would have been 
effective on its own, it is necessary to think carefully about whether the existence of 
several concurrent interventions might have diluted the effect of one component on 
its own, or even that one component might have counteracted the effect of another. 
Another disadvantage is that, if an effect is demonstrated, it is not possible to be sure 
of the contribution to the overall result of each of the various components of the 
intervention.
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3.4 Choice of comparison intervention
The best way to evaluate an intervention is to compare its effect with that of another 
intervention in the same population at the same time. Whenever possible, the al-
location of individuals or groups of individuals to the different interventions should 
be ‘at random’ (see Section 4.1 and Chapter 11). In general, the intervention that is 
the current ‘best’ should be used as the comparison, but the choice of the ‘control’ 
intervention is not always straightforward and may involve difficult ethical consid-
erations (see Chapter 6). When no effective intervention is known, the comparison 
must be with a group in which ‘no intervention’ is made; ideally, a placebo should be 
administered in order to preserve ‘blinding’ (see Section 4.1). For example, before the 
development of ivermectin no effective and safe treatment for onchocerciasis existed. 
Thus, placebo-controlled trials of the drug were ethically acceptable, at least until 
the beneficial effects of ivermectin had been established. For most tropical diseases, 
however, some kinds of intervention already exist and may already be deployed by the 
health services or by a control programme in the area where a trial is planned. Only in 
very rare circumstances would it be ethical to withdraw these existing interventions 
for the purposes of a trial. A more complex issue is with respect to the extent to which 
they should be introduced in the context of a trial. It is known that regular prophylaxis 
with anti-malarial drugs reduces morbidity from malaria, for example, so would it be 
necessary to give this intervention to all those in the ‘control’ arm of a malaria vaccine 
trial, even though, in normal circumstances, very few, if any, of them would otherwise 
have been on prophylaxis? Indeed, would it even be ethical to withhold prophylaxis 
from those who would be receiving a malaria vaccine whose efficacy was unknown? 
The optimistic reader will seek a definitive answer to these questions in Chapter 6! 
Unfortunately, the search will be in vain, as there are no general definitive solutions 
to problems such as this; each situation has to be considered on its own merits, tak-
ing full account of the circumstances in which a particular investigation is planned. 
However, in Chapter 6, key principles are outlined that should be used when making 
such judgements.
In a leprosy vaccine trial in Venezuela, the new leprosy vaccine consisted of a mixture 
of BCG and killed Mycobacterium (M.) leprae bacilli. When the trial was designed, a 
choice had to be made between using BCG for the control arm (the efficacy of BCG 
alone against leprosy in Venezuela was unknown at the time) or using a placebo. BCG 
was chosen, even though doing this might reduce the chance of showing a protective 
effect (as BCG alone may have been protective). The inclusion of a third, placebo, arm 
would have allowed the protective effect of BCG alone to be evaluated, but the inci-
dence of leprosy was too small for a third arm to be feasible within the trial. The major 
purpose of the trial that was conducted was therefore to evaluate whether a leprosy-
specific vaccine (i.e. one which included M. leprae bacilli as well as BCG) was more ef-
fective than a non-specific vaccine (in this case, BCG). If the comparison had been with 
a placebo instead of BCG, any effect due to BCG could not have been distinguished 
from that due to the addition of M. leprae bacilli to the vaccine. In a larger trial of the 
same vaccine that was conducted in India, it was possible to include a placebo arm 
(Gupte et al., 1998).
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The use of a placebo may be very important to derive an unbiased measure of effect 
(see Section 4.1 and Chapter 11, Section 4), but it requires careful ethical justifica-
tion, and thought must be given to whether particular circumstances might lead to 
treatment being offered to participants, irrespective of their trial arm. In a placebo-
controlled trial of vitamin A supplementation in Ghana, for example, the objective was 
to determine if a reduction of child mortality was produced by supplementation. As 
eye signs of vitamin A deficiency are effectively treated by vitamin A supplements, all 
in the trial were monitored for such signs and treated immediately if such signs were 
detected, even though this was likely to reduce the power of the trial to detect an impact 
of vitamin A supplementation on mortality.
A related issue concerns trials which do not test new interventions as such but evaluate 
new ways of delivering existing interventions. In a cluster randomized trial in Bangladesh, 
the Integrated Management of Childhood Illness (IMCI) strategy promoted improved ways 
of delivering interventions such as antibiotics for pneumonia, oral rehydration therapy, and 
vaccines; these interventions were also available from routine services in comparison areas. 
It was judged ethical not to change routine practices in the comparison areas, because these 
reflected what was already in place in the country as a whole (Arifeen et al., 2009).
3.5 Complex interventions
The design of a trial to evaluate the efficacy of a new vaccine or drug is relatively 
straightforward, in the sense that there are many past examples of such evaluations 
to draw upon when planning a new trial. However, the evaluation of some interven-
tions, such as the deployment of a new procedure in the health service or public health 
practice, may involve consideration of several interacting components, including, for 
example, educational components and behavioural change. Such interventions pose 
special problems for evaluation, and these kinds of intervention have been called ‘com-
plex’. Many of the extra problems relate to the difficulty of standardizing the design and 
delivery of the interventions, their sensitivity to features of the local context, the organ-
izational and logistical difficulty of applying experimental methods to service or policy 
change, and the length and complexity of the causal chains linking intervention with 
outcome. See Chapter 2, Section 2.3.4 and the associated Box 2.1 for further discussion.
4 Allocation of interventions within the trial
4.1 Randomization and ‘blindness’
Once a potential intervention has been shown to be safe and acceptable for use in hu-
mans and the dose schedule established, trials should be conducted to evaluate quanti-
tatively the benefit attributable specifically to the intervention under trial, compared to 
some other intervention, while attempting to exclude the confounding effect of other 
variables. The best way to exclude the potential effects of other factors—both those al-
ready known to be confounders and also those that are confounders but are not known 
to be so—is to base allocation decisions as to which intervention is applied to a particu-
lar individual, or group, on a random process. Incorporation of randomization into the 
trial is an extremely important design issue (see Chapter 11).
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The randomized intervention trial is as close to a rigorous scientific experimental 
study involving human beings as it is possible to achieve ethically. The main study de-
sign features of a randomized trial are:
 1 to avoid bias in assignment to the alternative interventions, all eligible trial 
participants should be assigned at random to the alternative treatment groups. 
This involves two steps; the first is selecting participants on the basis of the pre-
established criteria for eligibility, and the second is the randomization procedures 
should ensure that each eligible participant has the same chance of receiving a 
particular intervention procedure
 2 to avoid bias in the assessment of the trial endpoints, whenever possible, the 
person(s) assessing the outcome measures should not know to which interven-
tion group the participant was assigned (i.e. the assessor should be ‘blind’ to the 
intervention group)
 3 to avoid bias in the behaviour or reporting by the participant, whenever possi-
ble, the participant should also be ‘blind’ (i.e. the intervention group assignment 
should not be known by the participant).
If neither the assessor nor the participant is aware of the intervention allocations, the 
trial is said to be ‘double-blind’. If only the assessors (or, more rarely, only the participants) 
are aware of the allocations, the trial is called ‘single-blind’. For situations in which there is 
no known effective treatment or preventive method, a placebo of some sort must be used 
if double-blinding is to be assured. The ‘double-blind’ approach is the key to the elimina-
tion of bias in the assessment of the impact of an intervention, and, wherever possible, a 
‘double-blind’ design should be used. Sometimes it is not possible because of the nature of 
the intervention procedure, for example, where participation in health education sessions 
is being compared to no intervention, or where cervical surgery is being compared to drug 
treatment for cervical cancer. But even if the providers of the intervention must know the 
assignments, the person who assesses the trial outcome should be kept ‘blinded’, if feasi-
ble. The more clearly defined and objective the outcome to be measured, the less critical 
it becomes to ensure blinding of the assessor. For example, as long as there is complete 
ascertainment of all deaths in all arms of the trial, blindness is unlikely to be important in a 
trial with mortality as the endpoint. Similarly, the less likely a patient is to be influenced by 
knowledge of which intervention they have received, the less important their blinding is.
4.2 Unit of application of the interventions
Different interventions can be applied either to an individual or groups of individuals, 
such as everyone in a family or household, everyone working in a particular company, 
or everyone in the community. The unit for randomization should usually vary in par-
allel with this. The choice of the unit for application of the intervention depends upon 
the nature of the intervention, the administrative method for its application, and the 
purpose for which the intervention is being applied. In statistical terms, the most effi-
cient design, in most circumstances, is to use the individual as the unit of application, 
and this should be the design of choice, unless there is good reason for household or 
community (group) application and randomization. There are four main reasons for 
applying an intervention to a group, rather than by individual.
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First, group allocation is appropriate when, by its nature, the intervention must be 
applied to everyone in the group such as all those living in a geographical area, work-
place, school, or community. Examples include most environmental alterations and 
many vector control interventions. It also applies to many educational or health pro-
motion interventions which, although they can be delivered at individual level, are 
likely to spill over or ‘contaminate’ other individuals living in the same community.
Second, it may be logistically easier to administer the interventions to groups, rather 
than on an individual basis. Sometimes it is administratively simpler and/or more ac-
ceptable to randomize by household or village, rather than by individual. Furthermore, 
with individual randomization of medications, for example, there may be a risk of in-
dividuals sharing medications within households or villages.
Third, if the purpose of applying the intervention is to reduce transmission of in-
fection by a parasite, for example, the appropriate unit of application would be the 
‘transmission zone’, i.e. the area in which people (and, where appropriate, vectors and 
intermediate hosts) may be interacting and sharing a common pool of parasites. Fac-
tors of importance in defining such zones may include the flight range of vectors and 
the movements of people, vectors, and intermediate hosts. To reduce interchange (‘con-
tamination’) among transmission zones, it may be useful to have intervening buffer 
zones that are not involved in the trial. For many diseases, however, the size of the 
transmission zones may be difficult to determine and may vary over time.
Some interventions may be applied to individuals, but with the expectation that 
there may be an effect on transmission, through applying them to a high proportion of 
individuals in the community, that goes beyond the effect that would be achieved dir-
ectly within the individuals who received the intervention (for example, through ‘herd 
immunity’). The extent of coverage required to produce such effects depends upon the 
epidemiological circumstances, the presence of other control measures, and the type 
of intervention being introduced. For example, the use of a malaria vaccine to reduce 
the transmission of malaria in parts of Africa where the disease is ‘holoendemic’ may 
require so near to complete coverage that such a purpose would not be seriously con-
sidered. However, in other parts of Africa where the disease is much less prevalent, 
achieving high coverage with a highly effective vaccine might be sufficient to interrupt 
transmission.
For some types of intervention procedures, when the procedure itself provides in-
dividual benefit, such as ivermectin in the treatment of onchocerciasis, a further im-
portant issue is whether reduction of transmission provides a benefit, in addition to the 
individual reductions of morbidity/mortality. Trial designs to demonstrate this add-
itional benefit are likely to be complex.
A fourth reason for applying interventions to a group or community as a unit would 
be for trials involving an intervention of already proven efficacy in individuals, but 
for which the delivery may be more effectively carried out on a group or community 
basis. The trial might consist of a comparison of different delivery systems. Generally, 
the end result desired in this type of trial is based upon cost-effectiveness criteria. Here 
the question would be whether it is possible to achieve a greater disease reduction for a 
given expenditure (or alternatively the same disease reduction for less expenditure) by 
use of a community-based distribution system than by the usual individual distribution 
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methods. Many types of community-based distribution systems require community 
participation studies. The basic principles involved in community participation studies 
and in cost-effectiveness studies are described in Chapters 9 and 19, respectively.
When group randomization is adopted, the efficiency of the design can be im-
proved by ensuring that the groups allocated to the different intervention arms are 
as similar as possible with respect to risk factors for the outcomes of interest, in 
the absence of the intervention. In other words, there is ‘balance’ between the risks 
of the outcomes of interest between the trial arms. When there are large numbers 
of units to be allocated, randomization itself will ensure comparability, but usually 
when communities or other groups are the units to be randomized, the number of 
units is relatively small, and randomization may leave considerable differences be-
tween the groups in the different arms. Attempts can be made in the analysis to allow 
for these differences, but the persuasiveness of the results may be reduced if the con-
clusions depend upon extensive statistical manipulation of the trial results. A more 
efficient approach to increase the comparability of the groups in the different arms is 
to stratify the groups into ‘blocks’ having similar underlying pre-intervention risks 
of the disease outcome in question and to randomize within each block. Stratifica-
tion should be either in terms of variables which are strongly related to the risk of the 
outcome under study or in terms of this risk itself. For example, in trials of interven-
tions against malaria in which villages are to be randomized, the villages might be 
stratified according to their pre-trial malaria prevalence or incidence rates, if such 
information is available, and the randomization done within each of these strata. 
An extreme type of stratification is when each ‘block’ includes the same number of 
groups (for example, villages) as there are arms of the trial, with each village within 
each ‘block’ having similar malaria rates. One village in each block is then randomly 
allocated to each intervention (see also Chapter 11, Section 3).
An alternative to stratification, when the number of available units for simple ran-
domization, or even for stratification, is too small, is known as ‘constrained’ or ‘re-
stricted’ randomization. Assume there are 20 villages to be randomized. All possible 
combinations of ten versus ten villages are evaluated, and only those combinations with 
good baseline comparability between the two sets of villages are selected. Next, one of 
the shortlisted combinations is chosen at random, and one of the two sets of ten villages 
is randomly selected to become the intervention group (Moulton, 2004). An example 
of the use of this approach is given in Sismanidis et al. (2008). See also Chapter 11, 
Section 3.3.
Often, good information on the distribution of the outcome measures will not be 
available in the trial population. In such circumstances, baseline studies to obtain the 
required information should be considered. Sometimes, as an alternative, surrogate 
measures must be used (i.e. measures which are thought to correlate closely with the 
outcome measures of principal interest). In the absence of detailed data on the popu-
lation, geographical proximity and socio-economic level may be used as stratification 
characteristics. Thus, if a small geographical area is chosen as the randomization unit, 
the total trial area would be divided into regions containing a small number of rela-
tively homogeneous units and, within each region, an equal number of units allocated 
to each treatment arm.
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4.3 ‘Stepped wedge’ design
The issue of the ethics of randomization is presented in acute form in situations where pre-
vious studies, perhaps using short-term endpoints or a more intensive intervention than is 
feasible on a population basis, indicate that the intervention is likely to be beneficial. With-
holding the intervention from those in one of the treatment arms for the duration of the 
trial may then be argued to be unacceptable. Also, some individuals or organizations have 
an inherent, if irrational, distrust of randomization, worrying that it is ‘experimentation’ 
(which of course it is!) or even ‘treating humans like laboratory animals’. Such positions 
can make it impossible for a straightforward RCT design to be accepted. An approach that 
can be adopted in this situation is the phased introduction of the intervention on a group-
by-group basis, until the entire target population is covered. In order to avoid bias, the 
order in which the groups are given the intervention should be randomized and the num-
ber of groups should not be too small—at least six, preferably many more. This approach 
was first used in The Gambia to evaluate the long-term effects of vaccination against the 
hepatitis B virus (HBV) (The Gambia Hepatitis Study Group, 1987). A recent example of 
this design was a trial in Ghana to evaluate the impact on child mortality of treating fever 
using anti-malarials, with or without also treating with antibiotics (Chinbuah et al., 2012). 
Other examples are given in Brown and Lilford (2006).
The trial design is illustrated in Figure 4.1. This type of design has been called a 
‘stepped wedge’ design. The power of this approach, compared to a simple allocation 
Start of HBV vaccine programme
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Figure 4.1 The ‘stepped wedge’ trial design used to evaluate the impact of hepatitis B 
vaccination on liver cancer rates in The Gambia.
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of groups to one or other treatment arms, is of the order of 75–80%, depending on the 
number of groups. The same considerations apply to stratification and blocking, as in 
the static allocation designs.
In the trial in The Gambia, hepatitis B vaccine was introduced into the routine child 
vaccination programme over a period of 4 years. The order in which the different vac-
cination teams (there were 17 at the time the trial was planned) began to use the vaccine 
was random. At the end of 4 years, there was a cohort of children who had received the 
vaccine and a cohort who had not. These cohorts are being followed to compare the 
incidence rates of liver cancer and chronic liver disease. At the end of the 4 years, all 
vaccination teams had started vaccinating children, so subsequent cohorts of children 
were vaccinated. This phased introduction of the intervention mimicked the way in 
which many public interventions are introduced, but the key feature of the random 
order of the introduction of the intervention across the ‘clusters’ (in this case, vaccin-
ation teams) brought the crucial benefit of reducing the potential for the trial produ-
cing biased results.
4.4 Other approaches to allocation of the interventions
The allocation of interventions to individuals based on a random scheme is the best 
approach to rigorously exclude the potential biasing effects of other factors. However, 
non-randomized designs are often used. For example, a common approach is the 
 ‘before–after’ or ‘pre–post’ design, in which the incidence or prevalence of the disease 
under study is compared before and after the intervention has been applied, and an 
attempt is made to attribute any difference to the effect of the intervention. This ap-
proach has important limitations as it may be wrong to assume that, in the absence of 
the intervention, the disease rate would have remained the same. Many diseases, and 
especially those of parasitic or infectious origin, vary greatly in incidence and severity 
from year to year and place to place, for reasons that are incompletely understood. Cer-
tainly variations in climate (for example, temperature and rainfall) can have profound 
effects. Some diseases show marked declines (or increases) over time in some com-
munities (for example, TB and malaria), and sometimes these cannot be predicted in 
advance, or even related to any obvious specific factor. ‘Before and after’ evaluations of 
interventions in such situations may be very misleading. Also, it is not uncommon that 
the methods used to ascertain the trial outcomes change over time, either in terms of 
the actual data collection method or the person or organization doing the data collec-
tion changes, and the two produce systematically different results.
Another commonly employed approach is to apply an intervention in one commu-
nity, and not in another, and to attribute any difference in disease rates between the two 
communities as being due to the intervention. This also may be very misleading, as a 
change may have occurred in one community, but not in the other, for reasons that had 
nothing to do with the intervention. Random, rather than purposive, allocation of the 
intervention to one of the two communities does not make any difference to this.
The commonest reason that is advanced for using a non-random allocation between 
intervention groups is for simplicity of design and administrative ease. Approaches 
like these also seem easier to explain to officials and to gain public acceptance. The ra-
tionale for randomization is difficult to communicate, even to other scientists, but the 
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arguments in favour of randomization, as outlined in Section 4.1, are extremely strong, 
and failure to accept this approach has frequently led to studies from which erroneous 
conclusions have been drawn.
There are, however, situations in which allocation cannot be made on a randomized basis. 
There are occasions when the benefits of an intervention appear so clear that a properly 
randomized trial cannot be contemplated, or when the intervention or package has already 
been subjected to randomized trials and is being scaled up under routine conditions. The 
value of the intervention then has to be assessed by comparison of the situation before and 
after its introduction, or by the use of case-control studies after the intervention has been in-
troduced (Smith, 1987). Although before vs after studies suffer from the major limitations 
described earlier in this section, the plausibility of the trial’s conclusions can be increased 
by trying to rule out alternative reasons why the changes might have occurred (Bonell et al., 
2011; Victora et al., 2004). First, if possible, data should be collected on more than one oc-
casion, both before and after the intervention is introduced (sometimes called a time-series 
study). This allows checking that the outcome of interest was not already declining at the 
same rate prior to the start of the intervention, and that any decline after the intervention 
was introduced was consistently present, rather than only there at one time point. Second, a 
comparison should be made with time trends in disease rates in neighbouring populations 
where the intervention or package of interventions has not been delivered, and/or in the 
country or region of the country as a whole. Third, the sharpness with which changes in 
disease rates take place should be consistent with what might be reasonable to expect from 
the intervention and related to the speed with which the intervention is introduced over 
the entire population. Fourth, knowing and recording possible confounding variables in 
the before and after periods or in the populations being compared in a non-randomized 
study may also aid  interpretation of differences. For example, in a study in which an objec-
tive is to reduce transmission of lymphatic filariasis by treating the human population with 
antifilarial drugs, monitoring the vector population for changes in density and infectivity 
might be undertaken.
While acknowledging these exceptions to the use of randomization as the basis 
of allocation, such studies do not have the rigour of a randomized design, and any 
conclusions drawn from them must be viewed with some caution. It is reasonable to 
think of there being a hierarchy of evidence from intervention studies, with (1) well-
designed and well-conducted RCTs providing the strongest evidence, followed by (2) 
quasi-experimental studies, in which there is a similar contemporaneous comparison 
group, but the receipt of the intervention has not been allocated randomly, and then (3) 
non-experimental designs, in which there is no similar, contemporaneous comparison 
group such as the before–after, time-series, or after-only designs outlined earlier in this 
section. Formal guidelines have been developed by the GRADE working group (Guyatt 
et al., 2008) (<http://www.gradeworkinggroup.org>) to rank the quality of evidence on 
the effect of an intervention, based on different kinds of study, ranging from the RCTs, 
which are judged to provide the highest quality of evidence (if properly conducted), 
through to other kinds of study, providing lower-quality evidence, including observa-
tional studies. The WHO has now adopted these guidelines and attempts to undertake 
a formal grading of the quality of the evidence, with respect to policy recommendations 
they make regarding specific interventions. The main focus of this book is on RCTs.
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5 Choice of outcome measures and trial duration
For many interventions, there will be a range of outcomes that could be affected and 
which might be of interest to study (see also Chapter 12). Nutritional supplements, for 
example, might affect any or all of the following:
 1 biochemical measures
 2 short-term acute consequences of deficiency
 3 the consequences of chronic deficiency
 4 mortality due to the specific causes of death that the intervention is intended to 
rectify
 5 total (all-cause) mortality.
In determining which outcome is of the greatest importance for the trial, consider-
ation must be given to whether:
 1 the outcome is of clinical or public health importance
 2 the probable effect on that outcome is large enough to be of clinical or public 
health interest
 3 it can be accurately measured.
A substantial impact on total and age-specific mortality rates is always of public 
health importance, and systems can usually be set up to ensure that they are well re-
corded (even though such systems often require considerable input if they are not al-
ready in place), but they are unlikely to be sufficiently affected by most interventions to 
enable effects to be detected with studies of manageable size. Mortality from the spe-
cific causes that the intervention is designed to reduce should be more greatly affected, 
of course, but is usually much more difficult to measure accurately. In most low-income 
settings, routine reporting of births and deaths by medically certified cause of death is 
not available or is very incomplete and therefore potentially misleading. In these cir-
cumstances, measuring cause-specific mortality rates will require interviews with close 
relatives or friends of the deceased to try to ascertain the signs and symptoms preced-
ing death, so that an attempt can be made to assign a likely cause of death. Such inter-
views are known as ‘verbal autopsies’. The International Network for the Demographic 
Evaluation of Populations and Their Health in Developing Countries (INDEPTH) has 
produced model verbal autopsy questionnaires (<http://www.indepth-network.org>). 
Using total mortality as the trial outcome, however, will dilute the effect that might be 
seen if specific causes were examined, since the variation in deaths due to the unaf-
fected causes is included. The choice may have to be made between setting up special 
mechanisms to collect high-quality information on the cause of each death or to allow 
for a dilution of the observed effect by increasing the size of the trial. It should be 
stressed that, for conditions that are life-threatening, mortality is an important out-
come to evaluate and, wherever possible, should be a primary trial outcome, but this 
generally has substantial implications, with respect to the size of the trial.
Short-term outcomes are clearly attractive in that, if used as the outcome on which 
the design is based, the trial size will be smaller and the duration shorter than if mor-
tality were to be used. The danger is that the short-term measure in itself may not be of 
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principal public health importance, and the effect of the intervention on that outcome 
may not correlate well with the effect on more serious conditions. There is, for example, 
little point in measuring an antibody response to infection if it bears no or little relation 
to the risk of disease. Conversely, in the relatively rare situations where it is known that 
a short-term outcome is highly correlated with an outcome of greater public health 
consequence (and is effectively a surrogate measure of the more important outcome), it 
will be more efficient to focus the trial on the surrogate outcome.
In most circumstances, the appropriate outcome for determining the duration and 
size of the trial would be the most serious consequence of the specific condition at 
which the intervention is aimed. However, it is not always feasible to use such outcomes 
in a trial. For example, in a trial of a new measles vaccine in a HIC where death in some-
one who has measles illness is rare, the onset of measles illness might be a sensible trial 
endpoint, rather than death from the disease or total mortality. In contrast, in a country 
where a relatively high proportion of children with measles die, death from measles 
might well be the outcome of choice. If mechanisms for establishing accurate diagnosis 
were inadequate, total mortality might even be considered (especially as measles vac-
cine may reduce the risk of death attributable to diseases other than measles).
Even in trials where total or cause-specific mortality are the primary trial endpoint, 
short-term ‘intermediate’ outcomes should also be collected as valuable secondary 
monitoring and explanatory outcomes, as laid out in the impact model. They provide 
information, as the trial progresses, as to whether the trial is on target to meet its pri-
mary goals and, if it is not on target, should help to identify what remedial action might 
be required. Also, if the trial does not find a significant impact on its primary outcome, 
the ‘upstream’ outcomes may help provide an explanation for why. For example, in a 
trial of the impact of insecticide-treated nets on malaria mortality, it would be import-
ant to also measure net coverage and use, and data on the incidence of malaria illness 
and age-specific prevalence of malaria parasitaemia by trial arm. When short-term 
outcomes are used in this way, any assumptions about the natural history of the disease 
should be clearly thought through and stated in the trial protocol.
Definition of the primary trial outcome will have consequences for the duration of 
the trial. Prior information should be available on the time needed for the intervention 
to affect the outcome. In some situations, such as the prevention of liver cancer in adult 
life by hepatitis B vaccination in the first year of life, the final outcome measure may 
not be observed for several decades. The need for monitoring of intermediate outcomes 
(such as the hepatitis B carriage rate) then becomes even more important.
The choice of trial duration is critical for interventions whose impact does not in-
crease linearly over time. For example, the impact of a health education programme in 
schools to reduce sexual risk taking might be relatively small, until a high proportion 
of the students have become sexually active. But even then, the impact might be small, 
until both the students and their sexual partners (who might be several years older or 
younger) had been through the programme. And finally, the impact may reach a ‘tip-
ping point’ when enough people had been exposed to the programme to change gen-
eral social and sexual norms in the population as a whole. However, the choice of trial 
duration is complicated by the fact that few funding agencies are keen to fund research 
projects that last more than 3–5 years. A common strategy is to apply for initial funding 
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for a 3- to 5-year trial that will be able to measure the intervention’s impact on impor-
tant intermediate outcomes but is large enough to measure the impact on the primary 
trial outcomes if continued into a second trial follow-up phase, with the application for 
further funding based on the results of the first phase.
A final and important point to stress in this section is that it is essential that attention 
is given to monitoring the severity and frequency of adverse effects of an intervention. 
In their desire to assess the effectiveness of an intervention, investigators often do not 
pay sufficient attention to finding and documenting adverse effects, which may require 
additional effort and resources. In most situations, the future applicability of the con-
clusions drawn from a trial will involve an assessment of the balance between positive 
and negative (adverse) effects.
6 Trial population
6.1 Criteria for selection of trial population
The criteria for selection of the population to be included in the trial depends primar-
ily upon what condition the intervention is directed against and upon the purpose of 
the trial. In general, the population will be chosen from an area in which there is high 
incidence of the condition of interest, because the higher the incidence of the primary 
trial outcome, the smaller the study population for the trial has to be. Exceptions are 
when the purpose of the trial is to determine the efficacy under special epidemiological 
circumstances or in special population groups such as in pregnant women.
Good community and governmental co-operation and participation are also key fac-
tors in the successful conduct of a trial. The trial area should be accessible at the times 
surveys are to be conducted (for example, during the rainy season). Well-qualified and 
experienced field teams should be available or be able to be recruited. In addition, ac-
cess to high-quality clinical and laboratory facilities may be necessary for the trial. If 
required, entomological, behavioural science, economic, and other appropriate discip-
linary expertise should be available. Planning the trial will be much simplified if base-
line data are already available in the trial area.
If the trial design involves the repeated follow-up of members of the study popula-
tion over several years, as will be the case for many intervention trials, it is important to 
select a location for the trial in which substantial migration into, or especially from, the 
area is unlikely to occur. Migration rates in excess of 10% per year are not uncommon 
in many rural areas and may be considerably higher in urban or peri-urban settings. 
Unless the trial is conducted within a demographic surveillance population, migration 
rates may well not be known in advance, so a rapid survey of a sample of the proposed 
trial population may be useful to determine if a reasonable proportion of the popula-
tion have been resident in the area for several years.
The choice of trial population may affect the external validity of the trial results. For 
example, many micronutrient trials are carried out in areas with high prevalence of 
the specific deficiency. The health impact from supplementation in such areas is likely 
greater than what would be expected in areas where micronutrient deficits are less fre-
quent, which may represent the majority of areas where supplements will be used in 
the future.
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6.2 Inclusion and exclusion criteria
In general, the trial population should be chosen to represent the group that would 
be the target for the intervention in a potential future public health programme, if the 
intervention is found to be effective within the trial. Care should be taken to define the 
target population. To the extent feasible, those included should be the persons for whom 
benefit is likely to be the greatest, and those excluded should be the persons for whom 
benefit is likely to be minimal or indeed who may be harmed. Specific inclusion and ex-
clusion criteria should be developed for the trial. For example, because the major mor-
bidity and mortality associated with malaria in a holoendemic area are seen in infants 
and young children, these groups are likely to be the focus of a major field trial of a mal-
aria vaccine in such an area, though older children and adults might be used in prelim-
inary studies to test the safety of the vaccine in those who already have some immunity 
or may be the focus of a vaccine trial where malaria transmission is much less intense.
In early trials of an explanatory nature, special groups at high risk may form the trial 
population, either to maximize the potential effect, to ensure good compliance, or to 
facilitate the logistics. Valuable information concerning the potential of the interven-
tion can result, but the extent to which the results can be extrapolated to the general 
population may be limited.
Exclusion criteria need to be carefully considered so as to eliminate subjects who 
may be put at greater risk by the intervention or who have underlying conditions that 
may interfere with the assessment. Exclusion criteria should be stated explicitly and 
unambiguously, before the trial begins. It is usual to exclude from trials those who are 
seriously ill, those who are very old, those who are very young, and pregnant women, 
unless any of these are the specific target group for the intervention. These groups are 
excluded either because it is considered that they are unlikely to derive benefit from the 
intervention, or if they are thought to be more likely to be susceptible to possible ad-
verse effects of the intervention, or they are likely to suffer adverse events (AEs) which 
might incorrectly be associated with the intervention if they are included. Ascertaining 
pregnancy is difficult, especially in its early stages, without specific testing, and, in some 
trials, this may not be feasible. Sometimes all women of childbearing age are excluded 
from trials, if it is thought that damage may be caused by the intervention to the fetus. 
Against this must be balanced the potential benefit that the excluded groups may re-
ceive from the intervention. Also, if pregnant women or children, for example, have 
been excluded from a trial that shows the intervention to be effective, resulting public 
health programmes may consider it is inappropriate for them to receive the interven-
tion, in case there are unforeseen risks to them or because the safe and optimal dosage 
of any drugs involved are not known. As a result, it may be appropriate to include them 
in later ‘bridging’ trials, with careful monitoring of pregnancy outcomes.
6.3 The size of the trial population
Attention needs to be given to the required size of the trial, in terms of the precision 
of the effect estimates and of the power to detect important differences. These aspects 
are discussed in detail in Chapter 5. It is important to allow for the loss of power that 
results from group randomization if such a design is adopted (see Chapter 5, Section 6).
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For interventions that are likely to be given to large numbers of individuals, if they 
are subsequently introduced into disease control programmes, there are strong argu-
ments in favour of designing trials of the interventions to also be large not only to pick 
up any rare side effects, but also to obtain a relatively precise measure of their expected 
impact.
6.4 Compliance
Conclusions from a trial will be based on a comparison of the outcome measures 
adopted for the trial in those allocated to the alternative intervention arms of the trial. 
Only a certain proportion of those allocated to a particular intervention will receive 
that intervention effectively. Effective delivery of an intervention requires both that 
the provider carries out the intervention procedure correctly and that the trial partici-
pants co-operate in the desired fashion. In field trials, the provision of the intervention 
will usually be under the control of the investigator, but a successful trial also requires 
the compliance of the participants, who are not under the control of the investigator, 
and will depend on the understanding and co-operation of the community involved. 
Hence, the strong emphasis in this manual on the importance of communication and 
feedback between the investigating team and the participating communities has a prag-
matic, as well as an ethical, basis.
In most trials, however, some participants will not fully comply, and the interven-
tion procedure either will not be carried out or it will not be done in an effective 
manner. For trials to determine the public health value of an intervention (pragmatic 
trials), some degree of non-compliance may give a more realistic measure of effective-
ness than a tightly controlled trial in which every effort is made to ensure that the in-
tervention is effectively delivered, but for explanatory studies, in which an important 
objective may be to determine the maximum effect possible, every effort should be 
made to keep compliance high. Wherever possible, the degree of compliance should 
be continually monitored, at least on a sample basis. This might be done, for example, 
by doing urine or blood analyses to check that the expected drug or nutritional sup-
plement has actually been ingested. For intervention measures that are administered 
sequentially over time or on a continuing ongoing basis, repeated specimens should 
be taken. In a trial to measure the impact of introducing improved water supplies, 
for example, it will be important to measure the proportion of the target population 
who actually access the improved water source. This is particularly relevant in trials 
in which a health effect is mediated through a change in behaviour, as is the case in a 
breastfeeding promotion trial with morbidity or mortality as endpoints. Document-
ing compliance with counselling—assessed through changes in feeding practices—is 
essential.
A further aspect of compliance that is sometimes overlooked is that those in the 
‘control’ arm of a trial, who are allocated to routine care or placebo, may adopt 
the test treatment under study. For example, if health centres in some villages 
are allocated to receive an intervention, such as offering voluntary medical male 
circumcision or improved STD treatment, while those in other villages serve as 
controls, people in the control villages may go to the health centres in the interven-
tion villages to obtain the intervention. Monitoring for the possible occurrence 
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of this latter form of non-compliance (sometimes called ‘contamination’) is im-
portant. Care should also be taken in the construction of the different treatment 
groups to minimize the opportunity for such contamination. In the circumcision 
example, ensuring there is clear geographical separation of villages in the differ-
ent arms of this trial by leaving a ‘buffer zone’ would be one means of minimizing 
contamination.
7 Implementation
7.1 Community acceptance
Critical to the conduct of a successful trial is that the trial population co-operates dur-
ing the conduct of the trial and takes up the intervention offered. They must feel a part 
of the trial and perceive it to be for the benefit of their community. To ensure these 
aspects will require careful planning and investigation before the trial starts, including 
appropriate discussion with, and explanation to, community leaders and potential par-
ticipants. Feedback and interaction should be continued throughout the course of the 
trial. These aspects are discussed in several chapters, and especially in Chapters 6 and 
9 and part of Chapter 15.
7.2 Feasibility studies and pilot testing
Unless the acceptability and feasibility of implementing the intervention and the evalu-
ation procedures that will be used in the trial have already been tested locally, it is 
usually wise to conduct a smaller feasibility study in advance of the main trial. The 
feasibility study may only include some aspects of the trial, such as the acceptability and 
feasibility of delivering the intervention, or the feasibility of enrolling trial participants 
or of administering a questionnaire or collection and testing of laboratory specimens. 
Whether or not such a feasibility study has been conducted, it is essential that all the 
trial procedures are tested together in a pilot study, exactly as they will be applied in the 
actual large-scale field trial. However, the pilot study should be conducted on a much 
smaller number of participants and with enough time for the trial procedures to be 
modified in the light of the findings. Feasibility studies and pilot studies are discussed 
in detail in Chapter 13.
7.3 Staff recruitment, training, and retention
The dedication and commitment of the staff employed to conduct a field research pro-
ject are essential. This will involve their careful selection, training, and then support. 
They must understand the importance of their role in the trial and how it relates to that 
of others. The importance of high-quality work must be emphasized, and this must be 
monitored throughout the trial (see Section 9 and Chapter 16). Trials of long duration 
present the additional challenge of keeping staff motivated and performing at adequate 
levels of quality and avoiding excessive turnover. Open and frank discussions with staff 
are essential, and benefits, such as regular increases in salaries over time, may help mo-
tivation and retention.
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7.4 Field organization
All aspects of field procedures should be planned in advance, and potential problems 
and solutions anticipated (for example, in case of staff sickness or vehicle, computer, or 
laboratory equipment failure). The trial design must reflect not only what is ideal, but 
also what can be done, given the constraints under which the trial must be conducted. 
These aspects are considered in detail in Chapters 16 and 17. Issues relating to mapping 
and conducting a census of the trial area are covered in Chapter 10.
8 Data handling
8.1 Data collection
A necessary part of most trials will be the collection of baseline (pre-intervention) data. 
These will include identification information on participants, such as name, age, sex, 
place of residence, and information on other factors that may influence the risk of oc-
currence of the outcome measures under study in the trial. Although randomization of 
a large enough number of individuals, or clusters of individuals, should result in an ap-
proximately equal distribution of all the important characteristics between trial arms, 
such baseline data, which should ideally include all known confounders, can be used to 
check that this balance has actually occurred in practice. And if it has not, then it can 
also be used to adjust for such imbalances in the trial analyses.
In addition, it may be important to collect general baseline data on the population 
where the trial is being carried out. These may include not only the epidemiological 
characteristics of the population, but also the socio-economic, cultural, political, health 
services, nutritional, and other relevant characteristics. Such contextual factors may be 
essential to interpreting whether the trial’s results can be generalized to another setting.
Additional data will be collected during the course of the trial to monitor the ap-
plication of the interventions and to record information on the outcomes of interest. 
The conduct of a population census is described in Chapter 10, and methods to obtain 
high-quality data at the start of a trial and during its course are described in Chapter 14. 
Obtaining data using social or behavioural methods is outlined in Chapter 15, and for 
measuring the costs of the interventions is outlined in Chapter 19. Of crucial import-
ance in any trial is the proper measurement of the incidence of endpoints against which 
the intervention is designed to protect, and these aspects are discussed in Chapter 12.
8.2 Data processing
Methods of coding, entering, and then managing computerized data collected in a trial 
are described in Chapter 20.
9 Quality control
In most intervention studies, members of the population are invited to participate, the 
intervention is applied, perhaps repeatedly, and the population is kept under surveil-
lance, until the final trial outcomes are recorded. The quality of each step in this pro-
cess must be monitored. The two major reasons, which hardly need stating, are first to 
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ensure that each operation is being performed to an acceptable standard, and second to 
identify areas where attention is required. A third reason is to be able to ascertain, at the 
end of a trial that failed to show anticipated effects, the possible reasons for failure. The 
damage done by a misleading ‘negative’ result can be serious. The following are major 
aspects of quality control (QC) that need attention.
9.1 The intervention
Regular monitoring of the delivery of the intervention should be an integral part of the 
design to ensure that there is no change in the quality, as a trial goes on. For example, in 
a vaccination trial, continual review would be needed of the quality of the vaccination 
techniques being used by fieldworkers and of the quality of the vaccine(s) used in the 
intervention. For example, the potency of each batch of vaccine used should be assayed, 
together with monitoring of the maintenance of any required cold chain. Particularly 
relevant for trials where the intervention includes case management or counselling is 
monitoring the quality of these procedures through regular observation of a sample of 
provider–client interactions.
Short-term endpoints may be used for monitoring the quality of the intervention. 
At the individual level, repeated surveys of physiological measures of response to the 
intervention will provide an assessment of whether an effective intervention agent 
has been delivered. Examples would be antibody levels against a vaccine or levels of 
a micronutrient in serum. In trials including provider–client interactions, exit inter-
views with clients can be used to monitor their understanding of the advice that was 
provided. Such evaluations may have to be done or be evaluated by an independent trial 
monitor to ensure that those who will assess the main endpoints in the trial are kept 
blind—whenever possible—to the identity of those in intervention and control groups.
9.2 Follow-up
For many intervention studies, the endpoints of interest may not emerge until a lengthy 
period after the start of the intervention. It may not be necessary to keep the entire 
trial population under active observation, and this is often not feasible (for example, 
cases might be detected, as they report to clinics, rather than by conducting periodic 
surveys of the trial population), but it is essential that the trial is designed in such a way 
that losses to the trial population (for example, cases who do not go to clinics) will not 
distort the conclusions. The follow-up rate should be monitored, in order to identify 
potential problems at an early stage (for example, disgruntlement in a particular village 
or to identify a fieldworker whose work quality is declining). If possible, the reasons 
that individuals are lost to follow-up should be ascertained. Some losses may be inevi-
table, such as participants who die or who move out of the trial area, while it may be 
possible to take remedial action to prevent others such as participants who withdraw 
their participation or who are temporarily absent but could be found by repeated visits 
to their homes. The baseline characteristics of those who are lost to follow-up should 
be compared with those of participants who remain in the trial, and this information 
should be analysed to assess any effect that the losses might have on the interpretation 
of the results of the trial.
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9.3 Assessment of trial outcomes
Mechanisms have to be established to ensure that the quality of information on all the 
trial outcomes is acceptable. Ongoing monitoring is required to establish that the data 
on trial outcomes are maintaining acceptable quality and that no biases are present in 
the way outcomes are recorded in different treatment arms. Attention needs to be paid 
to inter-observer variation in the assessment of the outcomes and changes that may 
occur in this variation, as the trial progresses.
9.4 Other field and laboratory procedures
QC should pervade all field activities, and the question as to how high quality is to be 
achieved and maintained should be addressed specifically for all activities. This is dis-
cussed in most of the chapters that follow, and specifically in Chapter 16, Section 7.
Laboratory procedures should be subject to constant scrutiny, and ‘blind’-coded du-
plicate samples or known positives or negatives should be introduced into the work-
load regularly to monitor performance.
In interview surveys, a proportion of respondents should be re-interviewed by a sec-
ond interviewer, blind to the results of the first interviewer, to check on the repeatability 
of the responses. If the questionnaire is long, the re-interviews might focus on a subset 
of key questions, rather than repeating the full questionnaire, in order to avoid undue 
demands on participants.
It is important that all involved in the trial accept and understand the need for constant 
checking and re-checking. This is both so that any sanctions that are taken for repeated 
poor performance do not come ‘out of the blue’, but, more importantly, as a way of en-
couraging all trial staff to maintain high quality at all times, because they know that errors 
will be spotted reasonably quickly. On the other hand, errors are bound to occur, and 
their detection should usually result in support and, where necessary, additional training, 
with reprimands being reserved for where there is evidence of dishonesty or continual 
carelessness. Incentives or rewards to encourage high-quality work may be worthwhile.
All members of the field team are, and must be made to feel, important contributors 
to the research project. Feedback of results and progress should be continuous and fre-
quent, so that they can appreciate where their contribution fits into the overall project. 
Neglect is a great stimulus to poor-quality work.
10 Analysis, monitoring, and reporting
10.1 Planning the main analyses
The main analyses that are expected to result from the trial should be developed in 
some detail, with the use of dummy tables. Such an exercise is a great help when plan-
ning the trial, as it helps clarify exactly what data are actually needed and highlights 
redundant data. All specific objectives should be tied to planned analyses.
10.2 Analyses during the trial
Analysing relevant data from a trial, as they accumulate during the trial, is an important 
way of monitoring the satisfactory progress of a trial. Administrative analyses of the 
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numbers of participants recruited each day or week and of the data collected by differ-
ent fieldworkers are important for QC. A running tally should be kept of the numbers 
of participants experiencing the various trial endpoints to verify that the estimates of 
incidence rates used to plan the size of the trial were appropriate. Ideally, the investi-
gators will be blind with respect to which interventions have been allocated to which 
participants, but differences between the different interventions might be analysed by a 
data and safety monitoring committee (as discussed in Section 10.3). Other aspects of 
interim analyses are discussed in Chapter 5, Section 7.1 and Chapter 7, Section 4.1.3.
Increased reliance on the use of smart phones or personal data assistants (PDAs) to 
record data when interviewing participants facilitates real-time data quality checks and 
analyses. Considerable ahead-of-time preparation and planning, however, are neces-
sary, in order to programme devices to be able to produce such analyses regularly.
Interim reports, based on such ongoing analyses, may be required during the course 
of a trial by national authorities and by the trial’s funding agency, in order to check that 
the original proposal is being adhered to and that the assumptions underlying the trial 
design were correct.
10.3 Data and Safety Monitoring Committee
For large trials, it is advisable for the investigators to set up an independent DSMC. 
Such a committee generally has access to selected unblinded data during the course 
of a trial and, for example, will conduct analyses to monitor whether there are an un-
acceptable number of adverse events (AEs) associated with an intervention. In such 
circumstances, the committee may recommend changes to the design of the trial or, in 
more extreme cases, that the trial be stopped, either temporarily or permanently.
The DSMC might also be charged with conducting interim analyses of the trial with 
respect to the primary endpoint, so that if the efficacy of intervention is substantially 
lower or substantially higher than expected, changes to the trial design, including early 
stopping, might be recommended.
The roles and functioning of DSMCs are discussed in Chapter 7. The most important 
function is usually to hold the randomization code for the trial and to monitor the 
results of the trial, both in terms of effectiveness and safety, as they accumulate. If 
there is evidence of a substantially increased risk of adverse reactions associated with 
any of the interventions under study, the committee would have the power to advise 
the Trial Steering Committee to stop further recruitment. Similarly, if evidence ac-
cumulates that one intervention is substantially better than the others (or one is sub-
stantially worse), the committee would usually recommend that the trial be ended or 
that at least one of the trial arms is discontinued. In blinded trials, a major advantage 
of these functions being undertaken by an independent committee is that the inves-
tigators can remain blind to the randomization codes, which is an important way of 
ensuring unbiased assessment of the trial endpoints. But, even where the trial is not 
blinded, it still has the considerable advantage of ensuring that the recommendation 
of stopping or continuing a trial is as objective as possible, because stopping a trial 
early usually has considerable logistic implications and may not be popular with the 
investigators, staff (who may even need to be laid off early), or participants.
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The circumstances in which a trial will be prematurely ended should be carefully 
considered when the trial is being designed, and the DSMC should be party to such 
discussions. It will not be possible to predict all possible situations that may cause a 
decision to be taken to end a trial, but this should be done to the extent possible. In 
particular, there should be consideration as to how large a difference may be apparent 
between the interventions, with respect to their impact on specific endpoints, before 
it is decided to end the trial. In some circumstances, it may be important to go on be-
yond the point where statistical significance is reached. These issues are discussed in 
Chapter 5, and there are also ethical considerations which are discussed in Chapter 6.
The DSMC might also set up independent QC checks on trial procedures and, for ex-
ample, may arrange to review the diagnoses of all cases of the diseases of interest arising in 
the trial (which should be done, of course, ‘blind’ to knowledge of the randomization codes).
The committee usually works on a pro bono basis and does not have auxiliary staff. If 
its activities will require QC checks or diagnostic reviews, it may be necessary to budget 
for these activities when preparing the protocol.
In some trials, the DSMC may consist of one person, sometimes called the ‘clinical 
monitor’.
10.4 Analysis methods
The analysis of a large field trial will usually be a complex undertaking and will usually 
require the involvement of a professional statistician, sometimes under supervision of a 
senior statistician or epidemiologist. It is not feasible in a manual of this kind to detail all 
of the analysis methods that it might be appropriate to employ in different trials. How-
ever, in Chapter 21 an outline is given of the main methods of analysis that are likely to 
be employed. It is included as it summarizes relevant methods that are not covered as 
comprehensively in the most basic epidemiological texts or books on medical statistics.
10.5 Reporting results
Once a field trial has been completed and the results analysed, it is essential that the re-
sults and their implications are made available to the scientific community, to those who 
participated in the trial, and to those responsible for designing and implementing re-
gional and national disease control strategies. These aspects are discussed in Chapter 23.
10.6 Further studies
Many trials will provoke questions amenable to further research. One example might 
be if a trial of a hookworm vaccine shows that it provokes good specific antibody- and 
cell-mediated immune responses and reduces the incidence of infection by 80% but is 
associated with prohibitive adverse reactions, further studies may well be needed to 
explore which antigens are causing the adverse reactions and whether removing these 
will also reduce the vaccine’s effectiveness against hookworm.
Alternatively, if a trial of traffic-calming measures in one city shows that they are highly 
effective in reducing road traffic accidents, questions may well arise on how best to imple-
ment similar measures in other settings and/or to monitor the effectiveness of such inter-
ventions when implemented on a wide scale and over a long period of time. Such studies 
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are often called Phase IV studies, as they evaluate interventions in real-world settings after 
the Phase III trial has been completed. These are discussed in Chapter 22.
11 The 'SPIRIT' checklist for standard protocol items 
for clinical trials
Nearly all intervention trials will need to have a protocol developed, which serves as the 
basis for trial planning, conduct, and reporting. Before a trial starts, it is recommended or, 
in many cases, required that the protocol is deposited in a trial register (see Chapter 7, Sec-
tion 5). Until recently, there has not been specific guidance as to exactly what items should 
be included in such a protocol. However, such guidance has recently been published (Chan 
et al., 2013a; Chan et al., 2013b) as a component of the EQUATOR project (Enhancing the 
QUAlity and Transparency Of health Research) (<http://www.equator-network.org/>). 
The publications include a 33-item checklist, the so-called SPIRIT (Standard Protocol 
Items: Recommendations for Intervention Trials) 2013 checklist, which is reproduced in 
Table 4.1. This gives a useful outline of how a trial protocol might be organized, bearing 
in mind the issues we have discussed in this chapter. Readers should refer to the SPIRIT 
website (<http://www.spirit-statement.org/>) for the most recent version.
Table 4.1 The SPIRIT 2013 checklist: recommended items to address in a clinical trial 
protocol and related documents*
Section/item Item no. Description
ADMINISTRATIVE INFORMATION
Title 1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym
Trial registration 2a Trial identifier and registry name. If not yet registered, name 
of intended registry
2b All items from the World Health Organization Trial 
Registration Data Set
Protocol version 3 Date and version identifier
funding 4 Sources and types of financial, material, and other support
Roles and 
responsibilities
5a Names, affiliations, and roles of protocol contributors
5b Name and contact information for the trial sponsor
5c Role of study sponsor and funders, if any, in study design; 
collection, management, analysis, and interpretation of 
data; writing of the report; and the decision to submit the 
report for publication, including whether they will have 
ultimate authority over any of these activities
5d Composition, roles, and responsibilities of the coordinating 
centre, steering committee, endpoint adjudication 
committee, data management team, and other individuals 
or groups overseeing the trial, if applicable (see item 21a for 
data monitoring committee)
continued
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Section/item Item no. Description
INTRODUCTION
Background and 
rationale
6a Description of research question and justification for 
undertaking the trial, including summary of relevant studies 
(published and unpublished) examining benefits and harms 
for each intervention
6b Explanation for choice of comparators
Objectives 7 Specific objectives or hypotheses
Trial design 8 Description of trial design, including type of trial (for 
example, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (for example, superiority, 
equivalence, non-inferiority, exploratory)
METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES
Study setting 9 Description of study settings (for example, community clinic, 
academic hospital) and list of countries where data will be 
collected. Reference to where list of study sites can be obtained
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, 
eligibility criteria for study centres and individuals who 
will perform the interventions (for example, surgeons, 
psychotherapists)
Interventions 11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will be 
administered
11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (for example, drug 
dose change in response to harms, participant request, or 
improving/worsening disease)
11c Strategies to improve adherence to intervention protocols 
and any procedures for monitoring adherence (for example, 
drug tablet return, laboratory tests)
11d Relevant concomitant care and interventions that are 
permitted or prohibited during the trial
Outcomes 12 Primary, secondary, and other outcomes, including the 
specific measurement variable (for example, systolic blood 
pressure), analysis metric (for example, change from 
baseline, final value, time to event), method of aggregation 
(for example, median, proportion), and time point for each 
outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended
Participant timeline 13 Time schedule of enrolment, interventions (including 
any run-ins and washouts), assessments, and visits 
for participants. A schematic diagram is highly 
recommended (see figure at <http://annals.org/article.
aspx?articleid=1556168>)
Table 4.1 (continued) The SPIRIT 2013 checklist: recommended items to address in a 
clinical trial protocol and related documents*
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Section/item Item no. Description
Sample size 14 Estimated number of participants needed to achieve study 
objectives and how it was determined, including clinical and 
statistical assumptions supporting any sample size calculations
Recruitment 15 Strategies for achieving adequate participant enrolment to 
reach target sample size
METHODS: ASSIGNMENT OF INTERVENTIONS (FOR CONTROLLED TRIALS)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (for 
example, computer-generated random numbers) and list 
of any factors for stratification. To reduce predictability 
of a random sequence, details of any planned restriction 
(for example, blocking) should be provided in a separate 
document that is unavailable to those who enrol 
participants or assign interventions
Allocation  
concealment 
mechanism
16b Mechanism of implementing the allocation sequence 
(for example, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal 
the sequence, until interventions are assigned
Implementation 16c Who will generate the allocation sequence, who will enrol 
participants, and who will assign participants to interventions
Blinding (masking) 17a Who will be blinded after assignment to interventions 
(for example, trial participants, care providers, outcome 
assessors, data analysts), and how
17b If blinded, circumstances under which unblinding is 
permissible and procedure for revealing a participant’s 
allocated intervention during the trial
METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS
Data collection 
methods
18a Plans for assessment and collection of outcome, baseline, 
and other trial data, including any related processes to 
promote data quality (for example, duplicate measurements, 
training of assessors) and a description of study instruments 
(for example, questionnaires, laboratory tests), along with 
their reliability and validity, if known. Reference to where 
data collection forms can be found, if not in the protocol
18b Plans to promote participant retention and complete 
follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from 
intervention protocols
Data management 19 Plans for data entry, coding, security, and storage, including 
any related processes to promote data quality (for example, 
double data entry; range checks for data values). Reference 
to where details of data management procedures can be 
found, if not in the protocol
Table 4.1 (continued) The SPIRIT 2013 checklist: recommended items to address in a 
clinical trial protocol and related documents*
continued
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Section/item Item no. Description
Statistical methods 20a Statistical methods for analysing primary and secondary 
outcomes. Reference to where other details of the statistical 
analysis plan can be found, if not in the protocol
20b Methods for any additional analyses (for example, subgroup 
and adjusted analyses)
20c Definition of analysis population relating to protocol non-
adherence (for example, as randomized analysis) and any 
statistical methods to handle missing data (for example, 
multiple imputation)
METHODS: MONITORING
Data monitoring 21a Composition of Data Monitoring Committee (DMC); 
summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing 
interests; and reference to where further details about its 
charter can be found, if not in the protocol. Alternatively, an 
explanation of why a DMC is not needed
21b Description of any interim analyses and stopping guidelines, 
including who will have access to these interim results and 
make the final decision to terminate the trial
Harms 22 Plans for collecting, assessing, reporting, and managing 
solicited and spontaneously reported AEs and other 
unintended effects of trial interventions or trial conduct
Auditing 23 frequency and procedures for auditing trial conduct, if 
any, and whether the process will be independent from 
investigators and the sponsor
ETHICS AND DISSEMINATION
Research ethics 
approval
24 Plans for seeking research ethics committee/institutional 
review board (REC/IRB) approval
Protocol amendments 25 Plans for communicating important protocol modifications 
(for example, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (for example, investigators, 
REC/IRBs, trial participants, trial registries, journals, 
regulators)
Consent or assent 26a Who will obtain informed consent or assent from potential trial 
participants or authorized surrogates, and how (see item 32)
26b Additional consent provisions for collection and use of 
participant data and biological specimens in ancillary 
studies, if applicable
Confidentiality 27 How personal information about potential and enrolled 
participants will be collected, shared, and maintained, in order 
to protect confidentiality before, during, and after the trial
Table 4.1 (continued) The SPIRIT 2013 checklist: recommended items to address in a 
clinical trial protocol and related documents*
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Section/item Item no. Description
Declaration of  
interests
28 financial and other competing interests for principal 
investigators for the overall trial and each study site
Access to data 29 Statement of who will have access to the final trial dataset 
and disclosure of contractual agreements that limit such 
access for investigators
Ancillary and post-trial 
care
30 Provisions, if any, for ancillary and post-trial care, and 
for compensation to those who suffer harm from trial 
participation
Dissemination policy 31a Plans for investigators and sponsor to communicate trial 
results to participants, health care professionals, the public, 
and other relevant groups (for example, via publication, 
reporting in results databases, or other data sharing 
arrangements), including any publication restrictions
31b Authorship eligibility guidelines and any intended use of 
professional writers
31c Plans, if any, for granting public access to the full protocol, 
participant level dataset, and statistical code
APPENDICES
Informed consent 
materials
32 Model consent form and other related documentation given 
to participants and authorized surrogates
Biological specimens 33 Plans for collection, laboratory evaluation, and storage of 
biological specimens for genetic or molecular analysis in 
the current trial and for future use in ancillary studies, if 
applicable
* Reproduced with permission of the SPIRIT group. It is strongly recommended that this checklist be read in 
conjunction with the SPIRIT 2013 Statement (Chan et al., 2013a), in order to fully understand the scope 
and context of the checklist. It is important to note that this is a minimum list of items, and certain trial 
protocols may warrant the inclusion of additional items. This table is distributed under the terms of the 
Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is 
available at http://creativecommons.org/licenses/by-nc/4.0/.
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1 Introduction to trial size
One of the most important factors to consider in the design of an intervention trial 
(or indeed in the design of any epidemiological study) is the choice of an appropriate 
trial size to answer the research question. Trials that are too small may fail to detect 
important effects of an intervention on the outcomes of interest or may estimate those 
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effects too imprecisely. Trials that are larger than necessary are a waste of resources and 
may even lead to a loss in accuracy, as it is often more difficult to maintain data quality 
and high coverage rates in a large trial than in a smaller one.
The choice of an appropriate trial size may be based on either the precision of out-
come measures desired or the power of the trial wanted. In Section 2, there is a discus-
sion of the criteria used to make this choice. In Sections 3 and 4, procedures are given 
for calculating trial size requirements in the simplest case where two groups of equal 
size are to be compared. More complex designs are considered in Section 5. Special 
methods are necessary when the interventions are allocated to groups (for example, 
communities, schools, or health facilities), rather than individuals, and these are de-
scribed in Section 6. Following this, in Section 7, two other factors that may influence 
the choice of trial size are discussed—first, the need to allow for interim analyses of the 
results (see Section 7.1), and second, the effects of losses to follow-up (see Section 7.2). 
In Section 8, the consequences of trials that are too small are discussed. Computer pro-
grams can be used to carry out sample size calculations, and these are briefly discussed 
in Section 9.
The procedures described in this chapter should be regarded as providing only a 
rough estimate of the required trial size, as they are often based on estimates of ex-
pected disease rates, subjective decisions about the size of effects that it would be im-
portant to detect, and the use of approximate formulae. However, a rough estimate of 
the necessary size of a trial is generally all that is needed for planning purposes. More 
comprehensive reviews of methods for the determination of trial size requirements 
are available (Chow et al., 2008; Machin, 2009), but the methods given in this chapter 
should be adequate for most purposes.
Readers who are not familiar with methods for the statistical analysis of trial data 
and, in particular, with the concepts of confidence intervals (CIs) and significance tests 
may find it helpful to read Chapter 21, Section 2, before embarking on this chapter, 
which is placed here because of the importance of considering trial size requirements 
at the design stage of a trial.
A principal objective of most intervention trials is to estimate the effect of the inter-
vention on the outcome or outcomes of interest. Any such estimate is subject to error, 
and this error has two main components: bias and sampling error. Possible sources of 
bias and ways of avoiding them are discussed in Chapters 4, 11, and 21. The second 
component sampling error arises because the trial data come from only a sample of the 
population. This second component of error is the focus of this chapter. Sampling error 
is reduced when the trial size is increased, whereas bias generally is not.
2 Criteria for determining trial size
2.1 Precision of effect measures
To select the appropriate sample size, it is necessary to decide how much sampling error 
in the estimate of the effect of the intervention is acceptable and to select the sample size 
to achieve this precision. When the data are analysed, the amount of sampling error is 
represented by the width of the confidence interval around the estimate of effect. The 
narrower the CI, the greater the precision of the estimate, and the smaller the probable 
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amount of sampling error. When designing a trial, it is necessary therefore to decide 
the width of an acceptable CI around the chosen intervention effect. Having made this 
decision, the method to select the required trial size is given in Section 3.
2.2 Power of the trial
An alternative approach is to choose a trial size which gives adequate power to detect 
an effect of a given magnitude. The focus is then on the result of the significance test 
which will be conducted at the end of the trial. The significance test assesses the evi-
dence against the null hypothesis, which states that there is no true difference between 
the interventions under comparison. A statistically significant result indicates that the 
data conflict with the null hypothesis and that there are grounds for rejecting the hy-
pothesis that there is no difference in the effects of the interventions under study on the 
outcomes of interest.
Because of the variations resulting from sampling error, it is never possible to be cer-
tain of obtaining a significant result at the end of a trial, even if there is a real difference. 
It is necessary to consider the probability of obtaining a statistically significant result in 
a trial, and this probability is called the power of the trial. Thus, a power of 80% to detect 
a difference of a specified size means that, if the trial were to be conducted repeatedly, a 
statistically significant result would be obtained four times out of five (80%) if the true 
difference was really of the specified size. The power of a trial depends on the factors 
shown in Box 5.1.
The power also depends on whether a one-sided or two-sided significance test is to 
be performed (see Chapter 21, Section 2.3) and on the underlying variability of the 
data. How the power may be calculated for given values of these parameters is ex-
plained in Section 4.
When designing a trial, the objective is to ensure that the trial size is large enough to 
give high power if the true effect of the intervention is large enough to be of public health 
importance.
2.3 Choice of criterion
The choice of which criterion (precision or power) should be used in any particular 
trial depends on the objectives of the trial. If it is known unambiguously that the in-
tervention has some effect (relative to the comparison (control) group), it makes little 
1 The value of the true difference between the study groups, in other words, the 
true effect of the intervention. The greater the effect, the higher the power to 
detect the effect as statistically significant for a trial of a given size.
2 The trial size. The larger the trial size, the higher the power.
3 The probability level (p-value) at which a difference will be regarded as 
‘statistically significant’.
Box 5.1 The power of the trial depends on:
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sense to test the null hypothesis; rather the objective may be to estimate the magnitude 
of the effect and to do this with some acceptable specified precision.
In trials of new interventions, it is often not known whether there will be any impact 
at all of the intervention on the outcomes of interest, and what is required is ‘proof 
of concept’. In these circumstances, it may be sufficient to ensure that there will be a 
good chance of obtaining a significant result if there is indeed an effect of some speci-
fied magnitude. It should be emphasized, however, that, if this course is adopted, the 
estimates obtained may be very imprecise. To illustrate this, suppose it is planned to 
compare two groups with respect to the mean of some variable, and suppose the true 
difference between the group means is D. If the trial size is chosen to give 90% power 
(of obtaining a significant difference with p < 0.05  on a two-sided test) if the differ-
ence is D, the 95% CI on D is expected to extend roughly from 0.4 D to 1.6 D. This is a 
wide range and implies that the estimate of the effect of intervention will be imprecise. 
In many situations, it may be more appropriate to choose the sample size by setting the 
width of the CI, rather than to rely on power calculations.
2.4 Trials with multiple outcomes
The discussion in Sections 2.1 to 2.3 concerns factors influencing the choice of trial 
size, with respect to a particular outcome measure. In most trials, several different 
outcomes are measured. For example, in a trial of the impact of insecticide-treated 
mosquito-nets on childhood malaria, there may be interest in the effects of the inter-
vention on deaths, deaths attributable to malaria, episodes of clinical malaria, spleen 
sizes at the end of the malaria season, PCVs at the end of the malaria season, and pos-
sibly other measures.
Chapter 12, Section 2 highlights the importance of defining in advance the primary 
outcome and a limited number of secondary outcomes of a trial. In order to decide on 
the trial size, the investigator should first focus attention on the primary outcome, as 
results for this outcome will be given the most weight when reporting the trial findings, 
and it is essential that the trial is able to provide adequate results for this outcome. The 
methods of this chapter can then be used to calculate the required trial size for the pri-
mary outcome and each of the secondary outcomes.
Ideally, the outcome that results in the largest trial size would be used to determine 
the size, as then, for other outcomes, it would be known that better than the required 
precision or power would be achieved. It is often found, however, that one or more 
of the outcomes would require a trial too large for the resources that are likely to be 
available. For example, detecting changes in mortality, or cause-specific mortality, 
often requires very large trials. In these circumstances, it may be decided to design 
the trial to be able to detect an impact on morbidity and accept that it is unlikely to 
be able to generate conclusive findings about the effect on mortality. It is important 
to point out, however, that, if a trial shows that an intervention has an impact on 
morbidity, it may be regarded as unethical to undertake a further, larger trial to as-
sess the impact on mortality. For this reason, it is generally advisable to ensure that 
trials are conducted at an early stage in which the outcome of greatest public health 
importance is the endpoint around which the trial is planned. This issue is discussed 
further in Chapter 6.
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Sometimes, different trial sizes may be used for different outcomes. For example, it 
might be possible to design a trial in such a way that a large sample of participants are 
monitored for mortality, say by annual surveys, and only a proportion of participants 
are monitored for morbidity, say by weekly visits.
If it is not feasible to design the trial to achieve adequate power or precision for the 
primary outcome, the trial should either be abandoned or a different primary outcome 
should be adopted.
2.5 Practical constraints
In practice, statistical considerations are not the only factors that need to be taken into 
account in planning the size of an investigation. Resources, in terms of staff, vehicles, 
laboratory capacity, time, or money, may limit the potential size of a trial, and it is often 
necessary to compromise between the results of the trial size computations and what 
can be managed with the available resources. Trying to do a trial that is beyond the ca-
pacity of the available resources is likely to be unfruitful, as data quality is likely to suffer 
and the results may be subject to serious bias, or the trial may even collapse completely, 
wasting the effort and money that have already been expended. If calculations indicate 
that a trial of manageable size will yield power and/or precision that is unacceptably 
low, it is probably better not to conduct the trial at all.
A useful approach to examine the trade-off between trial size (and thus cost) and 
power is to construct power curves for one or two of the key outcome variables. Power 
curves show how power varies with trial size for different values of the effect measure. 
Figure 5.1 shows power curves for malaria deaths in the mosquito-net trial discussed 
in Section 2.4, assuming that equal numbers of children are to be allocated to the inter-
vention and control groups and statistical significance is to be based on a two-sided test 
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Figure 5.1 Power curves for a trial of the effect of mosquito-nets on malaria deaths.
Malaria death rate in the control group assumed to be 10/1000/year. R, relative rate in the interven-
tion group. Assumes equal-sized groups, two-sided test, and significance p < 0.05.
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at the 5% level. R represents the rate ratio of malaria deaths in the intervention group, 
compared to the control group, so that R 0.3=  represents a reduction in the death rate 
of 70%. The assumptions used to construct these curves are described in Section 4. The 
curves indicate that, if 1000 children were followed for 1 year in each group (making 
2000 children in all), there would be about a one in two chance of obtaining a signifi-
cant result (power = 50%), even if the reduction in the death rate was as high as 70%. 
A trial five times as large as this would have a good chance (about 80%) of detecting 
a reduction in the death rate of 50% or more but would be inadequate (about 40%) to 
detect a 30% reduction in the death rate.
3 Size to give adequate precision
This section describes how the trial size is determined if the aim is to obtain an esti-
mate of the outcome of an intervention with a specified level of precision. The simplest 
case to consider is where just two groups of about the same size are to be compared 
(for example, the outcome of an intervention compared with that of a control group, 
or the comparison of outcomes of two interventions). More complex designs are dis-
cussed in Section 5. The methodology varies according to the type of outcome meas-
ure; the comparison of proportions, incidence rates, and means are considered in 
Sections 3.1 to 3.3.
3.1 Comparison of proportions
In this section, outcomes are considered that are binary (yes or no) variables. This in-
cludes cumulative incidence or risk, for example, the proportion of children experienc-
ing at least one episode of clinical malaria during the follow-up period. It also includes 
examination of the prevalence of some characteristic, for example, the presence of a 
palpable spleen in a survey conducted at the end of the trial.
Suppose the true proportions in groups 1 and 2 are p1  and p2 , respectively, giving a 
risk ratio (relative risk) of =R p p/ .1 2 The approximate 95% CI for R extends from R f/  
to Rf where, in this case, the factor f is given by:
 p np p npf exp 1.96 1 / 1 /1 1 2 2{ }( ) ( ) ( ) ( )= √ − + −   
where n is the number of children in each group, and f is commonly called the error 
factor.
The required value of f is chosen, and rough estimates are made of the values of p2  
and R to enable the number required in each group n to be calculated as:
 n f R Rp1.96 / log 1 / 2e
2
2{ }( ) ( )( )= + + −  
where floge is the natural logarithm of f.
For example, in the mosquito-net trial, one of the outcomes of interest is the preva-
lence of splenomegaly (the proportion of children with enlarged spleens) at the end 
of the trial. Prior data from the trial area suggest that, in the control group, a preva-
lence of approximately 40% would be expected. Suppose the intervention is expected 
to roughly halve the prevalence, so that R 0.5,=  and an estimate of R is wanted to 
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within about ±0.15. This suggests setting f to about 1.3 (because then the upper 95% 
confidence limit on R is = × =Rf 0.5 1.3 0.65, which is 0.15 above R(= 0.5)), and thus 
{ }[ ]( ) ( )= × − =n 1.96 / log 1.3 1.5 / 0.5 0.4 2 307.e
2  so that around 300 children would 
need to be studied in each group.
3.2 Comparison of incidence rates
Suppose a comparison of two groups is required, with respect to the rate of occurrence 
of some defined event over the trial period. Suppose the true incidence rates are r1  and 
r2  in groups 1 and 2, respectively, where each rate represents the number of events per 
person-year of observation. The rate ratio R (sometimes called incorrectly the relative 
risk, instead of the relative rate) of the incidence rate in group 1, compared to the inci-
dence rate in group 2, is given by R r r/1 2=  (see Chapter 21, Section 5 for methods of 
analysis for the comparison of rates). If the total follow-up time for those in each group 
is y years (for example, y persons are each followed for 1 year, or y /2  are each followed 
for 2 years), each group is said to experience y person-years of observation. The ex-
pected numbers of events in the two groups will be e yr1 1=  and =e yr ,2 2  respectively. 
When the results are analysed, the approximate 95% CI for R is expected to extend from 
R f/ to Rf  where:
 f e eexp 1.96 1/ 1/ .1 2{ }( ) ( )= √ +   
To decide on the necessary size of the trial, make a rough estimate of the likely value 
of R, select the precision that is required by specifying a value for f, the error factor, and 
calculate:
 e f R R1.96 / log 1 / .2 e
2[ ]( ) ( )= +  
The trial size is then fixed so that the expected number of events in group 2 during 
the trial period is equal to the calculated value e .2  The expected number of events in 
group 1 will be Re .2
It should be noted that these methods are only appropriate in the situation where 
each individual can experience only one event during the trial period or where the 
number of individuals experiencing multiple events is very small. If most individu-
als experience at least one event and many experience two or more, it is preferable 
to define a quantitative outcome for each individual, representing the number of 
events experienced during the trial period, and to use the methods described in 
Section 3.3.
Example: in the mosquito-net trial, suppose the trial groups are to consist of children 
aged 0–4 years and that the death rate associated with malaria in the trial area for that 
age group is estimated to be roughly 10 per 1000 child-years. If group 1 is the inter-
vention group (treated bed-nets) and group 2 is the control group (no protection), R 
represents the ratio of the intervention and control death rates. Suppose R is expected 
to be about 0.4, corresponding to a reduction in the death rate of 60%. Suppose also 
that f is selected to be equal to 1.25, so that the 95% CI for R is expected to extend from 
0.4 /1.25 0.32( )=  to ( )× =0.4 1.25 0.50 .  In other words, it is desired to estimate the 
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protective efficacy to within about 10% of the true value (i.e. 50–70% around the esti-
mated efficacy of 60%). Then:
 e 1.96 / log 1.25 1.4 / 0.4 270.2 e
2[ ]( ) ( )= =  
To expect 270 deaths in the control group, it would be necessary to observe an 
estimated 27 000 child-years 270 / 10 /1000[ ]( )= . This could be achieved by fol-
lowing 54 000 children for 6 months, or 27 000 children for 1 year, or 13 500 for 2 
years, and so on, assuming an expected death rate of ten per 1000 child-years in 
each of these scenarios. The magnitude of the required trial size (27 000 child-
years of observation in each group) illustrates that, when rare events are being 
studied, very large samples are needed to obtain a precise estimate of the impact 
of an intervention.
3.3 Comparison of means
Quantitative outcomes may be analysed by comparing the means of the relevant vari-
able in the intervention and control groups. This could be the mean of the values re-
corded at a cross-sectional survey, for example, the mean weight of children in the 
trial at the end of the trial. Alternatively, it could be the mean of the changes recorded 
between baseline and follow-up surveys, for example, the mean change in weight (or 
weight velocity, i.e. the change in weight divided by the time between the two measure-
ments) among the children in the trial.
Suppose the true means in groups 1 and 2 are µ1  and µ .2 These would generally be 
compared in terms of the difference in the means, D .1 2= µ −µ The 95% CI for D is 
given by ± f,D  where:
 f n1.96 /1
2
2
2σ σ( )= √ +   
where σ1  and σ2  are the standard deviations of the outcome variable in the two groups.
An acceptable value of f is chosen; values of 1σ  and 2σ  are selected, and the required 
number in each group is calculated as:
 n f1.96/ .2 1
2
2
2σ σ( )( )= +  
An estimate of the standard deviation of the outcome variable is often available 
from other studies. It is usually reasonable to assume that the standard deviation 
will be roughly similar in the two trial groups. If no other estimate is available, a 
rough approximation can be obtained by taking one-quarter of the likely range of 
the variable.
Example: In the mosquito-net trial, another outcome of interest is the PCV, or haem-
atocrit, measured in blood samples taken from the children at the end of the trial. From 
previous data, the mean PCV in the control group is expected to be about 33.0, with 
a standard deviation of about 5.0 (the normal range is about 33 10± , and it has been 
assumed that the normal range covers four standard deviations (i.e. 2± ). An increase 
in mean PCV in the intervention group of between 2.0 and 3.0 is expected, and it is 
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required to estimate the difference D between the two groups to within about 0.5, so 
that f 0.5= . Assuming that the standard deviation is about 5.0 in both groups:
 n (1.96 / 0.5) (5.0 5.0 ) 768.2 2 2= + =  
4 Size to give adequate power
The alternative approach to setting trial size is based upon selecting the trial size to 
achieve a specified power. In order to do this, the following must be specified:
 1 What size of difference, D, between the two groups would be of clinical or public 
health importance? The trial size will be chosen so it would have a good chance of 
detecting this size of true difference, i.e. there would be a good chance of obtain-
ing a statistically significant result, thus concluding that there is a real difference 
between the two trial arms. D is the true difference between the two groups, not 
the estimated difference as measured in the trial. Very small differences are gener-
ally of no public health importance, and it would not be of concern if they were 
not detected in the trial. The general principle, in most cases, is to choose D to be 
the minimum difference which would be of public health relevance and therefore 
be important to detect in a trial. Note that ‘detecting’ D means that a significant 
difference is obtained, indicating that there is some difference between the two 
groups. This does not mean that the difference is estimated precisely. To ensure a 
precise estimate is obtained, the approach of Section 3 should be used.
 2 Having specified D, the investigators must decide how confident they wish to be 
of obtaining a significant result if this were the true difference between the groups. 
In other words, the power is set for this value of D. Note that, if the true difference 
between the groups is actually larger than D, the power of the trial will be larger 
than the value set. The required power is specified in the calculations by choosing 
the corresponding value of z ,2 as shown in Table 5.1. Commonly chosen values 
for the power are 80%, 90%, and 95%, the corresponding values of z2 being 0.84, 
1.28, and 1.64. It would generally be regarded as unsatisfactory to proceed with a 
trial with a power of less than 70% for the primary outcome, because that means 
that one would have a more than 30% chance of ‘missing’ a true difference of D.
 3 The significance level must also be specified for the comparison of the two groups 
under study. This is entered into the calculations in terms of the parameter z .1  The 
commonest choice for the required p-value is 0.05, corresponding to a z1 of 1.96. 
Alternative values might be 0.01 or 0.001, corresponding to z1 values of  
2.58 or 3.29, respectively. It is assumed throughout this chapter that two-sided 
significance tests are to be used (see Chapter 21, Section 2.3). A significance level 
of 0.05 is assumed in the numerical examples, unless otherwise stated.
 4 In addition, certain additional information must be specified, which varies ac-
cording to the type of measure being examined. This may be a rough estimate of 
the rates or proportions that are expected, or an estimate of the standard devia-
tion for a quantitative variable. Note that, if these quantities were known exactly, 
no trial would be needed! Only rough estimates are required.
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Having specified these values, the formulae or tables given in Sections 4.1 to 4.3 can 
be used to calculate the required trial size.
It is often useful, however, to proceed in the opposite direction, i.e. to explore 
the power that would be achieved for a range of possible trial sizes and for a range 
of possible values of the true difference D. This enables the construction of power 
curves, as illustrated in Figure 5.1. Formulae for this approach are also given in 
Sections 4.1 to 4.3.
4.1 Comparison of proportions
The trial size required in each group to detect a specified difference D p p1 2= − , with 
power specified by z2  and significance level specified by z ,1  is given by:
 ( ) ( ) ( )= + −

 −n z z p p p p2 11 2
2
1 2
2
 
where p is the average of p1  and p2 .
For 90% power and significance at p < 0.05, this simplifies to:
 ( ) ( )= −  −n p p p p21 1 .1 2
2  
Table 5.2 shows the required trial size for a range of values of p1  and p2  for 80%, 
90%, or 95% power.
To calculate the power of a trial of specified size, calculate as follows, and refer the 
value of z2 to Table 5.1.
 ( ){ } ( )( )= √ −  − −z n p p p p z/ 2 1 .2 1 2 1  
Example: assume that the spleen rate in the control group of the mosquito-net trial 
is around 40%. To have very high power (say 95%) of detecting a significant effect if the 
Table 5.1 Relationship between z2 and % power (numbers in the body of the table show 
power corresponding to each value of z )2
First decimal place of z2
z2 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
−3.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−2.0 2.3 1.8 1.4 1.1 0.8 0.6 0.5 0.3 0.3 0.2
−1.0 15.9 13.6 11.5 9.7 8.1 6.7 5.5 4.5 3.6 2.9
−0.0 50.0 46.0 42.1 38.2 34.5 30.9 27.4 24.2 21.2 18.4
+0.0 50.0 54.0 57.9 61.8 65.5 69.1 72.6 75.8 78.8 81.6
+1.0 84.1 86.4 88.5 90.3 91.9 93.3 94.5 95.5 96.4 97.1
+2.0 97.7 98.2 98.6 98.9 99.2 99.4 99.5 99.7 99.7 99.8
+3.0 99.9 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Note: for example, =−z 0.72 corresponds to a power of 24.2%.
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Table 5.2 Sample size requirements for comparison of proportions
Smaller 
prop. p1
Difference D = p – p2 1
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60
0.05 435 141 76 50 36 28 22 18 15 13 11 10
583 189 102 67 48 37 30 25 21 18 15 13
719 233 126 83 60 46 37 30 26 22 19 16
0.10 686 200 101 63 44 33 26 21 17 14 12 10
919 268 135 84 59 44 34 28 23 19 16 14
1134 330 166 104 72 54 42 34 28 24 20 17
0.15 906 251 122 74 50 37 28 22 18 15 13 10
1212 336 163 98 67 49 38 30 24 20 17 14
1497 415 201 122 83 60 46 37 30 25 21 18
0.20 1094 294 139 82 55 40 30 24 19 16 13 11
1464 394 186 110 74 53 40 31 25 21 17 15
1808 486 230 136 91 66 50 39 31 26 21 18
0.25 1250 329 153 89 59 42 31 24 19 16 13 11
1674 441 205 119 79 56 42 32 26 21 17 14
2067 544 253 147 97 69 52 40 32 26 21 18
0.30 1376 357 163 94 61 43 32 24 19 16 13 10
1842 478 219 126 82 58 43 33 26 21 17 14
2274 590 270 156 101 71 53 40 32 26 21 17
0.35 1470 376 170 97 63 44 32 24 19 15 12 10
1968 504 228 130 84 58 43 32 25 20 16 13
2430 622 282 160 103 72 53 40 31 25 20 16
0.40 1533 388 174 98 63 43 31 24 18 14 11
2052 520 233 131 84 58 42 31 24 19 15
2534 642 287 162 103 71 52 39 30 24 19
0.45 1564 392 174 97 61 42 30 22 17 13
2094 525 233 130 82 56 40 30 23 18
2586 648 287 160 101 69 50 37 28 22
0.50 1564 388 170 94 59 40 28 21 15
2094 520 228 126 79 53 38 28 21
2586 642 282 156 97 66 46 34 26
0.55 1533 376 163 89 55 37 26 18
2052 504 219 119 74 49 34 25
2534 622 270 147 91 60 42 30
continued
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
82 CHAPTER 5: TRIAL SIZE
Smaller 
prop. p1
Difference D = p – p2 1
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60
0.60 1470 357 153 82 50 33 22
1968 478 205 110 67 44 30
2430 590 253 136 83 54 37
0.65 1376 329 139 73 44 28
1842 441 186 98 59 37
2274 544 230 121 72 46
0.70 1250 294 122 63 36
1674 394 163 84 48
2067 486 201 104 60
0.75 1094 251 101 50
1464 336 135 67
1808 415 166 83
0.80 906 200 76
1212 268 102
1497 330 126
0.85 686 141
919 189
1134 233
0.90 435
583
719
Shown in the body of the table are the sample sizes required in each group to give the specified power.*
* Upper figure: power, 80%; middle figure: power, 90%; lower figure: power, 95%. Using a two-sided sig-
nificance test with p<0.05. The two groups are assumed to be of equal size.
Table 5.2 (continued) Sample size requirements for comparison of proportions
intervention reduces the spleen rate to 30% (so that p = 0.35), the number of children 
required in each group is given by:
 n 1.96 1.64 2 0.35 0.65 / 0.3 0.4 590.2 2( ) ( ) ( )= + × ×

 − =
 
If the true risk ratio is R and we wish to power the trial, such that the lower confi-
dence limit on the risk ratio will be greater than or equal to R ,L where RL is the lowest 
acceptable efficacy (say, for whether or not to implement the intervention in a public 
health system, i.e. we need to be sure that the efficacy is at least RL ), the required sam-
ple size is:
 n z z p p p p R R1 / 1 / / log / .1 2
2
1 1 2 2 e L
2
( )( ) ( ) ( ) ( ) ( )= + − + −     
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4.2 Comparison of incidence rates
For a specified difference D r r1 2= −  and values of z1 and z ,2 representing the required 
significance level and power, the required number of person-years in each group is 
given by:
 ( ) ( ) ( )= + +

 −y z z r r r r1 2
2
1 2 1 2
2
 
where r1  and r2  are the expected rates per person-year in the two groups. A rough 
estimate of the average of the two rates is therefore required, i.e. r r / 2 .1 2( )+   For 90% 
power and significance at p < 0.05, this formula simplifies to:
 ( ) ( )= +  −y r r r r10.5 .1 2 1 2
2
 
An alternative, but equivalent, formula gives the number of events required in 
group 2, the control group, in terms of the rate ratio R, for which the specified power 
is required:
 ( ) ( ) ( )= + +

 −e z z R R1 1 .2 1 2
2 2  
This formula was used to construct Table 5.3, which shows the number of events 
needed in group 2 to detect a rate ratio of R with 80%, 90%, or 95% power. The total 
number of events needed in both groups can be calculated as e R1 .2( )+  Since this can 
be computed without specifying the assumed rates in the two trial groups, this provides 
a particularly helpful approach when the rates are uncertain. Thus, in an endpoint-
driven trial, we can specify the number of events that need to be observed to reach the 
required power, after which recruitment or follow-up may be terminated.
To calculate the power for a given trial size, compute:
 z n r r r r z/2 1 2 1 2 1{ }( )( )= √ +  − −  
where r r1 2−  is the absolute value of the difference between the two rates.
Refer the resulting value of z2  to Table 5.1 to determine the power of the trial.
Example: Assume, in the mosquito-net trial, that the death rate from malaria in 
the control group is 10/1000 child-years, so that r 0.010.2 =  Eighty per cent power is 
wanted to detect a significant effect if the true rate in children with bed-nets is reduced 
by 70% to r 0.003.1=  The number of child-years of observation required in each group 
is given by:
 ( ) ( ) ( )= + +

 − =y 1.96 0.84 0.003 0.010 0.007 2080.
2 2  
The power curves shown in Figure 5.1 were constructed using the same assumption 
concerning the death rate in controls. For example, with y  =  2000 and a rate ratio of 
R 0.7=  (corresponding to a death rate of 7 per 1000 child-years in the intervention 
group), giving a power of 18% (Table 5.1):
{ }( )[ ]( )= √ + − − =−z 2000 / 0.007 0.010 0.007 0.010 1.96 0.93.2
These formulae are used to ensure that there is a high probability of rejecting the 
null hypothesis if the true effect is of the assumed size. However, this may still mean 
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that the lower confidence limit for the effect size is close to the null, and this may pro-
vide insufficient evidence to recommend widespread adoption of the intervention. A 
larger sample size will be needed to ensure that the lower confidence limit exceeds a 
given value.
Suppose the assumed value of the rate ratio is R and that we wish to power the trial 
so that there is a high probability that the CI excludes a value RL  corresponding to the 
lower limit of efficacy desired. Then the required sample size is given by the formula:
 ( ) ( ) ( )= + +  y z z r r R R1/ 1/ log / .1 2
2
1 2 e L
2  
Example: In the mosquito-net trial, we found that 2080 child-years were required in 
each trial group to reject the null hypothesis with 80% power if the true rate ratio R was 
Table 5.3 Sample size requirements for comparison of rates
Relative rate R * Expected events in group 2 to give+
80% power 90% power 95% power
0.1 10.6 14.3 17.6
0.2 14.7 19.7 24.3
0.3 20.8 27.9 34.4
0.4 30.5 40.8 50.4
0.5 47.0 63.0 77.8
0.6 78.4 105.0 129.6
0.7 148.1 198.3 244.8
0.8 352.8 472.4 583.2
0.9 1489.6 1994.5 2462.4
1.1 1646.4 2204.5 2721.6
1.2 431.2 577.4 712.8
1.4 117.6 157.5 194.4
1.6 56.6 75.8 93.6
1.8 34.3 45.9 56.7
2.0 23.5 31.5 38.9
2.5 12.2 16.3 20.2
3.0 7.8 10.5 13.0
5.0 2.9 3.9 4.9
10.0 1.1 1.4 1.8
Numbers in the body of the table are expected number of events required in group 2 to give specified power 
if relative rate in group 1 is R.
* R, ratio of incidence rate in group 1 to incidence rate in group 2.
+ Using a two-sided significance test with P < 0.05. The two groups are assumed to be of equal size.
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0.3, corresponding to an efficacy of 70%. Now suppose we wish to ensure that there is 
an 80% chance that the lower 95% CI for the efficacy exceeds 30%, corresponding to 
R 0.7.L =  Applying the formula, we obtain the following, demonstrating the substan-
tial increase in sample size that this would necessitate:
 [ ]( ) ( ) ( )= + + =y 1.96 0.84 1/ 0.010 1/ 0.003 log 0.3 / 0.7 4732.2 e
2
4.3 Comparison of means
The trial size required in each group to detect a specified difference =µ −µD ,1 2 with 
power specified by z2  and the significance level specified by z ,1 is given by:
 σ σ ( )= + +  µ −µn z z( ) ( )1 2
2
1
2
2
2
1 2
2
 
where 1σ  and 2σ  are the standard deviations of the outcome variable in groups 1 and 
2, respectively.
For 90% power and significance at p < 0.05,  this simplifies to:
 σ σ( ) ( )= + µ −µn 10.5 .12 22 1 2
2  
To calculate the power of a trial of specified size, calculate the following, and refer the 
value of z2  to Table 5.1:
 σ σ{ }( ) ( )= √ +  µ −µ −z n z/ .2 12 22 1 2 1  
Estimates of 1σ  and 2σ  may be obtained from previous studies or from a pilot study. 
If appropriate values cannot be determined, an alternative is to dichotomize the con-
tinuous outcome variable and use the sample size formulae for comparison of propor-
tions given in Section 4.1. This will give a conservative estimate of sample size, as it 
ignores some of the information, but will ensure an adequate sample size in the face of 
uncertainty regarding the standard deviations.
Example: In the mosquito-net trial, the mean PCV in the control group at the end 
of the trial is expected to be 33.0, with a standard deviation of 5.0. To have 90% power 
of detecting a significant effect if the intervention increases the mean PCV by 1.5, the 
number of children required in each group is given by:
 ( )( ) ( )= + +  =n 1.96 1.28 5.0 5.0 1.5 233.
2 2 2 2  
Suppose it turns out that only 150 children are available for study in each group. The 
power in these circumstances is given by the following, corresponding to a power of 
about 74%:
 { }( ) ( )= √ +  − =z 150 / 5.0 5.0 1.5 1.96 0.64.2 2 2  
A summary of the various formulae that have been given for calculating the trial size 
requirements for the comparison of two groups of equal size is given in Table 5.4.
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Table 5.4 Summary of formulae for calculating trial size requirements for comparison of 
two groups of equal size
Type of 
outcome
Formula Notation Section 
in text
A: Choosing trial size to achieve adequate precision
Proportions:
n f R Rp= 1.96 / log 1 / 2e
2
2{ }( ) ( ) ( )+  −
n = number in each group
R = prop. in group 1/prop.  
 in group 2
Gives 95% CI from R/f to Rf
3.1
Rates:
e f R R= 1.96 / log 1 /2 e
2( ) ( )+ 
e2 = expected events in  
 group 2
R = rate in group 1/rate in  
 group 2
Gives 95% CI from R/f to Rf
3.2
Means:
n f= 1.96/
2
1
2
2
2σ σ( )( ) + n = number in each group
= SDiσ  in group i
D = mean in group 1 − mean  
in group 2
Gives 95% CI of ±D f
3.3
B: Choosing trial size to achieve adequate power
Proportions:
n z z p p p p= 2 1 /1 2
2
1 2
2( ) ( ) ( )+ −

 −
n = number in each group
pi = proportion. in group i
p = average of p1  and 2p
4.1
Rates:
y z z r r r r= /1 2
2
1 2 1 2
2( ) ( ) ( )+ +

 −
y = person-years in each  
 group
ri = rate in group i
4.2
Means:
n z z= /1 2
2
1
2
2
2
1 2
2σ σ( )( ) ( )+ +

 µ −µ
n = number in each group
= SDiσ in group i
=iµ mean in group i
4.3
1.961z =  for significance at p < 0.05 .  
Power 80%, 90%, 95%
=z 0.84, 1.28, 1.64.2
5 More complex designs
5.1 Two groups of unequal size
Sections 3 and 4 considered the simplest situation where the two groups to be com-
pared are of equal size. Sometimes, there may be reasons for wishing to allocate more 
individuals to one group than to the other. For example, if an experimental drug is 
very expensive, it may be desired to minimize the number of patients allocated to the 
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Table 5.5 Trial size necessary to achieve approximately the same power in a trial with two 
groups, one of which contains k times as many individuals as the other
k n1 n2 n n+1 2
1 n n 2n
2 0.75n 1.5n 2.25n
3 0.67n 2.0n 2.67n
4 0.62n 2.5n 3.12n
5 0.60n 3.0n 3.60n
10 0.55n 5.5n 6.05n
100 0.50n 50.0n 50.50n
drug, and so the trial may be arranged so that there are two or three patients given the 
old drug for every patient given the new drug. In order to maintain the same power as 
in the equal allocation scheme, a larger total trial size will be needed, but the number 
given the new drug will be smaller. Conversely, in a trial of a new vaccine, it may be 
decided to allocate twice as many participants to the vaccinated group as are included 
in the placebo group, in order to increase the size of the safety database for the new vac-
cine, before it goes into public health programmes.
Let the size of the smaller of the two groups be n ,1 and suppose the ratio of the two 
sample sizes to be k, so that there will be kn1 individuals in the other group >k( 1).  
Then, to achieve approximately the same power and precision as in a trial with an equal 
number n in each group, n1 should be chosen as:
 n n k k1 / 2 .1 ( ) ( )= +  
Examples are shown in Table 5.5 for various values of k. Notice that the number al-
located to the smaller group can never be reduced below half the number required with 
equal groups. Little is gained by increasing k beyond 3 or 4, since, beyond this point, 
even a substantial increase in n2 achieves only a small reduction in n .1
5.2 Comparison of more than two groups
Field trials comparing two groups (for example, intervention and control, or treatment 
A and treatment B) are by far the commonest. However, in some trials, three or more 
groups may be compared. For example, in a trial of a new vaccine, there may be four 
trial groups receiving different doses of the vaccine. It is unusual for field trials to have 
more than four groups, because of logistical constraints or trial size limitations.
It is suggested that, in designing a trial with three or more groups, the investigator 
should decide which pair-wise comparisons between groups are of central interest. The 
methods of Sections 3 and 4 can then be used to decide on the trial size required in 
each group. Where there is one control group for comparison with several intervention 
groups, it is likely that the main pair-wise comparisons will be between each interven-
tion group and the control group. Note, however, that direct comparisons between the 
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intervention groups may then be inadequately powered, since, if each of the interven-
tions has some effect, differences between the intervention groups may be smaller than 
when each is compared with the control group.
5.3 Factorial designs
As discussed in Chapter 4, Section 3.2, some trials are designed to look simultaneously 
at the effects of two interventions, using a factorial design. In a 2 2× factorial trial of 
two interventions A and B, for example, participants are randomly allocated between 
four trial groups receiving A only, B only, both A and B, or a control group receiving 
neither intervention. If the effects of A and B can be assumed independent, so that the 
effect of A is the same in the presence or absence of B and vice versa, then this trial 
design allows us to measure the effects of the two interventions for roughly the price of 
a single two-group trial measuring the effect of one intervention.
Under these conditions of independence, the main change to the calculation of sam-
ple size for a 2 2×  factorial trial is that the expected outcome in the intervention and 
control groups for intervention A has to be adjusted for the expected effect of interven-
tion B. This is explained with an example.
For example, suppose we are interested in the effects of iron supplements (interven-
tion A) and anti-malarial prophylaxis (intervention B) on anaemia during pregnancy. 
Suppose that the prevalence of anaemia in the control group that receives neither A 
nor B is expected to be 30%, that each intervention is expected to reduce the preva-
lence proportionally by 20%, and that these effects are independent. Then the ex-
pected prevalences in the four arms of the trial will be: control—30%; A only—24%; 
B only—24%; A B+ —19.2%. In this factorial trial, the effect of intervention A will be 
estimated by comparing the prevalence between groups A B+  and B only, and be-
tween group A only and the control group. The overall prevalence in the two groups 
given intervention A will be [ ]( )= +21.6% 24 19.2 / 2 , and in the two groups not given 
A 27% 30 24 / 2 .[ ]( )= +  Since the difference in prevalences is slightly smaller than in a 
simple two-group trial, the total sample size will be somewhat larger for the factorial 
design.
In some factorial trials, we may wish to look explicitly at whether the effects of the 
two interventions are independent. This requires a test for interaction or effect modifica-
tion, since we are interested in whether the effect of A, for example, differs according to 
the presence or absence of B. Testing for interaction generally requires a much larger 
sample size than a simple comparison of two groups. As a rough guideline, the total 
sample size for a 2 2×  factorial trial would need to be multiplied by at least four to 
detect a substantial interaction (of similar size to the main effects of the interventions) 
between the effects of two interventions.
5.4 Equivalence and non-inferiority trials
In most field trials, the objective is to determine whether a new intervention is superior 
to a control intervention, for example, an existing intervention. In some cases, how-
ever, we may wish to demonstrate that a new intervention is equivalent, or at least not 
inferior, to an existing intervention. For example, suppose the current treatment for 
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some condition is known to be highly effective, but it is also expensive and has some 
unpleasant side effects. Now suppose that a new treatment has been developed which 
is less costly and has fewer side effects. This would probably be considered for imple-
mentation, as long as it is as effective as the old treatment. In this case, we may decide 
to conduct an equivalence trial aimed at determining whether the two treatments have 
similar efficacy.
For a full discussion of such trials, the reader is referred to Blackwelder (1982) or 
Wang and Bakhai (2006). However, a simple example is given to illustrate the required 
sample size calculations.
Example: Suppose that the current treatment for TB has a cure rate of around 90% 
but requires a prolonged course of treatment. A new shorter-course regimen has been 
developed which would have advantages, in terms of cost, convenience, and adherence. 
We wish to carry out a trial to determine whether the cure rate for the short-course 
regimen is equivalent to that of the current regimen. We would usually do this by de-
fining a lower limit for the cure rate, below which we would no longer consider the 
treatments to be ‘equivalent’. If we set this at 85%, the trial would need to be powered to 
demonstrate that the difference in cure rates is no more than 5%. The null hypothesis 
is now that the new treatment is inferior to the old treatment, and we power the trial 
to reject this null hypothesis and declare equivalence of the two treatments if the new 
treatment has a cure rate that is not inferior to the standard treatment by more than the 
specified 5%.
Modifying the first equation in Section 4.1 appropriately, we need n patients in each 
group, where:
 n z z p p D2 1 / .1 2
2 2( ) ( )= + −


 
In this equation, p is the expected cure rate of 90% in both groups, assuming equiva-
lence, and D is the acceptable margin of inferiority, which is 5% in this example. Thus, 
for 90% power and a two-sided significance test with p = 0.05, we have:
 n 1.96 1.28 2 0.90 0.10 / 0.05 756.2 2( )= + × × ×

 =  
In general, large sample sizes are needed to test equivalence.
6 Interventions allocated to groups
The methods described in Sections 3 to 5 all assume that individuals are to be the units 
of allocation. In other words, the trial groups will be constructed effectively by making 
a complete list of the individuals available for the trial and randomly selecting which 
individuals are to be allocated to each trial group. As explained in Chapter 4, Section 4, 
however, many field trials are not organized in this way. Instead, groups of individuals 
are allocated to the interventions under study. These groups are often called clusters 
and may correspond to communities, for example, villages, hamlets, or defined sectors 
of an urban area; institutions such as schools or workplaces; or patients attending a 
particular health facility.
Trials in which communities or other types of cluster are randomly allocated to 
the different arms of the trial are known as cluster randomized trials, and sample size 
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calculations for such trials are presented in Section 6.1. Stepped wedge trials are a modi-
fied form of cluster randomized trial and are discussed in Section 6.2.
6.1 Cluster randomized trials
If clusters are randomly allocated to the different trial arms, the cluster should also be 
used as the unit of analysis, even though assessments of outcome are made on individu-
als within clusters (see Chapter 21, Section 8). For example, suppose the mosquito-net 
trial is to be conducted as follows. A number of villages (say 20) are to be randomly 
divided into two equal-sized groups. In the ten villages in the first group, the entire 
population of each village will be given mosquito-nets, while the second group of ten 
villages will serve as controls. The analysis of the impact of mosquito-nets on the in-
cidence of clinical malaria would be made by calculating the (age-adjusted) incidence 
rate in each village and comparing the ten rates for the intervention villages with the 
ten rates for the control villages. This would be achieved by treating the (age-adjusted) 
rate as the quantitative outcome measured for each village and comparing these, using 
the unpaired t-test or the non-parametric rank sum test (see Chapter 21, Section 8). If 
analysing proportions, rather than incidence rates, the principle is the same—the (age-
adjusted) proportion would be treated as the quantitative outcome for each cluster.
When allocation is by cluster, the trial size formulae have to be adjusted to allow for 
intrinsic variation between communities. Suppose first that incidence rates in the two 
groups are to be compared. The required number of clusters c is given by:
 c z z r r y k r r r r1 ( ) ( )/ ( ) / ( ) .1 2
2
1 2
2
1
2
2
2
1 2
2= + + + + +

 −  
In this formula, y is the person-years of observation in each cluster, while r1  and r2  
are the average rates in the intervention and control clusters, respectively. The intrinsic 
variation between clusters is measured by k, the coefficient of variation of the (true) 
incidence rates among the clusters in each group, and is defined as the standard devia-
tion of the rates divided by the average rate. The value of k is assumed similar in the 
intervention and control groups, so that the relative variability remains the same fol-
lowing intervention.
If proportions are to be compared, the required number of clusters is given by:
 c z z p p n k p p p p1 ( ) 2 (1 )/ ( ) / ( ) .1 2
2 2
1
2
2
2
1 2
2= + + − + +

 −  
In this formula, n is the trial size in each community; p1  and p2  are the average 
proportions in the intervention and control groups, respectively; p is the average of p1  
and p ,2 and k is the coefficient of variation of the (true) proportions among the clusters 
in each group.
An estimate of k will sometimes be available from previous data on the same clusters 
or from a pilot study. If no data are available, it may be necessary to make an arbitrary, 
but plausible, assumption about the value of k. For example, =k 0.25  implies that the 
true rates in each group vary roughly between ±r kr2i i , i.e. between 0.5r and 1.5r. In 
general, k is unlikely to exceed 0.5.
Example: Suppose the mosquito-net trial is to be conducted by allocating the inter-
vention at the village level. The incidence rate of clinical malaria among children before 
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Figure 5.2 Number of communities required in each group in a trial of the effect of 
mosquito-nets against clinical malaria.
intervention is 10 per 1000 child-weeks of observation, and the trial is to be designed 
to give 90% power if the intervention reduces the incidence rate by 50%. There are 
about 50 eligible children per village, and it is intended to continue follow-up for 1 year, 
so that y is approximately 2500 child-weeks. No information is available on between-
village variation in incidence rates. Taking , the number of villages required per group 
is given by the following, so that roughly seven villages would be needed in each group:
( )( ) ( ) ( )= + + + + +  − =c 1 1.96 1.28 0.01 0.005 /2500 0.25 0.01 0.005 / 0.01 0.005 6.8.
2 2 2 2 2
Note that this would give a total of 17 500 child-weeks of observation in each group, 
compared with 6300 child-weeks if individual children were randomized to receive 
mosquito-nets. Figure 5.2 shows the number of villages required in each group, de-
pending on the child-weeks of observation per village and the value of k.
The effect of group allocation on the total trial size needed will depend on the degree 
to which individuals within a cluster are more likely to be similar to each other than 
individuals in a different cluster for the outcome measure in the trial. If there is no het-
erogeneity between clusters in the outcome of interest, in the sense that the variation 
between the cluster-specific rates or means is no more than would be expected to occur 
by chance, due to sampling variations, the total trial size will be approximately the same 
as if the interventions were allocated to individuals. For most outcomes, however, there 
will be real differences between clusters, and, in these circumstances, the required trial 
size will be greater than with individual allocation. The ratio of the required trial sizes 
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with cluster and individual allocation is sometimes called the design effect. Unfortu-
nately, no single value for the design effect can be assumed, as its value depends on the 
variability of the outcome of interest between clusters and on the sizes of the clusters, 
and so it is recommended that the required sample size is estimated explicitly.
Note that, even if the calculations suggest that less than four clusters are required in 
each group, it is preferable to have at least four in each group. With so few units of ob-
servation, the use of non-parametric procedures, such as the rank sum test, is generally 
preferred for the analysis, and a sample size of at least four in each group is needed to 
have any chance of obtaining a significant result when this test is used.
It may be possible to reduce the required number of communities by adopting a 
matched design. For example, this can be done by using the baseline study to arrange 
the clusters into pairs, in which the rates of the outcome of interest are similar, and 
randomly selecting one member of each pair to receive the intervention. However, it is 
difficult to quantify the effect of this approach on the number of clusters required. To 
do this, information is required on the variability of the treatment effect between com-
munities and on the extent to which the baseline data are predictive of the rates that 
would be observed during the follow-up period in the absence of intervention, and this 
information is rarely available. With a paired design, at least six clusters are required in 
each group in order to be able to obtain a significant difference using a non-parametric 
statistical test.
Further information on sample size calculations for cluster randomized trials is 
given in Hayes and Bennett (1999) and Hayes and Moulton (2009).
According to the number of child-weeks of observation in each community 
and the extent of variation in rates of clinical malaria between communities (k is the 
coefficient of variation of the incidence rates; see text). The average incidence rate of 
clinical malaria in the absence of the intervention is assumed to be ten per 10 000 weeks 
of observation, and the trial is required to have 90% power to detect a 50% reduction in 
the incidence of malaria at the p < 0.05 level of statistical significance.
6.2 Stepped wedge trials
The stepped wedge design was introduced in Chapter 4, Section 4.3 and is a modi-
fication of the cluster randomized trial, in which all clusters commence the trial in 
the control group. The intervention is then introduced gradually into the clusters 
in random order, until, at the end of the trial, all the clusters are in the intervention 
group.
A consequence of the stepped wedge design is that, at most time points during the 
trial, there will be unequal numbers of clusters in the intervention and control groups. 
This means that, when secular trends are accounted for by comparing intervention to 
control groups at each step, a stepped wedge trial can have lower power and precision 
than a standard cluster randomized trial of the same size, in which the numbers of in-
tervention and control clusters are equal throughout. When there is zero intra-cluster 
correlation, the trial will need up to 50% more clusters. To adjust for this, the number 
of clusters has to be multiplied by a correction factor which depends on the number of 
‘steps’ in the stepped wedge design. If there are five steps, the correction factor is 1.3, 
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rising to approximately 1.4 for numbers of steps between 10 and 20. When intra-cluster 
correlation is large enough, the gain in efficiency that can be made by taking advantage 
of the pre–post information on each cluster can overtake this factor, making a stepped 
wedge trial more efficient than a parallel trial. To be conservative, however, it may be 
best to inflate the number of clusters.
Example: In the mosquito-net trial discussed earlier, the sample size calculation 
showed that we needed seven clusters in each arm or a total of 14 clusters. If we now 
propose to carry out this trial using a stepped wedge trial, a conservative correction 
would be to multiply this number by 1.4, giving 20 clusters. For example, this might 
be implemented with ten steps over a 5-year period, providing nets to two randomly 
chosen clusters each half year.
7 Other factors influencing choice of trial size
7.1 Allowance for interim analyses
It is sometimes desirable to incorporate interim analyses into the trial plan, involving 
review of the results at (say) 6-monthly or annual intervals. If an interim analysis indi-
cates that there is already strong evidence of the superiority of one of the interventions 
under study, the trial can be terminated in order that participants are no longer sub-
jected to an intervention which is known to be inferior. The incorporation of interim 
analyses may be particularly valuable if the trial is planned to continue for several years, 
with the gradual accumulation of cases of the outcome of interest, or if individuals or 
communities are entered into the trial sequentially.
There are also disadvantages in carrying out interim analyses, however. If the trial 
is terminated early, because the intervention appears to be beneficial, there may be no 
opportunity of detecting any long-term effects of the intervention, including how ef-
ficacy changes with time or long-term adverse consequences of the intervention. Also, 
although a significant effect of the intervention may be demonstrated, the precision of 
the estimate of effect may be too low to be of much value.
If, after careful consideration, it is decided that interim analyses are to be conducted, 
these need to be planned in the trial design. It is necessary to employ a more stringent 
significance level for each analysis (interim and final) to maintain the same overall level 
of significance.
Details of the implications of interim analyses are given by Geller and Pocock (1987). 
As a rough guide, the following approach is suggested. It is rarely advantageous to plan 
for more than three or four interim analyses. It is recommended therefore that, for tri-
als planned to continue for 2–4 years, the trial plan should include no more than two 
interim analyses (plus the final analysis). To compensate for this, the maximum trial 
size (i.e. the maximum person-years of observation if the trial proceeds to completion) 
should be increased by about 15%. A stringent significance level of p = 0.01 should be 
used at each interim analysis to decide whether or not the trial should be terminated. 
This means that, if the trial proceeds to completion, an unadjusted p < 0.04 would cor-
respond to an adjusted p < 0.05 if the interim analyses are taken into account, i.e little 
power has been lost in performing the interim analyses.
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7.2 Allowance for losses
Losses to follow-up occur in most longitudinal studies. Individuals may be lost, be-
cause they move away from the trial area, they die from some cause unrelated to the 
outcome of interest, they refuse to continue with the trial, they are away from home at 
the time of a follow-up survey, or for some other reason.
Losses like these are of concern for two reasons. First, they are a possible source of 
bias, as the individuals who are lost often differ in important respects from those who 
remain in the trial. Second, they reduce the size of the sample available for analysis, and 
this decreases the power or precision of the trial.
For these reasons, it is important to make every attempt to reduce the number of 
losses to a minimum. However, it is rarely possible to avoid losses completely. The ex-
tent of the problem will vary, according to circumstances, but, as a rough guide, in a 
longitudinal trial of a rural community with 2 years of follow-up, losses of around 20% 
would not be unusual.
The reduced power or precision resulting from losses may be avoided by increasing 
the initial sample size, in order to compensate for the expected number of losses. For 
example, if sample size calculations suggest that 240 subjects are required and a 20% 
loss rate is expected, the sample size should be increased to 300 (because 80% of 300 
gives 240). It is important to stress that sample size inflation only deals with the problem 
due to the reduction in the size of the sample available for analysis; it does not solve any 
potential problems due to bias. So, even if the sample size has been inflated to allow for 
losses to follow-up, it is still necessary to strive to minimize losses, in order to avoid bias.
8 The consequences of trials that are too small
The methods outlined in this chapter for selecting an adequate sample size have been 
available for many years, but it is probably not an exaggeration to state that the majority 
of intervention trials are much too small. Although there is an increasing awareness of 
the need to enrol a large enough sample, this chapter is concluded by discussing the 
consequences of choosing a sample size that is too small.
First, suppose that the intervention under study has little or no effect on the outcome 
of interest. The difference observed in a trial is likely therefore to be non-significant. 
However, the width of the CI for the effect measure (for example, the relative risk) will 
depend on the sample size. If the sample is small, the CI will be very wide, and so, even 
though it will probably include the null value (a zero difference between the groups, 
or a relative risk of 1), it will extend to include large values of the effect measure. In 
other words, the trial will have failed to establish that the intervention is unlikely to 
have an effect of public health or clinical importance. For example, in the mosquito-net 
trial, suppose only 50 children were included in each group, and suppose the observed 
spleen rates in the two groups were identical at 40%, giving an estimated relative risk of 
R 1.=  The approximate 95% CI for R would extend from 0.62 to 1.62 (see Section 3.1). 
A relative risk of 0.62 would imply a very substantial effect, i.e. a reduction in spleen 
rate from 40% to 25%, and this small trial would be unable to exclude such an effect as 
being very unlikely. If the sample size in each group were increased to 500, the 95% CI 
would extend only from 0.86 to 1.16, a much narrower interval.
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Suppose that the intervention does have an appreciable effect. A trial that is too small 
will have low power, i.e. it will have little chance of giving a statistically significant dif-
ference. In other words, there is little chance to demonstrate that the intervention has 
an effect. In the example, if the true effect of the intervention is to reduce the spleen rate 
from 40% to 25%, a sample size of 50 in each group would give a power of only 36%. 
A total of 205 children would be needed in each group to give 90% power (Table 5.2). 
Even if a significant difference is found, the CI on the effect will still be very wide, so 
there will be uncertainty at the end of the trial whether the effect of the intervention is 
small and unimportant, or very large and of major importance.
The conduct of trials that are too small has consequences extending beyond the re-
sults of the specific trial. There is considerable evidence that trials showing large effects 
are more likely to be published than those showing little or no effect. Suppose a num-
ber of small trials of a specific intervention are conducted. Because of the large sam-
pling error implied by small sample sizes, a few of these trials will produce estimates of 
the effect of the intervention that are much larger than the true effect. These trials are 
more likely to be published, and the result is that the findings in the literature are likely 
to overestimate considerably the true effects of interventions. This publication bias is 
much smaller for larger trials, because a large trial showing little or no effect is more 
likely to be published than a small trial with a similar difference.
9 Computer software for sample size calculations
Most of the formulae given in this chapter are simple enough to do by hand, with the 
aid of a simple calculator. However, computer software is also available to carry out 
some of these calculations. This can be particularly helpful when a large number of cal-
culations need to be carried out, for example, to explore sample size requirements for 
different outcomes or under different assumptions, or to produce power curves. Most 
statistical packages have some provision for sample size calculations. Here we mention 
three packages which readers may find helpful when planning field trials.
The sampsi command in Stata allows the user to obtain the required sample size for 
the comparison of means or proportions. Alternatively, if the chosen sample sizes are 
entered, the user can determine the power that these will provide. The command allows 
for different sample sizes in the two trial arms. The sample size formulae used by this 
package differ slightly from those presented in this book, but the results should be quite 
similar in most cases.
The POWER and GLMPOWER procedures in the statistical analysis program package 
SAS can handle sample size calculations for a range of situations, including survival analy-
sis, as can the PASS module (a trial version of which is available at <http://www.ncss.com>).
A variety of free sample size calculators may be found on the Internet. These include 
the program PS which is described by Dupont and Plummer (1990) and available at 
<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>); and Open Epi which 
can be downloaded from <http://www.openepi.com/Downloads/Downloads.htm>.
Table 5.6 gives a spreadsheet which facilitates the calculation of the required size 
(number of clusters) for a cluster randomized trial, using the formulae given in Section 6 
(as in Hayes and Moulton, 2009).
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Table 5.6 Spreadsheet calculation of the number of clusters required in an unmatched cluster 
randomized trial. Table 5.6 shows the calculations, for some example situations, for (a) comparison 
of proportions and (b) comparison of rates. formulae are given which allow the calculation of 
required trial size for any (unmatched) cluster randomized trial in an Excel spreadsheet
(a) Comparison of proportions
Significance  
level
Power z1 z2 z z( + )1 2
2 p1 %  
reduction
p2 Person-
years per 
cluster
k # 
clusters 
per arm
Rounded 
up
A B C D E F G H I J K L
0.95 0.80 1.96 0.84 7.85 2.0% 50% 1.0% 500 0.25 8.08 9
0.95 0.80 1.96 0.84 7.85 3.0% 50% 1.5% 500 0.25 6.51 7
0.95 0.80 1.96 0.84 7.85 4.0% 50% 2.0% 500 0.25 5.73 6
0.95 0.90 1.96 1.28 10.51 2.0% 50% 1.0% 500 0.25 10.48 11
0.95 0.90 1.96 1.28 10.51 3.0% 50% 1.5% 500 0.25 8.38 9
0.95 0.90 1.96 1.28 10.51 4.0% 50% 2.0% 500 0.25 7.33 8
0.95 0.80 1.96 0.84 7.85 2.0% 50% 1.0% 250 0.25 12.71 13
0.95 0.80 1.96 0.84 7.85 3.0% 50% 1.5% 250 0.25 9.57 10
0.95 0.80 1.96 0.84 7.85 4.0% 50% 2.0% 250 0.25 8.01 9
0.95 0.90 1.96 1.28 10.51 2.0% 50% 1.0% 250 0.25 16.68 17
0.95 0.90 1.96 1.28 10.51 3.0% 50% 1.5% 250 0.25 12.48 13
0.95 0.90 1.96 1.28 10.51 4.0% 50% 2.0% 250 0.25 10.38 11
(b) Comparison of rates
Significance 
level
Power z1 z2 z z( + )1 2
2 r1 %  
reduction
r2 Person-
years per 
cluster
k # 
clusters 
per arm
Rounded 
up
A B C D E F G H I J K L
0.95 0.8 1.96 0.84 7.85 0.050 50% 0.025 300 0.25 6.46 7
0.95 0.8 1.96 0.84 7.85 0.050 45% 0.028 300 0.25 7.99 9
0.95 0.8 1.96 0.84 7.85 0.050 40% 0.030 300 0.25 10.18 11
0.95 0.8 1.96 0.84 7.85 0.050 35% 0.033 300 0.25 13.44 14
0.95 0.8 1.96 0.84 7.85 0.050 30% 0.035 300 0.25 18.57 19
0.95 0.8 1.96 0.84 7.85 0.050 50% 0.025 300 0.20 5.58 6
0.95 0.8 1.96 0.84 7.85 0.050 45% 0.028 300 0.20 6.86 7
0.95 0.8 1.96 0.84 7.85 0.050 40% 0.030 300 0.20 8.68 9
0.95 0.8 1.96 0.84 7.85 0.050 35% 0.033 300 0.20 11.39 12
0.95 0.8 1.96 0.84 7.85 0.050 30% 0.035 300 0.20 15.65 16
Excel expressions:
C = NORMSINV(1− (0.5*(1 − A))); D = NORMSINV(B)
K = 1 + E*((f*(1 − f)/I) + (H*(1 − H)/I) + (J*J)*((f*f) + (H*H)))/((H − f)^2)
L = INT(K) + 1
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It is fairly straightforward to set up a spreadsheet, for example, in Excel, to apply any 
of the formulae given in this chapter. The freeware computer package Epi-Info has a 
useful component, called StatCalc, for calculating sample sizes for simple trials.
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1 Introduction to ethical considerations
For any research investigation involving human subjects, there must be careful con-
sideration of ethical issues that may arise in the planning, conduct, and reporting of 
the study. With very few exceptions, such research is not permitted unless the study 
has been approved by at least one formal ethics review committee (ERC). All research 
funding agencies require approval of the research by the appropriate ERC(s) before 
they will confirm an award for an intervention study. Often ethical review will be re-
quired from more than one such committee, for example, by both an institutional and 
a national ethics review committee, and/or in each of the countries involved in a trial. 
The ethics committee(s) will not only review the study protocol but usually will require 
full details of the study plan and procedures and will usually have specific application 
forms that must be completed. They may require payment of an administration fee for 
considering an application, irrespective of the outcome of the application. The commit-
tee will pay particular attention to informed consent documents and how consent to 
take part in the research will be obtained from potential study participants. Any signifi-
cant changes in the study plan, either before it starts or during the conduct of the study, 
such as adding new objectives, extending the trial catchment area, or adding/removing 
inclusion or exclusion criteria, require approval by the ERC.
It is important that the ethical aspects of a research study are considered from its 
inception; for that reason, this chapter is placed early in the book. An underlying phi-
losophy in this chapter is that it is difficult, and often inappropriate, to lay down ethical 
rules that apply to all studies in all places; each study should be judged in the con-
text of the circumstances in which it will be conducted. A study judged unethical in 
one place might be considered ethical in another, and both of these might be ‘correct’ 
judgements.
Most ethical issues arise from conflicts between competing sets of values. For ex-
ample, the medical practitioner is dedicated to the provision of the best medical care 
for an individual who is his or her patient. However, this dedication may be in direct 
conflict with that of the public health professional whose goal is to achieve maximum 
health benefits in a community with the limited resources available, which may en-
tail restricting resources available to any one patient. Consuming large amounts of 
resources on one patient may deprive others of benefit. The appropriate balance be-
tween benefit for the individual and benefit for the community depends very much 
on the particular situation. The conflict is most obvious in situations of poverty and 
deprivation—just those conditions in which most field trials are conducted in LMICs. 
Those conducting field trials of interventions against diseases associated with poverty 
are likely therefore to be faced with especially difficult ethical dilemmas. Resolution 
of such dilemmas often depends upon where the investigators place their horizon of 
responsibility. If they consider their responsibility is confined to the participants in a 
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trial, then some studies to resolve important public health issues might be viewed as 
unethical. But to assess the likely public health impact of an intervention in the wider 
community, it may be important to continue a trial beyond the point when it is estab-
lished that one intervention is superior to another, in order to obtain a better estimate 
of the magnitude of the beneficial effect. Knowledge of the extent of benefit is needed, 
in order to make an informed decision about whether the benefit is sufficient to intro-
duce the intervention on a widespread basis, especially if it is more expensive than the 
intervention that is currently available. If the investigators consider their responsibility 
is extended to the entire population, then they may regard it as unethical to stop a trial 
before a reasonable estimate of that benefit is obtained.
It is important to recognize that the primary purpose of an intervention trial is not 
to benefit the specific participants in the trial, but rather to obtain information about 
the effects of the intervention that will inform decisions about whether the intervention 
should be introduced on a widespread basis. Although trial participants may derive 
benefit, for example, they might receive better medical care in the trial than they would 
with the normal medical services, this is incidental to the main purposes of the trial.
Although intervention trials are not conducted with the prime aim of benefiting 
those in the trial, investigators have a specific responsibility for participants in a trial 
and must ensure that they are not harmed as a consequence of taking part in the trial 
and might derive some benefit. In so far as is possible, at a minimum, participants in a 
trial should be placed in no worse a situation than would have been the case had they 
not participated in the trial. It is, of course, not always possible to guarantee this, as 
sometimes there may be unexpected adverse events associated with an intervention, 
but it is important to minimize the possibility of harm to trial participants.
There is sometimes a conflict between what is best for the ‘future population’ and 
what is best for those participating in a trial. Such conflicts may pose serious ethical 
dilemmas, for which there are few ‘cookbook’ solutions. Each situation has to be con-
sidered individually and preferably during the planning of the trial, so that potential 
ethical issues can be thought through in advance and, where necessary, guidance can 
be sought from properly constituted ethics committees. This issue is discussed further 
in Section 2.
It is not the purpose of this chapter to provide comprehensive guidance on all of 
the ethical considerations that must be considered in designing and conducting a field 
trial. Substantial sets of ethical guidelines have been published by a number of inter-
national bodies, and we give reference to these in the chapter, especially in Section 2.8. 
Rather we highlight some of the basic ethical principles related to randomized trials in 
Section 2 and then focus on some of the particularly difficult, and sometimes contro-
versial, issues that arise in field trials in LMICs.
2 Widely accepted ethical principles concerning research 
on human subjects
The ethical principles related to medical research involving human subjects were 
summarized in the Declaration of Helsinki. This declaration was first formulated 
in 1964 and has subsequently been debated and revised a number of times, most 
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recently in 2008 (World Medical Association, 2008). While some parts of the decla-
ration remain hotly debated, the basic principles are generally accepted. They were 
reproduced and further elaborated with special reference to LMICs by the Coun-
cil for International Organizations of Medical Sciences (CIOMS) (Council for In-
ternational Organizations of Medical Sciences, 2009). The main principles are the 
following.
2.1 Scientific merit
To be ethical, research must have scientific merit, preferably in the judgement of an 
independent scientific committee, rather than only by the researchers themselves. This 
assessment will generally be made in the peer review process employed by funding 
agencies. The methods of the research should be appropriate to the aims of the research, 
and results from any relevant previous or ongoing research should be taken into ac-
count in its design. Over the last decade or so, there has been much greater insistence 
by research funding bodies and ethics committees, as well as research journal editors, 
that some kind of systematic review of prior research on a topic is conducted before 
further research on the topic is planned. This is to avoid unnecessary duplication of 
research where a new study needlessly addresses research questions that have been ef-
fectively answered previously. An outline of how to conduct systematic reviews is given 
in Chapter 3. Anyone proposing a trial should also review the clinical trial registers (see 
Chapter 7, Section 5), so that they are aware of trials that are already under way which 
might be addressing similar issues.
The investigator is also obliged to design and conduct the research in such a way 
that the results from the study are likely to provide answers to the questions being ad-
dressed. This includes attention to the appropriate size and duration of the study, as well 
as to other aspects of its design. For example, a study that is too small to address prop-
erly the principal research question may be deemed to be unethical. Furthermore, for 
research concerning interventions, achievement of the trial objectives must be linked, 
directly or indirectly, to some kind of action that is expected to lead to improved health 
for the population, or future population, of which the trial participants are in some way 
representative. Not all research findings will have immediate health consequences for 
the population, but the research should be on the pathway that is expected to lead ul-
timately to such benefit.
2.2 Equitable selection of subjects
The potential benefits of research and the risks and burdens associated with the re-
search should be distributed equitably among communities and among individuals 
within communities. The economically and socially deprived are often at the highest 
risk of disease. There is, on the one hand, an imperative to ensure that the appropriate 
research is conducted in such groups and, on the other hand, an imperative to ensure 
that they are not exploited in research that will mainly benefit the more wealthy and 
privileged. For example, it would generally be deemed unacceptable to conduct a trial 
of an expensive treatment in a deprived group, unless it was expected that the cost of 
the treatment was likely to be reduced in the immediate future to a level that could be 
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afforded by the community or that, even if there was no reduction in cost, the treat-
ment would at least be made accessible to those in the community in which the trial 
was conducted, should it be found to be efficacious. Such treatment should not be re-
stricted solely to those who had participated in the trial but should also be provided to 
those in similar circumstances in the community. Whether the ‘community’ is the local 
population in the trial area or a much larger, possibly national, group will often be an 
important aspect to consider before a trial is started.
2.3 Voluntariness
Voluntariness implies that individuals and communities enrol, continue, or withdraw 
from the study of their own free will, with full knowledge of the consequences of their 
participation or withdrawal. They should not be forced or coerced by investigators, 
officials, family, or friends, enticed by financial or other rewards. Nor should their deci-
sions be constrained by socio-economic or political conditions. The principle of volun-
tariness is a key component of the informed consent process. Voluntariness, however, 
applies only as far as community leaders, adult individuals, or legal guardians of chil-
dren are at liberty to make free choices. In some LMICs, researchers must take extra 
efforts to understand, for example, the influence that unequal gender relations might 
have on voluntariness and design information and procedures to minimize this influ-
ence. Illiteracy is another factor that may influence voluntariness when the information 
channels for the study favour those who can read over those who cannot. Any monet-
ary compensation for participants’ time or transport fares should be of a level that does 
not interfere with their freedom of choice, i.e. it should be sufficient to cover the actual 
costs, but not be an undue inducement to participate in the study (see Section 3.3). Par-
ticular attention should be paid to thanking potential participants who want to partici-
pate in a trial but are excluded because they are found not to meet the inclusion criteria.
2.4 Informed consent
It is now an established principle that ‘informed consent’ must be obtained from all 
participants in a medical or social research investigation on human subjects. Where the 
participant is not able to give informed consent for themselves, it is usually acceptable 
to request this from their parent or legal guardian.
Each potential participant should be given a comprehensive explanation as to why 
the research is being conducted, why they are being invited to participate, what possible 
benefits, risks, and burdens may arise for them personally as a result of participating in 
the research, and what benefits are expected to accrue to them and to the community 
as a result of the research. Translating these goals into a set of procedures that will be 
used to convey this information in a specific study is often challenging. Special prob-
lems arise with respect to field trials in LMICs, commonly involving large numbers of 
subjects, in obtaining assurance that all individuals are properly informed about these 
aspects.
Often, a research funding body or ERC will require the use of a consent form that 
participants must sign in the presence of a witness. The form must give full details of 
the study, with respect to the aspects outlined in Sections 2.1 to 2.3. It is becoming 
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more widely recognized, however, that, in some societies, the insistence on obtain-
ing a witnessed signature, or thumbprint, on such a form may not guarantee that the 
consent was fully informed, especially in communities where many are not literate. 
Moreover, in some societies, the requirement to sign a consent form may actually 
cause undue fear and anxiety, as when people in the local culture would typically sign 
or mark documents only in connection with legal transactions such as transferring 
property or if they were to be arrested. The ethical review process may include an 
option to request a waiver of signed consent, provided that certain other protective 
conditions are met. With or without the collection of a signature, what is most im-
portant is the consent process, through which study personnel have a conversation 
with prospective participants to make sure that they understand all the key points 
of information, have an opportunity to ask questions, and understand that they are 
free to say ‘no’. It is always the investigator’s responsibility to ensure that subjects are 
properly informed of the potential risks and benefits of participation in a study. It is 
common practice, in some trials, to include a short ‘test’ to check that the potential 
study participant has understood the key information before they are asked to sign the 
consent form, with the opportunity to receive further explanation of points that they 
do not fully understand.
Lema et al. (2009) conducted a systematic review on consent procedures in clini-
cal trials in Africa and reported that consent often was not truly voluntary; consent 
procedures are difficult to implement, due to cultural factors and low literacy, and 
local ethical review committees may be weak or ill-equipped. These findings are rein-
forced by a study of informed consent for HIV testing in South Africa that found that, 
although all women had given informed consent for the testing, they were coerced in 
direct and indirect ways into providing consent, and many felt they did not, in fact, 
have a choice (Groves et al., 2010). It is therefore very important that investigators 
endeavour to ensure that consent is truly informed and non-coercive.
Special provisions must be made for potential participants who are not competent to 
provide informed consent such as children or patients who are comatose. Such persons 
require an advocate who is legally and morally responsible for decisions taken on their 
behalf. Even when the advocate provides consent, the subject should have the right to 
refuse, if he or she is able to, but, in practice, it may be difficult, for example, for a young 
child to exercise that right. In general, research procedures should not be conducted 
on children, unless they have already been demonstrated to be safe in adults and, if ap-
propriate, efficacious in adults also.
The information provided to potential participants to obtain consent for taking part 
in a trial would be expected to include that listed in Box 6.1.
The checklist in Box 6.1 was drawn up in the context of trials in HICs, but the same 
principles apply for trials in LMICs. In the latter, however, it may be necessary to go to 
some lengths to give the required explanations and in ways that will be comprehensible 
in the context of the local attitudes and beliefs in the communities in which the trial will 
be undertaken. Often investigators will first meet with community leaders to explain 
the trial and to seek permission to conduct the investigation. This might be followed 
by community meetings at which the trial investigators explain the trial and the pro-
cedures to be followed and then answer any questions. After that, potential participants 
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1 A statement that the study involves research, an explanation of the purposes 
of the research and the expected duration of the subject’s participation, 
a description of the procedures to be followed, and identification of any 
procedures which are experimental.
2 An explanation of why the subject has been asked to participate in the 
trial.
3 A description of any reasonably foreseeable risks or discomforts to the 
subject.
4 A description of any benefits to the subject or to others which may reasonably 
be expected from the research.
5 A disclosure of appropriate alternative procedures or courses of treatment, if 
any, that might be advantageous to the subject.
6 A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained.
7 For research involving more than minimal risk, an explanation as to whether 
any compensation and an explanation as to whether any medical treatments 
are available if injury occurs and, if so, what they consist of or where further 
information may be obtained.
8 An explanation of whom to contact for answers to pertinent questions about 
the research and research subjects’ rights and whom to contact in the event of a 
research-related injury to the subject.
9 A statement that participation is voluntary, that refusal to participate will 
involve no penalty or loss of benefits to which the subject is otherwise entitled, 
and that the subject may discontinue participation at any time without penalty 
or loss of benefits to which the subject is otherwise entitled.
Additional elements of informed consent
When appropriate, one or more of the following elements of information shall also 
be provided to each subject.
1 A statement that the particular treatment or procedure may involve risks to the 
subject (or to the embryo or fetus, if the subject is or may become pregnant) 
which are currently unforeseeable.
2 Anticipated circumstances under which the subject’s participation may be 
terminated by the investigator without regard to the subject’s consent.
3 Any additional costs to the subject that may result from participation in the 
research.
Box 6.1 Information that should be provided to 
potential participants to seek consent for taking part 
in a trial
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might be given further information, often in written form, that they can take home and 
discuss with neighbours, friends, and others advisors in the community, before they 
are asked to provide informed consent. Although key steps of the informed consent 
process should usually be done face-to-face, it is sometimes effective to get a prospect-
ive participant to watch a video or listen to an audio message that explains aspects the 
study. And sometimes photographs or diagrams can be very useful to supplement a 
verbal explanation.
2.5 Confidentiality
The confidentiality of all information collected in a research investigation must be 
maintained and only released to others with the explicit consent of all those concerned. 
The proportion of individuals who agree to participate in a study, especially one in 
which sensitive information is being collected (for example, whether or not an indi-
vidual is infected with HIV), may be increased if careful explanations are given as to 
how confidentiality will be maintained and who within the study team will have access 
to such information. In many studies, it will be appropriate to identify individuals on 
record forms by a code number only, with the list linking names to the codes being kept 
separately in a secure place, with access limited to only those who must be able to link 
trial data back to specific individuals.
2.6 Coercion
In general, there are fewer legal and institutional safeguards to protect the rights of 
individuals in LMICs than there are in most HICs. When research workers are em-
ployed by, or identified with, the state authorities or with those who provide medical 
care, there is a danger that they might be tempted to exploit this position, with greater 
or lesser degrees of subtlety, to coerce subjects to participate in a study. Coercion and 
deception, even when rationalized as being for the ‘greater good’, are unacceptable. Full 
and open explanations of all study procedures, with the explicit understanding that 
participation is voluntary and those who decline will not be penalized, may be time-
consuming, but this is the only acceptable approach.
4 A statement that significant new findings that arise during the course of the 
research which may relate to the subject’s willingness to continue participation 
will be provided to the subject.
5 The approximate number of subjects involved in the study.
Adapted from U.S. Food and Drug Administration, Code of Federal Regulations, Title 21, Section 
50.25, 2013, available from <http://www.fda.gov>. This box is not covered by the Creative Com-
mons licence terms of this publication. For permission to reuse please contact the rights holder.
Box 6.1 Information that should be provided to potential participants to seek 
consent for taking part in a trial (continued)
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2.7 Review and approval by ethics committees
Most research investigations must go through several levels of scientific and ethical 
review to assess their acceptability. The number of levels will depend on the nature of 
the research, national regulations, and from which agencies support for the research is 
being sought.
All ethical review bodies will require that each individual participant in a study is 
provided with sufficient information on potential risks and benefits to enable them to 
make an informed decision on whether or not to participate. Illiteracy and differing 
cultural concepts of health and disease do not alter the basic requirements for informed 
consent. If permission to approach and recruit individual members of the population 
has been obtained by virtue of a communal decision, individual informed consent is 
still necessary, and the research worker and the ethics committee must assure them-
selves that there is no coercion on individuals to participate. The principles that consent 
must be given by each individual, rather than assumed, and that all prospective partici-
pants have the right of refusal must be regarded as the minimal safeguards.
As well as being acceptable to individual participants, a trial may be reviewed at a 
community level through either a formal or an informal review committee. In addition, 
there may be local and national ethical and scientific review bodies to satisfy. If funding 
for a study is sought from an international agency, there may be a further level of eth-
ical review. For example, research proposals submitted to the WHO are reviewed by the 
WHO Research Ethics Review Committee (WHO ERC). The committee will only re-
view proposals that have first been approved by national and, if appropriate, local ethics 
committees. Given all these potential steps, it is very important that investigators allow 
sufficient time for research and ethics approval. Although many are much faster, it is not 
uncommon for some ethics committees to take as long as 6 months to review a proposal.
In the case of multicountry studies, it is common that the ethics committees review 
a master protocol and then subsequently individual or country-specific protocols. The 
latter are needed to describe how the master protocol was adapted to local reality and 
resources. The review of protocols for additional study sites is usually more straightfor-
ward, given that the main ethical and methodological issues of the study have already 
been reviewed. In some cases, a centralized ethics committee has been used to review 
multicentre studies, but generally ERCs are reluctant to delegate responsibility for re-
view to a committee outside of their own country.
Ethics committees should be properly constituted and operating under defined 
standard operating procedures (SOPs) (see first reference in Section 2.8). Their main 
role is to ensure that ethical principles, as established by universal guidelines, are 
applied in the research and the rights, safety, well-being, and confidentiality of par-
ticipants are protected. The committee review should focus on ethical and quality as-
surance aspects of the protocol, addressing its relevance, risks (physical, psychological, 
social, economic), and potential benefits. In some cases, the trial does not bring imme-
diate benefit to the participants, but the knowledge generated will be for the benefit of 
broader society. In local committees, the inclusion of members representing the group 
of patients or communities under study enables a better understanding of the social 
and cultural aspects involved. Ideally, the members of ethics committees comprise 
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a multidisciplinary group with experience in research and should include lay persons 
who can bring a non-medical perspective to the review. As the focus of review is on 
fairness and ethical issues, in most cases, there is no need for all members to be know-
ledgeable about the medical or scientific aspects. However, it is also helpful that a med-
ical or scientific member be available to explain in more detail the rationale or concept 
for the procedures to be carried out and products to be administered.
The protocol should include copies of case report forms, examples of questionnaires 
to be used, as well as a model of informed consent in the committee’s working language 
and in the local language, as it is going to be applied. Social sciences methodologies, 
such as focus group discussions, or in-depth interviews, also require proper descrip-
tion and a list of the topics that will be covered in the protocol.
It is common that, before approval, the ethics committee requests additional infor-
mation or description of procedures not fully detailed in the protocol, so investigators 
should endeavour to be comprehensive in their initial application. The queries or delib-
erations of the ethics committee are transmitted by the secretary to the PIs or sponsor, 
who should submit a revised version of the protocol with amendments and clarifica-
tion, following the instructions of the committee. The more complete and detailed the 
protocol is, the less time will be required for reviewing. However, very often, a resub-
mission is needed, and the investigator should allow for time for clearance.
Some ethics committees require reports during a trial to ensure compliance with 
procedures and to evaluate any protocol deviations or to follow up AEs. Serious adverse 
reactions occurring during a trial that are considered related to the intervention should 
be reported to the ethics committee, and the balance between risks and benefits should 
be continually reassessed by the investigators (or by the Data and Safety Monitoring 
Board, (DSMB) on behalf of the investigators; see Chapter 7, Section 4). Frequency 
and procedures for reports and review of trial operations and data are laid down by the 
committee on a case-by-case basis.
Ethics committees pay special attention to studies involving vulnerable individ-
uals, and the protocol should ensure that there is no undue inducement to participate. 
Vulnerable individuals, according to Good Clinical Practice (GCP) guidelines (Inter-
national Conference on Harmonisation, 1996), are individuals whose willingness to 
volunteer in a clinical trial may be unduly influenced by the expectation, whether justi-
fied or not, of benefits associated with participation or of a retaliatory response from se-
nior members of a hierarchy in case of refusal to participate. Other vulnerable subjects 
include children (commonly defined as all those below 18 years of age, but this varies 
between countries), patients with incurable diseases, persons in nursing homes, un-
employed or impoverished persons, patients in emergency situations, ethnic minority 
groups, homeless persons, nomads, refugees, prisoners, and those incapable of giving 
consent. In some countries, there are special regulations regarding research involving 
indigenous populations.
Before initiating a trial, the investigator should have written approval of the protocol, 
written informed consent documents, subject recruitment procedures, and any other 
written information to be given to participants. The investigator is responsible for com-
plying with the study protocol that was approved by the ethics committee and agreed by 
the sponsor and regulatory authority (if appropriate).
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A clinical trial legal and financial liability insurance, which is compulsory in some 
countries, provides the participants and sponsor financial protection against specific 
contingencies such as death, disability, or other health-related complications that may 
occur from the participation in a trial. In most cases, liability is product-related, and 
lawsuits against pharmaceutical companies have increased over the years, as more care-
ful pharmaco-epidemiological studies have been able to identify adverse effects of new 
products when used in a large number of people or over a long period of time. Some 
ethics committees will not review a protocol without having a copy of the clinical trial 
insurance certificate.
2.8 Useful guidance documents
Research involving human subjects is conducted in countries with widely varying 
socio-economic, health, and research ethics infrastructure. However, irrespective of 
where the research is conducted, for the ethics infrastructure to be effective, it must 
have officially recognized regulations or guidelines, a system for oversight and moni-
toring, and well-functioning research ethics committees. Many LMICs lack laws or 
regulations governing ethics in research and face the challenge of deciding which 
international guidelines to use. These guidelines are increasing in number, are not 
harmonized, and require interpretation or adaptation to local circumstances. Many 
ethics committees also face the challenge of ensuring adequate ethical review of re-
search protocols.
The following is a selection of the most important guidance documents.
2.8.1 Operational guidelines for ethics committees that review 
biomedical research
These were produced by the WHO Tropical Diseases Research Programme in 2000. 
They set out operational guidelines for ethics committees, in order to facilitate, sup-
port, and ensure quality of the ethical review of biomedical research in all countries of 
the world. Targeted for use by national and local bodies, these guidelines define the role 
and constituents of an ethics committee and detail the requirements for submitting an 
application for review. The review procedure and details of the decision-making pro-
cess are provided, together with necessary follow-up and documentation procedures. 
They can be downloaded from <http://www.who.int/tdr>.
2.8.2 International conference on harmonisation/WHO good clinical 
practice standards
This document (International conference on harmonisation, 1996) provides a unified 
standard for the European Union, Japan, the USA, Australia, Canada, the Nordic coun-
tries, and the WHO. Thus, any country that adopts this guideline technically follows 
this same standard.
2.8.3 The Declaration of Helsinki—ethical principles for medical 
research involving human subjects
The Declaration of Helsinki is a statement of ethical principles for medical research 
involving human subjects, including research on identifiable human material and data. 
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It was adopted in 1964 and has since undergone several amendments, including one 
in 2008 (available at <http://www.wma.net/en/30publications/10policies/b3/17c.pdf>.
2.8.4 International Ethical Guidelines for Epidemiological Studies
In 2009, the CIOMS published its revised guidelines (Council for International Organi-
zations of Medical Sciences, 2009). The book contains ethical guidance on how epi-
demiologists—as well as those who sponsor, review, or participate in the studies they 
conduct—should identify and respond to the ethical issues that are raised by the re-
search process. The book can be ordered from WHO through e-mail: cioms@who.int.
2.8.5 The ethics of research related to health care in developing 
countries
This book was produced in 2002 (Nuffield Council on Bioethics, 2002) and updated 
in 2005 (Nuffield Council on Bioethics, 2005). It defines the ethical standards 
for health care research in LMICs (<http://www.nuffieldbioethics.org/research- 
developing-countries>).
2.8.6 Consolidated Standards of Reporting Trials (CONSORT)
CONSORT 2010 provides a checklist of information to include when reporting a 
randomized trial. It includes a flow diagram of the process through the phases of a 
randomized trial. Diligent adherence to these guidelines facilitates clarity, comprehen-
siveness, and transparency of reporting (Schulz et al., 2010).
2.8.7 Extending the CONSORT statement to randomized trials of non-
pharmacologic treatments
The CONSORT statement has been extended to address specific issues that apply to 
trials of non-pharmacologic treatments and behavioural intervention (Boutron et al., 
2008).
2.8.8 Other useful background documents
◆	 The Belmont report: ethical principles and guidelines for the protection of human 
subjects of research (<http://www.hhs.gov/ohrp/humansubjects/guidance/ 
belmont.html>)
◆	 The common rule, title 45 (public welfare), code of federal regulations, part 46 (pro-
tection of human subjects), subparts A–D; The international ethical guidelines for 
biomedical research involving human subjects. (CIOMS) (<http://www.hhs.gov/
ohrp/humansubjects/guidance/45cfr46.html>)
◆	 Canada: Tri-council policy statement: ethical conduct for research involving humans 
(<http://www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf>)
◆	 Indian Council of Medical Research: Ethical guidelines for biomedical research on 
human participants (<http://icmr.nic.in/ethical_guidelines.pdf>)
◆	 Finally, see the very useful international compilation of human subjects protec-
tions maintained by the US Office for Human Research Protections (OHRP) 
(<http://www.hhs.gov/ohrp/international/index.html>).
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3 Special issues in field trials in low- and middle-income 
countries
Trials of an intervention should be undertaken only when there is uncertainty about 
the balance of potential benefit and potential harm, with respect to the intervention. 
The assessment of the extent of such uncertainty will be a critical factor in deciding 
whether or not it is justifiable to conduct a trial. If one trial provides good evidence of 
a beneficial effect, further trials of the same agent or procedure, even under very differ-
ent epidemiological circumstances, will be more difficult to justify than if the first trial 
had not been conducted. Only if there are good reasons to believe that the results might 
be different under these different circumstances would further trials be indicated, and 
indeed a case could be made that it would be unethical not to conduct a further trial in 
such circumstances.
In communities which are poor and deprived and whose inhabitants may be at sub-
stantial risk of premature death and serious disease from many causes, the balance 
between the potential benefits of an intervention and the risk of harm may be different 
from that which might apply in a more privileged community. For example, a higher 
level of vaccine-related adverse effects might be acceptable in a trial of a vaccine against 
a disease that was responsible for many deaths and considerable disability in a commu-
nity than would be acceptable in a study in a community in which the disease was rarely 
fatal and rarely caused severe disability.
In general, it is easier to persuade those who are sick than those who are well to 
participate in a medical research investigation. Field trials of preventive measures 
often involve those in the latter category and, unlike most clinical trials, take place 
in the community, rather than in a clinic or hospital. The task of obtaining consent 
for the conduct of a study in such a setting involves some special issues discussed in 
Section 3.1.
3.1 Obtaining communal and individual consent
In communities in many LMICs, decisions about participation in a particular project 
may be taken initially at a communal level. The permission of community leaders needs 
to be sought for a research investigation to take place in their community. Only once 
such approval has been granted is it appropriate to seek approval at a household, and 
then an individual, level. Thus, permission to conduct a research project may be ob-
tained first through trusted and respected community leaders, rather than through 
individual community members or through the heads of households. Although such 
procedures may seem strange and be unnecessary in many HICs and might even be 
regarded as challenging the right of an individual to make autonomous decisions, they 
are part of the cultural norm in many other societies.
In a clinical trial conducted in a hospital or clinic setting, the investigator may be 
able to take considerable time to explain the nature of the trial to each participant, as 
usually the total number of subjects in a study is relatively small. Field trials of some 
interventions (for example, vaccines) may be large, sometimes involving thousands, 
or even tens of thousands of participants, and it is more challenging to explain the 
trial in detail to all participants. Some of the potential methods for informing potential 
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participants about the study have been outlined in Section 2.4. It is important to note 
that obtaining ‘communal consent’ does not dispense with the need to also seek and 
gain individual informed consent. However, those from whom communal consent is 
sought should be able to represent properly the participants and to protect their inter-
ests. In reality, judgements about whether or not to participate in a research investiga-
tion depend greatly on the level of trust that investigators enjoy in a community. If a 
participant trusts an investigator to protect their interests, then they are more likely to 
agree to take part in the research. Participants will generally expect community leaders 
to protect their interests also and thus the importance of communal consent, as well as 
individual consent.
Before a community is approached regarding the possible participation of members 
of the community in a trial, it will usually be necessary to seek permission from the 
relevant local health authority, including those responsible for the medical care of the 
population. Subsequently, the initial approach to a community is likely to be best made 
to those recognized as leaders in the community. Generally, field trials are likely to be 
carried out by, or in direct co-operation with, the Ministry of Health and local health 
authorities. In such circumstances, it will usually be appropriate for discussions with 
community leaders to be initiated by such authorities, or at least to include their active 
participation. The extent of such discussions, and precisely who within a community 
should be involved, depends on the nature of the intervention that is to be studied. 
Most communities are heterogeneous, and sometimes there are factions within a com-
munity that have their own leaders whose co-operation must be sought. The people 
may not recognize those who are considered as the ‘official’ leaders, and others must be 
brought into discussions. Public notices and public meetings may also be useful.
It must be re-emphasized that obtaining communal consent for a study does not 
relieve investigators of their responsibility to explain the study procedures and the 
potential risks and benefits to those individuals who are being invited to participate, 
and those individuals must also be informed and be aware that they are free to refuse 
to participate or to withdraw from the investigation at any time without penalty of 
any kind.
It is also important to stress that consent to participate in a research investigation is 
not a one-off event in which the ethical requirements are satisfied, for example, once a 
signature is appended to the informed consent document. Consent to participate in a 
trial requires an ongoing dialogue between investigators and participants from the start 
of a trial through to its end. Investigators must take pains to keep participants informed 
of the progress of a trial, unexpected developments, and other findings, possibly from 
parallel studies that may impact on the trial.
3.2 Potential benefit and the risk of harm
The simple Hippocratic caveat ‘do no harm’ is not a sufficient guide to ethical decisions 
concerning trials of interventions. The introduction of a new intervention requires the 
demonstration of benefit. Furthermore, since almost any intervention procedure in-
volves some risk of harm, albeit usually small, it is necessary to assess in intervention 
trials the balance of benefits against risks. In general, ethical review committees are dis-
inclined to approve studies in which healthy persons will be exposed to more than very 
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small risks in the context of a research investigation. Thus, it may be unacceptable to 
carry out a trial using a vaccine associated with serious side effects, even if it offers pro-
tection against a disease that is more serious than the side effects. For example, if one 
person dies as a result of vaccination for every ten persons who are saved from dying, it 
is unlikely that such a product would be used, even though the ‘public health’ balance 
appears to be in favour of the vaccine. More weight is given to harm that results from a 
deliberate medical intervention than is given to the harm done by the ‘natural’ disease 
against which the intervention protects. Furthermore, legal concerns of litigation may 
sometimes be given greater weight than would seem appropriate from a strictly public 
health viewpoint.
A proposed research investigation should be viewed within the context of the overall 
problems facing the community in which it is to be conducted. The community should 
have a reasonable expectation of benefiting from the research in both the short and 
long term. The effects of the conduct of a field trial in a community may be immediate 
and evident or may be quite subtle. Even the mere presence of the research workers 
in a community may have side effects (for example, increased cash flow, availability 
of transport to other centres), and the impact of such effects should be considered in 
planning the research.
The possibility of long-term harm must be considered, even if there are short-term 
benefits.
3.3 Incentives
In some circumstances, it may be reasonable to provide direct incentives as an encour-
agement to participation in a research project. If this is done, it must be recognized 
that there may be a fine line between compensating individuals for time and income 
lost as a result of participation in the study and ‘bribing’ subjects to take part. It may be 
considered reasonable to give a small snack after a blood sample has been taken, or to 
repay bus or taxi fares to participants who travel to a research centre, or to give simple 
medications for minor ailments, but monetary payments to encourage individuals to 
participate in a trial that are greater than the wages they forego or the expenses they in-
curred will usually be viewed as a form of undue inducement. It is difficult to lay down 
any absolute rules as to what is acceptable, and it is necessary to review each situation 
on its merits in the local context. The level of compensation to be offered will generally 
be considered carefully by the local ERC, whose concern will be that the level proposed 
does not constitute undue inducement for individuals to participate in the research.
3.4 Standard of care
There are two aspects of standard of care that have been much debated in the context 
of trials in LMICs. The first is with respect to the choice of the control intervention 
against which the effects of some new intervention is to be compared. This is discussed 
in Section 3.5. The second is the standard of medical and other care offered to all the 
participants in a trial. When a trial is conducted in a poor community, the resources 
available for the trial (including additional medical personnel) may enable the stand-
ard of medical care to trial participants to be greatly improved over what would be 
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available in the absence of the trial. Some such improvements may be essential for the 
scientific purposes of the trial such as improving the diagnostic facilities for detection 
of the disease that is the primary focus of the trial. However, the extent to which the 
general medical care provided to trial participants should be enhanced will need to be 
carefully considered in the context of each specific trial. Introducing improvements 
that cannot be sustained beyond the duration of the trial may, in the long run, be 
damaging to local communities or provoke unrealistic expectations of the local med-
ical services. To the extent possible, improvements implemented during a trial should 
be designed so that they can be maintained with the resources available to the local 
medical service after the trial. This may involve specific training of local staff, intro-
ducing improvements in the routine medical records system, rather than setting up a 
parallel system, or ensuring a regular supply of drugs and other treatments that could 
be maintained by the local medical service after the trial. Inevitably, however, there 
will be some enhancements that are introduced that may be difficult to maintain after 
the trial. The aim should be that these are not disproportionate. In general, the provi-
sion of health care for a community is the responsibility of the national or local health 
services, and the research should neither usurp nor undermine existing services. It is 
essential therefore that the organizers of a field trial develop and maintain close links 
with those responsible for the normal provision of health care. Discussion of these 
aspects is an essential component of the submission for permission to conduct the trial 
to the local ethics committee.
3.5 Choice of ‘control’ interventions
The Declaration of Helsinki states that ‘the benefits, risks, burdens and effectiveness of 
a new intervention must be tested against those of the best current proven interven-
tion’. Using this principle, comparison with a placebo is acceptable only if there is no 
convincing evidence that any intervention is effective. This principle of comparing a 
new intervention with the best current proven intervention seems reasonable at first 
sight, but it has given rise to much controversy. The controversy has centred on global 
‘best’ interventions that are neither currently available nor likely to become available 
to the population in which the trial is being conducted, either because of their cost or 
because of the feasibility of implementing the intervention (for example, radiotherapy 
for conditions in countries in which there is little or no provision for such treatment). 
The ‘purists’ hold that, if the global ‘best’ intervention is not included as the control 
arm, then the trial is unethical and should not be conducted. The pragmatists, who 
often have experience of conducting trials in LMICs, hold that this position is itself ‘un-
ethical’, as it prevents research investigations that may lead to important public health 
benefits in deprived populations. There is no space to expand on these arguments in 
detail here, but the issue is discussed at some length in other publications (for example, 
Council for International Organizations of Medical Sciences, 2009; Nuffield Council 
on Bioethics, 2002; Rid et al., 2014). The view of the pragmatists, including ourselves, 
is that, if an effective intervention is known, but its cost is beyond that which would 
make it feasible to introduce it into the local health care system (and there is little pros-
pect that the cost can be reduced by means such as shifting production of pharma-
ceuticals to generic manufacturers), then it may well be acceptable to exclude it from 
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consideration as a possible comparison intervention in a trial. In some circumstances, 
it may be acceptable to try to test a new intervention that might be, at best, equivalent 
to an existing intervention or may even be inferior to it if, for example, it is cheaper or 
simpler to apply, or more stable, or associated with fewer adverse reactions, or is more 
acceptable to the community than the existing intervention. In such circumstances, the 
purpose of the trial might be to show that the efficacy of the intervention was ‘equally 
good or not much worse than’ the existing intervention.
3.6 Choosing the primary endpoint
The choice of the primary endpoint for a trial, which will usually determine the neces-
sary minimum size and duration of the trial, will generally depend on scientific, rather 
than ethical, considerations. Generally, the most important endpoints, in terms of as-
sessing the impact of an intervention, will be in the reduction of severe disease or death. 
However, in a trial with either of these as the primary endpoint, there may be less se-
vere outcomes, which occur with greater frequency than the severe forms of disease. 
The benefits of the intervention against these, often chosen as secondary, endpoints 
may become apparent, before sufficient cases of the more severe primary trial out-
come have accumulated to reliably assess the impact of the intervention on the primary 
outcome. For example, in a trial of a vaccine to measure the impact of the vaccine on 
the incidence of severe malaria (primary trial outcome), the impact on milder malaria 
(secondary trial outcome) may be apparent much sooner than the impact on severe 
disease. Having demonstrated impact on the secondary trial outcome, some may argue 
that it is unethical to continue the trial, because there is no longer ‘equipoise’ between 
the effects of the control and the new intervention. There is no simple answer to such 
debates, but it is very important that careful consideration is given to such possibilities 
at the time the trial is designed, so that a clear decision can be taken at that stage, rather 
than being taken ‘on the hoof ’ when the situation emerges. Sometimes, this may result 
in some secondary outcomes not being measured so as to avoid the potential problem! 
Alternatively, the decision may be taken not to break the allocation code for secondary 
trial outcomes until the end of the trial, or the interim results may be made available 
only to the DSMC, and not to the trial investigators. Alternatively, the prior decision 
may be taken to continue the trial until the numbers necessary to satisfy the primary 
trial outcome have been achieved, because of the public health importance of knowing 
the impact on severe disease or death. These aspects should be clearly presented to the 
relevant ethics committees when they consider the trial. Also relevant is what feedback 
will be given to trial participants of results that become available during the conduct 
of the trial, so that they can assess whether or not they wish to withdraw from the trial.
3.7 Duration and size of a trial
In field trials, it may be necessary to establish the efficacy of the intervention not only in 
the population as a whole, but also in special subgroups. This may involve the measure-
ment of efficacy in persons of certain ages or for persons with underlying or associated 
conditions such as malnutrition. It will also be necessary to determine the duration of 
efficacy and to have a reasonably precise estimate of the degree of efficacy.
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It may be argued therefore that the appropriate point at which to stop a trial should 
be when sufficient evidence has been collected to support, or reject, the introduction 
of the intervention by the health services generally, rather than at the point when the 
difference in response in intervention and control groups is first established beyond 
reasonable doubt. For many interventions, it is important to establish both the degree 
and the duration of protection. Thus, a trial might be continued beyond the point at 
which protection is first established to determine if there is long-lasting protection. For 
example, it may be established in the first 6 months of a malaria vaccine trial that the 
vaccine is protective, but, to be of public health value, it may be necessary to demon-
strate that long-lasting protection is achieved. This may necessitate continuing the trial 
for at least 2 or 3 years with the maintenance for this period of an unvaccinated group 
or of a group whose members had received an inferior vaccine. In some circumstances, 
this will be considered acceptable, but, in others, it will not. Again, each situation must 
be considered on its own merits, and much will depend on how far the investigators 
extend their horizon of responsibility, with respect to the public health use of the inter-
vention they are evaluating.
Often, the most important outcome in a trial may not be observed until a consid-
erable time after the intervention has been applied, but there may be intermediate 
outcomes against which the intervention is also assessed. For example, a vaccine may 
produce a good antibody response long before any protection against disease is shown. 
Demonstration of efficacy against the intermediate outcome (antibody response) 
might be considered grounds for ending a trial if it is reasonable to assume that the 
effect observed on the intermediate outcome would necessarily carry over to the more 
distant trial outcome (protection against disease), even though efficacy against that 
outcome had not been formally demonstrated. What is ‘reasonable to assume’ is often 
a matter of considerable debate, and the ethics of continuing a trial, once protection 
against intermediate endpoints has been established, must be argued in the particular 
circumstances surrounding a trial. Immunological measures which are thought to cor-
relate with protection against clinical disease may not so do. For example, in one trial 
in which this aspect was examined, the protection that BCG conferred against TB did 
not correlate well with the induction by the vaccine of sensitivity to a tuberculin skin 
test (D’Arcy Hart et al., 1967), even though it was possible to put forward plausible im-
munological arguments for believing that such a correlation should exist.
An example of the ethical difficulties that may arise is provided by trials of malaria 
vaccines. Early treatment with appropriate anti-malarials is normally curative for falci-
parum malaria, and, in a trial, it would be unethical to withhold such treatment from 
those with clinical malaria. Yet the main purpose of such a vaccine is the prevention of 
death from malaria, not of infection, nor even the prevention of minor malaria illness. 
Indeed, it is conceivable that there may not be a good correlation between the protec-
tion of a vaccine against the last two outcomes and the protection against death as the 
outcome. The dilemma is that, in most of Africa where malaria continues to kill hun-
dreds of thousands of children annually, medical services are not adequate to provide 
the level of curative care that would be provided in a trial, nor are they likely to be so 
in the near future. Because malaria is a treatable disease and effective treatment should 
be made available to all those who are diagnosed with malaria during a trial, it is likely 
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that mortality from malaria in a trial would be at a very low level—too low to allow 
this to be a primary outcome in a reasonably sized trial—and therefore the primary 
outcome may have to be either clinical malaria or severe disease (which may also be 
at a lower level, because of the treatment and care provided in the context of the trial). 
The assumption would have to be made that any efficacy demonstrated against clinical 
malaria and/or against severe disease would be likely to carry over into the prevention 
of malaria mortality. It may not be possible to address the impact on mortality until the 
vaccine is in public health use, and assessment might be made through specially set-up 
surveillance or Phase IV studies (see Chapter 22). Such studies may be set up to be very 
large, such that it would only be realistic to leave the treatment of cases of malaria to the 
existing system of medical care.
There are very strong reasons for conducting early trials of a new intervention to 
assess the impact of the intervention against the outcomes which are of greatest public 
health importance, rather than starting with trials against intermediate outcomes, if, 
by studying intermediate outcomes, further trials against more important outcomes 
may be compromised. Sometimes, knowledge from other studies may be sufficient to 
be confident that, if effects are demonstrated against intermediate outcomes, then im-
pacts on more important outcomes will necessarily follow, but all too often, such an 
assumption is not warranted.
There are strong reasons for conducting very large trials of interventions that are 
likely to be used on large numbers of people in the future if the interventions are ef-
fective, much larger than would initially seem necessary to achieve only a statistically 
significant difference in outcome. The results of very large trials, if the trials have been 
adequately managed, can be much more convincing and are more likely to lead to the 
implementation of the intervention in disease control programmes than are the results 
of small trials.
Again, part of the dilemma relates to where the investigator places the horizon of 
responsibility. If the view is taken that the investigator, by taking on the responsibility 
of a field study, also takes on responsibility to provide full medical care of the subjects 
under study, then a study of a malaria vaccine with prevention of death as the endpoint 
could not be undertaken. If the view is taken that the horizon of responsibility extends 
to all those who are at risk of dying from malaria, including those who would not 
be included in the trial but who may benefit eventually from the vaccine, then a trial 
might be conducted with death as an endpoint, but the design of such a trial would be 
challenging!
3.8 Monitoring safety during a trial
All clinical studies require safety monitoring throughout the duration of the trial and, 
in some cases, for a defined period after the completion of the study. Investigators are 
responsible for the detection and reporting of adverse events or serious adverse events 
and to the sponsor, the ethics committee, and regulatory authorities, according to the 
time period and procedures specified in the protocol (see Chapters 7 and 12).
The ethics committee should review a study when serious and unexpected adverse 
events related to the conduct of a study or study product are reported, as the events 
may affect the benefit/risk balance of the study. Refer to the International conference 
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on harmonisation guideline for clinical safety data management: definitions and stand-
ards for expedited reporting for more detail (<http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2009/09/WC500002749.pdf>).
3.9 Special ethical issues in cluster randomized trials
In addition to ethical issues common to all randomized trials, additional ethical con-
cerns can arise in cluster or group randomized trials (Edwards et al., 1999).
Most ethical issues specific to cluster trials are related to: (1) the legitimacy of in-
formed consent when sought at group level, (2) the potential conflicts between indi-
vidual autonomy vs group consent, and (3) the differential benefit that one cluster may 
have over another in some trials.
Most of the issues concerning informed consent in cluster randomized trials are 
discussed in Section 3.1. These include the identification of different levels at which 
consent can, or should be, sought and who has the legitimacy to determine whether 
researchers may approach groups or communities.
A potential issue in cluster randomized trials is when the request for individual con-
sent is obtained after randomization and allocation of the cluster to the intervention 
or control arm of the trial. This should not cause an ethical concern per se, but it could 
lead to bias in the nature of the consent in the different intervention groups and thus 
be of scientific concern.
3.10 Reporting and feedback of results
At the completion of an investigation, there is a responsibility to inform the com-
munity in which a trial has been conducted of the results of the study in such a 
way that its members can understand the implications of the findings. Indeed, such 
feedback should be ongoing, as the research progresses. Not only is it important 
ethically that participants should be kept informed of the progress of the research, 
but, if this is done, it is also likely to encourage their continued participation. The 
procedures to ensure this feedback takes place should be planned from the start of 
an investigation.
There is also a responsibility to feed back the results of the research to the relevant 
local or national health services and disease control programmes, so that these groups 
can assess the implications of the findings for their own activities.
These issues are discussed in greater detail in Chapter 23.
The anonymity of participants in a trial should always be respected, and there should 
be no danger that any of them will be identified through any publication of the results 
of a trial. The same rights of confidentiality should be considered for communities, 
as well as for individuals. It will sometimes be appropriate to keep the identity of the 
community anonymous, particularly if sensitive issues are discussed, such as hygiene 
practices or sexual or other practices that are sometimes condemned by other cultures 
(such as female genital cutting, infanticide, or anal sex). Sometimes, it is not possible to 
disguise a particular location, and, in some circumstances, it may be important that the 
community be identified to aid interpretation of the study results. Indeed, communi-
ties are sometimes proud to be associated with a particular research programme, and 
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the name of the community or place may be used as the title of the project (for example, 
the Garki malaria project (Molineaux and Gramiccia, 1980)).
3.11 What happens after the trial?
The closure of a trial presents special challenges, especially when the intervention 
group receives significant improvements in the quality of care, while the control group 
receives usual care, which, in many LMICs, will be suboptimal care or even no care. 
The challenges are even greater when the intervention has been shown to be successful. 
Should the benefits of the intervention be sustained in the study group and, if so, how 
and with whose resources? Should the intervention be extended to the control group 
(at the minimum), and possibly to the whole community in which the trial was con-
ducted? If yes, how and with whose resources? These are often difficult questions and 
should be addressed from the inception of the trial, and the implications included in 
any discussions with the trial funder and trial sponsor. How they are tackled will de-
pend on the setting, the nature of the intervention, the strength of the health system, 
and the availability of other partners working the study area. If the intervention can 
be mainstreamed into the health or other services of the community, this should be 
explored with the relevant decision makers. If, for example, the intervention concerns 
children and there is a United Nations Children's Fund (UNICEF) programme in the 
area that can help to extend it to the communities, these alliances should be established. 
If there is an opportunity for the local health administration to apply for a local, re-
gional, or international grant to help extend the intervention, the trial team should help 
with preparing this grant. If the trial team plans to take responsibility for extending the 
intervention, appropriate funding and timelines should be reflected in the project plan 
and budget.
3.12 Special ethical issues in Phase IV (post-licensure) studies
Phase IV studies with drugs and vaccines are needed to evaluate effectiveness, long-term 
safety, and potential drug interactions. For safety surveillance, or pharmacovigilance, a 
system should be in place for collecting, monitoring, and evaluating information from 
health care providers and patients on AEs that may be associated with medications and 
biological products. These issues are discussed in greater detail in Chapter 22.
Ethical concerns, as well as quality of data, should be carefully examined in rela-
tion to the physician’s relationship with the sponsors, marketing of products, incen-
tives, and biased observations. Special informed consent is not always needed when the 
intervention under study is already part of the routine public health system. However, 
if participants are asked for more detailed follow-up than would usually be required, 
to answer specific questionnaires or to perform additional examinations, special in-
formed consent for research may be needed and ethical review of the Phase IV study 
protocol required.
Post-licensing studies are also used to explore new routes, formulations, and new or 
modified indications or drug associations of a registered product. In the case of evalu-
ation for a new indication for a known product (label extension studies), the develop-
ment protocols and ethics review should follow the same path as for a new product.
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1 Introduction to trial governance
Since the first edition of this book was published in 1991, there has been a very large 
increase in the number of field trials of health interventions being conducted in LMICs 
and, in parallel with this expansion, an increasing number of regulations and guide-
lines put in place to govern the conduct of clinical trials. Most of these regulations have 
been developed in the context of clinical trials in HICs, particularly with respect to the 
evaluation of new drugs and vaccines, but there is a strong expectation, and in many 
instances a requirement, that these regulations are followed, no matter where a trial is 
conducted.
A particularly important development occurred in 1990 when representatives of 
regulatory authorities and pharmaceutical companies in Europe, Japan, and USA 
agreed on scientific and technical aspects of drug registration. Guidelines were devel-
oped from their deliberations called ‘The International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Human Use’, com-
monly known by the initials ‘ICH’. Since then, ICH has evolved, in response to the 
increasingly global nature of pharmaceutical development, with the mission to achieve 
greater harmonization in the planning, conduct, and reporting of trials to ensure that 
safe, effective, and high-quality medicines are developed and registered in the most 
resource-efficient manner (<http://www.ich.org>).
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In this chapter, we highlight aspects of trial design and conduct that have evolved 
significantly in recent years, particularly with respect to the role of the sponsor, the 
functioning of steering committees and data safety and monitoring boards (DSMBs) 
and requirements for trial registration.
2 The trial sponsor
Whenever a field or clinical trial is conducted that involves human participants, it is 
necessary that an individual, or more commonly an institution, has legal responsibility 
for the trial, ensures that the trial is conducted properly, according to a defined proto-
col, and has overall responsibility for the management and financing of the study. This 
person, or institution, is known as the sponsor of the trial. While, in principle, the PI of 
a trial may act as the sponsor, for legal reasons most institutions prohibit members of 
their staff from taking on this role and insist that there is institutional sponsorship. In 
the case of the trial of a new pharmaceutical product, the sponsor is usually the com-
pany that is developing the product. With respect to trials of licensed products or trials 
that do not involve specific products (for example, hygiene interventions), the sponsor 
would generally be the agency that is funding the trial or the research institution or 
university of those conducting the trial. Many funding agencies are not prepared to 
act as the sponsor for the studies they fund, unless those conducting the study are dir-
ectly employed by the agency, and, in such cases, the institution employing the PI will 
generally take on the role of sponsor. In such situations, the sponsor is not responsible 
for financing the trial directly but does have responsibility for arranging that the funds 
needed to conduct the trial to a high standard are available from the funding agency 
and for administering the grant. The sponsor also has legal liability for any harm that 
might arise during the conduct of the trial.
The sponsor must ensure that the trial meets all relevant standards and regulations 
and must ensure that arrangements are put in place for carrying out the trial, for moni-
toring that it is being conducted properly, for meeting all required ethical standards (see 
Chapter 6), and for reporting the results of the trial at the end of the study. The sponsor 
also has responsibility for ensuring the safety and well-being of participants in the trial 
and for ensuring that treatment and care are available, usually free of charge, for any trial 
participants who are harmed as a consequence of their involvement in the trial.
Usually, sponsors will delegate different elements of their responsibility to the trial’s PI, 
steering committee, or DSMB, but the sponsor remains ultimately accountable for all as-
pects of the governance of the trial, whether or not some components have been delegated.
For clinical trials of drugs and vaccines and, in some cases, also for other interven-
tions, national regulatory authorities usually require that the sponsor has insurance or 
indemnity for any potential liabilities of the sponsoring institution and the investigators 
in the trial. Whether or not this is required, it is a good idea, as the cost of any legal action 
taken against the trial could be considerable. The regulations will also often require that 
the sponsor ensures that the trial conforms to GCP (see Chapter 16), for which guidelines 
have been also produced by ICH (International Conference on Harmonisation, 1996).
The PI of a trial is accountable directly to the sponsor. Furthermore, although any re-
ports from a steering committee or DSMB are formally to the sponsor, the sponsor may 
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delegate responsibility for receiving and acting upon such reports to the PI. Similarly, 
the sponsor has the formal responsibility for liaison with those who have an oversight 
responsibility for the trial, such as the funding agency and relevant ethics committees. 
Formally, therefore all communication between these bodies and, for example, the trial 
steering committee or the DSMB, and vice versa, should be through the sponsor.
3 Steering committee
It is common in large trials, particularly multicentre trials, for a steering committee 
to be set up, to which the PI reports and from which the PI may seek guidance or au-
thorization, with respect to aspects of the conduct of the trial. These will include any 
significant protocol amendments, which will also usually have to be approved by the 
ethics committees which approved the original protocol for the trial. There is no obli-
gation on an investigator to set up such a committee (unless required by the funding 
agency), and, for smaller trials, a steering committee may be considered unnecessary. 
Such a committee should usually consist of senior investigators in the trial, together 
with appropriate independent experts.
The role of a trial steering committee is to provide overall supervision of the trial 
and ensure that it is being conducted in accordance with the principles of GCP and 
the relevant regulations. The trial steering committee should agree the trial protocol 
and any protocol amendments and provide advice to the investigators on all aspects 
of the trial. The steering committee often has responsibility for approving the analytic 
plan for a trial (see Chapter 21, Section 3)—see also the ICH guidelines on statistical 
principles for clinical trials (International Conference on Harmonisation, 1998). The 
committee will usually have some members who are independent of the investigators, 
and, in particular, the chairperson should be independent. Decisions about continu-
ation or termination of the trial or substantial amendments to the protocol are usually 
the responsibility of the trial steering committee, advised by the DSMB (see Section 4).
The trial steering committee is distinct from a trial management group, which nor-
mally includes those individuals responsible for the day-to-day management of the 
trial such as the PI, statistician, trial manager, and data manager. The role of the man-
agement group is to monitor all aspects of the day-to-day conduct and progress of the 
trial to ensure that the protocol is adhered to and to take appropriate action to safe-
guard participants.
4 Data and Safety Monitoring Board
For trials of interventions that may entail the possibility of significant harm, as well as 
benefit, to participants, the trial sponsor should establish a DSMB—sometimes termed 
a committee (DSMC), a Data Monitoring Board (DMB) (or Committee (DMC)), or In-
dependent Data Monitoring Committee (IDMC). The DSMB is independent of those 
conducting the trial and separate from the ethics review committee (ERC) to monitor 
the safety of the trial, while it is being conducted. Not all trials will require a DSMB, but 
listed in Box 7.1 are the types of trial for which WHO has recommended that it would 
be considered desirable to set up such a committee (World Health Organization, 2005).
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A DSMB will usually be set up for trials which are double-blind, in which the in-
vestigators and sponsor do not know which intervention individual participants have 
received, but the DSMB will have access to the randomization code, which it can break 
during the course of the trial for specific reasons, including safety concerns or interim 
analyses (see Section 4.1.3). For trials where the intervention allocation is not blinded, 
the investigators and the sponsor can assess on a continuous basis if there is an excess of 
AE s in one of the intervention arms of a trial. Even so, it is usually a good idea to have a 
DSMB, as this committee may take the responsibility for advising the PI, steering com-
mittee, and sponsor on critical decisions, such as whether to stop a trial because of ad-
verse effects or signs of failure of the intervention during the course of a trial. Although 
members of DSMBs are often not paid for their services, a budget will still be required 
to cover their meetings and any visits they may need to make to the trial site(s).
◆	 Controlled studies with mortality and/or severe morbidity as a primary or 
secondary endpoint.
◆	 Randomized controlled studies focused on evaluating clinical efficacy and 
safety of a new intervention intended to reduce severe morbidity or mortality.
◆	 Early studies of a high-risk intervention (risk of non-preventable, potentially 
life-threatening, complications; or risk of common, preventable AEs of interest 
(especially adverse drug reactions)), whether or not randomized.
◆	 Studies in the early phases of a novel intervention, with very limited informa-
tion on clinical safety or where prior information raises concern regarding 
potential serious adverse outcomes.
◆	 Studies where the design or expected data accrual are complex or where there 
may be ongoing questions with regard to the impact of accrued data on the 
study design and participants’ safety, particularly in studies of a long duration.
◆	 Studies where the data justify an early termination such as the case of an inter-
vention intended to reduce severe morbidity or mortality, which might turn 
out to have adverse effects or lack of effect, resulting in increased morbidity or 
mortality.
◆	 Studies carried out in emergency situations.
◆	 Studies which involve vulnerable populations.
Reproduced with permission from the World Health Organization, Operational Guidelines for the 
Establishment and Functioning of Data and Safety Monitoring Boards, Copyright © World Health 
Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 
2005, available from <http://whqlibdoc.who.int/hq/2005/TDR_GEN_Guidelines_05.1_eng.pdf>. 
This box is not covered by the Creative Commons licence terms of this publication. For permission 
to reuse please contact the rights holder.
Box 7.1 WHO recommendations for the types of trial for 
which a DSMB is relevant
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In this section, we outline the functions and responsibilities of a DSMB, the selection 
of members, the major issues with which it has to deal, and lines of reporting to those 
involved in the trial.
4.1 The functions of a Data and Safety Monitoring Board
The prime function of the DSMB of a trial is to safeguard the welfare of participants 
in the trial. A key aspect of this is to monitor the occurrence of adverse events (AEs) 
by trial arm and to recommend action to the investigators in the event of finding evi-
dence of harm. In ‘blinded’ trials, the DSMB will be the only group to have access to 
the randomization codes during the conduct of the trial, so that, if necessary, they can 
ascertain which intervention an individual participant received. The DSMB may also 
be called upon to ‘break the code’ for a trial at pre-specified time points to make a rec-
ommendation as to whether or not a trial should be stopped prematurely because of 
‘overwhelming efficacy’ or ‘futility’.
4.1.1 Monitoring the conduct of the trial
An important aspect of safeguarding the welfare of trial participants is to check that 
trial procedures are being followed, according to the protocol, and there are no signifi-
cant deviations from the trial plan. If there is a trial steering committee, responsibility 
for monitoring trial conduct will lie principally with that committee, and the DSMB 
should receive reports from the steering committee—often the chair of the DSMB at-
tends all or part of the steering committee’s meetings. However, if there is no steering 
committee, then the responsibility for monitoring trial conduct falls more heavily on 
the DSMB. Usually, this function is satisfied by the DSMB receiving detailed reports 
from the investigators on the progress and conduct of the trial at each DSMB meeting, 
but DSMB members may also make visits to the trial sites. Day-to-day monitoring 
of trial procedures, including data collection, is often provided by clinical trial moni-
tors (see Chapter 16, Section 7.2) who should report regularly to the sponsor. If there 
are issues of concern, the sponsor has responsibility for reporting these to the DSMB, 
through the steering committee if there is one. Clearly, monitoring the conduct of a 
trial can be a major undertaking, and exactly what part the DSMB is expected to play in 
this should be detailed in the DSMB Charter (see Section 4.3).
4.1.2 Monitoring the safety of trial participants
Different kinds of AE should be reported to the DSMB on an ‘immediate’ or regular 
basis, the frequency depending on the seriousness of the AE .
Any serious AEs (SAEs) (see Chapter 12) that are judged by the investigators to be 
likely to have been due to the intervention (‘potentially intervention-related SAEs’) 
should be reported very quickly to the DSMB, within a few days of their occurrence 
or their first notification to the trial investigators. Similarly, any deaths among trial 
participants, whether or not judged related to the intervention, should be immediately 
reported to the DSMB. As much relevant detail as possible should be provided to the 
DSMB about the nature and circumstances of the death or SAE, along with a cumula-
tive update of all such events. Deaths and potentially intervention-related SAEs would 
normally be reported to the sponsor at the same time as being reported to the DSMB. 
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When such events are reported, the chair of the DSMB should communicate with 
members to ascertain if any members consider the events are sufficiently serious and 
linked to the intervention that they require further investigation or, in extreme cases, 
might require that the trial is paused or terminated. If major changes to the conduct of 
the trial are suggested, the committee would generally meet by telephone conference or 
have a face-to-face meeting.
For SAEs that are not considered by the investigators to be directly related to the inter-
vention, the DSMB should be informed of these on a regular basis, possibly monthly, 
depending on the size of the trial. At regular meetings of the DSMB, the accumulated 
SAEs should be considered. They should be classified by the type of SAE (for example, 
by hospital admission diagnosis), when they occurred in relation to the application of 
the intervention, and whether they affected participants in the intervention or control 
group. Displaying data by intervention and control groups requires breaking the code, 
and this is usually done either by an independent statistician (i.e. not one of the inves-
tigators, but a statistician contracted by the sponsor to perform the analyses) or by a 
statistician on the DSMB. Ideally, the tabulations should be presented to the DSMB by 
trial arm, without specifying what each arm has received intervention or control, and 
they should consider whether they are concerned by the size of any relative excess of 
events in any of the trial arms. Only if the answer to this question is ‘yes’ should they 
ask which arm was which. This procedure is adopted to avoid unnecessarily exposing 
the DSMB to unblinded data, unless there is good reason for concern, and to avoid 
their being biased in their assessment of the distribution of SAEs by knowing which 
arm any excess is in.
For more minor AEs, such as a minor local reaction to a vaccine or mild nausea, the 
DSMB can be presented with analyses of these on an occasional basis, though usually 
this should happen at least once a year. Again, they should initially be presented with-
out identification of what each arm has received. Data on AEs are usually presented 
for information, rather than action, though occasionally action might be considered if 
there is a substantial excess of AEs in the intervention arm.
4.1.3 Conducting interim analyses
In some trials, a plan is made to examine interim efficacy results before the trial’s ex-
pected end date. There are two main reasons for doing this. First, if the intervention 
proved much more effective than anticipated, then there might be grounds for termi-
nating the trial early on the basis of ‘overwhelming efficacy’, such that it might not be 
considered ethical or necessary to continue with a control arm. Such analyses and their 
timing should be clearly specified in the trial protocol, as should the circumstances 
in which the results would lead to a recommendation to terminate the trial. In other 
words, the ‘stopping rule’ should be predefined. Second, the DSMB might recommend 
stopping a trial because of ‘futility’ if the interim results show a difference in study out-
comes between the intervention group and the control group which is much less than 
expected if the intervention is effective and it is clear that, even if the trial is continued 
until its planned end, it is very unlikely to show an important difference in the rates of 
the primary outcome between the two groups. Again, such analyses should be planned 
in advance of starting the trial, and the stopping rules specified in the trial protocol. The 
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DSMB has responsibility for conducting these analyses, because they require break-
ing the code of the trial; if the decision is to continue the trial, the investigators have 
not been compromised by knowing either the interim results or which participants 
were allocated to which intervention. In such circumstances, the DSMB should not be 
tempted to share the interim results with the investigators but should merely tell them 
to carry on as planned. Having an independent DSMB is very valuable if a decision 
needs to be made about stopping a trial early, because this usually has considerable 
logistic and funding implications and may not be popular with the investigators, staff 
(who may even need to be laid off early), or participants.
Another common reason for conducting an ‘interim’ analysis is if the incidence of 
the primary outcome in the trial is less than anticipated or if recruitment to the trial is 
slower than expected. In such circumstances, it may be clear that the funds for conduct-
ing the trial will be exhausted before the planned number of participants or outcome 
events has been achieved. The investigators may then wish to seek further support from 
the funding agency to complete the trial. That agency may well request an interim anal-
ysis to know if the results to date already show the one arm of the trial to be convinc-
ingly superior to the other(s) or, conversely, whether there is little difference between 
the results in the different arms of the trial and collecting further data is unlikely to 
produce a convincing result, so it would be futile to extend the trial.
4.1.4 Modification of trial procedures and other advice
During the course of a trial, there may be a need for the DSMB to recommend modi-
fications to the study, because of considerations of patient safety such as eligibility cri-
teria, dosages, treatment duration, and/or concomitant therapy. When there is a trial 
steering committee, the DSMB would normally propose these recommendations to 
that committee (as representing the sponsor).
In the absence of a trial steering committee, investigators may well turn to the DSMB 
for advice on other aspects of the conduct of the trial. The DSMB is a useful source of 
independent unbiased advice, especially as it will often include persons with substan-
tial trial experience.
4.1.5 Reporting to the sponsor
After each meeting of the DSMB, minutes should be drawn up relating to confidential 
and non-confidential parts of the meeting. In the non-confidential parts of a meeting, 
the trial investigators or their representatives may be present, in order to update and 
inform the committee on the progress of the trial, any deviations from planned proced-
ures, and any AEs among trial participants. Confidential (closed) parts of the meeting 
will be restricted to DSMB members and may involve looking at data from the trial on 
outcome measures or AEs, unblinded with respect to the intervention arms. The min-
utes of this part of the meeting should be kept securely and confidential to the DSMB 
members until the end of the trial, at which time they should be given to the sponsor.
At the end of each of its meetings, the DSMB should draw up a report to the sponsor. 
This is often short and along the lines of ‘We have reviewed the safety and other data 
from the trial and find no evidence of a safety concern that would lead us to suggest 
any change to trial procedures at this time’. However, if discussion of the trial data does 
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cause the DSMB specific concerns and leads them to suggest specific changes to the 
conduct of the trial, these should be conveyed to the sponsor. The most extreme ad-
vice would be to halt the trial, but other advice might suggest, for example, changes to 
trial procedures, such as more frequent reporting of SAEs to the DSMB, more careful 
follow-up of a subset of participants, or changing diagnostic methods.
Sometimes, the investigators or sponsor will seek specific advice from the DSMB on 
aspects of trial procedures. For example, in some trials, the DSMB, or a subset of its 
members, may be asked to classify suspected cases of the disease of interest, accord-
ing to levels of diagnostic certainty (without knowledge of which intervention they 
received)—though, depending on its composition in terms of expertise, this role might 
also be assumed by the steering committee or contracted to other independent experts 
(sometimes referred to as an ‘endpoint committee’).
It is important to note that the normal line of responsibility for reporting the deliber-
ations of the DSMB is from the chair of the DSMB to the sponsor, and the responsibility 
for liaising with investigators and ethics committees lies with the sponsor. Sometimes, 
the sponsor will delegate this role to the trial steering committee, so that the DSMB re-
ports directly to that committee. However, the DSMB should not report directly to the 
trial investigators, unless delegated to so do by the sponsor.
4.2 Composition and appointment of the Data and Safety 
Monitoring Board
The membership of a DSMB is usually decided by the trial sponsor, or the sponsor may 
delegate this task to the PIs or to the trial steering committee. Persons invited to join a 
DSMB are typically independent experts in the area of study of the trial, either working in 
the same field or in a related discipline, who have no personal or professional involvement 
with the intervention being tested, in that they will not profit either professionally or 
financially, according to the outcome of the trial. That is, the membership should be per-
sons who are considered to be unbiased experts. Persons with strong views about the rela-
tive merits of the interventions under test would generally be considered unsuitable for 
DSMB membership. Those invited to join the committee should usually be familiar with, 
or have experience of, the conduct of RCTs. The chair of the committee should certainly 
have such experience and ideally should have experience of previous service on a DSMB.
The size of a DSMB will vary, according to the size and complexity of a trial and the 
likelihood that any of the trial interventions or procedures may cause significant harm 
to participants. The minimum size is three, and it is rare to have more than ten mem-
bers, though the DSMB of large multicentre trials may approach that upper limit. The 
typical composition of a DSMB is outlined in Box 7.2.
In multicountry trials, it is common to have DSMB members drawn from at least some, 
if not all, of the countries included in the trial. Whether or not (lay) community members 
or advocates are included as members varies between trials. The inclusion of such mem-
bers may help bring to the DSMB the perspectives of the population under study. Such 
members should not be participants in the trial, but the member could be someone with 
the disease or condition under study or a close relative of such an individual. For exam-
ple, it has been common to include such persons in trials of HIV vaccines, but practice 
varies in trials of other interventions, and often lay members are not included.
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For ‘high-profile’ trials of interventions, or with study procedures that might be con-
troversial or have unusually high risks, the DSMB might include a medical ethicist 
knowledgeable in the design, conduct, and interpretation of clinical trials.
Anyone appointed to a DSMB must be prepared to respect the strict confidentiality 
of the discussions that take place within the committee and of the data that the com-
mittee may be given access to. They may also require training, for example, in the prin-
ciples of GCP. Such training is now widely available either online (which is often free) 
or face to face.
Generally, members of a DSMB are not paid, but they may be recompensed for loss of 
earnings, travel, and other expenses incurred as a consequence of DSMB membership. How-
ever, in some industry-sponsored trials, members may be paid a fee for their participation.
Before an individual is appointed to a DSMB, it is important that they are given the 
opportunity to study the trial protocol, so that they fully understand the purposes of 
the trial and how it will be conducted. Often they will also be given the opportunity to 
suggest changes to the protocol—especially related to issues such as reporting of AEs 
and trial stopping rules. Once more, it is important to stress that their advice should go 
to the sponsor and the trial steering committee, and not directly to the investigators.
4.3 The Data and Safety Monitoring Board charter
In many trials, a specific ‘charter’ is drawn up by the sponsor that details exactly the 
terms of reference and responsibilities of DSMB members. The charter should take ac-
count of the particular needs of the trial and the questions it is addressing. It should 
detail the relationship between the DSMB and the sponsor, investigators, steering com-
mittee, ethics committees, and others with responsibilities in the study. It also gives 
details of how meetings will be organized, how often they will take place, how many 
members constitute a quorum, and how confidential and non-confidential minutes will 
be produced, distributed, and stored securely until the end of the trial. All members of 
the DSMB will be required to sign the charter at the time of their appointment. Guide-
lines are available on drawing up a DSMB charter (DAMOCLES Study Group, 2005).
◆	 At least one clinician with knowledge of the disease(s) under study.
◆	 A biostatistician knowledgeable about statistical methods for clinical trials and, 
if interim analyses are to be conducted, knowledgeable about the specific issues 
related to sequential analysis of trial data.
◆	 At least one clinician or scientist familiar with the kinds of intervention(s) 
under test and their possible adverse effects.
◆	 Others who bring special expertise to the committee relevant to the 
intervention or its application such as toxicologists, epidemiologists, and 
clinical pharmacologists.
It is possible for a single individual to cover more than one of these skill areas.
Box 7.2 Typical composition of a DSMB
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5 Trial registration
Until relatively recently, there were no comprehensive sources of information about on-
going clinical trials. Not infrequently, trials would be started and would be prematurely 
ended with knowledge of their conduct known only to those closely associated with 
the trial if the findings were not published in the medical literature. Other trials were 
completed, but their results were never reported for various reasons, including that 
the investigators or sponsors did not like the findings of the trial! Other investigators 
might start a new trial, ignorant of the fact that a trial addressing essentially the same 
question was already under way or had even been completed but not yet published. 
Those conducting systematic reviews (see Chapter 3, Section 2) would be aware of the 
published literature but would be ignorant of such unpublished trials. It has been well 
documented that trials that show a ‘positive’ outcome are more likely to be published 
than those that do not, and thus the published literature may constitute a biased sample 
of all of the evidence related to the effects of a specific intervention.
In the 1990s, it was proposed that registers should be set up, in which those con-
ducting trials should be required to record their trial before the first participant 
was enrolled into it. The record should consist of basic information about the trial 
(Box 7.3). This recommendation was given teeth in 2005 when the International Com-
mittee of Medical Journal Editors (ICMJE), which comprises the editors of many of the 
major journals that publish papers on the results of trials, made it a requirement for 
publishing that the trial should have been properly reported to a public clinical trials 
register before any participant was enrolled into the trial (<http://www.icmje.org>). 
Initially, the requirement covered only randomized clinical trials, but it has been sub-
sequently expanded to include ‘any research study that prospectively assigns human 
participants or groups of humans to one or more health-related interventions to evalu-
ate the effects of health outcomes’, so that Phases I and II trials and non-randomized 
intervention studies, as well as Phase III RCTs, are included.
Several coordinated trial registries have been set up, so that any individual trial is 
issued a unique number which is recorded in the International Standard Randomised 
Controlled Trial Number Register (<http://www.controlled-trials.com/isrctn>). Trials 
are only eligible for publication by ICMJE journals if they have been registered in one 
of the following registries:
◆	 <http://www.anzctr.org.au>
◆	 <http://clinicaltrials.gov>
◆	 <http://www.isrctn.org>
◆	 <http://www.umin.ac.jp/ctr/index.htm>
◆	 <http://www.trialregister.nl/trialreg/index.asp>
◆	 <http://eudract.ema.europa.eu> (new registrations after 20 June 2011), or
◆	 any of the primary registries that participate in the WHO International Clinical 
Trials Portal (see <http://www.who.int/ictrp/network/primary/en/index.html>). 
This includes the Pan African Clinical Trials Registry (<http://www.pactr.org>). 
This registry enables African trial registration for those who do not have reliable 
access to the Internet.
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◆	 Title of the trial.
◆	 Acronym for the trial (if there is one).
◆	 Study hypothesis/trial objective, i.e. what question(s) is the trial design to 
address.
◆	 Ethics committee approval—which committees and when approved
◆	 Study design—individual or cluster, whether or not randomized, double-blind, 
etc.
◆	 Countries of recruitment.
◆	 Disease/condition/study domain—nature of study population and diseases of 
interest.
◆	 Inclusion criteria for participation in trial.
◆	 Exclusion criteria for participation in trial.
◆	 Anticipated trial start date.
◆	 Anticipated trial end date.
◆	 Current status of trial—ongoing, waiting ethics approval, etc.
◆	 Patient information material—is information about the trial publicly available 
and where?
◆	 Target number of participants.
◆	 Description of the interventions (for example, name, dose, duration).
◆	 Primary outcome measures.
◆	 Secondary outcome measures.
◆	 Sources of funding.
◆	 Trial website (if there is one).
◆	 Publications.
◆	 Name and contact details for PI and, where different, of person(s) responsible 
for providing information about the trial to the public and the scientific 
community.
◆	 Name and contact details for sponsor.
Box 7.3 (Minimal) information that is required when 
registering a clinical trial
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1 Introduction to preparing grant applications
Research funding agencies want to support outstanding researchers to conduct cutting 
edge studies to advance knowledge that contributes to the solution of health problems. 
Applicants for grants must convince the funding agency that they are high-quality 
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scientists whose research proposal addresses important question(s) and that the stud-
ies planned will deliver the answer(s) on time and within budget. Research proposals 
have many common elements, but, in intervention trials involving human subjects, 
some critical aspects, such as ethical, legal, and social issues, must be addressed par-
ticularly carefully in the grant application. Determination, good planning, and meticu-
lous attention to details are essential for a successful application.
2 Grant awarding agencies
There are many national and international funding agencies that include intervention 
trials in their funding portfolio. These include, but are by no means limited to, the 
WHO Tropical Diseases Research Programme, the European and Developing Coun-
tries Clinical Trials Partnership, the Bill and Melinda Gates Foundation, the UK Med-
ical Research Council, the US National Institutes for Health, the Wellcome Trust, the 
Volkswagen Foundation in Germany, and the French Institut National de la Santé 
et de la Recherche Médicale (INSERM). The pharmaceutical industry and several 
non-governmental public–private partnerships created in the last decade have part-
nered with academic institutions in the development of new drugs and vaccines for 
LMICs, including supporting clinical trials. In addition, some government develop-
ment agencies, such as United States Agency for International Development (USAID) 
and UK Department for International Development (DFID), also support studies on 
the evaluation of public health interventions.
2.1 Understand the remit
All funding agencies have their own specific remits and priorities. Even for interven-
tion trials, some agencies have specific programmes for particular diseases or will 
only support certain kinds of study. It is imperative to be familiar with the remit of 
the agency to which a funding application is planned and to understand what they ex-
pect from supporting a research proposal; otherwise, a lot of unnecessary time can be 
wasted by applicants.
Many funding agencies will ask why they, rather than some other group, should sup-
port a specific trial. For example, for a trial of a new vaccine that has been developed by 
a pharmaceutical company, a likely question is why the company is not providing the 
support, as it will stand to benefit if the vaccine is found to be efficacious.
2.2 Early contact
Those wishing to conduct a specific trial must decide on the most suitable funding 
agency to approach for support. One sure way of ensuring that a particular funding 
agency is an appropriate recipient of an application is to make early contact. Most agen-
cies have detailed information on their websites where information about the forms 
of support offered, the application process, and deadlines for applications are avail-
able. Where there is uncertainty, it is always a good idea to contact individual officers 
in the agency. They usually welcome an early opportunity to discuss a potential ap-
plicant’s plans, and they will suggest the best way to submit a grant application. Im-
portantly, they will advise if the agency is unlikely to support a particular application 
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(for example, because the topic is outside of their remit or priorities). Such informa-
tion early in the process of seeking a grant may be invaluable. A common mistake is to 
leave the preparation of an application and contact with the grant agency until close to 
a deadline. Plan ahead, and leave plenty of time for discussions with the grant agency’s 
officers and to prepare an application. A rushed application is almost always a poor one. 
Many funding agencies will offer to look at an outline application, sometimes known as 
a letter of intent or a concept note, to advise on whether or not it is within their remit or 
how it might be modified to better fit their funding schemes.
3 Grant types
The type of support needed for an intervention trial depends on the personal and insti-
tutional circumstances of the applicants. For example, an applicant in a tenured position 
in an academic institution may not require salary support but just need direct and indir-
ect research project costs for equipment, staff, materials, and administrative costs. If the 
principal applicant is not in a salaried position, salary support will be needed, in which 
case, for some funding agencies, a fellowship may be an appropriate avenue of support.
3.1 Project and programme grants
In the parlance of many funding agencies, a project grant is for a specific piece of work 
to answer just one or two specific questions, usually for a period of about 3 years. It may 
be, for example, a clinical trial to test the safety of a drug in its early development phase. 
A programme grant is for a larger, more complex set of studies to answer several related 
questions and is often for 5–7 years. A clinical trial may sometimes form part of an ap-
plication for programme grant support. Some agencies may not support project or pro-
gramme grants but only fellowships, or vice versa, so it is important to check this early.
Once a grant has been awarded, in most cases, funds are released on a yearly basis, 
taking into account technical progress and financial implementation. Estimating the 
cost of a project can be a very complicated exercise, especially with respect to indirect 
costs associated with the study. These aspects are discussed in Chapter 18.
3.2 Personal fellowships
Personal fellowships are for researchers who do not have a salaried, tenured, or sub-
stantive ‘permanent’ position. Fellowship applicants request for their personal salary, 
in addition to partial or complete research costs. Many agencies have programmes to 
support scientists throughout their career, from the Masters/PhD stage through one 
or more intermediate phases where they establish their independence, and finally to 
senior levels.
3.3 Special initiatives
Investigators should be on the lookout for special initiatives such as calls for support to 
conduct a trial on a particular topic. When there is a special initiative, research propos-
als are competing within a smaller specified area of science, and applicants are likely to 
be reviewed by people who work in roughly the same subject area.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
4: GRANT AWARDING PROCESS 135
It is not unusual that large clinical trials are conducted as a collaborative effort. For 
example, vaccine trials might have to be conducted in multiple sites and countries where 
there are significant differences in population structure, host genetic factors, public 
health systems, environment, and prevalence of co-infections. In this case, it may be 
important to collaborate and coordinate approaches to more than one funding agency.
4 Grant awarding process
4.1 Peer review
Nearly all funding agencies subject applications for support to some form of independent 
peer review. Usually, this will take the form of soliciting comments on the proposal from 
scientific experts. Some will be selected for their expertise in scientific areas included in a 
proposal, while others may be chosen for their broad experience to give a generalist per-
spective. Thus, the application should include a balance of appropriate details and a broader 
vision, as the familiarity of those conducting the review with the subject area may vary.
Most agencies do not reveal the identity of independent reviewers, so that they pro-
vide frank objective comments, including for applications from persons they know or 
are known by. Agencies sometimes solicit suggestions from applicants as to who might 
review a proposal, although they may choose not to use anyone suggested. On rare 
occasions, applicants request that certain individuals not be asked to review their ap-
plication. This may be because of potential conflicts of interest or because the applicant 
considers that the individuals may not be objective. Funding agencies do try to take 
such requests into consideration in their choice of reviewers.
Most agencies allow applicants to see the anonymized reviews or extracts from them, 
in which reviewers will usually highlight strengths and weaknesses of a proposal. These 
comments may be sent either after a funding decision has been made or to applicants 
requesting a response before the funding decision is made. Policies vary from agency 
to agency. If applicants are given the opportunity, they should always respond carefully 
and concisely to criticisms or suggestions made by referees, as both the referees’ reports 
and the response to them will be considered by the panel that makes the final funding 
decision (see Section 6).
It is common that the review process is conducted in two stages. Some agencies rec-
ommend that the applicants first submit a ‘letter of intent’ that gives a brief description 
of the proposed research. The agency will then advise whether or not it falls within their 
remit and will advise whether or not a full proposal should be prepared. Changes that 
would improve the proposal’s chances of being supported might also be suggested. One 
of the purposes of this two-stage approach is to allow the funding agencies to reduce 
the number of full proposals reviewed, so they can focus on the most promising ones. 
If an opportunity is given for submission of a letter of intent, applicants should make 
use of this before preparing a full proposal.
4.2 Funding committees
Decisions whether or not to fund applications are usually made or recommended by 
an advisory committee. In some funding schemes, applicants may be asked to attend 
for an interview, as part of the proposal review process. Members of these committees 
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will have expertise in the general area of all the proposals they have to deliberate on. 
The identities of members of funding committees are usually made available, and it is 
a good strategy, especially if an interview is involved, for an applicant to read some of 
their recent work to try to guess some of the issues on which they are likely to focus in 
their questioning. The detailed discussions that funding committees have, in order to 
come to a decision on a specific application, are usually strictly confidential. The fund-
ing agency will usually convey an appropriate summary of the discussions, if relevant, 
to applicants. This is particularly useful if an application has been rejected, as a sum-
mary of the reasons for rejection may help the development of an improved proposal 
for the same or another funding agency. Most funding agencies regard it as highly in-
appropriate for applicants to have direct contact with members of funding committees 
regarding the application, and members are instructed specifically not to discuss appli-
cations outside committee meetings. Whenever a proposal is being reviewed where a 
member of the committee has a potential conflict of interest, they are usually asked to 
leave the room. Examples include where the individual or someone from their institu-
tion is involved in the proposal.
Funding agencies endeavour to support the best proposals where the research ques-
tion, the timeliness of the study, the ability of the scientists involved, and the potential 
impact of the results all come together to make a compelling case for support of the 
proposal. In a proposal for an intervention trial, applicants should think carefully about 
how their study will stand out among potentially competing proposals. Whatever the 
area, the applicant needs to convey that the proposed study is important and timely and 
has achievable goals.
Most field trials are conducted in partnerships between research institutions and 
public health systems. For this reason, it is very important to have a clear definition of 
roles, responsibilities, and complementary expertise of the parties involved. How any 
ethical or legal issues related to potential consequences of the study will be handled 
should be carefully explained.
4.3 Competitive process
Obtaining grants is a highly competitive process. All agencies receive far more applica-
tions than they are able to fund, so a rejection does not necessarily mean that the proposal 
was weak. The decision on whether to resubmit a revised proposal to the same or another 
agency should take the feedback into account. Sometimes, but not always, the funding 
agency’s officer administering the application may be willing to give advice on this.
5 Developing the proposal
When developing the proposal, it is wise to follow a systematic approach. In Box 8.1, a 
10-step chronological, algorithmic approach is summarized that might be helpful for 
less experienced grant writers.
5.1 What is the problem, and why should it be studied?
The first step is to define clearly the primary research question to be addressed by 
the trial. Next, articulate why it is important and how the knowledge or evidence 
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 1 What is the problem, and why should it be studied?
•	 Primary	research	question
•	 Why	is	it	important?
 2 What information is already available?
•	 Literature	review
 3 What are the objectives of the research?
•	 Purpose	of	the	trial
•	 Specific	objectives
 4 How will the information be collected and analysed?
•	 Study	design
•	 Data	collection	methods;	sampling;	data	processing
•	 Study	size—what	criteria	and	assumptions?
•	 Data	analysis	methods
•	 Ethical,	legal,	and	social	issues
 5 Who will do what and when?
•	 Work	plan	with	a	timetable
•	 Human	resources;	collaborations;	training
 6 What are the risks?
•	 Contingencies.	Is	there	a	‘plan	B’?
 7. What resources are needed to carry out the research?
•	 Budget
•	 Justification
 8 How will the project be supervised and administered?
•	 Identification	of	advisors	and	planning	for	trial	administration
•	 Trial	governance,	including	data	and	safety	monitoring	and	trial	steering	
committees, if relevant
 9 How will results be disseminated?
•	 Plan	for	utilization	of	research;	identification	of	potential	users	of	results
•	 Data	and	sample	archiving,	access,	and	availability
10  How will the application be presented to funding agencies?
•	 Submission	forms;	deadlines
•	 Attention	to	detail;	presentation
Box 8.1 A 10-step guide to preparing a grant 
application
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derived from the trial will contribute to addressing one or more health problems. 
Many proposals fail because too many questions are being asked and the proposal is 
unfocused.
5.2 What information is already available?
A good, but brief, literature review of what has already been done in the research area 
is an important element of any grant proposal. It demonstrates that the applicant has 
looked at the relevant publications to identify gaps and opportunities in the field on 
which the study is based. Wherever possible, past work should be summarized in the 
form of a systematic review, as discussed in Chapter 3. This stage should also include a 
review of any relevant registered trials that have not yet been completed.
5.3 What are the objectives of the research?
The title of a proposal is the first thing that the reader sees. After identifying the re-
search question, produce a title that gives the reader a clear idea of what it is hoped to 
discover. Respect any word limits imposed by the funder.
The next step is to formulate the aims and specific objectives. These vary, according 
to the nature of the study. For a straightforward trial, for example, comparing the ef-
fects of two drugs, it may be relatively simple to state the aim. It may simply be to show 
whether drug A is superior to drug B in curing a specific disease in an individually 
randomized controlled trial.
In more complex studies, it may be necessary to articulate a general aim, followed 
by a list of specific objectives, some of which may include sub-objectives. Sometimes, 
several sequential steps may need to occur. In vaccine studies, for example, the immune 
status of the target population may need to be assessed first to select the target group 
for vaccination, and, before that, immunological assays may need to be developed, or 
tested and evaluated in the specific target population for the trial.
5.4 How will relevant information be collected and analysed?
The study design is a major component of a trial. Whether it should be placebo- 
controlled, double-blind, stratified, cluster randomized, etc. depends on many factors. 
State why a particular approach is necessary, and, if apparently superior designs have 
not been chosen, state why not. Many of these issues are discussed in Chapter 4.
The data to be collected and how they will be analysed must be described. If any of 
the data are to be from a sample of trial participants, the sampling technique needs to 
be explained and justified. Describe how the data will be processed and what statistical 
tests will be used in the analysis. Discuss any ethical, legal, and social issues that could 
arise from the specimen or data collection, storage, and dissemination. For example, 
it is important to describe informed consent processes for the trial population, what 
examinations will be performed on participants, and who will be responsible for their 
health care during the trial. Issues related to the taking, storage, and analysis of bio-
logical specimens should be addressed. If there are no previous published data to guide 
study design, will existing preliminary data or a pilot study be important? These issues 
are dealt with in detail in other chapters.
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5.5 Community engagement plan
The proposal should include a description of how the community will be engaged in the 
planning and conduct of the trial (see Chapter 9). This should include a brief descrip-
tion of any formal structures, such as a Community Advisory Board (CAB), and other 
mechanisms that will be used to solicit the trial community’s support and advice and to 
keep them fully informed of the trial’s progress and results.
5.6 Who will do what and when?
The work plan is important to show in a logical way what aspects of the trial will be done 
and when. If a trial is ‘high risk’, this should be because the topic being studied is intel-
lectually and conceptually challenging, not because it has been inadequately planned.
For nearly all trials, certain steps need to be conducted first, before others can pro-
ceed. A ‘Gantt chart’ is a helpful tool for project planning and presenting the proposed 
work plan, especially if there are complex dependencies among several components. 
Gantt charts are used to illustrate a project schedule, indicating in a graphical way start 
and end dates of specific components and activities to show how the individual tasks 
are sequenced.
It is important to identify specific milestones in the planning, conduct, and analysis 
of the trial and if strategic decisions will need to be made and when, such as whether the 
trial should continue or be stopped, given defined developments or outcomes.
Typical intervention trials involve large teams of people such as recruiters, interview-
ers, nurses, clinicians, laboratory technicians, public health officials, data management 
staff, statisticians, collaborators, and consultants. These have to be carefully managed, 
and their work budgeted for. In many cases, additional training may be needed. How 
the trial team will be managed and the work will be coordinated should be summarized 
in the proposal.
5.7 What are the risks?
In any research undertaking, there is a chance that the objectives will not be 
achieved because of unexpected changes in circumstances. It is a good strategy to 
have contingency plans to cover areas where there are such potential risks. While it 
is impossible to anticipate all risks, list the known ones. Do not wait until reviewers 
point them out. It shows awareness and preparedness to alter plans without jeop-
ardizing the main aims of the proposal. A good risk management plan would an-
ticipate potential issues and corresponding solutions to prevent delays, increased 
cost, or poor quality to the study data. An example of a potential, and not uncom-
mon, risk would be that the trial recruitment rate will be slower than anticipated. 
Potential ways of dealing with this could include close monitoring, so that remedial 
action can be taken early, using conservative recruitment estimates or planning re-
cruitment at times in the year when the population in most accessible, for example. 
Contingency plans are particularly important in high-risk research. Identify the 
potential pitfalls, and describe how plans will change if they arise. For example, 
what is the alternative strategy if it proved impossible to conduct the trial in one of 
the trial populations?
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5.8 What resources are needed?
Some funding programmes invite proposals that must cost less than a specified amount, 
and it is necessary to design a study that fits within that budget limit. Whether or not 
there is a specified budget limit, much thought needs to be given to the budget. On the 
one hand, an inflated budget could render a proposal uncompetitive if equally strong 
proposals cost less. On the other hand, an under-budgeted trial may not be completed, 
and the results will be unpublishable. Be honest about what is needed. Discuss with the 
officer at the funding agency if guidance is required.
Funding agencies usually provide a list of costs that are eligible to be included in 
a grant application, i.e. costs that they are prepared to cover. It is important to study 
the conditions carefully. Salaries must be commensurate with qualifications, fairness, 
and compatible with local contexts. If equipment is being requested, maintenance costs 
may need to be factored in. In intervention trials, other costs associated with medical 
treatment and social care may have to be included. Some agencies do not fund institu-
tional overheads or limit them to a maximum percentage of the total budget, so it will 
be necessary to check that these are acceptable to the applicant’s institution in advance. 
Institutional contributions could be important to show their commitment to the trial.
Sometimes, it is possible to leverage donations of drugs or supplies from pharma-
ceutical companies—these can lower the overall costs and make a proposal more cost-
effective to funders. If the specific proposal is linked to other projects, provide detail of 
what is already funded, and be clear about how much funding is being sought and how 
much will come from other sources. The key message is to cost the trial carefully, and 
justify all the costs requested.
5.9 How will the project be supervised and administered?
The grant application should demonstrate, for the conduct and analysis of the trial, that 
the trial team either has all the necessary skills and experience or will have access to 
the appropriate expertise. This may include aspects of trial governance and monitor-
ing of GCP and Good Clinical Laboratory Practice (GCLP) (see Chapters 16 and 17). 
It may be possible to delegate some of the trial procedures to specialist clinical research 
organizations (CROs). These units often have specialists in clinical trials to run certain 
aspects of a trial such as GCP or GCLP monitoring procedures.
Unless the trial is small, it is worth considering setting up a trial steering committee 
to guide and support the organization and monitoring of trial activities and guide its 
development, as the trial progresses. The steering committee should include members 
that represent a broad range of perspectives relevant to trial management. The steering 
committee also has the task of working with the DSMC to monitor progress and results 
without compromising the study design, especially in blinded studies (see Chapter 7).
5.10 How will results be disseminated?
The results of intervention trials are generally expected to contribute to the formulation 
of health policies and practice. It is important to think about how the results of a trial 
might be used. Including policy makers and officials from the public health sector in 
the early planning and design stages of a trial, and keeping them informed during the 
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conduct of the trial, can lead to a faster adoption of trial results into policy and practice 
after the trial. Funding agencies like to see a quick impact for their funds, so specific 
provision for this in the application can be an advantage (see also Chapter 23).
Intervention trials, by their nature, often produce very large amounts of personal data 
and biological specimens. Specimen and data storage and access may present compli-
cated ethical and legal issues. Who owns the specimens and data, who can see the per-
sonal data, how long the information and specimens should be kept, how the storage will 
be paid for, etc. are all pertinent questions. Funding agencies often require open access 
to data after the end of a trial, and the investigators may have to explain in their applica-
tion how they will manage this requirement, taking into account confidentiality issues.
5.11 How will the application be presented to funding 
agencies?
Most funding agencies have detailed instructions on the application process available 
on their Internet sites. Read the instructions carefully, and contact staff at the funding 
agency if anything is not absolutely clear.
Meeting deadlines is important. Sometimes, funding committees meet only once a 
year, and, if the deadline is missed, it may be a year before another submission can be 
made. Do not aim to submit just before the deadline—allow time, and submit ahead of 
the deadline. Sometimes, funding organizations need clarification if something is not 
clear in the application. Submitting early allows these issues to be sorted out, before the 
funding committee meets.
Do pay attention to details. Answer all the questions in the application form. For 
good presentation, make sure the proposal reads easily, for example, by minimizing 
the use of abbreviations and acronyms. Avoid technical jargon where unnecessary, and 
supply clear definitions of any technical terms that must be used. The proposal should 
be clear and succinct, free of contradiction or ‘leaps of faith’, and readily understood 
by scientists outside the immediate field of the investigator. Pay careful attention to its 
structure, ensuring it is logically ordered and argued. The aims and objectives of the 
proposal should be clearly defined at the start. Most space should be given to study 
design and methods. Use flow diagrams and figures where these will help the reader.
Allow time to go through the form several times. Make sure the final application is free 
of errors (spelling, typing errors, grammar, etc.), so as not to distract the reader. A care-
lessly put together application is often interpreted to indicate a careless investigator. It is 
valuable to have one or more colleagues, who have not been involved in writing the pro-
posal, to review it before submission, as they will often pick up inconsistencies and errors 
that the investigator has missed simply through being too familiar with the proposal.
6 Responding to referees
Many funding agencies allow applicants to respond to referees’ comments before the 
applications are considered by the funding committee. It is critical to make full use of 
the opportunity. Referees may have considerable experience in the field of the proposed 
research, and it is important to consider carefully their remarks and suggestions. Chal-
lenge comments that appear to be incorrect, preferably citing a reference. However, if 
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suggestions are made that might improve the design of the study, consider carefully 
how the study might be modified to address the concerns, and include these in the 
response that will go to the funding committee. The length of the response allowed to 
referees' comments is usually limited, so be precise and concise.
7 Funding decision
Members of funding committees will usually have to read a large number of proposals in a 
relatively short period of time, and thus it is important that grant applications are written 
clearly and unambiguously to facilitate rapid understanding. Brevity, precision, and clar-
ity therefore have great merit! The length of the grant application should be the minimum 
necessary to demonstrate the competence of the investigator and of the appropriateness 
and importance of the study proposed. It should never exceed the limits set by the fund-
ing agency. Reviewers will usually be annoyed, rather than impressed, with information, 
however erudite, that is not directly relevant to the research that is being proposed.
In reviewing a grant application, reviewers and committee members will be looking 
for the answers to some key questions, which are summarized in Box 8.2.
 1 What are the research questions that will be addressed by the proposed study?
 2  Why is it important that this research be carried out? How will the study 
contribute, directly or indirectly, to the advancement of public health?
 3  Are the applicants familiar with previous work in the area of the research, and 
does the study proposed build on and complement that work?
 4  Have the applicants done preliminary or pilot studies that demonstrate the 
feasibility of the proposed research?
 5  What is the research design, and how will it be implemented? Is the design 
appropriate?
 6  Are the estimates of the impact of the intervention reasonable? Is the size of the 
study correct to detect an impact of the magnitude expected? Is the expected 
impact of the intervention of public health importance?
 7 Is the time schedule for the work appropriate?
 8 How much will the research cost? Are the costs justified?
 9  Have the applicants considered the possible obstacles they might encounter in 
conducting the research and devised ways of overcoming these?
10  Have the applicants assembled the right team to do the research? What is 
their track record in research of this kind? Are their training and experience 
appropriate?
Box 8.2 Key questions that reviewers and funding 
committee members will consider when reviewing  
a grant application
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8 Common problems in grant applications
The amount of detail to include on the trial design is a tricky one to get right. Some 
forms allow only a limited space, so care is required to provide the key details con-
cisely but clearly articulated, so that reviewers can make an informed judgement. 
Standard methodologies can be simply referenced. A common fault is that appli-
cants do not discuss obvious potential problems or limitations with their study de-
sign and just hope that they will not be picked up by reviewers. This strategy rarely 
works, and it is better to show awareness of the issues and explain how they will be 
addressed.
A list of common problems in grant applications is given in Box 8.3.
9 Roles and responsibilities
Expect a response from funding agencies in a timely manner. Most funding agencies 
will inform applicants of the date by which a decision will be made on an application. 
Remember that the reason for rejection may not be due to obvious flaws in the proposal 
◆	 Poorly formulated objectives.
◆	 Too ambitious—trying to address too many questions in one study.
◆	 Insufficient attention to previous literature on the research question.
◆	 Poorly identified target population.
◆	 Poor research design—inadequate attention to what specific research question 
is being addressed.
◆	 Insufficient explanation of why it is important to answer this question and 
what impact it may have on public health practice.
◆	 No data, preliminary results, or pilot studies to support the feasibility of the 
proposed approach.
◆	 Inadequate description of the study design and procedures—derivation of 
sample size is often done poorly (consult a statistician!).
◆	 Analysis methods not specified sufficiently in relation to the main objectives.
◆	 Inadequate description as to who is doing what and when; lacking a detailed 
timetable for the research.
◆	 Insufficient attention to quality and quality control.
◆	 Inadequate allowance for data entry and analysis—often arrangements for 
analysis of data are not addressed at all in a proposal, other than that it will all 
go into a computer!
◆	 Inadequately justified budget.
◆	 Poorly structured; hard to follow the logic; inconsistencies.
Box 8.3 Common problems with grant applications
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but may just be that the application was not competitive, compared to others consid-
ered by the funding committee.
Remember that a successful application is only the start. Funders are interested in 
the progress of the project. They should be informed of any major findings, especially 
if there are going to be publications or if the results are controversial or groundbreak-
ing. Funders may wish to publicize these, and they often have the resources to do so 
effectively.
Funding agency staff are usually prepared to offer advice on grant issues, and keep-
ing them informed of important developments in a timely manner is advisable, for ex-
ample, unavoidable delays to a study, changes to the study design, extension requests, 
etc. If delays are anticipated, it is much better to notify the agency early, so they are not 
wrong-footed but can work with you to mitigate the impact of these delays. For ex-
ample, given sufficient notice, they may be able to revise the trial budget to allow money 
to be spent later than was originally agreed.
10 Further advice
There are numerous sources of general advice on how to write a successful research grant 
proposal such as a book by Gitlin and Lyons, 2008. Some are even produced by specific 
funding agencies such as the Medical Research Council of South Africa (<http://www.
mrc.ac.za/researchdevelopment/researchgrant.pdf>). Clearly, it is a smart move to read 
such advice if you are applying to an organization that provides it!
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1 Introduction to community engagement
The impetus to conduct trials of major public health interventions will often be from re-
search centres or universities, in collaboration with the Ministry of Health (MOH). The 
intervention trial team will usually select the communities which they consider are most 
suitable for the conduct of a trial. The active and continued engagement with people 
within these communities is essential for the successful execution of the field trial. This 
chapter aims to provide practical guidance to researchers on ways of approaching com-
munity engagement in trials in LMICs, including identifying some common pitfalls.
The terms ‘community’ and ‘engagement’ attract debate and controversy around 
their meanings and the social, ethical, and political implications of their application 
in development and biomedical research practice. These aspects will not be explored 
in detail in this chapter but are discussed elsewhere (Participants in the Community 
Engagement Consent Workshop, 2013). The present chapter should also be read in 
conjunction with Chapters 6 and 15, as understanding of the ethical responsibilities 
of researchers working in LMICs underpins the overall importance of community en-
gagement and the planning of its components (see Chapter 6), and community engage-
ment is essentially a social endeavour, with many overlaps with social and behavioural 
research approaches and methods (see Chapter 15).
For the purposes of this chapter, community engagement will be defined as the pro-
cess of the trial team working collaboratively with the community on all aspects of 
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the study which affect the community and its well-being. Overall, engagement should 
typically involve continuous mutual learning and communication between researchers 
and a range of community members before and during a trial and after a trial ends.
2 Planning and initiating community engagement
2.1 Defining communities and aims of engaging communities
The overarching goal of community engagement is to create and maintain mutual 
understanding and trust between researchers and the communities in which the trial 
takes place. Community engagement is supportive of many different aspects of good 
science and ethics in research. Examples are fostering broad support for research 
activities, facilitating good informed consent processes, encouraging sustained par-
ticipation, reducing risks of rumours and loss of trust, and making falsification of 
information less likely. From a community perspective, engaging with the trial team 
can help to ensure that the benefits of participation by community members outweigh 
the costs to them and supports their autonomy (i.e. informed, uncoerced decision 
making) within the trial. But community engagement is also seen as a good in itself, 
in demonstrating the trial team’s respect for the community and what has been de-
scribed as ‘cultural humility’ (Participants in the Community Engagement Consent 
Workshop, 2013).
As a first step, it is important to establish clearly who ‘the community’ is, or commu-
nities are, in relation to the trial and who the leaders or representatives of those com-
munities are. In many instances, the community will be defined, at least initially, by the 
trial team and may thereby be relatively artificial. Often, trial communities are defined 
as all those living within a particular geographical area, but, for some trials, the com-
munity may be a social or an activity-based group such as intravenous drug users or sex 
workers. Defining communities is not necessarily straightforward. For example, what 
are the relevant communities for trials whose participants are regular migrants (for 
example, people who move seasonally between two geographical locations in pursuit 
of employment) or for trial participants who are selected at their place of work, such as 
factory workers, who live within wider social and geographical communities? In many 
trials, researchers have to engage with several communities and several different types 
of communities. If problems arise in relation to the trial in any one community, this 
may slow, or in extreme cases, jeopardize the conduct of the whole trial.
When the participants in a trial are selected from a specific subgroup of the popula-
tion, such as a particular occupational group, or people who share a particular behav-
iour, such as men who have sex with other men, careful thought needs to be given to 
which aspects of the community engagement will apply only to the social community 
that the trial participants come from, and which will apply to the wider community 
from which they are drawn. For example, in a trial in Tanzania, women who worked 
in specific locations, such as bars, restaurants, and guesthouses, were invited to par-
ticipate in an HIV prevention trial, because they were at relatively high risk of HIV 
infection. It was decided that the reason why this ‘high-risk’ occupational group had 
been selected for the trial would not be discussed explicitly in community engagement 
activities with the wider geographical community and their representatives. It was also 
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decided that community engagement structures (such as the representatives of the tri-
al’s CAB and its subgroups) would be drawn from trial participants and that communi-
cation with the wider geographical community would be kept to a minimum to avoid 
further stigmatization of women from these occupations (Shagi et al., 2008). In Kenya, 
a similar approach was adopted for a study working with men who have sex with men, 
but, over time, members of the wider geographical community became concerned that 
researchers were promoting homosexuality; following protests and media attention, 
far greater attention was placed on communication with the wider community.
While the overarching goals for community engagement have been described earlier 
in this section, this must be followed by defining the specific objectives of community 
engagement with each of the specific trial communities. These objectives will help to 
define the overall strategy, in relation to who should be involved, how, throughout and 
after the trial, and what methods and resources will be needed for the community en-
gagement process.
Both the trial and community engagement activities will inevitably have implica-
tions and impacts which are not expected or intended. Community engagement can 
never be a prefabricated and entirely predictable set of activities that could apply to 
different settings; rather it needs to be seen as a dynamic and an ever-changing set of 
negotiated relationships (Lavery et al., 2010). The objectives and activities identified 
at the outset may need to be modified over time, in response to emerging issues and 
shifting priorities over the course of the trial. For this reason, community engagement 
must not be seen as an entirely linear process, nor its effectiveness evaluated as though 
it were.
2.2 Preliminary investigations in study communities
As early as possible, even during the process of identifying the communities, the trial 
team should work together with community leaders and local experts to begin to de-
velop a strategy for achieving and sustaining community engagement throughout the 
trial. Many of the specific issues to be considered will depend upon the nature of the 
intervention and the kind of participation anticipated from the community, so it is 
important to contextualize planning to the specifics of the trial. The aim is to develop 
as close a partnership as possible between the trial team and all relevant communities 
in all aspects of the trial’s design, implementation, interpretation, and dissemination. 
To achieve this, sustained two-way channels of communication must be created that 
facilitate regular exchange of information between community stakeholders and the 
trial team. The formation of a specific CAB, in some cases with representation from 
several Community Advisory Groups (CAGs), is one means of supporting this on-
going communication and is discussed in more detail in Section 2.3. Given some of the 
recognized problems with CABs, many trials engage with several CAGs, without one 
overall CAB. For simplicity, we shall use CAB/G to represent both concepts in the rest 
of this chapter.
Figure 9.1 outlines the main steps involved in engaging communities with the many 
activities involved in a field trial.
Preliminary studies and participatory planning processes can reduce the risk of 
potential pitfalls by accommodating the perspectives and preferences of different 
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community members, as far as possible, and can provide some accountability. Various 
ethnographic and participatory methods can be used to explore community charac-
teristics to ascertain the local relevance of the diseases under study and to facilitate the 
participation of community members in the proposed trial. Some of these methods are 
described in more detail in Chapter 15. Participatory rural appraisal (PRA) and par-
ticipatory learning and action (PLA) methods may be particularly helpful (Chambers, 
2008). Of particular note, exploration of views around aspects of trials that are unfa-
miliar to community members are likely to need methodological approaches, based 
on participatory forms of information sharing and discussion to generate meaningful 
engagement.
Deciding who should speak for the community, based on accurate knowledge of 
local interest groups and their likely representativeness, can be an essential, but diffi-
cult, step, given the likely range of different interests. Errors at this stage can damage the 
relationship of the trial team with the community. It may be useful for the trial team to 
listen to multiple community voices. It should also be recognized that some communi-
ties may simply not be interested in a trial as it is planned, or at all. A common failing in 
planning is for researchers not to recognize the complexity of, and dynamics between, 
various interest groups in a community and to assume that the official community 
Identify and map community
structure(s) and the linkages between
interest groups, formal and informal
councils, potential representatives,
community health workers, and other
health providers.
Focus group discussions with key
constituents to determine current
perceptions, care practices, and local
terms for the health conditions that
will be aected by the planned
intervention.          
Intervention trial team
liaises with Ministry of
Health to seek approval at
national level and seeks
appropriate national and
local ethical approval.     
Selection of potential trial
communities by trial team,
with input from community
stakeholders.   
Form a Community Advisory
Group Board (CAB). With them,
determine types of community
participation, incentives,
integration with other sectors.
Develop the engagement
strategy with clear objectives
and indicators.       
Working in a participatory
planning process with these 
groups, begin formulation of
a community engagement
strategy to assure sustained
engagement of the
community throughout the
trial.     
Seek approval for the conduct of the
trial, as required, at dierent levels of
social, political, and administrative
structures. Maintain close coordination
with the district health team and local
service providers.     
At study completion: nal results
communicated to, and discussed
fully with, the CAB and
community as a whole. Arrange
a nal forum for open
discussion of the trial’s ndings
and any plans for continuing
activities.        
Execution of research: in addition to the
consents above, obtain household and
individual consent.  Ensure systems are
set up to allow regular interaction with
key communities, front-line sta, and
Ministry of Health to identify and
respondincluding through changes to
the trialto any unexpected questions or
concerns.  Ensure organized and regular
feedback to all levels.         
Working with the CAB and
community leaders, obtain
community understanding
and consent through
contextually appropriate
mechanisms via village
religious leaders,
community councils. Create
awareness about the study
purpose. Consider a public
forum for open discussions.         
Figure 9.1 Community engagement for an intervention trial.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
2: PLANNING AND INITIATING COMMUNITY ENGAGEMENT 149
authorities, such as government administrators or traditional leaders, accurately rep-
resent the views of all groups within the community. If the trial requires active involve-
ment of, for example, the poorest and least educated, a careful investigation of who 
could best represent their views will be important. These complexities and dynamics 
are also reflected within and between extended families and households, such that the 
views of the least empowered (often young mothers) may be particularly difficult to 
ascertain and take into account.
In relation to understanding community perceptions and practices relevant to the 
trial, researchers can draw on preliminary participatory planning processes, including 
local experts and community representatives and leaders. It may be easy for researchers 
to overlook important differences between their own health beliefs and practices and 
those of community members, in ways that can have major practical and ethical im-
plications for the conduct of the trial (including the engagement of the community in, 
or its rejection of, the trial and any future research). For example, in some areas where 
infection with Schistosoma haematobium is endemic, some people regard blood in the 
urine as a normal part of a child’s development, so an intervention that prevents this 
may be unpopular, unless this belief is taken account of in planning the intervention. 
Differences in health beliefs and practices are also likely to exist across the community, 
making them less easy for researchers to recognize and generating the need for flexibil-
ity in the way research is implemented. The preliminary investigations undertaken to 
explore community perceptions and practices can also begin to sensitize communities 
in a positive way to the future research. In some situations, these early investigations 
will reveal that more focused and detailed social science or multidisciplinary studies 
are needed to explore particular issues (see Chapter 15).
There is a growing body of work documenting experiences with community engage-
ment from many different settings (for example, Cheah et al., 2010; Gikonyo et al., 
2008; Marsh et al., 2010, 2011; Reddy et al., 2010; Shubis et al., 2009). These studies 
illustrate how community engagement and input, particularly where well planned, 
can improve consent procedures and promote better understanding of the purposes 
of research among study participants. However, they also illustrate the complexity of 
doing community engagement well (it can never be an easily ticked off checklist!). It is 
also important to recognize that community engagement can sometimes lead to unex-
pected, and sometimes unwanted, outcomes such as raised expectations among com-
munity members, confusions about the roles of community members, and conflicts 
within communities (Angwenyi et al., 2013). These studies illustrate the importance 
of thinking about community engagement goals, activities (for example, roles of dif-
ferent boards or committees), and monitoring and responding to issues and ideas, as 
they arise.
2.3 Setting up Community Advisory Groups or Boards
An important initial step to facilitate community engagement in a trial is often the 
establishment of a CAG or CAB. The exact form of a CAG/B is likely to vary, depend-
ing on the context of the trial, but each one is generally made up of representatives 
of the trial community and serves as a liaison body between the trial team and local 
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communities. Investigators can liaise with the CAG/Bs to ensure there is a clearly 
articulated engagement strategy which has defined objectives and appropriate ap-
proaches to assess effectiveness. Issues of governance, such as the degree of responsi-
bility and formality of the CAG/Bs and their relation to other district and community 
organizations, must be worked out, according to the specific needs of the trial and 
circumstances of the community. One engagement approach, adopted by a long-term 
international research programme in Kenya, has been to have regular interactions with 
a relatively large network of local residents put forward as representatives by their own 
communities. This network is consulted on a range of studies for a fixed period of time 
(Kamuya et al., 2013).
The primary role of a CAG/B is to provide input to study planning, including early 
stage advice on the acceptability of planned research and how to maximize this, and 
continuous advice throughout the study, including:
◆	 practical study arrangements for transport, follow-up, informed consent, and as-
sent processes at individual and community levels, reimbursements, and study 
compensations and benefits
◆	 consideration of the potential issues and sensitivities associated with the trial in 
the context in which it will be conducted. For example, past or current exposure 
to research programmes or interventions may have an adverse or a positive effect 
on the planning for a future trial. Knowledge and understanding of this history 
is an important topic to discuss in the early stages of engagement. Since some of 
these sensitivities and issues are likely to emerge during the course of the trial, 
rather than being anticipated at the start, the advice of a CAG/B throughout the 
trial is likely to be important
◆	 identification of important people and groups to involve in the trial, for what 
purpose, and at what stage in the conduct of the trial. Examples include those to 
consult on study design, the ‘gatekeepers’ whose support must be sought, those 
to assist in creating awareness of the study within the community, and those best 
placed to provide feedback from the various interest groups about the research 
activities.
While working through CAG/Bs has been shown to strengthen research relation-
ships and ethical practice, challenges include defining which communities should be 
represented, selecting representatives as CAG/B members, ensuring clarity in roles and 
adequate training to fulfil those roles, facilitating appropriate motivation of members, 
moving beyond tokenism or window dressing, and avoiding politicization. These chal-
lenges are most likely for small groups or boards with long-standing, highly formal-
ized structures. A specific set of tensions have been identified around the potentially 
conflicting dual functions that some CABs have of both advancing the research and 
protecting the community.
Given these issues and the overall importance of seeking community inputs to trial 
planning and conduct throughout the trial, it will generally be important for researchers 
to seek actively to understand the views of a wider range of community members. This 
will involve the use of a range of different community engagement mechanisms and 
require the skills of experienced community liaison staff. In complex or controversial 
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situations, social science research methods can help to understand, and sometimes to 
build on, wider community views to support decision making on appropriate research 
practice.
Taken together, creative engagement of community stakeholders and champions 
who have local knowledge and expertise, through CAG/Bs and other formal and infor-
mal mechanisms, is important for establishing community rapport and trust, imple-
menting the research, and ensuring community involvement and counsel throughout 
the execution of the research.
3 Engaging community stakeholders
3.1 Engaging national and regional administrations
Appropriate regard must be paid to the local and national social, political, and admin-
istrative structures and procedures. It is important to determine in which order the 
various preliminary contacts should be made (Figure 9.1).
At the national level, research investigators must comply with appropriate admin-
istrative, political, and research consent procedures. These may include obtaining 
consent from national research councils, ethics committees, and civil society inter-
est groups. With increasing community-based efforts in many LMICs in recent years, 
many different groups may be active at the research site. Their activities may compete 
with, or enhance, the proposed research operations. Where other groups are operat-
ing in the study area, it is important to create strategic alliances with the programme 
implementers to ensure their support and cooperation for the various elements of the 
study. However, investigators must exercise caution, especially if tensions exist between 
different groups in the communities, as allying the trial to such a group may adversely 
impact the trial’s community partnerships. Religious organizations are often powerful 
advocates, favoured by the communities, but may be strongly opposed to some inter-
vention strategies or to each other, so it is important to think carefully and act strategi-
cally, in terms of how the trial team approaches and relates to them.
3.2 Engaging district health teams and health providers
Generally, research trials are conducted at the sub-national level and therefore require 
close coordination with local authorities and ongoing programmes and activities at 
that level. Investigators should seek opportunities for leveraging the interest, advice, 
and support of the local health authorities, including building synergy between re-
search and routine health care programmes and services, as far as possible. An early 
meeting with the local health management team(s) for the area covered by the trial 
(in this book, referred to as the district health management team(s) (DHMTs)) should 
be arranged to discuss the planned trial, review the specifics of the interventions to 
be tested, and explore opportunities for partnership in planning and execution. De-
pending on the relevance of the trial for international and national policy, it may be 
important to have early discussions with the DHMT on ways in which the new inter-
vention could best be integrated with ongoing programmes if the trial were to show 
a beneficial effect of the intervention under study. The involvement of MOH health care 
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providers in the research will help align operations, prevent conflict in services and 
scheduling, and facilitate their perceptions of transparency, so they do not feel threat-
ened or intimidated by the trial. Their endorsement is critical, as study participants 
are likely to consult them for advice or to alleviate their fears about possible adverse 
outcomes of the intervention. Physical integration of research activities within routine 
health service facilities can also provide opportunities to develop local health system 
infrastructure, with further positive effects on these key relationships, as well a provide 
long-term benefits to the community.
The DHMT can also foster community partnerships between the researchers and in-
formal networks of opinion leaders, potential champions, and service providers such as 
traditional birth attendants, community health workers, and community health coun-
cils. Inclusion of influential traditional healers in the community engagement process 
may also help, since they will be consulted by some community members and are often 
highly influential within the community. Endorsements from the DHMT and other 
health care providers trusted by the communities can facilitate subsequent engagement 
within the communities.
3.3 Engaging community leaders
A multi-pronged, multi-stage strategy may be essential to explore and identify appro-
priate community leaders from the communities and to ascertain their willingness to 
support the planned trial activities. Community advocates from the private or public 
sector, including health providers from the local health facility or district hospital, or 
researchers who have previously worked in those sites can facilitate the identification of 
these formal and informal community leaders. They may include village leaders, trad-
itional healers, religious leaders, traditional birth attendants, leaders of women’s clubs, 
farmers’ clubs, midwives, or others. The first consultation may involve discreet enquiries 
to determine these power structures and the level of influence and trust that they have 
among the community members. Usually, there are multiple leaders, and a CAG/B could 
include members from among these, with representatives from each community seg-
ment that is relevant to the trial—political, geographic, religious, and socio-economic.
Appropriate formative research methods, such as key informant interviews, focus 
group discussions, and observation (see Chapter 15), can be applied to appreciate local 
norms and to guide effective and appropriate protocols for community engagement. 
The best ways of providing the information on the purpose of the trial, potential ben-
efits and risks, roles and expectations within the trial, how best to detect and address 
potential AEs, etc. can be established through dialogue with key informants within the 
community. This may be particularly important if the health problem being addressed 
is a community priority and a placebo arm is part of the study design. If community 
volunteers are to be engaged for enrolment of trial participants, follow-up, distribution 
of interventions, or data collection, their recruitment, oversight, and norms for remu-
neration should be discussed with community representatives, where possible (for ex-
ample, CAG/Bs or other established mechanisms), as these can be complex (Molyneux 
et al., 2013). Community representatives can also help with the design of appropriate 
household and participant consent procedures. Concepts, such as trial ‘blinding’ and 
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randomization, are not likely to be readily understood by community members, so the 
investigators should work with community representatives to establish how best to com-
municate these ideas to potential participants, using local illustrations and rationale.
The duration of this process will depend on the past exposure of the community to 
research trials, the complexity of the trial or trial-related issues, and the trial team’s pre-
existing knowledge of the community. In isolated communities, with poor linkages to 
health personnel or other public entities, the process may need to be longer and require 
more rigorous dialogues with the community leaders to ensure that locally appropri-
ate ways of interacting are not violated. Some traditional practices may require tokens 
of appreciation. For example, in some societies, it is appropriate to give a community 
leader a small gift at the commencement of a formal visit. In others, the norm is for 
‘visitors’ to be given a small gift. These local practices must be within research norms 
and should not unduly influence participation or compliance. Cultural and language 
barriers should be considered in approaching the leaders and decision makers in com-
munities. Locally employed community liaison staff, other front-line research staff, and 
local representatives might assist in selecting a respected advocate who speaks the local 
dialect or language, where needed.
3.4 Working with the wider community
It is often important and useful for community liaison staff or researchers to intro-
duce the study to the wider community, from which participants may be drawn, at 
public meetings organized in conjunction with community leaders or representatives. 
In some situations, CAG/B members or other community representatives may play an 
important role in this introduction, including explaining the expectations from the 
community of the trial team and describing the characteristics of the potential par-
ticipants who will be recruited. Community representatives or leaders must have a 
reasonable level of understanding of the technical and ethical aspects of the study to 
take on this initial introduction, since there are risks of important (often inadvertent) 
misrepresentation.
Early on, it may be sufficient to provide a general introduction to the trial, along with 
some details of the benefits and potential risks associated with participation. A trans-
parent process should be adopted to solicit questions and to address concerns truthfully. 
It is critically important to establish mechanisms to ensure that there is a continuing 
dialogue and interchange between the community and the researchers throughout the 
trial, and regular meetings with representative groups (such as a CAG/B or community 
leaders) and periodic open meetings with the community should usually be a part of 
this process.
Initial public meetings can be used to begin the process of recruitment in some situ-
ations by inviting interested individuals or families to attend follow-up meetings that 
will feed into later informed consent processes.
3.5 Roles of front-line research staff in community engagement
With respect to the engagement of the trial team with the community, it is very im-
portant to consider the range of formal and informal interactions that front-line staff 
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(fieldworkers, research assistants, community facilitators, counsellors, health work-
ers) have with trial participants, their families, and the wider community from which 
participants are drawn. Front-line staff often come from the communities involved in 
the research and have the greatest amount of formal and informal interaction about 
the trial (i.e. engage the most) with community members. In mediating between the 
often very different priorities and concerns of well-resourced research institutions and 
relatively poor communities without good access to affordable quality health care, 
front-line staff are not simply neutrally observing and adhering to formal, externally 
derived ethical rules. Instead, they play a crucial, and often under-recognized and 
under-supported, role in ‘doing ethics’ in the field, for example, negotiating tensions 
between benefits approved in protocols with participants’ and communities’ needs 
and demands (Kamuya et al., 2013). In establishing and maintaining interactions and 
relationships between study participants, non-participants in a community, and re-
search staff, front-line workers also have a central role in the success and quality of the 
science itself.
Front-line research staff vary enormously in how embedded they are in the com-
munities of a trial, and how embedded they are has differing implications for their 
social relationships and associated practical and ethical strengths and dilemmas. At 
one end of the spectrum, staff may continue to live in their own homes and neigh-
bourhoods over the course of the trial, and, at the other end, they may not live in 
any of the specific study communities but be employed to work across a large geo-
graphical area and travel out to work in trial communities every day. There should 
be careful consideration at the outset of a trial of how different strengths and chal-
lenges, related to how closely each member of the trial team is related to the trial 
community, might be balanced across a team. Where a trial is employing new staff 
in areas of few opportunities for paid employment, this can be a highly conten-
tious issue. It can be helpful, where possible, to introduce systems that are open and 
transparent (as opposed to being solely based on, for example, community leader 
recommendations).
Also important is ensuring careful participatory training and interactions with 
front-line staff from the outset and throughout the trial. These interactive sessions 
should be two-way—staff should feel free to make supervisors and PIs aware of 
gaps in their own understanding, challenges that they face, and ideas on how to 
strengthen research, and researchers should share their perceptions, understanding, 
and knowledge of the requirements for trial success. This open, respectful two-way 
exchange will help the senior researchers to learn about local priorities and con-
cerns and how to respond to these in a way that balances local needs and priorities 
with trial and (inter)national requirements, while, at the same time, maximizing the 
understanding and ownership of key trial issues among front-line staff, and hence 
their ability to communicate these effectively with the trial community. Training and 
supportive supervision sessions are likely to need to include information on what a 
trial is and how the rights of participants are protected in trials, benefits to local com-
munities from this trial, and what happens when the trial ends. Role plays and dem-
onstrations, based on local knowledge and experience, can help to develop a range 
of strategies for field staff to cope with both expected and unexpected scenarios. 
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In some scenarios, such as discussion of highly sensitive topics or where there are 
interactions with very vulnerable communities, it may be important to ensure that 
fieldworkers have access to counsellors. Where trials or research programmes are 
large or long-term, it may be important to professionalize this cadre of staff, includ-
ing establishing systems by which such workers can, if performing well, advance 
their careers and increase their remuneration. This may include giving such staff 
training opportunities.
4 Strategy and content of information  
for communication
Appropriate communication strategies and content should be designed and developed 
for different community audiences, depending on the nature of the information to be 
conveyed in the trial (also see Chapter 23). Depending on the specific requirements 
of the trial, these strategies may need to operate at several levels of the trial commu-
nity, including communication with individuals, specific target groups, or the wider 
public. For example, community engagement can feed into, and overlap with, consent 
processes, which are discussed in Chapter 6 and are a clearly key activity in any trial 
(Participants in the Community Engagement Consent Workshop, 2013). All commu-
nication activities must use culturally appropriate methods and take into consideration 
the target audience’s beliefs and norms, numeracy and literacy skills, power structures, 
gender issues, and other community dynamics that may differ from those of the trial 
team. Special issues may arise related to the collection of blood, urine, or stool speci-
mens (see Chapter 17, Section 2).
Participatory methods, using visual aids, can be used to illustrate and simplify sci-
entific concepts related to the trial. Community health workers, traditional birth at-
tendants, and other community health care providers with established credibility may 
sometimes be appropriate people to communicate with community members at vari-
ous levels throughout the trial. But their motivation, training, other activities, and 
sustained engagement will need to be managed in collaboration with other commu-
nity representatives (Angwenyi et al., 2013). Forms of participatory theatre, song, and 
dance can be effective in introducing new studies in contexts where these are estab-
lished and valued means of communication. In some settings, radio, roadshows, and 
mobile phone messaging have been used to communicate with communities about 
research (Ndebele et al., 2012).
While much of the content of the information to be conveyed will depend on the de-
tails of the trial, it will be important in all cases to emphasize general information on the 
nature of research, including the voluntary nature of participation and the confidenti-
ality of any information provided by the participants. Given common public concerns 
about safety in intervention trials, it may also be helpful to give a basic explanation 
of international and national research review processes for all studies and, for trials 
of drugs and vaccines, the trial phases, so that the current study is widely seen in this 
context. CABs and front-line staff can provide good support in assessing the appropri-
ateness and comprehensibility of information included in messages and materials to 
support communication about the trial.
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5 Sustaining community engagement
The initial discussions with the community leaders will provide insights for developing 
good strategies for sustained community engagement. Intervention studies evaluating 
medical products or vaccines will require close monitoring, and therefore continuous 
surveillance and frequent engagement with a CAB and other community members. 
AEs, often unpredictable, may worry local communities, harm the reputation of the 
trial and its parent research institutions, and damage the credibility of the researchers. 
Such events need to be appropriately managed. Effective management and reporting 
mechanisms, with clearly defined protocols, should be established as part of wider 
community engagement strategies. Informal meetings and fora can be held period-
ically to engage community members about their perspectives of the trial and to ad-
dress any concerns in a timely manner. Frequent two-way information flow between 
the investigators, front-line staff, CAGs, other representative groups, and individual 
community members can foster trust, ensure sustainability, and enhance management 
oversight.
In long-term field trials, even if excellent procedures have been established to in-
corporate the ideas of community members and to respond to concerns at the outset, 
new expectations may evolve over time, and perceptions may change. Good sustained 
community engagement mechanisms should ensure that the trial team is aware of 
these issues, and it will be necessary to work with the front-line staff and representative 
groups to decide how best to address them.
Some trials may involve community members in substantial inconvenience. If pro-
cedures are time-consuming, participants may become fatigued and their initial enthu-
siasm may wane. Generally, it is important to discuss what time of day, or what time of 
year, is most convenient for the community members. Sometimes, compensating indi-
viduals, in the form of money or food, for time lost from work or other activities may 
be warranted, and, in some cultures, it may be considered appropriate to compensate 
the participant if a blood sample is taken. However, this could be a disastrous practice 
in some settings, as it may fuel commonly held rumours that blood is being bought 
and sold by researchers. Various strategies have been adopted by researchers to ensure 
culturally appropriate compensation for trial participation such as through the provi-
sion of health care services. These strategies need careful thinking through for each 
trial, ideally with community input. Mechanisms for referral to appropriate health care 
and compensation if harm does occur are key elements of trial protocols and could be 
informed by community representatives. All benefits must be viewed carefully from an 
ethical standpoint, with the aim of ensuring that people are compensated appropriately, 
but intra-family and community conflicts are minimized, and individuals are not ‘co-
erced’ to participate in the study against their will (Molyneux et al., 2012). See Chapter 6 
for further discussion of these issues.
Consideration of the frequency and nature of feedback of results is important in all 
trials and must be considered from the outset. It is important to distinguish between 
feedback of individual and of overall (aggregate) trial results.
For individual test results, a common reason for a participant to refuse to provide a 
second blood sample is that no information was provided regarding the result of tests 
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on the first sample. Sometimes, this problem may be avoided by conducting some la-
boratory tests on site. For example, haemoglobin, rapid tests for malaria, and tests for a 
large number of other conditions can be performed in the field. Rapid diagnostic tests 
for malaria, for example, can be done on the spot, and immediate treatment can then be 
provided, if indicated. Where this is not possible, individual results can be fed back to 
participants, and the practical and health implications of doing so for individuals and 
the research team may need careful deliberation and clear communication with both 
trial participants and the wider trial community.
For overall trial results, it is important to keep local health workers and the 
DHMT informed of the progress of the trial and of the results, as they accumulate 
and at the end of the trial. Newsletters or district and provincial meetings can be 
used to communicate the results to them. At the completion of the trial, the final re-
sults of the study should be communicated to, and discussed with, the participants 
and the trial community as a whole. The implications for the community should be 
discussed with them, as well as with all the authorities involved. Such feedback is 
essential, not only from an ethical point of view, but it may also pave the way for 
co-operation in future research activities and for sustained health-seeking behav-
iour on the part of the community members. For example, research on the feedback 
of findings from a malaria vaccine trial in Kenya showed that sharing of aggregate 
findings was very much appreciated and that the inclusion of individual results in 
feedback sessions reassured participants of trial safety and helped ensure that posi-
tive results of the trial were not over-interpreted. Feedback sessions also offered 
an opportunity to explain key information and respond to emerging community 
questions and ultimately re-evaluate and re-negotiate trial relationships and bene-
fits (Gikonyo et al., 2013).
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1 Introduction to conducting censuses and mapping
In nearly all intervention trials, it will be necessary to compile a register of individuals 
included in the trial. The register should include sufficient identification information 
on each person to enable participants to be followed over time, with minimal pos-
sibility of confusing one individual with another. To assemble a suitable group for 
inclusion in a trial, it may be necessary to enumerate (i.e. count and identify) all the 
members of a geographically, or otherwise, defined population or a specific subgroup 
of it (for example, children aged less than 5 years). Such a population enumeration 
(census) may serve as a sampling frame to select a representative subset of the popu-
lation or may be used to assess how representative the study group is of the whole 
population, if some individuals refuse to participate, or are not included, in the trial 
for other reasons.
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Identification and follow-up of the members of a population and selecting a sample 
of them will usually be easier if a map is drawn of the area, marking individual homes 
and prominent topographical features. Mapping may also be valuable in planning the 
logistics of fieldwork and in studying the epidemiology of a disease, for example, to 
determine if cases of a disease tend to occur near water courses or in some other non-
random fashion geographically.
Mapping and enumeration of a population are not always necessary, but often such in-
formation collected at the start of a trial is vital to its successful conduct. For example, in a 
leprosy vaccine trial in Venezuela, the trial group was defined as the household and other 
close contacts of prevalent leprosy cases (Gupte, 1999). The prevalent cases were distrib-
uted over a very wide area, in which most of the population were not included in the trial. 
It was necessary to enumerate the household and other contacts of prevalent cases, but 
it would have been inappropriate to enumerate the entire population or to map the lo-
cations of all households, other than was necessary to be able to find the contacts during 
the course of the trial. Conversely, in a malaria chemoprophylaxis study in The Gambia, 
an attempt was made to include all children in a defined area, and detailed mapping and 
enumeration were undertaken to facilitate the conduct of the study (Jukes et al., 2006).
In this chapter, guidelines are given on mapping and on ways of compiling a popula-
tion register to facilitate long-term follow-up of the participants in a trial. Resources, 
including tools and advice on doing this in LMICs, are available from INDEPTH 
(<http://www.indepth-network.org>).
2 Uses of maps and censuses in intervention trials
A map of the trial area and a population enumeration (census) provide:
◆	 a sampling frame for the selection of those in the target population who will be 
included in a trial
◆	 denominators for the computation of morbidity and mortality rates
◆	 baseline population characteristics, which may affect the impact of an interven-
tion and which can also be monitored for changes during the study
◆	 a basis for planning the logistics of the fieldwork, for example, which households 
should be visited by one fieldworker and in which order or to demarcate clusters 
within a cluster randomized trial
◆	 a means for studying factors that affect disease rates. Age, sex, and place of resi-
dence affect the risk of many diseases, and information on these and other factors 
that may influence exposure or susceptibility to disease, or which may influence 
its outcome, should be recorded at the start of a trial.
3 Preparations for a census
3.1 Planning
Early in the planning of a census, it is important to ascertain what information already 
exists about the population, either in national censuses or from local or national surveys 
that may have been conducted previously. In planning a census, it is important to seek 
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the active collaboration of the community, generally through the community advisory 
board (CAB) and the local health services, using the special knowledge these groups are 
likely to have on the local population (see Chapter 9). This will also enable them to get to 
know their area better, and they may wish to use the information collected in the census 
for the benefit of the population, while the trial is in progress and after it has finished. In-
deed, if local health workers and community leaders are not involved in the planning, they 
may be antagonistic to the study and may transmit these feelings to the study population.
In some populations, local administrative offices maintain up-to-date lists of tax 
payers that may give a good indication of the size of a population (or may not if large 
numbers of people avoid registering for tax collection!). Lists of voters or of residents 
may also be available through local administrative offices. Health or other surveys may 
also have been conducted previously. Gathering this information will entail visits to 
the study area, to government statistical offices, and possibly to universities or other 
institutions that may have organized specific surveys.
Useful data are usually available from national censuses, generally undertaken every 
10 years. In the planning of a trial, census data may be used to select a suitable area 
such as a group of contiguous villages whose population is of adequate size for the trial. 
Often, however, the information in a national census is out of date or may be inaccu-
rate. For example, a population census for a trial in Ghana found that the study census 
numbers matched those of the recent national census very well, except in one area that 
had applied to become a separate district where the national census numbers were 
roughly 50% higher than those in the study census! From a national census, it will usu-
ally be possible to obtain data for an area regarding the distribution of the population, 
with respect to age, sex, ethnic group, household size, and population density, though 
this may require a specific request to the census bureau. Estimates of mortality, fertility, 
and migration rates may also be available. Migration rates may be especially useful to 
estimate potential losses to follow-up in a longitudinal study.
For detailed planning and conduct of a trial, a special enumeration will usually be 
necessary. The population may be enumerated at the same time as the intervention is 
being started or as a separate exercise in advance. The decision regarding which to use 
will depend on the specific circumstances of the trial. In the rest of this chapter, the cen-
sus is assumed to take place shortly prior to the start of the intervention, but the basic 
principles of enumeration are similar whenever it is conducted.
The initial census may be the first formal contact that most members of a popula-
tion have with the trial team, though it should have been preceded by liaison of the 
trial organizers with local officials and local leaders (discussed in Chapter 9). The enu-
meration exercise provides an opportunity to explain the aims, objectives, and pro-
cedures to be used in the trial. For example, an information sheet or newsletter might 
be left with each household explaining key issues, announcing community meetings 
where the trial will be explained in more detail, and giving contact details for further 
information.
Although adequate time needs to be allocated for enumeration and mapping, these 
tasks should be conducted fairly rapidly to minimize the amount of migration, includ-
ing from one house to another house within the study area, during the course of the 
census. The aim of a census is to enumerate the resident population as completely as 
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possible, so the timing of the census is often very important. In areas where there is 
seasonal migration, the census might be planned for a period when most people are 
at their normal residence, and, in some populations, trading seasons and market days 
should be avoided. It may also be important to avoid the rainy season when areas may 
be inaccessible or the harvest season when people may spend most of the day away 
from their homes working in their fields. In urban areas, weekends may be the best time 
for surveys, since, during the week, a high proportion of people may be at work. The 
time of day may also be important. In some areas, it has been found best to conduct a 
census after dark, when people have returned from work, but this may not be accept-
able or safe in other settings.
It is tempting to try to collect as much information as possible about the study popu-
lation during the initial census such as information on education or fertility histories. 
In the interests of speed, however, it is usually preferable to collect such information in 
a separate round of interviews after the initial census.
Once they have been entered into a computer, data from the census may be used for 
printing questionnaires, lists of children, and so on, which will aid subsequent surveys 
(see, for example, Schellenberg et al., 2001).
To conduct a census, a house-to-house enumeration is necessary in most popula-
tions. In densely populated villages, with only a few items of data being collected for 
each individual, a fieldworker going from house to house might be expected to com-
plete census schedules for about 200 people in a day. The number of households this 
will comprise will depend upon the population structure. In less densely populated 
areas or with a longer census schedule, 50 persons a day might be a realistic target (see 
also Chapters 14 and 20).
3.2 Pre-testing
The design and testing of questionnaires, including their pre-testing and pilot testing, 
whether developed for use with pen and paper or on mobile electronic devices such as 
mobile phones, tablet computers, or PDAs, are discussed in Chapters 13 and 14. This 
process will involve several steps, from initial drafting and pre-testing to pilot testing 
under field conditions on, say, between 50 and 200 households. Field testing will pro-
vide an opportunity to train and evaluate the performance of staff and may assist in the 
identification of those suitable to become supervisors for the main enumeration.
3.3 Recruitment and training of field staff
Guidelines for the recruitment of staff are given in Chapter 16. Training in census tech-
niques is a good way of introducing staff to field research methods. Following instruc-
tional ‘classroom’ sessions, trainees should practise conducting a small census themselves.
3.4 Mapping
While a population census can be conducted without a detailed map being drawn, 
for many trials, especially large ones, or when the trial will last several years, they will 
greatly benefit from maps being drawn of the study area. These can be used for planning 
and conducting an initial census, for subsequent house-to-house surveys, and/or for 
following up participants, but also for displaying trial results and for spatial analyses. 
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The type and accuracy of mapping will depend on how maps are to be used, but there 
are two main types: paper maps (either official or hand-drawn) and digital maps.
The simplest mapping is the use of existing maps from Departments of Lands and 
Surveys (or their equivalents) and from special sources such as the Army, Agriculture 
Departments, Tourist Offices, and the Central Statistics Office (for example, maps that 
were specially drawn for a national census). These maps may provide enough informa-
tion for the trial to be carried out without the need for further mapping. More likely, 
they will form the initial starting point for additional mapping.
While existing paper maps and hand-drawn maps may supply all the information 
required, digital maps provide far better functionality. For example, if looking at the 
relationship between a population and a water source or access to services, distances 
can be calculated quickly and easily, using digital mapping software.
Digital maps do not need to be expensive or complicated, and modern Internet map-
ping sites (for example, <https://maps.google.com> or <http://www.openstreetmap.
org>) may provide maps of sufficient resolution to identify individual houses, streams, 
and tracks. Where data are missing, a global positioning system (GPS) device can be 
used to record the location of each household, uploading this information to a com-
puter. These Internet mapping packages allow simple maps to be produced but have 
very limited scope for spatial analysis. If any spatial analysis is going to be carried out 
or in order to provide more flexibility with the mapping, dedicated mapping software is 
required. There is an increasing amount of both commercial and open source or free-
ware mapping software available such as ARCGIS (<http://www.esri.com>), MapInfo 
(<http://www.mapinfo.com>), and Quantum GIS (<http://www.qgis.org>).
GPS devices use signals from at least three satellites orbiting the earth to give the 
longitude and latitude of the hand-held device. The accuracy of the positioning depends 
upon the number of satellites from which a signal can be received and the strength of 
their signals. Usually, the accuracy is to within 20 metres, but, in open areas, with single-
storey buildings or huts, it can be to within less than 10 metres, while, in areas with poor 
satellite coverage or where it is heavily forested, it can be worse than 50 metres. There 
are many ways to collect GPS data, including specific GPS receivers, data loggers, and 
modern mobile phones. The choice of which to use depends on how the GPS data are 
to be collected and used. If GPS data will be collected at the same time as other survey 
data, a GPS-enabled data logger may be most efficient. However, if the mapping is to 
be done as a separate exercise, dedicated GPS receivers are more cost-effective. Most 
GPS receivers can store several hundred ‘waypoints’ (for example, households or other 
points of interest for the map), which can be uploaded into computers at the end of 
each day’s work. The cost of a simple GPS receiver is around $100. Commonly used sys-
tems are produced by Garmin (<http://www.garmin.com>), Magellan (<http://www. 
magellangps.com>), and Trimble (<http://www.trimble.com>).
When either paper or digital maps are obtained, the information recorded may 
be incomplete or inaccurate, and it should be checked in the field. Names of villages 
may have changed or they may be known by different names locally, and villages and 
households may have been abandoned or been newly formed if the maps are not re-
cent. Checks, and alterations as necessary, should be made on the positions of roads 
and tracks, health facilities, schools, official offices, markets, churches, mosques, bars, 
shops, hotels, boreholes, and other locally important features.
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In field trials, the first time that a map is likely to be needed is for planning the baseline 
survey. In longer-term field trials where houses will be revisited, individual houses are 
usually mapped. It is good practice to assign a code number to each house on the map. 
This may consist of a location (for example, village), code (for example, village BS), and a 
number to indicate the house within that location (for example, BS374). If it is locally ac-
ceptable, the number can be painted on the house or fixed to a board (take care: numbers 
painted on mud walls may be washed off in the rains or painted over, and boards with 
numbers can be taken down and moved by the residents to a new house!). This helps to 
ensure that each house is only mapped once and as a quick check on arrival at a house.
The numbering system should be designed to take account of the local family struc-
tures and their living arrangements. For example, in studies in some parts of Africa, 
the same number might be assigned to all houses that comprise a ‘compound’ where 
extended family members live. This is not always straightforward to do and is discussed 
further in Section 4.2.
Figure 10.1 shows part of four trial clusters of a large vitamin A trial in the Kintampo 
area of central Ghana (Kirkwood et al., 2010). The map was produced using ARCGIS soft-
ware and shows roads, paths, schools, a hospital, a market, a refuse site, and two commu-
nal latrines, along with the location of each compound (identified with a 4-digit number).
Once each house or compound has been mapped and assigned a code, fieldworkers can 
use either a printed or digital map to locate the households that they need to visit. If small 
numbers of fieldworkers are involved, the list of households to be visited can be uploaded 
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Figure 10.1 Part of a trial map.
Reproduced courtesy of C. Grundy, B. Kirkwood, and S. Owusu-Agyei. This image is distributed 
under the terms of the Creative Commons Attribution Non Commercial 4.0 International licence 
(CC-BY-NC), a copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
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into a GPS receiver, and a ‘GO TO’ function used to direct the fieldworker to the location 
of the house. While these methods may not be exact, they can save large amounts of time.
Once a census has been carried out, the combination of the map and household 
population data can be used to delineate trial clusters or fieldwork areas. If the house-
holds have been mapped digitally, there are functions to allow this to be done manually 
or using an automated method. Users simply specify the number of people required in 
each cluster, and either the user or the computer will group houses together to form 
clusters or groups of the appropriate size. Once fieldwork starts, maps can be printed 
out, as required, or displayed on a hand-held computer to report on progress.
Maps are also very useful for dissemination of trial results and for community engage-
ment. Because they can display data in a visually striking way, maps, if used well, can 
have a much bigger impact than other methods of displaying results such as tables or text. 
They can also be used at routine staff meetings during the trial, such as to display which 
areas still need to be surveyed or to highlight where unusual results have been recorded.
In many field trials, only simple mapping is required, but the more data that are available, 
the more spatial analyses can be carried out. The two commonest ways maps are used in 
analysis are spatial overlays and for calculation of distances. Many health outcomes have 
a spatial relationship to a risk factor, for example, schistosomiasis to water sources, or ma-
laria to swamps, elevation, and climate. Here, the ‘exposure’ to these risk factors can be 
calculated, using Geographical Information System (GIS) software. This requires two geo-
graphical datasets: one for the population data and one for the risk factor data. Often, the 
risk factors, such as rivers and lakes, are collected as part of the mapping process. In other 
cases, datasets of vegetation type, rainfall, and elevation are available online or from satellite 
images. In simple cases, these ‘layers’ can be overlaid to link the population to the risk factor, 
for example, what the elevation, mean daily temperature, or annual rainfall at the location of 
each house is. If useful, the results from a regression analysis of such overlays can then be fed 
back into the computer mapping software to produce risk maps. There are very good exam-
ples of such risk maps for infectious diseases such as soil-transmitted helminths, trachoma, 
or malaria, for which global atlases have been produced (<http://www.thiswormyworld.
org>, <http://www.trachomaatlas.org>, <http://www.mara-database.org>).
The other spatial analysis that is commonly used is for calculating distances, for ex-
ample, from a house to the nearest river or to the nearest health facility. This type of 
analysis is widely used to investigate access to services. An example of this in a multisite 
community-based social mobilization trial related to HIV counselling and testing in 
South Africa is given in Chirowodza et al. (2009).
Computer mapping and spatial analysis are increasingly being used in trials, and the 
methods available are constantly being improved and refined. For example, satellite 
imagery is increasingly being used to plan surveys, as this does not require someone to 
physically visit and locate each house, in order to create the map. It is possible to use the 
images provided by sites, such as Google Earth, to mark the location of each structure 
in the trial area. Once all structures are marked, these can either form the basis for a full 
survey or a random selection of structures can be selected and surveyed. In some cases, 
the approximate population can be estimated by multiplying the number of structures 
by a population per structure estimate. These methods currently tend to be used by 
research groups with relatively advanced GIS expertise but will increasingly be used 
more widely, as user-friendly software packages are developed.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
166 CHAPTER 10: CENSUSES AND MAPPING
4 Enumeration
A census of the population may be conducted after, or at the same time as, mapping. 
The census will involve the collection of information on the composition of each house-
hold and demographic, and possibly other, data on each household member.
4.1 Organization of enumeration of households
A combination of speed and accuracy is required in the conduct of a census. It is useful 
to draw a flow chart of the data collection and processing operations. Simple examples of 
such charts are shown in Figure 10.2 for collection of data on paper or on an electronic 
device.
(a) Data collected on paper
Field worker: household interviews, enumeration
Completed questionnaires
Daily receipt by project 
Receipt by project leader
Checks for:
• errors
• omissions
• inconsistencies
Production of population register
Data entry, verication, and checks
Further data checks in database
Uploading to main database
Field worker: household interviews, enumeration with 
immediate checks for completeness, range, and consistency
(b) Data collected on a digital device
Checks for:
• errors
• omissions
• inconsistencies
Production of population register 
Figure 10.2 flow chart of census data collection.
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A field manual is essential and should include a checklist of equipment that the inter-
viewers will need to take with them each day (see Chapter 16).
4.2 Definition of dwelling units
The definition of a village and a household (or compound) within a village will vary, de-
pending on the location of the trial. Villages generally share the same leaders, although 
the inhabitants may be dispersed over a wide area. In parts of Africa, for example, in the 
Sahel zone of West Africa, a compound is a cluster of households fenced or partitioned 
off from other compounds and may have features, such as a well or latrine, which all the 
households of a particular compound share. In parts of Asia, such as in parts of Borneo 
and Indonesia, several households live together in a single building called a ‘longhouse’.
A household is usually defined as a nuclear or extended family group, whose members 
usually eat together (the ‘from the same cooking pot’ definition of a household). The exact 
definition of a household should be decided before mapping and enumeration begin and 
clearly defined in the field manual. Households can be spread over several buildings, or 
several households may share the same building. There are no uniquely correct ways of 
defining households, compounds, or dwellings, but, in any particular study, it is important 
that clear definitions are agreed for all of the different terms to be used in describing people’s 
living arrangements. New investigators in an area should find out what systems others have 
used who have worked in the same area, and whether or not these worked satisfactorily.
4.3 De facto and de jure populations
Before conducting a census, it is necessary to decide which individuals will be reg-
istered as members of the study population. The two commonest options are the so-
called de facto and de jure populations. The de jure population comprises the ‘normal 
residents’ and includes individuals who usually live in a particular household but who 
may be absent during the enumeration. The de facto population consists of those who 
slept in the household the night before the census. In national censuses, it is usual 
to enumerate the de facto population, but, for the purpose of most intervention tri-
als, the de jure population is the most appropriate. In some cultures, the definition of 
household membership may be difficult to specify. Some individuals may live in one 
household but spend a significant amount of time in another household either within 
or outside the study area. These individuals may be incorrectly enumerated twice, un-
less care is taken to assess the unique ‘normal’ domicile of each person. When using a de 
jure enumeration, each resident’s status can be recorded as ‘absent’ or ‘present’. This will 
give some indication of the degree of temporary migration and would allow the cal-
culation of the de facto population from the de jure census. Similarly, fieldworkers will 
have to distinguish between ‘temporary’ visitors and those who will remain for a long 
time. It may be difficult to obtain such information reliably, as respondents may inform 
a fieldworker that a temporary visitor is ‘permanent’ if it is thought that some benefit 
may derive from this. The definition of who is a normal resident will depend upon the 
objectives of the trial. It is important to decide upon a period of time that a person 
should have been in or out of a community to be considered as having migrated in or 
out. In general, a clear and full definition is required as to who should be considered 
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as a resident, especially in long-term studies that may involve multiple census updates. 
The definitions should be clearly stated in the field manual.
4.4 Ensuring completeness of the census
As houses may be empty at the time the interviewer calls or some residents may be away, 
the interviewer may have to rely upon proxy reporting in some instances. If a house is 
empty, arrangements should be made to call back at a time when someone is likely to be 
there. Whenever possible, all households reported as being empty should be revisited, 
ideally later the same day, by a supervisor or another interviewer. This helps to avoid 
interviewers reporting remote households as being empty to reduce their workload.
Information about the composition of the household is best elicited if there is a 
standard order in which information is sought about individuals (discussed in Sec-
tion 4.5). In a simple census, it is not necessary that the information on all members of 
a household should be given by a single respondent, nor that the interviews are held 
privately, unless sensitive information is also being collected. Whenever there is some 
lack of certainty, respondents can be encouraged to consult others in the household 
or compound to provide information. It is useful to specify in advance who would be 
regarded as an acceptable informant in a household. For example, for information on 
young children, the list, in order of preference, is often first the mother, second another 
adult female relative living in the household, and third the father.
Whether or not a respondent is willing to co-operate in the study may depend on 
the initial impression an interviewer makes and on the respondent’s understanding 
of the reasons for the census. Co-operation may be poor if the study subjects suspect 
that the information collected may be used to their disadvantage (for example, for tax 
collection). Involvement of local leaders and the CAB, if one is set up, may be crit-
ically important in obtaining co-operation (see Chapter 9). The interviewers should 
introduce themselves properly to the respondents, explain the purpose of the study, 
and assure them that any information given will be regarded as confidential. It may be 
necessary to reassure them, specifically, if appropriate, that the information will not be 
made available to the local administration for compiling lists of taxable adults. If those 
in a household refuse to participate, the field supervisor should be informed, and, with 
input from the CAB, the reasons for their refusal investigated as soon as possible. An 
initial refusal should not be taken as final. Individuals may be unwilling to collaborate 
merely because they have not properly understood the objectives of the trial or have not 
appreciated the potential benefits to them. However, the right of an individual not to 
participate in a survey should always be respected. If more than a small proportion of 
individuals refuse to participate, the generalizability of the trial findings may be com-
promised. Discussions should be held with village leaders if it appears that such prob-
lems are developing, in order to ascertain the reasons and to seek suitable remedies.
If data are collected using mobile phones or PDAs, these should be synchronized 
with computers, and the data uploaded each day. Whether the data have been collected 
on paper or electronically, at the end of each day, all completed forms should be care-
fully checked by the interviewers and, whenever possible, also by a supervisor for errors 
or omissions, so that these may be corrected either immediately or on the following 
day, before the team moves on to another area. Plans should be made to revisit any 
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household that could not be enumerated, because of the absence of eligible informants 
or because the house was empty.
4.5 Numbering and identifying individuals
One purpose of a census is to allocate a unique identification number to each member 
of the population. This number will remain assigned to the individual for the duration 
of the trial, since it may be used to link information on an individual from different 
sources, such as from interviews, clinical examinations, and laboratory studies, and 
also on different occasions such as baseline, interim, and final surveys. Therefore, the 
person’s identification number must never be changed or reallocated to any other in-
dividual, even if they die or move either within or outside the study area. There are 
several different ways that are commonly used to allocate identification numbers. As 
an example of one such system, suppose, in village B, the first compound is numbered 
01. Within compound 01, the first household is numbered 01, and the household head 
is given the number 01 within the household. Thus, this individual has the unique 
identification number B010101, plus a check digit (see later within this section and 
Box 10.1). (Note that such a numbering system assumes there are fewer than 27 villages 
Suppose the trial number consists of a six-digit number, and it is desired to add a 
one-digit check number that will guard against transcription errors (such as revers-
ing the order of two digits or recording one digit incorrectly). The number will take 
the form of:
The first six prime numbers are shown below the digits of the trial number. The 
check digit c is calculated by multiplying each digit by the corresponding prime, 
summing the results, and the last digit of the result is taken as the check digit. Thus, 
for example, we would have:
Trial 
number
Trial number  
with check digit
467913 4 × 11 + 6 × 7 + 7 × 5 + 9 × 3 + 1 × 2 + 3 × 1 = 153 4679133
476913 4 × 11 + 7 × 7 + 6 × 5 + 9 × 3 + 1 × 2 + 3 × 1 = 155 4769135
567913 5 × 11 + 6 × 7 + 7 × 5 + 9 × 3 + 1 × 2 + 3 × 1 = 164 5679134
Source: based on methods supplied W. Meade Morgan (personal communication).
Box 10.1 Method of assigning check digit to six-digit 
number
d1 d2 d3 d4 d5 d6 c
(Prime 11 7 5 3 2 1)
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in the study, fewer than 100 compounds in every village, fewer than 100 households in 
every compound, and fewer than 100 persons in every household (see also Chapter 20, 
Section 5).) If this identification system is used, a separate record should also be kept of 
the location of this individual at each study visit. If, for example, this same individual is 
currently within their original household, their current household will be B0101 plus 
a check digit. However, if they have moved to household 28 within compound 17 of 
village K, then their identification number will still be B010101 plus a check digit, but 
their current household will be K1728 plus a check digit.
Alternatively, numbers might be allocated in a simple continuous sequence to each 
member of the trial population, without building codes for village or household into 
the number. An advantage of this system is that forms can be pre-numbered before they 
are taken to the field, and the number allocated to an individual is simply that on the 
form that is filled in for them.
Whichever system is used, it is important to supplement the number with a check 
digit or character to aid the detection of transcription errors. These work by using a for-
mula whereby any number can only correspond to one character or digit. If the number 
is transcribed wrongly, then the check digit or character will not match. One source for 
check digit systems is available at <http://code.google.com/p/checkdigits>. A simple 
method of generating check digits to guard against common transcription errors (such 
as reversing the order of two digits or recording a digit incorrectly) is given in Box 10.1.
In addition to, or instead of, the check-digit system, the practice in some trials is to 
record, for data linkage purposes, both an individual’s identification number and the 
first few, say five, letters of their name. Checks are made that both of these items match, 
before any linkage procedures are undertaken. However, this system does require that 
an individual does have a name with an explicit spelling. Sometimes, people use several 
different names and are not consistent about how they are spelt, so we recommend 
using a check digit.
4.6 Household or individual forms within a census?
After mapping the study area and assigning numbers or codes to villages, compounds, 
and households, the household and/or individual census survey forms can be marked 
with household identification numbers. Whether all members of a household should 
be recorded on one form or on separate individual forms will depend on the way in 
which the survey is organized, the amount and degree of standardization of the data 
collected on each individual, and the design of the data processing system. Sometimes, 
both a household form and individual forms will be required—the former to collect 
basic demographic information on all members of a household, and the latter to record 
more detailed information on some, or all, members of the household.
If the census is being conducted at the same time that other procedures are being 
undertaken on the study subjects, it may be best to use individual forms, in addition to 
household forms, as otherwise it may be necessary to wait until a complete household 
has been registered before other procedures can start. If household sizes are large, this 
may lead to significant delays for those following the interviewers, especially at the start 
of each day.
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Figure 10.3 is an example of a simple household form to collect basic demographic 
information. General issues related to production and coding of questionnaires and 
forms are considered in Chapters 14 and 20.
4.7 Coding relationships
Interviewers should be instructed regarding the order in which individual household 
members should be registered, as a systematic approach is less likely to lead to omissions. 
Compound Head _______________________________ No.  |__|__|                                           Date|__|__|__|__|__|__|
Hhold Person Names Relat. Sex Birth date Resid.
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
|__|__| |__|__| |_______| |__| |__|__|__|__|__|__| |__|
Comments: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Survey form number |__| of |__|
Village name ______________________________________ |__|__|                     Interviewer code |__|__|
Figure 10.3 A census schedule.
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In polygamous households, it would be usual to begin recording with the male house-
hold head (if there is one), followed by his first wife, and all her children living in the 
household; his second wife and her children; and so on. Next might be any brothers of 
the household head, each followed by their wives and children, as for the head. Unre-
lated individuals, such as lodgers and employees, might be recorded last. Relationships 
between different household members may be coded so that, in so far as possible, eve-
ryone is linked to one or two others in the household in a simple way, using as close a 
relationship as is possible. Codes for brother, sister, mother, and so on should only be 
used when wife, son, or daughter cannot be used to describe a relationship. To the ex-
tent possible, terms, such as granddaughter, grandson, grandmother, grandfather, niece, 
nephew, uncle, aunt, and cousin, should be avoided. An example of a coding system for 
relationships that was used in a vaccine trial in Uganda (Smith et al., 1976) is given in 
Box 10.2. Two alternatives to this procedure may be better in some circumstances—
either everyone is related to the household head or detailed records are made of the 
name of each individual’s mother and father (even if they are dead or do not live in the 
household).
In some societies, it may be very difficult to ascertain the precise relationship between 
individuals. For example, no apparent distinction may be made between children and 
nephews/nieces—both the father and uncle might refer to them as his children. So long 
as this is appreciated it may cause little confusion, but it may be very important if, say, 
genetic studies are being conducted.
Coding of relationships
In this column, write down the relationship of the individual to the other persons 
in the household. Since each person will be entered against a person number (the 
second item in the columns), the relationship can conveniently be expressed by ref-
erence to these numbers, for example, ‘Wife of 01’ or ‘Son of 01 and 02’.
The following abbreviations may be used:
Box 10.2 Example of instructions for coding 
relationships
Head of household H Sister SR
Wife W Grandson GS
Son S Granddaughter GD
Daughter D Grandfather Gf
Mother M Grandmother GM
father f Other blood relative R
Brother BR Unrelated X
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4.8 Names and addresses
The most important way of identifying an individual will be through his or her names, 
and these must be recorded with special care. Interviewers must be instructed how to 
spell names, including those given by semi-literate individuals. It is important to try 
to record all of the names of a person, including nicknames, as it is not uncommon, in 
some cultures, for individuals, and especially children, to employ different names in 
different situations. The most frequently used names should be recorded first. In some 
areas, confusion may arise, as many people have the same names, especially in cul-
tures in which the first-born males or females are always given a set name or in which 
they are always named after their grandmother or grandfather. In some societies, very 
young children are not named until some time after birth, and, until this time, they may 
have to be recorded as ‘unnamed’. In some cultures, young infants are not thought to 
be part of society, and specific questioning may be necessary to elicit information, even 
about their existence.
In addition to the names, the complete addresses of study participants should be 
recorded. In some instances, this will be just the name of a village, but, if there is some 
system of subunits within a village, then this also should be recorded. Often, it will be 
useful to record the name of the local leaders or elder who have some responsibility 
in the area in which a participant resides, though it should be remembered that this 
person may change during the course of a study.
Example: A household consists of the head, his two wives, and five children, three 
by his first wife and two by his second, and also his mother, and an unrelated visitor 
and her child. These would be coded as follows.
Box 10.2 Example of instructions for coding relationships (continued)
Person number Person Code
01 Head H
02 Wife 1 of household head W01
03 Child 1 (M) of household head and his wife 1 S01,02
04 Child 2 (f) of household head and his wife 1 D01,02
05 Child 3 (M) of household head and his wife 1 S01,02
06 Wife 2 of household head W01
07 Child 1 (f) of household head and his wife 2 D01,06
08 Child 2 (M) of household head and his wife 2 S01,06
09 Mother of household head M01
10 Visitor X
11 Child 1 (M) of visitor S10
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4.9 Ages
In some societies, it takes only a few seconds to elicit an individual’s age or date of birth 
through a simple question, but, in others, these are very difficult to obtain, as individu-
als do not know their age or date of birth and this information has no special signifi-
cance to them. The importance of collecting accurate information on ages or dates of 
birth will depend upon the objectives of the trial.
Accurate dates of birth may not be necessary for all age groups, and those in age 
groups not pertinent to the trial may not have their specific age recorded at all (for ex-
ample, but just be recorded as ≥50 years). In some trials, however, accurate estimates of 
dates of birth may be needed for all age groups. It is generally better to record the date 
of birth, rather than the age at last birthday, as the latter will change during the course 
of a trial. During the census, field staff can convert ages to dates of birth, using a simple 
application on a PDA or mobile phone or transcription tables (relating ages to years of 
birth), which should be included in their manual. Protocols and methods of estimating 
dates of birth, such as those described in this section, should be an integral part of the 
interviewers’ training and be included in their field manual. Even if the study area does 
not have universal civil registration of births, various other sources of information may 
be available. For children, health cards and the mother’s antenatal card may be a good 
source of information. However, one should remember that, for children who were 
born at home and not taken to a health facility immediately after birth, they may be 
less accurate. Mothers can be questioned as to how many days or weeks old the child 
was when taken to the health facility. Antenatal cards should have dates of delivery or, 
if not, when the mother was seen and the estimated gestational age. In the absence of 
any documentation, various other methods of estimating dates of birth of a child have 
to be employed.
Developmental characteristics, such as the ability of the child to place the right arm 
over the head to touch the left ear (roughly possible from age 5 years onwards), the abil-
ity to sit upright unaided, walking, talking, and so on, can all be used to estimate the 
developmental age, and hence the approximate date of birth of young children.
Older children are more difficult to age by means of physical and developmental 
characteristics, due to variations in growth patterns. Age may be inferred from their 
grade in school or the grade in which they would be if they went to school. However, 
some educational systems make pupils repeat grades if they are thought unsuitable for 
higher grades, or a child may start school late.
If the interviewers can accurately age one child, the ‘index child’ method can be used. 
The mother is asked about her other children in relation to this child. For example, the 
fieldworker might ask questions such as: ‘Before Ebrima, did you deliver a live birth? Is 
that child here? How many rainy seasons passed before you became pregnant again?’. 
With such information on the birth interval, the preceding child’s date of birth may be 
estimated. Similarly, procedures can be used for the following child’s date of birth and 
all her other children.
To estimate the month of birth, calendars can be constructed. The calendar will 
list the months of rains, dry season, and so on. Religious or cultural festivals, such 
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as Ramadan, Easter, or Christmas, can be included for recent years. For example, a 
mother might be asked if her child was born in the rains and, if so, whether at the be-
ginning, middle, or end of the rains. At set times of the year, members of the village will 
be ploughing, planting, sowing, weeding, or harvesting different crops. An example of 
part of a monthly event calendar that was used in a study in Ghana is given in Box 10.3 
(D. A. Ross, personal communication).
Children whose dates of birth are accurately known can be used as index children to 
estimate the dates of birth of children in other neighbouring households.
Having estimated the ages of all members of a household, the fieldworker should 
look at all the family together to assess if the ages are plausible, bearing in mind any 
infant or childhood deaths, stillbirths, or abortions.
The age of adult women can be estimated in several ways. Although age at menarche 
varies between women, a question about whether the woman had reached menarche 
before a certain event of known date can give a rough estimate of their date of birth 
(though, in many cultures, it may be difficult to discuss). Similarly, age at marriage may 
be, or may have been, fairly uniform for women in some societies, and women can also 
be asked if they married early or late, compared to their contemporaries. But when 
‘marriage’ is deemed to have occurred must also be elicited, as, in some societies, the 
marriage process involves numerous stages.
Given an estimated age at first marriage, birth histories can be elicited to estimate a 
woman’s current age. Under conditions of natural fertility, on average, approximately 
2.5, 1.5, 1.0, and 1.0 years elapse between births, which are respectively, a live birth that 
was weaned, a live birth that died in infancy, a stillbirth, and an abortion. This method 
assumes no infertility, spouse separation, or use of contraception. In areas where these 
conditions are common, different assumptions have to be made.
Historical event calendars are one of the most commonly used methods to estimate 
ages. This method is especially useful where societies have a predominantly oral tra-
dition. Historical event calendars require much effort to develop, and, before doing 
this, it is worth finding out if they already exist in government census departments 
or elsewhere. If they do not, a calendar can be created, with the assistance of local 
members of staff, teachers, and community leaders. The calendar should include all the 
major national historical events, and their dates, and all outstanding local events such 
as major bush fires, murders, drownings, deaths of religious and political leaders, wars, 
droughts, floods, famines, and so on. If an individual can remember an event and can 
estimate how old he or she was (for example, just married, just started school) at the 
time of that event, their date of birth can be estimated. This method is time-consuming 
and should be pilot-tested before use. It may be decided that it is too slow and cum-
bersome to be of use or there may be too few significant events that can be dated that 
individuals will remember for the method to be used. To be most useful, it is necessary 
to construct calendars which focus on local, rather than national, events and which are 
particular to a relatively small geographical area.
An example of an event calendar that was used in the same vitamin A trial in north-
ern Ghana, that was referred to in Box 10.3, is given in Box 10.4 (D. A. Ross, personal 
communication).
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SEPTEMBER
Specific dates: none
OCTOBER
Specific dates: 1 to 31 ‘Rosary’
NOVEMBER
Specific dates: 1 All Saints; 2 All Souls
Box 10.3 Example of part of a monthly calendar of local 
events used in the Ghana Vitamin A Supplementation 
Trial (VAST)
Farming: Harvesting of groundnuts, cowpeas, and maize starts
Harvesting of sweet potatoes, peas, and wet-season rice starts
General: Heavy rains continue (Duliu)
Drumming and other loud noises banned
Beginning of the school year
Farming: Harvesting of groundnuts, cowpeas, maize, sweet pota-
toes, pesa, and wet-season rice ends
General: Rains slackening off
Season of abundant food (Womodaabu Ch’ana)
Ban on drumming and other loud noises is lifted
Farming: Late millet harvest
Construction of dry-season gardens starts
Coccidiosis disease (Choguru) tends to start in fowls
General: Harmattan (dust-laden wind from the north) starts
Cutting of ‘sange’ and grass starts
Firewood collecting season starts
Frog hunting season starts
School Nov/Dec exams start
The age of adult men can also be estimated using event calendars, but there are fewer 
cross-checks, such as menarche or parity, to confirm the approximate date of birth. 
Even in traditional societies living in rural areas, adult males may have dated doc-
umentation, such as voting cards, military service papers, and other official papers, 
which may include age information. As for children, if the age of some adults can be 
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Box 10.4 Example of part of a calendar of local events 
used in Ghana Vitamin A Supplementation Trial (VAST)
1900 
(approx.)
◆ War with Zabog people from Burkina faso
1906 ◆ founding of the Catholic Mission in Navrongo (by father Oscar Morin)
1908 ◆ first Kassenas enrolled for Catechism training
1913 ◆ Baptism of the first Kassenas in Navrongo
1916 ◆ first conscription of local people into the British army for the first World War
1918 ◆  Collection of mats from each household for roofing of houses for British 
people to stay in
1919 ◆ Bad plague of locusts
Box 10.3 Example of part of a monthly calendar of local events used in the Ghana 
Vitamin A Supplementation Trial (VAST) (continued)
DECEMBER
Specific dates: 19 Feok Festival in Sandema; 25 Christmas Day; 26 Boxing Day; 
27–29 Fao Festival in Navrongo; 31 Anniversary of the 31 December Revolution
Farming: Dry-season tomatoes and other vegetables start to become available
Collection of kapok starts
Harvest of ebony fruits starts
Gathering of millet stalks starts
Storing of grain
Domestic animals allowed to move about freely again
General: Harmattan continues
Making of bricks and repairing of houses start
Bush fire season starts
Hunting season starts
Many Northerners start to move South, looking for farm work
Christmas school holidays start
Source: data courtesy of D. A. Ross (personal communication).
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Box 10.4 Example of part of a calendar of local events used in Ghana Vitamin  
A Supplementation Trial (VAST) (continued)
Source: data courtesy of D. A. Ross (personal communication).
1977 ◆ Introduction of first Phase of Junior Secondary Schools
1978 ◆ Achaempong overthrown by General Akuffo (5 July)
◆ Change of currency notes (50 cedi note added)
1979 ◆ J. J. Rawlings first came to power (4 June)
◆ Shooting of Colonel felli and others by firing squad
◆ Elections for the Third Republic (Hilla Liman elected)
1981 ◆ PNDC revolution (31 December)
1983 ◆ Year of drought, bush fires, caterpillars, and food shortages
1984 ◆ Bumper harvest
◆ Cancellation of all O- and A-level results throughout West Africa
1985 ◆ Major dust storm, when it was dark all day (13 March)
◆  25th anniversary celebrations of Navrongo Secondary School (Navasco) and 
Notre Dame Secondary School
◆ Start of the Mamprusi/Kusasi War in Bawku
◆ fighting between Saboro and Wusungu started (Nov–Dec)
1986 ◆ Good harvest
◆ Heavy rain storm which destroyed part of the Bolgatanga–Navrongo road
1987 ◆ Introduction of Second Phase of Junior Secondary Schools (September)
◆ Ritual murder of an old man in Navrongo
1988 ◆ Start of armyworm invasion (June)
◆ Ordination of three local men to the RC priesthood in Navrongo (23 July)
◆  The bodies of three Kassenas who had been killed in a road traffic accident 
in Nigeria were brought back (August)
◆ Very heavy rain storm and floods with many houses destroyed
◆ President J. J. Rawlings’ visit to Sandema (15 December)
◆ first Navro Fao festival celebrations for many years (27–29 December)
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determined accurately, that of others may be estimated in relation to those of known 
age by asking if any of them attended circumcision ceremonies together, grew up to-
gether, played together, or went to school together. If not, perhaps they did so with the 
older brothers or sisters of the index individuals, and so on. Interviewers must review 
their data to check that the age information derived is plausible. If data are collected 
digitally, such checks can be made automatically on entry and time-consuming errors 
avoided. For example, a woman born in 1935 could not have had a child in 1942; in 
many societies, it is very unlikely that a woman would be 10 years older than her hus-
band, and birth intervals of less than 9 months are uncommon and those of less than 
7 months are not possible. Interviewers and supervisors must be trained to check for 
such inconsistencies.
Well-known problems with age reporting are age ‘heaping’ and ‘shifting’. Age heap-
ing refers to terminal digit preference—the tendency for ages to be recorded as 10, 
20, 30, 40 years or 25, 35, 45 years, and so on. Interviewers should be made aware of 
this during their training. However, there are examples where such training resulted, 
at the end of the census, in there being too few individuals with ages ending in 0 or 
5! Such effects may be of no great consequence for older adults, for whom precise age 
estimation is rarely necessary. Age shifting is more difficult to detect and is common-
est where age is a criterion of social status. Individuals may falsify their ages, so that 
they will appear to interviewers to have higher ‘age status’. Conversely, women who 
have not yet married may falsify their age downwards, as may young men who wish 
to avoid taxes or military draft. In Muslim communities, the ages of women may be 
especially difficult to estimate, as women may be secluded and the men may respond 
on their wives’ behalf.
4.10 Other identifying information
In some countries, a full name and date of birth are usually sufficient to identify a 
person. In many others, this will not be enough, but the addition of the individual’s 
parents’ names, place of residence, and their relationships to other household mem-
bers is likely to be sufficient. Individuals may be issued with an identity number by the 
state or with a social security number that they keep throughout life, and these should 
be recorded, whenever possible. For trials involving adults, it may be worthwhile to 
take photographs of all those registered and give each person a laminated photo–ID 
card that also includes their trial number, with a copy of their photo kept in the trial 
records. In some trials, involving long-term follow-up of large populations, hand-, 
foot-, or fingerprints may be used to check identities. This last method was used in 
a large BCG trial against TB in South India (Tuberculosis Prevention Trial Madras, 
1979), and also in a large study to assess whether vaccination with hepatitis B vaccine 
shortly after birth protects against liver cancer in adult life (The Gambia Hepatitis 
Study Group, 1987). There are now several commercially available digital print scan-
ning and reading devices that can be used for this; some are combined with hand-held 
digital data entry devices that can be used for the completion of census and other 
forms in the field.
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5 Processing of census data
Most censuses involve the collection of substantial amounts of data. It is important 
to plan how these data will be processed, before the study is started. Usually, it will 
be desirable that the information is either entered electronically on collection into a 
PDA, tablet computer, or mobile phone or is entered into a computer shortly after it is 
collected, so that a large backlog of work does not accumulate. Rapid data entry and 
checks for transcription errors are especially important if the information collected at 
the census is to be used to produce forms for the recording of additional procedures 
to be performed on the trial participants shortly after the census. Furthermore, once 
the information is in a computer, consistency checks can be conducted, and errors or 
queries referred back to the relevant fieldworkers. Such feedback should occur as soon 
as possible after the original information has been collected.
In recent years, there have been major advances in computer systems and transmis-
sion of digital information, enabling the collection, processing, and checking of data 
virtually anywhere, eliminating many of the bottlenecks that, until quite recently, so 
slowed analysis of trial data in LMICs. Nevertheless, data management is a major task 
in all field trials and requires a well-defined data management strategy, as discussed in 
Chapter 20. The design of the recording system may need to allow for changes in the 
composition of the study population over time, due to in-and-out migration, and for 
movement between households within the population. It is usually desirable to seek 
help and guidance from an experienced statistician or data analyst for these aspects. 
This should be done at the start, rather than in the middle, of a study.
6 Post-enumeration checks and quality control
As discussed in Chapter 20, SOPs should be drawn up for QC at all stages of a trial, and, 
since the mapping and census are usually the first major field data collection stages of 
a trial, it is usually these steps that require the most preliminary pre-testing and pilot 
testing of all procedures, including post-enumeration checks and QC. After the census, 
the list of the population can be checked against other sources of information on the 
population. For example, school attendance records can be compared to the eligible age 
bands in the census, and the information collected can also be compared with other 
census data from the Central Statistics Office or elsewhere. Population pyramids can 
be drawn to see if there are any unusual features such as age heaping or disproportion-
ate numbers of individuals at certain ages. Sex ratios can be checked, though one must 
allow for selective migration of certain age groups and of males or females.
7 Keeping the census up to date: demographic 
surveillance
In some trials, the enumeration of the population at the start of the study is all that is 
required, and there is no reason to monitor the population ‘continuously’ for births, 
deaths, and migration. In other trials, however, a system of registration of vital events 
may be required. This is usually known as demographic surveillance. A good source of 
advice on how to do this is available at <http://www.indepth-network.org>.
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After the initial census and when the intervention has started or been applied, fol-
low-up surveys may be required to assess the effects of the intervention. For diarrhoeal 
or respiratory illness episodes, weekly or twice-weekly visits may be required, whereas, 
for deaths, annual or quarterly surveys may be adequate. These visits provide an op-
portunity to update the census by ascertaining births, deaths, address changes, and 
migration into or out of the study area.
Maintaining an up-to-date population database in this way is a major undertak-
ing. It requires good organization, especially in areas with substantial migration 
such as in peri-urban slums. For example, in a study carried out in southern Brazil, 
one half of the families with young children changed address within 2 years (Bar-
ros et al., 1990). It may be difficult to conduct long-term follow-up studies in such 
populations.
A census is relatively easy to update if a computer listing is available, either on paper 
or on a digital device, which gives the names of the residents in each household at the 
previous survey, with appropriate spaces for updating information (for example, see 
Stephens et al., 1989). Pregnant women should be noted, so that, in the next survey, 
enquiries may be made about the outcome of that pregnancy. Maps should be updated, 
marking any new or abandoned houses. To obtain reasonable information on births 
and deaths, the maximum interval between surveys should not exceed a year and pref-
erably will be less—ideally every 3–6 months.
The recording of deaths occurring in the population is usually of special interest. 
Information on these may be obtained by employing ‘village informants’ to notify 
the trial investigators when deaths occur. Information may also be available through 
health facilities, religious institutions, or cemetery records. Usually, it will be necessary 
to supplement this information with periodic re-surveying of the population if com-
plete ascertainment of such events is required. Deaths tend to be missed, unless specific 
questions are asked about each individual who was registered in the last round of the 
fieldwork, and stillbirths, neonatal, and infant deaths may well be missed, unless full 
demographic surveillance with frequent survey rounds is employed. Such questioning 
must be done with sensitivity, and the responses may need to be interpreted in the light 
of any local taboos against speaking of the dead.
References
Barros, F. C., Victora, C. G., and Vaughan, J. P. 1990. The Pelotas (Brazil) birth cohort study 
1982–7: strategies for following up 6,000 children in a developing country. Paediatric and 
Perinatal Epidemiology, 4, 205–20.
Chirowodza, A., Van Rooyen, H., Joseph, P., Sikotoyi, S., Richter, L., and Coates, T. 2009. 
Using participatory methods and geographic information systems (GIS) to prepare for an 
HIV community-based trial in Vulindlela, South Africa (Project Accept-HPTN 403).  
Journal of Community Psychology, 37, 41–57.
Gupte, M. D. 1999. Vaccine trials in leprosy—Venezuela, Malawi and India. International  
Journal of Leprosy and Other Mycobacterial Diseases, 67, S32–7.
Jukes, M. C., Pinder, M., Grigorenko, E. L., et al. 2006. Long-term impact of malaria chemo-
prophylaxis on cognitive abilities and educational attainment: follow-up of a controlled trial. 
PLoS Clinical Trials, 1, e19.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
182 CHAPTER 10: CENSUSES AND MAPPING
Kirkwood, B. R., Hurt, L., Amenga-Etego, S., et al. 2010. Effect of vitamin A supplementation 
in women of reproductive age on maternal survival in Ghana (ObaapaVitA): a cluster- 
randomised, placebo-controlled trial. Lancet, 375, 1640–9.
Schellenberg, J. R., Abdulla, S., Nathan, R., et al. 2001. Effect of large-scale social marketing of 
insecticide-treated nets on child survival in rural Tanzania. Lancet, 357, 1241–7.
Smith, P. G., Revill, W. D., Lukwago, E., and Rykushin, Y. P. 1976. The protective effect of 
BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of 
Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 70, 449–57.
Stephens, J., Alonso, P. L., Byass, P., and Snow, R. W. 1989. Tropical epidemiology: a system 
for continuous demographic monitoring of a study population. Methods of Information in 
Medicine, 28, 155–9.
The Gambia Hepatitis Study Group. 1987. The Gambia Hepatitis Intervention Study. Cancer 
Research, 47, 5782–7.
Tuberculosis Prevention Trial Madras. 1979. Trial of BCG vaccines in south India for tubercu-
losis prevention. Indian Journal of Medical Research, 70, 349–63.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
Chapter 11
Randomization, blinding, 
and coding
1 Introduction to randomization, blinding, and coding 183
2 Randomization schemes for individual participants 185
2.1 Unrestricted randomization 185
2.2 Restricted randomization 186
2.2.1 Small block sizes 187
2.2.2 Larger block sizes 187
2.3 Stratified randomization 188
3 Randomization schemes for community or group-based 
interventions 189
3.1 Matched-pairs design 189
3.2 Stratified design 189
3.3 Constrained randomization design 190
4 Blinding 193
5 Coding systems 194
5.1 Individual allocations 194
5.2 Group allocations 195
1 Introduction to randomization, blinding, and coding
As discussed in Chapter 4, the random allocation of participants in a trial to the dif-
ferent interventions being compared is of fundamental importance in the design of 
investigations that are conducted to produce the highest-quality evidence of any dif-
ferences in the effects of the interventions. Only if the units to which the interventions 
are applied (for example, individuals, households, or communities) are randomized 
between the interventions under study and the study is of a sufficient size is it possible 
to be confident that differences in the outcome measures of the trial among those in the 
different intervention groups are due to the effects of the interventions, rather than to 
underlying differences between the groups. Randomization should ensure that any po-
tential confounding factors, whether known or unknown, are similarly distributed in 
each of the intervention groups and therefore cannot bias the comparisons of outcome 
measures between the groups.
Randomization, if done properly, eliminates the possibility of subjective influence 
in the assignment of individuals to the different intervention groups. Sometimes 
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‘pseudo-randomization’ methods are employed in trials for reasons of convenience 
such as alternate assignment of the different interventions to successive trial entrants 
or allocation based upon the date of birth or date of entry (with, say, one intervention 
being assigned to those reporting on even dates and another to those reporting on odd 
dates). However, proper randomization is superior to any systematic method of allo-
cation, and these other methods should be avoided, unless there are very compelling 
reasons for using them. With systematic allocation, it is possible for the investigator, 
and sometimes the participant, to know in advance the group to which a participant 
will be allocated, and this may introduce conscious or unconscious bias into the alloca-
tion procedure. For example, such knowledge may affect the investigator’s judgement 
as to whether or not an individual is eligible for entry into a particular trial. For this 
reason, it is essential that the randomization is done (or the randomization allocation 
is revealed to the investigator) only after it has been ascertained both that an individual 
is eligible for entry into a trial and also that he or she is prepared to participate in the 
trial, no matter which intervention is assigned.
As Schulz (1995) pointed out, the success of randomization depends on two inter-
related processes. The first entails generating a sequence by which the participants in 
a trial are allocated between intervention groups. To ensure unpredictability of that 
allocation sequence, it should be generated by a random process. The second process 
allocation concealment shields those involved in a trial from knowing upcoming assign-
ments in advance, so that investigators cannot change who gets the next assignment, 
potentially making the comparison groups less equivalent and thus biasing the meas-
urement of the effects of the intervention.
In this chapter, various ways are described in which interventions may be randomly 
assigned among trial participants. The simplest method, if there are two intervention 
groups, is by using a procedure which is equivalent to tossing a coin to decide the al-
location for each individual unit. This can either be done literally, or an equivalent 
procedure may be simulated using a table of random numbers or by using a computer 
to generate random numbers, as described in Section 2.1. In large trials, the use of such 
a simple randomization procedure is highly likely to ensure that there are nearly equal 
numbers of units allocated to the different intervention groups and the distribution of 
potentially confounding factors will be similar in all groups. However, if the total num-
ber of units in a study is small, such an assignment procedure may result by chance in 
the compositions of the different intervention groups being markedly different with re-
spect to factors that may affect the outcome measures in the trial, or markedly unequal 
numbers of participants may be recruited to each intervention group. Such imbalance 
may arise by chance as, for example, it is possible that, if a coin is tossed ten times, 
it will come down heads, say, only twice. In fact, the chance that it will come down 
exactly heads five times and tails five times is only about 25%. For trials involving sev-
eral hundreds of participants or more, any such imbalance is likely to be small and can 
be taken into account in the analysis of the trial. In a small trial, imbalance may make 
the trial more difficult to interpret, and it is advisable to design the randomization 
procedure to ensure balance. For this purpose, ‘restricted’ or ‘blocked’ randomization 
(see Section 2.2) can be used to ensure balance in group sizes. Blocked randomization 
also helps to achieve balance on time sequence and, in multicentre trials, study site. 
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Stratum-matched designs (see Section 2.3) can be employed to produce balance in the 
composition of the groups, with respect to those variables on which the matching is 
based.
The techniques described in Sections 2 and 3 may be used whether the interven-
tion is assigned to communities or to individuals. However, when communities are 
randomized, as in cluster randomized trials, the number of randomization units (com-
munities) may be relatively small (often 20 or less), and more sophisticated methods of 
randomization have been devised to reduce sources of potential bias in the allocation of 
interventions in such trials. These methods are summarized in Section 3.
Whenever possible, intervention studies should be both randomized and double-
blind, i.e. neither the participants nor the investigator should know to which group 
each participant has been allocated. This guards against biases that may result from 
knowledge of the intervention affecting the way an individual behaves, is treated, or is 
monitored during the trial, or assessed during, or at the end of, the trial. Blinding is dis-
cussed in Section 4. In Section 5, there is a discussion of coding systems for recording 
intervention allocation that may be used in trials.
2 Randomization schemes for individual participants
2.1 Unrestricted randomization
Simple random allocation of individuals between the different intervention groups is 
carried out most conveniently by using a computer. For example, in Microsoft Excel, 
the instruction ‘= RANDBETWEEN(1,3)’ will produce a random number between 1 
and 3, i.e. each of the numbers 1, 2, or 3 has an equal chance of being generated. The 
equivalent of tossing a coin is = RANDBETWEEN(1,2). Some calculators also have a 
key which generates a random number on the display (usually a decimal number be-
tween 0 and 1, so that, for example, the equivalent of coin tossing would be to allocate a 
number less than 0.5000 as ‘heads’ and a number 0.5000 or greater as ‘tails’).
In large trials, it is common for a centralized randomization system to be used. When 
an investigator has decided that a participant meets the entry criteria for a trial, and the 
participant has given informed consent to be randomized to one of the trial interven-
tions, the investigator telephones, or sends a text, to a central office to give the iden-
tification details for the participant, and the office then tells, or texts, the investigator 
to which intervention the participant has been randomly assigned or, in the case of a 
double-blind trial, the code for the intervention that should be administered to the 
participant. Systems are now commonly used whereby this process has been automated 
and does not require an individual to answer the telephone in the central office or for 
a similar automated procedure to be followed over the Internet. The advantage of this 
method of intervention assignment is that there is no way in which the investigator can 
influence the randomization procedure, and if, for example, the investigator decides 
not to allocate an intervention to a participant after knowing the random assignment, 
there is a central record of this.
For investigators who cannot set up access to a procedure for remote randomization, 
a frequently used alternative procedure is for a set of opaque, sealed, and numbered 
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envelopes to be prepared, containing the intervention allocations (or possibly even the 
actual interventions if these are, for example, drugs). The envelopes are opened in nu-
merical sequence, as each new person is entered into the trial. Entry criteria must be 
checked and eligibility satisfied before an envelope is opened, in order to exclude the 
possibility that the decision to accept a subject into the trial is influenced by the know-
ledge of the group to which he or she would be allocated. For large trials, the use of 
envelopes may be too cumbersome. Coding systems and alternative procedures appro-
priate for use in the case of ‘double-blind’ designs are discussed in Section 5.
Where the study product (for example, drug, vaccine) package is individually num-
bered and labelled (and randomization has been done before the numbering and 
labelling and where there is an indistinguishable placebo or control intervention), ran-
domization may simply be achieved by registering each new recruit and assigning them 
the number on the product package.
In some circumstances, it may be better to design the randomization system, 
such that it is completely transparent to participants that a random allocation pro-
cess is being used. A trial may be more acceptable if the trial population is involved 
in the randomization procedure. For example, in a trial in Ghana, the allocation of 
 insecticide-impregnated bed-nets was randomized, such that, in some communities, 
all households received a bed-net immediately and, in other communities, the distri-
bution of nets was deferred until a later time (Binka et al., 1996). At a public meeting 
involving all of the trial communities, the name of each community was written on 
a slip of paper. All the slips were put in a bucket, and a child was asked to draw some 
of the slips from the bucket to determine which communities received the bed-nets 
first. By using this procedure, it was apparent that the allocation was random and that 
no favouritism was operating. The fairness of the procedure was demonstrated to the 
population by the fact that, by chance, the community in which the area chief resided 
was not selected for early bed-net allocation (much to the surprise of the population)! 
(Fred Binka, personal communication.)
Unrestricted randomization is often employed in large trials, as it is likely that any 
imbalance between the intervention groups with respect to risk factors for the occur-
rence of the outcomes of interest will tend to even out. Furthermore, it is possible to 
adjust for any residual imbalance during the analysis of the study without important 
loss of statistical power.
2.2 Restricted randomization
Although an unrestricted randomization procedure should lead to approximately 
equal numbers of participants in each group, this is not guaranteed. For example, there 
is more than a 5% chance that, if 20 participants are allocated to one of two groups at 
random, six or fewer may be allocated to one group, and 14 or more to the other. A 
better balance is achieved by using a ‘restricted randomization’ procedure, also called 
‘blocked randomization’ or ‘randomization with balance’. This procedure ensures equal 
numbers in each group, after there have been a fixed number of allocations. For ex-
ample, the allocation procedure might be designed in blocks of ten, such that, in every 
ten allocations, five are to one group and five to the other. The total number of interven-
tion groups must be a multiple of the size of the blocks.
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In order to minimize the possibility that an allocation can be deduced from previous 
allocations, the block size should not be too small (in particular, it should not be two!), 
and, if possible, it should not be known to the investigator responsible for the admin-
istration of the interventions. Indeed, as far as possible, those giving the interventions 
should not be aware that blocking has been carried out, or, if the block size is a fixed 
number, the person giving the intervention would know in advance what the interven-
tion allocation of the last individual or group in the block would be. Another safeguard 
is to use several different block sizes for allocating interventions in a trial. For example, 
in a trial with two arms, the block size might be varied, at random, between eight, ten, 
and 12.
Two different procedures for carrying out restricted randomization are described in 
Sections 2.2.1 and 2.2.2, one appropriate for small block sizes and the other appropriate 
for larger block sizes, say eight or more.
2.2.1 Small block sizes
If two interventions, say A and B, are to be allocated using a block size of, say four, it is 
possible to list all the different possible combinations of the allocations that will yield 
two As and two Bs. This is illustrated in Table 11.1. A number is allocated to each com-
bination, and a random number is chosen to select a particular allocation.
The selection of each random number (between 1 and 6) generates four interven-
tion allocations. Thus, if the random numbers 4, 5, and 1 are generated, these yield 
a list of twelve intervention allocations (to be assigned to participants in sequence) 
(Table 11.2).
2.2.2 Larger block sizes
Listing all possible combinations of allocations within a block becomes unmanageable, 
as the block size increases. For example, with a block size of ten, there are 252 differ-
ent possible combinations, each yielding five participants in each of two intervention 
groups A and B. An alternative approach is necessary therefore. Suppose the block size 
is to be 12 and six allocations are to be made to group A and six to group B. Random 
numbers between 1 and 12 are generated, until six different numbers in that range 
have been generated (numbers that duplicate a previous one are ignored). Algorithms 
Table 11.1 Example of allocation rule for a block size of 
four, with two intervention groups A and B
Allocation Corresponding random number
AABB 1
BBAA 2
ABAB 3
BABA 4
ABBA 5
BAAB 6
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are easily available on the Internet to generate such random numbers. (For example, 
at <http://www.random.org/integers>, it is straightforward to generate X random in-
tegers between Y and Z where the user inserts values for X, Y, and Z.) Thus, we might 
request six random numbers between 1 and 12 and obtain 1, 2, 4, 7, 11, and 12. Then, 
the first, second, fourth, seventh, eleventh, and twelfth participants within the block are 
allocated to one of the interventions, say A, and the other participants to B. The com-
plete sequence for the block of 12 is shown in Table 11.3.
A similar procedure, with a different set of random numbers, is used to allocate inter-
ventions in the next block (i.e. 13 to 24), and so on.
In general, it is better to choose block sizes which are not too large, in order to reduce 
the risk of a long sequence of individuals being allocated to the same intervention. A 
maximum block size of 12 is suggested.
2.3 Stratified randomization
If different subgroups of participants, say males and females, have different background 
rates of disease, it may be desirable to design the allocation procedure such that the in-
terventions are equally divided in each subgroup. This may be achieved though ‘strati-
fied’ randomization. The population is stratified, for example, by sex or by age group, 
and the allocation of the interventions is carried out separately in each stratum.
Stratification may be based on more than one factor. For example, there may be a sep-
arate allocation of interventions in each of a number of different age–sex groups. The 
greater the number of strata, the more complex the organization of the randomization 
is; in general, the number of strata should be kept small. Separate randomization lists 
will have to be maintained for each stratum. This may be achieved by using different 
sets of coloured envelopes, packages, or sticky labels for each stratum.
Stratified randomization should be considered if it is known that there are large dif-
ferences in disease risk between different groups of individuals in a trial (or in response 
to treatment in the case of a therapeutic trial) and if it is possible to place individuals in 
strata corresponding to different levels of risk prior to entry to the trial. The objective 
of stratification is to try to include in each stratum those at similar risk of disease (or 
response to treatment) and to randomize between interventions separately within each 
stratum. In multicentre trials, randomization is often stratified on study site.
Table 11.2 Example of random allocation to two 
groups using a block size of four
Block number 1 2 3
Random number 4 5 1
Allocation sequence BABA ABBA AABB
Table 11.3 Example of random allocation to two groups using a block size of 12
Participant 1 2 3 4 5 6 7 8 9 10 11 12
Intervention A A B A B B A B B B A A
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3 Randomization schemes for community or group-based 
interventions
As discussed in Chapter 4, trial designs have been increasingly employed in recent 
years, in which the unit of allocation of the intervention is a community or group, 
rather than an individual. These cluster randomized trials may involve the randomiza-
tion of communities that can be quite large; consequently, the number of communities 
that can be included in a trial is often relatively small and may be of the order of 20 com-
munities or fewer. If a method of simple unrestricted randomization is used to allocate 
interventions to communities, there is a reasonably high chance that there may be dif-
ferences between the two groups of communities, unrelated to the interventions, that 
may bias the measurement of the effects of the intervention. It is common therefore to 
employ some method of restricted randomization in the allocation of interventions to 
communities (see also Chapter 4, Section 4.2).
3.1 Matched-pairs design
A matched-pairs design is a special case of stratified randomization, in which the strata 
are each of size two. Communities are matched into pairs, the pairs being chosen so 
that the two communities in a pair are as similar as possible with respect to potential 
confounding variables; in the absence of any intervention, the two communities would 
be expected to have similar incidence rates of the disease or other outcome under study. 
One member of each pair is assigned at random to one intervention group and one to 
the other. Similar matching procedures can be employed when there are more than 
two intervention groups. For example, with three groups, matched triplets would be 
employed.
Recent research on the design of cluster randomized trials has indicated that, al-
though matched-pairs randomization remains a valid study design, other methods 
of randomization, such as stratified randomization or constrained (restricted) ran-
domization, discussed in Sections 3.2 and 3.3, may generally be more appropriate 
design strategies (Hayes and Moulton, 2009). The major reason for this is because, 
if a trial is designed as a matched-pairs study, then it must be analysed as such. In 
technical terms, pairing reduces the number of ‘degrees of freedom’ that are available 
in the statistical comparison of the outcome measures in the intervention and com-
parison communities, compared to an unmatched design. This has little consequence 
if the number of communities is large, but, if the number is small, as is typically the 
case, then matching reduces the statistical power of a trial to detect an intervention 
effect of a given size (unless the matching factors are very closely correlated with the 
outcome).
3.2 Stratified design
For the reasons outlined, unrestricted randomization in a cluster randomized trial may 
lead to imbalance with respect to potential confounding factors between the different 
comparison arms of the trial, unless the number of clusters is very large. Pair matching 
of communities is one way of attempting to overcome this problem to ensure better 
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balance between the arms of the trial, but this strategy may be associated with a sub-
stantial loss of statistical power. An intermediate alternative is to adopt a stratified, 
rather than a matched-pairs, design. A stratified design involves the grouping of com-
munities into a number of strata, based on the expected rate of disease in the absence 
of the intervention. For example, in a study on malaria, communities with high trans-
mission intensity would be put into the same stratum, and those with low transmission 
intensity would be put into a different stratum. The communities within each stratum 
are then randomly allocated between the different intervention arms of the trial.
In practice, it is often challenging to decide which communities should go into the 
same stratum. If there are baseline rates available for the disease under study from 
surveillance or from a previous study, then these may provide a reasonable guide 
as to the expected rates in the different communities in the absence of the interven-
tions. However, the rates of some diseases may vary substantially from year to year, 
and what happened in the past may not be a very good guide for what will happen 
in the future. Quite commonly, such rates are not available, and the investigator has 
the alternative of conducting a pre-trial study to estimate disease rates in each com-
munity or, based on ecological and epidemiological considerations, of making some 
estimate of what the rates might be. The first of these options adds to the cost of the 
study, whereas there may be considerable uncertainties regarding the utility and ac-
curacy of the second approach. A fuller discussion of these issues is given in Hayes 
and Moulton (2009).
A stratified design is associated with less loss of statistical power than a matched-
pairs design and will assist in making the communities in the different arms of the trial 
more comparable with respect to potential confounding factors. There may still remain 
some imbalance with respect to these factors, but it is possible to adjust for this in the 
analysis of the trial, provided, of course, the relevant confounding factors have been 
measured. Methods for the analysis of cluster randomized trials and the adjustment for 
confounding factors are beyond the scope of this book and will generally require the 
input of a specialist statistician.
Hayes and Moulton (2009) suggest that, in practical situations, it is likely that the use 
of three or four strata will provide most of the advantages provided by pair matching, 
such that communities can be very accurately paired with respect to expected disease 
rates during the trial. With respect to the choice of the number of strata, these authors 
suggest that there should be no more than two strata if there are six or fewer clusters per 
arm, and no more than three strata if there are 7–10 clusters per arm.
3.3 Constrained randomization design
A further method of controlling for confounding is to adopt a method known as con-
strained or restricted randomization. Consider a trial to be conducted in 12 commu-
nities, six of which will be allocated to the intervention under test, the remaining six 
serving as control communities. Using a simple unrestricted randomization design, 
six communities would be selected at random to receive the intervention, and the 
other six would serve as controls. By chance, it might happen that the six intervention 
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communities all turn out to be close to a major highway, and the six control commu-
nities are all more distant from the highway. If the disease we are studying might be 
related to proximity to the highway (for example, HIV infection rates show this charac-
teristic in some situations), then we may be rather unhappy with this particular selec-
tion of intervention communities, as there would be a priori reasons for believing there 
would be differences in disease rates, irrespective of the effect of the intervention we 
wanted to test. In these circumstances, we might reject the initial random selection of 
communities and select another set of random numbers to determine which our inter-
vention communities are. While this strategy may not seem unreasonable, it is clearly 
dangerous to allow an investigator to override a randomization procedure if he or she 
does not like the result!
Constrained randomization designs aim to exclude from consideration random al-
locations that result in unsatisfactory imbalance between communities in the inter-
vention and control arms. In the study already outlined, involving 12 communities, 
there are 924 possible different allocations of which communities comprise the six in 
which the intervention will be applied. Conceptually, we could imagine examining 
each of these possible allocations and deciding which of them we would be happy with 
and which would cause us concern. Suppose there were, for example, 400 for which 
there seemed to be a reasonable balance of confounding factors between the putative 
intervention and control communities. We could restrict our consideration of possible 
allocations to these 400, and choose one of these at random to be the one that was 
actually used in the trial. This is the basic principle of the constrained or restricted 
randomization design.
Examining all 924 possible allocations would be a considerable undertaking and 
would be even more difficult if the total number of communities was more than 12. 
It is therefore necessary to seek some more automated method of deciding which 
randomizations are acceptable. In practice, what is done is to define some key vari-
ables for which we wish to achieve reasonable balance across the intervention and 
control arms. These key variables are then compared in each of the possible rand-
omizations, and a rule is set up to exclude a randomization if the difference between 
the key variables in putative intervention and control arms is more than some speci-
fied amount. Thus, the selection of ‘acceptable’ randomizations can be programmed 
into a computer, so that the selection is done automatically once the acceptability 
criteria for balance between the intervention and control communities have been 
defined.
The procedure described as a modification of simple unrestricted randomization can 
also be incorporated into a stratified design, so that there is a selection of acceptable 
possible randomizations within each stratum.
Both stratification and restricted randomization can be used to achieve good balance 
(avoid confounding), but stratification also aims to reduce between-cluster (within-
stratum) variation, and hence to increase power and precision.
An example of the use of restricted randomization in the design of a trial of an ado-
lescent sexual health intervention carried out in Tanzania (Hayes et al., 2005) is given 
in Box 11.1.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
192 CHAPTER 11: RANDOMIZATION, BLINDING, AND CODING
In this trial, carried out to evaluate the impact of a multi-component sexual health 
intervention on HIV and other adverse outcomes among adolescents in Tanzania, 
the 20 rural study communities were grouped into three strata, based on their ex-
pected risk of HIV infection (Hayes et al., 2005). There were six communities in 
the low-risk stratum, eight in the medium-risk stratum, and six in the high-risk 
stratum.
There is a total of 28 000 ways of assigning half the communities in each stratum 
to the intervention arm and half to the control arm. Because the total number of 
communities is quite small, not all of these 28 000 allocations would provide a 
good balance of key characteristics across treatment arms. Restricted randomiza-
tion was therefore used to achieve an acceptable balance by applying the following 
criteria:
◆	 mean HIV prevalence in each treatment arm within 0.075% of overall mean
◆	 mean prevalence of Chlamydia trachomatis (CT) infection in each treatment 
arm within 0.1% of overall mean
◆	 two of the 20 communities were close to gold mines, and one of these was to 
be allocated to each treatment arm
◆	 even distribution of intervention communities across the four administrative 
districts in which the trial was carried out.
HIV and CT prevalence were based on an initial survey of young people carried 
out in each study community. Prevalences of HIV and CT (also an STI) were as-
sumed to be correlated with sexual behaviour in the study communities and there-
fore to be predictors of the risk of acquiring HIV infection during the trial. HIV 
prevalence is often increased in mining communities, and it was important to en-
sure that one mining community was allocated to each treatment arm. Finally, en-
suring an even distribution of intervention communities across districts helped to 
ensure that the trial was acceptable to local leaders.
A computer program was used to check each of the 28 000 possible allocations 
against the balance criteria, and 953 allocations satisfied the criteria and were listed. 
One of these was chosen randomly at a public randomization ceremony.
Source: data from Hayes, R. J., et al., The MEMA kwa Vijana project: design of a community ran-
domised trial of an innovative adolescent sexual health intervention in rural Tanzania, Contem-
porary Clinical Trials, Volume 26, Issue 4, pp. 430–42, Copyright © 2005 Elsevier Inc. All rights 
reserved.
Box 11.1 Use of restricted randomization in a 
community randomized trial of an adolescent sexual 
health intervention in Tanzania
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4 Blinding
Whenever possible, neither the participants nor the investigators should know to 
which intervention group each participant belongs until after the end of the trial. Such 
‘ double-blind’ designs (both the investigator and the participants are blind to the know-
ledge of who have received each intervention) eliminate the possibility that knowing to 
which intervention an individual is allocated may affect the way the individual behaves, 
is treated, or is monitored during the trial, or the way an individual is assessed at the 
end of the trial. Sometimes, a double-blind trial is not possible, and a ‘single-blind’ 
design might be used, in which the investigator knows to which group a participant 
belongs, but the participant does not.
‘Blinded’ designs are especially important when those in one of the groups under 
comparison are given an intervention that is expected to have no effect on the out-
come of interest. To maintain blindness in these circumstances, a placebo should be 
used, if possible, which should look and smell as similar as possible to the interven-
tion itself (and have a similar taste if it is being given orally). Sometimes, an identical-
looking placebo cannot be obtained, and, in these circumstances, the investigator and 
the participants should be kept blind to which treatment is the active one. While this 
may be the best that can be done in some trials, it is generally undesirable. Either the 
participants or the investigator may form a view as to which the active treatment is 
(possibly erroneously), and this may affect differentially the amount of other care given 
to the participants or the likelihood that a participant reports apparently beneficial or 
harmful effects. For example, there is evidence that the colour of a tablet may affect the 
perceived action of a drug and seems to influence the effectiveness of a drug in some 
situations (de Craen et al., 1996).
For some interventions, it may be possible to preserve blindness in the initial phase 
of a trial, but this may be more difficult later. For example, in placebo-controlled studies 
of ivermectin against onchocerciasis, it was found that some participants were able to 
guess that they had received an active drug, rather than a placebo, because of the effect 
of ivermectin on other helminth infections, such as Ascaris, through the passage of 
worms in their stools, whereas those receiving placebo rarely experienced this effect. 
In placebo-controlled trials of BCG vaccination, most of those who have received BCG 
develop a lasting scar, whereas those who have received placebo do not. The possible 
bias that this might induce in the assessment of whether or not a participant developed 
leprosy, following vaccination, was overcome in a trial in Uganda by covering the vac-
cination site with sticking plaster for all participants before each clinical examination 
(Brown and Stone, 1966).
For some intervention trials, in which the unit of randomization is the commu-
nity, the use of a placebo is straightforward and is no different, in principle, from the 
situation for an individually randomized trial. This was the case, for example, in a 
cluster randomized trial to assess the impact of regular vitamin A supplementation 
on child mortality. Those in the control communities received supplementation 
with an inert liquid that was administered in such a way that it was indistinguish-
able from the administration of vitamin A (Ghana VAST Study Team, 1993). 
For some interventions, however, a suitable placebo may be impossible to find. 
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What would be a suitable placebo for an improved water supply and sanitation pro-
gramme in a village, for example?
5 Coding systems
In some circumstances, it may be necessary to break the intervention code for an indi-
vidual. This might arise, for example, if a severe adverse event becomes manifest and 
the treatment for it may be influenced by knowledge of what intervention the indi-
vidual received. The coding system which is used to record which individuals received 
which intervention should be designed, such that, if it is necessary to break the code 
for one individual, the blindness of the investigator, with respect to the interventions 
received by other trial participants, should be preserved. For example, if one interven-
tion is coded A and the other B, breaking the code for one individual effectively breaks 
the code for all participants (if the investigator knows who has received A and who has 
received B). The use of a single code for each intervention is generally a poor design. It 
is better to have a unique code for each participant and to have a separate list linking 
participant numbers with the intervention allocated, or to have only a very small num-
ber of participants sharing the same code number. For example, in a BCG trial in South 
India for tuberculosis prevention, ampoules (each containing several doses of vaccine) 
were packed in boxes of three. Each box held three vials containing one of two different 
vaccine doses or a placebo preparation. The three ampoules were randomly coded 1, 2, 
and 3. The vaccine received by a participant was coded in the trial records by a com-
bination of the box number and the ampoule number (Tuberculosis Prevention Trial 
Madras, 1979). If it had been necessary to break the vaccine code for an individual, it 
would only have been broken for those participants who received vaccine from the 
same ampoule in the same box.
The randomization list should usually be prepared in advance of the trial, and the 
codes assigned by someone other than the PI. If the intervention is a drug or a vac-
cine, the manufacturer may agree to supervise the packaging and coding, but the al-
location procedure should be overseen, and the code should be held during the trial 
by a disinterested party. Often, the code is held by the data safety and monitoring 
committee (see Chapter 7, Section 4). It is also worth checking, for a random sample 
of the drugs or vaccines, that the codes are correct and errors have not been made in 
the packaging.
5.1 Individual allocations
Suppose two interventions are to be allocated between 200 individuals. A good cod-
ing scheme would be to choose 100 random numbers between 1 and 200 and allocate 
these codes for intervention A, say, and allocate the other 100 for intervention B (there 
may also be some ‘blocking’ within the total group of 200, say in blocks of size ten; see 
Section 2.2). When an intervention is allocated to the 127th patient in the trial, they 
would be given the drugs in envelope number 127, and this would be noted in their trial 
record. A master list of the interventions corresponding to each number would be kept 
in a secure place by a third party not directly connected with the trial. If it were neces-
sary to break the code for an individual patient, the third party could do this without 
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revealing any of the other codes to the investigator. Only at the end of the trial would 
the list be released to the investigator for the analysis of the results of the trial.
5.2 Group allocations
If a trial involves many thousands of participants, it may be logistically too compli-
cated to allocate a separate treatment code number to each participant, though this will 
depend upon the circumstances, and, in some cases, having thousands of individual 
codes poses no problem. An alternative approach is to use a fixed, but not too small, 
number of codes for the different interventions. If there are N participants in the trial 
and C codes for the interventions, then breaking the code for one participant would 
break the codes for N/C in total. For example, the coding system used for a vaccine trial 
in Venezuela is given in Box 11.2. In this trial, 998 different codes were used (499 for 
one vaccine and 499 for the other) for about 30 000 participants. Breaking the code for 
one individual would break it for about 30 others (Convit et al., 1992).
A simpler system might be required if participants had to be given the same interven-
tion on a number of occasions. A method that was used in a trial of ivermectin against 
The coding system described was that used in a leprosy vaccine trial conducted in 
Venezuela (Convit et al, 1992). Randomization was to one of two vaccines.
The vaccine vials were labelled with a number between 1 and 998. A total of 499 
of these numbers were allocated at random for one vaccine, and the other 499 for 
the other vaccine. A check letter was added to each number, so that transcription 
errors would stand a high chance of being detected. The code was devised, such 
that every possible permutation of the same three digits in a number had a different 
check letter, as illustrated:
Box 11.2 Assignment of check letter for three-digit 
vaccine code
001A 010B 100C
002D 020E 200f
.
.
009M 090N 900P
010B—already allocated—see line 1
011R 101S 110T
.
.
123W 132X 213Y 231A 312B 321C
124D 142E 214f 241G 412H 421J
etc.
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onchocerciasis in Sierra Leone was to allocate 20 codes for ivermectin or placebo treat-
ments (A, B, C, D, and so on) (Whitworth et al., 1991). The drugs were taken to the 
field in 20 tins, with the code letters on them (ten of which contained ivermectin, and 
ten contained placebo tablets), and participants were allocated to one of the 20 codes at 
random. If a participant was allocated, say to code E, then each time they were treated, 
the dose was taken from tin E. About 1000 patients were included in the trial, so that 
breaking the code for one individual would have also broken it for 1000/20 = 50 others. 
A similar system was used in a trial of a pneumococcal vaccine in The Gambia, which 
involved many thousands of participants, and each participant was scheduled to re-
ceive three doses of the vaccine at different times (Cutts et al., 2005).
With either individual or group allocations, it is helpful if the intervention codes are 
on removable sticky labels that can be affixed to an individual’s form, thus minimizing 
the likelihood of recording errors. Where possible, the coding system should be de-
vised so that transcription errors in recording may be detected. How this was achieved 
in the leprosy vaccine trial in Venezuela is illustrated in Box 11.2. More commonly 
now, bar codes are used to identify interventions in trials using drugs or vaccines, and, 
provided that suitable computer systems are set up, this should eliminate the possibility 
of transcription errors.
In some countries, number 1 and number 7 are distinguished clearly when written, 
as it is the custom for the number 7 to have a horizontal stroke put through it. In 
other countries, however, this is not the custom, and there is a danger that these 
numbers will be confused. In such cases, it would be advisable to change the check 
coding system, such that, if a 1 is confused with a 7, or vice versa, the check letter 
will enable the error to be detected. Thus, the system outlined might be modified, 
as indicated:
Source: data from Peter Smith (personal communication).
Box 11.2 Assignment of check letter for three-digit vaccine code (continued)
001A 0l0B 100C 007D 070E 700f
002G 020H 200J
003K . .
.
.
.
011R 101S 110T 017V 071X 107Y 170A 701B 710C
077D 707E 770f
012G etc.
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1 Introduction to outcome measures and case definition
Field trials of health interventions are designed to assess the impact of one or more inter-
ventions on the incidence, duration, or severity of specified diseases, or on intermediate 
variables or risk factors considered to be closely related to these measures of disease 
(for example, hygiene behaviours for diarrhoeal diseases, reduction in density of para-
site vector, reduction of indoor air pollutants for pneumonia, or reduction of salt intake 
for hypertension). The measures chosen to assess the impact of the interventions are 
called the outcome measures in the trial (or the trial endpoints). Such measures should 
be defined at the time the trial is designed and should be specified in detail in the study 
protocol. The outcomes should be compared between those in the different intervention 
groups and should be measured in a consistent way during the course of the trial in the 
different groups. Clear definitions are also necessary, so that the measures can be rep-
licated in other trials and meaningful comparisons made between trials. Failure to pay 
sufficient attention to the precise definition of the primary outcome measures at the start 
of a trial may lead to confusion in interpreting the results or can even invalidate them.
As discussed in Chapter 4, Section 5, several different outcome measures may be em-
ployed in a trial. It is important to decide which is of most interest (primary outcome), as 
this has major design implications, particularly in terms of the study size and duration. 
Trials may have other outcomes (secondary or tertiary) that may be important to meas-
ure, although they will generally not determine the size of the trial. In Table 12.1, there are 
some examples of primary and secondary outcomes for trials of different interventions.
In this chapter, different types of outcome measures are reviewed in Section 2, and 
factors influencing the selection of these are discussed in Section 3. The importance 
of standardizing measurements between different observers is stressed in Section 4.1, 
Table 12.1 Examples of primary and secondary outcomes for trials of different 
interventions
Intervention trial Primary outcome(s) Secondary outcomes Comment
Phase III trial of 
9-valent conjugate 
pneumococcal 
vaccine in The 
Gambia (Cutts  
et al., 2005)
◆  first episode of 
radiological  
pneumonia
◆  Clinical or severe 
clinical pneumonia
◆  Invasive 
pneumococcal  
disease
◆  Invasive 
pneumococcal 
disease due to 
serotypes in 
vaccine
◆  All-cause hospital 
admissions
◆ All-cause mortality
The main purpose of the 
trial was to evaluate the 
public health impact of the 
vaccine. first episodes of 
radiological pneumonia 
were reduced by 37% 
(and all-cause mortality 
by 16%—not a primary 
endpoint in the trial). 
Highest efficacy was 
expected against invasive 
pneumococcal disease due 
to serotypes in the vaccine, 
but the aetiology of most 
cases of pneumonia is 
difficult to establish.
continued
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and there is a discussion of how the results of a trial may be influenced by poor sensitiv-
ity or specificity in the outcome measures in Section 4.2. Finally, ways of avoiding bias 
and maintaining quality control (QC) in case ascertainment methods are reviewed in 
Sections 4.3 and 4.5.
2 Types of outcome measures
2.1 Primary, secondary, tertiary
2.1.1 Primary outcomes
Primary outcomes are the most important outcomes of the study, the ones that deter-
mine its design and the study size. They represent the main reason the trial is being 
Table 12.1 (continued) Examples of primary and secondary outcomes for trials of 
different interventions
Intervention trial Primary outcome(s) Secondary outcomes Comment
Cluster 
randomized 
trial to assess 
the impact of 
an adolescent 
sexual health 
intervention in 
Tanzania (Ross  
et al., 2007)
◆  Incidence of HIV 
infection
◆  Prevalence of 
herpes simplex 
type 2 (HSV 2) 
infection at end 
of trial
◆  Six biological 
measures (for 
example, syphilis 
and gonorrhoea  
prevalence at end 
of trial)
◆  five behavioural 
endpoints (for 
example, use of 
condoms during  
sexual intercourse)
◆  One attitudinal 
endpoint
◆  Three knowledge 
endpoints (for 
example, how HIV 
is transmitted)
The intervention was 
designed to reduce 
HIV incidence through 
behaviour change 
brought about by sexual 
health education. A 
substantial number of 
secondary outcomes 
were included to 
facilitate understanding 
of the main results. 
This was important, as 
the intervention was 
shown to substantially 
improve knowledge, 
reported attitudes, and 
some reported sexual 
behaviours but had no 
consistent impact on 
biological outcomes.
Trial of 
intermittent 
treatment of 
infants for 
malaria and 
anaemia control 
at time of routine 
vaccinations 
in Tanzania 
(Schellenberg  
et al., 2001)
◆  first or only 
episode of clinical 
malaria
◆  Multiple malaria 
episodes
◆ fever episodes
◆ Severe anaemia
◆  Admissions to 
hospital
◆  Outpatient 
attendances
This was a test of a new 
approach to malaria 
control by administering 
anti-malarial drugs 
routinely to infants 
attending clinics for 
vaccination. Clinical 
malaria was reduced by 
59%, and severe anaemia 
by 50%
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conducted. Normally, a trial has only one primary outcome, so, for each main question 
in the development of a new drug, vaccine, or intervention, one specific trial is usually 
conducted. However, more than one primary outcome may be selected in some trials, 
provided the design and sample size allow it and if measuring them in the study does 
not substantially add to the cost or complicate the design or conduct of the trial. For 
example, Phase I or II clinical trials usually have several primary outcomes (such as the 
safety of a new drug or vaccine, evaluated through a series of clinical outcomes, as well 
as the immunogenicity of the vaccine or pharmacodynamics of the drug). Phase III or 
IV trials have fewer primary outcomes, and often only one. Primary outcomes need 
careful definition prior to the start of the trial (indicator, instrument to be used, meas-
urement to be taken, values which will be considered as a positive or negative result, 
which laboratory will be used, etc.); these should be agreed upon among investigators, 
sponsors, and any regulatory agencies overseeing the trial.
2.1.2 Secondary and tertiary outcomes
Trials often have additional important outcomes, but these are not usually used to de-
termine the trial design and sample size. They are included as secondary or tertiary 
outcomes to be measured in the trial. These outcomes may not be statistically conclu-
sive, since the trial may not have been designed with the power to evaluate them, but 
they can be very useful to generate further hypotheses and guide future trials. Because 
of their importance in justifying future studies, these additional outcomes also need 
careful definition and measurement and should be fully specified in the protocol, since 
extra resources often are needed to measure and evaluate them.
2.1.3 Other variables which are not study outcomes
Often, trials have other variables measured in the study not directly related to the study 
outcomes. Variables, such as age, gender, educational or socio-economic level, and nu-
tritional status, may be used to evaluate potential effect modifiers or confounders to the 
study outcomes. These variables also need to be defined and considered at the begin-
ning of the study, so they may be included in any pilot investigations.
2.2 Clinical case definitions
2.2.1 Physician-based case definitions
In some trials, outcomes are based on a clinical diagnosis by a physician, without any 
type of laboratory confirmation. For example, pneumonia may be diagnosed by aus-
cultation in a trial evaluating the impact of an intervention designed to reduce indoor 
air pollution. This type of outcome is subjective, and interpretation may vary among 
doctors, and even among experienced specialists. Nevertheless, in many clinical trials, 
physician-based clinical diagnosis determines the main outcome of the study, since 
no alternatives exist. For many diseases, standardized criteria for defining a ‘case’ have 
been established by experts. The International Classification of Diseases (World Health 
Organization, 2010; see also <http://www.who.int/classifications/icd/en>), which is re-
vised about every 10 years, provides a basis for coding all diseases in a systematic way 
and is widely used for clinical and epidemiological research.
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If standardized criteria for a ‘case definition’ have not been developed for the disease 
under study, a suitable definition should be established before the trial starts. For infec-
tious diseases, there is often the need to distinguish between infection and disease, since 
clinical manifestations of infections may vary widely, from subclinical to overwhelming 
disease. For many trials, the main outcome of public health interest may be those infec-
tions that are severe or fatal. Careful definitions of these types of clinical categories are 
important, and, if available, the criteria used in other studies should be used to facilitate 
comparability across studies. The physicians charged with making diagnoses in the trial 
should discuss and agree the criteria they will be using to make a diagnosis and should 
compare their diagnoses on a range of patients prior to the start of the trial and at pe-
riodic intervals throughout the trial (see Section 2.2.5). Cases may also be classified as 
suspected, probable, or definite, using clinical and/or laboratory criteria.
In some populations, the conduct of a clinical examination may be problematic. 
Physical examinations are virtually always highly personal and may raise sensitive 
issues concerning individual dignity. In those populations when privacy is required, 
a third person in the examination room is often important, both to reassure the pa-
tient and to provide protection against possible charges of misconduct. In the case of 
children, the mother’s presence should normally be requested; for the examination of 
women, a nurse and an appropriate family member may be needed, even when the ex-
aminer is a woman. If there are local codes of behaviour that cover such circumstances, 
these must be adhered to.
2.2.2 Laboratory-based case definitions, including any diagnostic 
procedure
Commonly, a clinically defined study outcome involves the combination of a clinical 
assessment with the support of a confirmatory laboratory, or other diagnostic, pro-
cedure. For example, the clinical diagnosis of malaria may be supported by a positive 
identification of the parasite in the blood, or the diagnosis of dengue fever in a subject 
with 48 hours of elevated temperature with a positive immunoglobulin M or viral an-
tigen present in the blood, as detected by polymerase chain reaction, or the clinical di-
agnosis of pneumonia with a confirmatory chest X-ray. All these diagnostic procedures 
need careful definition, including the technique, machine, or equipment to be used, 
reference values considered normal for the study population, and the level at which 
they will be considered abnormal. It is important to describe, in the protocol, how the 
test or procedure will be conducted and whether a reference laboratory will be used 
to validate the site laboratory or procedure—also, how procedures used by laboratory 
personnel to interpret results will be standardized and how monitoring for QC will 
be done. Some diagnostic results are also affected by subjectivity such as reading the 
results of a chest X-ray. In such cases, protocols have been developed to try to stand-
ardize the diagnosis, such as establishing defined criteria for each type of pathology in 
advance, having two independent, blinded radiologists read all X-ray films, with a third 
radiologist reading all films where there were disagreements, with their result used as 
the tiebreaker. Similar procedures have been developed to read blood smears for ma-
laria. All these options have important consequences on the trial logistics and cost, so 
careful consideration needs to be given to them when designing the trial and selecting 
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its study outcomes. Issues concerning laboratory tests of relevance to diagnosis in field 
trials are outlined in Chapter 17.
2.2.3 Lay worker-based case definitions
Some trials use lay workers (fieldworkers) to measure a study outcome. Examples of 
such trials are diarrhoeal diseases where prevalent diarrhoea might be defined as three 
or more liquid or semi-liquid stools passed in a 24-hour period, as reported by the 
mother or the child’s caretaker to a fieldworker, or hygiene behaviours observed by 
fieldworkers in spot household checks during a hand-washing intervention trial. These 
types of outcomes are usually captured in questionnaires or study forms. Interviewing 
techniques and questionnaire design are discussed in Chapter 14.
Fieldworkers may also measure a clinical indicator such as the body temperature or 
respiratory rate. Because of the high cost of using physicians, in many trials, lay work-
ers or paramedical workers are trained to assess clinical signs and symptoms. When 
using lay workers or professional fieldworkers, such as nutritionists, auxiliary nurses, 
or nurse technicians, it is essential to train them and standardize the methods they use, 
in order to assure uniform implementation of these procedures in the field throughout 
the study, with good supervision and QC procedures.
2.2.4 Case definitions using secondary data sources
In some trials, such as in phase IV trials, existing surveillance systems may be used to 
define a study outcome. These secondary data sources, in which trial outcomes are not 
measured directly by study staff, will have the limitations intrinsic to the quality of the 
existing surveillance system. Examples of such study outcomes are post-marketing pas-
sive surveillance of vaccine or drug-related SAEs, such as hospitalizations of any type, 
after the introduction of the intervention into general use. They could also be used to 
evaluate the efficacy of a new vaccine or intervention on an important outcome which, 
for reasons of cost or ethics, could not be measured in a phase III trial such as the im-
pact of a new vaccine on mortality.
2.2.5 Standardization
All study outcomes to be used in a clinical trial need to be properly standardized. 
When an outcome requires physicians, other professionals, or lay workers to measure 
it, standardization usually requires predefined exercises, with the use of an expert to 
act as the ‘standard’ against which the group is compared, defining differences which 
will be considered acceptable as part of the precision of the study. These standardiza-
tion exercises could be done with real patients or mock subjects who may be trained 
actors. The use of videos showing different types of patients, which all participants 
evaluate independently, is a very useful exercise to help standardize them against the 
‘standard’ observer. Standardization of this sort is not easy; it requires resources, time, 
and, in many cases, patients or volunteers willing to be examined by multiple persons. 
Ideally, the same set of samples, films, blood smears, subjects, or videos would be evalu-
ated again by the same individual in a random order, under code, to allow the cal-
culation of intra-observer reproducibility. All these procedures need to be carefully 
described in operating manuals and recorded, so they can be reviewed by investigators, 
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collaborators, or regulatory agencies. In studies that last for several years, it is impor-
tant to re-standardize observers every 6 to 12 months or if any observer needs to be 
replaced, to assure that the quality of the study is maintained.
2.2.6 Inclusion and exclusion criteria
An important component of an outcome definition is the description of the inclusion 
and exclusion criteria for the subjects to be evaluated in the trial. Ideally, the trial re-
sults should be able to be generalized to the whole population in which the interven-
tion will be used. Under ideal circumstances, nobody should be excluded from the 
trial. However, for ethical, logistic, or analytical reasons, most trials establish stringent 
inclusion and exclusion criteria to exclude certain persons from participation. These 
criteria could be established on the basis of factors such as age, gender, literacy, being 
healthy or not, not affected by chronic diseases different from the study outcome, or 
not affected by other conditions such as abnormal baseline laboratory results. All these 
criteria need careful evaluation and discussion not only within the research team and 
the sponsor of the trial, but also with the ethics committees, the regulatory agencies 
overseeing the trial, and the communities in which the trial will take place, to assure 
that the trial results can be generalized to the intended population. It is common prac-
tice to exclude persons who are very sick from a trial (unless, of course, the trial inter-
vention is directed at such persons). This is done because early deaths, or other SAEs 
in such persons, may occur independently of the trial intervention but may complicate 
interpretation of the effects of the intervention.
Signing a written informed consent form is now a standard inclusion criterion in 
most clinical trials (see Chapter 6). However, such a requirement will select a subgroup 
of the population who accept to sign such a form and participate in the study, generat-
ing a potential selection bias. To measure how strong that bias may be, it is important to 
register all eligible subjects who were considered as potential participants in the trial, 
indicating the reasons for refusal for those who did not enter into the trial.
2.3 Death and verbal autopsies
Preventing deaths (or severe disabilities) is one of the most important public health 
outcomes of any type of treatment or preventive intervention. It is the most important 
outcome in driving disease control policies and the introduction of new interventions 
or treatments into the population, once they have been found to be safe and effective. 
These types of outcomes have the heaviest weight in terms of disability-adjusted life-
years (DALYs), when undertaking cost-effectiveness analyses of new drugs or inter-
ventions (see Chapter 19). Therefore, trials designed to evaluate these outcomes are 
very important. But, for many reasons, they may be difficult and costly to conduct, and, 
in many cases, they may not be feasible or ethical to do. Counting deaths in the conduct 
of a trial is a very sensitive issue, particularly in developing countries with poor health 
systems. It may create moral issues or generate political tension that may stop the trial. 
Therefore, few trials are done with these important outcomes, despite their major im-
portance. However, those trials that are done with this endpoint and which demon-
strate that an intervention significantly reduces mortality are most likely to influence a 
policy decision on a more widespread introduction of the intervention.
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When deaths or severe disability are chosen as study outcomes, several problems 
emerge, depending on the setting where the study is conducted. In many LMICs, the 
quality of vital registration systems is poor or they are non-existent, precluding their 
use. Therefore, methods are needed to identify deaths, as well as to establish causes of 
death. In LMICs, the most commonly used method to ascertain causes of death are 
‘verbal autopsies’. A verbal autopsy is a structured interview, conducted with the rela-
tives of the deceased person, with the intention to reconstruct the series of events that 
led to the death (or severe complication or disability). Standard verbal autopsy ques-
tionnaires have been developed (World Health Organization, 2012). Such ‘autopsies’ 
should be conducted neither too soon after the death (to avoid asking questions when 
relatives are still very upset by the death) nor too long after the death (to avoid recall 
bias). This interview is then analysed in a standardized way, either by physicians or 
using a computer algorithm, to classify the likely cause of the death, following a prede-
fined set of criteria (Lopez et al., 2011).
The reliability of verbal autopsy methods varies according to the cause of death, as 
some causes of death may be confused because signs and symptoms in the illness lead-
ing up to death may be similar. The usefulness of verbal autopsies is also dependent on 
the culture of the population under surveillance. It is essential to pilot-test the (trans-
lated) questionnaire to assure that appropriate local words are used to ascertain signs 
or symptoms of the causes of death.
In many populations, there could be a wide range of reasons why deaths may not be 
reported, and therefore special care should be taken to ensure that ascertainment is 
as complete as possible. This becomes crucial when the study outcome is death in the 
perinatal period, since an important proportion of live births that die in the minutes 
or hours after birth could be either missed or wrongly reported as stillbirths. In some 
trials, members of the study community may be hired as local informants to report any 
deaths. Other techniques include enumerating all members in a community and check-
ing for the absence of any of them in frequently conducted cross-sectional surveys. 
Special attention should be paid to households for which all members are absent during 
one of these follow-up surveys, because the death of an adult may lead to dissolution 
of a household or migration of household members. Enquiries should be made with 
neighbours in such circumstances. Training and standardization of interviewers are es-
sential. The frequency of surveillance will be a critical decision in designing trials with 
mortality outcomes, since a long recall period (such as 1 year) may miss deaths, partic-
ularly of children or infants; but each additional surveillance round will be expensive.
2.4 Non-clinical case definitions
Non-clinical case definitions can also be used in trials such as quality of life in trials 
of the use of chemotherapy for advanced cancer, antibiotic use in children in settings 
where they are available without prescription, satisfaction of users of a health service, 
and economic outcomes (costs) which are discussed in Chapter 19. They also may in-
clude outcomes that come directly from patients about how they feel or function in rela-
tion to a health condition and its therapy (so called patient-reported outcomes), without 
interpretation by health care professionals or anyone else. For these case definitions, 
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instruments that have been developed previously or that are created especially for the 
trial need to be validated, in order to have valid and comparable results.
2.5 Proxy measurements as study outcomes
Some trials may select outcome measures that are associated with the outcome of inter-
est such as reported risky sexual behaviour, which are either easier to measure, cheaper, 
or more socially acceptable. Those outcomes are called ‘proxy’ measurements of the 
outcome of interest. Such measures, however, may be subject to invalidity and bias 
(for example, misreporting, differential degrees of desirability bias between trial arms).
2.5.1 Behavioural changes
A behaviour thought to be critical to reduce the disease of interest might be selected 
as a study outcome. For example, in a study to investigate the effectiveness of a health 
education campaign to promote the use of latrines, where the ultimate objective was to 
reduce diarrhoeal disease, the frequency of use of latrines might be measured. Some-
times, health-related behaviours may be measured by direct observation.
Changes in knowledge or attitudes are sometimes an important initial step before 
a behaviour is changed, which, once changed, should reduce the risk of the disease of 
interest. Knowledge or attitudes can be assessed with reasonable reliability, using ques-
tionnaires or other interview methods, but observational studies may be required to 
determine if behavioural changes have actually occurred. For example, in a study to in-
vestigate the effectiveness of a health education campaign to promote the use of latrines, 
it may be relatively straightforward to assess, after the campaign, whether individuals 
have a better knowledge of why using latrines is desirable, but observational studies, be-
fore and after the campaign, may be necessary to ascertain whether or not the frequency 
of use of latrines had actually changed, let alone whether behavioural change led to a 
reduction in the incidence of diarrhoea. Similar issues arise with respect to the evalua-
tion of a hand-washing intervention campaign. Further studies may then be needed to 
determine whether the changed behaviour has led to a reduction of diarrhoeal diseases.
Some trials have the incidence of a self-reported behaviour as one of their outcomes. 
For example, in evaluating the effectiveness of sexual behaviour change interventions, 
it is not possible to observe sexual behaviours directly, so self-reported behaviours are 
frequently recorded. But such measures are very open to desirability bias where the 
respondent reports the behaviour that they think the investigator would judge to be 
the desirable one. Furthermore, the desirability bias may be differential between the 
trial arms. For example, if the intervention group has been encouraged to reduce their 
number of sexual partners and always use a condom, while the control group has not, 
the intervention group may be more likely to over-report these ‘desired’ behaviours at 
follow-up. Self-reported behaviours, though sometimes the only practical outcome for 
a trial, are potentially misleading and should be avoided, at least as the primary out-
come measure in a trial, if at all possible.
2.5.2 Transmission reduction
The purpose of interventions, based on vector control or environmental alteration, may 
be to reduce or interrupt transmission of the infectious agent of interest. Generally, the 
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first priority is to determine whether the intervention has accomplished the immediate 
changes intended. For example, in trials in which insecticides are applied to reduce vec-
tor populations in order to reduce the transmission of some infectious agent, the first 
step would be to determine the impact of the intervention on the vector population. If 
the vector population is little affected, it may be reasonable to conclude that any impact 
on human disease is unlikely. However, if there is a reduction in vector population, it 
may be erroneous to conclude that the human disease load will also fall. A further study 
to determine the impact on disease may be required. Similarly, if interventions are 
being evaluated that may reduce indoor air pollution as a measure against respiratory 
disease, it may be best to focus initial studies on the assessment of changes in pollution 
levels, before assessing the impact on respiratory diseases. Usually, it will be more effi-
cient to carry out trials to monitor the impact on disease only after there is evidence of 
an effect on the vector or on the agent against which the intervention is directed.
In order to assess a change in transmission, any, or all, of several different outcomes 
may be used:
◆	 incidence of infection or disease
◆	 prevalence of infection or disease
◆	 severity of disease
◆	 intensity of infection (for example, for helminths)
◆	 intensity of infective agent in the vector.
Any changes to these different outcomes will happen at different intervals after the 
intervention is in place, and may require studies over time to measure the overall study 
impact. For instance, in an onchocerciasis control programme, the first evidence that 
an intensive larviciding of Simulium damnosum (black fly) breeding sites is having an 
effect may be a dramatic drop in fly-biting rates in the intervention area. Over the next 
several years, there may be a steady fall in the intensity of microfilarial infections among 
those living in the endemic area, but only after some years might it be possible to detect 
evidence of a fall in the prevalence of infection, and later still an impact on blindness 
rates which is the major adverse health consequence of onchocercal infection.
2.6 Adverse events
An important outcome of all trials is to assess the safety of the intervention under evalu-
ation (for example, of a new drug or vaccine). Adverse events (AEs) are defined as any 
untoward clinical or laboratorial medical occurrence in a patient or clinical investiga-
tion subject, related or not to the use of an intervention in a trial. Serious AEs (SAEs) 
are defined as any events that are life-threatening or result in death. They include patient 
hospitalization or prolongation of existing hospitalization, events that result in persis-
tent or significant debilitation or incapacity, and congenital anomalies and birth defects. 
All SAEs should be reported immediately to the sponsor (or the DSMB on behalf of the 
sponsor), followed by detailed written reports (see Chapter 7). Usually, two types of 
study outcomes are defined: (1) the active, prospective evaluation of a set of predefined 
potential AEs known or suspected to be associated with the type of drug, vaccine, or 
product under evaluation, and (2) recording all clinical or laboratory abnormalities, 
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expected or not, that occur in study subjects during a specified time period or through-
out the conduct of the trial, by active or passive surveillance, which may reveal an ad-
verse consequence previously not known to occur with the drug, vaccine, or product 
under evaluation. For both types of safety outcomes, criteria must be developed to as-
sess the severity, as well as the incidence of AEs associated with the drug, vaccine, or 
product under evaluation. Severity can be measured by the magnitude of a laboratory 
or clinical test abnormality, or by the subjective perception on how much the AE al-
tered the function or quality of life of the individual. For instance, a reaction at the site 
of injection of a vaccine could be graded as mild if only a colour change is noted with 
mild pain, without  induration and without any restriction on the arm or leg movement; 
moderate if, in addition to colour change of the skin, induration is noted and there is 
some restriction of movement; and severe if the subject cries out or winces if the area 
is touched and the arm or leg cannot be moved without pain. In many studies, a diary 
card may be provided to the study subject or, in case of children, to the mother or care-
taker to record these reactions during a 7- or 14-day period after the administration of 
a vaccine or during the drug therapy. To aid measuring an injection site reaction, a ruler 
may be provided to the subject. And to standardize the measurement of temperature, 
a digital thermometer may be provided as well. Study subjects or children’s mothers or 
caretakers need to be appropriately trained in using these study cards and instruments. 
In addition to its severity, these reactions are usually classified as unrelated, unlikely to 
be related, or possibly related to the intervention under evaluation. The criteria used for 
this classification may include proximity of the event to the administration of the inter-
vention (for instance, a rash developing within 20 minutes of an injection would most 
likely be classified as possibly related), the unusualness of the clinical event (a disease 
which normally occurs in that age group or a complication expected to happen in the 
disease under study), or even the subjective interpretation of the investigator. Whatever 
criteria are used should be stated. The incidences of AEs, graded by the severity and 
likelihood of being related to the interventional product, are later compared between 
the study group exposed to the intervention and the control group (using placebo or 
an active comparator) to assess statistically if AEs of different kinds were or were not 
associated with the drug, vaccine, or product.
All safety measurements need careful definition in the study protocol, study forms 
to record them, using standardized measurements and codes to register them, and ac-
tive monitoring of their occurrence. Most trials require those AEs that are considered 
serious to be individually reported to the sponsor and to an ethics review board, to the 
regulatory agency overseeing the trial, and to an independent DSMB for their careful 
evaluation during the conduct of the trial, to allow the possibility for the trial to be 
stopped or modified before its completion if it is suspected that SAEs are associated 
with the drug, vaccine, or product under investigation.
3 Factors influencing choice of outcome measures
The choice of the outcome measures in a specific trial largely depends on the purpose of 
the trial and how relevant, feasible, and acceptable the measures will be in a particular 
study population. Furthermore, the choice may be constrained by economic, logistic, 
or ethical considerations.
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3.1 Relevance
Interventions are generally designed to reduce disease and/or to promote health. The 
outcome measures chosen should reflect these objectives as fully as possible, but, when 
intermediate variables are used, rather than those of main interest, care must be taken 
to choose variables of direct relevance to the main outcome. This is not always straight-
forward. For example, it may be decided to assess the impact of a vaccine by measur-
ing the proportion of individuals who develop antibodies to the vaccine. This may be 
reasonable if it is known that there is a high correlation between the development of 
antibodies and protection from clinical disease. For many diseases, however, this rela-
tionship has not been established, and it would not be warranted to base conclusions 
regarding protection against disease simply on antibody determinations.
A health education intervention may be designed to change behaviour to reduce 
disease risk, but, as discussed in Section 2.5.1, asking individuals if they have changed 
their behaviour may give a measure of impact that correlates poorly with true changes 
in the risk of disease. Are individuals responding truthfully? Are they doing what they 
say they do? Even if behaviour changes, is this associated with a lowering in the inci-
dence of disease?
The outcome variable measured should be as close as possible to the outcome of 
main interest. While this may seem an obvious suggestion, it may have major impact 
on the design of a study. For example, if the prevention of death is of prime interest, 
then, whenever possible, this should be made the endpoint of the trial. To do so might 
require an increase in the size of the trial from hundreds to thousands, or even tens of 
thousands, of individuals. Such a large trial might be difficult to find funding for, and 
there may never be an adequate test of whether the intermediate variables measured are 
acceptable surrogates for effects on mortality.
3.2 Feasibility
To be successful, a trial must be designed to have achievable objectives. A trial which 
has mortality as the endpoint, but which is too large to be successfully completed, may 
be of less value than a well-designed smaller trial aimed at assessing the impact on 
some intermediate endpoint such as severe disease. There must often be a compromise 
between relevance and feasibility. It is pointless to set unachievable goals, even if they 
look attractive in the objectives section of a proposal. Also, it may be of little value to 
measure the effect of an intervention on an outcome measure which is only distantly 
related to the measure of prime interest. The outcome measures selected will be much 
influenced by the resources available for the trial, the availability of skilled personnel, 
and the necessary laboratory support to diagnose cases of disease. In many large trials, 
every individual in the study population may have to be screened for disease or infec-
tion in a relatively short time. With such time constraints, some individuals may be 
misdiagnosed. The consequences of reductions in diagnostic sensitivity and specificity 
are discussed in Section 4.2.
3.3 Acceptability
The acceptability of the measurement of an outcome variable to the study population is 
critical to the successful conduct of a trial. For example, the recording of birthweights 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
210 CHAPTER 12: OUTCOME MEASURES AND CASE DEfINITION
may not be possible in a population that allows only close relatives to have access to a 
mother for a few days or weeks after the child’s birth. Taking venous blood samples or 
repeated blood samples is unpopular in many societies. If the method for measuring 
the outcome involves pain or inconvenience to the participants, it may be necessary to 
modify or abandon it. An outcome, of which the assessment involves a long interview 
with participants at a time when they would otherwise be planting crops or taking care 
of their household chores, may be unacceptable; it may either have to be abbreviated or 
carried out at a more convenient time.
3.4 Opportunity for add-on studies
Some trials offer the opportunity to measure outcomes that are not directly related 
to the objectives of the original study itself. These opportunities can be exploited by 
researchers to answer questions with minimal additional funding. For example, a diar-
rhoeal surveillance study might be carried out within a clinical trial in which a cohort 
of healthy children is being followed over time. However, it is very important that the 
add-on study does not interfere with the original study outcome measure. Such addi-
tions should be considered at the beginning of the study and should have a separate 
study protocol. It is also important to inform sponsors, participants, and all stakehold-
ers of the original trial of the coexistence of the proposed add-on study. Such investiga-
tions will usually require separate ethical approval and informed consent.
4 Variability and quality control of outcome measures
4.1 Reproducibility
The extent to which different observers will make the same diagnoses or assessments on 
a participant and to which observers are consistent in their classifications between par-
ticipants may have an important influence on the results of a trial. Clearly, it is desirable 
to choose outcome measures for which there is substantial reproducibility and agree-
ment among observers, with respect to the classification of participants in the trial.
For objective outcome measures, variations between observers, or by the same ob-
server at different times, may be small and unlikely to influence the results of a study. 
For outcome measures requiring some degree of subjective assessment, however, such 
variations may be substantial. The likely degree of such variations will influence the 
choice of outcome measures, as it will be preferable to select those measures that have 
the smallest inter- and intra-observer variations, yet still give valid measures of the 
impact of the intervention.
Variation among observers is often much greater than expected, for example, in the 
reading of a chest X-ray to assess whether there is evidence of pneumonia. If a study 
involves several observers, pilot studies should be conducted, in order to measure the 
extent of the variation and then to seek to standardize the assessment methods to mini-
mize the variation. With suitable training, it is usually possible to reduce the variation 
between observers substantially.
For some outcomes, independent assessment by two observers should be routine, 
with a third being called in to resolve disagreements. It may be costly to screen the 
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whole trial population in this way, but a common approach is to have all suspected 
cases of the disease of interest examined by a second observer, mixed in with a sample 
of those not thought to have the disease. Sometimes, it is possible to have the observer 
examine the same individual twice, but these examinations may not be independent, 
unless the survey is large and the observer does not remember the result of the first 
assessment.
It is important to make every effort to reduce variability to the maximum extent 
possible. Having done so, however, it is also critical to know the extent of the remain-
ing ‘irreducible’ variability for purposes of analysis. The purpose of trials is usually to 
demonstrate the effect of an intervention or to compare differences between interven-
tions. Knowledge of the inherent variability in diagnostic procedures is essential for 
this demonstration, and the best way of assessing this is through replicate measures. 
It is especially important to take account of between-observer differences when com-
munities are the units of randomization in a field trial. Differences between observers 
may produce biases if different observers are used in different communities. In such 
situations, it is better to organize the fieldwork so that the workload within each com-
munity is split among different observers and differences between the observers are not 
confounded with the effect of the intervention.
4.2 Sensitivity and specificity
The choice of an appropriate definition of a ‘case’ in a field trial will be influenced by the 
sensitivity and specificity associated with the diagnostic criteria. Sensitivity is defined 
as the proportion of true cases that are classified as cases in the study. Specificity is the 
proportion of non-cases that are classified as non-cases in the study. A low sensitivity is 
associated with a reduction in the measured incidence of the disease. This decreases the 
likelihood of observing a significant difference between two groups in a trial of a given 
size. In statistical terms, it reduces the power of the study (see Chapter 5, Section 2.2). If 
the incidence of the disease in both the intervention group and the comparison group 
will be affected proportionately in the same way, as is often the case, it does not bias 
the estimate of the relative disease incidence in the two groups, though the absolute 
magnitude of the difference will be less than the true difference. Thus, in the context of 
a vaccine trial, because protective efficacy is assessed, in terms of relative differences in 
incidence between groups, the estimate of protective efficacy will not be biased, but the 
confidence limits on the estimate will be wider than they would be using a more sensi-
tive case definition. In theory, the reduction in power associated with low sensitivity 
can be compensated for by increasing the trial size.
In general, a low specificity of diagnosis is a more serious problem than a low sensi-
tivity in intervention trials. A low specificity results in the disease incidence rates being 
estimated to be higher than they really are, as some participants without the disease 
under study are classified incorrectly as cases. Generally, the levels of inflation in the 
rates will be similar, in absolute terms, in the intervention and comparison groups, 
and thus the ratio of the measured rates in the two groups will be less than the true 
ratio, though the difference in the rates should be unbiased. Thus, in vaccine trials, for 
example, the vaccine efficacy estimate will be biased towards zero, though the absolute 
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difference in the rates between the intervention and control groups will not be biased 
(unless there is also poor sensitivity). Increasing the trial size will not compensate for 
the bias in the estimate of vaccine efficacy.
In algebraic terms, suppose the true disease rates are r1 and r2 in the two groups 
under study, the true relative rate R is r1/r2, and the true difference in disease rates D is 
r1 − r2. If sensitivity is less than 100% (but specificity is 100%), and only a proportion 
k of all cases are correctly diagnosed, the measured disease rates in the two groups will 
be kr1 and kr2; the measured relative rate will be kr1/(kr2) = R; and the measured dif-
ference in disease rates will be kr1 − kr2 = k(r1 − r2) = kD (which will be less than D). If 
specificity is less than 100% (but sensitivity is 100%), and the rate of false diagnoses is s, 
the measured rates in the two groups will be (r1 + s) and (r2 + s); the measured relative 
rate will be (r1 + s)/(r2 + s) (which will be less than R); and the measured difference in 
disease rates will be (r1 + s) − (r2 + s) = D.
To measure the sensitivity and specificity of the diagnostic procedures used in a trial, 
it is necessary to have a ‘gold standard’ for diagnosis (i.e. it is necessary to have a diag-
nostic procedure that determines who really is a case and who is not). Sometimes, this 
is not possible, and, even if definitive diagnostic procedures exist, it may be necessary to 
use imperfect procedures in a field trial for reasons of cost or logistics. In this situation, 
if an assessment is made of sensitivity and specificity, it is possible to evaluate the conse-
quences for the results of a field trial, and possible even to correct for biases in efficacy 
estimates due to the use of a non-specific diagnostic test. Unfortunately, in many situa-
tions, there is no ‘gold standard’, and so the sensitivity and specificity of the diagnostic 
methods used remain uncertain. For example, there is no universally agreed definition 
of a case of clinical malaria. Most would agree that the presence of parasites in the blood 
is necessary (unless a potential case has taken treatment before presenting to the study 
clinic), and many would agree that the presence of fever associated with parasitaemia 
increases the likelihood of the disease being clinical malaria, but it is also possible that 
the fever is due to other causes, rather than the parasitaemia being the cause of the fever.
The bias induced by a low specificity of diagnosis is most severe for diseases that have 
a low incidence. A good example of this is provided by leprosy, which is both difficult 
to diagnose (in the early stages) and also of low incidence. Consider a vaccine trial in 
which the true disease incidence in the unvaccinated group is ten per thousand over the 
period of the trial, and the true efficacy of a new vaccine against leprosy is 50%, i.e. the 
true disease incidence in the vaccinated is five per thousand over the period of the trial. 
If the sensitivity of the diagnostic test used for cases is 90%, but the specificity is 100%, 
the observed disease incidences would be 10 × 0.9 = 9.0 and 5 × 0.9 = 4.5 per thousand, 
respectively. Thus, the estimate of vaccine efficacy is correct (50%). The power of the 
study is reduced, however. To achieve the power that would be associated with a ‘per-
fect’ test, the trial size would have to be increased by about 11%.
On the other hand, if the specificity of the diagnostic test is as high as 99% and the sensitiv-
ity is 100%, the observed disease incidences would be ten true cases + (990 × 0.01 = 9.9) false 
cases = 19.9 per thousand in the unvaccinated group, and five true cases + (995 × 0.01 = 9.95) 
= 14.95 per thousand in the vaccinated group. Thus, even with a test with 99% specificity, the 
estimate of vaccine efficacy is reduced from the true value of 50% to 25%. If the specificity of 
the test were 90%, the expected estimate of vaccine efficacy would be only 4%.
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In vaccine trials, the sensitivity and specificity of the diagnostic test are of conse-
quence in different ways at different times in the trial. When individuals are screened 
for entry to the trial, it is important that the test used should be highly sensitive, even 
if it is not very specific, as substantial bias may be introduced if undiagnosed ‘cases’ are 
included in the trial and included in the vaccinated or unvaccinated groups. If the vac-
cine has no effect on the progression of their disease and they are detected as cases later 
in the trial, a false low estimate of efficacy will result. Thus, individuals whose diagnosis 
is ‘doubtful’ at entry to the trial should be excluded from the trial. Conversely, once 
individuals have been screened for entry into the trial and they are being followed for 
the development of disease, a highly specific test is required to avoid the bias illustrated 
in the preceding paragraph.
In situations where there may be no clear-cut definitions of a case (for example, early 
leprosy or childhood TB), studies of intra- and inter-observer variation may be under-
taken, using various definitions of the disease. The definition that shows the least disa-
greement between observers and gives maximum consistency within each observer 
may be the appropriate one to use in a trial, but the investigator should be aware of the 
potential for bias if the specificity of the diagnostic procedure is less than 100%.
4.3 Bias
The most powerful way to minimize bias in the assessment of the impact of an intervention 
is through the conduct of a double-blind randomized trial. If these two aspects are built 
into a trial, an effect of an intervention is not likely to be observed if there is no true effect. 
However, as pointed out in Section 4.2, if the specificity of the diagnosis for the outcome of 
interest is poor, the estimate of the efficacy of an intervention, measured in relative terms, 
may be biased towards zero, even in a properly randomized double-blind investigation.
It is highly desirable that the person making diagnoses in a trial is ignorant of which 
intervention the suspected cases have received. If the diagnosis is based on laboratory 
tests or X-ray examinations, blindness should be easy to preserve. In some circum-
stances, it may be possible to determine from the results of a laboratory test which in-
tervention an individual has received, as the test may be measuring some intermediate 
effect between the intervention and the outcome of prime interest (for example, an an-
tibody response to a vaccine). In such cases, those making diagnoses in the field should 
not be given access to the laboratory results. For example, in placebo-controlled studies 
of praziquantel against schistosomiasis in communities where the infection is common, 
those who had received the active drug would be easily detected by a rapid reduction 
in egg counts in stool or urine samples following treatment. If the outcome of main 
interest is morbidity from the disease, then the egg count information should be kept 
from those making the assessment of morbidity. It would generally be inappropriate to 
use measures of antibody level to make diagnoses of disease following vaccination, if 
the vaccination itself induced antibodies indistinguishable from those being measured. 
Similarly, tuberculin testing should not be part of diagnostic procedures for TB in stud-
ies of the efficacy of BCG vaccination, as the vaccine alters the response to the test.
If the diagnosis of disease is based on a clinical examination, it may be necessary 
to take special precautions to preserve blindness. An example is given in Chapter 11, 
Section 4, with respect to a BCG trial against leprosy, in which all participants had the 
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upper arm area, where BCG or placebo was injected, covered during the clinical exami-
nation, since BCG leads to a permanent scar. Even if the participants know which inter-
vention they had, it is important to try to keep this knowledge from the person making 
any diagnoses. Thus, participants might be instructed not to discuss the intervention 
with the examiner, and the examiner would be similarly restricted. Such a procedure is 
obviously not fail-safe, but great efforts should be made to preserve blindness, if at all 
possible, especially if the diagnosis is made on subjective criteria.
If randomization in a trial is by community, rather than by individuals, it may be es-
pecially difficult to keep examiners ignorant of the intervention an individual received. 
Sometimes, ways can be found of doing this, for example, by conducting surveys for 
disease by bringing all participants to a clinic outside the trial communities. If commu-
nities are randomized to receive an improved water supply or not, one outcome meas-
ure of interest might be the incidence of scabies infection. It may be difficult to avoid 
the possibility of the diagnoses of scabies being influenced by the observer’s knowledge 
of whether or not the participant was in a village with an improved water supply. In 
such a case, it may be best to seek other measures of impact, based upon objective crite-
ria or laboratory measures, or to take photographs of the relevant body parts and have 
these assessed objectively and ‘blind’ to intervention group.
4.4 The Hawthorne effect
Trials that require active home visits by study personnel during the surveillance period 
to evaluate the effect of an intervention may be affected by an indirect effect of the home 
visits on the study objective, even when not intended. The presence of a study member in 
a subject’s home may have a positive effect on the health status of the subject, since it may, 
for example, stimulate better health behaviour of the subject or improve hygiene prac-
tices in the house or better health care utilization. In studies with such effects, rates of ill-
nesses or of severe illness may be reduced in both study arms—an indirect effect known 
as the ‘Hawthorne effect’ (named after a study in the 1930s in the USA at the Hawthorne 
Works, in which it was documented that worker behaviour changed as a consequence of 
them being observed). This effect reduces the power of the study and may make it incon-
clusive. There is no easy way to control for it, so, if such a Hawthorne effect is expected 
in a field trial, the sample size may need to be increased to maintain statistical power.
4.5 Quality control issues
The sensitivity and specificity of the diagnostic procedures employed in a trial should 
be monitored for the duration of the trial, as they may change as the study progresses. 
Such changes may be for the worse or for the better. With experience, diagnostic skills 
may improve, but also, as time passes, the staff may become bored and take less care. It 
is important that the field staff are aware that their performance is being continuously 
monitored. If this is done, then anyone who goes ‘off the rails’ can be steered back or 
removed from the study, before much harm is done. Such monitoring is important for 
both field and laboratory staff.
The methods used to monitor the quality of diagnostic procedures may include the 
re-examination of a sample of cases by a supervisor or a more highly trained investigator 
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and, for the laboratory, may be done by sending a sample of specimens to a reference 
laboratory and by passing some specimens through the laboratory in duplicate, in a 
blinded fashion, to determine if the differences between results on the same specimen 
are within acceptable limits (see Chapter 17, Section 5).
If the disease under study is relatively rare, it may be difficult to measure sensitivity 
based on small numbers of individuals being examined twice. While it will be possible 
to check if specificity is poor (a high proportion of those classified as cases are wrongly 
diagnosed), checks on sensitivity may involve the examination of thousands of individ-
uals twice to determine if cases are being missed. Fortunately, in most trials, specificity 
is of more critical importance than sensitivity, although the relative importance can 
change as the survey goes on, as discussed in Section 4.2.
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1 Introduction to preliminary studies and pilot testing
The time between the idea for an intervention trial and first entering participants into 
the trial is usually long, generally at least a year and often several years. Even when 
funding for a trial has been obtained, which, in itself, may take a year or more, there is 
often much work to do before the first participant can be enrolled into the trial. This 
chapter outlines the kinds of investigations and studies that may be carried out before 
starting the main trial to try to maximize the possibility that the trial will be conducted 
successfully. We divide these into two kinds of study. First are preliminary studies to de-
velop different aspects of the trial procedures or to collect data to facilitate the planning 
and conduct of the trial. Second are pilot studies which are tests of the full trial proce-
dures on a small sample of potential participants to make sure, in so far as is possible, 
that any problems with the conduct of the trial will be identified, so that procedures can 
be changed before the full trial starts.
Though often very useful, no specific type of preliminary study is invariably essential, 
whereas a pilot study should always be planned, though such studies can range from 
a relatively brief testing of the intervention and its evaluation that lasts a week or less 
through to an extensive period of testing and refinement of the intervention and evalu-
ation methods that spans several months, or even a year or more.
2 Preliminary studies
2.1 Purposes
Preliminary studies are often conducted to refine the intervention and evaluate its ac-
ceptability, feasibility, cost, and uptake. For example, prior to a large field trial of a 
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multi-component intervention that aimed to improve adolescent sexual and repro-
ductive health in Tanzania, a preliminary study was carried out to test and refine the 
intervention. The main cluster randomized trial was planned to involve about 10 000 
adolescents in over 120 schools, with an initial follow-up period of 3 years. A prelim-
inary study was conducted to develop and refine the intervention methods that would 
be used to train and support teachers and class peer educators who would deliver the 
in-school sexual and reproductive health education intervention to be used in the trial 
(Obasi et al., 2006).
Preliminary studies may be needed to provide local up-to-date data, in order to 
calculate or confirm the sample size required for the main trial. For example, before 
embarking on a field trial of a malaria vaccine that will be evaluated for its effect in re-
ducing the incidence of clinical cases of malaria, a preliminary study may be required 
to obtain estimates of the incidence of cases of malaria in the study population, prob-
ably spanning a complete year, in order to allow for seasonal variation in transmission. 
The outcome from such preliminary studies provides the data necessary for designing 
the size of the main trial. It is commonly found in trial design that investigators are 
over-optimistic about the likely frequency of outcome events in their trial population. 
Consequently, after a preliminary (baseline) study, the size of the main trial needs to 
be increased. Sometimes, the reverse happens, but not so commonly! In so far as is 
possible, the baseline study should be conducted under similar conditions to those that 
will hold in the main trial. Thus, for example, if insecticide-impregnated bed-nets are 
to be distributed to all children participating in a trial of a malaria vaccine, as may be 
required for ethical reasons, this should be done for the baseline studies to avoid over-
estimating the likely incidence of malaria in the trial population (Leach et al., 2011).
In some cases, preliminary investigations may even show that the proposed study 
population will not be suitable. A trial of a vaginal microbicide gel to prevent HIV 
transmission among women in Ghana was based upon an assumption of an annual 
transmission rate of HIV in the trial population of 5% a year. Baseline studies were not 
conducted to verify this assumption, and, once the trial had started, it was discovered 
that the actual transmission rate was only about 1% a year. Thus, an expensive trial had 
to be abandoned, because of a lack of statistical power (Peterson et al., 2007). Had it 
been known, before the trial started, that it should have been five times as large, it per-
haps would never have been started.
Preliminary studies may also be needed to estimate how long it will take to enrol 
the target number of trial participants, the proportion of participants who are likely to 
be lost to follow-up, the best interval to have between follow-up visits, and the overall 
duration of the trial.
Other preliminary studies are helpful to refine the design of specific methods for use 
in the process and/or impact the evaluation within the main trial, and to evaluate their 
acceptability, feasibility, and cost. For example, will taking blood specimens, skin snips, 
or self-administered vaginal swabs be feasible and acceptable? Can the cold chain be 
maintained for vaccines or specimens that need to be kept cold, and for how long, since 
this will govern how frequently they need to be taken to or from the field research 
team? How many staff will be required, and how much will it cost, to carry out and col-
lect data and specimens from 60 participants a day, for example?
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It will also be necessary to explore the likely community acceptance of the trial (see 
Chapter 9), staff training needs, and other logistic requirements related to field and la-
boratory activities, data management, and study clinics. Some of these data may have 
already been collected in studies previously conducted by the trial team or by others, 
but, in other circumstances, special preliminary studies are required.
Many preliminary studies can be small and quick such as a qualitative study to ask 
potential trial participants to review a draft information sheet for clarity and accept-
ability. On the other hand, others may take over a year such as a study to check the inci-
dence of a seasonal disease that must cover at least one 12-month period.
An example of a relatively large preliminary study conducted prior to a trial was the 
feasibility study for a multicentre trial of the impact of a vaginal microbicide on HIV in-
cidence among women at high risk of acquiring sexually transmitted infections (STIs) 
that was conducted in four East and Southern African countries (McCormack et al., 
2010). The main trial was planned to be conducted over several years at a likely cost of 
tens of millions of pounds, so it was crucial to ensure, prior to starting the main trial, 
that the sample size was right and that the methods planned for all aspects of the trial 
were both feasible and acceptable. Within the Tanzanian site for the trial, for example, 
a preliminary study was designed (Vallely et al., 2007). This lasted more than a year, to:
◆	 identify the population groups to invite to participate in the trial
◆	 work out how best to deliver the intervention and related clinical services
◆	 evaluate the likely acceptability of the microbicide gel
◆	 test and refine the study methods and instruments
◆	 estimate the incidence of the primary (HIV) and secondary (STIs, reported use of 
the microbicide gel) outcomes for the main trial, and
◆	 estimate the costs of each of the activities needed for the trial.
2.2 Design of preliminary studies
The design and methods used for preliminary studies should be tailored to address 
the specific issues and questions to be answered. Often, both qualitative and quanti-
tative methods will be required, drawing upon social and behavioural sciences, and 
economic, epidemiological, laboratory, statistical, and community development ap-
proaches. Usually, a preliminary study will be relatively short term and inexpensive, 
in comparison to the main trial. Ideally, the main trial should be started soon after the 
preliminary study to avoid the situation changing between the two. This frequently 
raises the question of whether preliminary studies should be built into the funding pro-
posal for the main trial, or whether they should be the subject of one or more separate 
preliminary funding proposals. If the latter approach is adopted, there may be a delay 
between the preliminary investigations and funding being secured for the main trial. 
A reasonable approach might be to present the design of the main trial to the funding 
agency, but acknowledging that preliminary studies will be necessary to confirm some 
of the assumptions in the proposal such as disease incidence rates. The funding for the 
main trial might then be made conditional on the results of the preliminary investiga-
tions. If the preliminary studies indicate that additional funding will be required for 
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the main trial, for example, because the sample size has been underestimated, then 
the agency may wish to reconsider the proposal. The best strategy will often depend 
on the work that has been done in the past and the degree to which the results of the 
preliminary studies might affect the size, duration, or cost of the trial. Further details on 
some of the social and behaviour science methods that can be used within preliminary 
studies can be found in Chapter 15.
It is usually best to conduct the preliminary studies in the same general population, 
but in different individuals (or clusters) from those who will be involved in the main 
trial.
A preliminary study for the in-school intervention component of the Tanzanian ado-
lescent sexual and reproductive health trial mentioned in Section 2.1 was conducted 
over a period of about 6 months in five schools that would not be included in the sub-
sequent trial but that were conveniently located close to the offices of the research in-
stitution coordinating the trial. Teachers and class peer educators were selected and 
trained to deliver the in-school sessions and were then observed actually teaching the 
sessions to evaluate the session quality and how long it took to teach each session. The 
study identified misunderstandings and that there were some topics that the teachers 
obviously felt uncomfortable teaching, for example. Researchers also interviewed the 
teachers, peer educators, school headteachers, some of the students, and their parents 
to get their impressions of each session and the course as a whole and their sugges-
tions for improvements. In the course of this preliminary study, many lessons were also 
learned about the resources that would be needed, the best ways to select the teachers 
and peer educators, and how to gain the trust of the local education department, school 
authorities, local religious leaders, students, and their parents.
The feasibility study in the Tanzania site of the microbicide trial mentioned in Sec-
tion 2.1 involved conducting a rapid assessment and mapping of bars, guesthouses, 
restaurants, shops, sellers of local brew, and wayside food sellers, and enumeration of 
the number of women working in them to identify the potential numbers that could 
be invited to join the subsequent trial. A group of these women were invited to join a 
preliminary longitudinal cohort study which would receive all the proposed trial pro-
cedures, except being given either the microbicide or placebo gel. The procedures in-
cluded setting up study clinics that the women were asked to attend on a quarterly 
basis and the regular monitoring of the outcomes that were proposed for the trial, in-
cluding tests for HIV and other STIs, pregnancy, and reported sexual behaviours. The 
opportunity was taken to conduct comparisons of alternative ways of collecting data on 
self- reported sexual behaviours (including face-to-face interviews and use of pictorial 
diaries kept by the women) and of testing various alternative methods for interacting 
and exchanging information with women participants, their representatives, the own-
ers and managers of the institutions in which they worked, community leaders, and 
relevant local officials. Discussions and negotiations were held with health facilities 
where women were referred for clinical care beyond the scope of the trial team them-
selves. The feasibility study also allowed detailed preparations and negotiations with 
national and international regulatory authorities.
Pre-testing of procedures for data and specimen collection and analysis should al-
ways be part of the preliminary studies for a trial. For example, any information sheet 
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or questionnaire should be translated and back-translated if it is to be administered 
in a different language from the original in which it was designed. If it is going to be 
administered in several different languages, this can take a considerable amount of 
organization and time. The document should be pre-tested by administering it to a 
small number of volunteers. This will usually reveal problems with the order or clarity 
of information or questions, or with the coding of answers. Clearly, enough time must 
be left to act on the lessons learned during the pre-testing, and it may be necessary to 
pre-test several sequential versions of an information sheet or data collection form, 
before it is considered ready for pilot testing. More details on questionnaire design are 
given in Chapter 14.
3 Pilot testing
3.1 Purpose
Every field trial should be preceded by a pilot study (also known as a pilot test) prior 
to launching the main trial. This should test, on a small scale, all the study procedures, 
including the selection of eligible potential participants, their enrolment, recording the 
required data, specimen collection (if applicable), supervision systems, quality control, 
and data processing. If the trial involves multiple data collection rounds, where either 
staff or procedures change between rounds, it is a good idea to pilot test the procedures 
before each round.
3.2 Design of the pilot test
The design of the pilot study should be as similar as possible to the design of the proced-
ures in the main trial, and the population selected to take part should be representative 
of the trial population (though not part of it). In a drug or vaccine trial, the actual inter-
ventional and comparison products (for example, drug or vaccine or placebo) might 
be administered, and procedures tested for monitoring immediate outcomes and re-
sponding to any potential AEs. However, sometimes, only the standard comparison 
product or placebo is used in the pilot study, as those included in the pilot study might 
not be included in the long-term safety monitoring that would be present in the main 
trial. For example, only the placebo gel was used in the pilot test for the microbicide 
trial described in Sections 2.1 and 2.2. For other types of intervention, such as the 
combination of in-school sexual and reproductive health education, training of health 
workers and youth condom promoters, and community-wide supportive activities that 
were evaluated within the trial that was also mentioned in Sections 2.1 and 2.2, the 
interventions were pilot-tested in separate communities.
Usually, it is best to conduct the pilot study in individuals or a cluster that will not be 
included in the main trial, in order to avoid having to go back to the same individuals 
to collect similar data in the main trial. In a multi-round trial, the same specific indi-
viduals or clusters might participate in the pilot test that precedes each data collection 
round. This has logistic advantages. The field teams will get to know the community 
in which the pilot tests are conducted, facilitating logistics such as where to conduct 
the survey, where to stay overnight, and who the best local people are to ask to help 
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introduce the study to householders or to help find people who do not come forward 
for the trial. It also has the technical advantage that the individuals and communities 
involved in subsequent rounds of the pilot test will have had similar prior exposure to 
the procedures to those in the main trial population.
The pilot study can often be linked to staff training. For example, in a multi-round 
field trial of vitamin A supplementation in children, staff received a specific training 
course that covered all the field data collection methods that would be used in the sub-
sequent trial round. This course lasted a total of 2 weeks and included both classroom 
and practical training. During the first week, the practical training included ‘mock 
interviewing’ their colleagues and role plays, in which one interviewer asked questions 
of the trainer, while all the field interviewers entered the answers into the question-
naire. The pilot test was carried out early in the second week, so that any necessary 
changes could be made to the procedures, or even to the data collection forms, in time 
for the interviewers and their supervisors to be brought up to speed on the modifica-
tions before the end of the 2-week training period.
Every step in the field trial processes should be tested in the pilot study. Impor-
tantly, the pilot test of data and specimen collection procedures must allow enough 
time for the pilot data to be entered on to computers, ‘cleaned’, and analysed, so that 
these systems can also be checked for functionality. Similarly, whenever possible, any 
specimens collected during the pilot test should be processed, so that, at a minimum, 
it is possible to check that the specimens have been collected and transported correctly 
and are in good condition. In addition, enough time must be allowed between the 
completion of the pilot test and all its checks, for revisions to be made to the instru-
ments and procedures if they are needed. All too often, inexperienced trial managers 
do not allow enough time for this and hope that no changes will be needed or are then 
under pressure to ignore indications from the pilot test that improvements would be 
desirable.
Sometimes, investigators are tempted to use the results from a small, time-limited 
pilot test to predict whether the sample size that was calculated for the main trial will 
be sufficient. While a small pilot test can give rise to worries about recruitment rates 
and suggest ways of increasing these, pilot studies will usually not have been designed 
with sufficient numbers or duration to give a precise enough estimate of trial outcomes 
to make it sensible to attempt to use it to test sample size calculations. Given very wide 
CIs around the outcome estimates that are likely in a small pilot test, such projections 
may be very misleading. If there is a need for checks on the assumptions used in the 
trial sample size calculation, these should be tested within a preliminary study, as de-
scribed in Section 2.2.
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1 Introduction to questionnaires
The collection of information by asking questions of members of the study popula-
tion is likely to be a component of any health intervention trial. Such information may 
be relatively simple and straightforward to collect (for example, a census of the study 
population in which the name, age, and sex are recorded for the members of each 
household in the study area) or may be very difficult to elicit reliably from respondents 
(for example, beliefs about the causes of illness or details of income or sexual behav-
iour). The focus of this chapter is on quantitative surveys, in which data are collected by 
asking the same questions to multiple members of the study population. The responses 
are recorded in a standardized way, either on paper or electronically, and analysed later. 
Qualitative approaches to investigate the beliefs, attitudes, and practices of members 
of a study population, such as anthropological studies based on participant observa-
tion, in-depth interviews, or focus group discussions, are discussed in Chapter 15. In 
this chapter, we discuss key issues related to the methods of collection of quantita-
tive survey data. The selection, training, standardization, monitoring, supervision, and 
support of the interviewers to ensure that they do a good job of collecting the data are 
discussed in Chapter 16.
The commonest approach to the collection of quantitative survey data is through 
face-to-face interviews where an interviewer asks each of the questions and records the 
participant’s answers, either on paper or electronically. The major advantages of this 
method are that the participants do not need to be literate and will usually be familiar 
with this approach. However, it is relatively labour-intensive, since each participant has 
a questionnaire administered by an interviewer on a one-to-one basis.
In literate populations, questionnaires may be ‘self-administered’, i.e. either a paper 
questionnaire is distributed to study participants that they are asked to complete them-
selves or the participant is given an electronic device such as a computer (desktop, 
laptop, tablet, PDA) or mobile phone on which they read each question and enter the 
answer. These methods can be ‘audio-assisted’ where the participant can listen to each 
question being read out and select the answer from a list. Such approaches have been 
successfully used with semi-literate participants where the participants can listen to the 
pre-recorded questions and possible answers and only need to be able to identify and 
select the answer code (such as A, B, or C) (Langhaug et al., 2010).
The basic principles of planning and designing self-administered questionnaires are 
similar to those for the interviewer-administered questionnaires. Interviews of several 
respondents at the same time (group interviews or focus group discussions) are dis-
cussed in Chapter 15, Section 3.3.
In addition to asking questions, an interviewer may carry out observations. For ex-
ample, questions about the use of bed-nets could be supplemented by inspection, and 
observations on their location and state of repair. Similarly, the participant may be 
asked to demonstrate how they do something. For example, in a study of diarrhoea, 
they might be asked to show how they would prepare oral rehydration salts or how they 
wash their hands.
The methods outlined in this chapter are most appropriate when information on 
a relatively small number of well-defined subject areas is required, for which the 
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responses to enquiries are either numerical (for example, number of pregnancies) or 
may be classified into a small number of different categories (for example, current feed-
ing mode of an infant). Even simple items of information may be difficult to elicit accu-
rately, unless adequate research has been conducted to find out how questions should 
be asked and phrased in the study community. The methods described in Chapter 15 to 
obtain such background information are relevant here.
In a particular trial, the study subjects may be visited and interviewed once only or, 
more commonly, several times. Simple cross-sectional surveys provide an example of 
the former. An example of the latter would be the collection of regular information 
on child morbidity from the mothers of study children through weekly or fortnightly 
interviews such as might be used for the evaluation of the efficacy of a vaccine against 
diarrhoeal disease. The first interview might be more extensive, with a shorter list of 
questions asked at each subsequent visit. Intervention trials often involve an initial 
cross-sectional survey, followed by periodic surveys of either the same or different in-
dividuals from the trial population, the frequency of which will be determined by the 
nature of the outcome variables under study.
In this chapter, the different components of a questionnaire survey are reviewed. 
The formulation and validation of questions to be included are considered in Section 
2. Section 3 deals with the construction of the complete questionnaire; Section 4 deals 
with the interviewers, their selection, training, and standardization; Section 5 discusses 
the alternative ways of ‘capturing’ the data, using pen and paper or electronic methods, 
while Section 6 discusses factors relating to the actual interview.
As with most aspects of field research, there is no satisfactory substitute for experience 
to know how to formulate and administer a questionnaire satisfactorily. The inexperienced 
investigator would be well advised to seek guidance of those who have previously con-
ducted surveys in the study area, if possible, as well as searching for examples of question-
naires that have been extensively validated in similar contexts such as national censuses and 
Demographic and Health Surveys (DHS). Those with social science, statistical, and data 
processing skills are also likely to make important contributions. A recently updated guide 
to questionnaire construction and question design is Woodward and Chambers (2012).
2 The questions
Quantitative data may be collected in field trials by a series of questions asked of the 
respondents that are compiled into a questionnaire. Additional quantitative data may 
be obtained by direct observation (for example, of what the house’s roof is made of or 
of whether a male has been circumcised), measurement (for example, weight), or after 
taking a tissue sample (for example, haemoglobin level). This section will cover issues 
related to data that are collected through questions.
2.1 Relation to study objectives, content, and duration
The questions to be included in a questionnaire should be developed to relate directly 
to the objectives of the study. Usually, at least an outline questionnaire will be drawn up 
in parallel with the formulation of the protocol for the trial. Most grant review commit-
tees expect to see such an outline in the trial funding application.
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Questionnaires must be realistic, both in terms of content and length. For example, it 
may not be possible to obtain valid data on highly sensitive questions such as illegal or 
stigmatized behaviours through a structured questionnaire.
When a questionnaire survey is being planned, it will often seem attractive to add 
questions that do not relate directly to the objectives of the study but which may be 
of interest for other reasons (see also Chapter 12, Section 2.1). As a general rule, this 
temptation should be resisted, as lengthening interview schedules is likely to lead to 
a higher non-participation rate, and time devoted to questions of peripheral interest 
may be at the expense of time on more important questions, with a consequent lower-
ing of the quality of the information collected on the latter. It is good practice to go 
through a draft questionnaire, specifying which objective or important trial outcome 
each question will contribute to, with the aim of deleting any which cannot be clearly 
justified on these grounds. Nonetheless, in some circumstances, it may be desirable 
to ask other questions if this increases the likelihood of participation in the survey or 
serves to divert attention away from the main questions, in order to reduce the chance 
of biased responses. For example, it may be more acceptable to ask questions about 
sexual behaviour in the context of a more general behavioural survey than to include 
only questions that concern sexual behaviour. Similarly, if particular adverse effects are 
expected from an intervention, it will usually be best to also include questions about 
effects thought to be unrelated to the intervention, as this may help identify any biases 
in response between intervention and control groups that are not directly attributable 
to the intervention.
Few respondents will be willing to complete a questionnaire that takes more than 
20–30 minutes, and, even if they do, the quality of responses may well decline if the re-
spondent gets bored or tired. In general, it is best if a questionnaire can be kept to less 
than 30 minutes, though this can sometimes be extended if it includes a variety of dif-
ferent activities, such as answering questions about photographs or scenarios or taking 
physical measurements, rather than only questions and answers.
2.2 Development of questions
A plan for the development of the questions to be included in a questionnaire survey 
is given in Box 14.1, and Box 14.2 gives a checklist of points that should be considered 
in drafting questions.
Increasingly, standardized questionnaires are being developed and shared. These 
draw on questionnaires and interviews that have been conducted in many countries 
and studies, and often the questions and responses have been translated into many 
different languages. An example of this is the Economic and Social Research Coun-
cil (ESRC) question bank (<http://www.surveynet.ac.uk/sqb>), which has hundreds of 
survey questionnaires in it. With the advent of standards for data documentation (see 
<http://www.ddialliance.org>), searching and browsing for questions on particular 
themes will be easier and more extensive. While it is unlikely that complete question-
naires can be copied for new trials, it is important to utilize the resources and know-
ledge from previous studies to avoid making the same mistakes and to build on existing 
knowledge.
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 1 Define the information that is required from the questions. Some items of 
information may only require a single question, such as name or sex, while 
others require a series of questions such as socio-economic status or episodes 
of illness in the past week.
 2 Formulate draft questions. Attention to the wording of questions is important, 
as slight variations may result in different responses. For example, ‘Where do 
you normally seek help when your child has diarrhoea?’ vs ‘Where did you 
seek help when your child last had diarrhoea?’. Box 14.2 gives a checklist of 
points that should be considered in drafting questions. In general, it is a good 
idea to search for, and to critically review, how others have asked specific 
questions, especially if these questions have been formally validated.
 3 Informally test the questions. This may involve trying them out on different 
members of the study team and discussing them with those knowledgeable 
of the study area, including residents. It may be necessary to base someone in 
the community under study (ideally, someone with anthropological or social 
science skills) to investigate how different questions will be perceived to find 
out if there are taboos regarding certain topics, if there are local words for 
some illnesses or conditions, and the extent to which these correspond to the 
investigator’s definitions (for example, many communities have special words 
for measles, night blindness, sexual intercourse, depression, or lethargy). 
The investment warranted for such qualitative studies will depend upon 
local sensitivities regarding the items on which information is required and 
the degree to which each question is critical for the trial. For example, it will 
require less work to find out how to ask questions about breastfeeding practices 
than to formulate appropriate questions on aspects of sexual behaviour. As 
a result of such investigations, the original draft questions may have to be 
modified. Some may even have to be abandoned if research indicates that valid 
information is unlikely to be elicited through a questionnaire survey.
 4 Prepare a first draft of the questionnaire for pilot testing.
 5 Translate each question into the language(s) of the study population, followed 
by independent back-translation by someone who does not know the original 
questions, with reconciliation of any discrepancies—ideally followed by 
further independent translation and back-translation (see Section 2.5).
 6 Prepare a draft instruction manual for interviewers and their supervisors (see 
Section 4.4).
 7 Pilot-test the questionnaire in field conditions, preferably in an area adjacent 
to the study area and using the interviewers who will work on the main survey 
(see Chapter 13).
Box 14.1 Checklist for the development  
of a questionnaire
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 8 Analyse the experience in the pilot test and the data collected.
 9 Reformulate the questionnaire, with further translation and back-translation 
of any amended questions, followed by further pilot testing, especially 
if important changes have been made to questions related to primary or 
secondary trial outcomes.
10 Finalize the questionnaire for the main survey, along with the instruction 
manual for interviewers (see Section 4.4).
Box 14.1 Checklist for the development of a questionnaire (continued)
 1 Keep wording informal, conversational, and simple. Avoid words longer than 
three or four syllables.
 2 Avoid jargon and sophisticated language; assessing understanding at the 
pre-test and pilot test stages is essential. The wording of all questions must 
be appropriate to the educational, social, and cultural background of the 
respondents.
 3 Check the cultural relevance to the respondents of concepts used. Ensure 
mutual understanding between the interviewers and the respondents, paying 
attention to cultural and educational differences.
 4 Avoid long questions, but vary the length of questions to avoid administration 
of the questionnaire becoming repetitive and boring for the interviewer or 
interviewee.
 5 It may be necessary to define a term or a concept before asking about it. If the 
definition is short, it can be included in the question, but otherwise it is better 
given separately before the question is asked.
 6 Avoid leading questions that may bias the respondent to a particular answer 
(for example, ‘Do you think the improved clinic arrangements are better?’).
 7 Avoid open questions beginning ‘Why?’.
 8 Avoid negative questions (for example, ‘Do you not think . . . ’—in some 
cultures, the answer ‘no’ indicates ‘I do not think . . . ’; in other cultures, the 
answer ‘yes’ indicates ‘Yes, I do not think . . . ’!).
 9 Where possible, avoid hypothetical questions, as some respondents will find 
these difficult to answer (for example, ‘If the bus fare was less, would you come 
to the clinic more often?’).
 10 Keep to a single subject for each question. For example, do not say ‘Do the cost 
and times of the clinic prevent you going?’.
Box 14.2 Checklist of points to consider when drafting 
questions
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2.3 Types of question
Information may be sought on opinions or facts through a questionnaire. The distinc-
tion between the two is not always clear, but, in general, the collection of data on the 
latter is easier to plan. Local sensitivities will influence the reliability with which either 
kind of information may be obtained. For example, in some cultures, it is considered 
unlucky to count your children, so asking a parent ‘How many children do you have?’ 
may be too direct an approach.
2.3.1 Historical recall
Information may be sought about the present (for example, ‘Does your child have 
fever now?’) or about the past (‘Did your child have an episode of fever in the last 
month?’). The advantage of asking about the present situation is that responses are 
not susceptible to memory lapses, and furthermore they will usually be more ame-
nable to validation (see Section 2.4). The reliability of historical information de-
creases the further back in time the question relates to, and is influenced greatly 
by the importance of the event to the person (also referred to as its salience). Thus, 
deaths will be remembered better than hospital admissions, which, in turn, will 
be remembered better than illness episodes not requiring hospital admission. To 
obtain reliable information on mild, or even moderately severe, fevers, diarrhoea, 
or respiratory infections, the recall period probably should not exceed a week. The 
implication of this for longitudinal studies in which these outcomes are of interest, 
is that at least weekly surveys of the study group will be necessary to collect reliable 
information.
 11 Pay particular attention to sensitive issues. Review the inclusion of very 
sensitive ones. If they are to be retained, pay very careful attention to the 
wording, and consider the use of indirect approaches. Think carefully about 
their position within the questionnaire (see Section 3.2).
 12 Check the adequacy of the lists of responses to ‘closed’ (see Section 2.3.2) 
questions. For example, ensure a food list covers most things normally eaten 
in the community concerned. It is usually a good idea to include an ‘other 
(specify)’ category, unless you are sure that every possible answer is in the 
list (such as male and female for gender). But it is also important that only 
a relatively small proportion of responses (definitely less than 10%) end up 
being in the ‘other (specify)’ category. This should be checked in the pilot test, 
with additional categories being added for the commoner responses that were 
initially in the ‘other (specify)’ category.
 13 Never include an ‘other’ category without asking the respondent to specify 
what the response was—as in ‘other (specify)’—and leave space for the 
respondent or interviewer to write the specific answer next to this code.
Box 14.2 Checklist of points to consider when drafting questions questionnaire 
(continued)
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2.3.2 Open and closed questions
A ‘closed’ question is one that allows only a defined set of answers which have been an-
ticipated and categorized in advance (for example, ‘Do you own a radio?’ 0 = No; 1 = Yes). 
Replies to an ‘open’ question can take any form and should, whenever possible, be recorded 
in the respondent’s own words (for example, ‘What were the symptoms your child had be-
fore being taken to the health facility?’). It is possible to ask a question with a closed list of 
responses in an open way, with the answer being assigned to one of a previously compiled 
list of codes held by the interviewer (for example, ‘What did you eat yesterday?’, with a list 
of types of food on the questionnaire for the interviewer to tick off those mentioned). This 
may produce a different response from asking closed questions about each of the items on 
the list. Reading out the list will remind the respondent of the possibilities but may also tend 
to produce affirmative answers as a gesture to ‘please’ the interviewer or because the re-
spondent is embarrassed to admit that they have not eaten a high-status food such as meat. 
If the information is sufficiently important, both approaches can be used, the list of unmen-
tioned possible answers being read out after initial responses are recorded without such 
prompting. The two responses should be recorded separately. For example, against each 
category, there could be three options: ‘0 = No’; ‘1 = Yes, unprompted’; ‘2 = Yes, prompted’. 
An analogy is medical history taking where questions about specific signs and symptoms 
might be asked after an initial neutral enquiry such as ‘What is the problem today?’.
In preliminary qualitative investigations, open questions are likely to be preferred to 
determine the full range of possible responses. As a general rule, however, for questions 
that are to be administered in a large survey, closed questions are better, as it is very 
tedious and time-consuming to go back to code the open answers subsequently. It is 
important that they are the ‘right’ closed questions, of course. This requires careful re-
search and the avoidance of the premature administration of a questionnaire that may 
be simple to administer, code, and analyse but which does not provide the information 
required to meet the study objectives.
2.4 Validation
The principles underlying the validation of a questionnaire are similar to those for val-
idating a diagnostic test. The objective is to determine to what extent the answers given 
to a question correspond to the ‘true’ situation. Problems arise if there is no independ-
ent way of ascertaining what is ‘true’. If a mother is asked ‘Does your child have fever 
now?’, the temperature of a child might be measured independently, and the response 
to the question validated against the direct measurement (by defining temperatures 
above some limit as ‘fever’). It will usually be impossible to validate the responses to 
a question such as ‘Did your child have fever yesterday?’. If a ‘gold standard’ exists, 
i.e. a means of obtaining an independent measure of the true response, the sensitivity 
and specificity of a given question can be assessed. The sensitivity of the question is the 
proportion of true positive responses that are reported as positive (for example, the 
proportion of all children with a current fever who are reported as having fever by their 
mother). The specificity is the proportion of true negative responses where the question 
produces a ‘negative’ response (for example, the proportion of all children without a 
current fever who are classified as not having a fever by questioning their mother). 
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The relative importance of sensitivity and specificity in intervention trials is discussed 
in Chapter 12, Section 4.2.
If there is no ‘gold standard’, other characteristics of the responses to questions must 
be evaluated to assess their usefulness in a particular survey. A minimal requirement 
for a question should be that the respondent gives the same answer to the same ques-
tion at different times if the circumstances have not changed (i.e. responses should be 
‘repeatable’). Also, if different interviewers administer the same question to the same 
person, the same answer should be obtained (i.e. responses should be ‘reproducible’). 
Repeatability and reproducibility are not a guarantee of validity, of course. The question 
‘Do you beat your spouse?’ might be answered consistently over time to the same inter-
viewer and reproducibly to different interviewers, but it may still be a very poor way of 
detecting spouse beaters! Also, a man might consistently report that his wife is his only 
sexual partner, even if this is not the case.
If a question fails to induce consistent answers, either within or between interview-
ers, it may be because of a fault in the question or in the interviewers or be due to the 
respondent deliberately varying their responses for some reason. For example, the re-
spondent might reason that, ‘if I am being asked the same question a second time, this 
must be because they didn’t like my first answer, so I’d better change it’!
2.5 Translation
It will often be necessary to translate the questionnaire into local languages. Such transla-
tion should be undertaken with care and attention to detail, as it is easy for the sense of a 
question to be changed, sometimes substantially, by the translation process. For example, 
apparent differences in responses to a question asked to those in different language groups 
may be due entirely to variations in the translation processes. Words for some illnesses 
or concepts may not exist in a language, and this may necessitate major changes in the 
wording of questions. An apparently equivalent word may exist, but it may be used in a 
different way and cover a narrower, or wider, range of conditions. For example, there may 
be several local words used to describe acute respiratory infections, one of which corres-
ponds closely to what we mean by pneumonia. Conversely, difficulties may be encoun-
tered when one local word is used to encompass several different conditions. In studies 
of meningitis in The Gambia, for example, there was difficulty in finding terms to dis-
tinguish between a ‘floppy’ and a ‘stiff ’ neck (B. Greenwood, personal communication).
Once a questionnaire has been translated into a local language, it should be inde-
pendently back-translated into the original language. Comparing the original text with 
the back-translated text will indicate possible areas of confusion where attention to the 
original translation will be required.
3 The questionnaire
3.1 Length
Adequate time must be allowed for the interviewer to solicit the correct responses to all 
the questions included in a questionnaire. The time that an interview will take may be 
difficult to estimate and may depend on the inherent interest of the subject matter to 
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respondents, as well as the amount of time they can spare. The likely duration of an in-
terview can be evaluated during pilot testing. Neither the interviewer nor the respond-
ent should feel under time pressure to complete the interview. Also, the questionnaire 
should be long enough to allow the required information to be collected, but without 
unduly inconveniencing the respondent. The work schedule of interviewers should be 
planned, such that they are not tempted to hurry through interviews. In general, it is 
not a good policy to pay interviewers according to the number of interviews completed, 
unless it is certain that this will not compromise quality. Sufficient time must be al-
located to allow the interviewer to explain why the survey is being conducted, to em-
phasize the importance of truthful responses, and to reassure the respondent regarding 
the procedures undertaken to ensure the confidentiality of any information divulged 
in the interview.
Interviews lasting an hour or more are rarely feasible in the context of a large-scale 
survey; usually, it is more realistic to aim for a maximum of around 30 minutes per 
interview. Respondents may not complete an interview that is too long, and this may be 
particularly problematic if crucial questions are towards the end of the questionnaire. 
Problems of compliance may also grow, as the interviewers’ reputations go before them. 
Brevity is especially important if repeated follow-up questionnaires are planned.
It is a good practice to have the interviewers record the time that each interview starts 
and finishes. This is one way of checking how interviewers spend their days (though it is 
obviously susceptible to manipulation), and, more importantly, it provides a measure, 
for example, of whether different degrees of attention are being given to those in the 
intervention or control groups, with a consequent possibility of bias.
3.2 Order of questions
The initial questions in an interview will seek to verify the identity of the respondent 
(to ensure the correct person is being questioned) and to collect basic demographic 
information (for example, age, sex, marital status). The most sensitive questions should 
usually be asked in the second half of the questionnaire. This is done to give the inter-
viewer time to establish a rapport with the respondent and also so that, if the respondent 
should be upset by the questions and withdraws from the interview, at least this happens 
after most other information has been collected (though such questions should have 
been weeded out during pilot testing). However, it is usually best not to have the most 
sensitive questions last, to avoid the respondent ending the questionnaire with these at 
the top of their mind. Questions which are not judged to be sensitive should tend to be 
asked in their order of importance (to the study objectives), the most important ones 
being asked first, to minimize the losses due to any premature cessation of an interview.
Responses to some questions may condition the responses to other questions, and 
this should be taken into account in their ordering. For example, a question asking if 
the respondent is generally ‘well’, which produces a ‘yes’ response, may bias questions 
about specific illnesses if the respondent feels obliged to justify their overall ‘wellness’. If 
the interest of the study is in specific diseases, it might be better to focus on these first, 
before questions about general health.
Some questions may seek to obtain the same information in different ways as a vali-
dation procedure. If this is done, the questions should not be too close together in the 
questionnaire.
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3.3 Layout
A questionnaire should be able to be used in the field with, at most, infrequent ref-
erence to manuals or instructions. It should provide the interviewer with sufficient 
information to conduct the interview smoothly and without difficulty, after suitable 
training (see Section 4.2). At the same time, it should not be a bulky document, as this 
may alarm the respondent (in terms of the time they think it will take to complete), and 
it may add to the problem of paper storage (see Section 5). Instructions to interviewers 
may be distinguished from questions to respondents by printing them in a different 
typeface (for example, italics). Each interviewer should be issued with an interviewer’s 
manual (see Section 4.4), which contains information to supplement instructions to 
interviewers on the questionnaire itself. Interviewers should be instructed to consult 
their manual if they are uncertain about how to ask a question or how to record re-
sponses or carry out any other procedure.
It is especially important that the initial introduction the interviewer gives a respond-
ent is clear and consistent from interview to interview. It is common for the text of this 
introduction to be printed at the start of the questionnaire. Usually, interviewers will be 
instructed to ask questions exactly as they are written in the questionnaire. This is an im-
portant way to achieve greater reproducibility and standardization between interviewers.
Whether printed on paper or on an electronic device, the questionnaire should be well 
designed. If paper is being used, the size and quality should be chosen to suit field condi-
tions. Cards are often easier to work with in the field than paper sheets but may be unsuit-
able if more than one is required for an interview and they are also bulky to carry around. 
The layout of the questionnaire should be sufficiently spaced to allow those with large 
handwriting to record all the required information. If whether or not a question is asked 
depends on the response to a previous question, this should be indicated on the question-
naire with clear instructions and appropriate ‘branch and skip’ explanations (see Appendix 
14.4). If the questionnaire is being administered from an electronic device, it is essential 
that such branches and skips have been correctly pre-programmed (see Section 5.2).
All questions should be assigned a number. For questions that are repeated several 
times, such as questions about each of a mother’s children, a tabular layout can be used 
(see Appendix 14.5), but this should be designed with care, as such a layout puts more 
demands on the interviewer, or on the respondent if the questionnaire is self-completed.
To facilitate later checking and coding, it may be useful to include, on the ques-
tionnaire, the names that variables are going to be assigned for computer processing 
(see Section 3.4). These are often typed in capital letters and placed just to the right of 
the coding boxes on the questionnaire.
3.4 Coding
Coding is discussed in detail in Chapter 20, Sections 5.4 and 7.3, and only a few points 
pertinent to questionnaire design are covered here. Coding is the process of converting 
the recorded answers to questions into a numerical or alphabetical code. The answers 
may be numeric (for example, age) or be the replies to closed questions. For closed 
questions, there are two possible ways of coding, depending upon whether only one an-
swer, out of the list of possible responses, can be given or whether several are possible. 
Examples of the former are any ‘yes/no/don’t know’ answers or answers to questions 
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such as relationship to the head of household (for example, wife, child, brother, or sis-
ter, etc., where only one answer is allowed). An example of where several answers on the 
list are possible for a single respondent is a question about food consumed on the previ-
ous day. In the first case, the possible responses are each given a code, usually a letter 
or a digit, and a respondent’s answer is coded accordingly. In the second, each possible 
response must be coded for the answer ‘no’ or ‘yes’ (often coded as ‘0’ or ‘1’, respectively, 
or as ‘N’ or ‘Y’) or ‘don’t know’ (if applicable) (often coded as ‘9’), and the codes for each 
of them will make up the respondent’s reply.
It is important to allow codes for ‘don’t know’, rather than leaving the code blank. On 
paper questionnaires, answers to questions that are skipped (i.e. which are not relevant) 
are normally left blank during the interview. It may be convenient to leave the codes 
blank as well, or a specific code for ‘not applicable’ (for example, ‘8’) can be used. The 
choice depends on data processing requirements (see Chapter 20). With lists of pos-
sible responses, a category ‘Other (specify)’ is often included and needs to have its own 
code. There should be space on the questionnaire to write or type in the actual reply, 
but, as mentioned in Box 14.2, the pre-testing and pilot work should ensure that the 
‘Other (specify)’ category is uncommonly used for a reply.
Appendices 14.1 to 14.10 give some examples of different ways of designing a ques-
tionnaire and examples of different types of questions.
4 The interviewers
4.1 Selection
Interviewers should be selected with careful attention to the tasks they will be expected 
to perform. They must be seen by the respondents as individuals who can be trusted 
to keep sensitive and confidential information to themselves. They must be of pleasant 
disposition, and be well-mannered, well-dressed, reliable, and punctual. They must not 
make promises to respondents that they do not honour (for example, if they say they 
will return on a given day they must do so or, at least, send a message in advance to 
explain and apologize if they cannot). The study investigator must attempt to assess 
whether potential interviewers have these characteristics during initial selection pro-
cesses, which should include written tests and interviews.
In general, contracts of employment for interviewers should include a probation-
ary period, during which their suitability is further assessed and at the end of which 
a decision about longer-term employment is made. In some countries, it is possible 
to offer initial contracts solely for the training period. If so, the trial can select more 
interviewers that are needed and train them. This has two considerable advantages. It 
gives the trial team much more time for a detailed assessment of their character and 
performance than is possible through a short written test and interview, and also it is 
possible to select the best potential interviewers at the end of the training period, which 
should have included actual pilot testing of their tasks in the field. Other interviewers 
who have performed satisfactorily can be put on a waiting list, so that they could be 
offered the job at a later date, without the need for a full training course if one or more 
interviewers drops out or falls sick. Even after this, there must be provision for remov-
ing an interviewer from fieldwork if their performance is unsatisfactory.
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If possible, interviewers should speak the same language as the respondents; other-
wise, interviews will have to be conducted through interpreters, which is usually unsat-
isfactory (for the reasons outlined in Section 2), although it is sometimes unavoidable.
The sex, age, and normal place of residence of an interviewer may be important. For 
example, in some societies, male interviewers are less likely to get reliable information 
from women and may even not be allowed by local custom to interview them at all. If 
interviewers clearly belong to the health services, replies may be biased towards sup-
port for those services. Well-educated interviewers may not be best for interviews with 
less educated respondents; substantial differences in social status between interviewer 
and respondent should be avoided. Young interviewers may not be regarded as reliable 
or trustworthy recipients of sensitive information by adults but may be best able to elicit 
sensitive information from other young people. Also, sometimes sensitive information 
may be more readily given to a stranger than to a member of the same community, pro-
vided the respondents are assured of confidentiality.
The most skilled and reliable interviewers are not always the most intelligent or 
highly educated. Indeed, highly educated interviewers may be more likely to become 
bored with repeated administration of the same interview schedule, especially if they 
do not see a clear and feasible career path by which they can progress, for example, to 
being a supervisor or to getting the opportunity for further training.
4.2 Training
The training of interviewers might initially be done as a group exercise, with classroom-
type teaching. This must be supplemented with practical exercises. These might consist of 
one interviewer administering the survey questionnaire to the trainer (or another inter-
viewer or someone else), while others look on, followed by a critical evaluation and dis-
cussion of the interview with the group. The person acting as the respondent should not 
be expected to answer any sensitive questions honestly but can make up plausible answers.
The draft interviewers’ manual (see Section 4.4) should be used extensively in the 
training process, so that, by the end of training, the interviewer should be familiar with 
all aspects of the manual and know which parts to consult for advice on queries about 
particular questions or aspects of field procedures. Also, the training process usually 
reveals aspects of the manual that need revision or further clarification.
Only after interviewers have been through a preliminary training course should they 
be allowed to try out interviews in the community. Initially, such interviews might 
be done by pairs of interviewers, in the presence of a trainer, with detailed ‘post- 
mortems’ being conducted after each interview or series of interviews. The training pro-
cess will merge with the processes of standardization (see Section 4.3) and validation 
(see Section 2.4) and should be continually reinforced throughout the trial through 
supervision visits and meetings, and, when necessary, refresher training courses.
4.3 Standardization
As discussed in Section 2.4, an interview must be both repeatable and reproducible. 
Standardization of interview technique within and between interviewers is neces-
sary for reproducibility. Interviewers must be trained to follow instructions on the 
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questionnaire, as well as all other instructions, exactly. This extends to asking all ques-
tions exactly as written, if this is appropriate. As well as questions, the introduction 
to the interview, explanations and definitions made to the respondent, and transition 
statements that explain a change of subject of the questions should be said as written. 
The points in the interview to use probes and prompts to get the respondent to reply 
more fully should also be clearly specified.
Standardization may also apply to the place and time of interviews. For example, 
interviews conducted in a home and health centre will, in many circumstances, prod-
uce different responses.
It is not realistic, however, to insist on interviewers being merely reading and tran-
scription ‘machines’. They must have some leeway to add extra explanations and guid-
ance when it is clear that a respondent does not understand a question or a definition. 
Interviewer training should cover this and detail the extent to which this is permissible. 
However, stress should be placed on following the written wording, whenever possible.
Standardization needs a certain degree of regimentation, and this can act against rap-
port and personal contact. Since the wording of questions is laid down in advance, it is 
important to ensure that it is friendly and does not alienate the respondent. If different 
interviewers are getting different responses to the same questions, it is important to 
investigate why. For example, one of the interviewers may be deviating from the inter-
view schedule and giving undue emphasis to part of a question. Different interviewers 
attempting to collect the same information from one respondent at different times will 
normally be a part of the validation procedures (see Section 2.4).
No matter how well interviewers are trained and standardized against each other, 
it is as well to assume in the design of a survey that some differences will exist in the 
responses obtained by different interviewers. This will influence the way different inter-
viewers are deployed for fieldwork. Not only is it important to record on the interview 
schedule who conducts each interview, so that differences between interviewers can be 
analysed, but also interviewers should be deployed in a ‘balanced’ way, so that inter-
viewer differences are not confounded with other differences of potential interest. For 
example, in an intervention trial, each interviewer should question similar numbers 
of subjects from the intervention and control groups. The worst situation would be for 
one interviewer to question those in the intervention group and another interviewer to 
question those in the control group.
4.4 Interviewers’ manual
An interviewers’ manual should be developed for use during the field survey. This 
should be reviewed during the training programme for interviewers and revised, as 
necessary. Careful version control will be needed to ensure that the current versions 
of the manual and questionnaire match each other. The manual should give detailed 
instructions regarding how individuals are to be selected and approached for inclusion 
in the study and for each specific interview, and it should detail any special instructions 
regarding each question in the questionnaire and how the responses should be entered. 
It should include guidance on how to deal with unusual situations and how to code un-
usual responses. It should also outline what checks are to be conducted on completed 
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questionnaires and how and when completed questionnaires should be submitted for 
data processing and analysis.
During the conduct of fieldwork, regular meetings should be held of interviewers 
to discuss the progress and queries. When new problems arise, the solutions should 
be incorporated into the field manual, so that there is consistency in dealing with the 
problem in the future and a permanent record is kept of the solution adopted. The 
manuals held by each interviewer should be updated regularly, and the text should 
be kept electronically to facilitate this. Again, careful version control is essential, and 
any changes to the manual (or questionnaire) should be documented in the trial diary 
(see Chapter 16).
5 Data capture
Traditionally, data, whether from interviewer-administered or self-completion question-
naires, have been entered initially (captured) on to paper, but there is increasing use of 
electronic data capture. The latter has many advantages and has become more generally 
feasible, as the sizes, prices, and robustness of suitable electronic devices have improved.
5.1 Pen and paper
The major advantages of data capture by pen and paper are that it involves relatively little 
capital expenditure and does not require interviewers to be familiar with using an elec-
tronic device. Also, if an interviewer detects some specific problem with a question or 
an answer code, they can easily make a note of this in the margin of the paper form and 
move on to the next question. However, if many questionnaire forms are being used, the 
paper becomes bulky and heavy to transport and store. Paper forms can easily be dam-
aged by rain, insects, or other animals, and a further step of data entry on to computers 
causes extra expense and delays and can result in transcription errors (see Chapter 20). 
Some projects scan the data from the paper form into a computer or fax the data to a cen-
tral data management facility for subsequent scanning or manual data entry. Such meth-
ods require relatively high-quality scanners or fax machines and that the questionnaires 
are completed neatly, using standardized writing styles to avoid transcription errors.
5.2 Electronic
Electronic data capture involves either the interviewer or the respondent entering the 
responses directly into an electronic device. This allows electronic range and consist-
ency checks to be done at the time of data capture when it is still possible for the in-
terviewer or the respondent themselves to correct a mistake or misunderstanding that 
leads to an ‘impossible’ response. Even in most rural areas of low-income countries, 
electronic devices, and especially mobile phones, are now widespread, so using them 
for data capture is now rarely likely to faze respondents, though this must be checked in 
preliminary pre-testing and pilot studies.
Some electronic devices incorporate GPS (see Chapter 10), so that the coordinates 
of a household or other interview location can be recorded, and the device can even 
be used to guide the interviewer to the same location subsequently. Many electronic 
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devices also incorporate an audio function, so that the respondent can listen to the 
questions and answer options through a loudspeaker or earphones. It is also possible 
to allow the respondent to have the question repeated, and, if necessary, they can be 
allowed to go back to correct an earlier answer.
Data captured onto one electronic device can be easily transferred to another. It is es-
sential that all such data are kept confidential through password protection and, when 
applicable, encryption.
Until recently, initial hardware, software, and programming costs prohibited the 
widespread use of electronic data capture in field trials in LMICs, but there are now 
cheap smartphones that are capable of displaying a substantial questionnaire and cap-
turing data in a way that is very simple for interviewers or respondents to use. There is 
also free user-friendly software that can be programmed by non-specialists for ques-
tionnaire design and data capture (for example, <http://opendatakit.org>).
Although electronic data capture has major advantages over traditional pen and 
paper approaches, it is important to allow sufficient time for someone on the team to 
fully familiarize themselves with the hardware and software to be used and for elec-
tronic questionnaire development and careful testing. All programming ‘bugs’ need 
to be ironed out before fieldworker training starts, and procedures need to be carefully 
tested and rechecked during training and in any pilot test. Unlike with a paper ques-
tionnaire, a problem with the programming of an electronic questionnaire can result 
in it being impossible for an answer to be entered or for the respondent to move on to 
the next question, being made to skip questions they should have answered, and even 
for whole batches of data being lost, for example, during data transfer. Furthermore, 
during the early stages of transferring from using paper questionnaires to electronic 
devices, all investigators, data managers, and fieldworkers must become fully famil-
iar with the new method and device, and someone must be immediately available to 
solve any unexpected problems that arise (see Chapter 20, Section 5 for further de-
tails). During the transition period from a team using pen and paper to electronic data 
capture, it is often a sensible precaution to give the interviewers paper versions of the 
questionnaire as a backup, in case there is some unexpected problem which makes the 
electronic version unusable, at least during the pilot test and perhaps the first few days 
of the main survey. This is particularly important if the interviewers will be a long way 
from the trial’s coordinating centre.
Some examples of using mobile phones to capture different kinds of data are given in 
Appendix 14.8, Appendix 14.9, and Appendix 14.10.
6 The interview
As much as possible, a face-to-face interview should approximate to a conversation 
between the interviewer and respondent and must not be an interrogation. Good rap-
port between the two is vital, and the onus is entirely on the project team to ensure this.
6.1 Who, where, and when
In studies of children, the best informant regarding their health or behaviour is likely to be 
their mother or guardian. Only as a last resort should someone else be interviewed for this 
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purpose. This may necessitate repeated visits to a household, until the mother or guard-
ian is at home. Other than for children, proxy informants should be avoided, if possible.
The choice of the place of interview will be influenced by logistic considerations and 
the nature of the information to be collected. Usually, the place will have to be chosen 
for the convenience of the respondent, rather than for that of the interviewer. Privacy 
will be easier to ensure in a hospital or a clinic than in a village setting, but special ar-
rangements may be made to ensure greater privacy in a village. For example, an inter-
view might be conducted slightly away from the house under a shady tree. If interviews 
are to be conducted in homes, as far as possible, the time should be chosen to fit the 
convenience of the residents. If possible, they should be consulted, or at least informed, 
in advance regarding when an interview will be scheduled. Preliminary investigations, 
before the main survey, should be made to ascertain when the most convenient time 
will be for most participants. In rural communities, during planting or harvesting sea-
sons, evening interviews may be preferred. But, if interviews take place after dark, poor 
lighting may be a problem, and attention to clear printing and a well-spaced layout for 
the questionnaire becomes even more important (as well as the provision of torches 
and batteries to interviewers). In some areas, security after dark may also be a signifi-
cant problem, and interviewing at that time may be inadvisable.
6.2 Non-response
Steps that can be taken to ensure data completeness within a single questionnaire are 
discussed in Chapters 16 and 20. Here, we discuss the problem of non-response where 
a trial participant is either not seen or refuses to take part in the trial or in a particular 
data collection ‘round’ or survey.
Non-respondents in a study are rarely representative of the rest of the study popula-
tion. They are a self-selected group, and thus their exclusion will usually introduce bias 
into the results of a survey, but the degree to which that has occurred is not usually 
directly measurable. Thus, if a high proportion of the target population for interviews 
are not interviewed, the valid interpretation of the results from those who are inter-
viewed, and in particular the generalization of these results to the whole community, 
may be open to serious question. Therefore, great care must be taken to ensure that 
the response rate is high. This may be achieved in several ways. First, the questions 
included in the questionnaire should be thoroughly tested in a pilot study, so that any 
that a significant proportion of respondents cannot, or will not, answer adequately are 
eliminated. Second, an appropriate explanation of the survey should be given to study 
participants in advance, and any false suspicions they have about the motives or inten-
tions of the investigators must be dispelled. Third, interviewers must be selected who 
are persistent, yet polite, and who will probe for a correct response to a question and not 
accept a ‘don’t know’ response too readily. Fourth, interviewers must be instructed to 
call back repeatedly if a house is empty or a respondent is away, before abandoning an 
interview. Their work schedule should take into account the need for such return visits.
Systems should be put in place to monitor the non-response rate within a trial on 
an ongoing basis, so that steps can be taken to attempt to decrease this, before it is too 
late. The non-response data should be disaggregated by the interviewer, the trial team, 
and other important groupings, where appropriate, such as language, location, etc., and 
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all outliers investigated carefully. For example, in a trial of human papillomavirus vac-
cination within schools, it was discovered that the non-response rate was substantially 
higher for one field team than for the other. This turned out to be due to the way the team 
members were introducing themselves and the trial within the  schools—something that 
could be changed, and the problem was quickly solved.
Even in the most well-conducted surveys, a 100% response rate is rare. Indeed a 
100% response rate should be viewed with some suspicion! As much information as 
possible should be obtained about non-respondents, where necessary from proxy in-
formants, so that the characteristics of non-responders for which information is avail-
able (for example, age and sex) may be compared with that available on responders. 
This may give clues to the extent of possible biases resulting from their exclusion.
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Appendix 14.1 Options for recording responses  
on a questionnaire
There are many ways in which the responses to a question can be recorded within a 
questionnaire. Three of the commonest ways are shown in Figure A14.1.
CODE FOR 
COMPUTER
(1) Q27 Do you usually listen to the radio every day?
(CIRCLE RESPONSE)
No..……0
Yes…….1 |____|
(2) Q27 Do you usually listen to the radio every day?
(No = 0; Yes = 1) |____|
(3) Q27 Do you usually listen to the radio every day?
(No = N; Yes = Y) |____|
Note: Using option (1), the response would usually be coded in the box on the far 
right-hand side, either at the end of the day or at the end of the interview, so that the 
interviewer can check that the question was not missed, and, if it was, ask it again. 
The data entry clerk would only look at the boxes when entering the data into the 
computer. Using options (2) or (3), the interviewer codes directly into the boxes 
with no intermediate step. Whichever system is used, it is advisable to adopt and use 
the same system throughout all questionnaires to avoid confusing the interviewers.
Figure A14.1 Three alternative options for recording the response to a single question 
(face-to-face interview using pen and paper).
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Appendix 14.2 Pre-coded responses which are mutually 
exclusive
If there are multiple potential responses to a question, but these are mutually ex-
clusive, so only one answer is permitted, then it is possible to use a layout as in 
Figure A14.2.
Figure A14.2 Design of a question with multiple, mutually exclusive responses (face-to-
face interview using pen and paper).
CODE FOR  
COMPUTER
Q49 What is the main source of drinking water for members  
of your household?
(CIRCLE ONE RESPONSE)
    Piped into residence…………………………………...01
    Piped into yard or plot………………………………...02
    Public tap……………………………………………....03
    Well with hand-pump………………………………...04
    Well without hand-pump………………………….....05
    River, spring, surface water…………………………...06
    Tanker truck or other vendor………………….……...07
    Rain water……………………………………………..08
  Other (specify)………………………………………….... .09
  Not known…………………………………………..........99
|____|____|
Note: A special code has been allocated for ‘Not known’—in this case, 99. It is 
good practice to use a standard code for answers such as ‘Not applicable’ (such as 
serial 8s (8 or 88 or 888…)) or ‘Not known’ (such as serial 9s (9 or 99 or 999…)). 
In this example, it would also be possible to subdivide and add further codes for 
the ‘Other’ responses at the analysis stage. This would require that all the ques-
tionnaires coded ‘09’ were re-examined, and the responses given new codes such 
as 10, 11, 12, and so on. Such re-coding is time-consuming, and it is usually bet-
ter to try to ensure during the pilot study that all, or almost all, the responses will 
fall into the specific coded categories to avoid having to do such later re-coding.
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Appendix 14.4 Questions with a ‘skip’ instruction
Some questions on a questionnaire may not be applicable for some respondents, based 
on their answers to earlier questions. Although it is possible to design the questionnaire 
so that a special ‘Not applicable’ code is allocated for any such questions, an alterna-
tive is to design the questionnaire to allow the respondent to skip such questions. An 
example is given in Figure A14.4.
Appendix 14.3 Pre-coded responses which are not mutually 
exclusive
If there are multiple potential answers to a question, but these are not mutually exclu-
sive so multiple responses are permitted, then each option must have its own response 
(for example, Yes/No) within the questionnaire (Figure A14.3.).
CODE FOR COMPUTER
Q33 Which of the following items does your household own?
(ENTER NO = 0 OR YES = 1 FOR EACH ITEM)
Radio………………………….......
Television...…………………….....
Sewing machine……………….....
Bicycle……………………….…....
Motorcycle……………….…….....
Car………………………………..
Tractor…………………….……....
|____|
|____|
|____|
|____|
|____|
|____|
|____|
Figure A14.3 Design of a question with multiple responses that are not mutually exclusive 
(face-to-face interview using pen and paper).
CODE FOR COMPUTER
Q39 Have you ever given birth to any children who  
were born alive?
NO = 0 → GO TO Q42
YES = 1→ GO TO Q40 |____|
Q40 How many of these children are still alive? |____|____|
Q41 How many of these children are dead? |____|____|
Q42 Is your mother still alive?
(NO = 0; YES = 1) |____|
Figure A14.4 Design of a sequence of questions which allow questions that are not applicable 
to be skipped by appropriate respondents (face-to-face interview using pen and paper).
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Appendix 14.5 Recording of multiple items of information 
for direct computer entry
Sometimes, one needs to ask a series of questions about each person in a group (for 
example, household). In such situations, the questions series might be structured in a 
table, as shown in Figure A14.5.
Figure A14.5 Design of a form to record a series of questions about children born to the 
same woman (face-to-face interview using pen and paper).
Q93 for all your children who were born alive, give the following details 
(starting with the first born):
Child 
number
Name Alive (1) or 
dead (2)
Sex Age*
(1 = Male; 2 = female) Years Months
01 |____| |____| |____|____| |____|____|
02 |____| |____| |____|____| |____|____|
03 |____| |____| |____|____| |____|____|
04 |____| |____| |____|____| |____|____|
05 |____| |____| |____|____| |____|____|
06 |____| |____| |____|____| |____|____|
07 |____| |____| |____|____| |____|____|
08 |____| |____| |____|____| |____|____|
09 |____| |____| |____|____| |____|____|
10 |____| |____| |____|____| |____|____|
If NUMBER Of CHILDREN IS DIffERENT fROM TOTAL NUMBER RECORDED IN Q40, 
PROBE AND RECONCILE.
* If DEAD, GIVE AGE AT DEATH.
RECORD AGE IN COMPLETED YEARS AND MONTHS.
If LESS THAN 1 MONTH, RECORD AS ‘00’ YEARS AND ‘00’ MONTHS.
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Appendix 14.6 ‘Open’ questions
Although open questions should be avoided if possible in questionnaires, as collating 
and post-coding such questions can be very time consuming in large studies, occasion-
ally it is essential to have an open question. An example is given in Figure A14.6.
Q82 What do you do when your child has diarrhoea?  
(RECORD MOTHER’S RESPONSE)  
(PROMPT: DO YOU INCREASE OR DECREASE FLUID INTAKE?)  
(PROMPT: IF YOU SEEK HELP, WHO DO YOU GO TO FIRST?)
Note: The prompts are included, so that the interviewer is asked to enquire about 
these issues if the mother does not volunteer the information spontaneously.
If the responses to this ‘open’ question are to be analysed quantitatively, the 
information must be coded after all the questionnaires have been completed and 
the full range of different responses has been assessed. If the survey is large, this 
can be a lot of work, and it is usually better to have explored this in pilot studies, 
so that as many questions as possible are in the form of ‘closed’ questions on all 
questionnaires that will be analysed quantitatively within the main trial.
Figure A14.6 Example of an ‘open’ question (face-to-face interview using pen and paper).
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Appendix 14.7 Questions for self-completion by the 
respondent
Questionnaires can be designed for the respondent to enter their responses directly, 
rather than this being done by an interviewer. Figure A14.7. gives two examples.
Now we have some questions which are related to having sex. Please be as truthful 
as possible.
First, we would like to learn/know about the first time you had sex.
Figure A14.7 Example of questions for self-completion by the respondent (pen and paper).
29  When you had sex for the first time, what kind of a person did you have sex 
with? (tick all boxes that apply)
□ A. He/she was a relative of mine.
□ B. He/she was a student in my school.
□ C. He/she was another person about my age.
□ D. He/she was a teacher.
□ E. He/she was another person I knew who was older than me.
□ F. He/she was a stranger.
□ Z. I have not had sex.
Note: Using a self-completion questionnaire, the respondent reads (or listens 
to) each question and enters the answers themselves. They can be completed, 
either using pen and paper or onto an electronic device such as a computer or 
mobile phone. They often give more valid answers than face-to-face interviews 
conducted by an interviewer, especially for sensitive questions like the ones in 
this example, which were asked of school-going adolescents. If administered on 
an electronic device, the questionnaire can also be ‘audio-assisted’ where the re-
spondent can listen to each question and potential response being read out loud, 
and can have this repeated as many times as they need. If completed on pen and 
paper, this can also be done by having a research assistant read out each question 
and potential response to a group of respondents.
28. Have you ever had sex? (tick one box)
□ A. Yes
□ B. No
If yes, how old were you the first time that you had sex?
I was ______________  years old when I had sex for the first time.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
246 CHAPTER 14: QUESTIONNAIRES
Appendix 14.8 Questionnaires on a mobile phone
Increasingly, questionnaires are being designed so that the responses are recorded di-
rectly into an electronic device such as a computer (desktop, laptop, tablet), PDA, or 
mobile phone. This can be done either by an interviewer or the respondent themselves. 
An example is given in Figure A14.8., which shows photographs of mobile phone 
screens showing data on sexual behaviour that has been entered directly into an An-
droid phone using Open Data Kit (ODK) software by three different trial participants.
Participant 1
Data can be checked for
range or consistency as
they are entered  
Numbers (or letters) can
be entered 
Participants can be given 
the option to refuse to
answer a question 
Multiple choice
response option
selected via touch
screen, and entered by
swiping the screen to
see the next question
One question appears on
the screen; previous
answers are saved so
that they can either be
revisited or not
Have you ever had sex?
ODK Collect>Questionnaire ODK Collect>Questionnaire ODK Collect>Questionnaire ODK Collect>Questionnaire ODK Collect>Questionnaire
Yes
No
Have you ever used a 
condom?
Yes
No
I don’t want to
answer
Did you use a condom 
the last time you had 
sex?
Yes
No
I don’t want to
answer
How many sexual 
partners have you ever 
had?
3
How many sexual 
partners have you had in 
the last 12 months?
4
Sorry, this response is
invalid!
Participant 2
Based on the “No” response to the “Have you ever used a
condom?” question, the form was pre-programmed to skip the
question “Did you use a condom the last time you had sex?”  
Have you ever had sex?
ODK Collect> questionnaire ODK Collect> questionnaire ODK Collect> questionnaire ODK Collect> questionnaire
Yes
No
Have you ever used
a condom? 
Yes
No
I don’t want to
answer
How many sexual
partners have you ever
had?  
1
How many sexual
partners have you had in
the last 12 months?  
1
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Appendix 14.9 Collecting geolocation data on a mobile 
phone
Electronic devices can be used to collect geolocation coordinates if the device has that 
facility. Figure A14.9. reproduces photographs of mobile phone screens showing data 
on the coordinates (geolocation) where a questionnaire has been completed that have 
been entered directly into an Android phone, using ODK software.
Geolocation can be captured on suitable devices
e location is shown
below. Swipe the screen
to continue.   
Latitude: S 33º55´18˝
Longitude: E 18º25´16˝
Altitude: 178.7m
Accuracy: 23m  
Press the button below
to show the location
where the interview was
conducted   
ODK Collect> questionnaire ODK Collect> Record Location ODK Collect>geopoint_photo
Loading Location
Using gps. Accuracy is 21 m.
Record Location Cancel
Record Location
Figure A14.9 An example of collecting geolocation data on a mobile phone.
Reproduced courtesy of Zachary Kaufman and Rebecca Hershow, GOAL Trial, South Africa. This image 
is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 International 
licence (CC-BY-NC), a copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
Figure A14.8 Examples of questions answered directly on a mobile phone by three 
different study participants.
Reproduced courtesy of Zachary Kaufman and Rebecca Hershow, GOAL Trial, South Africa. This image 
is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 International 
licence (CC-BY-NC), a copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
Participant 3
Based on the “No” response to the “Have you ever had sex?”
question, the form was pre-programmed to skip to the end of the
series of questions about condom use and sexual partners  
Have you ever had sex?
Yes
No
Now I’m going to ask you 
some questions about 
your medical history.
ODK Collect> questionnaire ODK Collect> questionnaire
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Appendix 14.10 Recording a laboratory test result on a 
mobile phone
Electronic devices can be used to collect photographs if the device has that facility. 
Figure A14.10. reproduces photographs of mobile phone screens showing a photo-
graph of a pregnancy test result that has been taken using an Android phone which will 
be saved for the record.
Take a photo of the
pregnancy test result
Photos or videos can be recorded. Here a Pregnancy test
result has been photographed for the record.
ODK Collect> questionnaire
Take Picture
Figure A14.10 Example of a photograph taken with a mobile phone as part of a 
questionnaire.
Reproduced courtesy of Zachary Kaufman and Rebecca Hershow, GOAL Trial, South Africa. This 
image is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 
International licence (CC-BY-NC), a copy of which is available at http://creativecommons.org/licenses/
by-nc/4.0/.
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1 Purposes of social and behavioural research 
in intervention trials
Social and behavioural research is often conducted during the design and evaluation of 
health interventions. In the design phase, ‘formative research’ is conducted in the com-
munity in which the proposed trial is to be conducted to explore the context in which 
the intervention will be delivered and to examine ways in which the intervention might 
be optimized. Examples are given later in this chapter. The outcome of such research 
should help define the content and delivery of the intervention package and ensure that 
the study protocol takes proper account of local conditions. In the evaluation phase, 
either during or after a trial, social and behavioural research is often used as part of a 
‘process evaluation’ to understand aspects of the implementation of the intervention, 
such as in the context of intervention coverage, comparing how the intervention was 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
250 CHAPTER 15: SOCIAL AND BEHAVIOURAL RESEARCH
supposed to be delivered, compared to how it was actually delivered, and to understand 
‘pathways of change’ in the case of behavioural intervention trials (i.e. what the compo-
nents of the intervention that led to, or did not lead to, behaviour change were).
The methods applied derive from a variety of disciplines, including anthropology, 
sociology, and psychology. They include both qualitative and quantitative approaches. 
In Section 3, we outline qualitative methods that are commonly incorporated in the 
design and conduct of intervention trials. Rather than detailing all possible methods, 
examples are given of how different methods can be used in the context of such trials.
1.1 Formative research to define the intervention package
All of the component parts of an intervention (the ‘intervention package’) to be tested 
in the field trial and the method of delivering the intervention should be clearly defined. 
To maximize the potential for the intervention package to be effective, it should draw 
on local priorities and contexts, as well as best practice from elsewhere. With the poten-
tial exception of some ‘proof of concept’ trials, the intervention must have the realistic 
prospect of being affordable, given the resources available at the household level and to 
the local health system, either immediately after the trial or in the foreseeable future. It 
must be acceptable to the community, and it must be feasible for it to be implemented 
by those charged with delivering the intervention in the trial (e.g. local health workers). 
If the intervention tested in the trial is poorly designed or does not have the potential to 
meet these criteria, this greatly reduces the chance that the intervention will be adopted 
into routine practice at the conclusion of the trial, even if it is found to be effective. To 
optimize evaluation methods, particularly in the context of ‘complex’ interventions, the 
intended mechanisms of effect should be clearly articulated in advance, for example, 
through a logic model (see Section 1.1.2).
In the context of this chapter, we use the term ‘intervention package’, rather than 
simply intervention, to emphasize that, even if the core intervention under evaluation 
is a single item, such as a vaccine or a drug, it will always be necessary to deliver it as 
part of an intervention package, which will have a number of different components 
that have to fit together for there to be a significant effect on the health outcomes of 
interest. An intervention package can be regarded as composed of the core interven-
tion and complementary activities to promote uptake and use of the core intervention. 
Varying amounts and types of formative research are required, depending upon the 
nature of the core intervention and how fully it has already been defined. As discussed 
in Chapter 2, the core intervention under trial varies widely from products or tech-
nologies such as vaccines, drugs, food supplements; behaviours such as hand-washing 
and exclusive breastfeeding, or care seeking from a health facility in response to danger 
signs; different methods of delivering or managing health services, such as delivery of 
services through visits by community health workers to the home, rather than through 
visits by users of the services to a clinic or dispensary, or different methods of supervi-
sion of health workers. Whichever intervention type, it is likely that the intervention 
and package will require one or more components beyond the core idea or technology.
Formative research to define intervention packages typically involves fieldwork and 
review of the literature before an intensive period of design and pilot testing of the 
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intervention package. An example of the role of formative research in intervention de-
sign is shown in Figure 15.1, which was developed in the context of trials of the delivery 
of drug treatment interventions against malaria (see <http://www.actconsortium.org>).
1.1.1 Fieldwork
Formative research fieldwork aims to understand the ‘problem’ that will be targeted 
by the trial, to gain an understanding of the ‘audience’ for the intervention and to un-
derstand the context in which the intervention will take place. For example, the over- 
diagnosis of malaria by health workers has been identified as a major problem across 
malaria endemic countries. Prior to a trial to improve the diagnosis of fevers in north-
east Tanzania, anthropological research at hospitals had described how clinicians oper-
ated through shared ‘mindlines’, rather than following clinical guidelines, shaped by 
perceived patient expectations and norms established with peers and historically in the 
wider medical community (Chandler et al., 2008). An intervention package designed to 
improve the diagnosis of malaria would require changing these norms in a manner that 
would not undermine clinical autonomy. The audience for the trial intervention was 
defined to be both clinicians and patients at dispensary level facilities. Further qualita-
tive work was carried out with these groups to learn what existing ideas and situations 
supported the use of diagnostic tests and to discuss how these could be built upon to de-
velop intervention activities and messages that would encourage a change in practice.
Outline intervention parameters
(e ‘problem’, goals, intended recipients, restrictions to design)
Design intervention
delivery
(Materials, activities, actors)
Pilot, revise, and nalize intervention and logic model
Implement, document, and evaluate intervention
Design intervention components
(Identify the target audience, content, approach
for each intervention component) 
Dra logic model
(Proposed pathway of change)
Formative research to dene intervention package
(Fieldwork,desk research) 
Evaluation 
design
(To assess
processes,
pathways and
eects in
context)
Figure 15.1 Example of the role of formative research in intervention design.
Reproduced courtesy of Claire Chandler. This image is distributed under the terms of the Creative 
Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is 
available at http://creativecommons.org/licenses/by-nc/4.0/.
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Table 15.1 outlines four areas for exploration in formative research: understand-
ing the current policy and operational context of behaviour; understanding current 
practice in the local context; understanding current perceptions; and understanding 
whether the population of interest perceives a need for change, and their ideas for how 
this might be achieved. Each area may be explored, using different methods and with 
different participants.
The identification of existing practices, ideas, and scenarios upon which to build 
intervention design is important in formative research. Identifying only barriers to a 
particular health practice can be limiting in designing an effective intervention. An ap-
proach to identify existing beneficial practices is ‘positive deviance inquiry’, which uses 
multiple methods. For example, a research group may want to improve child malnutri-
tion by promoting beneficial child feeding behaviours that exist in the community but 
are only practised by a minority of households. Here, the study team might identify two 
sets of households with similar levels of material wealth and other characteristics, but 
with different levels of child nutrition. A small descriptive study, including structured 
observation of child feeding practices and interviews of various household members, 
can be carried out to try to identify potentially beneficial behaviours, which might 
subsequently be confirmed in a larger study with a representative sample. A detailed 
manual of how to apply this methodology is available (<http://www.positivedeviance.
org>) (Sternin et al., 1998).
An important characteristic of the core intervention to be explored at this stage may 
be its cost. In efficacy trials, the product or intervention is typically provided to research 
participants, free of change. In trials designed to mimic what might happen when an 
intervention is introduced into public health practice, a product may be sold to par-
ticipants, at the cost users will pay when the product eventually is available through 
routine distribution channels. One major focus of formative research at this stage may 
therefore be on evaluating not only the acceptability and feasibility of use, but also the 
willingness to pay for the intervention (see also Chapter 19).
1.1.2 Literature review
In addition to fieldwork, the formative stage of intervention design requires review of 
previous work. Systematic reviews of evidence of other interventions that have been 
more and less successful in achieving similar objectives are recommended as a first 
step (see Chapter 3 and Medical Research Council, 2008). In addition, identification 
and specification of the theory or theories used to guide the design of the interven-
tion and its delivery are recommended, in order to strengthen the effectiveness of the 
intervention, as well as to enable evaluations to contribute to wider bodies of theory 
about ‘what works’. This is especially relevant for behavioural interventions. Care must 
be taken in identifying an appropriate behaviour change theory to ensure that the the-
ory reflects well the situation found locally in formative fieldwork research. Certain 
 cognitive-based models, such as the health belief model, that centre on replacing ‘be-
liefs’ with biomedical ‘knowledge’ and replacing ‘myths’ with ‘truth’ have been criti-
cized for taking too little account of the local issues around health, care seeking, and 
care giving, and not relating these to their social, economic, and political contexts. 
Even in the absence of the explicit use of theory to guide intervention design, social 
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Table 15.1 Areas for exploration in formative research for the design of an intervention 
package to improve the diagnosis and treatment of fevers
Area of exploration Method Potential  
participants and 
sources
Information gathered
Understanding the 
context of behaviour  
and potential  
for change
In-depth  
interviews,  
desktop research
◆  Key stakeholders 
related to the  
current behaviour
◆ Policy documents
◆  Historical and 
anthropological 
reports
◆  Policy and operational 
influences on current 
practice (guidelines, 
supervision, in-service 
training)
◆  feasibility and 
willingness to implement 
behaviour change
◆  Existing or previous 
interventions with similar 
topics or behaviours
Understanding  
current practices
Direct  
observation
◆ families
◆ Mothers
◆ Drug sellers
◆ Policy makers
◆  How practices are 
enacted in context, 
looking at the role of 
spaces, time, economics, 
and other priorities in 
shaping practices
Understanding 
perceptions of  
practices
In-depth  
interviews
◆ Key informants
◆ Patients
◆ Health workers
◆  Prevailing perceptions of 
practices in the groups 
of interest
◆  Narratives of experiences 
of the group of interest, 
showing meaning 
interpreted in actions 
and words of selves and 
others, social context of 
behaviour of interest
Understanding  
priorities and  
logistics for change
focus group  
discussions
◆  Community  
groups
◆ Patients
◆ Drug sellers
◆ Health workers
◆ District officials
◆  Exploration of perceived 
need and priorities for 
change
◆  Generation of ideas for 
intervention messages 
and materials
◆  Exploration of 
readiness for different 
interventions in context
◆  Identification of social 
and structural issues 
to address in a given 
intervention activity
Reproduced courtesy of Claire Chandler. This table is distributed under the terms of the Creative Commons 
Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is available at  
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science approaches are useful in enabling depiction of the implicit pathway of change 
(how change will be brought about) and the hypotheses embedded within this. Such a 
depiction is often termed a ‘logic model’ or ‘theory of change’ or ‘impact model’ and can 
help to tighten up an intervention design as well as to identify where evaluation activ-
ities are required, in order to test hypothesized pathways of change. For a discussion of 
these aspects, see National Institute for Health and Clinical Excellence (2007).
Figure 15.2 shows a framework for a logic model.
Analysis of the intervention details and the context in which it is implemented is im-
portant for the proper interpretation of trial outcomes, so that the applicability of the 
trial results in other situations can be assessed.
1.1.3 Developing and pilot testing intervention delivery
Once the core intervention is defined, the details of the intervention’s delivery require 
development to promote understanding, acceptance, and utilization of the core inter-
vention, or to improve physical, financial, and cultural access to the core intervention. 
Details to develop and pilot-test for the effective delivery of the intervention include 
activities, materials, and ‘purveyors’ (explained in the following paragraphs).
Activities to accompany a core intervention might include the design of workshops, 
media spots, or engagements with opinion leaders. When the intervention to be intro-
duced is new to the potential recipients, a small-scale pilot introduction may be car-
ried out. This can help to refine the activities and identify needs for materials and the 
optimal characteristics of the purveyor(s) who will deliver different components of the 
intervention package. An example is a pilot feasibility study carried out in rural Zim-
babwe to design an intervention to target adolescent sexual health (Power et al., 2004). 
Teachers were trained in four schools to deliver weekly lessons on reproductive health. 
Feedback and responses to the materials and delivery were gained through question-
naires, in-depth interviews, focus group discussions, and participant observation with 
pupils, parents, teachers, and education officers. The research found that the interven-
tion as originally conceived was unlikely to be deliverable because the classroom was 
Intervention
inputs (resources
and activities)  
Fidelity, dose,
reach of  
Enabling
conditions 
Outputs
intervention
Outcomes
Human, nancial
and material
resources needed
for the intervention.
Specic activities in
which the target
audience (s)
participate, e.g.
training activities,
workshops, events,
requisition of
supplies. 
Measurable
process outputs of
the intervention
upon which the
intended
mechanisms of 
eect rely, e.g.
supplies delivered
or numbers of
target audience
attending an
event.           
Factors amongst
recipients and in
their environment
that are expected to
aect the
mechanism of
eect of an
intervention, e.g.,
political leadership
or presence of 
supporting
resources.        
Measurable
proximal outputs
of intervention
activities, e.g.
knowledge or
motivation of a
direct or indirect
target audience.       
Changes that
occur in the
target
audience(s),
which can be
proximal, e.g.,
drug use
behaviour,
patient
satisfaction, or
distal, e.g.,
community
health indicators.           
Figure 15.2 framework for a logic model of an intervention’s pathway of change.
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not the appropriate context for delivering the intervention, the school infrastructure 
was not suitable to deliver the intervention materials, and existing materials were inad-
equate for the intervention. As a result, substantial changes were made to the design of 
the intervention prior to formal testing in a large community randomized trial.
Materials for the intervention delivery might include printed instructions and/or 
a film of how to use the product or how to perform the behaviour; vouchers to be 
provided to the poor who otherwise could not afford the product; materials for the 
channels through which the product will be sold or distributed such as pharmacies, 
shops, and health facilities; and print or audiovisual materials for communication ac-
tivities such as radio broadcasts, protocols for community meetings, and posters. The 
development of these materials should draw on best practice in communication sci-
ence, together with either information already gained from local formative research or 
participatory research at the design stage. Participatory, or ‘action’ research, can lead 
to the development of intervention materials that are more effective and acceptable 
to end-users. An example is the development of a treatment guideline for the effect-
ive case management of malaria in children at home by caregivers (Ajayi et al., 2009). 
Several forms of modified focus group discussion sessions were undertaken, with ideas 
depicted in illustrations by a graphic artist. The emerging guideline, in a cartoon format 
with a local language script, was subject to multiple rounds of pre-testing by end-users, 
during which edits were made to the pictures and text to increase comprehension and 
interpretation of the stories. Pre-testing of materials with community members is es-
sential before finalizing them. Images, statements, and even colours can often portray 
different meanings to different people. To avoid misinterpretation, community mem-
bers should be shown drafts of materials and systematically asked for their compre-
hension and interpretation of each element of a poster, video, or audio broadcast. An 
excellent manual for pre-testing that includes principles for clear communication has 
been produced for the WHO (Haaland, 2001).
Purveyors are the people who will deliver the intervention. Attention must be given to 
their selection, training, and supervision. These may include facility-based health work-
ers, community health workers, traditional healers, private and informal sector provid-
ers, traditional birth attendants, women’s groups, and community or religious leaders. 
Small-scale studies can be conducted to investigate which type of person might be the 
most appropriate as the purveyors of the intervention. These might be based on either 
discussions of hypothetical options with the potential recipients of the intervention or 
pilot projects to implement one or more alternative options. Examples of projects with 
a comprehensive package of complementary activities and people to implement these 
activities in the field were a programme for the social marketing of bed-nets in Tanzania 
(Schellenberg et al., 2001) and an education and counselling programme on exclusive 
breastfeeding for HIV-infected mothers in a trial in Zimbabwe (Iliff et al., 2005).
1.2 Formative research to adapt the study protocol
1.2.1 Study design and procedures
Chapter 4 describes decisions to be made regarding study design such as selection of 
interventions, allocation of interventions and unit of randomization, and method of 
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implementation. Often, such decisions are made far from the study site, and they will 
always benefit from detailed information about the study site. Formative research con-
ducted to inform the study design may examine different topics, including:
Selection of study site: Typically, there are a number of possible locations at which 
a trial may be conducted. Requirements of the trial may include enrolment of 
people with specific characteristics, and long-term follow-up of those enrolled 
in the trial. The decision on the choice of site may be informed by analysis of 
existing census data or other datasets, or interviews on community characteris-
tics such as patterns of migration, economic activities, and observation of health 
programmes already being implemented by local organizations (see Chapter 9).
Randomization: Qualitative data can inform decisions about the unit of randomiza-
tion (individual, village, cluster of villages, sub-district, etc.) and the boundaries 
of the units for group randomization. An understanding of the social structure 
and the social context of the target behaviour is useful for identifying the im-
portance of administrative or social groups. For example, if a target behaviour is 
known to be habitual to a group and the intervention relies on individuals mak-
ing changes as part of a group, the unit of randomization should be that group, 
rather than individuals within the group. Another consideration may be defining 
boundaries to minimize the potential for contamination, due to interactions be-
tween those assigned to different trial arms. Formative research can reveal com-
mon interactions and social and logistic boundaries.
Promotion of trial participation: Prior to the start of a trial, its usefulness and the pri-
ority given to the research question should be established from the perspective of 
the hosting communities. If the question or methods are not aligned with local 
interests, changes to the intervention or evaluation may need to be made (see 
Chapter 9). Once a trial is launched, it is desirable that a high proportion of those 
eligible to participate in the trial agree to do so when invited. A high refusal rate 
may jeopardize the generalizability of the trial findings or may even threaten its 
viability. Thus, it is important to implement activities to promote understanding 
and acceptance of the research activities and create the conditions under which 
truly informed consent is possible. These might include community meetings to 
discuss why certain communities or persons will receive the intervention, while 
others will not, and print or counselling materials to explain the risks and benefits 
of participation. This component may also elicit community input to improve the 
trial protocol itself, as occurred in the design phase of a clinical trial on the safety 
and efficacy of antiretroviral and nutrition interventions to reduce post-natal 
transmission of HIV conducted in Malawi (van der Horst et al., 2009). Qualita-
tive studies were conducted to assess the acceptability of three alternative efficacy 
study designs and the feasibility of participant recruitment for such study designs.
Participatory methods can be used to engage communities in the design and imple-
mentation of the trial interventions. For example, a feasibility study for a microbicide 
trial in Mwanza Tanzania formed a city-level CAB, with representatives from among the 
potential trial participants elected from each ward. Through workshops and meetings, 
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both with the CAB and wider groups of potential trial participants, many modifications 
were made to both the trial design and the study procedures. CAB members expressed 
concerns about the sale of blood specimens for witchcraft purposes, whether speculae 
for pelvic examinations would be reused and therefore be unclean, insufficient trans-
port allowances for attending the trial assessments, and delayed reporting of laboratory 
test results. In response, the study team invited CAB members to observe the prepa-
ration and storage of blood specimens and the use of the autoclave in the laboratory, 
raised the amount for reimbursements, introduced HIV rapid testing, and accelerated 
the feedback of laboratory results (Shagi et al., 2008; Vallely et al., 2007).
1.2.2 Consent procedures and measurement tools
Obtaining truly informed consent for participation in an intervention trial is very chal-
lenging. The researcher’s perception of an intervention and its possible beneficial and 
adverse effects may be very different from those of potential trial participants. Social 
science investigations conducted in the trial community, prior to designing the in-
formed consent procedures, may give the investigator a much better understanding 
of how the community is likely to view the proposed trial and will inform the ways 
in which the trial should be presented to potential participants to facilitate their un-
derstanding of both the potential risks and potential benefits and of why the trial is 
being conducted. Issues around informed consent are discussed further in Chapter 6, 
Section 2.4.
Social and behavioural research methods can also help inform the design of quanti-
tative outcome measures for the trial. Tasks include formulation of questions and defin-
ition of appropriate forms of measurement. Some trials make the mistake of measuring 
outcomes through open questions, thinking that closed questions introduce bias. In 
addition to the fact that post-coding of open questions is very time-consuming (see 
Chapter 20), problems caused by incomplete responses to open questions may out-
weigh the limitations of closed questions. Also, open questions have lower test–retest 
reliability, leading to difficulties when pre–post comparisons are made. Nichter et al. 
(2002) outline a systematic process for informing the design of survey instruments 
through formative research.
2 Social and behavioural research in evaluation
Social and behavioural research conducted during and after the trial may facilitate 
understanding and interpretation of the trial results. Two methodological approaches 
for this purpose are process evaluation (process documentation, process learning) and 
evaluation of pathways of change.
2.1 Process evaluation to understand implementation
Process evaluation is a term applied to a range of data collection activities conducted 
during the implementation of a trial to assess, at a minimum, whether the intervention 
is being implemented according to the study protocol. This is important to document 
and report, in order to determine whether an intervention’s apparent success or failure 
is attributable to the intervention’s concept or theory or to the way it was implemented. 
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Table 15.2 shows six aspects of process evaluation that have been described by Saunders 
et al. (2005) to guide data collection activities.
Each of the intervention components and its delivery methods should be subject to 
a process evaluation, resulting in the documentation of the six aspects in Table 15.2. 
Data collection may be quantitative, such as the number of subjects who receive an 
information leaflet, or qualitative such as perceptions of the political agenda behind 
an information leaflet that affects the ‘dose received’ of a particular message. Data may 
be collected through self-completion questionnaires, for example, by trainers who can 
record the amount of content actually delivered, the relative participation of differ-
ent members of the group, and their impressions of the level of understanding for the 
various objectives of the training. Direct observations of activities can also provide an 
assessment of how well a particular intervention activity was delivered and can provide 
interpretations of the delivery in context, for example, to note other activities or events 
occurring at the same time that could support, or conflict with, the trial intervention. 
Interviews may also be used with both purveyors and intended recipients to under-
stand what was delivered and what was received, and to give an understanding of why 
some aspects of an intervention may have been more effective than others. The data 
Table 15.2 Six dimensions of process evaluation
Fidelity (quality) The extent to which the intervention was 
implemented, as planned
Dose delivered (completeness) Amount or number of intended units of each 
intervention or component of the intervention that 
were delivered
Dose received (exposure or adherence) Extent to which participants actively engage with, 
interact with, are receptive to, and/or use materials 
or recommended resources. Can include initial and 
continued use
Reach (participation rate or coverage) Proportion of subjects who receive or participate in 
the intervention; includes documentation of barriers 
to participation
Recruitment and retention Procedures used to approach and attract 
participants at individual or organizational levels; 
includes maintenance of participant involvement in 
the intervention
Context Aspects of the environment that may influence 
intervention implementation or study outcomes
Adapted with permission from Saunders, R. P. et al., Developing a process-evaluation plan for assessing 
health promotion program implementation: a how-to guide, Health Promotion Practice, Volume 6, Number 
2, pp. 134–47, Copyright © 2005 by Society for Public Health Education. Includes data from Steckler, A. and 
Linnan, L., pp. 1–24, in A. Steckler and L. Linnan (Eds.), Process evaluation for public health interventions and 
Research, Jossey-Bass, San francisco, USA, Copyright © 2002 by John Wiley & Sons; and Baranowski, T. and 
Stables, G., Process evaluations of the 5-a-day projects, Health Education and Behavior, Volume 27, Number 
2, pp. 157–166, Copyright © 2002 by Society for Public Health Education. This table is not covered by the 
Creative Commons licence terms of this publication. for permission to reuse please contact the rights holder.
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collected can be used in the interpretation of the final trial outcomes. The data can be 
incorporated into final analyses quantitatively, for example, in dose–response or per 
protocol analyses. The qualitative data can also be used to interpret what any change 
may be attributable to, in terms of the intervention delivered and received.
Process evaluation can also identify difficulties with implementation that occurred 
and how these difficulties were addressed.
2.2 Evaluation of pathways of change
In the evaluation of pathways of change, which is particularly relevant for behavioural 
interventions or multi-component interventions, the researcher aims to establish the 
relationship between any changes detected in trial outcome data and the intervention 
package, taking into account contextual factors that may have shaped the intervention 
and outcome variables. The objectives of an evaluation of pathways of change are to es-
tablish plausibility that outcomes are attributable to the intervention and to depict the 
mechanisms by which an intervention had effect, including identification of context-
ual factors considered significant in supporting these mechanisms. Two approaches 
can be taken to understanding pathways of change: hypothesis testing and hypothesis 
generating. These approaches are complementary and should be considered together to 
maximize understanding of the trial and generalizability of the results.
2.2.1 Hypothesis testing research
The hypothesis testing approach relies on prior specification of the intended pathway of 
change, for example, through a logic model. Steps along the pathway can be identified, 
and the relationships between these steps tested. For example, a multi-component trial 
in Uganda to enhance the quality of care at rural health facilities included a workshop 
series on patient-centred services. The hypothesized pathway of change was that health 
workers would attend the workshops and participate in individual reflection, concep-
tualization, experimentation, group reflection, and planning in the workshops; would 
feel motivated and able to change their practice; health worker interactions with care 
seekers would be more patient-centred; care seekers would detect, and be more satis-
fied with, this style of communication; and community members would subsequently 
be more attracted to attending the enhanced health facilities. The study included a pro-
cess evaluation to document the attendance, participation, and learning, followed by 
a pathway evaluation to assess communication between health workers and care seek-
ers using audio recordings, care seeker satisfaction with their interactions with health 
workers, and logs of attendance at health facilities (Chandler et al., 2013a).
2.2.2 Hypothesis-generating research
A hypothesis-generating approach intends to understand ‘what happened’ from the 
perspective of the target population, from the time of intervention delivery to outcome 
evaluation activities. Here, unintended pathways of change can be captured, together 
with information on factors that affect the delivery, uptake, and use of an intervention 
in practice, as well as factors that may influence the outcomes of interest in the trial. Un-
structured methods are best suited to this task to enable the research team to discover 
findings that may not have been hypothesized or depicted in the logic model. Project 
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ethnography is one methodological approach to capture what actually happened. Here, 
an anthropologist, or someone similarly trained, carries out detailed participant ob-
servation, for example, working alongside the intervention implementation team for 
the trial, or even as a member of that team. Analysis of the in-depth data from these 
observations can provide insights into why and how members of the target community 
took up, adapted, or ignored different intervention components. Project ethnography 
can capture interpersonal relationships and power dynamics among the multiple ac-
tors involved and provide insights that would have ordinarily been missed. Evans and 
Lambert (2008) provide an excellent example of the value of project ethnography in 
illuminating key factors in the successful implementation of an intervention related 
to HIV. Other methods include in-depth interviews and focus group discussions with 
implementers, stakeholders, and the target population.
Further information and examples about using social research to carry out formative 
studies and evaluations of pathways of change in LMICs can be found at <http://www.
actconsortium.org/qualitativemethodsguidance>.
3 Commonly used methods in social research
Qualitative research methods commonly used in field trials of health interventions in-
clude direct observation, interviews with key informants, focus group discussions, and 
participatory methods. These relatively open-ended techniques are suitable for explor-
ing how an intervention might be perceived, the priorities of different members of the 
community, and ways that people view a trial from the perspective of potential partici-
pants. These methods are used to provide information relevant to devising intervention 
components, such as communication strategies, as well as devising trial methods, for 
example, to ensure recruitment and designing effective and appropriate data collection 
instruments.
The aim of qualitative research is to understand the perspectives of specific groups of 
individuals. In doing this, researchers are attempting to learn about the social worlds 
in which others live: their experiences with specific issues, their points of reference 
around particular topics, and broader factors that shape these, from local to global, 
historical, and political economic factors. When studying the world from a social per-
spective, it is recognized that what people say and do is contingent on the scenario in 
which words are being spoken and the action taken. Qualitative research attempts to 
make sense of, or interpret, phenomena in terms of the meanings people bring to them, 
and qualitative research practice recognizes the role of the researcher in bringing out 
these meanings. Key concerns in qualitative research are therefore how best to interpret 
perspectives of others and how to integrate into analyses the subjective nature of this 
interpretation. Both of these issues are relevant in research to guide intervention devel-
opment, as well as to evaluate trial outcomes.
When considering methods to interpret others’ perspectives, most qualitative re-
search embraces the following four concepts: explorative flexibility, iteration, triangula-
tion, and contextualization. Although the researcher has specific topics to be explored, 
it is assumed that new questions will emerge frequently, as the research progresses. 
Specific techniques and associated data collection methods are refined and modified 
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throughout the research process. A flexible approach is adopted whereby unanticipated 
findings are explored, as new lines of inquiry develop, unproductive forms of data col-
lection are dropped, and new methods developed, without losing sight of the original 
research objectives. There is an emphasis on in-depth investigation. The same or dif-
ferent key informants and other respondents may be interviewed repeatedly, with each 
new interview building upon the previous one with increasing refinement and focus. 
This iterative process applies not only to specific methods, but also to the qualitative 
research process as a whole. Multiple fieldwork strategies may be employed, includ-
ing one-to-one conversation, as in key informant interviewing, group discussions, and 
direct observations of actual behaviour. The use of multiple methods in conjunction, 
or triangulation, adds depth to an inquiry of the phenomenon in question. Rather than 
being a strategy for validation, triangulation adds richness and breadth, enabling a 
more rigorous exploration of the complexity of a phenomenon, through its multiple 
representations. Qualitative research may be used to help researchers understand the 
social, cultural, historic, political, and economic context within which an intervention 
trial will be conducted. Such contextualization is particularly valuable during the initial 
planning phases and also to help understand unexpected trial findings.
When considering how to integrate the subjective nature of interpretation into ana-
lyses, the concept of reflexivity is crucial to qualitative research. This requires that the 
researcher explicitly acknowledges his or her motivations and theoretical positions in 
relation to a piece of research and makes an effort to reflect and articulate these in deci-
sions made in fieldwork and interpretations. For example, if a researcher feels alignment 
with ideals of market-led provision of health care, this may affect the way in which they 
ask questions and interpret responses, which can impact the shape of an intervention 
developed and the way a trial outcome is interpreted. Being reflexive about political, 
economic, and theoretical agendas underlying one’s own motives for, or implementation 
of, the research can allow greater transparency, as well as the opportunity to challenge 
and reconsider these perspectives. Methods for attaining a reflexive stance include keep-
ing reflexive diaries and field-notes and discussing decisions reflexively as a team. This 
approach has been proposed to be extended beyond qualitative activities to trial conduct 
in general to promote transparency and encourage more realistic accounts of trial con-
texts that are often in flux, allowing anticipation of barriers to recruitment and potential 
sources of bias which can be addressed in trial activities or analyses (Wells et al., 2012).
We have outlined some of the principal qualitative social science research methods. 
More detailed descriptions of the main qualitative research methods are given by Kiel-
mann et al. (2011) and Bryman (2012). Chandler et al. (2013b) have also produced a 
compilation of guidance for carrying out qualitative research in the context of health 
interventions and provide a parallel protocol template document which includes ex-
ample topic guides and standard operating procedures (SOPs) and a set of training 
materials for field teams (<http://www.actconsortium.org/resources.php/72/qualitative- 
methods-for-international-health-intervention-research>).
3.1 Direct observation
Direct observation includes both unstructured and structured observations. These 
methods are useful for learning about the everyday context relevant to an intervention. 
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Spending an extended time observing these enables the researcher to appreciate the 
factors that may be relevant to an intervention, in relation to other priorities in the 
community and activities and concerns of the group of interest. This may be important 
for both the development of appropriate interventions and in the interpretation of trial 
outcomes.
3.1.1 Unstructured observation
Unstructured observation is the cornerstone of ethnography, the classical methodology 
of anthropology. Ethnographers often undertake participant observation when they en-
deavour to become a functioning member of a community and engage in local activ-
ities, watching carefully what others do and how they react to the ethnographer’s own 
behaviour. The purpose is to attempt to view the community from the perspective of a 
participating member, rather than as an outsider. In many situations,  non-participant 
observation is more feasible and can allow for a more systematic description of ac-
tivities, in which the observer is not directly part of the activity under study. Non-
participant observations may concentrate on an individual (for example, a pregnant 
woman), location (such as the kitchen or a water collection site), or event (for example, 
a wedding party or a market). The observer attempts to record as much behaviour as 
possible, including actions, conversations, description of the physical locale, and other 
relevant features. Focused observations often require some preliminary examination 
of the activity or location to prepare the observer. For example, the investigator may 
have a general impression of the interior of a rural house but may not know the kind 
and quantity of cooking utensils, nor how they are washed or stored. Some research 
questions require detailed observations on how a procedure is actually carried out. For 
example, how a mother mixes water with rehydration salts at home for the treatment 
of diarrhoea or how a health worker interacts with a client and/or carries out a medical 
procedure. Such observations may be used in the design of questionnaires and to con-
firm or refine data collected through interviews.
Unstructured observational activities are often carried out together with informal 
and formal interviews and group discussions. Observations and reviews of discussions 
are typically recorded in detailed field-notes, following the activity. Analysis is ongoing, 
often involving a daily review and reflection on occurrences and the way they have been 
interpreted by the ethnographer. Unstructured observation can be useful at all stages of 
the research relating to a trial, for example, in understanding how guidelines are used 
in practice by health workers, in preparation for, or the evaluation of, an intervention to 
improve clinical practice relating to a particular guideline such as treatment with anti-
malarial drugs or antibiotics. The rate-limiting step is often the availability of trained 
researchers to carry out such activities and ongoing analyses.
3.1.2 Structured observation
Structured observations involve the recording of behaviours or the outcomes of be-
haviours by trained observers, through the use of a pre-coded or partly coded data 
collection instrument. Structured observation methods can be used for continu-
ous monitoring or for spot checks on a behaviour. These approaches are used when 
the behaviours that are to be studied in detail have been identified (possibly through 
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unstructured observation), and it is clear what information is needed (for example, 
time of day, frequency, duration, and types of behaviour).
The researcher observes, as unobtrusively as possible, occurrences of events or be-
haviours. A dilemma faced by every observer is where to focus attention and what 
details to record. The data collection instruments are designed to help focus the re-
searcher’s attention on matters of greatest relevance to the research question. Predeter-
mined structure limits discovery but assures relevance and consistency. The complexity 
of structured observation instruments varies. Some studies focus on detailed descrip-
tion of one or two events of interest, breaking them into fine units of activities, noting 
who performs them where, with what tools, and for how long, as was done in a study 
of hand-washing practices in Bangladesh reported by Stanton and Clemens (1987). 
Structured observations can form part of larger ethnographic studies, which has the 
advantage that the findings can be interpreted in the wider social context, enabling a 
more careful interpretation to feed into behaviour change interventions. For example, 
Chandler et al. (2008) conducted an ethnographic study of health workers’ treatment of 
malaria, incorporating structured observations of clinical consultations within a wider 
study of the over-diagnosis of malaria in Tanzania, informing the design of interven-
tions tested in a 3-arm cluster randomized trial. Unlike most methods described in this 
chapter, structured observation may yield data amenable to statistical analysis. This 
holds potential for repeated observations to monitor behaviour change over time.
3.2 In-depth interviews
In-depth interviews usually aim to get a comprehensive understanding of a partici-
pant’s perspective, in their own words, of the issues under study. Such interviews may 
take a narrative approach whereby the interviewer aims to hear the ‘story’ of the par-
ticipant in a historical perspective, probing for more detail on areas of interest to the 
research, for example, access to maternal health care services. In-depth interviews may 
also be used to explore individuals’ ideas and concepts about particular issues, with the 
interviewer asking questions relating to specific topics identified as being of interest 
to the research objective. In both cases, a topic guide or list of questions may be used, 
as an aide-memoire, and may include specific questions that have been pilot-tested. 
The objective is to use this guide to explore the experiences and perspectives of each 
respondent, as they feel able and willing to explain themselves. Thinking of relevant 
and useful probing questions is an important skill for the interviewer who must bear 
in mind the research objective, while engaging with, and pursuing, trains of thought of 
respondents. They must be able to use new pieces of information to take the interview 
in previously unplanned, but relevant, directions. A further key skill in interviewing is 
the ability to create rapport and ensure confidentiality, such that the respondent feels 
comfortable and confident in expressing their views and experiences.
In-depth interviews take significant time to set up, carry out, transcribe (and trans-
late), and interpret. This means they can usually only be conducted with a few carefully 
selected individuals. Depending on the objectives of the study, respondents for in-depth 
interviews may be ‘key informants’ or individuals selected as representing particular 
characteristics of interest (for example, mothers who have lost a child, migrants). Key 
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informants, in the context of intervention trials, tend to be of three types: adminis-
trators/community leaders or other persons in positions of power, community-based 
health workers, and individuals in the community with specialized areas of expertise or 
experience (for example, traditional birth attendants, traditional healers). Key inform-
ants are identified through casual inquiry of formal and informal leaders and other 
pivotal community members, or through more systematic methods such as consen-
sus analysis or social network analysis (Bernard and Ryan, 2010). Informants become 
‘key’, because they are more knowledgeable, co-operative, and accessible than other 
respondents and often are interviewed on multiple occasions. They serve to inform the 
investigator about selected aspects of the culture and customs of a community and may 
be used to provide information throughout the course of the study.
3.3 Focus group discussions
Focus group discussions are a useful method for getting to know shared values and 
points of reference. Focus groups can also be a good opportunity to generate and test 
out initial ideas for an intervention, with the ability for group members to offer, modify, 
or reject ideas for introducing changes relevant to a particular health problem.
In a focus group discussion, a small group of participants (usually six to 12), under 
the guidance of a facilitator, are encouraged to talk about topics which are thought to 
be of special importance to the respondents and to the investigation. Topic guides are 
utilized by the facilitator to stimulate discussions around areas of interest. Participants 
are selected from specific target groups whose ideas and experiences are germane to 
the study. Participants in a focus group are best chosen to avoid power differentials that 
could lead to some individuals dominating the discussion. Generally, participants are 
of the same sex and age group, but similarity in other characteristics may be important, 
depending upon the research question. For example, in the case of an evaluation of a 
trial to improve maternal health services, participants may include those who took up 
the intervention and those who did not, but they should not also include the health 
workers (whether from the formal or informal sector) who provide such services. It 
is important, but difficult, to ensure that participants are comfortable with one an-
other, which may mean a natural grouping, such as a village microfinance group of 
women which may or may not be desirable as a sampling unit, depending upon the 
research question and the potential for divulgence of confidential information during 
the discussion.
For discussions to be productive, the facilitator must have skills in understand-
ing and encouraging positive group dynamics and must be able to keep in mind the 
research objectives, in order to steer the discussion to maximize time spent on mat-
ters that may be relevant to the research question. In addition to the facilitator, it is 
useful to have an observer who makes notes and is alert for non-verbal cues. This 
observer may also collect demographic data from participants and ensure they re-
ceive refreshments. If possible, a focus group discussion should be tape-recorded and 
later transcribed in full. However, if it is thought that this would unduly inhibit open 
discussion, detailed notes should be taken by the observer as close to verbatim as 
possible.
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The number of focus groups held will depend on the number of different relevant 
groups in the community of interest. Focus group sessions usually last for at least an 
hour and continue until the facilitator considers that all the participants have expressed 
their opinions adequately on the topics under investigation. Transcribing and translat-
ing focus group discussions can take a considerable amount of time, with transcripts 
typically running to 50–100 pages. Coding and analysis of such transcripts takes a cor-
respondingly long time. To make the most of this method, it is therefore important to 
think carefully about sampling, the topics for discussion, and the facilitator’s level of 
experience and familiarity with the research questions.
3.4 Participatory research
Participatory research methods aim to enable change at a local level through a process 
of sequential reflection and action carried out with and by local people. This is dis-
tinct from the other methods outlined in this chapter, which, in a general sense, can be 
considered to be carried out ‘on people.’ In participatory research, the focus is on bas-
ing research and planning on local knowledge and perspectives, situating power more 
evenly between researchers and the researched. In their purest form, participatory, or 
‘action’, research approaches do not start out with a specific intervention in mind but 
aim to respond to local priorities and needs, and aim to empower local bodies to de-
fine and develop their own interventions. This is done through a series of facilitated 
discussions, workshops, planning sessions, and activities. In health research, a number 
of trials have adopted a form of this approach, by providing a structure within which 
local actors can define their priorities and intervention methods. An example is the 
Health Workers for Change programme, a series of six workshops which aimed to ad-
dress the interpersonal component of quality of care by enabling participants to explore 
provider–client relations within a gender-sensitive context. This programme was im-
plemented and evaluated in four country contexts, in each of which the intervention 
played out differently guided by the local participants, and was found to allow difficult 
issues to be discussed openly, fostered problem solving, and helped health workers to 
develop practical plans to address problems that could strengthen district health sys-
tems (Fonn et al., 2001).
References
Ajayi, I. O., Oladepo, O., Falade, C. O., Bamgboye, E. A., and Kale, O. 2009. The development 
of a treatment guideline for childhood malaria in rural Southwest Nigeria using participa-
tory approach. Patient Education and Counseling, 75, 227–37.
Bernard, H. R. and Ryan, G. W. 2010. Analyzing qualitative data: systematic approaches. Los 
Angeles: SAGE.
Bryman, A. 2012. Social research methods. Oxford: Oxford University Press.
Chandler, C. I., Diliberto, D., Nayiga, S., et al. 2013a. The PROCESS study: a protocol to evalu-
ate the implementation, mechanisms of effect and context of an intervention to enhance 
public health centres in Tororo, Uganda. Implementation Science, 8, 113.
Chandler, C. I., Jones, C., Boniface, G., Juma, K., Reyburn, H., and Whitty, C. J. 2008. Guide-
lines and mindlines: why do clinical staff over-diagnose malaria in Tanzania? A qualitative 
study. Malaria Journal, 7, 53.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
266 CHAPTER 15: SOCIAL AND BEHAVIOURAL RESEARCH
Chandler, C. I. R., Reynolds, J. L., Palmer, J., and Hutchinson, E. 2013b. ACT Consortium 
guidance: qualitative methods for international health intervention research. Available at: 
<http://www.actconsortium.org/qualitativemethodsguidance>.
Evans, C. and Lambert, H. 2008. Implementing community interventions for HIV prevention: 
insights from project ethnography. Social Science & Medicine, 66, 467–78.
Fonn, S., Mtonga, A. S., Nkoloma, H. C., et al. 2001. Health providers’ opinions on provider-
client relations: results of a multi-country study to test Health Workers for Change. Health 
Policy Plan, 16 Suppl 1, 19–23.
Haaland, A. 2001. Reporting with pictures. A concept paper for researchers and health policy 
 decision-makers [Online]. Geneva: UNDP/World Bank/WHO Special Programme for Re-
search and Training in Tropical Diseases. Available at: <http://www.who.int/tdr/publica-
tions/documents/pictures.pdf>.
Iliff, P. J., Piwoz, E. G., Tavengwa, N. V., et al. 2005. Early exclusive breastfeeding reduces the 
risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS, 19, 699–708.
Kielmann, K., Cataldo, F., and Seeley, J. 2011. Introduction to qualitative research methodology 
[Online]. London: Department for International Development. Available at: <http://r4d.
dfid.gov.uk/PDF/Outputs/HIV_AIDS/qualitativeresearchmethodologymanual.pdf>.
Medical Research Council. 2008. Developing and evaluating complex interventions: new guid-
ance [Online]. London: Medical Research Council. Available at: <http://www.mrc.ac.uk/
complexinterventionsguidance>.
National Institute for Health and Clinical Excellence. 2007. Behaviour change at population, 
community and individual levels [Online]. London: National Institute for Health and Clin-
ical Excellence. Available at: <http://www.ncsct.co.uk/usr/pub/guidance-on-behaviour-
change-at-population.pdf>.
Nichter, M., Thompson, P. J., Shiffman, S., and Moscicki, A. B. 2002. Using qualitative re-
search to inform survey development on nicotine dependence among adolescents. Drug and 
Alcohol Dependence, 68 (Suppl), S41–S56.
Power, R., Langhaug, L. F., Nyamurera, T., Wilson, D., Bassett, M. T., and Cowan, F. M. 
2004. Developing complex interventions for rigorous evaluation—a case study from rural 
Zimbabwe. Health Education Research, 19, 570–5.
Saunders, R. P., Evans, M. H., and Joshi, P. 2005. Developing a process-evaluation plan for 
assessing health promotion program implementation: a how-to guide. Health Promotion 
Practice, 6, 134–47.
Schellenberg, J. R., Abdulla, S., Nathan, R., et al. 2001. Effect of large-scale social marketing of 
insecticide-treated nets on child survival in rural Tanzania. Lancet, 357, 1241–7.
Shagi, C., Vallely, A., Kasindi, S., et al.; Microbicides Development Programme. 2008. A 
model for community representation and participation in HIV prevention trials among 
women who engage in transactional sex in Africa. AIDS Care, 20, 1039–49.
Stanton, B. F. and Clemens, J. D. 1987. An educational intervention for altering water- 
sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized 
trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. 
American Journal of Epidemiology, 125, 292–301.
Sternin, M., Sternin, J., and Marsh, D. R. 1998. Designing a community-based nutrition 
 program using the Hearth model and the positive deviance approach [Online]. Westport,  
CT: Save the Children. Available at: <http://www.positivedeviance.org/pdf/manuals/ 
fieldguide.pdf>.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
2673: COMMONLY USED METHODS IN SOCIAL RESEARCH
Vallely, A., Shagi, C., Kasindi, S., et al.; Microbicides Development Programme. 2007. The 
benefits of participatory methodologies to develop effective community dialogue in the con-
text of a microbicide trial feasibility study in Mwanza, Tanzania. BMC Public Health, 7, 133.
Van Der Horst, C., Chasela, C., Ahmed, Y., et al.; Breastfeeding, Antiretroviral, and Nutri-
tion Study Team. 2009. Modifications of a large HIV prevention clinical trial to fit changing 
realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in 
Lilongwe, Malawi. Contemporary Clinical Trials, 30, 24–33.
Wells, M., Williams, B., Treweek, S., Coyle, J., and Taylor, J. 2012. Intervention description is 
not enough: evidence from an in-depth multiple case study on the untold role and impact of 
context in randomised controlled trials of seven complex interventions. Trials, 13, 95.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
Chapter 16
Field organization and ensuring 
data of high quality
1 Introduction to field organization and ensuring data of high 
quality 268
2 Manual of field operations and study diary 273
3 Personnel issues 273
4 Physical location and facilities 276
5 Equipment and supplies 277
6 Timetable for field activities 279
7 Ensuring data of high quality 279
7.1 Regulatory requirements and good clinical practice 280
7.2 Supervision and data checks 281
1 Introduction to field organization and ensuring data  
of high quality
The complexity of the organization of a field trial will vary, according to the planned 
size of the trial population, the frequency of follow-up, the expected duration of the 
trial, and its location. For example, a trial of the long-term effects of a hepatitis B vac-
cine in The Gambia involved enrolling a population of 120 000 infants, many of whom 
lived in remote rural areas, and linking their vaccination status to outcome events 
measured several decades later (The Gambia Hepatitis Study Group, 1987; van der 
Sande et al., 2007). Such a trial is a much more complex undertaking than, say, a trial to 
assess the immunogenicity of a new measles vaccine, involving a few hundred subjects, 
conducted in or near a major population centre and completed within a year or two.
Whether a trial is small or large, it is important to plan the organization of the trial 
in detail before starting any substantial field activities. The design of the trial should be 
reviewed to identify all the procedures and tasks that it is necessary to undertake to meet 
the study objectives, and the logistics developed to carry out these procedures and tasks 
in a timely fashion. During this planning, it may become clear that compromises have to 
be made between what is theoretically desirable and what is logistically possible. For ex-
ample, in a vaccine trial, it may be of great interest to relate the immune response to vac-
cination to subsequent protection against disease on an individual-by-individual basis. 
This would involve collecting a blood sample from all participants before vaccination, 
shortly after vaccination, and possibly at repeated intervals thereafter. In practice, it may 
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not be feasible to do this in the full trial population, for reasons of cost or because those 
in the trial population would not accept repeated blood samples being taken. Thus, re-
lating protection against disease to individual responses to vaccination might have to 
be excluded from the objectives or restricted to a substudy in selected trial participants.
A checklist of some of the most important items that it may be necessary to consider 
when planning a field trial is given in Box 16.1. Trial investigators should draw up a 
detailed and specific list tailored to the requirements of their particular trial.
It is important that the field team understands, and is sensitive to, local customs and 
cultures. This will be facilitated if many of the field team members are recruited from 
the community in which the trial is to be conducted. The planning for the trial must 
take into account cultural practices that may affect both the acceptability of the trial 
and the organizational arrangements for conducting it.
In planning the organization of the trial, it is critical to always keep in mind the over-
all objectives of the trial, as specified in the study protocol. Detailed planning should 
start at an early stage, as, once activities get under way, it is easy to ‘lose sight of the wood 
for the trees’, unless there is a clear plan of activities to refer to. A checklist that covers 
some of the most important organizational aspects of field trials is given in Box 16.2.
1 Proposed trial
•	 Title
•	 Purpose
•	 Type
•	 Population	included:	location	
and numbers involved
•	 Expected	duration	of	trial
•	 Persons	in	charge:	both	central	
and field
•	 Address,	phone/fax	numbers,	
website, and e-mail addresses of 
trial headquarters
•	 Initiate	a	field	manual	and	study	
diary to record all decisions and 
changes made during planning 
and conduct of trial (see  
Section 2)
2 Clearances: legal and ethical
•	 Local	authority	(district	health	
officers, local government)
•	 Police
2 Clearances: legal and ethical (cont.)
•	 Government—MOH—others,	as	
appropriate
•	 Local	population—informed	
consent procedures
3 Location
•	 Climate
•	 Geographical	features
•	 Maps
•	 Roads,	including	routes,	
 distance, and time taken to  
travel between survey sites in 
different road conditions
•	 River	conditions
•	 Airstrips	(where	relevant)
•	 Electricity	supply
•	 Mobile	phone	network	 
coverage
•	 Internet	access
Box 16.1 A checklist for planning a field trial
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4 Data collection and storage
•	 Type
•	 Regularity
•	 Timing
•	 Method	of	data	collection	(for	ex-
ample, pen and paper, electronic)
•	 Logistics
5 Staff requirements
•	 Functional	categories
•	 Number
•	 Existing/new	staff
•	 Training	and	support/supervi-
sion requirements
6 Accommodation
•	 Location	(survey	team,	support	
group, females/males)
•	 Tents/housing	arrangements
•	 Electricity
•	 Water
7 Supplies
•	 Immediate
•	 Replenishments
•	 Stockpile
•	 Ordering	and	recording	systems
•	 Food/cooking
•	 Water/purification
•	 Fuel	(vehicles,	electricity	genera-
tors, cooking, etc.)
•	 Refrigeration
8 Transportation
•	 Vehicles	(for	example,	cars,	mo-
torbikes, bicycles, boats)
•	 Maintenance
•	 Tools	(for	repairs,	but	also	for	dig-
ging them out of mud holes, and 
for  emergencies—such as reflec-
tive vests and emergency triangles)
•	 Spares
 9 Equipment
•	 Field
•	 Laboratory
•	 Survey	equipment
•	 Record	forms
•	 Questionnaires
•	 Computer	hardware
•	 Computer	software
•	 Stationery
•	 Chemicals
•	 Generator
•	 Waterproofing
•	 Photographic	equipment
•	 GPS	equipment
•	 Electronic	data	collection	equip-
ment (PDAs, tablet computers, 
mobile phones, etc.)
•	 Tape	recorders
•	 Mobile	phones
•	 Backup	generators	(and	backups	
for other vital equipment)
•	 Medical	care	for	staff	(for	exam-
ple, drugs and instructions for 
needle-stick injuries)
•	 Medicines	and	drugs	for	
participants
•	 Records
•	 Other	equipment
10 Specimens
•	 Receipt	and	handling	(for	ex-
ample, gloves, sharps disposal 
boxes)
•	 Pick-up	schedules
•	 Refrigeration	containers
•	 Instruction	slips	for	participants
•	 Labelling	and	other	recording	
supplies
Box 16.1 A checklist for planning a field trial (continued)
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11 Other
•	 Develop	field	manual
•	 Data	entry	equipment,	staff,	and	
systems
•	 Other	communication	equip-
ment (for example, email, Inter-
net, radio)
11 Other (cont.)
•	 Written	SOPs	for	every	aspect	of	
the trial
•	 Job	descriptions,	staff	contracts,	
and a human resource manual
•	 Bank	and	accounting	systems
Box 16.1 A checklist for planning a field trial (continued)
The activities are listed in the order in which they might be done.
Planning
◆	 Define the trial question(s), and work out the implications of these for the 
planning of the trial.
◆	 Develop the preliminary study design that includes the purpose and estimates 
of population size and duration of the trial.
◆	 Consult with MOH officials at headquarters and district levels.
◆	 Consult those with relevant experience in local district government, commu-
nity leaders, and health workers.
◆	 Visit local communities to discuss the trial, and learn about the local popula-
tion, their needs and perceptions, and how the proposed trial would fit into 
their priorities.
◆	 Choose an appropriate population sample for the trial.
◆	 Decide which observations and measurements are needed, and standardize 
the techniques.
◆	 Conduct preliminary studies (for example, qualitative, feasibility, or validation 
studies).
◆	 Design and pilot-test record forms and questionnaires (electronic and/or paper).
◆	 Make arrangements for staff recruitment, training, and supervision; secure 
equipment, transport, and finance; arrange accommodation.
Organization
◆	 Obtain co-operation from local leaders.
◆	 Develop a manual of field operations and all specific SOPs.
Box 16.2 A checklist of organizational activities for a 
field trial
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◆	 Train survey staff.
◆	 Arrange for laboratory procedures and specimen storage, both short- and 
long-term.
◆	 Draw up a daily work plan for all staff.
◆	 Pilot-test all organizational details.
During the fieldwork
◆	 Supervise and provide feedback to all staff to ensure their work is at a high 
standard throughout.
◆	 Monitor participant compliance and follow-up with representatives of the trial 
participants and local leaders if there are problems.
◆	 Make both scheduled and unscheduled checks on all study procedures.
◆	 Conduct regular staff meetings for reporting progress, discussion of problems 
and potential solutions, and for maintenance of morale.
Analysis and communications
◆	 At an early stage, develop an analytical plan for each phase or round of data 
collection, and for the trial as a whole.
◆	 Enter data into a computer, and then check and analyse it as soon as possible.
◆	 Make regular checks on the data, preferably daily, to assess quality and 
completeness.
◆	 Discuss results and their interpretation with health workers, community lead-
ers, or others (as appropriate) to obtain their feedback and comments.
◆	 Write a report, incorporating comments on the trial’s strengths and 
limitations, its results, and recommendations for new or improved health 
programmes.
◆	 Distribute the report, and discuss the trial’s findings and recommendations 
with relevant local authorities, other organizations, and with local and interna-
tional media, as appropriate.
◆	 Disseminate the trial results and policy implications, using multiple dis-
semination channels—not just the main technical report. The audiences 
should include study participants and/or their representatives locally, na-
tionally, and internationally, as appropriate, for example, through meetings, 
newsletters, press releases and/or radio programmes, peer-reviewed journal 
articles, policy briefs, on the organization’s website, presentations at confer-
ences, etc.
Box 16.2 A checklist of organizational activities for a field trial (continued)
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◆	 Take steps to try to ensure that appropriate action is taken, based on the trial’s 
outcomes, at international, national, and local levels.
◆	 Consider evaluating any changes introduced as a result of the trial to estimate 
their effectiveness.
Box 16.2 A checklist of organizational activities for a field trial (continued)
2 Manual of field operations and study diary
The tasks and procedures necessary to achieve each objective of a trial should be listed. 
A manual of field operations should be prepared, in which each procedure to be car-
ried out is detailed and each task described fully (for example, step-by-step instructions 
for the administration and completion of questionnaires, the method to be used for 
weighing infants, including maintenance procedures for the weighing scales, check-
lists for equipment, and the materials required for each procedure). Each fieldworker 
should be given a copy of the manual, or of those parts of the manual that are relevant 
to their work, and these must be updated if changes are made to procedures, as the trial 
progresses. The field manual for the trial should not only provide a clear set of rules for 
actions under different circumstances, but it can also serve as a long-term record of the 
detailed design aspects of the trial. This latter feature may be of special value in trials of 
long duration where investigators may change or they may forget previous decisions or 
the reasons for them.
In addition to the field manual, it is very valuable to maintain a trial diary, in which 
the progress of the trial is recorded, problems noted, and solutions recorded. This will 
be useful in maintaining consistency of decisions throughout the trial. These notes may 
be of value for final reports on the trial, in which documentation of particular events 
during the course of the trial may be needed (for example, recording exactly when a 
particular disease epidemic took place or when fieldwork had to stop because of ad-
verse weather conditions or civil disturbance).
To guard against loss and to facilitate the subsequent search for events of interest, it is 
recommended that the diary is maintained as a computer file with backups, rather than 
just in a paper notebook. The latest version of the field manual should also be stored 
electronically, so that it can be updated and modified easily.
3 Personnel issues
Field trials may involve a large number of personnel, often for considerable periods, 
working under difficult conditions, and the staffing arrangements must be well organ-
ized. Each person should know what they have to do and when they have to do it, to 
whom they should report, and when, where, and how they should do this. A job descrip-
tion should be prepared for each position, incorporating the tasks specified in the field 
manual. Preparing such job descriptions forces the investigator to work out in advance 
what each individual will do, and then inform each worker formally what is expected 
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of him or her. The job descriptions specify not only the tasks to be undertaken, but also 
the workload (for example, the approximate number of thick and thin blood films to be 
collected per day) and the quality of work expected. The minimum educational levels 
and training required for each position should also be specified. Personnel for the posts 
should be recruited and trained for their specific tasks, based on their job descriptions. 
Training should include an overview of the objectives and flow of the study, research 
ethics, especially related to confidentiality and relationships with study participants, 
reporting and supervision systems, personal safety and security, and training on the 
specific tasks for that position. It may also need to include training related to teamwork 
and communication skills, and information technology skills (such as the use of lap-
tops, PDAs, mobile phones, or tablet computers for data collection, or the use of GPS 
devices). Increasingly, it is expected or required that at least relatively senior personnel 
have received basic training and ideally have been certified in ‘GCP’ (see Section 7).
It may be beneficial to provide staff with initial training in more than one set of tasks, 
as this will allow easier transfer of staff between positions, if necessary. Managerial and 
supervisory activities, with appropriate hierarchical relationships and lines of author-
ity, need to be established. An organizational chart illustrating the lines of authority 
may be useful. Each staff member should be broadly familiar with the responsibilities 
of other staff. Staff should be made aware of health and safety procedures, for example, 
what to do if there is a road traffic accident or an armed robbery or someone has a 
needle-stick injury (see Chapter 17, Section 8).
The composition of the field team should directly reflect the specific activities they 
must undertake. It might include, for example, a driver, a registration clerk, one or more 
interviewers, an assistant to take temperatures and to measure heights and weights or 
to test eyes, a clinician for physical examinations and the application of any clinical 
intervention procedures, a laboratory technician to collect blood, urine, or stool speci-
mens for laboratory tests, and a medical or pharmacy assistant or nurse for dispensing 
medications. A constraint on the size of a field team may be the number of persons who 
can be accommodated in the trial vehicle, along with the equipment they must use in 
the field. It will be useful to draw up an organizational plan outlining the activities and 
functions of the members of such a team, with a diagram showing how the team will 
operate in the field. This should include a careful, and if possible, pilot-tested, estimate 
of the average and range of times that each participant is expected to take at each step 
in the field survey. Ideally, these times should be approximately equal for each step to 
avoid bottlenecks developing. To achieve this, it may be necessary to have different 
numbers of workers at individual steps in the participant flow. For example, in a follow-
up survey in an adolescent HIV prevention trial in Tanzania, the main survey team 
of 14 people included two drivers with their vehicles, a team leader, one registration 
clerk, two male and two female interviewers, a laboratory technician and laboratory as-
sistant, a nurse who supervised young women taking self-administered vaginal swabs, 
two HIV testing counsellors, and a clinician (who also did dispensing).
Detailed descriptions of the procedures to be followed for each of the activities 
should be included in the field manual (for example, how the census form should be 
completed, how the items on the form should be checked, what should be done with 
the form at the end of the day).
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
2753: PERSONNEL ISSUES
Frequent and effective supervision of field activities is essential for ensuring the col-
lection of high-quality data (see Section 7.2), but also for keeping the fieldwork mov-
ing, according to the timetable, for maintaining field team morale, and for preventing 
the escalation of any disputes or disagreements. Field team leaders have primary re-
sponsibility for the activities of their team, and they should regularly report progress 
and any problems or issues arising to the field supervisors. The field supervisors should, 
in turn, report to the project coordinator who monitors overall progress of the study 
and reports to the PIs, government officials, and funders.
Mobile phones are commonly used during supervision of field activities. For 
example, they might be used by field team leaders to provide supervisors with daily 
updates which include basic data on the number of participants seen, refusals, and 
any problems encountered via text messages or phone calls. Supervisors, in turn, 
can use mobile phones to advise and guide team leaders and to provide field teams 
with lists of participants or households to interview or re-interview. Prompt trans-
fer and data entry of completed paper questionnaires can aid supervision through 
providing early and frequent feedback to field teams on data inconsistencies or 
errors. Wireless transfer of data collected in the field to the central data section, 
either via the Internet or mobile phones, is increasingly being used and offers in-
creased opportunity for the early identification of problems with data collection 
or the interpretation of questions by participants. Such data transfer should be 
encrypted and password-protected to ensure it remains secure and confidential. 
Timely transfer of field data to the central or field trial office allows databases of 
the data collected to be kept up to date and delays or other problems can be acted 
on promptly.
It is essential that checks on data quality are incorporated into routine field proce-
dures. Examples of these are given in Section 7. It is also important to keep a close check 
on the arrangements for laboratory specimen collection, storage, and shipment back 
from the field to the base laboratory (see Chapter 17).
As a general principle, the designer of fieldwork procedures should think carefully 
of everything that could realistically go wrong and put systems in place for what 
should be done in the event that these problems occur, for example, what should be 
done if one or more team member falls ill, a vehicle or other piece of equipment, such 
as a centrifuge or freezer, breaks down, or if a national holiday is declared at short 
notice. Overcoming such problems may require staff being trained to be able to fill in 
for each other, there being two of each vital piece of equipment, or the potential for 
emergency repair or replacement of equipment. The details of what should be done 
will partly depend on the remoteness of the field work from the trial coordination 
centre.
Field teams that spend extended periods of time in the field can be prone to in-
ternal disputes and disagreements, and the importance of good team dynamics and 
team leadership should not be underestimated. In some circumstances, movement of 
staff between teams during the course of the trial can be beneficial, for example, to 
strengthen a weaker team or to improve team dynamics.
Good financial management is essential for staff morale. Salaries and allowances 
should be paid on time, and staff provided with medical insurance cover and legal 
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protection against being sued in relation to their trial work. Petty cash should be avail-
able when required. A detailed record of expenditures should be kept together with 
receipts, as a senior staff member will have to account for all funds issued and spent. 
For large studies, it will be essential to employ an administrator to take care of these 
aspects, as they may be very time-consuming. Systems must be put in place to prevent 
fraud, and staff should be made aware of the policies regarding accountability when 
equipment or supplies go missing or are stolen (see Chapter 18).
4 Physical location and facilities
An issue to be resolved early in the planning of a field trial is whether the study partici-
pants should be seen at a central location, at a series of local assembly points, or be visited 
on a house-to-house basis. The decision will depend upon the procedures to be carried 
out, the nature of equipment required, the time the study procedures take, the popula-
tion size, density, and distribution, and the environmental and physical conditions.
A central assembly point may be most efficient for the study team, since more people 
can be seen in a day than in a house-to-house survey. If heavy or delicate non-portable 
equipment must be used, then a central assembly point cannot be avoided. Even if some 
of the data collection or physical or laboratory examinations have to be done at a cen-
tral location, it is often advisable to conduct the census, and sometimes questionnaire 
interviews, at the houses of participants.
One advantage of a house-to-house survey is that it is possible to be reasonably sure 
of being able to compile a list of most of those who are eligible for the trial. Any persons 
who do not report to a central assembly point can then be identified, and, if necessary, 
attempts made to find them. Individuals who are not present during the home visit 
might be able to attend the central assembly point at another time. Tracing those miss-
ing can be costly and time-consuming, and decisions about the benefits of doing this, as 
compared to the time and effort required to visit individual households, need to be con-
sidered in the planning phase. Also, the likely magnitude of ‘non-response’ may need 
to be estimated during the pilot phase (see Chapter 13). Sometimes, a combination of 
both approaches may be suitable, whereby someone visits each household to conduct 
a household census and identifies all potentially eligible individuals who are given an 
appointment to go to a central location for the actual data collection.
Careful planning of the physical layout for the flow of people from one part of the 
field station to the next is important. Special attention may have to be given for carry-
ing out the physical examination, in order to ensure both privacy and adequate light. 
Usually, there is little difficulty about making such arrangements when the examina-
tions are conducted at a central assembly point, but, for more mobile surveys, special 
arrangements may be necessary, ranging from simple screening under a shady tree to 
the use of a tent with special lighting.
In addition to whatever arrangements are made for the interviewing, examinations, 
and specimen collection from study subjects, there are supporting functions that will 
require physical facilities. These include a headquarters for administration; a room for 
team training courses, meetings, and review of activities and problems on a daily basis; 
space for computer processing of data; file storage space; laboratory accommodation; 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
2775: EQUIPMENT AND SUPPLIES
stores for equipment and supplies; and transport garaging. The various components 
may be needed at one place or at several places or may need to be mobile.
If the field team must live away from home for long periods, they may be able to obtain 
local accommodation, but other accommodation might have to be provided (for example, 
tents). Accommodation and cooking facilities should be arranged in advance, and employ-
ment of a cook will save on staff time and improve staff morale (if the cook is good!). Food 
may need careful storage and cooking, in order to avoid food poisoning. Water for drinking 
may need to be purified, filtered, or boiled. Refuse disposal and toilets may also be needed.
Where the field teams will use electrical equipment for their activities, a reliable 
source of electricity will be required. Even if there is a normally reliable local electricity 
supply, some form of backup supply should be considered. In some cases, using solar 
power or project vehicles to charge equipment may be sufficient, though it is usually 
wise to have an additional backup source such as a portable generator. In some places, 
there will be no local mains electricity, and then it is essential for the team to have 
their own electricity supply and strongly advisable to have a backup for that too in 
case of malfunction. Similarly, ease of access to the Internet and the quality and extent 
of mobile phone network coverage should be taken into account if field teams will be 
expected to communicate with headquarters in these ways.
5 Equipment and supplies
The major items of equipment and reagents required must be specified in the study proto-
col. The choice of what technical equipment to buy should be influenced by what the investi-
gators or others in the field have used and whether it has been found to produce valid results 
and is reliable in the specific field contexts required (and this will include servicing arrange-
ments). The power requirements of electronic equipment should be considered prior to 
purchase. Some equipment and supplies may need to be pre-ordered from abroad, as they 
may not be available locally, so considerable pre-planning may be required. This is likely to 
be particularly relevant for the clinical and laboratory equipment and supplies (see Chapter 
17). It may be important to order a basic supply of spare parts at the same time as ordering 
equipment, if local availability is in doubt. Purchasing of equipment and supplies locally 
can be open to many kinds of fraud (see Chapter 18), and steps should be taken to ensure 
not only that a fair price is obtained, but also that the goods are genuine and of high quality.
The field manual should include lists of all the equipment required for each of the trial 
procedures (for example, record cards, questionnaires, needles and syringes, laboratory 
supplies) and for the support of those procedures (for example, vehicles, filing cabinets 
and files, benches, screens, tents). Providing ‘packing lists’ to individual team members 
and checking that they have all the items on their list prior to departure from headquar-
ters each day can reduce the number of requests from the field for additional supplies. 
Systems need to be put in place to ensure that maintenance and quality control of equip-
ment is carried out, according to a standard schedule. Some laboratory equipment will 
need standardization, validation, servicing, and revalidation (see Chapter 17).
Provision for transport is essential in most LMICs. One of the most expensive items 
of equipment are trial vehicles, so the decision as to whether to purchase or hire them, 
and, if purchasing, whether to buy new or second-hand, requires careful consideration 
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and price comparisons. Key issues are not only the capacity, purchase price, or daily 
hire price, but also fuel consumption, type of fuel and its local availability and price, 
and vehicle maintenance and reliability. It is a false economy to purchase a cheaper 
vehicle if it is more liable to break down, losing days of work, while it is repaired or 
dug out of the mud. It is also important to check whether the funding agency imposes 
restrictions on which vehicles can be purchased or how vehicles should be disposed of 
at the end of the trial.
Transporting people and equipment will require careful planning. Extra time should 
be allowed for possible mishaps. If possible, backup transport should be available in 
case of emergencies. Maintenance of vehicles and close supervision of their use are 
essential. Control and discipline of vehicle use are key factors in the conduct of almost 
all field trials. Particular problems may arise if field staff are issued with vehicles (for 
example, motorcycles) that they keep at home, rather than return to a central parking 
place on a daily basis. When staying overnight in the field, all vehicles should be parked 
overnight in a secure site, such as the guesthouse or hotel where the team are staying 
where there is a security guard. If necessary, a guard should be hired for this purpose.
Great care should also be taken in hiring drivers, and a practical driving test that 
includes a section that mimics difficult field conditions should be included. It is impor-
tant to remember that having a good, safe driver could not only save considerable time 
wasted through breakdowns or getting stuck in mud, but may also save the lives of field 
team members. Linked to this, strict rules as to who may and who may not drive the 
trial vehicles and for what purposes should be specified and enforced.
Maintenance, fuel supply, and the use of vehicles for purposes other than those for 
which they were intended can pose substantial problems. Careful monitoring of vehicle 
fuel consumption is essential, as it is not uncommon for drivers to supplement their 
income through fuel fraud. Common tricks include having an agreement with the fuel 
supplier that the receipt will show a larger volume of fuel than is actually given, siphoning 
off fuel, or unauthorized use of the vehicle (for example, as a taxi). Although each such 
theft only costs the project a relatively small amount, fuel often accounts for a substantial 
proportion of the non-staff recurrent costs of a field trial, and the losses can quickly add 
up to a sizeable amount. As well as each vehicle having a logbook with each journey 
requiring signed authorization by a senior member of staff, other useful techniques for 
minimizing fuel fraud is to allocate each vehicle to a single driver, with checks on prior 
fuel consumption carried out whenever the vehicle passes from one driver to another, 
and regular checks of fuel consumption, with the record being from full tank to full tank.
Illicit exchange of vehicle parts by vehicle mechanics is also not uncommon, either 
with or without the driver’s knowledge. Again, this can be minimized by selecting a 
reputable garage and, if necessary, marking key vehicle parts. Vehicle theft can jeop-
ardize a field trial, so, where possible, it is very important to fit vehicles with a satellite 
tracking device, an immobilizer, and a gear-locking device.
Of all vehicles, motor bicycles are the most dangerous. They are often driven by 
fieldworkers who are young men who enjoy the status that the motorbicycle gives 
them and may be prone to showing off. Very strict monitoring of their use is essential. 
All the rules given above should apply to motorbicycle, as well as other trial vehi-
cles, plus all motorbicycle users (drivers and their passengers) should always wear a 
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full-face helmet. Motorbicycles are less stable, particularly in muddy or sandy condi-
tions, when carrying two (or more!) people, rather than one, so this should be avoided, 
whenever possible.
Loss of other stores and supplies can also be a major problem, particularly due to 
theft. A staff member at the trial base should be appointed to be solely responsible for 
all the stores, maintaining inventories and issuing items. Each item issued should be 
signed for by an individual team member who should also be expected to sign the store 
inventory book upon return of the item. Transferring equipment between team mem-
bers in the field should be discouraged and, if necessary, should be accompanied by 
documentation signed by both team members. Staff should be provided with an SOP 
for equipment, which includes instructions on the correct use, storage, maintenance, 
and charging of the equipment. Staff need to know what to do when equipment is lost or 
stolen or stops working properly. It is advisable to provide field teams with extra backup 
equipment. If this is not possible, such as for large or expensive laboratory equipment, 
plans should be in place to deal swiftly with breakdowns.
6 Timetable for field activities
An organizational timetable should be constructed which shows all of the field activi-
ties and indicates when each will be undertaken. An example of such a timetable, for 
a trial of the effect of regular vitamin A supplementation on episodes of diarrhoea and 
respiratory infections, is shown in Figure 16.1 (Betty Kirkwood, personal communi-
cation). The dates for fieldwork may have to be fixed some time in advance. The time 
required for preparations and pilot testing may overlap with training, but all three must 
be completed before the start of the main fieldwork. Similarly, analysis and consulta-
tions should be completed, before the final report is produced.
The planning of trial activities must take account of climatic and seasonal factors. 
These may affect access to the trial area (for example, flooding) and the activities of 
those in the area such as to make them difficult to survey (for example, seasonal migra-
tions for work, working on farms during the planting or harvesting seasons). It may 
be important to plan activities to take into account market days, local holidays and 
festivals, and activities of the local medical services (for example, antenatal clinics). 
Also, adequate plans must be made to allow for staff leave (both annual leave, sick-
ness absences, and compassionate leave such as to attend funerals or to look after a 
close relative). The timetable should fit into local practices, if possible (for example, in 
Muslim countries, if most people do not work on a Friday, the trial should be planned 
to fit in with this).
7 Ensuring data of high quality
To be able to derive reliable and accurate conclusions from a health intervention trial, 
it is important to ensure that all processes and procedures, at all stages in the conduct 
of the trial, are performed at high quality. The many steps involved in planning and 
carrying out trials are described in the other chapters of this book. Here, we focus on 
the actions needed to ensure that all data collected are of high quality and that this 
high quality can be demonstrated both to those directly involved in the trial and to 
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all those external to the trial but who have responsibilities or interests in relation to 
the trial. The general principles and some of the terminology that is commonly used 
related to what is called ‘Good Clinical Practice’ or ‘GCP’ will be described, but this 
chapter is not a GCP manual. Investigators who require formal training in GCP should 
contact a local internationally accredited institution that offers such training or one of 
the many internationally accredited online courses that are available from groups such 
as the Clinical Research Network of the United Kingdom (UK)’s National Institute for 
Health Research (<http://www.crncc.nihr.ac.uk>) or the OnlineGCP Group (<http://
www.onlinegcp.com>).
If high-quality data are to be achieved, the investigator and all of the trial team must 
accept the need for rigour in the collection of all data and in the checks built into every 
step of the trial.
7.1 Regulatory requirements and good clinical practice
The ICH (1996) (<http://www.ich.org>) is an internationally accepted set of standards 
that are intended to apply to all research on human subjects. It is mainly applied in the 
Year 1 Year 2 Year 3 Yr 4
Month J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M
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Detailed analysis
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sponsors & MoH 
Figure 16.1 Example of an organizational timetable for a field trial.
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context of trials of medicinal products, but increasingly there is an expectation that obser-
vational epidemiological studies will be conducted to a similar standard. The aim of the 
guidelines is to ensure the safety and rights of all participants in the research study, while, 
at the same time, ensuring that the study is likely to achieve valid and reproducible results.
Based on the ICH–GCP guidelines, regulatory bodies, such as the US Food and Drug 
Administration (<http://www.fda.gov>) and the European Medicines Agency (<http://
www.ema.europa.eu/ema>) have set out a rigorous series of procedures and checks that 
must be followed in clinical trials of new drugs and vaccines to provide the standard 
of evidence necessary for the licensing of a new product. There is a widespread mis-
conception that all trials (including field trials of social or public health interventions 
or of alternative delivery mechanisms for licensed drugs or other medical products) 
must meet all requirements of such regulatory bodies—often called being ‘fully GCP- 
compliant’. This is not the case, and some flexibility is appropriate as to exactly how 
closely the GCP guidelines are implemented for non-licensing trials (i.e. of an interven-
tion for which a licence is not being sought from a regulatory agency). However, all tri-
als should comply with the basic principles contained within the ICH–GCP guidelines. 
The basic principles are that all studies involving human subjects should be conducted 
ethically (including that the interests of participants should be central to the trial design 
and implementation) and that all data collected should be of high quality and be likely 
to be valid. Furthermore, the investigators must be able to demonstrate that both these 
fundamental principles have been met. A trial can comply with the principles of GCP 
without meeting all the regulatory requirements for the licensing of a new product. 
This is important, since the full regulatory requirements are very demanding and will 
greatly increase the cost and human resources required. At an early stage in the plan-
ning of any trial, and certainly before any proposal is submitted to a funding agency 
or ethics committee, the PI and sponsor must make a clear decision as to whether 
their proposed trial needs to be ‘fully GCP-compliant’. As discussed in Chapter 2, 
many field trials in LMICs do not test investigational products but test the effectiveness 
of alternative delivery strategies for licensed products, or test interventions that do not 
include any medicinal products at all, such as trials of health promotion or other public 
health interventions.
The key individuals and institutions that have responsibility for ensuring that a trial 
is complying with the principles of GCP have been defined in Chapter 7. The trial spon-
sor has overall responsibility for all aspects of the trial; the PI has primary responsibility 
for ensuring that the trial is carried out according to protocol; and the ethics committee 
(sometimes called the Institutional Review Board (IRB)) has primary responsibility for 
monitoring the ethical aspects of the trial. To ensure trial data are of high quality, the 
sponsor ‘should determine the appropriate extent and nature of monitoring which should 
be based on considerations such as the objective, purpose, design, complexity, blinding, 
size, and endpoints of the trial’ (International Conference on Harmonisation, 1996).
7.2 Supervision and data checks
Although, in some large trials, someone is designated to be the overall quality manager, 
the entire trial team should have data quality at the forefront of their minds. From the 
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start, the investigator should assign quality assurance tasks to the team and build qual-
ity assurance (QA) processes into the trial procedures.
The two key principles for obtaining high-quality data are to plan ahead and to check 
everything. Nothing should be taken on trust, and, while remaining optimistic, it 
should be assumed that anything that could go wrong might go wrong!
Key issues in data quality are covered in other chapters: clear case definitions and 
valid measures of all trial outcomes in Chapter 12; preliminary studies and pilot 
tests in Chapter 13; questionnaire design, selection, and training of fieldworkers in 
Chapter 14; and some of the checks that can be done on the quality of the data col-
lected are given in Chapter 20. In this chapter, we focus on steps that can be taken 
once fieldworkers have been deployed at the end of their initial training to ensure 
both that the data that they collected is of high quality and that this high quality can 
be demonstrated to external trial auditors. Most of these activities fall under field 
supervision.
In successful field supervision, prevention is better than cure. A supervision system 
should be designed not only to detect problems and provoke responses to solve them, 
but also to prevent problems from occurring in the first place. For example, if field-
workers know that every piece of data they collect might be checked but have no way 
to know which pieces will actually be checked, they are more likely to always be care-
ful. Conversely, if the fieldworker knows that only data collected on a Tuesday will be 
checked, then he or she may be less conscientious on other days.
Also, it is important to institute a system for checking all data collected, and espe-
cially data critical for identifying and linking data on the same individual throughout 
the trial. Examples of checks that should be built into field supervision include checks 
of completed forms, observation of work, replicated collection of a sample of data, 
checks without repeated data collection, review of errors detected after data collection, 
and checks with participants and community representatives.
The record forms that each fieldworker completes should be checked for accuracy 
and completeness. Because of delays between data collection and entering the data into 
a computer, if paper forms are used, some preliminary checks should be done before 
the forms are submitted, while the fieldworker is still in the vicinity of the participant, 
and before the participant’s situation may have changed. When the data are directly 
entered electronically, checks for data completeness, range, and consistency can be in-
corporated into the data capture program.
Each fieldworker should receive regular scheduled visits from their supervisor, dur-
ing which the supervisor observes them carrying out their routine data collection tasks 
and gives them constructive feedback and a chance to discuss any issues that they have 
faced. These scheduled visits should be particularly frequent during the early phases of 
the trial. Observation tests whether the fieldworker knows how to carry out their tasks 
(competence) and can do so when being observed, and provides an opportunity for the 
supervisor to identify and correct any problems with their understanding of how the 
data should be collected. For example, they may have misunderstood how to measure a 
child’s height or may not be asking questions exactly as they are written in the question-
naire. However, it does not show whether they actually do so when they are not being 
observed (performance) (see later in this section).
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Throughout a survey, it is important to monitor the performance of each interviewer 
and to institute corrective training, if required. One means of quality control (QC) is to 
organize for a proportion of respondents (selected at random) to be re-interviewed by 
another interviewer. Discrepancies in the two interviews may identify deficiencies in the 
interview methods of one or other interviewer. It is not an uncommon experience in large 
surveys that some interviewers complete some questionnaires without ever having seen 
the ‘respondents’. A good system of checking, supervision, and QC is necessary to prevent 
this, or at least to detect it soon after it occurs, so that remedial action can be taken.
To check whether the fieldworker actually collects the data correctly when not being 
observed, unscheduled checks need to be implemented. For example, in a field trial of 
vitamin A supplementation in northern Ghana, each fieldworker received unsched-
uled, as well as the scheduled, visits from the supervisor, who would ask permission to 
sit in on any interview that was happening or about to happen when they arrived and 
then collect the forms that the interviewer had completed earlier that day. These would 
be sealed in an envelope in front of the fieldworker. The supervisor would then go back 
to the previous five households that had been visited that day. In two households, they 
would merely ask the household whether the fieldworker had actually visited them, 
conducted an interview with an appropriate person, and taken the appropriate bio-
logical specimens from them. This checked that the fieldworker was not fabricating 
the data. In the other three households, they would request an independent partial re-
interview of the trial participant. When they returned to the trial office, the supervisor 
would then submit their own forms and the original forms collected by the fieldworker, 
and the data centre would generate a comparison of the two.
Various checks can, and should, be carried out after data collection. For example, 
all data incompleteness (for example, missing items on the questionnaire) or variables 
that are out of range (for example, an infant’s weight being recorded as 100 grams) or 
inconsistent (for example, a woman recorded with penile warts or a person recorded 
with fever in one part of the questionnaire but afebrile in another) should be identified. 
It is useful for all such errors to be tabulated on a regular basis by the fieldworker and 
the field team. Such tabulations will show which fieldworkers or field teams have more 
errors detected. The reasons for these can then be investigated, and steps put in place to 
rectify them. One method that has been used for this has been to send data queries back 
to the fieldworker. For example, if a check shows that a participant’s height is lower than 
it was in a previous study round, the fieldworker can be asked to go back to collect that 
participant’s height again. Ideally, the fieldworker should not be told why they are being 
asked to re-collect the height, let alone what they had entered the height as during their 
recent visit or during the previous round. In the field trial of vitamin A, this method 
was extended, so that each fieldworker received some such requests, even when there 
was no reason to suspect an error in the data. These checks occasionally identified er-
rors that were not detectable by routine range or consistency checks.
Finally, it is important that the trial team has periodic meetings with participants or 
their representatives and with other members of the trial communities to check that 
they are happy with the activities of the fieldworkers and their supervisors.
An important principle is that every error or problem that is detected should provoke 
a response. This is for two reasons. First, if errors are not investigated and acted on, the 
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effort of detecting them is wasted, and also the field staff may interpret this to imply 
that the importance of data quality is being neglected. Second, since it is never possible 
to check every piece of data collected, any errors that are detected are likely to be the 
‘tip of the iceberg’.
The actions taken when errors are detected should not generally be punitive but 
should include support and further training to help the fieldworker improve. However, 
if this fails to correct the problem, or if the errors have come about through data fabri-
cation, disciplinary mechanisms should be in place, and ultimately these may need to 
include termination of employment.
It is important that field staff are aware of all the types of checks that will be con-
ducted on the data they collect. This is partly to avoid their feeling that they have been 
spied on behind their backs, but also so that they will be encouraged to ensure that all 
data are collected as well as possible.
It is a good plan to have weekly fieldwork meetings which include reports from in-
dividuals, on progress, work accomplished, identified problems and how they were 
solved, queries, etc. This also provides an opportunity for systematic feedback from the 
central administration on fieldworker performance, including results of repeat inter-
views for quality checks. Meetings of this kind may greatly assist in maintaining staff 
morale and improving the quality of the data collected.
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1 Introduction to field laboratory methods
Laboratory tests may provide the definitive basis for the measurement of outcome vari-
ables in field trials, either directly by demonstration of the presence of the pathogenic 
agent under study or indirectly by demonstration of a host reaction or of biochemical 
changes due to the pathogen. They may also provide evidence of the mechanism of 
action of the intervention, for example, directly by measuring the drug or metabolic 
by-products or indirectly by measuring an immune response to a vaccine. In addition, 
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they may be used to detect or confirm the presence of adverse reactions and prior ex-
posure to an agent or to antimicrobials.
Rigorous laboratory process is crucial to the generation of good-quality data and may 
be important to ensure the safety of trial participants. Laboratories participating in tri-
als are expected to adopt the Good Clinical and Laboratory Practice (GCLP) guidelines, 
which govern the conduct of clinical trials globally (Stevens, 2003; World Health Organ-
ization, 2009). GCLP provides a framework covering the spectrum of laboratory stud-
ies, from planning to analysis and storage of specimens and archiving of data. The WHO 
publication documents a set of minimum requirements for laboratory involvement in 
clinical trials, including the use of standard operating procedures (SOPs), monitoring, 
quality control (QC), and external quality assurance (QA) arrangements (World Health 
Organization, 2009).
The organization and operation of a field laboratory for the support of a field trial are 
different from those of a routine medical laboratory and have become more demand-
ing in recent years. Laboratory accreditation (see Section 6) may be necessary when 
laboratory data are required for the process of product licensure. In field trials, the em-
phasis is often on the collection and processing of large numbers of samples, on which 
only a few specific tests will be performed. Aliquots of samples are usually required, so 
that different aliquots can be used for different tests, for storage as backup specimens, 
and for shipment for further analysis. Storage of specimens with computerized records, 
including electronic monitoring and bar coding, has been introduced, even in field 
laboratories in rural settings.
General aspects of the setting up and running of a field laboratory are discussed 
in this chapter. Other literature should be consulted for information on specific labo-
ratory tests and specific laboratory methods. Useful general texts containing relevant 
information for the operation of a field laboratory and for collecting specimens include 
Cheesbrough (1987), World Health Organization (2003), and World Health Organiza-
tion (2009). See also Chapter 16.
2 Sample collection
Accurate laboratory results depend on proper collection, processing, and handling of 
samples. The method of collection, timing, and handling of samples will be determined 
by the purpose of the trial and specified in the trial protocol. Careful attention must be 
given to the quantity and quality of samples, aseptic precautions, and prompt transport 
of samples and their processing and storage in the laboratory. Advances in technology 
and analytical chemistry have led to the development and use of direct testing in the 
field, using point of care (POC) diagnostics, and rapid diagnostic tests (RDTs) have 
been introduced in some areas.
2.1 Types of specimen
The kinds of specimen that are commonly collected in field trials include:
◆	 specimens from humans, including blood, stool, urine, sputum, skin snips, and 
other tissue biopsies, and swabs or smears collected from skin or mucosal surfaces
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◆	 entomological specimens for studies of vectors, and animal or malacological 
specimens for studies of intermediate hosts
◆	 food, water, and environmental samples.
In this chapter, we discuss only specimens collected from humans, though many of 
the issues (such as the use of sterile techniques) apply to the other types of specimen.
2.2 Handling specimens
The collection of samples for laboratory studies will usually involve the steps outlined 
in Box 17.1.
The procedures for collecting and processing samples must be unambiguously speci-
fied, including to where they are to be transported and how they will be labelled. When-
ever required, the type of shipment must be specified, for example, in dry ice or liquid 
nitrogen. If samples are to be transported by air, safe shipment of samples is mandatory, 
and procedures must follow the International Air Transport Association (IATA) guid-
ance for infectious substances and diagnostic specimens, which detail packaging and 
shipment methods. Each package must contain a primary and a secondary container, and 
both of these must be leak-proof to avoid accidental spillage during transport. The whole 
process must be performed only by trained staff, whose competence has been certified. 
The regulations governing the transport of potentially hazardous samples are designed to 
ensure that samples reach their destination in good condition and to eliminate exposure 
of those handling the shipment to any potential hazard. Prior communication with the 
recipient and tracking information are vital, in order that shipments can be dealt with 
promptly on arrival. On occasion, this may require staff to receive the specimens outside 
normal working hours to avoid the specimens sitting around and deteriorating.
All aspects of the collection, transport, and processing of samples must be pilot-
tested. Often, much attention is paid to the proper design and testing of questionnaires, 
but much less care is taken to finding the most appropriate and culturally acceptable 
methods for the collection of blood, stool, urine, or tissue samples. Yet, this may be cru-
cial to sustained community involvement and participation (see Chapter 9, Section 5).
1 Collection of specimens from the study participants.
2 Placement in a suitable container.
3 Labelling of the container.
4 Temporary storage at an appropriate temperature.
5 Initial processing (for example, serum separation from whole blood), with 
appropriate re-labelling.
6 Transport to intermediate or final destination for further processing, testing, 
and storage.
Box 17.1 Steps involved in the collection of samples  
for laboratory studies
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2.3 Blood
The usual methods by which blood is collected in field surveys are by venepuncture 
or by finger- or heel-pricks, depending on the nature of the investigations required. 
If small quantities of blood are required, finger-pricks are usually taken from adults, 
with heel-pricks more commonly used in infants and young children, whose fingers 
are very small and whose heels do not yet have calluses. A finger-prick provides an ad-
equate volume of blood for many laboratory tests. Micro-techniques are to be preferred 
whenever they have acceptable validity, as they either avoid the need for venepuncture 
altogether or reduce the volume of blood that is needed. Micro-techniques have been, 
or are being, developed for many assays, and investigations should be conducted before 
a study starts to find out the latest availability of such techniques (for example, by litera-
ture search or contact with those in a central or reference laboratory). It is important to 
verify that the methods have been adequately validated. Some tests require larger quan-
tities of blood, however, and it will often be necessary to collect blood by venepuncture 
from at least a sample of the population.
After collection, blood may be separated into several components, including serum, 
plasma, red cells, and white cells. The separation must be done shortly after the blood 
has been collected, and it is common for this procedure to be carried out close to where 
the samples have been collected or in a nearby field laboratory.
A sample of blood taken from a finger-prick may be collected in one of several ways, 
including:
 1 collection into capillary tubes, for example, narrow glass tubes, by capillary ac-
tion, or microtubes by gentle squeezing of the finger
 2 dropping onto a glass slide for direct examination of a blood smear
 3 dropping onto strips or discs of absorbent paper (filter paper).
Fingertips are swabbed with alcohol before pricking, and the first drop is wiped off. 
Sufficient blood can be obtained for two thick, and two thin, malaria smears to do one 
or two haemoglobin level measurements (for example, with the Haemocue® system or 
the older haematocrit tubes), to collect 50–100 microlitres of blood in a microtube or 
Microtainer® for serum, and to place a drop on filter paper (World Health Organiza-
tion, 2003). Filter paper samples need to be air-dried, before storing with silica gel. 
Tubes with plasma or serum can be stored on dry ice, in a freezer, or in liquid nitrogen. 
The amount of plasma or serum recovered from a finger-prick sample will be sufficient 
to perform serological tests, such as enzyme-linked immunosorbent assay (ELISA) or 
Multiplex® assays, and is sufficient for the determination of some micronutrients such 
as vitamin A or zinc (minimum serum requirements of 25–40 microlitres). Establish-
ing volume requirements for the tests to be conducted is a prerequisite.
If repeated blood sampling is to be undertaken from participants during the course 
of a study, it is likely to be more appropriate ethically, and easier to maintain the co- 
operation of most study populations, if finger-prick, rather than venous blood, sampling 
is used. While filter paper samples are satisfactory in many cases, the larger sample vol-
umes from venous sampling are currently needed for some tests (for example, tests for 
cell-mediated immunity, human leucocyte antigen (HLA) typing, bacterial cultures). 
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A variety of systems using an evacuated tube, such as Vacutainer® or Vacuette® collec-
tion tubes, and blood culture bottles are suitable for this purpose. For repeated sam-
pling, it is also essential to provide feedback to the individuals involved, and to the 
community if appropriate, about the earlier results (see also Chapter 9).
If multiple types of collection tubes are to be used, the order of draw should be writ-
ten into the SOP to minimize cross-contamination of tube additives.
Special care in handling and processing samples is needed if any DNA-based work 
is to be conducted, as the potential for cross-contamination between samples is high. 
Blood for bacterial cultures is collected by venepuncture and delivered directly into 
blood culture bottles containing bacterial growth media, before incubation in the labo-
ratory in either a conventional incubator or an automated incubator system such as the 
BACTEC® series. Blood for immunological and genetic analysis can be collected as 
whole blood and stored in specialized tubes such as PAXgeneTM or TempusTM or, when 
only small volumes are available, as spots collected on filter paper for later analysis in 
a specialist laboratory.
Special precautions should be taken when collecting blood. Disposable gloves should 
be worn, a sharps box provided, and water and detergent should be available for use 
by those taking blood. All blood samples should be considered to be potentially infec-
tious, and appropriate handling procedures must be employed to safeguard all those 
who will come into contact with the specimens during their collection, processing, 
analysis, or storage (World Health Organization, 2004). Guidelines and drugs should 
be available for use in the event of a needle-stick injury or blood spillage.
2.4 Cerebrospinal fluid
Collection of cerebrospinal fluid (CSF) requires lumbar puncture, which must be per-
formed by a clinically trained member of staff with prior supervised experience. Using 
aseptic techniques, CSF should be collected into a sterile container for prompt transfer 
to the laboratory for biochemical and microbiological analysis. An obviously ‘bloody’ 
sample may compromise the laboratory results, especially from biochemical analyses.
2.5 Stool and urine
A summary of different methods that may be used for collecting urine and stool samples, 
with details of different container types, is given in World Health Organization, 2003. The 
methods considered for use in a particular survey should be discussed with those knowl-
edgeable of local customs and taboos. In some cultures, sensitivity regarding the collec-
tion or public display of stool specimens may be greater than that for blood. A container 
that is technically appropriate may not be acceptable in a particular study community 
(for example, due to colour, transparency, or resemblance to a cultural design or pattern). 
In advance of a survey, the proposed stool and urine containers should be shown to the 
village leaders, and the proposed methods of sample collection discussed. As with all 
field procedures, it is important to undertake pilot testing to ensure that the procedures 
planned will be acceptable (both to the investigator and to the study population).
As stool samples can rarely be collected ‘on the spot’, it is usually necessary to leave 
the container with an individual overnight and to arrange to pick up the specimen on 
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the following day. A potential hazard in doing this is that containers may be exchanged 
between individuals or, for example, one person may provide a sample for the whole 
family. It is difficult to rule out this possibility, but it is important for fieldworkers to 
stress the importance of participants adhering to the correct procedures and to be alert 
to possible problems.
2.6 Sputum
The WHO manual (World Health Organization, 2003) gives a concise description of 
recommended methods of collecting sputum samples, using different kinds of jars, 
boxes, and containers, including transport media. Two general points merit special 
attention:
 1 all sputum samples should be considered potentially infectious
 2 careful attention should be given to the cold-chain requirements if sputum sam-
ples have to be sent to another laboratory for culture.
3 Labelling and storage
3.1 Labelling
Proper labelling of samples is essential. The labelling scheme should be as simple 
as possible, consistent with the study objectives, and must take due account of the 
size of containers and how the specimens will be handled, transferred, and stored. In 
most cases, computer-generated, self-adhesive, pre-printed labels, with the individ-
ual identification or code numbers duplicated on data sheets, can speed processing. 
Also, labels in a variety of materials suitable for differing storage conditions, and with 
each number duplicated several times, are available commercially. Bar codes for spe-
cimen containers that can be read automatically by bar code readers are also available 
commercially.
The information recorded on a label will vary, according to particular requirements. 
It may include a unique identification number assigned to a study participant, which is 
utilized during laboratory processing and which may be linked back to an individual 
by reference to records kept at the time the sample was taken. In some circumstances, it 
will be appropriate to include on the label a record of the date of collection, the type of 
specimen, if not evident, and possibly the location (for example, name of the village). 
Individual names may also be recorded on the label, but this can create problems with 
blinding and confidentiality, and often names are not a unique identifier, as several in-
dividuals may have the same name.
Containers should usually be labelled using waterproof marker pens (but see item 1 
in Box 17.2), writing directly onto the container-labelling area or onto adhesive labels 
attached to the container. If the container has a cap, the marking should be on the body 
of the container (and possibly on the cap as well, but never on the cap only). For smaller 
micro- or capillary tubes, an adhesive label with the identification information on it 
can be wrapped around a container with the two ends joined, such that they protrude 
(sometimes known as a ‘flag’). Flags can be written on with a waterproof marker pen, 
and tubes may be stored in labelled envelopes, as they are collected in the field.
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If smaller tubes are stored in boxes that are too large for them, staff need to be careful 
to record and maintain the correct numbering and not to invert or tip the box, so that 
they can fall out and move around in the box. Packing with cotton wool will help to 
keep the tubes in place in a box, and tape can be used to secure the lid.
Filter paper can be written on either directly or on the protective cardboard surround.
It is not possible to recommend a single standardized form of labelling for different 
sample containers that will be appropriate in all circumstances. It will be necessary 
in a particular study to establish, through field testing, a method that guarantees the 
reliability of the labelling from the time the sample is first collected, through trans-
portation, processing, analysis, and storage. Using sets of labels with series of iden-
tical numbers on them, for coding samples and associated record forms, reduces the 
chances of labelling errors.
Some warnings regarding labelling and storage are given in Box 17.2.
3.2 Storage
The storage area of a field laboratory should be designed to be adequate for the studies 
to be conducted. This will require estimation of the rate at which samples will be col-
lected and processed and for how long they must be stored before being transported 
on to another location (for example, for processing or long-term storage in the base 
laboratory). Serum and plasma samples should be frozen as soon as possible after sepa-
ration, and storage in a field laboratory at −20 °C is adequate for most purposes, at 
least for several weeks, although some tests require immediate storage at −70 °C. The 
location and positioning of any fridges, freezers, and liquid nitrogen containers need to 
take account of access, power supply, and consistency of ambient temperature. Specifi-
cally designed freezer rooms with conduits to vent air from the freezer exhaust exter-
nally are often a good option.
Stool, urine, and tissue samples may be stored under various conditions, using ap-
propriate fixatives and stabilizers; different possibilities are summarized in World 
Health Organization (2003).
1 If the transport cold chain includes a stage where samples are frozen in salt–
alcohol mixtures, never use felt pens (even waterproof ones). Always use 
ordinarily pencils or pre-printed highly adhesive labels.
2 Written numbers and letters must be in a clear and standardized form. For 
example, 191 looks the same as 161 upside down!
3 The methods to be used for collection, storage, and transport of specimens 
should be thoroughly researched and pilot-tested.
4 Special containers and labels are required if samples are to be stored in liquid 
nitrogen.
Box 17.2 Some warnings regarding labelling 
and storing specimens
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3.3 Aliquoting
Biological samples are easily damaged by repeated freezing and thawing. This can be 
avoided if samples are divided into small portions (aliquots) before freezing; moreover, 
this provides a backup sample if problems are encountered during shipping. Ideally, the 
size of aliquots should be chosen so that there is just sufficient material in each aliquot 
to perform the tests that will be required at one particular time. This is not always possi-
ble, and, in practice, compromise procedures may have to be adopted (for example, on 
grounds of cost). It is important that the laboratory recording procedures are such that 
the histories of each aliquot are properly documented (especially recording how many 
times each one has been thawed and re-frozen), so that any recipient of the samples can 
be given detailed information about their preparation (for example, whether volumes 
are precisely measured or are approximate) and subsequent storage.
3.4 Storage system
When large numbers of samples are collected and stored, a storage and record system 
must be devised that allows the rapid retrieval of particular samples. If this is not 
done, sorting through large numbers of samples can be a very time-consuming activ-
ity. The particular storage system used should be tailored to the design of the specific 
study. Often, it is appropriate to store samples in batches, according to the date they 
were collected or frozen, with a record being kept of the contents of each batch. For 
longer-term storage and/or transport, storage boxes of standardized tube capacities 
(for example, nine by nine or ten by ten) with coded slots can be used. These boxes 
can be part of a racking system, for which a detailed inventory can be maintained as 
part of a computerized laboratory data management system. Generic software sys-
tems (some of which are free) are available. These computerized systems are used to 
record the receipt and storage of samples and can be used to track everything that 
happens to a sample, from when it was collected until it is disposed of or used up. 
Two of the most widely used examples are the Laboratory Data Management System 
(LDMS) and the Laboratory Information Management System (LIMS), though nei-
ther of these is free.
4 Documentation of laboratory procedures
There should be clear and explicit documentation of all laboratory procedures as SOPs 
in the laboratory manual, which should be subject to periodic review. The degree to 
which the documentation is computer-based will depend on local capacity and, to 
some degree, on the demands of the sponsors. SOPs will help to ensure reproducibility 
and will facilitate comparisons with results from other laboratories. Logbooks and re-
cords should be made for equipment maintenance, the batches of supplies and reagents 
used at different times, and for the detailed test procedures and the duties and respon-
sibilities of staff members. Certification of staff competencies can also be included. 
Specific provision should be made for recording unusual events that may affect the 
results of a test (for example, power failures and fluctuations—though, in some places, 
these may not be unusual!).
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Depending on the size of the laboratory and the variety of tests and procedures 
undertaken, the documentation should be arranged in a single or several logbooks that 
are arranged chronologically (World Health Organization, 2009).
4.1 Supplies
One of the sets of laboratory logbooks should provide information on: the reagents, test 
kits, laboratory equipment (including brand names), the expiry dates of reagents and 
test kits, storage conditions, batch or lot numbers, specification sheets, and the relevant 
re-ordering arrangements (for example, when, how much, and by and through whom). 
A checklist of itemized activities is important to avoid irregular supplies or shortage 
of reagents and test kits. Regular, at least monthly, inventories and appropriate docu-
mentation of all supplies can help to keep track of expiry dates and check on pilferage. 
Supplies and reagents that have passed their expiry date should never be used. To avoid 
this happening, a ‘first in first out’ system should be used for issuing reagents and sup-
plies, i.e. the reagents or test kits that are closest to their expiry date should always be 
issued before the ones that are further from their expiry date. Where Internet access is 
available, the website addresses and e-mail addresses of suppliers should be recorded.
4.2 Equipment maintenance
Regular checks should be made on each piece of equipment to ensure that it is in good 
working order. Such checks should be recorded and, for key items, publicly displayed. 
Some of the items that should be checked regularly are listed in Box 17.3.
In laboratories in the tropics where air conditioning is not available, humidity may 
lead to problems with both equipment and storage of certain sample types (for ex-
ample, blood stored on filter paper). In these circumstances, storage with silica gel 
(as a desiccant) in airtight boxes is appropriate, and the silica gel will require regular 
(monthly) replacement.
Maintenance procedures are usually described in the instruction booklets for the 
relevant equipment, but these will need to be augmented with details relating to 
troubleshooting and contacts of qualified staff or engineers. The complete mainten-
ance instructions for each piece of equipment should be incorporated into a dedicated 
manual, and a logbook with checklists kept for each piece of equipment. Regular main-
tenance of certain pieces of equipment may be a prerequisite in some studies. It is im-
portant therefore that laboratory staff review these logbooks regularly. It is usually a 
good idea and cost-effective to have a maintenance contract for all major, complex, and 
expensive laboratory equipment.
4.3 Procedures and staff duties
Laboratory SOPs, detailing step-by-step instructions for individual procedures, should 
be collected together in a laboratory manual. The author of each SOP and those staff 
members who have read it and, where appropriate, been trained in it (and who can 
therefore perform the procedure) should sign the SOP cover sheet. SOPs will specif-
ically detail to whom staff should report and how they should record results, addi-
tional observations, mistakes, and other unusual events. These include, for example, 
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1 Twice-daily (morning and evening) recording of temperatures of refrigerators, 
freezers, and cool-rooms, using maxima and minima thermometers and/or 
digital data loggers where available, should be performed without fail—even 
on weekends and public holidays! These data should be updated daily on 
standardized forms to allow easy monitoring of any changes away from the 
norm.
2 Checking on the position of the cap and the level of nitrogen in liquid nitrogen 
containers.
3 Regular and systematic inspection of all items of equipment which require clean 
lenses (for example, microscopes, spectrophotometers) and checks on focus and 
adjustment of light sources.
4 Periodic checks on the position of centrifuge rotors (tight centre bolts) and 
regular cleaning. Rotor speeds can be calibrated with an anemometer.
5 Many automated pieces of equipment (for example, haematological and 
biochemistry analysers) will have self-test and self-calibration programmes that 
run at start-up and shutdown. The results of these runs should be recorded and 
archived. More elaborate procedures may be required before and after longer 
periods of storage without use.
6 Any regularly used field equipment, such as thermometers, portable 
haemoglobin machines, and other POC diagnostics, will need to be calibrated 
periodically and have new batches of reagents checked.
7 Regular calibration of routinely used equipment such as balances, pH meters, 
and variable volume pipettes.
Box 17.3 Equipment and maintenance: items 
that should be regularly checked
any change of kit or batch number of sera, media, or preservatives. Any changes in 
assay conditions (for example, changes in incubation time or temperature) will require 
amendments and updating of protocols, which should be validated by the laboratory 
supervisor. Staff members involved in distinct sequences of the procedures should be 
indicated on relevant flow charts, and these should be written into the logbook. A sepa-
rate staff file, containing details of relevant training and certification, may be warranted 
in some circumstances.
4.4 Unusual or adverse events
The logbook should be used to keep a record of errors in test procedures (operator- 
or machine-reported) and in the preparation of reagents, power failures, temperature, 
and humidity changes that might influence the results of the tests or the quality of 
stored samples. The remedial action taken and results of the rerun of the test should 
also be documented.
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5 Quality control and quality assurance
QC is an inherent component of any good study and a good laboratory. It is a process 
of routine checks designed to detect any deficiencies that could compromise the results 
of laboratory analysis and suggest how these might be corrected. An example would be 
checks that the laboratory always gets the same result for a split specimen. QC checks 
should be specified in the laboratory work plan and in SOPs. A useful resource that 
discusses general laboratory QC issues is Ratliff (2003).
QA is a set of activities aimed at evaluating the accuracy of laboratory analysis and to 
guide improvements if inaccuracies are detected. QA provided by a resource external 
to the field laboratory is complementary to QC and should be established to monitor 
and improve the quality of laboratory procedures and validate the effectiveness of a 
QC programme. For example, a reference laboratory may supply specimens that are 
analysed ‘blind’ with the results compared to those of the reference laboratory and all 
the other laboratories participating in the same QA scheme.
5.1 Reproducibility of test results
The reliability of laboratory results should be tested by regular checks on their repro-
ducibility. The level of acceptable variation will depend both on the test and study. 
This information is normally predefined in SOPs, test manuals, and the study proto-
col. Many test systems have inbuilt controls for this purpose, using standardized 
reagents of known concentration or quantity. The use of such standard controls is 
important, but not necessarily sufficient, to monitor the quality of test procedures. 
Depending on the procedure, samples should be tested in duplicate or re-read by a 
second technician. The frequency with which such repeats are performed depends 
upon how well the laboratory is running and how long it has been doing the test. 
Typically, when a test is first introduced or a new staff member is conducting the 
test, a high frequency of such checking is appropriate, with a decreased frequency as 
the procedures become more familiar, assuming the re-tests are showing negligible 
differences to the original results. In many circumstances, it will be appropriate to 
ensure that duplicate analyses are done on between 5% and 10% of samples on a rou-
tine basis. It is sometimes possible and advisable to seed known positive or known 
negative samples into test runs, which are labelled in such a way that the laboratory 
staff running the test cannot spot them. This is particularly important if it is expected 
that the great majority of samples will either test negative or test positive (for ex-
ample, seeding a positive result if a long run of negatives is expected). Needless to say, 
a system will need to be in place to remove these QC test results from the data on the 
study samples. Where POC diagnostic tests are administered by field staff, it may be 
essential for a supervisor to review or repeat tests in the field, as results may become 
less reliable over time.
Reproducibility should be checked within batches, between batches, and from day 
to day or week to week by the use of appropriate controls. Intra-observer variation 
can be determined by having duplicate samples processed by the same observer at dif-
ferent times, and inter-observer variation measured by having the same samples pro-
cessed independently by two different staff members. Inter-product variation is tested 
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by comparing new vs old batches of staining solutions, media, reagents, and so on, on 
a group of the same samples.
It is essential that immediate remedial action is taken if QC checks reveal a problem.
5.2 Internal quality control
Two types of QC can be distinguished—‘internal’ and ‘external’. Internal QC comprises 
procedures that are introduced within the field laboratory. External QC involves exter-
nal monitoring such as the duplicate testing of samples in another reference laboratory 
to serve as a ‘gold standard’ or ‘blind’ measurement in the field laboratory of a set of 
samples provided by an external reference laboratory.
The essence of internal QC lies in a tight circle of checks, reporting, evaluation, and 
action. It is essential to have detailed manuals of every procedure, with a checklist to 
be consulted each time the procedure is run. Well-kept records, with regular review of 
these by the supervisors, are key elements in QC. Laboratory QC procedures must be 
an integral part of the work plan for the study.
5.3 External quality assurance
A major reason for external QA programmes is to check the accuracy of test results. 
Reproducibility can be assessed adequately by internal QC procedures, but checks 
on accuracy are best done, for many tests, in collaboration with other laboratories. 
The results from a laboratory may be highly reproducible within that laboratory but 
might be consistently incorrect. There are a range of external QA programmes which 
offer both testing of site-generated samples and/or the provision of a panel of samples 
with known characteristics that are specific for each assay (for example, biochemistry 
and haematology analysers). If specimens are selected for QA checks after they have 
been analysed locally and in such a way that the laboratory staff will not know which 
specimen will be selected, the use of site-generated QA systems are to be preferred to 
QA that depends on specimens provided by the external laboratory, since the labora-
tory staff will know which these QA panel specimens are and may take particular care 
with them.
SOPs need to be developed for the shipping and reception of samples for QA. 
An investigation request form should accompany samples that are sent, and every 
effort should be made to ensure that transport conditions are appropriate and the 
same for all samples (for example, route, packing conditions, and type of con-
tainer). Attainment of levels of proficiency by the laboratory and its staff may be 
a prerequisite prior to involvement in some studies; but, after that, external QA 
activities would be most frequent during training phases and at the beginning of a 
field study but should continue throughout. If a problem is detected, it is essential 
that the reason for this is investigated immediately and that this leads to effective 
remedial action.
The WHO has produced a list of pre-qualified QC laboratories (<http://apps.
who.int/prequal/lists/pq_qclabslist.pdf>), and a link to the United Kingdom Na-
tional External Quality Assessment Service is <http://www.ukneqas.org.uk/content/
Pageserver.asp>.
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6 Accreditation and links between laboratories
In some cases, a field laboratory may be set up specifically for the conduct of a particu-
lar study and may have no regular links with other laboratories. Increasingly, however, 
there will be links with other laboratories, either as collaborative partners in projects 
or to provide specialized expertise and analysis. There should be a clear specification 
in the study protocol of which procedures and checks will be performed at each la-
boratory, how arrangements will be made for the transport of specimens and supplies 
between them, and how and which records will be exchanged. Links with an external 
reference laboratory may be desirable for independent checks, as part of QA proced-
ures (see Section 5.3).
If samples are to be sent to other laboratories for further storage, processing, or ana-
lysis (for example, blood, sera, slides), it will be important to give attention to the fol-
lowing points.
 1 It is risky to send entire samples to another laboratory or to send all of the sam-
ples from one survey or study at the same time. Duplicates should be kept, even 
when storage facilities are limited, to guard against loss during shipment.
 2 Samples should not be sent to another laboratory without a clear agreement as 
to what analyses will be done and how these will be reported back. It is essential 
that an SOP defines who does what, with what, and when. These arrangements are 
defined in Material Transfer Agreements (MTAs). An MTA is a contract that gov-
erns the transfer of research materials, such as blood or serum samples, between 
two organizations. The number of samples to be analysed and type of tests should 
be agreed beforehand, ideally as part of a predefined analysis plan. It is common 
practice to send samples to another laboratory in such a way that they are ana-
lysed ‘blind’ (for example, no details are sent of which trial arm the samples are 
from or of the age and sex of the individual subjects). Agreement with respect to 
publication procedures should also be made, before specimens are sent.
 3 The MTA agreed between the field and other laboratories should be part of the 
study protocol, in which the division of responsibilities should be specified. All 
parties must also adhere to the provisions of the MTA, in order to participate in 
the study (for example, local research clearance and ethical clearance).
7 Coding and linkage of results
In order to remove the possibility of bias, staff working in the laboratory should not 
know which trial arm any sample is from, and it should not be possible for this to be 
deduced from the labelling system employed. Specimens must be labelled in such a 
way, however, that each is identified uniquely, and any test results can be linked back to 
other records of the individual from whom the specimen was taken. While this seems 
to be stating the obvious, the problems that arise with these aspects of large studies are 
often substantial. Special care is necessary in longitudinal studies where individuals 
may be followed for many years, in studies involving many different research groups 
or laboratories, and in studies where results need to be linked with census information 
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that may be updated over time (for example, individuals may move house, and this 
may cause problems if the coding system for individuals is too closely linked to a house 
code). Pre-printed labels are highly advantageous.
Laboratory results will usually be recorded in laboratory books or on specially pre-
pared forms for data entry. Where the machine used for a particular test prints out the 
results, these should be carefully transcribed on to data forms, preferably using double 
entry (see Chapter 20, Section 5.1), and the printed output stored. Some machines 
generate printouts on heat-sensitive paper. In this case, a heat-stable photocopy must 
be made and stored. Increasingly, electronic record keeping will render these particular 
storage methods obsolete. Result codes that identify particular problems or features, 
such as lost and broken samples, technical problems with batches of samples (for exam-
ple, staining, storage, transport), and the identification of the technicians involved with 
each test (to check variations between observers) should be used. Errors in readings 
on some automated machines (for example, values outside the normal range) will be 
reported or ‘flagged’ immediately, so that the assay can be repeated, if necessary.
If the study uses laboratory numbers, in addition to individual identification num-
bers, as is often the case, both numbers should be entered on a computer form for data 
entry, so that cross-checks and data linkage can be done in the computer.
If multiple laboratory tests are being performed on samples from the trial popula-
tion, it may be best to wait until all the results have been assembled and collated before 
entering them into the computer, so that the checking and linkage back to other data 
on each individual can be done in relatively few steps. This will depend on how the data 
entry system is organized, but repeated processing of many small sets of data is liable to 
lead to confusion and may be unnecessarily time-consuming. However, a compromise 
may be necessary if results are needed in a timely manner for selection for QC or QA 
checks so that they can be used for the clinical care of the participant.
8 Laboratory health and safety
Detailed attention to health and safety are key aspects of any laboratory. This may be of 
special importance in some field laboratories, as they may be relatively accessible by the 
public or have other specific safety risks. It is important therefore to ensure that each 
laboratory has its own health and safety manual, addressing both general and specific 
risks, and that this is read by each new staff member or authorized laboratory visitor. 
A process of evaluation should be instituted to make sure that all the staff understand 
the health and safety rules, before performing laboratory tasks. If field staff are to col-
lect and perform primary processing of samples, they will need to be made aware of 
potential risks. Procedures that will need to be covered will include disposal of needles, 
blood, stool, urine, and sputum samples, and of used reagents, chemicals, and deter-
gents. Usually, all sharps should be disposed of in special sharps containers, which 
should be returned to the base laboratory for final disposal. Special attention should 
be paid to precautions concerning the transmission of blood-borne infections such as 
hepatitis B and HIV, and specific instructions given for what staff are to do if they are 
inadvertently exposed to potential infection. It should be standard procedure that field 
laboratories have at least a starter supply of antiretroviral drugs for HIV post-exposure 
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prophylaxis if blood is being collected or processed. This is obviously even more im-
portant in high HIV prevalence areas. Adequate personal protective equipment should 
be made available for the type of samples to be collected.
Safety procedures should be regularly reviewed by laboratory supervisors and all 
staff concerned. Laboratory safety guidelines are given in World Health Organization 
(2004).
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1 Introduction to budgeting and accounting
This chapter gives a brief introduction to budgeting and accounting requirements and 
associated methods in the context of field trials. For all but the smallest trials, a trained 
accountant should be part of the trial team, at least part-time. This chapter is not written 
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for such accountants. Rather its aim is to help non-specialists, such as PIs or trial man-
agers, understand the basics of what budgeting and accounting will be needed in the 
management of a trial, and why. Though this knowledge is essential for those conducting 
trials of interventions everywhere, well-qualified support staff who can do much of the 
checking of budgets and accounts are generally in short supply in LMICs, so the PIs and 
trial managers may need to do more of this themselves. The chapter does not attempt 
to cover what would be included in a full textbook on budgeting and accounting. For 
that, readers are referred to specialist textbooks, some of which are available free online 
(Walther, 2012). Most budgeting and accounting textbooks are written from the perspec-
tive of a profit-making business, but Mango’s excellent Financial management essentials: 
a handbook for NGOs (Lewis, 2013) is designed specifically for non-governmental or-
ganizations (NGOs) and is also available free. With permission, this chapter summarizes 
many of the issues discussed in the Mango handbook, and those who want to know more 
are advised to consult the Mango website (<http://www.mango.org.uk/Guide>).
Like any specialist discipline, accounting has its own ‘language’. The 2010 edition of 
a widely used dictionary of accounting runs to over 400 pages and has more than 3600 
entries (Law, 2010). The definitions of some of the most important terms are given in 
Section 7, and every time a term that is defined in Section 7 is used in the chapter it is 
written in italics.
All too often, those planning a trial put a great deal of effort into the scientific aspects 
of trial design, but relatively less effort into ensuring that the budget for the trial is ad-
equate. Yet the latter is critical for the success of the trial. Also, once the trial is funded, 
it is essential that the trial has a well-thought-through budgeting and accounting sys-
tem, with sufficient checks and balances built into it to ensure that ‘leakage’ of those 
hard-won funds will not occur and that funds will be available when and where they are 
needed, so that the implementation of the trial can flow in a timely and efficient man-
ner. PIs and other researchers do not usually need to do most of these tasks themselves, 
but they need to ensure that they will be done and know enough to be able to supervise 
them adequately.
There are four key principles of financial management of project grants:
◆	 use funding for the purpose for which it has been given
◆	 regularly monitor expenditure against the budget
◆	 maintain accurate accounting records
◆	 maintain a good filing and backup system for all financial information.
Keeping track of all purchases, donations, stores, and equipment is usually seen as 
a task for the accounting staff of an organization. These issues will not be dealt with in 
detail here, and those who want to know more about them are referred to the relevant 
sections of Lewis (2013). Monitoring and maintenance of clinical and laboratory sup-
plies raise special issues such as needing to keep careful track of expiry dates and the 
rigorous use of the ‘first in, first out’ system of disbursement from the stores. Some 
of these are discussed in Chapter 17, and others are covered in accounting textbooks 
(Walther, 2012).
All organizations hosting trials should have a financial manual or a set of finan-
cial regulations that sets out all the financial policies and procedures to be followed. 
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This may be developed from scratch, but usually it is possible to modify a manual 
from a similar institution. The manual should cover the procedures that will be 
used for the tasks listed in Box 18.1. Almost, but not all, of these issues are covered 
in this chapter. Readers are referred to accounting textbooks for further details 
(Walther, 2012).
Most trials will operate within an existing organization that already has its own finan-
cial manual and detailed methods for budgeting and accounting. Where this is the case, 
the PI, trial manager, and others involved in the trial should obtain a copy of these and 
make sure that they know the procedures and that they will provide all the information 
and necessary financial checks and balances. Occasionally, a trial will need to set up 
its own procedures, either because there is no pre-existing local organization involved 
The manual should include instructions and notes relating to the items listed:
◆	 financial accounting
◆	 the chart of accounts and cost codes
◆	 budget preparation and monitoring
◆	 management accounting routines and deadlines
◆	 managing internal risk, for example, delegated authority rules (i.e. who can do 
what), separation of duties, reconciliation, cash control, physical controls
◆	 procurement and tendering
◆	 expense claims
◆	 storekeeping
◆	 asset management, including vehicle management
◆	 bank and cash handling
◆	 management of exchange rate variations
◆	 payroll procedures and staff loans/advances
◆	 staff benefits and allowances
◆	 internal and external audit arrangements
◆	 how to deal with fraud and other irregularities.
It should also include:
◆	 standard forms
◆	 organization charts (organogram)
◆	 job descriptions.
Adapted with permission from Lewis, T., Financial management essentials: A handbook for NGOs, 
Management Accounting for Non-governmental Organisations (MANGO), Oxford, UK, Copyright 
© 2014, available from <http://www.mango.org.uk/Guide>. This box is distributed under the terms 
of the Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a 
copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
Box 18.1 Financial manual
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in the trial or because the trial will need to be run from a new remote office. Here, the 
PI should seek professional help to set up suitable financial systems but should know 
enough to ensure that the results meet the standards of good financial practice. The rest 
of this chapter gives a brief introduction to what these should include.
In this chapter, the focus is on the costs of conducting an intervention trial. In 
Chapter 19, the focus is on the costs of the intervention itself, as they would be when 
the intervention is implemented in a public health programme. The time horizon for 
the research is generally well circumscribed, whereas that for provision of an interven-
tion in a public health system is usually open-ended. This chapter is written from the 
perspective of accountants, whereas Chapter 19 leans more towards that of economists.
2 Budgeting
The trial budget should be prepared as part of the trial planning process and be used 
throughout the trial as a monitoring tool. Usually, the budget will need to be prepared 
as part of the grant application. The potential funder will usually have specific instruc-
tions for presentation of the budget, but the norm is to have a detailed budget and a 
budget justification as an annex to the application. In some cases, a summary budget 
may also be required within the main body of the application.
The costing of research is often an aspect of proposal development that gives inexpe-
rienced investigators considerable difficulty, and getting it wrong can have serious con-
sequences. Overestimating the required budget will be viewed poorly by the reviewers 
and the funding agency and may lead to the proposal being rejected, while under-
budgeting may result in resources being exhausted before the study is completed. Some 
funding agencies may be sympathetic to requests for supplementary funding if there 
are good reasons, for example, greater than expected inflation or unexpected currency 
devaluation, but are less sympathetic when investigators have not properly anticipated 
costs while preparing the original proposal.
It is difficult to give firm guidelines of what may or may not be included in the trial budget. 
Funding agencies often give specific guidelines. The important points to bear in mind are 
first that all costs should be justified, in terms of project needs, and second, if it is not asked 
for, it is unlikely to be given! The essential characteristics of budgets are that they should be:
◆	 reasonable. The costs shown should be appropriate for the purposes for which 
they will be used
◆	 well-researched. Actual costs in the past provide a good guide for anticipating fu-
ture costs for the same or similar equipment or procedures. Several independent 
quotations (three is the usual minimum) should be obtained for major items of 
equipment to ensure that the costs quoted represent the best value for money
◆	 detailed. All significant costs should be given in detail. ‘Fuel and servicing of vehi-
cles $10 000’ is inadequate! Even if the funding agency does not require the detail, 
the appropriate calculations should be done, in order to be able to arrive at an 
accurate final figure
◆	 well-justified and explained. The necessity for each cost should be given. A good 
general rule is to justify all costs!
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Most sponsors of research have specific forms for the budget, and they will usually 
specify what kinds of costs they will and will not cover. For example, some funders 
expect the institution in which the applicants are based to cover local telephone and 
postage costs and office accommodation and supplies, or to get the funds for these 
from the project’s indirect costs (also called overheads) (see Section 2.2.7), while others 
are happy for these to be included in the direct costs. If it is not ruled out by the funder’s 
guidelines, it is best to include as much as possible in the direct costs.
A common approach to categorizing costs is to separate them into capital and recur-
rent costs (Box 18.2).
Budgets for recurrent costs are usually done each year, whereas planning and budget-
ing for buildings, vehicles, and large equipment are often done for a 3- or 5-year period. 
It is critically important, however, to plan for the recurrent costs that will be required 
to maintain and use buildings, vehicles, and equipment. Generally, capital costs are 
discounted over the expected lifespan of the equipment or building and depreciated 
with use over time.
2.1 Capital costs
The purchase, construction, alteration, or renovation of a building is rarely needed for 
a single field trial, but, if this is required, the amount required would be included as a 
capital cost in the budget.
List each item of equipment required separately, and justify the need for each item. 
Sometimes, it might be possible to share equipment with another project in the same 
institution or a neighbouring institution, especially if the equipment is very expen-
sive such as vehicles or major items of laboratory equipment. Estimates for the cost of 
Capital costs—relate to investments in items that last for more than a year such as:
◆	 buildings
◆	 vehicles
◆	 equipment
◆	 basic training
◆	 land.
Recurrent costs—relate to those used up in the course of a year and needing regular 
replenishment such as:
◆	 personnel and other labour (wages, salaries)
◆	 supplies
◆	 building operating and maintenance costs (electricity, water, etc.)
◆	 in-service training (in-service courses for specific skills and knowledge)
◆	 information, education, and communication (IEC) costs.
Box 18.2 Division of costs into capital and recurrent
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equipment should be obtained from manufacturers or suppliers and should include 
shipping and associated insurance costs. Maintenance agreement costs should be in-
cluded under ‘other expenses’. Depreciation of equipment must be allowed for, but there 
are wide variations in what is allowed by funders. Purchase of vehicles is often one of 
the major equipment costs in a large field trial. If a new vehicle is requested, reasons 
should be given why any existing vehicles cannot be used. In some places, it may be 
possible to rent a vehicle commercially, so the costs of rental should be compared with 
the costs of purchase, and any proposals for purchase should be justified on this basis. 
Even with a new vehicle, there will be costs to add for fuel, lubricants, servicing, and 
maintenance, with the maintenance costs increasing with vehicle age. These should be 
budgeted under recurrent costs.
2.2 Recurrent costs
2.2.1 Personnel
Give details of the names (where known), positions, and roles of personnel to be en-
gaged on the project. Indicate the proportion of time that each person, including the 
PI, will devote to the project, and calculate the salary cost on a pro rata basis. Estimates 
should be made separately for each year of the study and should include provision for 
annual increases in salary, where appropriate. Some grant agencies will not contribute 
to the salary of the PI but will still expect to know what proportion of their time will be 
spent on the project. Appropriate amounts should be added to cover staff benefits such 
as the employer’s pension contributions, staff health insurance, cost of living allowances, 
and housing and leave allowances. Internationally recruited staff usually receive specific 
additional benefits such as travel costs from their normal country of residence to the 
project site and back for themselves and their dependants. Staff benefits and allowances 
may be a considerable proportion (often 25%, sometimes more) of the total gross salary 
costs to the project. If staff will need to be recruited, or might need to be replaced if they 
leave before the end of the trial, make an allowance for their recruitment costs.
2.2.2 Consultant or technical advisor costs
Sometimes, it is appropriate to buy in the time of a consultant or technical advisor, 
rather than hiring them as staff. The grant application should specify the number of 
days that will be spent on the project by each consultant, together with their daily rate 
of remuneration and any associated costs such as travel and per diems. The funding 
agency may have guidelines for the rates of remuneration that they are willing to pay 
for consultants to a project. The specific contribution that any consultant will make to 
the project must be justified.
2.2.3 Supplies
Supplies should be itemized in separate categories (for example, stationery and office 
supplies, communications (such as Internet, postage, phone calls), fuel and lubricants, 
laboratory supplies) and should be justified in terms of the needs of the project (for 
example, numbers of each laboratory test to be performed). If the trial requires the use 
of experimental animals, the PI should seek specific advice in advance on whether the 
funder will allow this and the specific information they will need in the proposal.
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2.2.4 Travel and per diems
Specify the destination of each trip, the number of persons, the mode of transport, 
and the basis for the costs (most funders will only pay economy air fares). Justification 
should be given for all travel. Funders have different rules about travel to conferences 
(some do not allow any, while others allow one or more attendance per year).
Per diem (overnight allowance) costs may be a significant proportion of the budget 
in field trials, and the rates paid should be based on existing practice of the research 
institution. These costs should be justified for each member of the project staff to whom 
they will be paid, in terms of the necessity for spending the specified number of days 
away from the home institution.
2.2.5 Patient care and participant costs
There are often patient care costs that may be incurred in a trial that are not directly 
related to the trial intervention. A frequent concern in field trials in LMICs is provision 
of adequate health care to those in the trial and the degree to which the research project 
should be responsible for these (see also Chapter 6, Section 3.4 concerning medical and 
other care offered to participants in a trial).
Reimbursement to participants in a trial for travel or loss of earnings should usually 
be listed under ‘other expenses’, but some funders suggest these are put under patient 
care costs or in a special section.
2.2.6 Other expenses
This section should contain items such as rentals and leases, equipment maintenance 
(service contracts, repairs), computer charges (if there is not a separate claim for pur-
chase of computers under ‘equipment’), publication costs, fees for services related to the 
project (for example, library searches), office supplies, postage and telecommunication 
charges (telephone, telex, fax, e-mail), and possible patient care costs (see Section 2.2.5).
For trials of drugs and vaccines and some other interventions, it is strongly advised 
to include indemnity insurance costs, i.e. insurance for claims against the sponsor for 
damage that might be done to participants in a trial through the trial procedures.
Not all costs listed above may be allowed by a funding agency, but, if in doubt, it is 
better to include them in the application (even though the agency may subsequently 
disallow them!).
2.2.7 Indirect costs (institutional overheads)
There are ‘hidden’ costs associated with all research. Someone must administer the 
grant, pay salaries, order supplies, supply heat or air conditioning and light to offices, 
supply the offices themselves, have them cleaned and maintained, provide security, etc. 
These costs, called indirect costs or ‘institutional overheads’, may be substantial. Such 
costs may amount to between 20% and 90% or more of the direct costs of the research 
project, depending on exactly what is included in the direct costs. These indirect costs 
should be added on to the direct costs of the research when a grant is submitted to a 
funding agency. Many institutions in LMICs have been lax about claiming such costs, 
with the result that scarce core institutional budgets have effectively subsidized specific 
research projects.
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Some funding agencies refuse payment of overheads (for example, most United Na-
tions (UN) agencies and charitable foundations), while others will pay them in their 
own country, but not outside (for example, US Public Health Service). Often, it is pos-
sible to directly budget for many of these items (to be listed in the direct costs as rental 
of office space, cost of utilities, administrative staff support, cost of library searches, 
etc.), and it is usually advantageous to do so.
It is common for an investigator to underestimate, rather than overestimate, the final 
costs of a trial, especially if it lasts several years. Though some funders may accept re-
quests for an additional allocation when increases in costs could not reasonably have 
been foreseen, even this cannot be guaranteed, let alone if something has been forgot-
ten or underestimated in the costing. Whenever possible, avoid cutting corners on a 
budget in order to fit it to a pre-specified total amount, as underfunding may result in 
many stressful months in trying to conduct the trial on an insufficient budget. It may be 
better either to not apply for the grant or to rethink the trial question and design, rather 
than knowingly under-budgeting the trial from the start.
3 Accounting
All money that is received and spent for the trial must be accounted for in a way that is 
both truthful and transparent, so it can be checked by an outsider (an ‘auditor’).
Accounts can either be maintained on an accruals or a cash basis. In the accruals 
method, income and expenditure are attributed to the month they are ‘incurred’. For ex-
ample, an item of equipment may be acquired during February, and so the expenditure 
for that equipment has been incurred in February, even if the invoice is not received 
and/or the payment made until April. Under the accruals accounting method, the cost 
would be accounted for in February, whereas, under the cash accounting method, it 
would be accounted for in April, i.e. when the invoice is paid. Some funders require 
one or the other method, while many leave it up to the grant holder. Clearly, a mixture 
of both methods should never be used within a single set of accounts.
Accounting records should include four main types of documents: supporting docu-
ments, books of account, reconciliations, and a list of cost codes. These will each be dis-
cussed briefly in this section, but a fuller description can be found Lewis (2013).
3.1 Supporting documents
These are the original documents that show how the money has been received and 
spent. They should all have a brief written explanation (a voucher), which has a unique 
sequential reference number that corresponds to an entry in one of the books of account 
(see Section 3.2).
They include:
◆	 receipts and receipt vouchers for all money received. Every receipt should be given 
its own receipt voucher, which should be assigned its own unique sequential 
reference number, along with the date of the receipt, the name of the person or 
organization that gave the money, a description of what the payment was for, the 
amount received, and the accounts or cost code (see Section 3.4)
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◆	 receipts and payment vouchers for all money paid out. These are the equivalent of 
the receipts and receipt vouchers for all money received and should have similar 
information on them
◆	 invoices provided by other organizations or individuals requesting payment. 
These should be certified and stamped as paid
◆	 pay-in vouchers for all money paid into the bank
◆	 bank statements
◆	 journal vouchers. These are vouchers that record adjustments, for example, if a 
payment or receipt has been entered incorrectly or allocated to the wrong cost 
code. They therefore relate to transactions where no actual cash changes hands, 
but they explain a change that has been made after an original entry into the ac-
counts was made.
With the above documents on file, it will always be possible to (re)construct a full set 
of accounts, and they form the basis for the audit trail.
Other useful supporting documents include:
◆	 local purchase orders. These are vouchers requesting that something be purchased
◆	 supplier’s waybill. This is a list of goods sent by a carrier (see Glossary, Section 7)
◆	 delivery notes (or goods received notes, goods receipt advice). These are vouchers 
that record any item received by the project such as a piece of equipment or a box 
of pencils
◆	 stores requisition vouchers, bin cards (tally cards), and stores issue notes. These are 
documents that record all the incomings, outgoings, and the balance of all items 
kept in the stores
◆	 approvals. These are specific notes or vouchers approving payments
◆	 petty cash vouchers. In order not to have to go to the bank every time a relatively 
small expenditure is made, it is useful to have petty cash in the office. The ini-
tial amount (petty cash float) for this comes from the bank account, and, under 
the commonly used ‘fixed float method’, the petty cash is topped up to the same 
amount when it falls below a preordained threshold. For example, if the petty 
cash float is $100, then it may be reasonable to top it back up to $100 whenever 
the balance falls below $50. A maximum limit for a single petty cash payment 
should be fixed, with any payments that are larger than this needing to come 
directly from the bank (for example, be made by cheque). Each payment from 
the petty cash should be backed up by a receipt and a petty cash voucher which 
records similar information to that on a payment voucher. Money that is paid 
into the project should not be paid into the petty cash, but directly into the bank. 
This is to ensure that it does not just ‘disappear’ but passes through an externally 
recorded system.
3.2 Books of account
Various books of accounts should be maintained, covering different aspects of income 
and expenditure, as follows:
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◆	 cash book (sometimes called the bank book). Rather confusingly, the cash book re-
cords all transactions that pass through a bank account, but, although ‘bank book’ 
would be the more logical name, ‘cash book’ is much more commonly used. Some 
of the transactions may relate to actual cash, while others will be based on cheques, 
for example. Every entry in the cash book should have a unique transaction num-
ber which corresponds to a specific receipt or payment voucher, and the entry itself 
should also appear on the bank statement, thus allowing cross-checking
◆	 petty cash book. The petty cash book records all transactions related to the petty 
cash and is the petty cash equivalent of the cash book. Any income to the petty cash 
book should match an expenditure in the cash book
◆	 advances ledger. This records all payments that have been made to anyone in ad-
vance. This may be a down payment on a large item of equipment, for example. 
However, the commonest recipients are members of staff receiving an advance on 
their salary, for example, as a loan or to allow them to pay their rent in advance. 
Usually, the staff member must pay these advances off in monthly instalments by 
deductions from their pay. The simplest way to keep a record of these advances 
and their repayment is to allocate a page in the advances ledger for each person or 
organization who receives an advance, and then the accountant enters each repay-
ment until the advance has been fully paid off
◆	 assets register (also often known as the fixed assets register). The assets of the trial 
are all the buildings or items of equipment that have been purchased by, or been 
donated to, the trial. The assets register should list all of these, along with identify-
ing details such as their make, model, and serial number. Each asset should be 
physically tagged with a unique reference number for identification purposes. The 
asset register should also, at a minimum, include the date and purchase price of 
each item. It is useful to split the list into major and minor assets. Major assets are 
items that are worth more than a specific amount when new (often between $500 
and $1000) such as buildings, vehicles, and major items of laboratory equipment. 
Many funding agencies will want to decide on the disposal of items at the end of 
the trial that cost the grant more than a certain amount, so, if there are such re-
strictions, it is sensible to fix the threshold for ‘major assets’ to that amount
◆	 taxes withheld ledger. This is a record of any taxes that the project has withheld, in 
order to pay them to the tax authorities. Examples include staff income tax and 
other national insurance payments.
3.3 Reconciliations
Reconciliations are undertaken to ensure that the books of account and supporting docu-
mentation are consistent. All too frequently, reconciliations either are not conducted 
or are not carried out frequently enough. Yet this can mean that errors, either due to 
mistakes or fraud, go unnoticed until a major problem has accrued. Reconciliations 
should be reviewed by a different staff member from the one who did them, in order to 
provide a check on their validity. This can be a challenge when the number of staff who 
are either qualified or senior enough to do this are few and over-stretched, but it is ask-
ing for trouble not to follow the rule of separation of duties in this regard.
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3.3.1 Bank reconciliation
The cash/bank book is checked against the bank statement. This should be done at least 
once a month. In practice, there will almost always be a difference because of delays 
such as:
◆	 money banked by the project has not yet been shown in the bank’s records
◆	 cheques issued by the project have not yet been presented to the bank
◆	 bank charges and interest may have been applied
◆	 errors may have been made by the bank or in recording entries in the cash/bank 
book.
The reasons for any discrepancies should be listed in the bank reconciliation report 
prepared by the project accountant.
3.3.2 Petty cash reconciliation
Petty cash should be counted and reconciled at least weekly (and also on an unsched-
uled basis from time to time) by someone who is not responsible for handling the petty 
cash.
3.3.3 Trial balance
Every month, or at least once a quarter, two lists of balances should be drawn up, one 
of the debit balances and the other of the credit balances, on all the accounts that relate 
to the trial. The totals of each list should match. If they do not, then checks need to be 
made to explain the differences, which should be resolved.
3.4 Cost codes
Cost codes (sometimes called analysis codes) identify specific budget lines for each 
transaction. They allow the accountant to summarize income and expenditure, accord-
ing to these budget lines such as personnel costs, travel, or laboratory consumables. It 
is important to give careful thought to the cost codes before the accounts are set up and, 
if in doubt, to subdivide the cost codes using a tree system, as any later changes to the 
cost codes will require the accountant to go back and recode the relevant vouchers and 
entries in the books of account. For example, if there is only one cost code for all travel, 
but later information is required on how much has been spent for international travel, 
as opposed to travel within the country, this will not be possible without going back to 
re-code all the travel expenditures.
4 Budget monitoring
Once the budget has been finalized and the necessary funds have been received, the 
budget acts as the basis for all future expenditure and financial reporting for the trial. 
The expenditure should be compared against the budget on a frequent and regular basis, 
such as every 3 months for a trial that lasts more than 1 year, and every month for a 
trial of a year or less. This process is known as budget monitoring. This is an activity 
that is frequently given too little attention—sometimes with disastrous consequences 
for the trial. Budget monitoring should include variance analysis where the difference 
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(variance) between the actual (past) and forecast (future predicted) expenditure is com-
pared with the budget to see whether there have been, or are predicted to be, any over- 
or under-spends, either overall or on specific budget line items.
The overall and future budget should be reviewed at least once a year to check whether 
it will still be adequate. If not, it is best to approach the funder early, rather than leaving 
it till towards the end of the trial when the money is about to run out.
4.1 Analysis of expenditure
Regular analysis of expenditure by cost codes is very useful to allow the detection of 
excessive expenditure on one or more cost codes. For example, if the laboratory seems 
to be getting through an excessive amount of laboratory supplies, this might be because 
the supplies of another project are being erroneously charged to the trial’s account or 
because the laboratory staff or storekeeper are stealing them. The level of detail pro-
vided by the cost codes is not usually needed for the summary accounts sent to the 
funding agency, but it is relatively easy to collapse the cost codes down to major budget 
line items such as all personnel costs or all travel costs.
Funders often have specific rules about virement of expenditure between budget line 
items. Many allow no more than 10% virement out of, or into, any budget line item, and 
some will not allow any virement into personnel or into equipment, for example.
4.2 Balance sheet
The balance sheet summarizes the current financial position of the project by showing 
all its assets and liabilities. It and the cash flow forecast are needed for budget monitoring. 
The assets include both fixed assets (tangible and likely to last more than 1 year) and 
current assets (cash or something that could be converted into cash within a year such 
as a savings account at a bank). Liabilities include current or short-term liabilities (to be 
paid within year) and long-term liabilities (long-term commitments).
4.3 Cash flow forecast
This shows the expected income and expenditure of the project into the future and is 
essential to be able to predict when there might be a shortage of funds to be able to meet 
future expenditure and to take steps to avoid this.
5 Accounts summaries and auditing
Once expenditure on the trial has started, the income and expenditure accounts will show 
the actual (past) income and expenditure within the cash book, and this should then be 
summarized periodically (ideally once a month, but at least once every 3 months) by 
major line items. The income and expenditure accounts can then be put into an income 
and expenditure statement, which will show actual (past) and forecast (future) income 
and the equivalent for expenditure, broken down by period (for example, monthly or 
quarterly) and by line items. This is used for budget monitoring. It is useful to include 
a column showing the percentage by which the budget has been over- or under-spent 
(known as a variance analysis). The income and expenditure accounts and statement are 
the most useful summary accounts for most time-limited projects such as a trial.
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The balance sheet summarizes the overall current financial position of a project or insti-
tution, taking into account the current market value of assets—fixed (for example, build-
ings, vehicles) and current (cash or savings that are likely to be converted into cash within 
12 months). However, for a specific trial, a balance sheet is likely to be less useful than the 
income and expenditure accounts, an income and expenditure forecast, a list of (major) as-
sets, and a cash flow report and forecast showing when expenditures can be expected rela-
tive to the income, in order to highlight potential periods when there may be a shortfall or 
when cash may need to be spent to avoid it being lost back to the funding agency.
It is essential that all accounts are subjected to external audit. Ideally, this should be 
done annually as soon as possible after year-end, based on the annual accounts. External 
audit is relatively expensive and needs to be included in the budget. Sometimes, the 
institution has arrangements in place that all their accounts are externally audited each 
year. Where this is the case, this is usually sufficient, but it is essential that this is checked 
with the funding agency, which may require a separate project-specific external audit.
Box 18.3 gives a checklist of questions to ask when reviewing financial information 
in a trial.
General
◆	 Do the accounts make sense? Do the various figures add up correctly? Do the 
amounts given in different parts of the accounts match each other?
◆	 Are the amounts given backed up by supporting documents?
◆	 Do spot checks of some of the original supporting documents match the 
amounts given in the accounts?
Funding and expenditure
◆	 Are funding and expenditure broadly in balance?
◆	 Is there a significant increase or decrease in activity levels from the previous 
reporting period?
◆	 What is the balance of direct project costs vs administrative and indirect costs?
◆	 Is expenditure reasonable for the size and nature of the project?
◆	 Are there any large bills outstanding which could substantially affect the fig-
ures shown?
◆	 Are bills paid in a timely manner? If not, creditors may refuse to supply the 
project or the institution as a whole in the future.
◆	 What is the projected year-end balance? Is this satisfactory? If not, what steps 
need to be taken to change things?
Box 18.3 Questions to ask when reviewing financial 
information
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6 Prevention of fraud and other losses
One of the duties of the PI in a trial is to ensure that there are systems in place to try to 
prevent or expose fraud. Preventing fraud is far better than exposing it after the event, 
so it is best to put systems in place in advance to check for potential fraud and to ensure 
that all relevant staff know that such checks are going to be carried out, in order to dis-
suade them from committing fraud.
One key mechanism for preventing fraud is through the separation of duties. This 
includes ensuring that a different person has custody of assets and cash from the person 
who does the recording of the related accounting entries. This provides a safeguard 
Variances and virement
◆	 Is the expenditure broadly in line with the budget (for example, ± 10%)?
◆	 Is the income broadly in line with the budget (for example, ± 10%)?
◆	 Are there any significant variances (for example, under-spending as a result of 
delayed activity plans, or overspending due to inflation or unexpected salary 
increases)? If so, have they been explained satisfactorily?
◆	 What action is being taken to correct significant variances? This might include 
going back to the funder to get permission for the budget to be changed.
◆	 Are all virements within the permitted range? If not, will it be possible to rec-
tify this before the end of the project? If not, has the funder been approached 
to give their permission?
Cash flow
◆	 Is the project owed any large sums of money? Are the project funds  
expended, borrowed, pledged, transferred, or otherwise used for reasons that 
are not directly associated with the project? What is being done to retrieve 
them?
◆	 Are there any unbudgeted expenses that may occur later in the financial year?
◆	 Is income still expected to come through on time?
◆	 Are spare cash balances invested to produce the best return? Is any interest 
being properly accounted for?
◆	 Has the income or expenditure been affected by exchange rate movements? 
Will the funder compensate for these if they were in a negative direction?
Adapted with permission from Lewis, T., Financial management essentials: A handbook for NGOs, 
Management Accounting for Non-governmental Organisations (MANGO), Oxford, UK, Copy-
right © 2014, available from <http://www.mango.org.uk/Guide>. This box is distributed under the 
terms of the Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-
NC), a copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
Box 18.3 Questions to ask when reviewing financial information (continued)
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against any misuse of funds but also protects the individuals involved from any un-
founded or malicious allegation of misuse. Separation of duties may be difficult to 
achieve where there are a limited number of personnel, but wherever possible:
◆	 staff responsible for ordering goods or services (procurement) should not also 
have the power to authorize payment for the goods
◆	 staff who raise cheques should not have the authority to sign them
◆	 the reconciliation of the bank statement to the cash/bank book should be carried 
out by a different person from the one who writes up the cash/bank book. It must 
always be checked and authorized by a senior member of staff
◆	 staff responsible for selecting and engaging new staff should not also operate the 
payroll system
◆	 petty cash and banking should be checked by a member of staff who does not nor-
mally have access to the cash and bank records.
Areas where fraud is particularly common include purchasing, debtors, and cash 
payments.
6.1 Purchasing
In many countries, it is possible for the purchasing officer to arrange with the sup-
plier whereby the supplier increases the price of the goods or services and the sup-
plier and the purchasing officer share the mark-up between them. Insisting on 
three quotations may help avoid this but does not get round the problem if the 
purchasing officer has a similar arrangement with all three suppliers. A standard 
way that is used to try to get around this problem is the institution of a Tender 
Committee which is responsible for the evaluation of tenders from the potential 
suppliers prior to procurement. However, it is very rare that the members of a 
Tender Committee have insider information on the real minimum costs of items, 
and so they usually have to accept the information provided to them by the pur-
chasing officer and can only spot obvious problems such as the purchasing officer 
recommending a supplier known to be unreliable simply because they have given 
the lowest quotation. An effective way to get round this problem is to periodically 
ask a trusted person (for example, from a different organization) to also price out 
some of the items, and the quotations can be compared with those obtained by the 
purchasing officer.
A purchasing plan should be made well ahead of time to try to ensure that all pur-
chases are made according to plan. This is both to avoid delays due to late availability 
of key items, but also to avoid last minute purchases where it is not possible to check 
for the lowest possible prices. This is particularly important for items that are much 
cheaper if bought in a large city or imported.
Purchasing of fuel is a specific area that is a common source of fraud. Often, it will 
be a driver who has to purchase the fuel, rather than a professional purchasing officer. 
In some places, it is possible to get a receipt for more fuel than has actually been put 
into the vehicle, and the purchaser shares the mark-up with the supplier. Alternatively, 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
3156: PREVENTION Of fRAUD AND OTHER LOSSES
some unscrupulous drivers have been known to siphon fuel out of the tank. One way of 
trying to avoid both of these problems is to allocate each vehicle to a specific driver and 
insist that the vehicle tank is always, or at least once per month, filled to its maximum 
capacity. It is then possible to monitor the fuel consumption accurately, i.e. from full 
tank to full tank. If the driver is made aware that this is going to be done and is given 
feedback on their vehicle’s fuel consumption each month, this can make such fraud 
less likely.
6.2 Debtors
Some of these may be staff who have been given loans or advances, so that they can 
make payments on behalf of the trial (such as for overnight accommodation, travel 
expenses, cash payments to local assistants in the field, etc.). It is sometimes difficult for 
the accountant to insist on repayment by their friends (or relatives) on the staff, includ-
ing the accounts staff themselves, or to resist the temptation to do a deal, so that the 
loan is accounted for as an expenditure and never recovered. To avoid this, each debtor 
should have a separate account within the advances ledger, in which all debts and their 
repayment are entered. These should be monitored by the accountant and checked by 
someone else at least once a quarter, so that action can be taken to follow up on debt 
retrieval.
As far as possible, staff should only be given advances or loans for specific and excep-
tional reasons, such as so that they can pay their rent in advance, since many landlords 
require a deposit that is only returned at the end of the rental period. Unless the ad-
vances ledger is kept up to date and checked against the payroll each month, advances 
can be very difficult for the accounts department to keep track of, and their repayment 
makes preparation and checking of the payroll complicated. Outstanding advances are 
difficult to recover at the end of a staff member’s contract, especially if the staff mem-
ber leaves at short notice. Staff have been known to deliberately get as many advances 
as possible just before they leave without notice, knowing that it will probably be too 
much trouble to pursue them. Where an advance is given to cover the purchase of a 
large item, such as a vehicle or for a rental down payment, it is advisable to require 
the original receipt for the item or rental agreement to be deposited with the trial of-
fice where it must, of course, be stored in a secure place such as in a safe. Where other 
advances are given to staff, it is rarely a good idea to allow these to exceed 1 month’s 
net salary, as this is likely to be recoverable, even if someone leaves their post without 
giving notice.
6.3 Cash payments
These must always be signed for. Even so, it is relatively easy to either get a friend to 
sign or to fabricate a signature. It is important therefore that checks are made, such that 
payments are reasonable and reflect the activities carried out. Many projects insist that 
all cash payment vouchers are countersigned by a senior member of staff.
Box 18.4 gives a checklist for good financial practice.
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Budget management
◆	 At least annual budget preparation/review.
◆	 Monthly (or at least quarterly) budget monitoring, including:
•	 variance analysis
•	 forecast, balance sheet, cash flow report.
◆	 Process to manage exchange rate movements.
Accounting records
◆	 Maintain and keep original supporting documentation for all financial 
transactions.
◆	 Maintain books of account recording all financial transactions, comprising as a 
minimum:
•	 cash/bank book for each bank account
•	 petty cash book
•	 assets register.
◆	 Undertake monthly bank reconciliations, and investigate any inconsistencies.
◆	 Undertake weekly petty cash book reconciliations, and on a surprise basis from 
time to time, and investigate any inconsistencies.
◆	 Regularly summarize records to feed into budget monitoring.
◆	 Use a cost codes system.
Financial and related policies and procedures
◆	 Have a written financial manual that details the budgeting and accounting 
procedures that will be used.
◆	 Use standard forms, such as payment vouchers, receipt vouchers, petty cash 
vouchers, purchase order forms, travel and subsistence expenses claims, as-
sets register, vehicle logs, bank reconciliations, journal vouchers, advance/loan 
applications, storekeeping forms such as stock cards/bin cards, goods received 
vouchers, and stock taking forms.
◆	 Have clear procedures for managing internal risk, including:
•	 delegated	authority
•	 separation	of	duties
•	 cash	control
•	 physical	controls	such	as	having	a	safe,	adequate	security,	and	insurance	
cover
Box 18.4 Financial good practice checklist
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◆	 Have clear rules and procedures for:
•	 procurement	and	tendering
•	 expense	claims
•	 storekeeping
•	 asset management (including vehicle management)
•	 payroll
•	 tracking	for	loans, advances, and repayments
•	 audit arrangements.
Other policies and procedures
◆	 Governance arrangements, such as a constitution for the organization hosting 
the trial, with a governing body that meets on regular occasions, procedures 
for declaring and handling potential conflicts of interest, etc.
◆	 Staff management arrangements, including for:
•	 recruitment	and	selection
•	 induction
•	 discipline	and	grievance
•	 contracts	of	employment.
Adapted with permission from Lewis, T., Financial management essentials: A handbook for NGOs, 
Management Accounting for Non-governmental Organisations (MANGO), Oxford, UK, Copyright 
© 2014, available from <http://www.mango.org.uk/Guide>. This box is distributed under the terms 
of the Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a 
copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
Box 18.4 Financial good practice checklist (continued)
7 Glossary of financial terms
Accruals Expenditure incurred in an accounting period that has 
not yet been paid or invoiced. Opposite of pre-payments
Actual Income earned and expenditure incurred over a given 
time period
Advance funding provided for future expenditure, which must 
be either accounted for or be repaid
Analysis code Also known as cost code. A coding structure which 
specifies clearly and consistently the type of income 
being received and the type of expenditure being 
incurred
Annual accounts The financial statements at year end (or each month 
or quarter) which include an income and expenditure 
account and balance sheet. The financial statements 
require external audit
continued
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Asset Anything that is of value to its owner. Also see assets 
register, fixed asset, fixed assets register
Assets register Shortened name for the fixed assets register. A list 
of the fixed assets of the organization, usually giving 
details of value, serial numbers, location, purchase 
date, etc.
Audit An independent check on the accounts of the project 
or organization. An external audit is done by a person 
who is independent of the organization, while an 
internal audit is done by someone from the project’s 
own organization, but by a person who is independent 
of the management of that particular project
Audit trail The ability to follow the course of any reported 
transaction through an organization’s accounting 
systems and supporting documents
Balance sheet Summarizes the current financial position by showing 
assets and liabilities
Bank book Also known as cash book. A record of all transactions 
passing through a bank account
Bank reconciliation The process of agreeing the entries and balance in the 
cash/bank book to the bank statement entries and 
balance at a particular date. Acts as a check on the 
completeness and accuracy of cash/bank book entries
Books of account These detail all financial transactions and normally 
consist of, as a minimum, cash/bank book for each 
bank account, petty cash book, and assets register
Budget Describes an amount of money that a project/
organization expects to receive and spend for a set 
purpose over a given period of time
Budget monitoring report A report showing actual performance against the budget 
for income and expenditure, with explanations provided 
for any significant variances. Budget monitoring reports 
are usually prepared at more than one level of detail
Capital expenditure Expenditure which creates a fixed asset
Cash flow The difference between cash received and cash spent 
in a period
Cash book Also known as bank book. A record of all transactions 
passing through a bank account
Chart of accounts A list of all the cost codes that are used to analyse 
transactions in an organization’s accounting system
Cost code Also known as analysis code. A coding structure that 
specifies clearly and consistently the type of income 
being received (for example, grant from the funder) and 
the type of expenditure being incurred (for example, 
salary costs, vehicle running costs)
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Credit A payment into the account
Creditor A third party that has provided goods or services but 
has not yet been paid
Debit A payment out of the account
Debtor A third party that has been invoiced for goods or a 
service rendered but has not yet paid. Hence, a ‘bad 
debtor’ is a third party from whom a debt is very 
unlikely to be recovered
Delivery note A voucher recording receipt of an item (i.e. that it has 
been delivered)
Depreciation An expense recorded in the accounts to reduce the 
value of a long-term fixed asset to reflect the fact that it 
will be worth less, the older it gets
Direct costs A cost that is directly attributable to an activity, service, 
or capital item (for example, purchase of a computer or 
a flight)
Expected income and expenditure Expected income is usually from the funder. Expected 
expenditures are the anticipated running/recurrent 
or capital costs. These expected costs will help with 
forecasting at year-end
Expenditure Money paid out; an amount of money spent
External audit Check on the accounts by a person who is independent 
of the organization, usually an accountant with special 
training to be an auditor
Financial manual (or financial 
regulations)
A manual containing a full set of financial policies and 
procedures. These will support financial management
Fixed assets Items (such as equipment, vehicles, or buildings) that 
are owned by an organization and are intended for use 
on a continuing basis in the organization’s activities. 
In practice, this means for more than one accounting 
period. The cost is usually apportioned (or depreciated) 
over the asset’s useful life
Fixed assets register Sometimes shortened to assets register. A list of the 
fixed assets of the organization, usually giving details of 
value, serial numbers, location, purchase date, etc.
Forecasting The estimation of the (future) year-end (or next 
month/quarter) position with regard to income and 
expenditure
Imprest There are two alternative definitions of this term, so it is 
best avoided. It is sometimes synonymous with petty cash 
float, but it is also sometimes used to mean an advance
Income Money paid in
continued
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Income and expenditure accounts The income and expenditure account includes all 
income generated and expenditure incurred over the 
accounting period and shows the resulting surplus or 
deficit achieved by the organization for the period. 
These accounts are usually broken down by cost codes
Indirect costs Also known as overheads. A cost which cannot be 
directly allocated to a specific activity, service, or capital 
item but which is more general in nature (for example, 
to cover the utility, insurance, infrastructure, general 
administrative, management, and governance costs, 
etc. for the running of an organization)
Inflation A general increase in prices and consequent decrease in 
the purchasing power of money
Internal audit An audit that is carried out by the organization that 
holds the account
Invoice A written request for payment received from a supplier 
for specific goods or services
Journal voucher A voucher that records an entry in the accounts that 
relates to a non-monetary transaction, for example, 
for recording a donation in kind or depreciation or to 
correct a previous error in the accounts
Ledger A collection of accounts of a similar type such as an 
advances ledger or a ‘taxes withheld ledger’
Liability An amount owed by your organization to others, 
including loans, accruals, grants received in advance, 
and outstanding invoices
Loan funding provided, which must be repaid
Overheads Also known as indirect costs. A cost which cannot be 
directly allocated to a specific activity, service, or capital 
item but which is more general in nature (for example, 
to cover the utility, insurance, infrastructure, general 
administrative, management, and governance costs, 
etc. for the running of an organization)
Petty cash Money kept as cash for making small payments below 
a certain threshold to save needing to go to the bank to 
withdraw funds too frequently
Petty cash book The day-to-day listing of petty cash paid in and given 
out
Petty cash float A sum of money, set at an agreed level, which is 
topped up by the exact amount spent since it was last 
reimbursed, to bring it back to its original level. See also 
petty cash and petty cash book
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Receipt A formal record received from a supplier that confirms 
that a specific amount of money was paid for certain 
goods or services. Also given to anyone who buys 
goods or services from the trial
Reconciliation Checking mechanism which verifies the integrity of an 
accounting system by comparing account balances to 
an independent source (for example, a bank statement) 
or by identifying the individual balances which make 
up a total account balance (for example, comparing 
the total of individual asset balances to the total of the 
fixed asset account)
Storekeeping The process for managing stock
Stores A generic term either for stock or for the place where 
the stock is kept when not in use
Supporting documents Original documents to support income and expenditure 
(for example, receipts, invoices, bank statements, 
journal vouchers, purchase orders, delivery notes, 
approvals, etc.)
Tender An offer made in writing by one party to another to 
execute specific work, supply certain commodities, etc. 
at a given cost
Trial balance A listing of the balances on all the accounts that relate 
to this specific account, with debit balances in one 
column and credit balances in another. The totals of 
each column should match
Variance Difference between the budget and actual amount 
of income and/or expenditure. Variances are often 
described as ‘adverse’ or ‘favourable’
Variance analysis Part of budget monitoring, looking at the significant 
variations between the budget and actual income and 
expenditure, and seeking to explain why they exist and 
what can be done to rectify the position
Virement Transfer of funds from one budget/budget line to 
another. If a virement exceeds the threshold that has 
been pre-agreed with the funder, this will require 
formal approval from the funder, usually in advance
Waybill A list of goods sent by a carrier, such as a courier, road 
haulage, railway, or air-freight company, that states the 
route that the goods will follow
Adapted with permission from Lewis, T., Financial management essentials: A handbook for NGOs, Manage-
ment Accounting for Non-governmental Organisations (MANGO), Oxford, UK, Copyright © 2014, avail-
able from <http://www.mango.org.uk/Guide>. This table is distributed under the terms of the Creative 
Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is available 
at http://creativecommons.org/licenses/by-nc/4.0/.
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1 Introduction to intervention costing  
and economic analysis
This book is focused on intervention trials in which the effectiveness of some new or 
modified intervention is compared with a control intervention, which would generally 
be the currently used intervention for a particular disease or condition. At the end of 
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the study, estimates should be available of the impact of the intervention, compared 
to the control intervention. However, the decision on whether or not to apply the new 
intervention in a public health programme will be governed not only by the effective-
ness of the intervention, but also by its costs. This chapter gives an overview of the main 
methods used to assess the costs of health interventions and summarizes the types of 
economic analyses that can be conducted to assist decisions concerning resource al-
location to the deployment of health interventions. Just as the statistical design and 
analysis aspects of a trial will generally require the involvement of a statistician, from 
an early stage, in the planning of a trial, similarly it is highly recommended that a health 
economist be involved from the stage of initially planning the trial to advise on how 
costs should be measured during the course of the trial and on how these will be used 
at the end for an economic analysis that may ultimately influence whether or not an 
intervention is implemented on a widespread basis. The chapter is aimed at those who 
will be working with economists, in order to help design and conduct the economic as-
pects of a field trial to collect the appropriate data and to obtain the most useful results 
from an economic analysis.
In the wider scheme of things, governments have to make decisions about resource 
allocation between health and all the other sectors such as defence, education, and 
agriculture. Along with social, political, and logistic considerations, economic analyses 
should be an important component in decision making about those allocations. In gen-
eral, economic analysis should take into account the benefits of using resources for a 
proposed action, compared to the use of those resources for any other purpose. How-
ever, such broad considerations are well beyond the scope of the present book! Instead, 
we focus on the more narrow comparison of the costs and benefits of deploying a new 
or modified health intervention, compared with the currently used intervention.
2 Types of economic analyses
The main types of economic analyses are cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA), and cost-benefit analyses (CBA). How the results of these different 
kinds of analysis are expressed is shown in Table 19.1. CEA and CUA are those most 
commonly used in the analysis of health interventions. The problem with CBA is that it 
requires putting a monetary value on a life saved.
Analysis of the costs involved in providing the health interventions under compari-
son in a trial is needed for all three types of analysis. Measurement of these costs can 
be made in the context of an intervention study, provided due account is taken of the 
fact that the costs associated with an intervention in a trial may be different from those 
which would apply if the intervention was applied in a public health programme. It is 
important therefore to separate out any trial-specific costs that would not be incurred 
in more widespread deployment of the intervention. For example, often checks are 
made in a trial that the intervention has been delivered to participants in the appro-
priate fashion at an appropriate time. Such checks might not be made, or not be made 
with the same rigour, in the context of the deployment of the intervention in the rou-
tine public health system. However, there may be additional costs in the public health 
deployment of an intervention that would not be incurred in a trial. For example, drugs 
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or vaccines for use in a trial are often donated, whereas, for public health use, they may 
have to be purchased.
2.1 Cost-effectiveness analysis
CEA has been the most commonly employed type of economic analysis used in relation 
to randomized trials of health interventions. CEA compares the costs to accomplish a 
specific technical goal by a new method with the costs of the present method such as 
the costs per case of a particular disease diagnosed by the new method with the costs 
per case of disease diagnosed using the current diagnostic method, or the costs of the 
prevention of a death from a given cause by the new intervention compared to the costs 
of the prevention of a death with the present intervention. Note that it is the incremen-
tal cost-effectiveness ratio that captures the value of the new method being examined, 
i.e. the difference in costs between the new method and the present method, divided by 
the difference in effects between the new method and the present method. This sum-
mary measure thus captures the extra cost per additional unit of effect and begs the 
question ‘is it worth it?’.
2.2 Cost-utility analysis
For CUA, the effects of an intervention are expressed as a measure of ‘utility’. Simply, 
the utility is a measure of the impact of the intervention on the health status of the in-
dividual or population, commonly stated as a combined measure of mortality (amount 
of life lost due to premature death) and morbidity (amount of life lived with disability, 
weighted according to its seriousness and duration). Commonly used utility measures 
are the disability-adjusted life-year (DALY) and the quality-adjusted life-year (QALY) 
(Hyder et al., 2012).
Table 19.1 Types of economic analysis
Type of analysis Costs Outcome (effect) Results expressed as:
Cost Monetary units 
(commonly US $)
Not relevant $ per unit of output 
(for example, $ per fully 
vaccinated child)
CEA Monetary units 
(commonly US $)
Effect of intervention (for 
example, cases prevented)
$ per effect (for example, 
$ per case prevented)
CUA Monetary units 
(commonly US $)
Premature mortality 
and disability averted 
(measured in DALYs) or 
healthy life time gained 
(QALYs)
$ per DALY averted or QALY 
gained
CBA Monetary units 
(commonly US $)
Monetary units (for 
example, value of a 
statistical life)
Benefit–cost ratio or 
net present value (for 
example, money value of 
benefits–costs)
DALY, disability-adjusted life-year; QALY, quality-adjusted life-year.
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2.2.1 Disability-adjusted life-years and quality-adjusted life-years
The DALY was first given prominence in the World development report 1993 (World 
Bank, 1993) and has become the most widely used composite measure of population 
health in LMICs. It built on earlier work by the Ghana Health Assessment Project Team 
(1981) who introduced the similar concept of ‘amount of healthy life lost’, combining 
measures of the effects of a disease, in terms of life lost both from mortality (expected 
years of life remaining had the disease not occurred) and from morbidity (severity and 
duration of disability).
DALYs are calculated by combining the years of life lost (YLL) from premature mor-
tality with the years of life lived with disability (YLD), weighted according to a severity 
grading. Thus:
                          DALY = YLL + YLD.
As originally formulated, the DALY directly incorporated three social value choices: 
(1) life expectancy values, (2) discount rates for future life, and (3) variable weighting 
for life lived at different ages. The recent Global burden of disease report for 2010, how-
ever, has dropped both discounting and age weighting (Murray et al., 2012).
A related measure, the QALY, was introduced in 1976 to provide a guide for indi-
viduals to select among alternative tertiary health care interventions (Zeckhauser and 
Shepard, 1976). The idea was to develop a measure of quality of life that would enable 
investigators to compare expected outcomes from different interventions, a measure 
that valued possible health states both for their impact on the quality of life and for their 
duration. The measure sums the time an individual spends in different health states, 
using weights on a scale of 0 (in a state equivalent to being dead) to 1 (perfectly healthy) 
for each health state; it is the sum of arithmetic products of the duration of time spent 
in a state and a measure of the quality of life in that state. QALYs in modified forms 
have come into widespread use in the UK (by the UK National Institute for Health and 
Clinical Excellence), Europe, and the USA (by the US Agency for Healthcare Quality 
and Research).
Despite distinctly different origins, DALYs and QALYs, with appropriate formu-
lation and comparable parameters, can be considered equivalent indicators to assess 
intervention utility. However, there are many versions of both DALYs and QALYs, 
and it is very important to know exactly what is being counted in the study under 
consideration.
2.3 Cost–benefit analysis
CBA goes a step beyond CEA or CUA and expresses both costs and effects (or util-
ity) of interventions in monetary terms. It directly compares the monetary costs of 
an intervention with the monetary benefits from the intervention. If the monetary 
benefits from an intervention exceed the monetary costs, the decision is straightfor-
ward in purely economic terms—implement the intervention. For most sectors, other 
than health, CBA is the standard form of economic analysis, and it lies at the centre 
of decision making in these sectors. For example, the decision to build a new road 
would be based on considerations of the cost of building the road, compared to the 
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economic benefits it would bring (which might include reduction of wear and tear on 
vehicles, increased speed of delivery of people and goods, increase in trade, and also 
reduction in injuries and deaths from accidents). The aspect that has impeded its use 
in the health sector is that, in order to use CBA, a monetary value must be placed on 
human life. Some argue that this is done implicitly in any decision process, but there 
has been a reluctance to do this explicitly. Nevertheless, it should be recognized that 
decisions are regularly being taken in both public and private sectors that implicitly 
do place a monetary value on life. There are several different approaches to valuing 
human life which may give marked different results (Australian Safety and Compen-
sation Council, 2008; Viscusi and Aldy, 2003), but further discussion is beyond the 
scope of this book.
Sometimes, a narrower perspective may be taken with respect to CBA. For example, 
in consideration of whether the public health service should introduce a vaccine against 
pneumonia, the costs assessed may be limited to those for the health system. If the vac-
cine reduces the incidence of pneumonia, the costs of delivering the vaccine to the 
at-risk population could be compared with the reduction of health service costs from 
fewer cases of pneumonia to treat. If there is a clear benefit, simply based on a CBA 
that only considers costs spent and saved by the health system, the decision about the 
introduction of the vaccine may be relatively straightforward. It becomes more compli-
cated if there is not a monetary saving to the health system (for example, it costs more 
to deliver the vaccine than the saving in health service costs), but there is a reduction 
in mortality and/or morbidity in the population. In fact, a ‘true’ CBA requires a com-
prehensive and comparable range of inputs and outcomes, all expressed in monetary 
terms and, for fatal diseases, that would include putting an explicit monetary value on 
human life at different ages.
3 Framing the analysis
For all types of economic analyses, the perspective, range of inputs and outcomes, and 
the time frame of all components of the interventions and of their effects should be 
comparable and explicitly stated. The focus of this chapter is on CEA conducted in 
the context of randomized trials. For purposes of health intervention assessment, we 
generally take the perspective of society as a whole and attempt a comprehensive con-
sideration of the range of inputs to be costed and of outcomes to be considered that 
result from the intervention. The time frame will be the period of time over which these 
inputs and outcomes will be assessed.
3.1 Perspective
Quantification of the economic consequences of disease and the full costs of an inter-
vention can be viewed from different perspectives, for example, an individual, family 
(household), community, health system, or government (local, district, national). The 
societal viewpoint examines the economy as a whole. Though, for some purposes, the 
perspective of the individual and family or of the health system may be appropriate, 
taking this narrower view can be misleading and lead to erroneous conclusions about 
the best use of resources from a societal perspective. For example, the cost to the health 
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service of providing access to treatment at a clinic would be much less than the cost of 
taking the treatment to patients at home. However, the reverse would be the situation 
for patients. A societal perspective would take both sets of costs into account.
3.2 Range of inputs and outcomes
The economic consequences (costs) of disease are directly related to the type and extent 
of disability and, for fatal diseases, to the age at death, with loss of expected healthy life 
that results from the disease. Ideally, all consequences of disease that the intervention 
addresses should be tracked (and valued), including loss of work, education, and leis-
ure of the patient, family, and friends, emotional stress, fear, and anxiety. To a large 
extent, these consequences may be subsumed in measures of utility lost from disease 
(see Section 2.2).
3.3 Time frame
Generally, time factors involved in assessing the costs of interventions are fairly 
straightforward, whereas the time factors for assessing the outcomes of an intervention 
may be much more problematic. For example, the costs of adding hepatitis B vaccine 
to an immunization programme are immediately expended, but the most important 
consequences of hepatitis B infection include chronic liver disease and liver cancer 
that occur many years after the initial infection. Adequate assessment of the impact of 
a hepatitis B vaccine will require continuing observations of the trial populations for 
very long periods. Usually, the longer term is modelled, rather than measured. Further-
more, since these gains in healthy life will occur in the distant future, some would argue 
that their value should be discounted in some way. The key issue related to the time 
frame concerns the differential timing of intervention costs and intervention effects, 
and this is particularly problematic if these differ between interventions under con-
sideration (for example, comparing measles vaccination with hepatitis B vaccination). 
Generally, there is a longer gap between a preventive intervention and realization of its 
effects than there is with treatment interventions. Whatever the nature of differential 
timing, discounting should be considered to equate future costs or effects to present 
costs or effects. It is generally accepted that discounting should be applied to costs, but 
discussions continue concerning whether to discount future effects and, if so, what rate 
of discounting to apply (Mathers et al., 2006).
Joint costs are those resources that are shared with other interventions or pro-
grammes. Costs frequently shared include buildings and their overhead costs such as 
for maintenance, electricity, and water. Other types of joint costs might include per-
sonnel or equipment such as those involved in diagnostic tests that typically are shared 
among several interventions. In practice, joint costs are estimated by applying some 
allocation rule related to the use of the resource. For example, personnel costs can be 
allocated to the intervention on the basis of the proportion of time devoted to it, ve-
hicle costs according to the proportion of the total distance travelled, and building costs 
by the proportion of the space used. The notion of joint costs is straightforward, but 
exactly how best to do that is often problematic. Creese and Parker (1994) discuss the 
allocation of joint costs.
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4 Health intervention costs
When planning to obtain cost information in the context of an intervention trial, it is 
important to plan and budget for the collection of cost data as an integral part of the 
trial design. While it is usually possible to carry out an economic analysis with retro-
spective estimation of costs at the end of the trial, this is likely to be less satisfactory 
than if the cost data are obtained concurrently.
4.1 Types of costs
Two types of costs should be considered in analysing the costs of a health intervention: 
the costs of providing the intervention (provider costs) and the costs of obtaining it 
(user costs).
4.1.1 Provider costs
Many kinds of inputs are needed to carry out health interventions. A helpful way to de-
scribe and catalogue the inputs required is to plot each step in the intervention process 
on a flow chart, reviewing all inputs needed (costs) at each step. The Panel of Experts 
on Environmental Management (PEEM) for Vector Control guidelines (Phillips et al., 
1993) provide an excellent framework for estimating both financial and economic costs 
of an intervention. Financial costs are expenditures on the inputs for the intervention 
(the usual lay use of the term ‘cost’); economic costs are the value of the benefits fore-
gone by employing the resources for the intervention, rather than for something else.
A common approach to categorizing costs is to separate them into recurrent and 
capital (Box 19.1).
The main categories of cost involved in providing a health intervention are likely to 
include staff time, provision of drugs or vaccines, laboratory tests, other diagnostics, in-
formation and education costs, transport costs, utilities, space or rent costs, equipment, 
any incentives or reimbursements provided to patients, and other administrative costs, 
including any indirect costs or ‘overheads’. Most of these data can be obtained from the 
project accountant or the health facility or the health programme itself. It may be worth 
focusing time and effort to get more precise estimates of costs of the items that account 
for a large share of the budget. Staff costs are likely to be a major component, and get-
ting as much precision as possible, in terms of the time allocation of different categories 
of staff and their different salary levels, will be essential. For example, if, in one arm of 
the trial, the patients are seen by a doctor and, in the other arm, by a nurse, it is import-
ant to establish the number of hours and the hourly rate of the two categories of staff. 
It is also useful to focus on those elements that are likely to differ between arms of the 
trial; if the trial is comparing a laboratory-intensive intervention with an intervention 
that depends simply on clinical signs, it will be important to obtain as much precision 
as possible on the costs of laboratory tests involved.
4.1.2 User costs
The second type of cost data to be collected includes the costs patients and families 
incur in seeking care or availing themselves of the intervention. Usually, these data can 
be collected fairly simply through a brief interview with patients. A short questionnaire, 
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using only a few questions, can provide sufficient data to estimate patient costs. PIs are 
often reluctant to add questions to existing instruments, and even more reluctant to 
add entire new questionnaires, however brief. But the downside of not collecting pa-
tient cost data may be large.
Patient cost elements may include:
◆	 cost of travel to and from a clinic to obtain the intervention
◆	 time of patients and, where relevant, their family for travel to the clinic or inter-
vention site
◆	 other costs incurred—lunch, overnight stay, childcare, etc.
◆	 wages/salary foregone or costs of work not done (for example, on the family 
farm).
As an example of the importance of estimating patient costs, in a trial in Uganda, 
HIV-infected patients were randomized to receive home-based or facility-based deliv-
ery of antiretroviral therapy. The outcomes (disease progression) for patients in the two 
arms were similar, but the home-based strategy, which relied on monthly home visits 
by trained lay workers, used less of the time of doctors and nurses. However, the main 
difference in cost-effectiveness was due to the costs to patients in obtaining care; the 
cost of a clinic visit was assessed as, on average, $2.30, which represented about 13% of 
reported monthly cash incomes for men and 20% for women (Jaffar et al., 2009). Given 
the disparities in average wealth, this level of expenditure would be approximately 
Recurrent costs—those used up in the course of a year and needing regular replen-
ishment such as:
◆	 personnel and other labour (wages, salaries)
◆	 supplies
◆	 building operating and maintenance costs (electricity, water, etc.)
◆	 in-service training (in-service courses for specific skills and knowledge)
◆	 information, education, and communication (IEC) costs.
Capital (fixed) costs—investments in items that last for more than a year such as:
◆	 buildings
◆	 vehicles
◆	 equipment
◆	 basic training
◆	 land.
Generally, capital costs are discounted over the expected lifespan of the entity.
Box 19.1 Categorization of costs into recurrent 
and capital
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equivalent to an average European taking an intercontinental flight every month for 
a clinic visit!
Saunderson (1995), in an economic evaluation of options for the treatment of TB 
in Uganda, found that 70% of the cost of tuberculosis treatment was borne by patients 
themselves. Similarly, Ettling et al. (1991) found that 90% of the costs of seeking treat-
ment for malaria fell on patients, while Needham et al. (1998) found that patient costs 
of seeking care for tuberculosis in Zambia were prohibitive.
4.2 Approaches to costing
Although categorizing and listing costs of inputs needed for interventions are an im-
portant first step, there are three further important aspects of costing that should be 
considered to ensure comparability and completeness. The first is to examine costs by 
unit of service (such as days in hospital, outpatient visits, education campaign, or deliv-
ery of bed-nets or vaccines to a community). The second is to use a functional approach 
to costing, such as activity-based costing (ABC), where each specific activity, such as a 
hospital-based delivery, is costed. This is more useful for understanding the nature of 
costs than that of a line item that simply lists costs by type of input such as personnel 
or travel. The third is to annualize all costs for a given population for a given period of 
time, using depreciation methods for capital expenditures and appropriate discount 
rates, to bring all costs to the current year value (see Section 3.3).
Functional costing is usually based on a unit of service such as an outpatient visit or a 
hospital stay. All activities (processes) needed to carry out a unit of service are mapped 
out by a flow chart; each step in the process is analysed for the inputs used, including 
personnel time and overhead; a cost schedule is constructed to determine the full costs 
of each activity; and finally these are summed to determine the costs of that unit of 
service.
The idea of putting all costs involved in providing a service (intervention) onto a 
comparable basis of time and population is straightforward, but the details of depreci-
ation and appropriate rates of depreciation for different inputs are beyond the scope of 
this chapter, and input from a health economist should be sought.
4.2.1 Valuing resource use
Sometimes, unit costs will be estimated from trial centres, but more commonly they 
are derived from national data. Another option is to use the estimates provided by the 
WHO-CHOICE programme (<http://www.who.int/choice/en>). WHO-CHOICE has 
the objective of ‘providing policy makers with the evidence for deciding on the inter-
ventions and programmes which maximize health for the available resources’. Among 
the data provided are unit cost estimates for a variety of health services, by country or 
region; examples include the cost of a hospital bed-day by type of hospital, outpatient 
visit, and other patient-level costs.
As indicated in Section 1, collection and management of costing data should be 
planned during the study design phase and linked to the intervention outcome data. 
As with any prospective study, there should be a plan for ongoing data quality moni-
toring to address missing and poor-quality data issues immediately. Queries should 
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be managed on an ongoing basis, rather than at the end of the trial, to maximize data 
completeness and quality and the timeliness of the final analysis.
5 Presentation of results
The incremental cost-effectiveness ratio (ICER) is a common way of summarizing re-
sults from a cost-effectiveness study (expressed as the ratio of two differences in costs 
and in effects of the alternative interventions):
ICER =  {Cost (new intervention) – Cost (current intervention)}/ 
{Effect (new intervention) – Effect (current intervention)}
The result can be considered as the cost of the additional effect obtained by switching 
from current practice to the new intervention. If the differential cost is low enough or 
the differential effect is large enough, the new intervention is considered ‘cost- effective’, 
as compared to the current. If an intervention is considered to be ‘cost-effective’, it 
means that local and/or global policymakers believe it is worth paying the amount es-
timated to produce an additional unit of effect.
Table 19.2 indicates the various ways a new intervention might be compared with 
the current intervention. Note that the decision is straightforward only if a new inter-
vention is both less effective and more costly (or both more effective and less costly).
CEA is sensitive to the choice of interventions being compared. Researchers should 
consider whether the choices of interventions being compared are really the choice of 
interest. Clearly, this decision must precede the final design of the trial.
Consider two strategies intended to lengthen life in patients with heart disease. One 
is ‘simple’ and cheap (for example, aspirin and beta (β)-blockers) and lengthens life, 
on average by 5 years; the other is more ‘complex’, more expensive, and more effective 
(for example, aspirin and β-blockers plus cardiac catheterization, angioplasty, stents, 
and bypass), lengthening life, on average, by 5.5 years. Table 19.3 shows the relevant 
(hypothetical) data.
The incremental cost of the simple intervention is the difference between the cost 
of that strategy ($5000) and the cost of doing nothing ($0), so the ICER = ($5000 − 
$0)/(5.0 − 0.0) = $1000/life-year gained. The incremental cost for the complex inter-
vention relative to the simple intervention is the difference between the cost of the 
complex intervention ($50 000) and the cost of the simple intervention ($5000), so the 
ICER = ($50 000 − $5000)/(5.5 − 5.0) = $90 000/year gained.
Table 19.2 Cost-effectiveness analysis as an aid to decision making
Effectiveness Cost
New intervention costs more New intervention costs less
New intervention is more 
effective
CEA needed Adopt new intervention
New intervention is less 
effective
Do not adopt new intervention CEA needed
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
3336: GENERALIZABILITY
Thus, implementation of the simple intervention costs $1000 for every year of 
life gained, and implementation of the complex intervention, compared to the sim-
ple intervention, costs $90 000 for every year of life gained. The decision maker will 
have to decide between these different options, based upon the resources available 
and taking into account the years of life that might be gained (and the cost of so 
doing) by intervening against different diseases (with different interventions). But, 
in this example, while paying $1000 for an extra year of life seems cost-effective, pay-
ing $90 000 for an additional year of life appears to be a less worthwhile use of scarce 
resources. In practice, comparison is often made to cost-effectiveness ‘thresholds’, in 
order to facilitate the interpretation of ICERs. The most commonly used threshold 
is the gross domestic product (GDP) per capita of the country in question, i.e. if the 
cost per DALY averted or QALY gained is less than the country’s GDP per capita, then 
the intervention being assessed is considered to be relatively cost-effective and hence 
worth implementing.
For those who wish to pursue these issues further, Drummond (2005) and Eichler 
et al. (2004) give a much fuller discussion of CEA.
6 Generalizability
6.1 Uncertainty
Results of economic evaluations in trials are subject to several sources of uncertainty.
6.1.1 Sampling uncertainty
Economic outcomes in trials are usually based on effectively a single sample drawn 
from the population. In general, there is uncertainty with respect to both costs and out-
comes, and this variability should be reflected in CEAs to determine to what extent un-
certainty in the estimates might influence the decisions that might be made as a result 
of the analyses. For example, if an intervention appears to be, on average, cost-effective, 
but the uncertainty interval includes instances of cost-ineffectiveness, then the confi-
dence with which the intervention can be recommended might need to be tempered. 
Methods for taking into account uncertainty are not always straightforward and gener-
ally benefit from the input of a health economist.
Table 19.3 Example of the application of cost-effectiveness analysis
Strategy Additional 
cost
Incremental  
cost
Effectiveness 
(years gained, 
compared to 
‘nothing’)
Incremental 
effectiveness
ICER ($/year 
gained)
Nothing (0) – – – 0.0 –
Simple 
intervention (S)
$5000 (S vs 0) $5000 5.0 5.0 − 0.0 = 5.0 $1000
Complex 
intervention (C)
$50 000 (C vs S) $45 000 5.5 5.5 − 5.0 = 0.5 $90 000
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6.1.2 Parameter uncertainty
Uncertainty related to parameter estimates, such as unit costs and the discount rate, 
should be assessed by the use of sensitivity analysis. For example, if a discount rate of 
3% is used, it may be desirable to assess the impact of this assumption by repeating the 
analysis, but using a 0% or 5% rate. Analysts should evaluate the effect of varying all 
major cost parameters (such as the proportion of personnel time allocated to the inter-
vention), as this may influence policy decisions.
6.2 Policy inferences
Policy inferences about the adoption of an intervention should be based on the level of 
confidence that the cost of the intervention for a unit of outcome, for example, a DALY, is 
affordable, with a threshold, or ceiling, beyond which it would be unacceptable to adopt it. 
Ranges of ceiling ICERs should be reported, for which the analyst: (1) is confident that the 
intervention is good value for the cost; (2) is confident that the intervention is not good 
value; or (3) is unsure that the cost-effectiveness of the two interventions differ from each 
another sufficiently to make a choice between them based on the ICER alone. Policymakers 
can then draw inferences by identifying into which of the ranges it falls. The ranges of ceil-
ing ratios where the analyst can and cannot be confident about the value of a new interven-
tion relative to the current intervention can be calculated by the use of confidence intervals 
(CIs) for the cost-effectiveness ratios, allowing for the various sensitivity analyses done.
6.3 External validity
Some field trials may have low external validity (i.e. they cannot be generalized easily, 
and the impact of the intervention may be different when applied in a public health 
setting). The threats to external validity come from:
◆	 inclusion of study sites with access and availability of health care services which 
are not representative of the wider population that would be targeted in a public 
health programme
◆	 restrictive inclusion and exclusion criteria (patient population, disease severity, 
co-morbidities)
◆	 artificially enhanced compliance (for the purposes of the trial).
In such circumstances, it might be possible to test the potential cost-effectiveness 
of the new intervention in programmatic conditions within sensitivity analyses, after 
making assumptions about how each of these factors might differ in the routine pro-
grammatic situation relative to the situation within the trial.
7 Modelling
The cost-effectiveness measured within the trial follow-up period may be substantially 
different from what would have been observed with longer follow-up. For example, at 
the time a phase III trial is completed and a vaccine is licensed, there may still be sub-
stantial uncertainty about the duration of protection offered by the vaccine beyond the 
follow-up period in the trial. Modelling of various kinds can be used to estimate costs 
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and outcomes that would have been observed had follow-up of the trial population 
been prolonged. This involves projecting costs and outcomes over the expected dur-
ation of disease and of the intervention and its effects. This may involve making sig-
nificant assumptions about the future, for example, the life expectancy of a patient on 
a given treatment. Any such assumptions should be specified. In general, modelling of 
costs and effectiveness of interventions is being more widely used to assist in decision 
making (World Health Organization, 2004) but is beyond the scope of this book.
8 Publication of findings
The impact of a publication on health practice and policy is likely to be strengthened if 
the results of an economic analysis are included in the main publication from an inter-
vention trial itself. However, constraints on word limits often mean that full details of 
the economic analysis methods cannot be included. Thus, it is common practice to 
write a companion paper, in which the data collection method, analytic techniques, 
and assumptions for the economic analyses are fully presented and discussed. An ex-
ample of the abstract from such a paper is shown in Box 19.2.
THE TRIAL: A community-randomised trial was undertaken to assess the impact, 
cost, and cost-effectiveness of averting HIV-1 infection through improved manage-
ment of sexually transmitted diseases (STDs) by primary-health-care workers in 
Mwanza Region, Tanzania.
METHODS: The impact of improved treatment services for STDs on HIV-1 in-
cidence was assessed by comparison of six intervention communities with six 
matched communities. We followed a random cohort of 12 537 adults aged 15–54 
years for 2 years to record incidence of HIV-1 infection. The total and incremental 
costs of the intervention were estimated and used to calculate the total cost per case 
treated, the incremental cost per HIV-1 infection averted, and the incremental cost 
per disability adjusted life-year (DALY) saved.
FINDINGS: During 2 years of follow-up, 11 632 cases of STDs were treated in the 
intervention health units. The incidence of HIV-1 infection during the 2 years was 
1.16% in the intervention communities and 1.86% in the comparison communities. 
An estimated 252 HIV-1 infections were averted each year. The total annual cost of 
the intervention was US$59 060, equivalent to $0.39 per head of population served. 
The cost for each STD case treated was $10.15, of which the drug cost was $2.11. 
The incremental annual cost of the intervention was $54 839, equivalent to $217.62 
per HIV-1 infection averted and $10.33 per DALY saved (based on Tanzanian life 
Box 19.2 Cost-effectiveness of improved treatment 
services for sexually transmitted diseases in preventing 
HIV-1 infection in Mwanza Region, Tanzania
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1 Introduction to data management
All intervention trials involve the collection and management of data, often in large 
quantities. In order to get the most out of study data, it is important to have worked 
through plans for the collection, management, and use of the data early in the plan-
ning stages of a trial. Previous editions of the Toolbox discussed the role and choice of 
computers in the management of trial data, but now they are so ubiquitous that there 
will be few trials in which they are not central to data handling and analysis. Indeed, de-
velopments in computing have changed the way that trials are conducted, from the way 
that data are collected through to the way data are used and disseminated. However, 
in the processing of data, it is important to remember the ‘GIGO’ principle ‘garbage 
in, garbage out’! The data used in final data tables are only as good as the data that go 
into their construction. Thus, while developments in computer hardware and software 
have made the processing and analysis of data much quicker, it is still necessary to pay 
careful attention to the way in which the original data are collected and recorded in the 
field and transferred from one program to another during the data management pro-
cess. Every instrument used in the study, including questionnaires, laboratory meth-
ods, and data management programs, must be properly validated and tested and have 
good quality control (QC) procedures in place throughout the trial. Great attention to 
detail is necessary in every step the data take, in the design of data forms, in the record-
ing of data in the field, in transferring the data from paper to the computer (if data are 
not collected digitally), in the transfer from one software package to another, and in 
how they are manipulated and managed in computer packages and programs. These 
data processing aspects are the focus of this chapter. The chapter focuses exclusively on 
quantitative data. 
Section 2 covers some of the data-related issues that should be resolved before the study 
starts, and Section 3 concerns the planning that should be done for the data flow within 
the study. Sections 4 to 7 deal with various specific issues related to data flow and data 
management. This chapter can only give a basic introduction to key issues related to data 
management. More detailed explanations are available in various books and other re-
sources. The general principles of data management are covered in books by Hernandez 
(2013), Powell (2006), McFadden (2007), Murrell (2009) (available free via <https://www.
stat.auckland.ac.nz/~paul/ItDT/>), Prokscha (2012), and Pryor (2012). Other free online 
resources are provided for specific data management software, such as Epi-Info (<http://
wwwn.cdc.gov/epiinfo>) and EpiData (<http://www.epidata.dk>), or Microsoft Access™ 
(<http://office.microsoft.com/en-us/access/>) such as for Access 2007 (<http://office.
microsoft.com/en-us/access/HA012242471033.aspx>), and there is a useful web-based 
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discussion group for data managers within the Global Health Trials website (<http://
globalhealthtrials.tghn.org/community/groups/group/data-management-statistics/
topics/290>).
2 Before starting to collect data
All trials need appropriate resources to collect data and information, to check the con-
sistency and quality of the data, and to organize the data into a suitable form for analy-
sis. It is important that all the steps of the trial and the associated data flow are planned 
before starting the trial, and the resources needed at each step are defined. This section 
describes the different hardware, software, personnel, and systems needed to process 
data in a trial. When considering the trial budget, resources must be allocated for all of 
these aspects, and often components have to be capable of multitasking, for example, 
computers that can be used for both data entry and administrative functions, and soft-
ware that can manage different data formats.
There are four components to the description of the data processing for a trial:
 1 hardware, i.e. any physical entity used for data processing. This may include com-
puters, printers, and electronic hardware, but also includes paper, pens, and other 
equipment used to collect, transfer, and archive the data
 2 software, i.e. the programs needed to make the hardware manipulate and process 
the data for the study
 3 personnel that are needed for the data processing
 4 the systems and organization that must be in place to bring all of the different 
components together.
2.1 Hardware
The commonest hardware used in a small trial is still paper questionnaires and forms. 
Much of what is done is recorded on paper, and, at all stages, paper copies are kept as 
the definitive record. The advantage of using paper is that it is a physical entity, which 
preserves the data content. The disadvantage is that it is difficult to process and analyse, 
particularly in large quantities. Data collected or stored electronically are much easier 
to manipulate and use in a variety of different ways.
If paper systems are used to collect data, it is important to include, in the planning, 
provision of all the necessary ancillaries for the paper collection such as pens, clip-
boards, and storage boxes. Management of the paper is also an issue that needs to be 
thought through to the end of the trial and beyond, with proper filing systems and 
archives for data storage. Paper systems need to be integrated with the computer hard-
ware and software used in the study, first to do the printing of the questionnaires and 
other forms, and second to take the data from the forms and input them into a com-
puter package for electronic checking and analysis.
The use of computers to collect, process, and analyse data is ubiquitous nowadays. 
There are so many different computers, and they are continually getting better and 
faster that it is impossible to give very specific guidance on which would be best for par-
ticular studies. Much depends on the way the data management for the study has been 
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planned and what software the analyst is already familiar with. One way to divide up 
the many computer hardware options is through the distinction between desktops, lap-
tops, mobile devices, and servers. Desktops are useful for data entry and when there are 
many people wanting to share a computer for short periods of time, for example, field 
supervisors who need to input a report at the end of the day. Desktops are also needed 
for some of the administrative functions, but, in general, it is good to keep the research 
data physically separate from the administrative computers that the project needs.
Laptops provide comparable computing power to desktops and can be used to col-
lect and manage data in the field, even where mains electricity is not widely available. 
Smaller devices, such as PDAs or ultra-mobile personal computers (UMPCs) or even 
‘smart’ mobile phones, are easier to use and transport in the field than laptops. With 
laptops and smaller mobile computing devices, two issues need to be considered; first, 
the smaller the device, the easier it is to lose or be stolen, and second, these devices have 
batteries that need recharging and periodically replacing. When purchasing laptops 
and smaller devices, buying a security cable for each machine, where appropriate, is 
often a good investment. It is also important to make sure that the person respon-
sible for the computer uses the security cable and the procedures are well known to 
all, as it only takes a minute to lose large amounts of data if a computer is stolen. If in 
continuous use, recharging laptops, PDAs, UMPCs, or mobile phones can be a time-
consuming task. Long-life batteries can be used to extend the time the machines can be 
used between charging, and, if mains power is available, recharging can be done at meal 
breaks and overnight. Otherwise, inverters can be used to charge from car batteries or 
from solar panels.
PDAs, tablet computers, mobile phones, and other devices can be programmed to ac-
cept electronic questionnaires and can also be purchased with GPS software, cameras, 
bar code readers, and automatic Internet capabilities, with the only drawback being the 
cost of the extra functions. In general, it is important to specify what is needed for the 
trial and to avoid expenditure on functions that are not needed.
All but the smallest trials will benefit from having a server, in order to store the data 
and to manage resources. A server can be a special computer with a large amount of 
data storage capacity or a standard desktop configured to organize data storage and 
administrative procedures. However, servers do need to be looked after carefully, with 
control of the temperature, dust, and humidity in the server room. If the trial operates 
out of an established institute, it is likely that it will be possible to use the institution’s 
server and network, perhaps through creating a virtual server for the use of the trial. 
The networking of the server can be through physical cables or could be set up as a sim-
ple local area network (LAN) using a wireless router, but note that, while laptops usu-
ally have built-in wireless capability, this is often not the case for desktops and PDAs. A 
good server and network can simplify many operations, such as access to the Internet 
and sharing of data, and should be high on the list of priorities for all but the smallest 
study.
Ancillary equipment (‘peripherals’) is also needed. This may include printers, scan-
ners, photocopiers, cameras, bar code readers, and backup devices. These can be in-
stalled and connected to one computer, but a simple network will make it easier for 
different members of the research team to access the different peripherals. The wider 
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access to the Internet needs to be planned as well. If the Internet service is poor, it may 
be necessary to have more than one way of accessing the Internet, perhaps through 
fixed lines or through mobile phone networks.
2.2 Software
In this section, we will not consider general software, such as word processing or anti-
virus, which are typically available to all computers, but concentrate on the specific 
options available for data processing. Data processing software comprises specialist 
packages which facilitate the collection, management, and organization of trial data. 
They can be used to prepare data for analysis by specialist data analysis packages. We 
consider three broad categories of software—freeware (free software packages), pro-
prietary software (which must be bought), and open source software—and give some 
examples of the different packages available, but the choice is wide. The most important 
consideration is to plan out how the data processing for the trial will be done and to use 
the appropriate package for each step in the data flow. It should be simple to transfer 
data from one package to another and is wasteful of time and resources to do any data 
operation in a package that is not designed for that purpose. In many ways, the selec-
tion of the software is more important than the hardware, and good selection can save 
a lot of time.
For the sort of data that are collected in epidemiological studies and trials, Epi-Info 
(<http://wwwn.cdc.gov/epiinfo>) is a very useful freeware package which can be used for 
many types of study. A similar freeware package Epi-Data (<http://www.EpiData.dk>) 
provides data management, analysis, and transfer capabilities. These packages are easy 
to learn and use and are ideal for small studies.
For larger studies, it is usually better to use a proprietary software package such as 
Microsoft Access™ or MS-SQL™. These are easy-to-use software, with good learning 
materials to help in developing and using the database. These software packages can 
be used to clean and manage data, and it is easy to transfer data from them to analysis 
packages. Free, but limited, versions of these software packages are available for those 
on limited budgets.
Open source software packages are also usually free to the user, and it is possible to 
access the source code and develop applications that are tailored to specific studies. 
A challenge, however, is learning how to manipulate the source code and make the 
software function appropriately for a specific study. Examples include RedCap which 
is aimed at investigators who do not have access to much computing support but who 
wish to quickly set up and manage clinical studies, including longitudinal ones, while 
OpenClinica targets researchers conducting clinical trials that must meet the regula-
tory requirements of the US Food and Drug Administration. Open Data Kit (ODK) 
is a suite of open source applications that allow the creation of questionnaires for data 
collection on Android-enabled mobile devices and facilitate online data management. 
Force.com is a powerful data management platform, for which a limited number of free 
licences are provided to non-profit organizations and higher education institutions. All 
of these packages are free to use and are highly customizable, and all but Force.com 
can be configured without highly specialized computer programming skills. All four 
systems are supported by knowledgeable end-user-driven online communities.
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2.3 Personnel
The personnel needed for data management will depend on the size of the trial and the 
computer and software systems being used. For a small study, using paper forms and 
a simple software package, such as Epi-Info, for data processing, one part-time data 
manager and one data entry clerk may be sufficient. For larger studies using paper 
forms, a team of data entry clerks and several data managers might be needed. Al-
though the requirements for data entry clerks can be greatly reduced or eliminated for 
studies using electronic data capture, skilled data managers and expert programmers 
may be needed to program some of the collection devices to validate the systems and 
to design the database.
Successful data management requires a variety of different skills at different times 
during the study. At the start of the study, except for simple software packages such as 
Epi-Info, someone with technical skills will be needed to set up the database and write 
the data check programs. If the study personnel are not skilled in database program-
ming, it may be better to hire a consultant to do it. When the study is under way, staff 
will be needed to enter data (unless all data are captured electronically), manage data 
checking, and clean the data on a daily basis. By the end of the study, data files must 
be prepared for the statistical analysis and report writing, and again buying in the ex-
pertise may be appropriate if there are no staff in the team with the necessary skills. 
Depending on the size of the study, some of these roles may be combined in a single 
individual, whereas, in larger research groups, individuals may be specialists who work 
full-time in one area of data management such as database development or writing 
data checks.
Staff must be recruited before the trial starts to be able to both develop, and be trained 
in the use of, the data processing systems. It is important to allocate sufficient time for 
training. Even staff who have previous experience of data management on other studies 
will need to be trained to use the system being used in the trial and become familiar 
with the study protocol. The most important attributes for data entry staff are consci-
entiousness, reliability, and attention to detail. Existing computing skills may be less 
important, as staff can be trained to use a computer and to enter data. Sometimes, staff 
who were originally employed to collect data in the field can be trained to be good data 
entry clerks. This has the advantage that they will be familiar with the kind of data being 
collected and the forms in use. They will also be aware of the problems that may arise 
in the collection of data in the field. However, data entry clerks and their supervisors 
are gradually being reduced in number in many research groups, as they move from 
collecting data on paper to electronic data capture.
A supervisor is likely to be necessary for every four to six data entry clerks to con-
trol the quality of their work, to ensure a proper and equitable distribution and flow 
of work, and to ensure that all data and forms are correctly processed and stored. The 
supervisor may be able to do some of the initial data checking and cleaning and take 
some of the data management tasks from the study data manager. A good way to iden-
tify persons who might be trained as supervisors may be to select them from among the 
data entry clerks, based on their performance and aptitude for this work, although the 
ability to type data quickly and reliably does not necessarily provide a good indication 
that an individual will make a good supervisor.
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Pilot studies may be necessary to determine how much data can be processed by a 
data clerk in a day, to know how many such individuals to include in the trial budget. 
This should be part of the pilot testing, which is covered in more detail in Chapter 13. 
As the work is repetitive, but requires considerable care, it is advisable to plan that a 
clerk should not be entering data for more than 5 or 6 hours a day. Data entry may be 
interspersed with filing tasks to maintain variety in the work.
If a trial is large, substantial numbers of forms may accumulate quickly, and the de-
sign of an appropriate filing and tracking system, such that individual forms can be re-
trieved, if needed, is important. The employment of filing clerks may also be necessary 
in large trials. Data entry and filing are tasks that need to be done in the same way, day 
after day. So it is important to devise ways of maintaining staff morale, so as to ensure 
high-quality work. For larger trials conducted over several years, working out career 
development structures within the project may be important (for example, the progres-
sion from filing clerk or fieldworker to data entry clerk to supervisor). Also, training 
in new techniques and the use of computer packages may be appropriate. Individuals 
must be aware that their work is considered important and that its quality is monitored, 
so that bad work is detected and will need to be corrected, while good work is noticed 
and rewarded appropriately.
The data management staff must be made to feel that they are an integral part of the 
project. Appropriate measures should be installed to allow field and data management 
staff to liaise with each other, so that they consider themselves part of the same team. 
See Chapter 16 for more details of field operations. Field staff must understand the 
problems that errors in data collection cause in the processing and analysis of data, and 
data management staff must appreciate the obstacles to high-quality data collection in 
the field. Visits by data staff to the field can do much to aid such mutual understanding, 
as can field staff spending short periods working or observing in the data office.
2.4 Data oversight
No matter how good data systems are, there is always benefit in getting someone out-
side of the study to look at them to see if they can be improved. The best time for this is 
before starting to collect real data, in time for the systems to be changed, if necessary. 
For small studies, this may be a matter of getting a colleague to check the data systems. 
In larger studies, outside advisors might be hired to look at the data system.
In most clinical trials, the requirements of good clinical practice (GCP) are such 
that the trial data must be collected and processed, in compliance with the ICH–GCP 
guidelines (see Chapter 16, Section 7.1). The practical implications of these require-
ments are that the data management process must be documented, and the computer 
systems used to collect, store, and process the data must be validated. The regulations 
governing the management of data from clinical trials can be broadly classified into: 
(1) clinical data-related; (2) technology-related; and (3) privacy-related. The guiding 
principle behind all of these regulations is the need to be confident that the data were 
collected as defined in the study protocol, are from real participants, and can be in-
dependently verified. Small studies may not be required to implement GCP, but, for 
all studies, there should be awareness that good practice and procedures should be in 
place, ensuring that data systems are checked for errors or oversights.
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Compliance with GCP requires that all phases of the data management processes are con-
trolled by standard operating procedures (SOPs). Data management staff must be trained 
in each process, and training must be documented. ICH–GCP does not require double 
data entry but requires that processes are in place to ensure that the data in the database 
accurately reflect what was recorded in the field on questionnaires or through other means.
The computer system used to store and manage the data will need to be validated, 
which requires a validation plan, user specification, testing, and change control. In the 
simplest form, an SOP that describes the steps necessary to build, test, and release a 
database can serve as the validation plan. The database and data entry screens will need 
to be tested to ensure that they function correctly, and the testing and its results should 
be documented.
A further requirement of GCP is that all changes that are made to the data in the 
study database are documented and that the original data are not deleted. This require-
ment is generally interpreted to mean an electronic audit trail must be created, in which 
the software system automatically records any changes that are made to the database, 
including when they were made and who made them. However, there are differences 
in how the term ‘audit trail’ is interpreted and implemented and at what stage the audit 
trail is ‘turned on’. Some audit trails may record changes after first entry into the data-
base, others after second entry when data have been verified, and others not until after 
initial data cleaning is done. Building a database with an electronic audit trail requires 
specialist skill and knowledge; however, software packages specifically designed for 
clinical trials, such as OpenClinica, have an audit trail as an inbuilt feature.
In a small trial that does not involve licensing of a pharmaceutical product, it may 
be possible to document data changes by other means to demonstrate compliance 
with GCP, for example, keeping a copy of the original database after second entry, a 
separate database containing all updates to the data, and a paper record of all changes 
that are made.
GCP also requires that a security system is maintained that prevents unauthorized 
access to the data. This would generally mean having a separate password to access the 
database and users having different levels of permitted access, depending on their role 
in the data management process. Randomization codes (see Chapter 11 for details) 
should always have restricted access, so that unauthorized staff cannot find out which 
treatment has been allocated to which participants.
GCP also requires that data are backed up adequately. Even in a study that is not 
being run to GCP, it is essential to develop a system for regular data backups. Failure 
to do so may result in the loss of data. Several types of media can be used for backup, 
including tapes, CDs, or external hard drives. Whatever is used, backup copies should 
be made regularly (at least weekly and possibly daily), once data entry has started. At 
least two backup copies of the database should always exist, and periodic ‘restores’ of 
the backed up data should be done to verify the data integrity. The copies should be 
updated regularly and frequently, although it is a good idea to keep some old versions 
as well, as errors are sometimes found in the more recent ones that make it neces-
sary to restart data entry from a previous copy. Some of the copies should be stored in 
a geographically separate location in a dry and relatively dust-free environment (for 
example, in a sealed plastic bag). Complete records should be kept of the data that are 
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stored on all backups, with one copy stored with the backup and at least one other copy 
stored in a separate place.
2.5 Summary
In this section, emphasis has been given to the need to plan the data system and all its 
dependencies before starting the trial. This involves planning the hardware and how it 
will be used, the software and what it needs to be able to do, the personnel, and the data 
practices. If the data systems are planned and thought through at the beginning of the 
study, the study progress is less prone to error and easier to operate.
It is useful to make a process flow diagram of the data indicating the people who 
will handle the data at each point in the flow diagram. Taking the time to highlight the 
resources needed and the person responsible for each action can make the implemen-
tation easier when the study is under way.
3 Planning the data flow
There are many advantages to collecting and storing research data electronically. Elec-
tronic storage of data facilitates easy retrieval, simpler generation of study reports, easy 
exportation to statistical packages, and rapid data sharing. The benefits of electronic 
storage of data can only be fully realized if the database storing the data is well de-
signed. A poorly designed database leads to poor performance, inefficient data queries, 
inaccurate and unreliable data, and redundant data that are duplicated in many places, 
making it difficult to check and clean. This section focuses on the key aspects of the 
processes in the data flow.
3.1 Database design
Database design is the process of organizing data in such a way that it can be stored and 
retrieved efficiently. It involves making decisions on how best to model a real-world 
information system, such as a paper-based data collection system, into a database. It is 
very unlikely that an analyst can correctly design a system without a full understand-
ing of the key processes and activities involved in the study. This requires researchers 
spending time with the system developers to ensure that the system developed is what 
is required.
It is good practice to use a structured approach, referred to as a system develop-
ment life cycle, when undertaking a database development project. The choice of the 
methodology is usually influenced by factors such as the complexity of the proposed 
database, the size of the database and the programming team, cost, time, and critical-
ity of the project. What is important is to get an approach that meets the needs of the 
project. An overview of the key phases involved in database development is presented, 
rather than focusing on a specific methodology. These procedures should not been seen 
as checklists, but rather key processes that can be incorporated in any methodology 
chosen. The key procedures are:
 1 project specification
 2 requirements gathering
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 3 programming and testing
 4 database implementation (‘going live’)
 5 database maintenance and change management.
A database project should start by clearly defining what the database will be expected 
to do. The high-level requirement is defined, which is the mission statement that states 
the intended goal of the new database. It should not be more than a few lines long. 
Other critical factors to define at this initial phase are the scope, resources, timelines, 
hardware, software, and the database team. The scope is the boundary of the system 
and database, and it states what data and functionality will be included and what will 
be excluded. It is important that the scope is defined clearly at the start of the database 
development project, as poor definition leads to ambiguity and poorly defined database 
requirements. It is also important to choose the hardware and software early, as this 
may affect some of the design features of the database. The output of this initial phase 
is a project specification document that defines the objectives, timelines, deliverables, 
and milestones.
The objective of the next phase is to transform the high-level requirements into more 
detailed manageable tasks and functions that can be programmed into a software sys-
tem. The requirements can be gathered by interviewing end-users of the proposed new 
database, examining the current database, if any, and also looking at existing forms 
such as questionnaires and reports. It is important to think of what extra functionality 
is required in the database. Will the data be shared? If so, which specific data will be 
shared? What are the security and compliance requirements? Have risks been assessed, 
and the database designed to mitigate the risks? The output of this process is a detailed 
requirements specification document, describing all the functional and non-functional 
requirements of the database. It is imperative that requirements are specified correctly 
and as comprehensively as possible at this phase; otherwise, it could lead to a system 
that does not meet its intended goal and may necessitate major changes during pro-
gramming and testing or after the database has gone live.
The third phase involves creating a conceptual design (logical diagram) that shows 
the different tables that will be required to store the data identified in the first two 
phases. A good place to start from when generating the list of possible tables and their 
attributes (data columns) is to look at the current process, if any, used to collect data. 
There are two possible scenarios—an existing computer system is being converted or 
modernized or a new system is being built from scratch. In the former scenario, the 
tables and data entry forms of the existing computer system should be used as a start-
ing point. If there was never a computerized system in place, begin with the existing 
paper-based data collection forms. If there are none, sketch out the forms, based on 
the requirements specification document, and discuss the sketches with the research 
team, and refine them further. Note that, while some of these data entry forms are 
sketches of what will eventually become data entry screens, others will properly re-
main in the realms of paper forms and will not necessarily map directly into data entry 
screens. If new requirements arise, while the conceptual design is being created, add 
them to the list of requirements that was created in the earlier phase. While sketching 
out the tables, also review the list of existing and new reports to establish a reasonably 
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definitive list of the reports that the system must produce if it is to satisfy the needs of 
the users. The objective of analysing the reports is to ensure that the tables sketched 
out will have all the attributes that are needed to generate the reports. If there are miss-
ing attributes or tables, they should be added now. The completeness is important, 
but it can sometimes be difficult to know if all the reports that are being, or will be, 
produced or used have been identified. The database developer can proceed to create 
the physical database when the team considers that the requirements are sufficiently 
comprehensive.
After the database has been created, a programmer designs the data entry forms and 
links them to the tables in the database. There are various types of software that can 
be used to create the electronic data entry forms to capture the data. The choice of the 
tools and programming language will depend on the technical skills and preference of 
the team. When the programming phase is done, the database application should be 
tested. It is recommended that someone other than the programmer who developed it 
tests the application. Testing is an important phase, because it ensures that the system 
is validated and verified, a major requirement for GCP compliance. Users have to be 
trained on how to use the database, before deploying it for actual use. The database ap-
plication should supplement user training by providing help features where users can 
access help through the application.
3.2 Data cleaning and integrity
Data cleaning should be an ongoing process, rather than something that is done at the 
end of the study. The process by which the data will be cleaned should be well thought 
out, planned, and documented at the beginning of the project, and certainly before any 
significant volume of data has been collected.
Double data entry is commonly used to minimize data entry errors. In this tech-
nique, two different people enter the same record independently, and the two entries 
are compared against each other. A validated data record is one where both entries are 
the same (see Section 5.1). It is important to remember, however, that no data entry 
system can avoid errors that were made by the interviewer using a paper-based ques-
tionnaire to record information in the field.
The database application can be programmed to flag inconsistencies in records, ei-
ther during or after data entry. One approach is to categorize errors as being critical and 
non-critical. A critical error is one that is so important that systems are put in place to 
ensure that the data record cannot be saved into the database until the error has been 
fixed, for example, lack of the respondent’s identity code or this being out of the valid 
range, as this code will be needed to link information in the database. The program-
mer would write these as checks embedded in the database application, sometimes 
called ‘online checks’. The downside to having too many such checks embedded into 
the data entry screens is that the users cannot save the data until all the errors have 
been fixed, which can lead to back-logs. Decisions about what errors will be critical 
and non-critical should be made early enough, so that these are programmed in the 
system. Non-critical errors should not stop the user from saving the data record. They 
would instead be flagged up as data queries and reports for the data manager to follow 
up, rectify, and update the database.
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Another approach is to incorporate data checks in a statistical program, for example, 
Stata, and run the checks against the data periodically. In the case of a paper-based col-
lection system, periodic monitoring visits can be made to ensure that SOPs are being 
adhered to. Further checks can be done by taking a random sample of paper forms and 
comparing them against the corresponding electronic data records.
3.3 Programming issues
Computerized data collection systems are driven by computer programs written by 
system developers. The resources used to develop these systems can be made more ef-
fective if good programming practices are used. Computerized data systems should be 
documented to a sufficiently detailed level, so that any other system developer could 
quickly take over the maintenance or extension of such a system. A poorly docu-
mented computerized data system makes it very difficult to make changes to the ex-
isting system, and it will take a second person longer to figure out what needs to be 
changed. Even the programmer who wrote the initial program may forget specific 
technical details after a few months. Investing the effort to document programs, as 
they are developed, makes them easier to maintain, and changes can be made much 
more quickly.
Prototyping is an iterative technique used in computer systems development where 
the programmer designs mock-ups and asks the user to try them out and give feedback. 
The advantage of prototyping is that the users do not have to wait until the system has 
been fully developed, before they can try it out.
3.4 Standard operating procedures
SOPs are a set of written instructions detailing how a particular process is carried out. 
Computer-based systems support trial processes by providing a means of storing, mod-
ifying, and retrieving data. The process by which these computer systems are developed 
and used should be documented and controlled by procedures (SOPs) that ensure that 
they are adequate, and, where necessary, GCP-compliant. SOPs allow different peo-
ple to check the procedures and ascertain whether what is done corresponds to what 
should be done. SOPs are also invaluable for training different people in the tasks that 
need to be undertaken in the study.
It is usually a good idea to split the SOPs into different categories such as database de-
velopment, database validation and testing, database implementation and site set-up, 
and database maintenance/backups/upgrades. SOPs should be written by the person 
responsible for the task (who knows what should be done) and checked by the person 
who supervises their work and finally approved by the study PI.
3.5 Version control
The purpose of version control is to keep track of changes made to a computerized sys-
tem during its development and after it has been implemented. The changes can come 
from various sources. For example, the users may find errors that need to be fixed when 
they start using the live system or may request new features or improvements to the 
system. Also, a change in environment may require a change in the computer system. 
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For example, a decision to move from Microsoft Access databases to SQL Server data-
bases will require changes to the data entry screens. Another example is a new compli-
ance requirement that requires a certain type of report to be generated by the system.
A requirement for GCP-compliant data management is the use of validated and 
verified computerized data collection systems. Systems are validated and verified by 
thorough testing, comparing the database system against the user requirements. A vali-
dated and verified system is one that meets its specifications and requirements and that 
fulfils the purpose it was created for. Any change made to an already validated com-
puter system may introduce new errors. Hence, the process of making changes needs to 
be done in a controlled environment. Previous versions of the program code are stored 
in a version control software, for example, Visual SourceSafe, Subversion. The system 
ought to be tested after making changes to ensure it remains in a validated state, before 
deploying the updated version. The detailed process for managing and maintaining 
changes to the system should be written in a version control and change management 
SOP. It is important that the SOP is adhered to strictly.
3.6 Confidentiality
Information that can be used to identify a person should be stored in a secure database 
that allows only authorized persons to access the data. Any data that can be used to 
identify a person, for example, name, address, date of birth, should be kept out of the 
public domain. Sensitive information should be identified from the onset, so that ap-
propriate controls are put in the database. If the data are to be shared, it is necessary 
to decide how this will be done and what kind of security checks will be put in place. 
Technical security mechanisms, such as audit trails, access control using user logins 
and passwords, and permissions should be supplemented by data-sharing contracts 
and user training. Encryption should be used when sharing or carrying data on port-
able devices to ensure that unauthorized users cannot read the data, even if they get 
hold of the portable device.
3.7 Training
However basic the database system may seem, users should be adequately trained and 
should fully understand what they are doing. This training may be in the form of pro-
fessional and in-house training and may involve using a prototype of the database in a 
pilot scheme. User training logs should be kept as evidence of training.
3.8 Pilot testing and database testing
User acceptance testing and pilot testing are commonly used to verify that the database 
performs well. In user acceptance testing, the end-users test the new database by enter-
ing data, following the SOP, and trying out the functionality provided by the database. 
The end-users feed back comments to the programmers and study leaders, who can 
make the necessary changes to the database programs and to the SOP that define how 
the procedures work. This is very useful, since database issues are identified early and 
rectified, before data have started being captured. Pilot testing also helps to identify 
potential issues that may arise when the study systems go ‘live’.
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4 Data collection systems
In this section, we review some of the ways in which data can be collected from the 
participants and put into an electronic database.
4.1 Questionnaires
Paper-based questionnaires are often used to capture responses from study subjects, 
especially in small studies. These will need to be printed, taken to the study site, col-
lated, batched for data entry, stored, and preserved for future reference. The design of 
questionnaires is discussed in Chapter 14.
4.2 Electronic data capture
Electronic data capture through the use of field computers, PDAs, UMPCs, or mobile 
phones is increasingly used. Using electronic data capture makes the data available im-
mediately and removes the need for separate data entry, but it increases the need for 
data quality checks at the time of data collection. Electronic data capture devices need 
to be programmed to ensure that checks on the data quality are performed at the time 
of collection, as it is difficult to verify the data afterwards. With electronic data capture, 
it is easier for additional modules to be administered to a sub-sample of participants. 
These additional modules can be triggered by specific questions, for example, loops to 
ask about all the children in the household or about all the medicines taken at the last 
illness.
Using electronic data capture properly can enable data to be collected quickly and 
allows for numerous checks of data quality to be built in at the time the data are col-
lected. Open source software exist for many applications, such as openXdata (<http://
www.openxdata.org>), OpenEHR (<http://www.openehr.org>), and ODK (<http://
opendatakit.org>), with the advantage that source code is available for modifying and 
adapting them.
Collecting data using mobile phone applications is becoming increasingly common. 
Mobile phones are relatively cheap, and telecommunications network coverage in most 
countries makes them available to large sections of the population. Information can 
be collected remotely, wherever the study subject might be, and the person does not 
have to be questioned face to face by an interviewer. Mobile phones can also be used 
to collect repeated data from individuals who may be difficult to locate or who may be 
in remote locations. Computer programs, such as FrontlineSMS or EpiSurveyor, allow 
data to be collected through simple text message or through interactive voice response 
or self-administered questionnaires. In all these cases, the data are stored directly in a 
central database, following transmission across the telephone network, and are avail-
able for processing almost immediately, following collection.
4.3 Laboratory data
Data from laboratory tests are important in many research studies, and it is important 
to design the stickers, labels, and linking mechanisms, so that samples collected in the 
field can be linked to the results of the laboratory tests and the other data collected on 
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the same individual. Many laboratories use laboratory data management systems 
(LDMS), such as LIMS, which automatically download laboratory results into a com-
puter database (see Chapter 17). Alternatively, the results can be entered on to paper or 
electronic forms, which are later merged into the database.
It is better to use a unique specimen identification number, rather than the individ-
ual’s study identification number. This is because a single individual may have several 
specimens of the same type taken during a trial. As a check, the questionnaire number 
should be written (or a sticky label can be used) on the laboratory form, and a copy 
of the specimen identification sticker placed on the questionnaire, as well as on the 
specimen itself. If both the individual’s study identification number and the specific 
specimen identification number are used on both forms, there can be assurance that 
the samples are correctly matched to the questionnaires when the analysis is done. Bar 
codes can be used for these laboratory numbers to enable the code to be read automati-
cally by the laboratory equipment (also see Chapter 17).
LDMS must be programmed and managed carefully. Often, several studies use the 
same laboratory for many different tests. The LDMS must allow a study team to access 
all the data for their study, but they must not be able to access data from other studies. 
This requires common protocols and database programs, and good SOPs to ensure that 
data access is controlled and monitored.
4.4 Clinic data
Data from hospitals and clinics are sometimes used in trials. Patient-level data may 
be collected by clinicians when they assess, diagnose, and treat patients who are par-
ticipating in the trial. The clinical data can be collected on a separate dedicated form, 
from which data are entered into the database later. Alternatively, there may be a trial 
research assistant in the clinic who enters the data into the computer from clinical re-
cords, or an electronic data collection tool may be introduced for use by the clinician, 
which removes the need for paper forms. With suitable choices for database program-
ming and hardware, such systems can be relatively cheap and cost-effective.
There are several software options for the collection and management of health 
records from clinics and other health facilities (such as openXdata, openEHR, open-
MRS). These support data entry at the time the patient is seen by the clinician.
4.5 Longitudinal data collection
Longitudinal data require a system to link individuals within the database with each of 
the occasions when they are followed up. To do this, personal information, such as the 
person’s names, address, and/or an identity number, needs to be stored in the database 
and used for subsequent survey visits to make a positive identification of the study 
subject. In order to make the identification more certain, photographs of the study sub-
jects or fingerprints might be collected. These methods are cost-effective for even small 
studies, using mobile technology such as PDAs, cameras, and mobile phones.
The first time any individual is seen, sufficient personal information must be col-
lected at the time that they are assigned a unique study identification number, so 
that unambiguous identification can be made on the second and subsequent visits. 
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Such personal identifiers must be kept secure and confidential, especially if these can be 
linked with health information or other sensitive data. However, appropriate informa-
tion for identifying individuals must be made available to the fieldworkers at follow-up 
visits, through printed lists or through access to the electronic database, using PDAs, 
UMPCs, or other mobile computing devices. Links between the study numbers of in-
dividuals who belong to the same family or household can be easily stored in relational 
databases.
4.6 Quality control
In all trials, there is a need to ensure the quality of the data collected. To do this, it is 
necessary to be able to answer, and show evidence for, the following questions. Are the 
data a true reflection of the response from the study subjects? Has anyone changed the 
data and, if so, how? Is there effective QC over the data collection and data manage-
ment? Are the data correctly matched and linked to the right respondents? (See also 
Chapter 14.) It is important to build quality checks and audits into the data collec-
tion and their subsequent management, in order to have the evidence to answer these 
questions. These checks fall into four main areas: design, training, supervision, and 
checking. Data collection should build in design features that allow checks and simplify 
coding and responses. Training should include a thorough examination of the instruc-
tions that all data collectors should know and follow. It should also explain and go over 
the ways that the data are checked at all levels, so that everyone knows that the process 
has checks and balances and that mistakes will be found and corrected. Supervision is 
important and should be supportive and non-threatening, with the objective of build-
ing quality and encouraging self-assessment and improvement. Regular tallies should 
be kept of the number of questionnaires completed, the number of refusals, and the 
number of errors or mistakes discovered. At the beginning of data collection, daily tal-
lies of these indicators may be needed, but even weekly or monthly tallies may ensure 
that difficulties with the data collection are picked up early, and re-training given to 
those who need it.
Audit trails are used to keep track of any changes in the data. While every effort 
should be made to collect the correct data at the time of the interview or measurement, 
there will always be times when data need to be changed. Before the advent of comput-
ers, data managers used to keep logs of their work in ledger books, recording all the 
changes made to the database. Now any changes that are made should be documented 
in the database, which will include a record of the old values and a record of the reason 
for the change. Computers should never be programmed to make changes automati-
cally. Rather they should be programmed to highlight probable errors, and a data man-
ager can make any necessary changes and record the reasons for each of the changes.
4.7 Future trends
The traditional ways of collecting data through paper-based questionnaires will con-
tinue to be needed for some studies, but there are increasingly diverse other methods 
available. The use of mobile phones for collecting data has grown substantially in recent 
years. They have the advantage of enabling data to be collected frequently, and at any 
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location or time, but currently are limited in the amount of data that can be collected 
at any one time.
Computer-assisted self-interviewing is a growth area. The advantages are that ques-
tions are standardized and confidential, and many people can be interviewed at the 
same time. Translations of questions can be made into different languages. The ques-
tions can be delivered in many ways, as an audio system for those who cannot read or 
through pictures and visual choices available through touch-screen technologies.
Online databases have become much more accessible and allow direct data collection 
into a master database located in the study centre or elsewhere. Mobile phone networks 
allow instantaneous transmission of data from the field to the data centre where it can 
be checked against the master database. Based on the data sent to the online database, 
fieldworkers collecting the data can be given instructions about the data to be collected 
and new study subjects to interview. These systems are increasingly used by large mul-
ticentre studies but will become more applicable to smaller studies where the online 
database can be linked to other resources, in order to improve the study design or data 
collection.
5 Managing data
Data management is a major task in most intervention trials. The main stages of the 
data management process are:
 1 entering the data into a computer system
 2 checking the data for errors and inconsistencies
 3 organizing the data into an appropriate form for analysis
 4 archiving the data.
Good data management requires a well-defined data management strategy—it is not 
something that will just happen. The complexity of the data management process will 
depend on the size and type of study. Attention to data management will greatly reduce 
the time needed in the analysis stage, because the data will be well organized and con-
sistent and have fewer errors.
5.1 Data entry
The process of data entry will usually involve a data manager who designs the data 
entry screens, while other staff, such as data entry clerks or field staff, do the actual 
entering of the data. Creating data entry screens is not difficult but requires care. The 
data entry screen should follow the questionnaire, so automatic skips can be used to 
follow the skips in the questionnaire, and drop down menus can be used to show the 
same options as in the questionnaire for individual questions.
If data are being entered from paper-based forms, data entry can be double or single. 
Double data entry is routinely used to minimize typing errors and to ensure that the 
data in the database accurately reflect what was recorded on the forms. There are two 
main techniques used for double data entry. In one method, two data entry clerks inde-
pendently enter the data without any knowledge of the other’s work, and both entries 
are stored. A program, which may have to be written by the data manager, compares the 
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two entries and identifies any discrepancies. The resolution of the discrepancies is gen-
erally referred to as ‘verification’ and can be done in different ways. In some systems, 
verification may involve both data entry clerks re-entering the specific data fields where 
discrepancies were identified and comparing the new entries. More commonly, a third 
person resolves the discrepancies, by referring to the original forms or questionnaires, 
and makes a decision as to the correct entry, changing the incorrect entry appropriately. 
Once the data have been double-entered and no discrepancies between the two entries 
are identified, the data are considered verified.
In the other method, which is used in specialist data entry programs, such as CSPro, 
the second person resolves the mismatches at the time of entry. After the first entry is 
complete, a second person enters the data, and any discrepancies are flagged up im-
mediately, as the data are being entered. The second person must decide what the cor-
rect value should be and enter it accordingly. With this method, the second person 
is generally chosen to be more experienced and is expected to make the final entry, 
corresponding to what is on the form. This method is quicker but more prone to error 
than the first method described.
Facilities for double data entry are a feature in some software packages, for example, 
Epi-Info. In other packages, such as Access, double data entry must be set up when the 
database is created and would require considerable time and skill. One option is to use 
a package, such as Epi-Info, for data entry, before transferring the data to a separate 
package, such as Access, for storage and management.
Single entry of data is relatively rare and not recommended. It should only be con-
sidered if there are extensive checking routines, strong supporting processes, and tech-
nology in place to identify possible errors. Generally, the cost of doing a second entry 
of data is less than the costs of the additional data management required to clean the 
errors that that may remain after just a single entry of data.
The task of entering data should be conceptually separated from the task of analysis. 
Different software may be used for data entry, data checking, and analysis. The data entry 
system should be designed to make data entry as simple as possible. Simplifying the key-
ing process will speed the task and make it less error-prone. Ideally, the data entry screens 
should closely resemble the paper form from which the data are being copied. Question-
naires should also be designed with data entry in mind. The data should be entered as 
recorded on the questionnaire. No hand calculations or transformation should be done 
before data entry—these can all be done during the analysis stage.
5.2 Data checks
Most data management time is taken up with checking the study data for errors and 
inconsistencies and ‘cleaning’ it. There are three main points to be considered when 
developing data checks: (1) deciding what will be checked; (2) working out when each 
check will be used; and (3) specifying how to resolve inconsistencies and errors identi-
fied by the checks.
Many software packages have inbuilt facilities for data checking. These automatic 
check programs can be set up when the database is created and run at different stages 
of the data management process. Before the check program is created, a specification 
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document should be prepared, defining the data that will be checked and the errors that 
the program will be designed to catch. This document is usually written by the data man-
ager or statistician, with input from the investigators, and is known as the data validation 
plan or check specification plan. Generally, the person who sets up the study database 
will also write the checking program and will be responsible for testing it. The program 
should be tested on ‘dummy’ data, before using it on the actual study data, to ensure that 
it is working correctly. Several ‘dummy’ questionnaires can be completed with deliberate 
errors and entered into the database; these can be used as test data for checking purposes.
Data checks can be incorporated into the data entry screens, so that illogical or im-
plausible values are flagged up at the time of entry. Furthermore, the entry screens can 
be designed, so that they do not allow entry of invalid values, such as an impossible 
date or a value of ‘5’ for a question that has ‘1’ to ‘4’ as the only possible answers. There 
are arguments for and against using data checks at the time of data entry. The checks 
will slow down the entry process, and, with double data entry, it can be argued that the 
checks are not needed to pick up errors in data entry, but they will pick up some data 
that have been incorrectly recorded on the questionnaire. If checks are incorporated 
into the entry screens, they should be designed so as to allow entry of invalid values, if 
that is what is recorded on the questionnaire. Otherwise, the questionnaire must be put 
to one side, until the error is resolved, and risks being lost or misplaced, so that it never 
gets entered in the database. Except for very small studies, it is often better to get the 
data entered in the database and to run checks to identify any errors afterwards, espe-
cially where there are a large number of questions that might need checking. However, 
interactive checking may be preferable when data are entered by the same field staff 
who completed the questionnaires earlier in the day. They may be slow typists but, hav-
ing the interviews fresh in their minds, are more likely to be able to correct errors at the 
time of entry. However, in this case, it would probably be even better to consider having 
the data entered at the time of the interview, using electronic data capture methods.
After data entry is complete and the data are verified, an automatic check program is 
run to identify errors. These checks can include range checks to identify out-of-range 
or missing values (for example, dates out of the expected range, participant’s age outside 
the range permitted by the study protocol) and cross-checks to identify inconsistencies 
between values (for example, males who are pregnant). The timing of when these checks 
are run requires careful consideration—for example, if a check compares data from dif-
ferent visits, the data from both visits must be present for the results to be meaningful.
In a longitudinal study, with repeated data collection visits to each subject, data 
checks should be run early on and continuously throughout the study. When errors are 
identified early in the study, it is often possible to uncover misunderstandings in the 
interpretation of the questionnaire or a flaw in the questionnaire design that was not 
picked up during the pilot phase. Clarification or further training can prevent those 
problems from recurring throughout the entire study.
The initial analyses are a continuation of the checking process and should include 
looking at cross-tabulations of the data to identify inconsistencies, and scatter plots and 
box-plots to compare groups and identify outlying observations. In large longitudinal 
trials, interim tabulations of data are recommended as a way of detecting possible data 
errors. Special checks might be made on observations that are more than two or three 
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standard deviations from the mean. Such observations should be checked individually, 
as they are not impossible, merely unlikely.
Lastly, it should be noted that discrepancies in data are time-consuming to identify and 
resolve. The implications for data checks and query resolution should be considered dur-
ing the questionnaire design stage. Asking for duplicate information in different parts of 
the questionnaire is one source of unnecessary queries. Queries will also arise if the ques-
tionnaire design does not make adequate provision for unavailable responses or permits 
ambiguous responses. Questionnaires frequently include questions that are deliberately 
used as cross-checks of other fields. This can be a very good policy when the data are 
actually different. For example, a check of sex against the subject’s pregnancy status pro-
vides a reasonable cross-check of whether the person could not possibly be pregnant be-
cause they are male. However, problems arise when questions duplicate the same data, for 
example, a questionnaire that asks to record both the age and birth date. Discrepancies 
and confusion are bound to be generated when the values do not agree. When designing 
a questionnaire with requests for repeat information, consideration should be given to 
the implications for data checking and whether the duplicate information is truly needed.
5.3 Data cleaning
Data cleaning involves raising and resolving data queries that are identified during the 
data checking process and making the appropriate changes to the database to correct 
the errors. The aim is to be sure that the data are as of high quality as possible, before 
they are analysed.
Some data queries can be resolved within the data management group, for example, 
an obvious error in the year of a visit date. However, most problems will need to be 
resolved by the field team or the investigator. Commonly, the data management group 
will send a list of queries to the field team; the team will resolve the queries by writ-
ing the correct answer next to each one and return the list to the data management 
group. Alternatively, corrections can be made to the questionnaire itself. However, it is 
very important that the original answer is not obscured—instead, it should be crossed 
through with a single stroke, so that it is still legible, and the new information writ-
ten on the side. It is good practice (and required for GCP) for the person making the 
change to initial and date the changes.
After the queries have been resolved, the database should be updated to reflect the 
corrected information. Some software systems have features to allow changes to the 
data after query resolution. These changes are usually made through the data entry 
screens and are recorded in an electronic audit trail. In a system without an automatic 
audit trail, changes may be made directly to the data tables themselves, although this 
can be more error-prone than changing the data via the data entry screens.
Correction or editing of data to reflect a resolution generally follows a different path 
from that of initial entry of the data. Most systems do not support double entry of cor-
rections, so it is good practice to have a visual check of the data after correction to be 
sure that the change was made correctly. After the changes are made, it is essential to re-
run the check program again, since it is possible that the update of the data has caused 
a new inconsistency to be identified.
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In some cases, it may not be possible to obtain a resolution to a query, particularly if 
it is some time since the data were collected. Some software systems keep an electronic 
record of the problems identified by the check program, and a code can be entered to 
indicate that the inconsistency cannot be resolved. Alternatively, the incorrect data can 
be given a code for ‘missing’ if the correct answer cannot be obtained. The number of 
times this is done should be kept as small as possible and should be documented.
It is important to have a single master copy of the database that contains all the data 
corrections that are made. Even after the data cleaning stage is complete, errors may be 
detected much later during analysis; these should all be corrected on the master copy, 
so that it is always up to date. A version control system should be in place to ensure that 
it is possible to know which version of the database was used for any particular analysis.
5.4 Variable naming and coding
One of the first things to be done, before developing the study database, is to create an 
annotated questionnaire, containing the names that will be given to different variables 
and the characteristics of the variables such as numeric or text, the length of the variable 
(maximum number of characters), and any specific code lists that will be used. Ideally, 
variable names should provide information about the data being recorded, for exam-
ple, ‘birthwt’ for birth weight or ‘intdate’ for interview date. In a longitudinal study, the 
same name should be used for those variables that are recorded at every visit. Some 
studies have used a convention of naming the variables at different visits with a number 
at the end corresponding with the visit, for example, ‘visit_date3’ and ‘visit_date6’ for 
visits 3 and 6. However, it is generally easier to run data checks and do other manipula-
tions on the data if the variables have exactly the same name at each visit. An additional 
variable for the visit number should be included to identify the visit.
Some software packages have restrictions on the length of variable names; in particu-
lar, some older packages do not allow more than eight characters. A good general rule 
is to use no more characters than are allowed by the most restrictive (in terms of the 
number of characters) software package that is likely to be used for the study.
Questions that have categories of answers are best entered as coded values, rather 
than text (for example, 0 = No, 1 = Yes). These fields have a limited list of possible 
answers and only present a problem for data management if the field can contain 
more than one answer or if the answer falls outside the predefined list. When more 
than one answer is possible (for example, a list of types of contraception ever used), 
the database design changes from a single field to a series of fields, each of which can 
hold any of the valid responses from the list (coded yes or no). If an answer occurs 
that is not on the predefined list, a value for ‘other’ may be needed. In this case, it is 
advisable to create an additional database field where the specific response can also 
be entered as text. If an answer that is not on the list occurs frequently, it may be 
worth creating a new code for it. New codes may also be needed if the questionnaire 
design changes during the study or between survey rounds. In these cases, it is es-
sential that the existing code list does not change. Instead, the new codes should be 
added at the end of the list. The coding of responses to questions is dealt with in more 
detail in Chapter 14.
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
3596: ARCHIVING
Some studies use free-text on the questionnaire and re-code the text into catego-
ries at the time of data management. Re-coding variables in this way is generally not 
recommended, as, if they have been collected and entered, the original data should be 
found in the final data set. If any re-coding is done after data entry, the new data should 
be put into a new variable, with a note to indicate how the variable and the codes were 
defined.
5.5 Data lock
When all the data checks have been run, the queries resolved, and all QC activities are 
complete, the data are declared ‘clean’, and the database is ‘locked’. This means that no 
further corrections will be made to the data. In GCP-compliant studies, the trial cannot 
be unblinded, i.e. the randomization codes made available to the study team and the 
main analyses cannot be performed, until the database is locked. At this stage, the locked 
database may be deposited with an independent body, such as the data safety and moni-
toring committee (DSMC), so that, if there are any later queries about the integrity of the 
data or changes that may have been made, comparison can be made with the locked set.
Even in studies that are not being run to be fully GCP-compliant, it is useful, at some 
stage, to make the formal decision that the data are ‘closed’, and no more corrections 
will be made. Sometimes, the data can be closed for one analysis, while corrections are 
ongoing for other data. The purpose of ‘closing’ the database is to ensure that the data 
are defined for a stable set of analyses and will not change every time the analysis pro-
gram is re-run. The closing of the database, or any part of the database, should not be 
done before all the errors that are correctable have been resolved.
6 Archiving
New data are brought into a data management centre daily, and many different data 
changes and decisions are made. It is important that these are recorded and docu-
mented. If an accident happens (for example, a fire in the data centre), these changes 
and decisions could be lost and may be difficult to re-create, with potentially serious 
consequences for the integrity of the trial. This section advises on some of the ways to 
backup and keep the data, both for short-term protection and long-term use.
6.1 Interim backups
Backups of data are essential and should follow a regular pattern. Backups should not 
be thought of as an archive of the data, but only as a temporary store of the latest work. 
The procedure for backup should include times when a complete, full backup is made 
(perhaps monthly) and times when an incremental or partial backup is sufficient. 
The backup procedures should be documented in a SOP and agreed with the trial PI. 
Backups should be automatically scheduled, using a program or backup package, but 
one person in the study should be given responsibility to check the backup happens as 
scheduled. If the backup fails for some reason, that person needs to know what to do. 
At periodic intervals (preferably at least once per month), data should be backed up 
off-site, which can usually be easily and cheaply done onto an independent website.
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What should be backed up? Everything should be kept in a backup, but not eve-
rything needs to be kept in every backup. The master database with the study data 
needs to be backed up regularly and completely. Other data that contribute to the 
master data should be backed up, and any changes recorded and backed up. Data 
entry files need to be backed up at least once but, as they should not be changed, may 
not need to be backed up again. Questionnaires and forms need to be included, as 
do coding sheets, reports, and correspondence with personnel inside and outside 
the study. Organization of the study data is important and should probably reflect 
the organization of the data on the main computer or server, and it should include 
a directory map to allow someone who is unfamiliar with the structure to find their 
way around.
An external hard disk is a cheap and easy way to make a backup. These are large 
enough to store many copies of the data (previous backups should not be deleted), but 
these external drives can suffer accidents and should not be considered a safe or secure 
storage of data. It is worth getting programs that will compress, encrypt, time-stamp, 
and validate the backed-up data to ensure that it does represent a true copy of the data 
at that time. Backups should not be considered a permanent solution, as technology 
moves on, and new systems and programs replace old ones. For example, backup data 
stored on floppy disks from 2000 were no longer readily accessible by computers or 
programs in 2012. This means that it may be necessary to copy backups onto new hard-
ware/software every few years, before they become obsolete. And the final archived 
data sets must always be kept accessible on current hardware and software.
6.2 Metadata
An archive of the data is of limited use without the extra information that specifies 
exactly what the data comprise. These additional pieces of information are called meta-
data and can include information about the study setting, inclusion and exclusion cri-
teria, the questions asked in any questionnaires, the codes for the variables, and a host 
of other information. Without such information, the data collected in the study are not 
interpretable. Note that metadata can include the names of the authorized users of the 
database and their passwords, as, without this information, it would not be possible to 
access the database and retrieve the data.
Extensible Markup Language (XML) is a set of rules that allow text, documents, 
codes, names, and even pictures to be stored in a machine-readable format. This allows 
the metadata for any study to be added to a repository and enhance the ability of others 
to use and understand the data. There are a number of XML schemes available, but, 
whichever is chosen, the metadata should be preserved for future use.
The Data Documentation Initiative (DDI) (see <http://www.ddialliance.org>) takes 
the storage of data and metadata one step further by defining a set of instructions for 
the storage, exchange, and preservation of statistical and social science data.
6.3 Data sharing policy
Usually, investigators will not allow sharing of the data from a trial with persons not 
directly involved in the trial, until the data collection and entry are complete, the 
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trial has been analysed, and the main results published. However, at this stage, 
others may be interested in accessing the data to undertake further analyses 
or to combine the data with those from other trials to conduct a meta-analysis 
(see  Chapter 3). Many funding agencies are moving towards insisting on sharing 
of data as a condition of funding. For example, the Wellcome Trust states that it is 
‘committed to ensuring that the outputs of the research it funds, including research 
data, are managed and used in ways that maximize public benefit. Making research 
data widely available to the research community in a timely and responsible manner 
ensures that these data can be verified, built upon and used to advance knowledge 
and its application to generate improvements in health’. Most other major charitable 
or governmental funding agencies have a similar policy. The US Institute of Medi-
cine published a consultation document in January 2014 on the guiding principles 
related to clinical trial data sharing (National Research Council, 2014), and their 
final recommendations in 2015 (National Research Council, 2015). Most large re-
search institutions have a data sharing policy. The data sharing policy will define 
what data have been collected, stored, and will be made available, and the proce-
dures to be followed for making some, or all, of the trial data available publicly or 
to selected recipients. Increasingly, the data collected in any trial, especially if it 
has been funded by a charitable or government agency, should not be thought of as 
belonging exclusively to the research team or to the director of the institute that con-
ducted the trial but as a public good. After a reasonable period of exclusive access, it 
is widely accepted that the data should be made available to other researchers, policy 
makers, and medical authorities to further the advancement of knowledge.
The data sharing policy should be drafted at the start of a trial, as it will influence the 
way in which data are stored and archived. In particular, consideration must be given to 
how the strict confidentiality of the identity of the study participants can be preserved 
in any data that are shared. Furthermore, shared data are only useful if the recipient has 
a proper understanding of the information being shared. This requires that the data 
collection and coding systems are carefully documented for possible future onward 
transmission. This is one reason why metadata are essential.
6.4 Archiving hard copies
Paper copies of data and study procedures need to be kept for some time after the end 
of a trial. Some funders require these hard copies to be kept for periods in excess of 10 
years after the completion of the trial, as the ultimate reference for the study data. Paper 
copies will need to be sorted and archived in a logical way. Space needs to be obtained 
for such storage, and protection ensured against fire, theft, and destruction by mould, 
insects, or other animals. Some studies are experimenting with scanning all documents 
and preserving the digital images instead of the hard copies, but this needs to be agreed 
in advance with the regulatory authorities and may not be acceptable to all. If data 
are collected electronically, the long-term storage of paper forms is no longer relevant. 
However, this puts even more emphasis on the need for careful and accessible archives 
of electronic databases, which should always include the original data as entered, as 
well as any final data sets.
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7 Preparing data for analysis
The ‘raw materials’ for data analysis are the data files created by the data management 
process. However, the variables, as recorded in the questionnaire and entered into the 
database as raw data, are not always the ones directly suitable for data analysis. Re- 
coding and creating of new variables is likely to be necessary. It is generally also neces-
sary to combine information from different data files.
When preparing the data for analysis, it is good practice to create a new data set with 
a different name to separate it from the original study data. Also, it is advisable to keep 
a copy of the commands used to prepare the data (either the program that was used or 
the ‘log’ files), in case it is necessary to re-create the file from the raw data.
7.1 Data dictionary
The data dictionary is part of the metadata and is the link between the questionnaire 
and the data files. It typically contains the name and a description of each variable, with 
additional information such as the data type (for example, numeric or text), coding (for 
example, 0 = No, 1 = Yes), and the questionnaire section and question number to which 
the variable relates. The data dictionary is essential for understanding how the data are 
structured and is used in preparing for data analysis.
7.2 Creating new variables
Sometimes, it is necessary to create a new variable from two or more existing variables, 
since this new variable may be more meaningful than the ones on which data were col-
lected directly. For example, body mass index (BMI, defined as weight in kilograms/
height in metres2) or weight-for-age may be better markers of nutritional status than 
weight on its own. Such composite variables may be calculated directly from the raw data 
or be obtained by comparison with a given standard (as in the case of weight-for-age).
Variables related to time, such as the length of residence or the duration of exposure 
to a risk factor, present a special case. Depending on the characteristics of the variable 
and of the population under study, it may be preferable to record relevant dates on the 
questionnaires and to subtract them during the analysis stage to compute the duration 
of residence, exposure, etc. These calculations can be done, without difficulty, with any 
statistical package.
After creating a composite variable, it is useful to check that the distribution of the 
new variable seems reasonable. It is also appropriate to check the range of the new 
variable, as data errors may only show up at this stage. For example, negative ages or ex-
treme weights-for-age may result from errors in the date of birth (or date of interview) 
in the questionnaire, though such errors should have been detected through consist-
ency checks at an earlier stage.
7.3 Coding and re-coding
Before beginning the analysis, it is usually necessary to re-code some variables, so that 
they can be grouped into categories. Since it is advisable to look at cross-tabulations 
of data before moving on to regression methods, re-coding is generally needed for 
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quantitative variables. Grouping makes it easier to understand the data and, in particu-
lar, to look for non-linear associations. But re-coding may also be necessary for categor-
ical variables with large numbers of categories, or few observations in some categories.
When re-coding quantitative variables, one strategy is to divide the range of the vari-
able into quartiles or quintiles, giving four or five groups with equal numbers of ob-
servations in each group. Alternatively, cut-off points may be chosen on the basis of 
established standards. For example, when grouping age, it is more natural to use 5- or 
10-year age bands (for example, 20–29, 30–39, etc.), rather than base the categorization 
on quartiles. Similarly, there are recognized international cut-points for variables such 
as BMI (less than 18.5 is considered underweight) or weight-for-age (less than −2.0 is 
considered stunted). A histogram of the data is often a good way of deciding how to 
categorize a quantitative variable with no standard cut-points.
With categorical variables, it may be necessary to combine groups if there are very 
few observations in some groups. When combining groups, an important principle to 
remember is that, for combining to be appropriate, the risk of the outcome should be 
similar in each of the combined groups. For example, in a study of child malnutrition, 
it may not be appropriate to group mothers with no schooling with those with primary 
school education.
The number of groups to use also depends, in part, on how the variable will be used 
in the analysis. If the variable is an exposure of interest, where it is planned to examine 
the pattern of dependence of the outcome on the amount of exposure (for example, a 
dose–response), it is important to use enough groups to get a reasonable picture of the 
relationship. For example, to examine the effect of alcohol intake during pregnancy on 
birthweight, one group might be non-drinkers, and there could be four or five groups 
for different levels of alcohol intake.
After deciding if and how each variable should be grouped, the different categories 
should be assigned ‘labels’ to describe them. These labels should be saved in the data 
set, which will eliminate the need to return to the questionnaires or code lists during 
the analysis. When a variable is re-coded, it is important to create a new variable and al-
locate it a different name, so as to preserve the raw data. Thus, the variable ‘AGE’ might 
be grouped and allocated to another variable called ‘AGEGP’.
7.4 Merging and linking data
The data required for a particular analysis may need to come from several different 
data sets (for example, questionnaire data on an individual’s recent sexual behaviour 
may need to be linked to laboratory results, demographic data collected previously, 
and household-level data on the socio-economic status). If complete data tables are 
extracted for analysis, merging of the data may be more easily managed in the statistical 
package used for the analysis.
Many data management packages allow the construction of complex views of the 
data and can be used to extract merged data for analysis. The data analyst can specify 
the variables for analysis, and these can be extracted from the database, using stand-
ard data management tools, thereby maintaining the confidentiality of the data. It also 
enables simple data extraction programs to be used at regular intervals for longitudinal 
data, giving regular snapshots of the data for analysis.
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1 Introduction to methods of analysis
This chapter describes simple statistical methods that are likely to be most useful for 
the basic analysis of intervention trials. Usually, a statistician will be closely involved 
in the design and analysis of a trial, and the more advanced analytical techniques that 
they might employ are not covered in this chapter. For more information on such tech-
niques, the reader is referred to statistical texts such as Armitage and Berry (1987), 
Kirkwood and Sterne (2003), and Rothman et al. (2008). However, the methods pre-
sented in this chapter should enable the analysis of the main results of a trial. More 
advanced statistical techniques usually result in relatively small changes in the esti-
mates of effect sizes through multivariate and associated analyses. Also, armed with the 
methods in this chapter, the reader should be in a good position to interpret and check 
the analyses reported in published studies.
The methods that are going to be used to analyse a trial should be considered at the 
time the trial is set up, so all of the appropriate data are collected and are assembled in 
a form suitable for the planned analyses. It is a common requirement nowadays for the 
statistical analysis plan to be fully developed, before any blinding in a trial is broken and 
in advance of a ‘frozen’ data set being prepared for analysis. Such plans are discussed 
in Section 3.
The choice of an appropriate method of analysis of a trial depends on the type of out-
come measure which is of interest. The different types of outcome measure are discussed 
in Section 2, which also includes a brief review of the concepts of confidence intervals 
(CIs) and statistical tests. In Sections 4, 5, and 6, methods are described which are appro-
priate for the analyses of data in the form of proportions, rates, and means, respectively. 
RCTs have been recommended as the method of choice for determining the effects of 
an intervention, because such trials generally avoid the problem of confounding. Some-
times, however, particularly in small trials, there may be differences between the ran-
domized groups, with respect to factors that might affect the outcome of interest, but 
which are unrelated to the intervention under test. If there has been a proper random-
ization process, any such differences should rise by chance only. If the trial is large, it 
is unlikely that there will be any important imbalance in this respect between the ran-
domized groups. In small trials, such chance differences may have a larger effect, and, in 
such circumstances, it may be important to adjust for any potential confounding due to 
these chance differences. In addition, where randomization is not feasible, any attempt to 
draw conclusions about the effects of an intervention must make allowance for possible 
confounding factors, and simple methods for doing this are described in Section 7. The 
analysis of trials in which interventions are allocated to groups, rather than individuals, 
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is discussed in Section 8. How the results of a trial may be used to assess the possible 
public health impact of an intervention is considered in Section 9.
2 Basics of statistical inference
2.1 Types of outcome measure
The appropriate method of statistical analysis depends on the type of outcome meas-
ure that is of interest. An outcome in an intervention study can usually be expressed as 
a proportion, rate, or mean. For example, in a trial of a modified vaccine, an outcome 
measure of interest may be the proportion of vaccinated subjects who develop a protect-
ive level of antibodies. In a trial of multi-drug therapy for tuberculosis, the incidence 
rates of relapse, following treatment, may be compared in the different study groups 
under consideration. In a trial of an anti-malarial intervention, it may be of interest to 
compare the mean packed cell volume (PCV) at the end of the malaria season in those 
in the intervention group and those in the comparison group.
2.2 Confidence intervals
An estimate of an outcome measure calculated in an intervention study is subject 
to sampling error, because it is based on only a sample of individuals and not on the 
whole population of interest. The term sampling error does not mean that the sam-
pling procedure or method of randomization was applied incorrectly, but that, when 
random sampling is used to decide which individuals are in which group, there will 
be an element of random variation in the results. The methods of statistical inference 
allow the investigator to draw conclusions about the true value of the outcome meas-
ure on the basis of the information in the sample. In general, the observed value of the 
outcome measure gives the best estimate of the true value. In addition, it is useful to 
have some indication of the precision of this estimate, and this is done by calculating 
a confidence interval for the estimate. The CI is a range of plausible values for the true 
value of the outcome measure, based on the observations in the trial. It is conventional 
to quote the 95% confidence interval (also called 95% confidence limits). This is calcu-
lated in such a way that there is a 95% probability that the CI includes the true value 
of the outcome measure.
Suppose the true value of the outcome measure is ø and that this is estimated from 
the sample data as øˆ . The 95% CIs to be presented here are generally of the form 
± ×øˆ 1.96 SE(øˆ), where SE (øˆ) denotes the standard error of the estimate. This is a meas-
ure of the amount of sampling error to which the estimate is susceptible. One of the 
factors influencing the magnitude of the standard error, and hence the width of the CI, 
is the sample size; the larger the sample, the narrower the CI.
The multiplying factor 1.96, used when calculating the 95% CI, is derived from tables 
of the Normal distribution. In this distribution, 95% of values are expected to fall within 
1.96 standard deviations of the mean. In some circumstances, CIs, other than 95% lim-
its, may be required, and then different values of the multiplying factor are appropriate, 
as indicated in Table 21.1.
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When analysing means, the multiplying factor sometimes has to be increased to 
allow for additional errors in estimating the standard error (see Section 5).
2.3 Statistical tests
As well as calculating a CI to indicate a range of plausible values for the outcome meas-
ure of interest, it may be appropriate to test a specific hypothesis about the outcome 
measure. In the context of an intervention trial, this will often be the hypothesis that 
there is no true difference between the outcomes in the groups under comparison. (For 
this reason, the hypothesis is often referred to as the null hypothesis.) The objective is 
thus to assess whether any observed difference in outcomes between the study groups 
may have occurred just by chance, due to sampling error.
A statistical test is used to evaluate the plausibility of the null hypothesis. The sam-
ple data are used to calculate a quantity (called a statistic) which gives a measure of the 
difference between the groups, with respect to the outcome(s) of interest. The details 
of how the statistic is calculated vary, according to the type of outcome measure being 
examined, and are given in Sections 4 to 6. Once the statistic has been calculated, its 
value is referred to an appropriate set of statistical tables, in order to determine the p-
value (probability value) or statistical significance of the results. The p-value measures 
the probability of obtaining a value for the statistic as extreme as the one actually ob-
served if the null hypothesis were true. Thus, a very low p-value indicates that the null 
hypothesis is likely to be false.
For example, suppose, in a trial of a vaccine against malaria, an estimate of the effi-
cacy is obtained of 20%, with an associated p-value of 0.03. This indicates that, if the 
vaccine had a true efficacy of zero, there would only be a 3% chance of obtaining an 
observed efficacy of 20% or greater.
The smaller the p-value, the less plausible the null hypothesis is as an explanation of 
the observed data. For example, on the one hand, a p-value of 0.001 implies that the null 
hypothesis is highly implausible, and this can be interpreted as very strong evidence of 
a real difference between the groups. On the other hand, a p-value of 0.20 implies that 
a difference of the observed magnitude could quite easily have occurred by chance, 
even if there were no real difference between the groups. Conventionally, p-values of 
0.05 and below have been regarded as sufficiently low to be taken as reasonable evi-
dence against the null hypothesis and have been referred to as indicating a statistically 
Table 21.1 Multiplying factors for calculating 
CIs, based on the Normal distribution
CI (%) Multiplying factor
90 1.64
95 1.96
99 2.58
99.9 3.29
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significant difference, but it is preferable to specify the actual size of the p-value attained, 
so that readers can draw their own conclusions about the strength of the evidence.
While a small p-value can be interpreted as evidence for a real difference between the 
groups, a larger non-significant p-value must not be interpreted as indicating that there 
is no difference. It merely indicates that there is insufficient evidence to reject the null 
hypothesis, so that there may be no true difference between the groups. It is never pos-
sible to prove the null hypothesis. Depending on the size of the study and the observed 
difference between the groups under comparison, the CI on the difference provides a 
range of plausible values in which the true difference might lie, which may include a 
zero difference.
Too much reliance should not be placed on the use of statistical tests. Usually, it is 
more important to estimate the effect of the intervention and to specify a CI around the 
estimate to indicate the plausible range of effect than it is to test a specific hypothesis. 
In any case, a null hypothesis of zero difference is often of no practical interest, as there 
may be strong grounds for believing the intervention has some effect, and the main ob-
jective should be to estimate that effect.
The statistical tests presented here are two-sided tests. This means that, when the 
p-value is computed, it measures the probability (if the null hypothesis is true) of ob-
serving a difference as great as that actually observed in either direction (i.e. positive or 
negative). It is usual to assume that tests are two-sided, unless otherwise stated, though 
not all authors adhere to this convention. A full discussion of the relative merits of 
one-sided and two-sided tests is given in Armitage and Berry (1987) and Kirkwood 
and Sterne (2003).
3 Statistical analysis plan
A common mistake in the planning of a trial is to delay consideration of the analyses 
until the data become available. It is essential that the main analyses that will be under-
taken are planned at the design stage, as this provides several major benefits. First, it en-
courages a clearer understanding of the basic questions to be answered and thus assists 
with the formulation of clear and specific objectives. For example, in a vaccine trial, 
a simple comparison of the numbers of cases of the disease occurring over a 5-year 
period in the vaccinated and unvaccinated groups may answer the question of the mag-
nitude of any protective effect. A comparison of the incidence rates of disease in vac-
cinated and unvaccinated individuals in the first, second, third, fourth, and fifth years 
after vaccination can be used to answer a rather different question, namely, whether the 
protective effect is constant over the 5-year period.
A second benefit of considering the analyses at the design stage is that it necessitates 
specification of what data need to be recorded. The investigator can check that arrange-
ments have been made to measure and record all variables that will be needed in the 
analyses. Also, and perhaps as importantly, it may become clear that some variables will 
not be needed, and these can then be omitted from the study.
The process of planning the analyses may identify also the importance of subgroup 
analyses. In a vaccine trial, for example, it may reveal a need to assess the efficacy of 
the vaccine in children vaccinated at different ages. This may have major implications 
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for the choice of sample size, as the need for age-specific estimates of efficacy requires a 
much larger sample in each age group than would be needed if only an overall estimate 
of efficacy was wanted.
Finally, advanced planning of the analyses is desirable to ensure that adequate ar-
rangements have been made for data handling, the necessary computer software is 
available, and sufficient time for data cleaning and analysis has been allowed for in the 
study schedule.
Prior to any formal statistical analyses of the kinds discussed from Section 4 onwards, 
it is essential to perform simple tabulations of data and to construct simple diagrams 
to summarize the information that has been collected. Simple statistical package com-
puter programs, such as Epi-Info (<http://wwwn.cdc.gov/epiinfo>) or STATA (<http://
www.stata.com>), greatly facilitate doing this. The investigator should use these simple 
approaches to gain a good understanding of the data collected, before embarking on 
more complex analyses. These simple analysis methods are not described further in 
this manual, but they are discussed in most good textbooks on medical statistics (for 
example, Armitage and Berry, 1987; Kirkwood and Sterne, 2003).
If the results of a trial are to be used for submission to an appropriate authority to 
grant a licence for a new drug or vaccine, the licensing authorities will require that a 
statistical analysis plan (SAP) is developed as a separate document, to be completed 
after finalizing the protocol and before the code is broken for who is in the interven-
tion and control groups (if it is a blinded trial). The SAP should contain a technical and 
detailed description of the principal analyses to be conducted on the trial data, which 
has more detail than would typically be included in the trial protocol. The plan should 
include detailed procedures for conducting the statistical analysis of the primary and 
secondary outcome variables and of other relevant data. Often, the licensing authority 
will require a copy of the SAP for them to examine and approve in advance of a trial 
being analysed.
It is good practice to prepare a SAP for any trial, even if the results are not to be used 
for product licensing. In addition to any necessary review by licensing authorities, the 
SAP should be reviewed and approved by the trial steering committee and also often 
by the trial data safety and monitoring committee (DSMC). A formal record should be 
kept of when the statistical analysis plan was finalized, as well as when the final data set 
was ‘frozen’ and when the trial was unblinded.
It is common to develop the computer programs for conducting the SAP in advance 
of breaking the treatment code. To check that these are working properly, some analysts 
assign study participants at random to intervention or control groups (irrespective of 
which group they were actually in) and run the programs on these ‘test’ data. In this 
way, they are able to check that the final tables are in an appropriate format to be in-
terpreted, once the code is broken. Conducting such a ‘dummy run’ analysis generally 
greatly speeds the analysis and interpretation of the trial, once the data are finalized.
Often, when an analysis is conducted, further analyses will be appropriate and 
prompted by an initial examination of the study results, rather than being pre-planned 
in the SAP. Such analyses are often called ‘exploratory’. They were not specifically 
planned in advance but were prompted by examination of the trial findings. Such ex-
ploratory analyses are sometimes informative and may suggest new hypotheses, but 
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it is important to distinguish them from the analyses that were included in the SAP, 
as they were suggested by the data, rather than being planned in advance of the code 
being broken. It is generally wise to interpret the results of such exploratory analyses 
with caution.
4 Analysis of proportions
4.1 Confidence interval for a single proportion
Methods appropriate for the analysis of proportions are used when the outcome of 
interest is a binary (‘yes/no’) variable (for example, the proportion of individuals who 
develop a disease). The standard error of a proportion p, calculated from a sample of n 
subjects, is estimated as p p n(1 )/ .[ ]√ −  For example, if the prevalence of splenomeg-
aly in a random sample of 200 children from a population is found to be 0.40 (40%) (i.e. 
80 had splenomegaly), the standard error (SE) is given by:
                       pSE( ) 0.40 0.60/200 0.035 3.5% .( ) ( )=√ × =
The 95% CI for a proportion is given by ± ×p p1.96 SE( ). In the example, the 95% 
CI is ± ×0.4 1.96 0.035  or (0.33, 0.47), i.e. 33–47%. There is a 95% chance that the true 
prevalence of splenomegaly in the population from which the sample of 200 was taken 
was between 33% and 47%.
4.2 Difference between two proportions
Suppose now that the objective is to compare the proportions observed in two groups 
of individuals, as is typically the case in a trial, comparing outcomes in an intervention 
and control group. The standard error of the difference between two proportions p1 and 
p2, based on n1 and n2 observations, respectively, is estimated approximately as:
 { }( ) ( )( )√ − + n np 1 p 1/ 1/1 2
where n p n p n np / .1 1 2 2 1 2( ) ( )= + +
For example, if the proportions to be compared are 90/300 (30%) and 135/300 
(45%), the observed difference between the two proportions is −0.15, =p 0.375, and 
the standard error of the difference is given by:
          0.375 0.625 1/300 1/300 0.040.{ }[ ]( ) ( )√ × + =
The 95% CI for the difference between the proportions is given by p p– 1.96 SE.1 2( )± ×  
In the example, this gives ( ) ( )− ±0.15 1.96 0.040 , i.e. (−0.23, −0.07), or −23% to −7%.
To test the null hypothesis that there is no true difference between the two propor-
tions, the data are first arranged in a 2 × 2 table, as in Table 21.2.
In the table, a is the number in group 1 who experiences the outcome of interest. The 
expected value of a, E(a), and the variance of a, V(a), are calculated under the hypoth-
esis of no difference between the two groups:
 E a m n N( ) /1 1=  (21.1),
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 V a n n mm N N( ) / 11 2 1 2
2( )= −   (21.2)
The chi-squared χ( )2 statistic is then calculated. This gives a measure of the extent to 
which the observed data differ from those expected if the two proportions were truly 
equal.
 a E a V a( ) 0.5 / ( )2 2χ ( )= − −  (21.3)
where −a E a( )  indicates the absolute value of [ ]−a E a( ) .
The calculated value of χ2 is compared with tables of the chi-squared distribution 
with one degree of freedom (df). If it exceeds 3.84, then p < 0.05, indicating some evi-
dence of a real difference in the proportions. If it exceeds 6.63, then p < 0.01, and there 
is strong evidence of a difference.
In the example, a = 90; E(a) = (225)(300)/600 = 112.50; and V(a) = (300 × 300 × 225 
× 375)/(600 × 600 × 599) = 35.215. Thus χ ( )= − − =90 112.50 0.5 /35.215 13.74.2 2  
From tables of the chi-squared distribution, a p-value of 0.0002 is obtained, indicating 
a difference as large as that observed would be very unlikely to arise by chance if there 
really was no difference between the two groups.
If any of the quantities E(a), E(b), E(c), or E(d) (for example, =E b m n N( ) /2 1 ) are less 
than 5.0 and N is less than 40, theχ2 test is invalid, and a test called ‘Fisher’s exact test’ 
should be used instead (Kirkwood and Sterne, 2003).
4.3 Ratio of two proportions
The ratio of two proportions is sometimes referred to as the relative risk (R). To con-
struct a CI for a relative risk, the natural logarithm of the estimate of the relative risk is 
computed (Table 21.2):
 R p p a n c nlog ( ) log / log / / / .e e 1 2 e 1 2( ) ( ) ( )= =
 
Its standard error is estimated by:
 R b an d cnSE log ( ) / /e 1 2{ }[ ] ( ) ( )=√  +    (21.4).
Table 21.2 Comparison of two proportions
Group Outcome Total Proportion with outcome
Yes No
1 a (90) b (210) n1 (300) p1 = a/n1 (0.30)
2 c (135) d (165) n2 (300) p2 = c/n2 (0.45)
Total m1 (225) m2 (375) N (600)
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The 95% CI for loge(R) is given by ±Rlog ( ) 1.96 SE,e and the 95% CI for the relative 
risk is obtained by taking anti-logarithms.
In the example given in Table 21.2, the relative risk is estimated as 0.30/0.45 0.667,=   
and =−Rlog ( ) 0.405.e The SE[loge(R)] is estimated as √{[210/(90 × 300)] + [165/
(135 × 300)]} = 0.109, and the 95% CI for loge(R) is given by −0.405 ±  1.96(0.109), 
i.e. (−0.619, −0.191). Taking anti-logarithms, the 95% CI for the relative risk is 
(0.538, 0.826).
4.4 Trend test for proportions
Sometimes, it is of interest to examine whether there is a trend in a series of proportions 
associated with different levels of some underlying characteristic. For example, con-
sider the proportion of leprosy patients who report regularly to collect their monthly 
drug supply from a clinic when the accessibility of the clinic is rated as very poor, poor, 
fair, or good (Table 21.3).
A ‘score’ (xi) is assigned for each kind of clinic, of which the value relates to the level 
of accessibility. For example, ‘0’ has been assigned to those with ‘very poor’ accessi-
bility and ‘3’ to those with ‘good’ accessibility. A test for the trend in the proportions 
a n/1 1 , a n/2 2 , a n/3 3 , and a n/4 4 is provided by testing, as a chi-squared with one df, the 
expression:
  (21.5).
For example, suppose the data are as shown in Table 21.3 (the respective percentages 
of regular attenders in the four rows are 20%, 30%, 50%, and 60%). The value of χ
2
is:
150 150 125 63 245 63 87 150 555 245 12.952 2{ [ ]}[ ]( ) ( ) ( )× − × × × − =
which is highly significant (p = 0.0003), based on a χ2 test with one df. It may be 
concluded therefore that there is strong evidence that the regularity of drug collection 
increases with the accessibility of the clinic.
Table 21.3 Regularity of collection of drugs by leprosy patients, according to accessibility 
of clinic
Accessibility of clinic Collection of drugs Total ‘Score’ xi
Regular Not regular
Very poor a1 (5) n1 – a1 (20) n1 (25) 0
Poor a2 (12) n2– a2 (28) n2 (40) 1
fair a3 (25) n3– a3 (25) n3 (50) 2
Good a4 (21) n4– a4 (14) n4 (35) 3
Total A (63) N – A (87) N (150)
[ ] { [ ]}χ = ( Σ )−( Σ ) ( − ) ( Σ )−(Σ )N N a x A n x A N A N n x n x2 i i i i 2 i i2 i i 2
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5 Analysis of rates
5.1 Risks, rates, and person-time-at-risk
The terms ‘risk’ and ‘rate’ are often used rather loosely and interchangeably to describe 
the frequencies of events in epidemiological studies. Usually, this is of no great con-
sequence, but, in some circumstances, the distinction is important and, in particular, 
may affect the way in which a study is analysed. A risk is essentially a proportion, or 
equivalently a probability. The numerator consists of the number of individuals who 
experience the event of interest (say, develop the disease) in a defined period. The de-
nominator consists of the total number of individuals who were followed for the de-
fined period, some of whom experienced the event of interest (for example, developed 
the disease) and the remainder of whom did not (ignoring, for the moment, compli-
cations that might arise if some individuals are lost to follow-up). A rate takes into ac-
count both the number of persons at risk and also the duration of observation for each 
person. In the simplest case, the numerator is the number of individuals who experi-
ence the event of interest during the study period (i.e. the same as the numerator for a 
risk), but the denominator is expressed as the person-time (for example, person-years 
or person-days) at risk for the individuals in the study.
For example, if 120 persons are observed for 3 years and 40 of them die at some time 
during the period, and none are otherwise lost to follow-up, the risk of death over the 
3 years is estimated as 40/120 = 0.33, whereas the death rate is estimated as 40/(the 
number of person-years-at-risk). The denominator for the rate calculation is (80 × 3) + 
(40 × 1.5) = 300 years, as 80 persons were ‘at risk’ for the full 3-year period, and 40 
were at risk until they died (which, on average, is likely to have been about halfway 
through the follow-up period if deaths occurred uniformly over the period). Thus, the 
death rate is 40/300 = 0.133 per person-year-at-risk (which is not the same as the risk 
of death during the 3 years of 0.33 divided by 3).
Mathematically, it is straightforward to convert rates to risks, and vice versa, if it may 
be assumed that the rates are constant over time (see, for example, Breslow and Day, 
1980). The reason for discussing the distinction in this chapter is that different methods 
of statistical analysis are appropriate for risks and rates. As mentioned in Section 4, 
risks are proportions, and thus the methods described in that section are applicable. 
Modifications of these methods are necessary for the analysis of rates.
Rates are useful if different individuals in a study have been followed for different pe-
riods. This may arise if recruitment to the study population is staggered over time, but 
follow-up is to a common date, or if individuals are lost to follow-up at different times 
(for example, because of death, migration, or non-co-operation).
An example of the computation of person-years-at-risk in a large study is given in 
Table 21.4. In this study, a census was done of the study population on the 1 November 
each year, and the number of persons remaining at risk was ascertained.
Alternatively, the exact period of follow-up may be known for each subject in the 
study (if the dates of entry and exit are available for each person), in which case these 
periods would be summed to derive the total person-years-at-risk.
Another situation in which rates, rather than risks, may be more appropriate is when 
each individual may be at risk of experiencing the event of interest more than once 
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during the study period (for example, an episode of diarrhoea). The incidence rate in 
the study population would be calculated as the total number of events (for example, 
episodes of diarrhoea) for those in the study divided by the total person-time-at-risk 
(which, in this case, would not end at the first episode). Responses such as this can al-
ways be converted to a risk by expressing the outcome as the proportion of individuals 
who experience more than a specified number of events (for example, one or more 
episodes of diarrhoea), but, in doing this, some information is lost, with a consequent 
reduction in the power of the study to detect a difference between groups being com-
pared. The analysis of rate data of this kind (where one individual may experience more 
than one episode of disease) is not straightforward, as the approach depends upon 
whether it is reasonable to assume that, once an individual has experienced one event, 
he or she is no more or less likely to experience another event than anyone else in the 
same intervention group (say, of the same age and sex). Usually, it is not reasonable to 
make this assumption, as it is frequently found that susceptibility and exposure to dis-
ease vary considerably between individuals in ways that cannot be predicted. A simple 
way out of the analytical problem is to classify individuals, according to whether or not 
they experienced any events or not. If this is done, the data can either be analysed as a 
proportion (using the methods given in Section 4) or the individual can be excluded 
from follow-up for purposes of analysis, from the time the first event occurs (i.e. they 
are not counted as ‘at risk’ after the first event), and the methods given in Sections 5.2 
to 5.5 can be used.
5.2 Confidence interval for a rate
Suppose e is the number of events that occurred during the study period, and the total 
person-years-at-risk during the period was y. (Note that the period does not have to 
Table 21.4 Example of the computation of person-years-at-risk in a large study
Date No. of  
persons under 
observation
Average of 
successive 
numbers
Years of 
observation
Person-years
(a) (b) (c) (d) (c × d)
Start date 1 November 2004 10140
1 November 2005 9145 9642.5* 1 9642.5
1 November 2006 8232 8688.5 1 8688.5
1 November 2007 7389 7810.5 1 7810.5
1 November 2008 6281 6835.0 1 6835.0
End date 1 April 2009 5779 6030.0 5/12 2512.5
Total 35489.0
* If 10140 persons were alive on 1 November 2004, and 9145 of them were known to be alive on 1 Novem-
ber 2005, and if losses to follow-up occurred evenly throughout the year, there would have been, on aver-
age, (10140 + 9145)/2 = 9642.5 persons at risk on each day during the first year, hence a total of 9642.5 
person-years.
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be measured in ‘years’; it could be in, for example, days, weeks, or months.) The event 
rate (r) is estimated by e/y. For example, suppose 5000 patients who have received a new 
tuberculosis (TB) vaccine have been followed for 5 years, but, due to losses in follow-
up, the total person-years-at-risk is 20 000 (instead of the nearly 25 000 that would have 
been appropriate if every patient—except the cases whose follow-up period would be 
counted up to the time they developed TB—had been followed up throughout the 5 
years). If the number of new cases of TB that were detected during the follow-up was 
80, the estimated incidence rate of TB would be 80/20 000 = 0.0040/person-year, i.e. 
four per thousand person-years.
The standard error of a rate (r) is, √(r/y) and the approximate 95% CI for the rate is 
given by r ± 1.96√(r/y). Thus, in the TB example, the 95% CI for the TB incidence rate is:
 ( )± √ = ±0.0040 1.96 0.0040/20 000 0.0040 0.0009,
i.e. 3.1–4.9 per thousand person-years.
5.3 Difference between two rates
Suppose it is required to compare event rates in two groups, and the number of events 
and the person-years-at-risk in the two groups are as in Table 21.5.
The standard error of the difference between two rates is given by: r y r y/ / ,1 1 2 2( )√ +  
and the 95% CI on the difference is given by( )− ±r r 1.961 2 SE.
Thus, for the example, the 95% CI on the rate difference of the vaccinated, compared 
to the unvaccinated, group in Table 21.5 is:
( ) ( )( )− ± √ +  =− ±
=− −
0.0041 0.0084 1.96 0.0041/19 470 0.0084/19 030 0.0043 0.0016
0.0059 to 0.0027
i.e. −5.9 to −2.7/1000/year.
To perform a statistical test, it is necessary to calculate a test statistic, which may be 
done along similar lines to those described in Section 4.2. If e1 is the observed number 
of events among those in group 1 (say, those vaccinated), then:
 Expected value of e E e ey y/1 1 1( )= =  (21.7).
 Variance of e V e ey y y/1 1 1 2
2( )= =  (21.8).
Table 21.5 TB incidence rates in vaccinated and unvaccinated groups
Number of events  
(new TB cases)
Person-years-at- 
risk (pyar)
Event rate (TB cases 
per 1000 pyar)
Vaccinated e1 (80) y1 (19470) r1 (4.1)
Not vaccinated e2 (160) y2 (19030) r2 (8.4)
Total e (240) y (38500) r
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Then:
 e E e V e0.5 /2 1 1
2
1χ ( )( ) ( )= − −  (21.9).
And the value of χ2 is looked up in tables of the χ2 distribution, with one df, to as-
sess the p-value.
In the example shown in Table 21.5, e 80;1= E e 240 19 470/38 500 121.37;1( )= × =   
and ( ) ( )( )= × × × =V e 240 19 470 19 030 / 38 500 38 500 59.99.1
Thus,χ ( )= − − =80 121.37 0.5 /59.99 27.84,2 2  and p < 0.000001, indicating that the 
difference is highly unlikely to have arisen by chance.
5.4 Ratio of two rates
In some situations, the ratio of two rates will be of greater interest than their difference. 
For example, vaccine efficacy is usually calculated from a ratio. The test of the null hy-
pothesis is identical in the two situations (i.e. the difference is zero, or the ratio is unity), 
but the CIs are calculated in a different way.
The ratio of two rates, sometimes called the relative risk, but more correctly called the 
relative rate, is e y e y/ / /1 1 2 2( ) ( ) , and the standard error of the logarithm of this ratio is 
approximated by e e1/ 1/1 2( ) ( )√ +  . In the example given in Table 21.5, the ratio of the 
rates is 0.489 (corresponding to a vaccine efficacy of 51.1%), and the standard error of 
the logarithm of the ratio is [ ]( ) ( )√ + =1/80 1/160 0.1369. The 95% CI of the logarithm 
of the ratio is given by ( )− ±0.715 1.96 0.1369 ,  i.e. −0.983 to −0.447. Thus, the 95% CI 
for the ratio of the two rates is 0.37–0.64 (or the 95% CI on the estimate of vaccine effi-
cacy is from 36% to 63%, i.e. 100(1−0.64) to 100(1−0.37).
5.5 Trend test for rates
Directly analogous to the trend test for proportions described in Section 4.4, there is a 
similar test for a trend in rates. Suppose data have been collected from the time since 
the start of a study to the first attack of malaria among children of different ages, and 
it is of interest to test whether the attack rate declines with age. The data may be sum-
marized, as in Table 21.6.
A ‘score’ has been assigned to each group. In the example, the scores have been taken 
as the mid points of the different age groups (for example, those aged 1–2 years range 
in age from 1.00 to 2.99 years).
Table 21.6 Malaria attack rates in children of different ages
Age of children 
(years)
‘Score’ xi No. with malaria 
attack (ei)
Child-weeks- 
at-risk (yi)
Attack rate  
ei/yi
1–2 x1 (= 2.0) e1 (30) y1 (200) 0.150
3–4 x2 (= 4.0) e2 (20) y2 (150) 0.133
5–7 x3 (= 6.5) e3 (10) y3 (150) 0.067
Total e (60) y (500) 0.120
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A test for trend in the attack rates in the three age groups e y/ ,1 1 e y/ ,2 2 and e y/3 3  is 
provided by testing the expression, asχ2 with one df:
 e x e y y x e y y y x y x/ /2 i i i i
2 2
i i
2
i i
2χ { }{ } ( )( ) ( )= Σ − Σ  Σ − Σ   (21.10).
For example, suppose the malaria attack rates (attacks/weeks-at-risk) were as in 
Table 21.6, then the value of χ2 is:
 { }( ){ }[ ]( ) ( )− × −  =205 60/500 1975 60/500 500 9537.5 1975 4.91
2 2 2
which has an associated p-value of 0.03, and thus there are grounds for believing that, 
in the study area, the risk of a malaria attack declined with increasing age.
6 Analysis of mean values
6.1 Confidence interval for a mean
If the outcome measure is taken as the mean (x−) of a sample of n observations, for 
example, the weights of a sample of newborn infants, the standard error of the mean 
is given by σ √n/ , where σ is the standard deviation of the variable measured (for ex-
ample, weights of newborn infants) in the population from which the sample of n ob-
servations was taken. The 95% CI on the mean is given by nx 1.96 /( )± σ √ .
In general, σ (the standard deviation in the population) will not be known but 
must be estimated, based on the n observations in the sample. Thus, the estimate of 
σ is subject to sampling error also, and this must be taken into account in the com-
putation of the CI on the mean. This is done by using a multiplying factor in the CI 
calculation taken from tables of the t-distribution, rather than from tables of the 
‘Normal’ distribution, on which Table 21.1 was based. The value of the multiplying 
factor will depend on the size of the sample from which the standard deviation was 
estimated. For example, for 95% CIs, appropriate multiplying factors for sample sizes 
of 10, 20, 50, and 100 are 2.26, 2.09, 2.01, and 1.98, respectively. (Note that, in using 
the tables, the values of t are given for different ‘degrees of freedom’. In the situation 
considered here, the degrees of freedom correspond to the sample size minus one, 
i.e. n − 1.) If the sample size is 30 or more, little error is introduced by using the value 
of 1.96 derived from the normal distribution when calculating 95% CI, rather than 
the appropriate t-value.
If the estimate of the standard deviation, based on the sample, is s, the 95% CI on the 
mean is given by ( )± √t s nx / .  For example, if the mean birthweight of 25 infants was 
3.10 kg and the standard deviation of the weights in the sample was 0.90 kg, the 95% 
CI would be given by 3.10 2.06 0.90/ 25 ,( )± √ i.e. 2.73 − 3.47 kg, where the multiplying 
factor 2.06 is taken from a table of the t-distribution corresponding to 24 df.
6.2 Difference between two means
In a trial, it is very common to want to compare the means of observations in different 
groups, for example, to compare observations from an intervention group with those 
from a control group. Suppose that two groups are to be compared and the means 
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are x1 and x ,2 respectively, and the corresponding standard deviations observed in the 
groups are s1 and s2. The standard error of the difference between the means is given by 
s n n1/ 1/1 2{ })( ) ( )√ +  , where s is the pooled estimate of the standard deviation, based 
on the observations from the two groups. s is estimated as:
 
s n s n s n n1 1 / 2 .1 1
2
2 2
2
1 2{ }( ) ( ) ( )=√ − + −  + −
The 95% CI for the difference between the means is given by:
 ts n nx x 1/ 1/1 2 1 2( ) ( ) ( )− ± √ +
 
where t is taken from a table of the t-distribution with ( )+ −n n 21 2  df.
For example, suppose erythrocyte sedimentation rates (ESRs) were measured in an 
intervention group and in a control group, as shown in Table 21.7. The standard de-
viation s may be calculated as { }( ) ( ) ( )√ × + ×  + − =9 2.41 11 2.54 / 10 12 2 2.48,2 2 and 
the 95% CI on the difference is given by:
{ }[ ]( ) ( ) ( ) ( )− ± × √ + = ± = −9.7 6.5 2.09 2.48 1/10 1/12 3.2 2.2 1.0 5.4.
To test the null hypothesis that there is no true difference in the mean ESRs between 
the two groups, a statistical test must be performed. A test statistic is calculated to assess 
the probability of the observed results (or more extreme) if there really is no difference 
between the two groups. The difference of the means divided by the standard error of 
the difference gives a value of a test statistic that may be looked up in tables of the t-
distribution with( )+ −n n 21 2 df.
For the example in Table 21.7, the test statistic { }( ) ( ) ( )= − √ + s n nx x / 1/ 1/1 2 1 2
= 3.01.  The associated p-value is 0.0035, i.e. if there really is no effect of the intervention 
on ESRs, the chance of observing a difference in the means as large or larger than that in 
the study is 0.35% (i.e. not impossible, but rather unlikely!).
6.3 Analysis of more than two groups
If a study involves the comparison of observations in more than two groups, it is neces-
sary to generalize the methods given in Section 6.2. This is straightforward but is be-
yond the scope of this book, and the reader is referred to standard statistical texts, such 
as that by Armitage and Berry (1987) or Kirkwood and Sterne (2003), for details. The 
relevant sections to which to refer are those on ‘one-way analysis of variance’.
Of course, it is always possible to use the methods given in Section 6.2 to compare 
groups, just two at a time. This is a reasonable approach, but some caution must be 
Table 21.7 ESR in an intervention and a control group
Intervention group (i = 1) Control group (i = 2)
Number of subjects (ni) 10 12
Mean ESR (x– i) 9.7 6.5
Standard deviation (si) 2.41 2.54
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exercised when interpreting the findings, as the chances of finding at least one pair to 
be significantly different (for example, p < 0.05) may be substantial, even if there are, in 
truth, no differences between the groups. To illustrate this, suppose six groups are being 
compared. In an analysis of variance, the question is asked: ‘Considered as a whole, 
is the variation between the means observed in the six groups more than might be 
expected to arise by chance if there were no differences in the true means?’. This ques-
tion may be answered with one statistical test in an analysis of variance, and the null 
hypothesis may, or may not, be rejected on the basis of this one test. Suppose, however, 
it was decided to examine all possible pairs of comparisons of the groups. There are 15 
possible pairs, and, if a t-test was done on each pair, there is a reasonable chance that at 
least one comparison would be found to be ‘p < 0.05’ by chance alone, because of the 
number of different tests that had been performed. There are ways of adjusting the sig-
nificance levels to allow for this effect, and the reader is referred to standard texts again 
for a discussion of ‘the multiple comparison problem’.
7 Controlling for confounding variables
7.1 The nature of confounding variables
A risk factor for the disease under study that is differentially distributed among the 
groups receiving different interventions in which the disease incidence is being com-
pared is called a confounding factor. Unless the trial is very small, confounding fac-
tors are not likely to bias the comparisons between intervention and control groups 
in randomized trials, as the process of randomization ensures that any such factors, 
whether known or unknown, will be equally distributed in the different groups (apart 
from random variation). In studies in which those in the different groups have not 
been allocated at random, the control of confounding factors is a critical component 
in the analysis. For example, consider a comparative study of TB incidence in persons 
who received BCG in a routine vaccination programme and those who were not vac-
cinated. BCG coverage is often higher in urban areas and, independently of any effect 
of BCG, those living in urban areas also tend to have a higher incidence of TB because 
of overcrowding and other environmental factors. In this instance, residential status 
(rural/urban) could be a confounding factor, and, if it is not taken into account in the 
analyses, any protective effect of BCG against TB might be underestimated. Consider 
the hypothetical situation depicted in Table 21.8, which shows the incidence of TB 
over a 10-year period in BCG-vaccinated and unvaccinated individuals in urban and 
rural areas.
BCG coverage is appreciably higher in the urban population (80%) than in the rural 
population (50%). Also, in unvaccinated persons, the incidence of TB is higher in the 
urban population (20 per thousand over 10 years) than in the rural population (10 per 
thousand). In consequence, although BCG vaccine efficacy is 50% in both urban and 
rural areas, the estimate obtained from a comparative study, in which the place of resi-
dence is ignored, is only 41%. This difference is due to the confounding effect of the 
place of residence on the estimate of efficacy (the place of residence being related to 
both the disease incidence and, independently, to the prevalence of vaccination).
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7.2 Adjusting for confounding variables
A powerful way of removing the effect of a confounding variable is to restrict compara-
tive analyses to individuals who share a common level of the confounding variable and 
then to combine the results across the different levels in such a way so as to avoid bias. 
Thus, in the example in Table 21.8, if the vaccine efficacy was first estimated separately 
for rural and urban dwellers, and then the two estimates were to be combined, the es-
timate of efficacy obtained (50%) would be free of the confounding bias of the place of 
residence. In general, to control for confounding, the study population is divided into 
a number of strata. Within each stratum, individuals share a common level of the con-
founding variable. Estimates of risk, rate or mean differences, or ratios are made within 
each stratum, and the resulting estimates are then pooled in some way across strata, in 
order to obtain an overall measure of the effect which is free of any confounding due to 
the variable on which the stratification was made. Such stratification may be carried out 
on several confounding variables simultaneously (for example, age and sex).
If it is known, when a study is planned, that it will be necessary to allow for con-
founding variables in the analysis, it is desirable to give consideration to this at the 
design stage, both in terms of the information which must be collected and because it 
will require an increase in the required sample sizes (to achieve the desired statistical 
power, see Chapter 5). Usually, the necessary increase in sample size to allow for con-
founding variables is not great (for example, less than 20%), and often the information 
needed for these sample size calculations is not available before the study starts anyway. 
Formal methods for calculating sample sizes, allowing for adjustment for confounding 
variables, are given in Breslow and Day (1987).
7.3 Adjusting risks
7.3.1 Overall test of significance
After stratifying on the basis of the confounding variable(s), the analysis is conducted 
one stratum at a time, and then the results are pooled. In the ith stratum, the data may 
be depicted, as shown in Table 21.9.
To test the hypothesis that the relative risk is 1 in all strata or equivalently that the risk 
difference is zero in each stratum, a generalization of the method given in Section 4.2 
may be used. The statistical test is known as the Mantel–Haenszel test.
Table 21.8 TB incidence rates by BCG vaccination status and urban or rural residence
BCG 
vaccination 
status
Urban Rural Both groups
Total popn. TB cases* Total popn. TB cases* Total popn. TB cases*
No. /1000 No. /1000 No. /1000
Vaccinated 16000 160 10 40000 200 5 56000 360 6.4
Unvaccinated 4000 80 20 40000 400 10 44000 480 10.9
Vaccine  
efficacy
50% 50% 41%
* Over a period of 10 years.
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In the ith stratum:
 Expected value of a E a m n N/i i 1i 1i i( )= =  (21.11).
 Variance of a V a n n m m N N/ 1i i 1i 2i 1i 2i i
2
i( ) ( )= = −   (21.12).
An overall test of the null hypothesis that the relative risk is unity is given by calculat-
ing a E a V a0.5 / ,2 i i
2
iχ ( )( ) ( )= Σ −Σ − Σ  where the summation is over all strata, which 
may be tested for statistical significance using tables of the chi-squared distribution 
with one df.
The calculations are illustrated in Table 21.10, with data on disease incidence rates 
in vaccinated and unvaccinated individuals in three areas—urban, semi-urban, and 
rural.
 a E a V a530; 738; 284.21.i i i( ) ( )Σ = Σ = Σ =
Thus:
 
530 738 0.5 /284.21 151.49.2
2
χ ( )]= − − =
Thus, there is very strong evidence against the null hypothesis, as p < 0.000001 (from 
tables of the chi-squared distribution).
Table 21.9 Comparison of proportions developing disease in two intervention groups for 
individuals in the ith stratum
Intervention group Developed disease Did not develop disease Total
1 ai bi ai + bi = n1i
2 ci di ci + di = n2i
Total ai + ci = m1i bi + di = m2i Ni
Table 21.10 Disease incidence rates in urban, semi-urban, and rural areas, according to 
vaccination status
Area (i ) Vaccinated Unvaccinated Grand 
total  
(Ni)
E (ai) V (ai)
Cases  
(ai)
Non- cases 
(bi)
Total 
(n1i)
Cases  
(ci)
Non-cases 
(di)
Total  
(n2i)
Urban (1) 160 15840 16000 80 3920 4000 20000 192 37.94
Semi- 
urban (2)
170 23830 24000 240 15760 16000 40000 246 97.39
Rural (3) 200 39800 40000 400 39600 40000 80000 300 148.88
Total 530 79470 80000 720 59280 60000 140000 738 284.21
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7.3.2 Pooled estimate of risk difference
If it is considered that the risk difference (rather than the risk ratio) is likely to be con-
stant across different strata, a pooled estimate of the common risk difference may be 
required. This is obtained by taking a weighted average of the risk differences in each 
stratum, weighting each by the inverse of its variance (as this may be shown to give the 
‘best’ estimate of the common risk difference).
In the ith stratum, the risk difference is:
 d p p a n c n/ /i 1i 2i i 1i i 2i( ) ( )= − = −
and the variance of the risk difference is:
 
V d p p n n1 1/ 1/i i i 1i 2i{ }( ) ( ) ( ) ( )= − + 
(as given also in Section 4.2), where:
 p n p n p n n a c n n/ / .i 1i 1i 2i 2i 1i 2i i i 1i 2i[ ] ( ) ( ) ( )= + + = + +
Now, let w V d1/i i( )= .
The pooled estimate of the common risk difference is given by =Σ Σd w d w/ .i i i  For 
the data in the example given in Table 21.10, the computations for the common risk 
difference are shown in Table 21.11.
Pooled estimate of the common risk difference =Σ Σ =−d w d w/ 0.0083.i i i
7.3.3 Pooled estimate of risk ratio
A pooled estimate of the common risk ratio R across strata may be obtained, using the 
following formulae.
In the ith stratum, the risk ratio is given by:
 R a n c n an c n/ / / /i i 1i i 2i i 2i i 1i( ) ( ) ( )= =  (21.13).
A pooled estimate across all strata is given by:
 R an N c n N/ / / .ii 2i i 1i i( ) ( )=Σ Σ
Table 21.11 Computation of the common risk difference for the data in Table 21.10
Area p1i p2i di V (di) wi
Urban 0.0100 0.0200 −0.0100 3.705 × 10–6 270 × 103
Semi-urban 0.0071 0.0150 −0.0079 1.057 × 10–6 946 × 103
Rural 0.0050 0.0100 −0.0050 37.219 × 10–6 27 × 103
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Thus, for the example in Table 21.10:
{
} {
}
[ ] ( )
( ) ( ) ( )
( )
( )( ) ( )
( ) ( ) ( )
( )
= +  
+    +  
+   = =
R 160 4000 /20 000 170 16 000 /40 000
200 40 000 /80 000 80 16 000 /20 000 240 24 000 /40 000
400 40 000 /80 000 200/408 0.49.
7.3.4 Confidence intervals
The easiest way of obtaining CIs on the estimates of the common risk difference or the 
common risk ratio is to use the ‘test-based’ method (Miettinen, 1976).
The approximate 95% CI on the risk difference is given by:
 d 1 1.96/ 2χ( )± √  (21.15).
Thus, in the example in Tables 21.10 and 21.11, the confidence limits are:
 0.0083 1 1.96/ 151.49 0.0096 to 0.0070.( )− ± √ =− −
The 95% CI on the logarithm of the relative risk is given by:
 Rlog 1 1.96/e
2χ( )± √  (21.16).
In the example, the confidence limits are:
 log 0.49 1 1.96/ 151.49 0.8269 to 0.5998.e ( )( ) ± √ =− −
And thus the confidence limits on the relative risk are 0.44 to 0.55.
7.4 Adjusting rates
The computations for adjusting rates are very similar to those for adjusting risks and 
involve only some changes to the formulae given in Section 7.3.
Suppose the results observed in the ith stratum are as shown in Table 21.12.
7.4.1 Overall test of significance
In the ith stratum, e1i  is the number of individuals who developed disease in group 1.
Table 21.12 Disease rates in two intervention groups for individuals 
in the ith stratum
Intervention group Developed disease Person-years-at-risk
1 e1i y1i
2 e2i y2i
Total ei yi
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 Expected value of e E e e y y/1i 1i i 1i i( )= =  (21.17).
 Variance of e V e e y y y/1i 1i i 1i 2i i
2( )= =  (21.18).
An overall test of significance (that the common rate ratio is unity or the common 
rate difference is zero) is given by:
 e E e V e0.5 /2 1i 1i
2
1iχ ( )( ) ( )= Σ −Σ − Σ  (21.19)
where the summation is over all strata.
The value calculated should be looked up in tables of the chi-squared distribution 
with one df.
7.4.2 Pooled estimate of rate difference
In the ith stratum, the rate difference is:
 ( ) ( )= − = −d r r e y e y/ / .i 1i 2i 1i 1i 2i 2i
Its estimated variance is:
 V d r y r y/ / .i 1i 1i 2i 2i( ) ( )= +
Let ( )=w V d1/ ,i i then the estimate of the common rate difference across all strata is 
given by:
 d w d w .i i i∑ ∑=
7.4.3 Pooled estimate of rate ratio
In the ith stratum, the rate ratio is:
 ( ) ( ) ( )= = =R r r e y e y e y e y/ / / / / .i 1i 2i 1i 1i 2i 2i 1i 2i 2i 1i
A pooled estimate of the common rate ratio is given by:
 R e y y e y y/ / /1i 2i i 2i 1i i( ) ( )=Σ Σ  (21.20).
7.4.4 Confidence intervals
The 95% CI on the common rate difference is given by:
 d 1 1.96/ 2χ( )± √  (21.21).
The 95% CI on the logarithm of the common rate ratio is given by:
 Rlog 1 1.96/e
2χ( )± √  (21.22).
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Example: In Table 21.13, the numerical computations are illustrated, as before, with 
data on the disease incidence in vaccinated and unvaccinated individuals in three areas: 
urban, semi-urban, and rural.
Overall test of significance:
 e E e V e0.5 /2 1i 1i
2
1iχ ( )( ) ( )= Σ −Σ − Σ  (21.23)
 ( ) ( )= − − = <245 359 0.5 /138.40 93.08 p 0.000001 .
2
The estimation of the common rate difference is shown in Table 21.14.
 =Σ Σ =−d w d w 0.0066.i i i
The 95% CI on the common rate difference is:
 d 1 1.96/ 0.0066 1 1.96/ 93.082χ( ) ( )± √ =− ± √  (21.24)
 0.0079 to 0.0053.=− −
The estimate of the common rate ratio is:
} {
}
{[ ] [ ]
[ ]( ) ( )
( )
( ) ( )
( )( ) ( )( )
( ) ( )( ) ( )
( )
=Σ Σ
= +
+  +  
+   = =
R e y y e y y/ /
80 2000 /10 000 85 8000 /20 000
80 20 000 /40 000 / 40 8000 /10 000 120 12 000 /20 000
200 20 000 /40 000 90/204 0.44.
1i 2i i 2i 1i i
Table 21.13 Disease incidence rates in urban, semi-urban, and rural areas, according to 
vaccination status
Area (i ) Vaccinated Unvaccinated Both groups E(e1i) V(e1i)
Cases  
(e1i)
Person-
years (y1i)
Cases  
(e2i)
Person-
years (y2i)
Cases  
(ei)
Person-
years (yi)
Urban (1) 80 8000 40 2000 120 10000 96 19.2
Semi-urban (2) 85 12000 120 8000 205 20000 123 49.2
Rural (3) 80 20000 200 20000 280 40000 140 70.0
Total 245 40000 360 30000 605 70000 359 138.4
Table 21.14 Computation of the common rate difference for the data in Table 21.13
Area (i ) r1i r2i Difference di V (di) wi = 1/V (di)
Urban (1) 0.0100 0.0200 −0.0100 11.250 × 10–6 89 × 103
Semi-urban (2) 0.0071 0.0150 −0.0079  2.465 × 10–6 406 × 103
Rural (3) 0.0040 0.0100 −0.0060  0.700 × 10–6 1429 × 103
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The 95% confidence limits on the logarithm of the common rate ratio is:
 
Rlog 1 1.96/ log (0.44) 1 1.96/ 93.08 0.988 to 0.654.e
2
eχ( ) ( )± √ = ± √ =− −
Taking the anti-logarithm, the 95% confidence limits on the common rate ratio are 
0.37 to 0.52.
7.5 Adjusting means
If the outcome variable is a quantitative measure, other than a risk or rate, adjustment 
for the effects of a confounding variable involves performing a stratified t-test.
A numerical example is given in Table 21.15 where the comparison is between sub-
jects using mosquito nets (intervention group) and those not using them (control 
group), and the outcome measure (x) is the number of episodes of malaria over a pe-
riod of 1 year. In this example, age is considered as the confounding variable, and the 
stratification has been made by dividing the study subjects into three age groups. The 
size of each subgroup has been made small to simplify the computations for illustrative 
purposes.
The data may be represented algebraically for those in the ith stratum, as shown in 
Table 21.16.
An estimate of the common difference in response between the intervention and 
control groups is obtained by calculating a weighted average of the differences within 
each stratum:
d w d w/i i i=Σ Σ
wherew n n n n/i 1i 2i 1i 2i( )= +  .
Difference d x x .i 1i 2i= −
Thus, in the example:
{ }[ ] [ ] [ ] {
}
( ) ( ) ( ) ( ) ( )
( )
= − + − + − +
+ =− =−
d 0.75 32 /12 0.45 132 / 23 0.20 50 /15 / 32 /12 132 / 23
50 /15 5.25 /11.74 0.45.
Table 21.15 Attacks of malaria in children of different ages in those using (intervention) 
and not using (control) mosquito-nets
(Stratum)  
Age group
Attacks of malaria/
child (x)
No. of  
children (n) Mean 
x( )
Standard 
deviation (s)
(1) <2y I* 1,0,2,3,1,2,1,0 8 1.25 1.0351
C* 2,3,1,2 4 2.00 0.8165
(2) 2–3y I 0,1,1,2,1,1,0,2,2,1,1,0 12 1.00 0.7385
C 2,2,1,1,1,2,1,1,2,2,1 11 1.45 0.5222
(3) 4–5y I 1,0,1,1,1 5 0.80 0.4472
C 1,1,2,0,1,1,0,2,1,1 10 1.00 0.6667
* I, intervention group; C, control group.
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An overall test of significance is obtained by calculating a test statistic as:
 Σ √Σ

w d s w/i i i
where { }( ) ( ) ( )=√ Σ − +Σ −  Σ + −s n s n s n n1 1 / 2 ,1i 1i 2 2i 2i 2 1i 2i  and the value of the test 
statistic can be compared with tables of the t-distribution with ( )Σ + −n n 21i 2i df.
In the example:
 s 23.0265/44 0.7234.( )=√ =
The test statistic (44 df) is:
 ( )− ×√

 =−5.25 0.7234 11.74 2.12.
The absolute value is larger than 2.02, which is the tabulated 5% value for t with 44 
df. Thus, there is statistically significant evidence regarding the efficacy of intervention; 
the reduction in the average number of episodes of malaria is estimated as 0.45 per 
child per year. The 95% confidence limits on the difference are given by:
 w d w ts w/ /i i i i( )Σ Σ ± Σ  (21.26)
where t is taken from tables of the t-distribution for 95% confidence limits with
( )Σ + −n n 21i 2i df.
Thus, the 95% confidence limits are:
 ( ) ( )− ± √ =− −0.45 2.02 0.7234 / 11.74 0.88 to 0.02 episodes/year/child.
If it is thought that the intervention is likely to affect the response measured in a 
relative, rather than an absolute, fashion (i.e. a constant percentage reduction in the 
number of malaria attacks, rather than a constant absolute reduction in the number of 
malaria attacks), then it would be appropriate to transform the data initially by taking 
logarithms of the number of attacks (or, say, loge(number of attacks + 0.1) to avoid zero 
numbers) and to perform the calculation on the transformed values.
8 Analyses when communities have been randomized
In some intervention studies, communities, rather than individuals, are used as the 
unit of randomization. If this has been done, it is inappropriate to base analyses on re-
sponses of individuals, ignoring the fact that randomization was over larger units. An 
appropriate method of analysis would be to summarize the response in each sampling 
unit by a single value and analyse these summary values as though they were individual 
values.
Table 21.16 Algebraic representation of data in Table 21.15 for those in the ith stratum
Intervention group No. in group Mean Standard deviation
1 (I) n1i x
–
1i s1i
2(C) n2i x
–
2i s2i
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The analysis of such trials, often called ‘cluster randomized trials’, is not straightforward, 
and only simple methods for performing statistical tests are given here. A comprehensive 
discussion of the design and analysis of such trials is given in Hayes and Moulton (2009).
8.1 Calculation of standardized responses
Often, trials in which communities have been randomized suffer from problems with 
confounding variables. If the number of units randomized is large, confounding vari-
ables are likely to balance out between groups, but, if the number of units is small (as 
may be the case when communities have been randomized, even though the number 
of individuals in each community is large), confounding may be a potentially serious 
problem, and some adjustment should be made in the analysis. One method of doing 
this is by standardization.
Within each community, the sampled population is divided into strata on the basis 
of the confounding variable(s) (for example, age and sex groups). The average value 
of the outcome measure is computed for those in each stratum (for example, a disease 
incidence rate). A weighted average of the rates in the different strata is then computed 
to give a single ‘standardized’ measure for the community, the weights being based on 
some ‘standard’ population. The same standard population is used for each community, 
and thus the standardized measures for each community are not biased by the differ-
ential composition of each community, with respect to the confounding variable that 
is being standardized for.
This method is called the ‘direct’ method of standardization. If the number of individ-
uals in some strata is small, it may be better to use the ‘indirect’ method, and details of both 
are given (see Armitage and Berry (1987) for a more detailed discussion of these methods).
Consider a community in which disease risks pi have been measured for individ-
uals in k strata (for example, age groups). This may be represented in Table 21.17. Also 
shown are the corresponding data for a ‘standard’ population. For example, this might 
be chosen as the combined data for all communities in the study.
The directly standardized disease risk for the community (standardized to the stand-
ard population) is given by:( )Σ Σp N N/ .i i i
Table 21.17 Disease risks in study community and in standard population in each  
of k strata
Stratum Study community Standard population
Total Cases Total Cases
No. Risk No. Risk
1 n1 a1 p1 N1 A1 P1
2 n2 a2 p2 N2 A2 P2
i ni ai pi Ni Ai Pi
. . . . . . .
k nk ak pk Nk Ak Pk
Total n a p N A P
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The indirectly standardized disease risk for the community is given by: 
( ) ( )Σ Σ a n P A N/ / / .i i i
Having calculated standardized values for each community, the means of the stand-
ardized values for the intervention communities may be compared with those for the 
control communities, using a simple t-test (see Section 6.2).
It is usually safer, however, to perform a non-parametric test if the assumptions 
underlying the t-test are in any doubt (Armitage and Berry, 1987)), as it may be impos-
sible to verify the assumptions if the study involves a small number of communities.
8.2 Non-parametric rank sum test
Suppose there are n1 communities in one group and n2 in the other( )≤n n1 2 and a sum-
mary response has been derived for each community. To perform a non-parametric 
test, consider all the( )+n n1 2 observations together, and rank them, giving a rank of 1 
to the smallest value and( )+n n1 2 to the highest. Tied ranks are allotted the mid rank 
of the group. Let T1 = sum of the ranks in group 1 with n1 observations. Under the null 
hypothesis, the expectation of T n n n 1 /21 1 1 2( )= + + . Then calculate:
=T T ,1 1 if T1 is less than or equal to the expected value
( )= + + −T n n n T1 ,1 1 1 2 1 if T1 is more than its expected value.
T1 may be compared with tabulated critical values (see Table A8 of Armitage and 
Berry, 1987) to determine the statistical significance.
Consider the example shown in Table 21.18 in which age-standardized leprosy 
prevalence rates are compared in 12 ‘intervention’ villages and ten ‘control’ villages.
Table 21.18 Age-standardized leprosy prevalence rates and ranks in 12 ‘intervention’, 
and ten ‘control’, villages
Intervention villages Control villages
Prevalence rate/1000 Rank Prevalence rate/1000 Rank
3  1.5 10 18.5
9 15.5 13 22
8 12.5  6  7.5
6  7.5 11 21
5  5 10 18.5
5  5  7  9.5
7  9.5  8 12.5
3  1.5  8 12.5
10 18.5  5  5
8 12.5  9 15.5
10 18.5
4  3
Sum of ranks T2 = 110.5 T1 = 142.5
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The expected value of T n n n 1 /2 10 10 12 1 /2 1151 1 1 2( ) ( )= + + = + + = . As T1 is 
greater than its expectation, T1 is 10 10 12 1 142.5 87.5.( )+ + − = The critical value of T1 
at the 5% level of significance is 84 (from tables in Armitage and Berry, 1987). As T1 is 
greater than the critical value, it is concluded that the intervention has not had a stat-
istically significant effect (the average prevalence was 6.5 per thousand in intervention 
villages, and 8.7 per thousand in control villages).
8.3 Tests on paired data
In some study designs, communities may be ‘paired’ on the basis of similarity, with 
respect to confounding variables and baseline disease prevalence or incidence rates. 
Within each pair of communities, one receives the intervention and the other serves 
as the control. If this has been done, the analysis should take the pairing into account.
First, standardized response rates are computed for each community (as discussed 
in Section 8.1), and then the standardized response rates are compared using a paired 
t-test (Armitage and Berry, 1987) or a non-parametric test.
To perform a paired t-test for n pairs of communities, suppose di is the difference in 
outcome measured between the intervention and control unit for the ith pair. Calculate 
a test statistic d n s n/ / /i ( )( )Σ √ where s is the standard deviation of the n differences. 
This value of the test statistic may be compared to tabulated values of the t-distribution 
with (n − 1) df.
Consider the data shown in Table 21.19, which shows leprosy prevalence rates in ten 
pairs of communities.
The mean difference d 19/10 1.9,=− =− and the standard deviation of the difference 
(s) is 2.23. Thus, the test statistic 1.9/ 2.23/ 10 2.69( )=− √ =− with 9 df. From tables of 
the t-distribution, p is <0.05, and it may be concluded that the prevalence of leprosy is 
significantly lower in the intervention villages.
Table 21.19 Leprosy prevalence rates in ten pairs of communities
Village pair no. Prevalence of leprosy  
(per thousand)
Difference (di) Rank (ignoring 
sign)
Intervention No Intervention
1  6 10 −4 8
2  9 13 −4 8
3  3  6 −3 5
4 12 11 +1 1.5
5 10 10  0
6  4  7 −3 5
7  7  8 −1 1.5
8  5  8 −3 5
9  7  5 +2 3
10  5  9 −4 8
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Alternatively, a non-parametric test may be preferred. In this instance, the appropri-
ate such test is Wilcoxon’s signed rank test.
The differences between each pair of villages are arranged in ascending order of mag-
nitude of the absolute value of the differences (i.e. ignoring the sign) and given ranks 1 
to n; zero values are excluded from analysis. Any group of tied ranks is allotted the mid 
rank of the group. Let:
T+ = sum of ranks of positive differences
T− = sum of ranks of negative differences.
The smaller of the two (T+ and T−) is compared with the tabulated critical value 
(see Table A9 of Armitage and Berry, 1987). If it is lower than the tabulated value, it is 
concluded that there is a significant difference. For the data in the table, T 4.5,+= and 
T 40.5;−= =n 9  (excluding one zero difference). The tabulated critical 5% value is 5. 
Since +=T 4.5 is less than 5, it is concluded that the difference is significant at the 5% 
level.
9 Prevented fraction of disease
The objective of most field trials is to measure the effect of an intervention in reducing 
disease rates. The results of such studies may be used to estimate the impact that an 
intervention might have on disease rates if it was introduced into a public health pro-
gramme. In such circumstances, the overall effect is much influenced by the coverage 
achieved by the programme.
The prevented fraction among individuals exposed to an intervention measure is de-
fined as the percentage of the disease incidence in such individuals that has been pre-
vented due to having received the intervention. For example, if the efficacy of BCG 
vaccination against TB is 60%, among persons who receive BCG vaccination, 60% of 
the TB cases that would have developed otherwise have been prevented by the vaccin-
ation. For vaccine studies, the prevented fraction is directly equivalent to the vaccine 
efficacy, but the former term may be used for interventions other than vaccines.
The prevented fraction is computed by subtracting the disease risk in individuals 
with the intervention measure (for example, an anti-leprosy vaccine) from the disease 
risk in individuals without the intervention, and expressing the difference as a pro-
portion of the latter. For example, if the annual incidence of leprosy is 2.8 per thou-
sand in the vaccinated and 4.2 in the unvaccinated, the prevented fraction is equal to 
[ ]( )− =4.2 2.8 / 4.2 0.33 (or 33%).
If the relative risk (R) (of disease in those who receive the intervention, compared 
to those who do not) is known, the prevented fraction may be obtained by calculating 
R1 .( )− For example, if the relative risk of developing malaria in homes where mos-
quito-nets are used is a quarter of that in homes where they are not used, the prevented 
fraction is equal to −1 0.25 , i.e. 75%.
The population prevented fraction is defined as the proportion of cases of the disease 
in the total population that have been prevented by the intervention. If the relative risk 
(R) and the proportion of individuals in the population who receive the intervention 
measure (P) are known, the population prevented fraction is obtained by calculating 
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P R1 .( )− Thus, the extent of reduction possible in disease incidence in the total popu-
lation, if all individuals were to receive the intervention measure P 1 ,( )= is R1 .( )−
Consider a situation in which the annual incidence of TB is 2.0 per thousand in 
those who do not receive BCG vaccination and 0.8 per thousand in those who do, i.e. 
the relative risk in those vaccinated is 0.8/2.0 0.4.= Table 21.20 shows the fraction of 
all cases prevented by the intervention, according to the disease incidence in the total 
population and the vaccination coverage.
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Population prevented 
fraction (%)  
[P (1 – R ) × 100]
0 2.00 0
20 1.76 12
40 1.52 24
60 1.28 36
80 1.04 48
100 0.80 60
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1 Introduction to Phase IV studies
The main focus of this book is on randomized controlled field trials of health inter-
ventions in LMICs, many of which can be classified as Phase III trials (see Chapter 2, 
Section 3). This chapter gives a brief overview of Phase IV studies that are often carried 
out after an intervention has been shown to be efficacious in Phase III trials. We give 
a brief description of the rationale and some of the terminology used in such studies, 
outline the main types of Phase IV study, discuss some key issues in the design of such 
studies, and give a brief description of two specific Phase IV studies.
For new drugs or vaccines, the evidence from one or more Phase III trials, taken 
together with the results of the Phase I and II trials, will be presented to licensing 
authorities to register the product for clinical or public health use. However, the total 
number of participants included in Phase I to III trials of a new product will often be 
no more than a few thousand, and there are usually important public health issues 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
3951: INTRODUCTION TO PHASE IV STUDIES
that will have been incompletely addressed at the time a product is licensed. For ex-
ample, individuals included in Phase III trials will often have been a carefully selected 
sample of the population and will not include all of those eligible for eventual admin-
istration of the product. Particular groups may have been excluded, such as children 
and adolescents, the very undernourished, or pregnant women, but these groups will 
often receive the product when it is in general use, and it is important to collect data 
on both the safety and the effectiveness of the product in these groups. Also, in most 
Phase III trials, great care will have been taken with product supply and storage, and, 
if the dosing regimen requires multiple doses, care will have been taken to ensure that 
the interval between doses was as recommended. Rigid adherence to such intervals 
is much less likely once the product is in general use. For these reasons, it will be 
important to measure whether the effect of the product, when it is administered in 
a routine health system or programme, is similar to the efficacy that was assessed in 
the Phase III trials conducted in a research setting. Phase IV studies are conducted to 
assess the effectiveness of an intervention when it is in public health use, as compared 
to the efficacy of the intervention as assessed in a carefully controlled Phase III trial 
(see Section 2.1).
Most Phase III trials will not have been large enough to detect reliably important, 
but relatively uncommon, side effects. For example, a serious adverse effect (SAE) of 
an intervention that occurs, on average, in one in every 2000 recipients may well be 
missed in a Phase III trial that involved only a few thousand participants. There may 
also be other unexpected effects when an intervention is implemented in a public 
health programme that were not apparent in the carefully controlled situation of a 
Phase III trial. For example, in a trial of a health education intervention in schools, 
teachers may be willing to promote condom use when they have been carefully 
trained, supported, and supervised, as part of the trial procedures. However, when 
the intervention is implemented on a widespread basis, in settings where condom use 
is unpopular and talking of such things with young people frowned upon, teachers 
might actually discourage use without the support that was included in the trial. It is 
important that studies are conducted to detect such adverse effects once an interven-
tion is in routine use. Whenever possible, such Phase IV studies should be used as the 
basis for developing systems that persist after the study, so that routine health systems 
can continue to detect such events.
Historically, assessment of how interventions work in ‘real-world’ public health pro-
grammes has been relatively neglected. However, presently, such Phase IV research is 
receiving increasing attention. It encompasses post-marketing surveillance of the effect 
of interventions and implementation research which investigates better ways of ensur-
ing the successful delivery of an intervention (such as how to increase the coverage of 
a vaccination programme). A common goal of Phase IV studies is to provide evidence 
that the health intervention can be successfully and safely integrated into public health 
or clinical practice where ‘successful’ means that it is not only feasible to do so, but also 
that the intervention remains effective and its implementation is not associated with 
any serious adverse effects.
This chapter focuses mainly on Phase IV studies related to the introduction of new 
drugs or vaccines, but similar studies can be used to evaluate other types of health 
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intervention such as surgical procedures, health education, or peer supporters to en-
courage adherence to treatment regimens.
Phase IV research serves three major functions:
 1 to support pharmacoviligance systems in monitoring the safety of new inter-
ventions used in large populations and in specific groups who were not studied 
adequately in the pre-marketing phases such as children, pregnant women, the 
elderly, or those with co-morbidities
 2 to determine the effectiveness of an intervention in a routine health system, as 
opposed to within a carefully controlled trial
 3 to assess new strategies of use of approved products or interventions, such as the 
evaluation of anti-malarials when used for intermittent presumptive treatment, 
rather than either for malaria prophylaxis or for treatment of a diagnosed malar-
ial infection.
Furthermore, studies to seek ways of widening the coverage, ensuring a more 
equitable distribution or conducting an economic evaluation of an intervention (see 
Chapter 19) may also be encompassed by Phase IV studies. A key issue with respect to 
such studies is that they are conducted after a product has been licensed or is already 
in widespread use. Thus, placebo-controlled trials are generally ruled out for ethical 
reasons, and observational designs are often employed. A full description of all the 
potential observational study designs is beyond the scope of this chapter. However, 
because of the importance of Phase IV studies and the overlap with many of the field 
research issues covered in this book, after defining some of the key terms and concepts, 
Section 2 of this chapter gives a brief overview of some of the commonest Phase IV 
research approaches.
1.1 Efficacy and effectiveness
A distinction should be made between the effect of the intervention, as measured in 
a Phase III trial, called the efficacy of the intervention, and the effect of the inter-
vention when it is delivered in a public health programme, called the effectiveness of 
the intervention. Generally, it is expected that the efficacy of an intervention will be 
greater than its effectiveness, for the reasons outlined in Section 1. However, this is not 
always the case. For example, when some vaccines are administered to large popula-
tions, there are at least two factors that may operate to reduce the incidence of disease. 
First, the vaccine may offer individual protection to recipients of the vaccine. Second, 
the reduction in the number of individuals who acquire the disease as a consequence 
of vaccination may reduce the overall level of infection in the community, and thus 
even those who are unvaccinated may be at lower risk of acquiring disease, simply be-
cause they are less likely to be exposed to someone with the infection. Such herd effects 
may be substantial for some person-to-person infections, for which humans are the 
main reservoir. If the vaccine coverage is high enough, the effectiveness of the vaccine 
may be higher than would have been predicted from Phase III efficacy trials, in which 
typically, at most, half of the eligible population is vaccinated. Fine et al. (2011) give an 
overview of herd effects.
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The overall impact of an intervention against a disease in a population, sometimes 
known as the community effectiveness or system effectiveness of the intervention, will 
depend on the effectiveness of the intervention and its effective coverage, i.e. the propor-
tion of the target population who receive it. The target population consists of all those 
who should receive (would benefit from receiving) the intervention. An example of 
how an evaluation of the effective coverage of a broad range of different health services 
was used to benchmark the performance of the health system in the various states of 
Mexico is given in Lozano et al. (2006).
1.2 Stakeholders
The primary audience for Phase IV studies is health policy decision makers, but other 
stakeholders may include regulatory agencies, industry, health care professionals, pa-
tients, community groups, media, and suppliers. Regulatory agencies and public health 
officials will seek to ensure the continuous evaluation of an intervention’s risks and 
benefits. Industry engages in Phase IV research to determine the effects of long-term 
use, as requested or demanded by regulatory agencies, but also to inform key strategic 
and operational decisions related to the marketing of their products. Governments, 
decision makers, and policy makers need high-quality evidence on effectiveness and 
cost-effectiveness in the real world, as well as in Phase III trial settings, in order to de-
sign and implement public health programmes that optimize health gains and reduce 
health inequity. For clinicians, Phase IV study data can guide their prescribing and the 
advice they give to their patients.
2 Types of Phase IV study
2.1 Safety/pharmacovigilance
Pharmacovigilance is defined as ‘the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other possible 
drug-related problems’ (World Health Organization, 2006). Pharmacovigilance stud-
ies are designed to detect and assess both long-term and short-term adverse effects 
of medicines (including drugs and vaccines). Regulatory agencies will often require 
that specific monitoring is conducted after a product is licensed (post-marketing safety 
monitoring or pharmacovigilance) that is designed to detect the occurrence of rare, 
but serious, adverse effects of the product. Similar issues apply to medical devices and 
prostheses.
Pharmacoviligance studies can include observational or intervention studies. Com-
mon designs include case-control studies, cohort studies (cohort event monitoring), and 
spontaneous (passive) reporting schemes. In some circumstances, RCTs might also be 
possible. The main method used in HICs is the collation of adverse drug reaction reports 
submitted by clinicians, which are compiled and analysed by national pharmacovigi-
lance centres. The reports may also be submitted to the WHO Programme for Interna-
tional Drug Monitoring (<http://www.who-umc.org>). However, this reporting system 
is not yet functional in most LMICs, and, even in HICs, the system is acknowledged to be 
an imperfect way to detect all of the adverse events (AEs) that might be associated with a 
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particular product. However, monitoring for product safety is particularly important in 
LMICs, often with their overburdened health care systems and frequent polypharmacy. 
Other potential safety issues in LMICs include the widespread manufacture and sale of 
counterfeit, substandard, or expired medicines, and potentially unsafe drug donation 
practices. An example of how pharmacovigilance can be built into a broader Phase IV 
study is given in Section 4.1.
2.2 Intervention effectiveness
As discussed in Section 1, the effectiveness of an intervention may well be different in 
the complex and dynamic situation of a routine health system, compared to the context 
of a carefully controlled Phase III trial. Effectiveness studies evaluate the impact of an 
intervention when delivered under real-world conditions in a routine health system. 
Such studies are especially important when a new intervention is first introduced into 
a public health programme. The decision to introduce the intervention will usually be 
based upon the results of one or more Phase III trials, including a cost-effectiveness 
analysis, often using data derived from the Phase III trials. However, it is important 
to evaluate both the effectiveness and cost of the intervention, as used in the public 
health programme, and this will generally require the setting up of specific studies. For 
example, a series of such studies were conducted when rotavirus vaccines were intro-
duced into public health use (Patel et al., 2011).
Phase IV studies may also be appropriate for interventions which are relatively 
well established in a public health programme. These may be drugs or vaccines that 
have been in use for a number of years already, or other interventions which may 
have been implemented with or without preceding efficacy trials or for which the 
effectiveness of the intervention is unknown, even if the efficacy had been estab-
lished in controlled intervention trials. For example, controlled trials were con-
ducted to measure the impact of introducing insecticide-treated bed-nets (ITNs) as 
a measure to reduce deaths from malaria in malaria-endemic areas. These showed 
that this intervention had a substantial impact on child mortality. A Phase IV study 
to evaluate the impact of such bed-nets, when implemented in a public health pro-
gramme, was conducted by Schellenberg et al. (2001). In this study, a programme 
was rolled out across two rural districts of southern Tanzania over a 2-year period, 
in which subsidized ITNs were made available at shops and kiosks. The proportion 
of young children who slept under an ITN was estimated through population-based 
surveys, and the impact on child mortality monitored through a case-control study, 
in which the prior use of an ITN was compared among children who had died from 
malaria and those who survived. All child deaths were identified within a demo-
graphic surveillance area. This Phase IV study confirmed that ITNs had a major im-
pact on child mortality within a routine programme, and the study also elucidated 
ways in which that impact might be increased by modifications to the programme 
delivery system.
Phase IV studies of health system effectiveness are designed to understand rea-
sons for the decay of the impact of an intervention that results from individual 
and system behaviour, including access to the intervention, diagnostic targeting, 
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provider compliance, and patient adherence. Figure 22.1 summarizes the outcome 
of Phase IV studies conducted in Tanzania to determine why highly efficacious 
anti-malarial treatments had low community effectiveness. Controlled trials had 
shown that artimisinen combination treatments (ACTs) have very high efficacy 
for the treatment of uncomplicated malaria, with roughly 98% of patients who re-
ceived treatment within carefully conducted efficacy trials cured. A community-
based survey found that only 60% of those with malaria sought care from a clinic 
that had ACTs. Studies within the clinics showed that 95% of those who came to 
these clinics had an appropriate diagnostic test performed, and, in 95% of those 
diagnosed with malaria, the correct treatment was prescribed. Further studies in 
the patients who were given the correct prescription of ACT showed that only 70% 
of them adhered correctly to the treatment as prescribed. Taken together, this ser-
ies of Phase IV studies showed that less than 40% of people with uncomplicated 
malaria in the community were effectively treated, despite ACTs, which had a 98% 
efficacy, being made available. Such Phase IV studies can not only document and 
measure the failings in the health system, but they can also be used to investigate 
the reasons behind these problems and the potential actions that can be taken to fix 
them (see Section 4.1).
Figure 22.1 represents what happened in the catchment population as a whole, but it 
is important, in such studies, to measure system effectiveness by socio-economic sta-
tus, and among specific vulnerable groups, as this may reveal substantial heterogeneity 
in the findings, according to these factors.
Figure 22.1 How the efficacy of highly efficacious malaria treatments translates into low 
community effectiveness for the treatment of malaria due to failings in the health system.
Reproduced courtesy of Don de Savigny (personal communication). This image is distributed under 
the terms of the Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-
NC), a copy of which is available at http://creativecommons.org/licenses/by-nc/4.0/.
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3 The conduct of Phase IV studies
Phase IV studies should follow the general guidelines, as described elsewhere in this 
book, with respect to the selection of the study population and study design, sample 
size calculations, ethics clearance and consideration of other governance issues, and 
the training and supervision of study staff.
3.1 Design issues
There are multiple observational designs and evaluation schemes that can be used in 
Phase IV studies to assess the effectiveness, cost-effectiveness, and safety of an inter-
vention in real-world settings. Details of these approaches is beyond the scope of this 
book, but the use of non-randomized study designs to evaluate interventions is dis-
cussed in Victora et al. (2004) and Bonell et al. (2011).
3.2 Study sites
Whereas Phase I to III trials are often restricted to relatively small-scale research set-
tings with good infrastructure, Phase IV studies are typically conducted over wider 
areas where health care and the intervention in question are delivered through rou-
tine health systems. A variety of service providers may be involved, including public, 
private-for-profit, private-not-for-profit, and community-based providers. A way of 
encompassing this complexity is to use the district as the unit of implementation 
and analysis within Phase IV studies. In many countries, districts are the core ad-
ministrative unit for governmental health and other programmes, and the smallest 
unit that includes all the major features of the health system, from a hospital down 
to community health workers. They are usually the lowest unit that plans and allo-
cates budgets, manages training, and aggregates health information. They are easily 
identifiable and often have some level of sociocultural and economic homogeneity. 
Wherever possible, Phase IV studies should support and strengthen existing health 
systems, rather than setting up special structures that may weaken the health system 
in the long term.
One of the challenges in conducting Phase IV studies in these situations is to bal-
ance the need to study the intervention in a real-world setting with the need to be 
able to collect reliable data. Health and demographic surveillance sites (HDSS) lon-
gitudinally monitor and register the total population living within a geographically 
defined area. They collect a broad array of important health-related parameters at the 
household and individual levels, including pregnancies, births, deaths, causes of death, 
socio-economic status, care-seeking behaviour, and immunization status. HDSS some-
times cover whole districts, with populations of 50 000 to more than 100 000 people, 
and therefore include the full range of health service providers. HDSS are increasingly 
being used for Phase IV studies of effectiveness and safety (see Section 4.1). Effective-
ness studies involving HDSS can measure the effectiveness of the system in delivering 
the intervention to the whole community, as well as the effectiveness of the delivered 
intervention in affecting individual health status. The large numbers of exposures to 
the intervention that can be monitored longitudinally in HDSS make them useful for 
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pharmacovigilance studies. The research infrastructure associated with HDSS also 
makes it possible to interpret results contextually and to estimate cost-effectiveness. 
The longitudinal history available on all residents in an HDSS provides data that makes 
HDSS highly valuable partners in effectiveness trials and Phase IV studies.
3.3 Ethics and governance
Planners of Phase IV studies are confronted with the need to maintain sufficient over-
sight of intervention delivery to ensure that the approach is as planned, while simul-
taneously allowing for realistic adaptation and tailoring by providers. Governance of 
such studies needs a balance between the requirements of routine health systems and 
international scientific standards. It is valuable to have a separate committee that in-
volves donors, governments, regulators, industry, and key stakeholders who discuss the 
approaches used and to offer guidance as to their selection, interpretation, and use of 
results. Also see Chapters 6, 7, and 9.
Phase IV studies, in which any new data on people are collected, generally need eth-
ical clearance from the relevant national and institutional bodies. Such studies pose 
some specific challenges, in terms of ethical considerations, as they may involve com-
parison of new vs old technology and expensive vs inexpensive drugs, and there may 
be concerns that some patients will not be receiving optimal care.
3.4 Stakeholder involvement
Mapping and involvement of stakeholders is even more important within Phase IV 
studies than in Phase III field trials, as described in Chapter 9. They should be part of 
the planning of large-scale activities that will affect policy and strategy, and they should 
have an active role in the selection of study sites. They should have the possibility to 
comment on study design, participate in the review and interpretation of preliminary 
results, and advise on the development of appropriate feedback mechanisms. Their ac-
tive involvement will be essential for a successful translation of results into policy and 
programmes.
3.5 Data collection, processing, and analysis
Phase IV effectiveness studies can make judicious use of health service attendance and 
other data that are routinely collected by health programmes or other sources. Possibil-
ities for linking population data with health facility data should be explored, although 
systems for doing this are difficult to set up in most LMIC contexts. Prospective studies 
provide greater opportunities than retrospective studies to gather essential additional 
data. Efforts should be made to simplify data collection and management and to im-
prove data quality by introducing real-time data collection directly on to computers or 
mobile devices. When using routine data sources, one issue to resolve early on, among 
all partners, is the question of data ownership, and it is essential to have a clear agree-
ment of where data will be managed, stored, cleaned, and analysed, and agreed publica-
tion and dissemination policies (also see Chapter 20). Additional study data collection 
is usually needed to fill data gaps and address specific questions. Potential methods 
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include health facility and household surveys, longitudinal health status studies, and 
qualitative research.
3.6 Contextual and confounding factors
In order to be able to adjust for confounding factors, contextual factors need to be 
closely monitored in observational Phase IV studies—factors that are external to 
the programme or intervention under consideration. These usually include socio- 
economic, environmental, demographic, and health system factors, as well as other 
locally relevant factors. Health outcomes are affected by socio-economic progress, 
changes in both public and private health services, and other initiatives in health or 
other sectors in the same geographical area. Because these changes can happen concur-
rently with the assessment of the effectiveness of the study intervention, they require 
special attention and need to be integrated in the interpretation and analysis of the data. 
The aim should be to collect contextual data to allow the evaluation of whether or not 
it is plausible that factors, other than the intervention being studied, could explain any 
improvements seen (Victora et al., 2004). Again, HDSS can play a central role here, as 
they can provide information on contextual factors and health system dynamics.
3.7 Reporting and dissemination
As for Phase III trials, a well-thought out system for reporting and dissemination of 
results is crucial if the results of Phase IV studies are to feed into policy and program-
matic action. Whereas reporting standards for Phases I to III trials have been widely 
agreed (see Chapter 2), those for observational research are more recent. However, 
the STROBE statement (STrengthening the Reporting of OBservational studies in Epi-
demiology) is widely accepted and has been endorsed by a growing number of bio-
medical journals (<http://www.strobe-statement.org>). Efforts are also being made to 
develop and strengthen scientific methods for conducting comparative effectiveness re-
search to improve the consistency, applicability, reliability, and validity of comparative 
effectiveness research findings for informing the health care decisions of patients, pro-
viders, and policy makers. An example is the DEcIDE (Developing Evidence to Inform 
Decisions about Effectiveness) Network created in 2005 (<http:// effectivehealthcare.
ahrq.gov/index.cfm/who-is-involved-in-the-effective-health-care-program1/
about-the-decide-network>).
3.8 Funding
Phase IV, and especially effectiveness, studies are often resource-intensive, due to large 
sample sizes and long follow-up periods. Also, a significant expansion of infrastructure 
and capacity is often required prior to the initiation of such studies, as many research 
groups are better placed to conduct efficacy trials than to conduct research within the 
health care delivery system. Raising funds for Phase IV research is challenging, but 
funders, including governments, have become increasingly interested in research to 
check that the interventions they fund provide the best possible value for money, so 
opportunities are improving.
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4 Examples of real-world effectiveness studies
4.1 The INDEPTH Effectiveness and Safety Studies (INESS) 
platform
The development of new drugs and drug combinations for the treatment of malaria 
has created the need for countries to select and integrate new anti-malarial drugs into 
their health systems. INESS was designed as a platform for the conduct of Phase IV 
studies to provide objective data on the system effectiveness and safety of artemisinin 
combination therapies (ACTs) in real-world settings in Ghana, Burkina Faso, Tan-
zania, and Mozambique. The INESS research sites are based in districts with health 
and demographic surveillance systems and represent a diverse range of health system 
capacities and malaria endemicities. INESS looks at the overall performance (effec-
tiveness) of deployment of the drug (ACT) in the system. It illuminates how the decay 
in the effectiveness of the ACTs occurs from efficacy to net or ‘system’ effectiveness, 
and at what levels the losses are the greatest (Figure 22.1). The research focuses on 
human behaviour, system behaviour, and drug behaviour in real-world contexts. Usu-
ally, there are lessons for all levels about how to optimize performance. By following 
a large number of patients with malaria who should benefit from the intervention 
through the system, this Phase IV study is in a powerful position to understand the net 
effectiveness of the intervention (see <http://www.indepth-network.org>).
Access and patient adherence seem to be the major bottlenecks creating the loss of 
effectiveness in the example shown in Figure 22.1. However, within each of the five 
compartments shown in the figure, the INESS study has identified and quantified the 
specific sub-determinants contributing to the loss in effectiveness. These include access 
failure (for example, due to distance, poverty, or lack of knowledge), diagnostics failure 
(for example, due to weaknesses in laboratory capacity or staff training), provider fail-
ure (for example, weaknesses in supply chain management, leading to drug or diagnos-
tic test stock-outs, or poor prescribing), and patient adherence failure (for example, due 
to problems with taste, perceived side effects, stopping treatment when feeling better, 
or incorrect provider instructions).
INESS also conducts qualitative studies to understand community perceptions 
of the intervention under study, as well as the health system contexts, that help to 
explain the results from the quantitative system effectiveness studies. The INESS 
platform generates evidence that is sufficiently representative to inform local, 
national, and possibly global policy and practice. The results provide evidence 
on what human behaviour, health system, and drug issues need to be addressed 
and where the most urgent needs are. It also highlights issues for the industry 
to consider, in order to improve effectiveness. For the safety component, INESS 
strengthens the national spontaneous reporting system and also runs a separate 
event-monitoring cohort to detect and report AEs. Though initially developed to 
examine ACTs, the INESS platform has the potential to assess the effectiveness of 
other health interventions. Because the platform operates at the level of whole dis-
tricts and follows a large number of exposures to the intervention, safety studies 
are easily incorporated.
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4.2 Effectiveness of intermittent preventive treatment 
for malaria
The potential efficacy of intermittent preventive treatment for malaria in pregnancy 
(IPTp), infants (IPTi), and children (IPTc—now called seasonal malaria chemopre-
vention (SMC)) has been established in numerous safety and efficacy trials (Aponte 
et al., 2009). Yet, to move to public health action and promote it on a large scale, evi-
dence is needed on the contextual determinants, costing, acceptability, and coverage 
rates. Taking IPTi using sulfadoxine–pyrimethamine (IPTi-SP) as an example, a cas-
cade of activities has been undertaken by the IPTi consortium (<http://www.ipti- 
malaria.org>) to establish the real-world effectiveness of this intervention if it were to 
be used on a large scale. First, a pooled analysis of the efficacy and safety of IPTi-SP 
was undertaken (Aponte et al., 2009), based on six studies conducted in different Af-
rican countries. The effect of IPTi-SP on immune responses to Expanded Programme 
on Immunization (EPI) vaccines and on the development of naturally acquired im-
munity to malaria was also studied, as well as the effect of sulfadoxine–pyrimethamine 
(SP) drug resistance on the efficacy of IPTi-SP. An effectiveness study of IPTi was 
carried out in Tanzania and included cost-effectiveness (Manzi et al., 2008), accept-
ability (Gysels et al., 2009; Pool et al., 2008), and delivery through the existing health 
system, as IPTi is delivered through the EPI (Manzi et al., 2009). Then, a pilot study 
of the implementation of IPTi was carried out in six African countries, with care-
ful evaluation of implementation bottlenecks and best practices, the evaluation of the 
impact of IPTi-SP on EPI coverage and other malaria interventions, its cost, accept-
ability, drug resistance, and pharmacoviligance safety profile. A separate study on the 
cost-effectiveness of IPTi followed and showed that IPTi-SP, when delivered alongside 
the EPI, is a highly cost-effective intervention. Overall, this series of Phase IV studies 
showed that IPTi-SP is a valuable addition to malaria control, but its benefits depend 
on the contextual factors of malaria endemicity and therapeutic efficacy of the drug. 
The decision on where to implement should take into account the local epidemiology 
of malaria. The IPTi consortium also conducted modelling of the impact of IPTi (Ross 
et al., 2008). One outcome of all these efforts is the IPTi decision support tool. It is a 
web-based tool, available at <http://ipti.lshtm.ac.uk>, and is intended to aid national 
and sub-national policy makers in assessing whether IPTi is a locally appropriate 
intervention. It includes drug resistance and cost-effectiveness components to assess 
the applicability of IPTi at a sub-national level.
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1 Planning communications
It is important to communicate the progress of a trial, from its initiation to its end, to all 
the people and institutions (the stakeholders) likely to have an interest in the trial and 
its results. Planning this communication should start before the proposal for the trial is 
submitted for clearance and funding, and the communication plan should be reviewed 
and updated periodically throughout the trial.
Many researchers do not give communication and dissemination sufficient atten-
tion. This can lead to resistance to its initiation, because community members or local 
or national officials feel annoyed that they have not been consulted or kept informed, 
and lack of communication may cause misunderstandings during the trial which may 
impede its progress. From an early stage in a trial, it is often useful to involve or to con-
sult a person with past experience in communicating with policy makers and the gen-
eral public about the conduct of a trial, ideally someone familiar with research in the 
context of the trial. At a minimum, in a large field trial, it is advisable to involve such an 
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expert during the planning of the overall trial communication action plan and during 
the planning of the final dissemination of the findings of the trial.
A useful starting point is for the trial team to construct a list of all the potential stake-
holders and to think through what information should be provided to each of them, in 
what format, and when. An example of extracts from the communication action plan 
for a trial of an adolescent sexual and reproductive health intervention in Tanzania is 
given in Appendix 23.3.
At a minimum, stakeholders must be told what the purpose of the trial is and what is 
going to happen from the start, be kept informed about the progress of the trial, and be 
given the results of the trial and a chance to comment on these.
There are many different communication formats and media, some, or all, of which 
can be used effectively at different stages in a trial. Depending on the circumstances, 
these may include public meetings, pamphlets, brochures, newsletters, films, press re-
leases and briefings, web pages, academic journal articles, technical briefing documents, 
and policy briefing documents. While interested academics and researchers are likely 
to read journal articles reporting the design and results of a trial in detail, few other 
stakeholders will. Conversely, policy makers will want a brief and concise report that fo-
cuses on the main findings and their implications for policy. Managers of public health 
programmes will want suggestions as to how the results of the trial might cause them 
to consider making specific modifications to their programmes, and they are also likely 
to want an indication of what any changes are likely to cost. So it is essential to consider 
what communication formats are most useful for different audiences. Communication 
and dissemination of trial progress and results should not all be left to the end of the trial.
Comprehensive guidance on formulating a communication plan for a clinical trial is 
given in Robinson et al. (2010).
2 Communication before and during the trial
We have emphasized, in other chapters, the importance of adequate preparation before 
starting a trial. A very important aspect of these preparations includes meetings with 
community leaders, community advisory boards (CABs), and public meetings involv-
ing potential trial participants to explain fully the purposes of the trial and what it will 
involve. There should be ample time allocated at these meetings for questions, and 
indeed suggestions from those in the local community may lead to changes in the trial 
plan. It is also crucial to obtain permission from local and national officials for the con-
duct of the trial and to allocate sufficient time for discussions with those officials, who 
may also suggest modifications to the trial. Ideally, there will be representation from 
local and/or national officials on the trial steering committee, which is a good way of 
keeping them in touch and being able to call upon their advice at all stages of the trial.
Once the trial has started, to ensure the continuing collaboration from the trial partici-
pants, those in the community in which the trial is being conducted will need both infor-
mation on the progress of the trial and the opportunity to comment throughout the trial. 
There will also be a need to keep the local health and government administration informed 
of activities. At a minimum, local and national officials should receive communication at 
least once a year; some may need this much more frequently (also see Chapters 7 and 9).
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It is very important that any problems which are encountered during the conduct of 
the trial are rapidly identified by the trial investigators, and immediate steps are taken 
to make any necessary modifications to trial procedures and to explain to trial partici-
pants and community officials the reasons for any changes. Problems which are dealt 
with quickly are less likely to endanger the continued conduct of the trial than problems 
which are ignored for too long, with effective action either being delayed or not initiated. 
Regular meetings with the CAB should be a good conduit for early recognition of prob-
lems or issues being raised by trial participants or other members of the community.
3 Reporting the final results
In the absence of major problems during a trial, the most intensive phases of communica-
tion are before the initiation of the trial and when the final results are available. Dissemina-
tion of the reports of the trial findings is a substantial undertaking and must be considered 
an integral part of the conduct of the study and a major responsibility of the investigators. 
Research that is not appropriately disseminated is likely to fail to achieve its proper impact.
3.1 Planning the sequence of communications
The order of reporting of the results of a trial needs careful planning. In general, it is 
a good idea to follow a sequence whereby the results are first reported and discussed 
in confidence with all senior trial investigators, then, in confidence, with national 
and local health or other relevant government officials, representatives of the funding 
agency, and, when appropriate, with institutions who may be contacted by govern-
ments or the press to give their opinion on the results (such as UN agencies). All people 
involved in these steps should agree not to divulge the results to anyone else. These 
steps should occur, before the results are made public internationally. For example, it 
is bad practice for the results of a trial to be reported at an international conference or 
through a press release before the national and local government officials, trial par-
ticipants, and representatives of the funding agency have been made aware of them. 
Also, some medical and scientific journals do not allow the results of a trial they are 
to publish to be presented at public conferences or released to the media before the 
journal article is published, so, where appropriate, it is worth trying to synchronize the 
publication of the trial results in a journal with the first international presentation of 
the results. Where this is not feasible (for example, the first suitable conference is not 
going to happen for several months after the results are ready, or the journal’s review 
process will be too lengthy), it is important to discuss this with the journal in advance.
3.2 Report to the sponsor
Whatever the outcome of a trial, a number of different communications must be pre-
pared. For all trials, it is recommended that a comprehensive report be prepared, detail-
ing all the trial procedures and the full results. The preparation of this report should be 
a work in progress throughout the trial, with the final complete report serving as a per-
manent record for the study team and a reference for anyone who wants to know exactly 
what was done in the trial. It will also be invaluable for the conduct of any re-survey of 
the trial population and may provide legal documentation with respect to registration 
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of a new product or if questions about the study arise, for any reason, in the future. If the 
results of a trial are to be used as part of the registration procedures for a new product, 
it is important to liaise with the regulatory authorities at an early stage in the planning 
of the trial, so that the appropriate records are kept and the proper recording proced-
ures are used (see Chapter 20). Specific guidance has been prepared by the ICH on what 
should be included in a clinical study report that is going to be used to support regis-
tration of a new drug or vaccine (International Conference on Harmonisation, 1995).
3.3 Trial participants and the study communities
It is the responsibility of the investigators to report back the results to those whose par-
ticipation made the trial possible, i.e. those in the study communities. As emphasized 
in Chapters 6, 7, and 9, the investigating team should be in regular communication 
with the participants and their communities throughout the trial, but there is a special 
responsibility to make the community aware of the findings at the end of the trial. 
This might be done through public meetings with community members, to answer any 
questions they may have regarding the study, and through meetings with community 
leaders and local officials. It might also be appropriate to prepare a short report on the 
findings, written in such a way as to be readily comprehensible to a lay audience and 
which can be distributed to community members.
3.4 Local and government officials
For most trials, it will have been necessary to have sought the permission for the conduct 
of the trial from the local administration, and often from the Ministry of Health (MOH). 
It is important that the results of a trial are carefully discussed with such officials, before 
they are made publicly available. When trial results are publicly released, it may be useful 
to have national meetings opened by the MOH or the Director of Medical Services, or 
their representatives, and to have regional, district, or local meetings opened by equiva-
lent local officials. Sometimes, it is appropriate to also disseminate the findings of a trial 
through local, national, and international mass media (print, radio, TV, and/or webcast 
(a live broadcast via the Internet) or podcast (a digital audio or video file that can be 
downloaded from a website to a media player or computer)), or in the form of a film.
The findings should also be reported formally to the local and national research and 
health policy decision makers. As well as reporting the results in full, the implications 
that the findings have for the health system should be reviewed with all appropriate 
health authorities, both governmental and non-governmental. It is important that a 
clearly written summary of the main results and their implications is included, usually 
at the front of the report, as many of those for whom the results are relevant will not 
have the time or inclination to study all the fine details.
3.5 Reporting in the scientific literature
It is expected that the results of all intervention trials will be published in peer-reviewed 
journals. Investigators will generally wish their findings to reach a wide audience and 
may target international journals as an outlet for the results of a trial. If the findings in 
a trial are mainly of local interest, a national journal may be more appropriate. Journal 
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
410 CHAPTER 23: REPORTING AND USING TRIAL RESULTS
papers will generally be much shorter than the comprehensive study report discussed 
in Section 3.2. A general guide on how to write a paper reporting the results of a trial is 
given in Appendix 23.1. Specific guidance on the form a paper should take is detailed by 
the particular journal selected. The choice of the journal to which to submit a manuscript 
will be influenced by a number of factors, including the target audience for the scientific 
results, their local or international significance, how quickly the paper will be published 
(journals vary substantially in the time they take to have a paper peer-reviewed and pro-
cessed for publication), how exciting the results are (it is unfortunately true that jour-
nals are biased towards publishing papers that have new or unexpected findings), and 
whether the journal has a history of publishing intervention trials of the kind conducted. 
It is a good idea to select the journal before starting to draft the article, as each journal 
has different requirements regarding, for example, the permissible length of articles and 
the referencing style for papers cited in the text. It is also strongly recommended that the 
most recent CONSORT guidelines are read for the particular trial design that has been 
used (<http://www.consort-statement.org>). These provide guidance on what informa-
tion should be included in any report of results of a trial, and they have been adopted by 
many journals. For example, it is now widely considered to be essential that a flow dia-
gram is prepared that starts with the number of all individuals (and, where appropriate, 
clusters of individuals) who were invited to participate in the trial and ends with all those 
who provided data on the primary trial outcome(s), showing when and why any parti-
cipants or potential participants ‘dropped out’. An example of a CONSORT diagram is 
shown in Figure 23.1. A checklist of items that the CONSORT guidelines specify should 
be included in the report of a randomized trial is given in Appendix 23.2.
Since different journals have different target audiences, it may be important to pub-
lish different aspects of the study in different journals, in order to ensure dissemination 
of specific findings to the most relevant groups. As mentioned in Chapter 7, to report 
trials in most journals, it is now essential that the trial has been registered on an inter-
nationally recognized trial registration site, so this must be done before the first partici-
pant is enrolled into the trial.
Traditionally, publication of an article in a scientific journal was free to the author, 
but the reader (or their library) needed to pay for the journal issue or individual article. 
However, in the era of electronic publishing, there is a rapidly increasing number of 
‘open access’ journals, in which the author pays for publication, but the article is then 
free to the reader. Also, it is increasingly possible for authors to pay so that an electronic 
version of their article is freely available to readers of traditional ‘closed access’ journals. 
Some funding agencies now insist on all research that they have paid for being open 
access. Such costs should be included in the trial budget, though some journals give 
discounts or waive the publication fees for articles submitted by research teams from 
LMICs. One major advantage of publishing in an open access journal is that readers 
who do not have access to well-resourced libraries, many of whom are in LMICs, but do 
have access to the Internet, can access the articles without payment.
3.6 Media coverage
A common practice is to prepare and disseminate a press release to selected media 
outlets a day or two in advance of the formal release of the trial results. This is to allow 
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journalists to prepare their stories in advance. All such press releases should clearly 
state that the information they contain is ‘embargoed’ until a particular time and date. 
This means that the journalist is not permitted to publish the results until after that 
deadline.
3.7 The funding agency
The funding agency will also require a final report on the outcome of the study, as 
well as a financial report. Sometimes, it is sufficient to send drafts of papers that are to 
be published, but often the agencies will require a special report in a specific format. 
Assessed for eligibility: 17080 (20 communities)
Excluded:
Did not meet inclusion criteria:
Did not attend school on survey days:
Date of birth >1985:
Unknown date of birth:
Did not enter standard 5
Actively refused to participate:
7435
7420
15 (<1%)
2764 (16%)
4574 (27%)
18 (<1%)
64 (<1%)
(0 communities)
(20 communities)Recruited and randomized:
Recruited and randomized in late 1998:
Recruited and randomized at interim follow-up in 2000:
9645
9219
426
Allocated to interventiona: Allocated to comparisona:
4870 (10 communities, mean 487, range 424–572) 4775 (10 communities, mean 478, range 437–515)
Lost to follow-up at nal (2001/2) survey: Lost to follow-up at nal (2001/2) survey:
1346 (28%)    (0 communities) 1259 (26%)   (0 communities)
Temporarily absent:
Permanently moved:
Refused:
Died:
Temporarily absent:
Permanently moved:
Refused:
Died:
697 (14%)
167 (3%)
94 (2%)
16 (<1%)
650 (14%)
178 (4%)
49 (1%)
21 (<1%)
Analysed:
 3524 (72%)  (10 communities, mean 352, range 302–438)
Analysed:
 3516 (74%) (10 communities, mean 352, range 317–397) 
Excluded from analysis: Excluded from analysis:
0 (0%)       (0 communities) 0 (0%)       (0 communities)
Key:
aAlthough the interventions were available to all cohort members, there was no way of recording each individual’s receipt of
each of the components of the intervention
Figure 23.1 CONSORT diagram for a cluster randomized trial of an adolescent sexual and 
reproductive health intervention in Tanzania.
Reproduced from Ross, D. A., et al., Biological and behavioural impact of an adolescent sexual 
health intervention in Tanzania: a community-randomized trial, AIDS, Volume 21, Issue 7, pp. 
1943–55, Copyright © 2007, with permission from Lippincott Williams & Wilkins, Inc. This image 
is not covered by the Creative Commons licence terms of this publication. for permission to reuse 
please contact the rights holder.
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Successful investigators need funding for their research, and many field trials cost very 
large amounts, so it is sensible to put considerable effort into ensuring that there is 
excellent communication and feedback provided to the funding agency—both to fa-
cilitate the current trial and future approaches for funding! Whenever possible, the 
investigators should seek an opportunity to report and discuss the findings of the trial 
with a person in the funding agency. As well as ensuring they know the outcomes that 
their funds have helped to generate, it also gives the investigators the opportunity to 
discuss how the funding agency might be able to help with implementation of the rec-
ommendations arising from the trial and to discuss further research ideas.
Most funding agencies are also keen to participate in the dissemination of research 
results and will, for example, put out a press release to coincide with the publication of 
a paper on a trial they have supported.
4 From research findings to public health action
4.1 Sharing and synthesizing findings
Major changes in public health policy are rarely based on the results of a single trial. It is 
important therefore for investigators to make themselves aware of any other trials that 
are being, or have been, conducted to answer similar questions to their own and to be 
open to the possibility of sharing their results, so they can be synthesized. If contact is 
made with those who are conducting other trials at an early stage, it may be possible to 
ensure that the data collected are comparable, which will greatly facilitate such synthe-
sis and the formal meta-analysis of the results (see Chapter 3).
4.2 Researchers and policy
Final analyses and the dissemination of results are essential tasks that must be com-
pleted at the end of a trial, but an important further responsibility of researchers is to 
review the findings with the relevant government and non-governmental authorities 
and to explore implications for the overall health policy of the country and for the 
design of specific disease control strategies and programmes. From the beginning of 
the planning of a trial directed towards an important public health problem, the ap-
propriate policy and planning (as well as implementation) arms of the MOH should be 
involved. Where the intervention involves other ministries, such as education, social 
services, agriculture, youth, women’s affairs, this applies equally to them. Even when 
the Ministry does not have direct responsibility for the actual conduct of the trial, for-
mulation of conclusions from the analysis of trial results requires their input and par-
ticipation, as they are usually responsible for changes to health programmes that may 
be necessary because of the results of the trial.
Sometimes, trials are conducted to establish a principle (for example, a particular 
way of constructing a vaccine results in some protection against the target disease), 
and they may be an intermediate step in developing an intervention that might be of 
public health value. However, most field trials are of interventions that could be po-
tentially used for specific public health actions. While the rigorous conduct of a trial 
is the primary responsibility of the researchers, the responsibility for ensuring that re-
search findings are put to their proper use in public health programmes generally lies 
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with policy makers, especially in the MOH. Unfortunately, in most countries, policy 
makers have a poor understanding, and sometimes appreciation, of health research, 
and frequently health researchers have a similarly poor understanding of the role and 
function of policy makers and of what they require from researchers to be able to do 
their job well. All too often in the past, researchers have considered that once they have 
conducted the trial and communicated the findings to the policy makers their job is 
done. As discussed in the next section of this chapter, it is not!
Furthermore, it is not sufficient for the research team to merely forward the main 
trial report or scientific article to the policy makers. Few will have the time to read 
such reports, and even fewer will have the inclination to do so. It is essential that the 
research team provides policy makers and programme managers with the results and 
their interpretation in a language and format that they will both understand and find 
easy to act upon. An example of how the abstract of a scientific article describing trial 
results was converted into a suitable summary for policy makers is given in Box 23.1.
Document A is the abstract from a paper that presented the main results from two 
parallel trials that compared vitamin A supplementation of young children vs placebo 
in northern Ghana. Document B is an excerpt from the Policy Brief prepared for dis-
semination of the results of the trials within Ghana and internationally.
A. The abstract from the scientific publication
Although most studies on the effect of vitamin A supplementation have reported 
reductions in child mortality, the effects on child morbidity are less clear. We have 
carried out two double-blind, randomized, placebo-controlled trials of vitamin A 
supplementation in adjacent populations in northern Ghana to assess the impact on 
childhood morbidity and mortality.
The Survival Study included 21 906 children aged 6–90 months in 185 geograph-
ical clusters, who were followed for up to 26 months. The Health Study included 
1 455 children aged 6–59 months, who were monitored weekly for a year. Children 
were randomly assigned either 200 000 IU retinol equivalent (100 000 IU under 12 
months) or placebo every 4 months; randomisation was by individual in the Health 
Study and by cluster in the Survival Study.
There were no significant differences in the Health Study between the vitamin 
A and placebo groups in the prevalence of diarrhoea or acute respiratory infec-
tions; of the symptoms and conditions specifically asked about, only vomiting and 
anorexia were significantly less frequent in the supplemented children. Vitamin 
A supplemented children had significantly fewer attendances at clinics (rate ratio 
0.88 (95% CI 0.81–0.95), p = 0.001), hospital admissions (0.62 (0.42–0.93), p = 
0.02), and deaths (0.81 (0.68–0.98), p = 0.03) than children who received placebo. 
Box 23.1 Example of how results in a technical journal 
article were rewritten for policy makers
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Box 23.1 Example of how results in a technical journal article were rewritten for 
policy makers (continued)
The extent of the effect on morbidity and mortality did not vary significantly with 
age or sex. However, the mortality rate due to acute gastroenteritis was lower in vita-
min A supplemented than in placebo clusters (0.66 (0.47–0.92), p = 0.02); mortality 
rates for all other causes except acute lower respiratory infections and malaria were 
also lower in vitamin A clusters, but not significantly so.
Improving the vitamin A intake of young children in populations where xero-
phthalmia exists, even at relatively low prevalence, should be a high priority for 
health and agricultural services in Africa and elsewhere.
B. The policy brief (excerpt)
Two randomised controlled trials were carried out in northern Ghana to evaluate 
the effect of 4-monthly vitamin supplements on child mortality and morbidity. They 
were conducted in neighbouring populations, where xerophthalmia, the eye disease 
caused by severe vitamin A deficiency, occurred but was not very common.
The mortality trial showed that vitamin A supplementation reduced child mor-
tality by 19%, and this result was very unlikely to have occurred by chance. This 
result confirms the results of earlier trials in Asia, but is the first in Africa to show 
such an effect.
The morbidity trial results were intriguing in that they showed that vitamin A 
supplementation reduced indicators of severe illness—hospital admissions and 
clinic attendances—but did not reduce the overall frequency of illnesses. In other 
words, it appears that vitamin A supplementation may not reduce the number of ill-
nesses that children will suffer from, but will reduce the number of those infections 
that go on to cause severe and life-threatening illness or death.
Taken together, these two trials’ results may help to explain puzzling findings re-
ported by previous morbidity trials which did not find any impact of vitamin A 
supplementation on the frequency of child morbidity, but only measured the overall 
frequency of illnesses rather than their severity.
The two trials show that improving the vitamin A status of young children should 
be given high priority by health and agricultural services in Africa and elsewhere in 
populations where xerophthalmia occurs, even when it is not very common.
Adapted  from the Lancet, Volume 342, Issue 8862, Ghana VAST Study Team, Vitamin A supple-
mentation in northern Ghana: effects on clinic attendances, hospital admissions, and child mortality, 
pp.7–12, Copyright © 1993, with permission from Elsevier, http://www.sciencedirect.com/science/
journal/01406736; and from Ghana VAST Study Team, Results and policy implications of the Ghana 
Vitamin A Supplementation Trials, Copyright © 1993. This box is not covered by the Creative Com-
mons licence terms of this publication. For permission to reuse please contact the rights holders.
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A variety of useful mechanisms that would assist in communication between de-
cision makers and researchers are implemented in some countries. Health planning 
units may have responsibility for regularly reviewing, and even funding, health sys-
tems research. Other mechanisms include ad hoc, or regular, seminars at the Ministry 
level. A more comprehensive approach can be achieved through national health policy 
or epidemiology boards. These boards are composed of scientists, government policy 
makers, leaders in non-governmental organizations, and often lay people, and they 
have responsibility for reviewing and funding important public health research activi-
ties. Whether this mechanism or some other is used, it is of critical importance to have 
a way of effectively and speedily translating research results into public health action.
Many health systems in developing countries have partially devolved responsibility 
for health care to sub-national levels such as the district level. Thus, health intervention 
research should be mentioned in the district health plan, even if the research itself is 
not undertaken by the district health team but by a specialized research group. This will 
ensure regular review of the progress and implications of the research. Decentralization 
offers an excellent opportunity to link research with local public health practice.
4.3 Introducing an intervention into public health programmes
The main results from a trial will state what the effects of the intervention were on the 
primary and secondary trial outcomes. However, for a policy maker to be able to decide 
whether a successful intervention should be introduced, they need additional informa-
tion. This includes knowing what the intervention will cost, how the intervention can 
best be integrated into existing health and social systems and what the likely positive 
or negative secondary effects of introducing such interventions will be on other inter-
ventions or outcomes, and whether the intervention is likely to be equally effective 
in all contexts or will only be effective in some, such as among specific age, sex, and 
socio-economic groups, or in certain geographical areas. While collecting such infor-
mation may well require additional research, sometimes through Phase IV studies (see 
Chapter 22), trial investigators should carefully think through whether it would be 
possible to collect some useful information on these areas during the original trial. For 
example, it is usually possible to collect data on the costs of the trial intervention (see 
Chapter 19), to document any implications for other health and social interventions, 
and to conduct appropriate analyses to provide some indications as to whether the ef-
fects of the intervention differed by subgroup. Further useful information on the likely 
reproducibility of the findings of the trial in other populations can also come from the 
synthesis of findings from different trials (see Chapter 3).
The costs of introducing a new intervention must also be analysed, and some of the 
key issues involved in collecting information of intervention costs have been covered 
in Chapter 19. Ideally, these costs should be assessed in relation to other uses of the re-
sources, and the benefits (years of healthy life gained or loss of DALYs averted) per unit 
expenditure required for adding the intervention to the health system would be com-
pared with benefits that could be gained by the same expenditure on another health 
programme. Issues related to such cost-effectiveness analyses have been discussed in 
Chapter 19. Even if cost-effectiveness analyses are not carried out, it is essential that 
the trial investigators are able to report what it costs to deliver the intervention within 
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the trial. Such costs should exclude the costs of the evaluation of that intervention (see 
Chapter 19).
Before a newly proven intervention can be put into operation, the Ministry must 
consider how the new intervention should best be integrated with other existing in-
terventions. For example, malaria vaccines, when developed, will have to be integrated 
into the existing vaccination programme for other diseases and will have to be added to 
whatever the existing malaria control strategy is, which may include vector control (for 
example, through insecticide spraying), vector–human biting reduction (for example, 
through the provision of insecticide-treated nets), and case detection and treatment 
measures. An overall integrated strategy for control will have to be developed, and this 
might require trials of various combinations of interventions to determine the optimal 
mix. Such studies are discussed in Chapter 22.
Another important issue that the Ministry must consider is that the efficacy of an 
intervention measured in the circumstances of a trial can rarely be attained when the 
intervention is implemented under routine circumstances. System-level or community 
effectiveness (coverage and efficacy as actually achieved by the routine health service), 
rather than trial eficacy, is the measure of relevance for the Ministry (Tanner et al., 
1993). Demonstration of high levels of efficacy under field trial conditions is important 
but, by itself, is not necessarily sufficient to justify the widespread introduction of the 
intervention, without further studies directly relevant to its implementation. Practical 
examples of this approach are given in Chapter 22.
The importance of understanding the setting and circumstances in which the inter-
vention will be used in a public health programme must be understood both by policy 
makers and researchers. When the public health importance of an intervention is being 
assessed, managerial constraints must be considered that may make it impossible to 
achieve useful levels of efficacy. The principles and methods of continuous quality im-
provement management, with its emphasis on making sure that the right things get 
done, in the right way, and at the right time, are proving to be a useful approach to the 
management of health systems in developing countries. Such approaches may help en-
sure that the efficacy, as demonstrated under trial conditions, can be approached under 
routine conditions. An example of the use of these methods applied to improving the 
primary health care system in rural Nigeria is given in Zeitz et al. (1993).
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Appendix 23.1 Guidance on how to write a scientific paper 
reporting the results of a trial
Planning the publication strategy
It is important that the results of an intervention trial are published as soon as possible 
after the trial data have been analysed and the results are available. Generally, the spon-
sor will require a comprehensive report covering all aspects of the trial. Once such a 
report has been prepared, papers for publication in scientific journals can be prepared, 
based on the full report. It is good practice to try to include all of the important find-
ings from the trial in one main paper and to avoid so-called ‘confetti’ publishing where 
the results are distributed among multiple different papers. While the trial is ongo-
ing, it may be worth publishing a paper on the design and methods used in the trial 
(some journals specialize in publishing summaries of trial protocols, for example, Tri-
als <http://www.trialsjournal.com>), as then reference can be made to this paper when 
the main results are published, without having to repeat details of the methodology.
The choice of which journal to submit a paper to will depend on the topic under 
study, and unfortunately on the results. Some journals are more likely to publish papers 
with ‘positive’ findings than those showing no effect of an intervention. Most authors 
will seek to publish their results in a journal with high ‘impact’ (i.e. likely to be read by 
many people), but it is important to think about who the target audience for the paper is 
and which journals that audience is most likely to read. It is a good idea to scan past is-
sues of the journal to see the sorts of paper they publish to judge whether there is likely 
to be interest in publication of the results of a specific trial.
Once the decision has been made of which journal to submit a paper to, it is import-
ant to read the instructions to authors, as these vary from journal to journal. Links to 
websites, which provide instructions to authors for over 6000 journals in the health and 
life sciences, are given at <http://mulford.utoledo.edu/instr/>.
Drafting a paper
Shown in Box A23.1 is the general structure that most scientific papers have if they are 
presenting original study results. Approaches to writing papers vary from author to 
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author, but one that we have found useful is outlined here. Also shown in the box is the 
order in which we suggest different sections of the paper might be drafted.
What parts of a paper are read and by whom?
The vast majority of readers of a journal will scan the title of a paper, and they may look 
at the list of authors. It is important therefore to highlight, in so far as is possible, the 
subject of the research and the ‘headline’ finding in the title, in order to provoke interest 
in reading further. A much smaller proportion of readers will read the abstract/sum-
mary than the title, but it is important to try to get all of the messages you want to con-
vey into the summary, as a very small proportion of readers will go beyond that point 
and read the main body of a paper. A small number of readers will scan the tables and 
figures, so these should be made as comprehensible as possible, without having to read 
the paper. Unfortunately, in most instances, a miniscule proportion of those who access 
the journal will read the whole paper, but these may be the people who really matter!
A good place to start the writing of a paper is to decide on the title! It is suggested 
that this is revisited, once the drafting of the paper is finished, to consider whether any 
revision is appropriate. Thus, it is listed as both 1 and 13 in Box A23.1.
Authorship
An issue which is frequently contentious is who should be included as an author in 
a paper and in which order the authors should appear. Journals give guidelines as to 
what contributions are sufficient to merit authorship. Also many journals require that 
Box A23.1 Structure of paper and suggested order  
in which to write the sections
1, 13 Title
2 Authors
10 Abstract/summary
9 Introduction/background
8 Materials and methods
6 Results
7 Discussion
12 Acknowledgements
11 References
3 Tables
5 Legends to figures
4 figures
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an account is given of the contribution that each author made to the research reported. 
There is no simple answer as to who should, and who should not, be included as an 
author, but it is good practice to plan the publications that are likely to come out of a 
specific trial well in advance of the final analysis of the results and to agree who will be 
included as an author in different publications. It should also be decided who will be 
the ‘lead’ authors with the primary responsibility of producing the first draft of specific 
papers. However, all authors share responsibility for the contents of the paper. It is im-
portant to remember this, even if you are only one of many authors in the middle of the 
publication list. Errors in a publication are usually permanent, and, even if corrections 
are made in a subsequent communication, these are often missed by readers.
Tables
The most critical component in constructing a paper is deciding on, and designing, the 
tables (or figures) that are needed to describe the study and to summarize the results. 
Once the tables and figures have been constructed, writing the paper around them 
should be relatively straightforward. There are four aspects of a trial to which the tables 
will generally relate:
 1 description of the characteristics of the study population
 2 main results
 3 secondary findings
 4 your findings in the context of other studies (though a table on these is not always 
needed).
Ensure that the title of each table is adequate to inform the reader of its content. Try 
to work out a complete description of the trial results through tables (and figures), 
even if later the content of smaller tables might be incorporated into the text. Avoid 
duplication of data in tables and figures. Plan the tables and figures, such that the paper 
can be largely ‘read’, based on these alone. Keep tables as simple as possible, and avoid 
unnecessary data, especially data that are not referred to in the text. Two simple tables 
are better than one complicated table. Label the rows and columns of each table very 
clearly, and, to the extent possible, avoid abbreviations. Avoid too many significant 
figures after the decimal point in numbers. For example, an OR of 4.7 is probably suf-
ficient, rather than 4.735. In general, relate the number of decimal places included to 
the width of the CIs. For example, OR = 1.2 (95% CI: 0.1, 9.7) is more appropriate than 
OR = 1.23 (95% CI: 0.13, 9.68), whereas OR = 1.48 (95% CI: 1.41, 1.55) is more appro-
priate than OR = 1.5 (95% CI: 1.4, 1.6). When the tables (and figures) have been drafted, 
it is a good idea to give them to a colleague who is unfamiliar with the trial for them to 
tell you how they interpret them.
figures
Figures may be a very powerful way of illustrating findings in a trial. They should be 
kept as simple as possible, but, if they are too simple, question whether they are really 
necessary. Consider whether a specific point is better made with a figure or table, and 
use one or the other, but not both. Label all axes of a graph very clearly, and give the 
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units of measurement either in the figure or in the legend to the figure. For maps and 
similar diagrams, give a key to all of the symbols used, and show the scale diagrammat-
ically (not 1 cm = 1 km, as the journal may shrink the figure). Have an arrow pointing 
north on all maps. Avoid using multiple colours, unless really necessary, as many jour-
nals are either only printed in black and white or charge extra for colour figures; and, 
anyway, many readers will print or photocopy a colour figure in black and white.
Results
The section of a paper describing the results of the trial should follow directly from 
the tables. Summarize what is shown in the tables, with appropriate reference to them. 
Start with the simplest analysis, for example, simple description of differences, without 
adjustment for confounding factors, etc. Then develop and describe more sophisticated 
analyses, as appropriate. Comment on all data shown in each table. If data are not com-
mented upon, question the need to include them in tables. When estimates of effect 
are given (for example, vaccine efficacy), also include the CIs (usually 95%) and the 
‘p-value’, but only if this contributes information beyond the CI.
Discussion
In the initial part of the discussion, focus on the key result(s) of the trial being pre-
sented, and summarize the overall findings. Discuss the strengths and limitations of 
the trial, for example, possible biases that could have influenced the results, and dis-
cuss the additional analyses that have been performed to control for potential biases, 
as appropriate. Then, put the findings of the trial in the context of other such studies, 
summarizing those studies as necessary, possibly in tabular or figure form. Then, draw 
overall conclusions derivable from the present study and other similar studies. Finally, 
make any recommendations for public health action or further research.
Materials and methods
Much of the materials and methods section may have been included in a previous 
paper, and it may be sufficient merely to summarize them and make reference back to 
that paper. However, this section of the paper must provide sufficient information for 
the reader to understand what was done, without having to go back to any previously 
published paper. The kinds of information that a reader will hope to glean from this 
section (or the earlier paper) are summarized in Box A23.2.
Introduction/background
The introductory section of the paper should be kept as brief as possible, giving the 
minimum necessary background information to explain any current controversies and 
why the trial was conducted. Make reference to any recent review papers, as appropri-
ate. Specify the hypotheses that the study was designed to evaluate in quantitative terms.
Summary/abstract
Most journals will give specific instructions of how the summary should be formatted 
and the maximum number of words allowed. The reasons for doing the trial and why 
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it is important should be summarized in one or two sentences. There should then be 
a concise summary of results, using the maximum number of words allowed by the 
journal. Include as many of the key findings as possible, including summary estimates 
of the effect, with CIs and p-values. Finally, in a sentence or two, summarize the impli-
cations of the results and their public health relevance.
Acknowledgements
Funding agencies for a trial will often require their contribution to be referred to in 
a specific way (for example, including the grant reference). There should also be ac-
knowledgement of the contributions of all those who facilitated the conduct of the trial 
who are not included as authors. These will usually include local health authorities, 
study participants, fieldworkers, laboratory workers, other study staff, including key 
administrative staff, local medical staff, and any advisors or consultants. If in doubt 
as to whether someone should be acknowledged or not, it is generally diplomatic to 
include them!
References
Authors should avoid trying to impress with how widely read they are and should only 
include references to papers which are key to the content of the current paper. Use 
recent review articles, and select from  more accessible journals (for example, open ac-
cess), wherever possible. Make sure that all of the references are complete (for example, 
Descriptions of:
◆	 study area (relevant features)
◆	 study design adopted (for example, cluster randomized trial)
◆	 study population
◆	 sample size determination
◆	 methods of selection/exclusion of participants
◆	 randomization methods and blinding
◆	 informed consent procedures
◆	 measurement methods
◆	 laboratory assays
◆	 follow-up methods
◆	 computing and statistical packages used
◆	 statistical methods employed
◆	 ethical approval (and data and safety monitoring arrangements).
Box A23.2 Information that should be included in the 
Materials and Methods section of a paper
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check using PubMed at <http://www.ncbi.nlm.nih.gov/pubmed>), and it is bad prac-
tice to include references to articles you have not read! Pay strict attention to the in-
structions that the journal gives for the formatting of references. For this purpose, it is 
useful to have invested in a good reference manager system (for example, Reference 
Manager, Endnote, or Mendeley (<http://www.mendeley.com>)—which is free).
Appendix 23.2 Checklist of information to include when 
reporting a randomized trial
The Consolidated Standards of Reporting Trials (CONSORT) Group have produced 
several very useful documents (see <http://www.consort-statement.org/>) about how 
to report trials. These include a very useful checklist (Schulz et al., 2010) which is 
reproduced with permission in Table A23.1 (abstracted from <http://www.consort-
statement.org>).
Table A23.1 Consort 2010—checklist of information to include when reporting a 
randomized trial
Section/topic Item no. Checklist item
Title and abstract
1a Identification as a randomized trial in the title
1b Structured summary of trial design, methods, results, 
and conclusions (for specific guidance, see CONSORT for 
abstracts)
Introduction
Background and 
objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial), in-
cluding allocation ratio
3b Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details 
to allow replication, including how and when they were 
actually administered
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed
6b Any changes to trial outcomes after the trial commenced, 
with reasons
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Section/topic Item no. Checklist item
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and 
stopping guidelines
Randomization
Sequence generation 8a Method used to generate the random allocation 
sequence
8b Type of randomization; details of any restriction (such as 
blocking and block size)
Allocation  concealment 
mechanism
9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions
Blinding 11a If done, who was blinded after assignment to interven-
tions (for example, participants, care providers, those 
assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary 
and secondary outcomes
12b Methods for additional analyses such as subgroup 
 analyses and adjusted analyses
Results
Participant flow  
(a diagram is strongly 
recommended)
13a for each group, the numbers of participants who were 
randomly assigned, received intended treatment, and 
were analysed for the primary outcome
13b for each group, losses and exclusions after randomiza-
tion, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical char-
acteristics for each group
Numbers analysed 16 for each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups
Outcomes and  
estimation
17a for each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision 
(such as 95% CI)
Table A23.1 (continued) Consort 2010—checklist of information to include when 
reporting a randomized trial
continued
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Section/topic Item no. Checklist item
17b for binary outcomes, presentation of both absolute and 
relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including 
 subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group 
(for specific guidance, see CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, 
 imprecision, and, if relevant, multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial 
findings
Interpretation 22 Interpretation consistent with results, balancing  
benefits, and harms, and considering other relevant 
evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed,  
if available
funding 25 Sources of funding and other support (such as supply of 
drugs), role of funders
Adapted from Schulz, K. f. et al., CONSORT 2010 statement: updated guidelines for reporting parallel group 
randomised trials, PLoS Medicine, Volume 7, Issue 3, Copyright © Shulz et al. 2010. Reproduced under the 
Creative Commons Attribution (CC BY) licence. This table is adapted from an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Table A23.1 (continued) Consort 2010—checklist of information to include when 
reporting a randomized trial
Appendix 23.3 A communication action plan for a trial 
(Annabelle South, Aoife Doyle, David Ross, personal 
communication)
These extracts are from the aims and objectives and then two key tables (Tables A23.2 
and A23.3) and a box (Box A23.3) within the initial communication action plan for the 
MEMA kwa Vijana (MkV) Trial’s Long-term Evaluation (Doyle et al., 2010). This was 
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Table A23.2 Example of extracts from a communication action plan for a trial: target 
audiences
Level Audience Importance Influence Objectives 
addressed
1. Inter-
national
1.1 All-party UK 
parliamentary 
group on SRH 
and HIV
Moderate.
Potential 
facilitator
Well placed to help to 
 increase awareness of 
MkV and stimulate debate 
about ASRH policy and 
programming
(1) (2)
1.2 USAID Moderate.
Potential 
facilitator
(1) (2)
1.3 CIDA Moderate.
Potential 
facilitator
(1) (2)
1.4 DfID, UK High.
Potential  
facilitator
DfID African Policy De-
partment and Irish Aid are 
 co-funding the trial and  
are well placed to help to in-
crease awareness of MkV  
and stimulate debate 
about ASRH policy and 
programming
(1) (2)
1.5 Irish Aid High.
Potential 
facilitator
(1) (2)
1.6 Scientific 
community
High.
Potential  
facilitators and 
blockers
Can help to disseminate our 
results and materials at scien-
tific conferences and in pub-
lications. Could try to block 
our findings if do not accept 
them
(2)
2. African 
regional
2.1 Afri-
can Union 
Commission
Moderate.
Potential facilita-
tor or blocker
Could disseminate findings 
and materials to high-level 
policy makers in Africa
(1) (2)
2.2 Southern 
African De-
velopment 
Community
Moderate.
Potential  
facilitator or 
blocker
Their recent expert Think  
Tank meeting recommended 
further studies to strengthen 
the evidence base in this  
area as an urgent priority
(1) (2)
2.3 New 
Partnership 
for Africa’s 
Development
Low.
Potential 
facilitator
Not clear yet how influential 
this group will be. Keep  
under review
(1) (2)
2.4 Pan-African 
Parliament’s 
Committee on 
Health, Labour, 
and Social 
Affairs
Low.
Potential  
facilitator or 
blocker
Not clear yet how influential 
this group will be. Keep  
under review
(1) (2)
2.5 Health Min-
isters’ and Edu-
cation Ministers’ 
forum
High.
Potential  
facilitator or 
blocker
Well placed to help to in-
crease awareness of MkV  
and stimulate debate 
about ASRH policy and 
programming
(1) (2)
continued
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Table A23.2 (continued) Example of extracts from a communication action plan for a 
trial: target audiences
Level Audience Importance Influence Objectives 
addressed
3. National 3.1 Ministry of 
Labour, Employ-
ment, and  
Youth Develop-
ment, Depart-
ment of Youth 
Development 
(DYD)
Medium.
Implementer. 
Potential  
facilitator or 
blocker
DYD oversees National  
Youth Policy and deals with 
out-of-school youth.
Potential implementer of 
Youth Condom Promoter  
and Distributor Component 
of MkV Intervention
(1) (2)
3.2 Ministry of 
Education and 
Vocational  
Training 
(MOEVT), AIDS 
Coordinating 
Unit (ACU)
High.
Potential  
facilitator or 
blocker
ACU coordinates all HIV 
and AIDS activities within 
MOEVT and handles NGO 
involvement
(1) (2)
3.3 MOEVT, 
Department of 
Primary Educa-
tion (DPE)
Very high.
Implementer of 
in-school com-
ponent of MkV 
intervention.
Potential facilita-
tor or blocker
DPE oversees activities in  
primary school
(1) (2)
3.4 Ministry of 
Health and  
Social Welfare, 
Reproductive 
and Child Health 
Services Section 
(RCHS) and Ado-
lescent Repro-
ductive Health 
Working Group 
(ARHWG)
Very high.
Implementer of 
youth-friendly 
health ser-
vices compo-
nent of MkV 
intervention.
Potential  
facilitator or 
blocker
The RCHS has taken the  
lead in developing and pro-
moting multi-sectoral  
ASRH materials.
ARHWG has direct policy 
influencing capacity
(1) (2)
3.5 Tanzania 
Commission  
on AIDS 
(TACAIDS)
High.
Potential  
facilitator or 
blocker
Is within the Prime Minister’s 
office and has the mandate 
for the coordination of all 
activities concerning the na-
tional response to HIV/AIDS
(1) (2)
3.6 family  
Health Inter-
national (fHI), 
Usadi, Juhudi, 
Ari, Nguzo za 
Afya (UJANA) 
Project and Co-
ordinating Com-
mittee of Youth 
Programming 
(CCYP)
High.
Potential  
facilitators or 
blockers
UJANA is likely to be the  
largest youth HIV  
programme in Tanzania  
for the next 4 years. CCYP is  
supported by fHI and is a  
useful forum for national 
coalition building
(1) (2) (3)
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Level Audience Importance Influence Objectives 
addressed
4. Regional 4.1 Regional 
Commissioner’s 
Office
High.
Potential facilita-
tor or blocker
Overall responsibility for all 
activities within the Mwanza 
region. The Regional Admin-
istrative Secretary has been 
fully informed and involved 
in MkV from the outset and 
appears supportive but may 
be transferred
(1) (2)
4.2 Regional 
Education  
Office and 
forums
High.
Potential facilita-
tor or blocker
The Regional Education Of-
fice provides the policy link 
between MOEVT national 
and district levels. The forums 
provide an important venue 
for influencing regional, and 
hence district, policy, and for 
information being conveyed 
to national level
(1) (2)
4.3 Regional 
Health Man-
agement Team 
(RHMT)
High.
Potential facilita-
tor or blocker
RHMT is the policy link be-
tween Ministry of Health and 
Social Welfare (MOHSW) head-
quarters, the regional adminis-
tration, and the districts
(1) (2)
4.4 Mwanza 
Policy Initiative 
(MPI)
Low.
Potential facilita-
tor or blocker
The initiative builds capacity to 
strengthen civil society engage-
ment in policy processes. Poten-
tial venue for publicizing MkV 
and its findings
(1) (2) (3)
5. District, 
ward, and 
village
5.1 full Council High.
Enabler
Main decision-making body 
in the district. ASRH is already 
within district plans
(1) (2)
5.2 Council’s 
Multi-sectoral 
AIDS Committee
High.
Potential facilita-
tor or blocker
Brings together all sectors to 
address HIV and AIDS
(1) (2) (3)
5.3 Young 
people
High.
Enablers and 
primary target 
group
Aim should be to actively 
engage young people in all 
aspects of the intervention
(1) (2)
5.4 farming 
associations
Low.
Potential facilita-
tors or blockers
MkV unlikely to be seen as 
important to their mandate
(1) (2) (3)
5.5 Religious 
leaders
Moderate.
Potential facilita-
tors or (espe-
cially) blockers
Could order young people 
not to participate in MkV ac-
tivities but could also support 
our messages and contribute 
choirs, etc. to events
(1) (2) (3)
Source: data courtesy of Annabelle South, Aoife Doyle, and David Ross (personal communication).
Table A23.2 (continued) Example of extracts from a communication action plan for a 
trial: target audiences
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Table A23.3 Example of extracts from a communication action plan for a trial: list of 
activities
Activities Target Time Lead person Expected 
results
Indicator
1. MkV 
 Advisory 
Committee
Gatekeepers 
in key  
government 
ministries  
from national 
and regional 
levels; trial 
funders; re-
searchers;  
Key NGOs 
working in 
ASRH
Annual meet-
ings: Jun 2007, 
2008, 2009
PI forum to 
update key 
stakeholders 
on MkV-related 
research and 
to receive 
feedback
Attendance  
lists and min-
utes from  
advisory  
committee 
meetings
2. Set up 
 mailing,  
e-mail, and 
phone  
lists
National  
policy makers
Regional/dis-
trict officials
NGOs/CSOs
Media
Scientific 
community
May 2007  
and then  
kept up  
to date
Communica-
tions officer
Mechanism  
for 
communicating 
with key 
stakeholders
Complete up-
to-date lists
3. Develop  
and dissem-
inate MkV 
introductory 
information 
packs
National  
policy makers
Regional/dis-
trict officials
NGOs/CSOs
Media
Scientific 
community
Young people
Development
April  
2007–July 
2007.
(a) Must be 
ready for 
national 
stakeholders’ 
meeting
Communica-
tions officer
MkV advocacy 
materials in a 
consistent, in-
novative,  
and profes-
sional format 
(MkV brand) 
that are  
suitable for 
different 
stakeholders.
Greater local 
and national 
interest in  
MkV interven-
tions and trial 
results when 
they become 
available
(a)–(f) Availabil-
ity of informa-
tion packs
Also: (d) Num-
ber of news-
paper articles, 
radio/television 
pieces mention-
ing MkV
(e) Articles, 
reports, pres-
entations that 
mention MkV
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Activities Target Time Lead person Expected 
results
Indicator
4. Develop-
ment of MkV 
website
(online pub-
lications, 
intervention 
materials, pho-
tos of activities, 
and  provides 
links to other 
ASRH pro-
jects and 
organizations)
National  
policy makers
Regional/ 
district 
 officials
NGOs/CSOs
Media
Scientific 
community
Young people
July 2007,  
then updated 
frequently  
with new 
material
Communica-
tions officer
Greater local, 
national, and 
global interest 
in MkV inter-
ventions, and 
trial results 
when they  
become 
available
Website metrics 
(hits, time, etc.)
5. Video  
shows with 
MkV  
video
Ward and vil-
lage level  
authorities  
and community 
members
September 
2007
Communica-
tions officer
Greater local 
understanding 
and accept-
ance of MkV 
interventions
Number at-
tending, infor-
mal feedback 
from organizers 
and attendees
Source: data courtesy of Annabelle South, Aoife Doyle, and David Ross (personal communication).
Table A23.3  (continued) Example of extracts from a communication action plan for a 
trial: list of activities
Messages about the MkV interventions
◆	 MkV aims to help young people to protect themselves from STIs and un-
wanted pregnancies.
◆	 MkV is an innovative adolescent health programme, including teacher-led, 
peer-assisted sessions in school classrooms. It uses carefully designed and 
tested education materials and provides youth-friendly health services.
General information on SRH education in schools
◆	 Half of all students in primary schools in rural Mwanza Region have had sex 
by the time they are 15 years old.
◆	 ASRH education in schools has previously been shown not to increase stu-
dents’ sexual activity in many studies around the world.
◆	 ASRH interventions in schools and health units need to be supported by sus-
tained interventions in the wider community.
Box A23.3  Example messages for different audiences 
(drafted after the trial results were known)
This is an open access publication. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial
4.0 International licence. For enquiries concerning use outside the scope of the licence terms, please contact academic.permissions@oup.com.
430 CHAPTER 23: REPORTING AND USING TRIAL RESULTS
a cluster randomized trial of an adolescent sexual and reproductive health (ASRH) 
intervention in rural Tanzania. The intervention had four main components (Obasi 
et al., 2006):
 1 in-school sexual and reproductive health education through teacher-led, peer-
assisted participatory lessons that included the use of drama, stories, and games
 2 youth-friendly reproductive health services, education of health workers about the 
needs, and methods of providing sexual and reproductive health (SRH) services to 
youth
 3 community-based condom promotion and distribution, for and by youth
 4 community activities to create a supportive environment for the adolescent sexual 
health interventions.
MEMA kwa Vijana (MkV) Communication Strategy (excerpts)
Aims
 1 Inform ASRH policy and programme design in Tanzania and internationally.
 2 Increase national and international awareness and uptake of relevant MkV find-
ings, materials, and activities.
Messages for international technical agencies (WHO, 
UNAIDS, UNESCO, UNFPA, etc.)
◆	 The MkV trial in Tanzania rigorously evaluated the impact of an innova-
tive, multi-component package of interventions delivered by government 
departments.
◆	 It demonstrated that the package of MkV interventions substantially improved 
participants’ sexual health-related knowledge, reported attitudes, and some re-
ported sexual risk behaviours, but there was no evidence that it reduced HIV, 
other STIs, or pregnancies.
Message for government department of primary education
◆	 After a pilot project in 60 schools, the MkV sexual health education pro-
gramme has been successfully scaled up to over 600 schools through existing 
government systems and has been shown to improve students’ knowledge.
Source: data courtesy of Annabelle South, Aoife Doyle, and David Ross (personal communication).
Box A23.3 Example messages for different audiences (drafted after the trial results 
were known) (continued)
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Objectives
 1 Increase stakeholder awareness of, and commitment to, the importance of evidence-
based ASRH policy making.
 2 Improve awareness of availability and policy relevance, and increase uptake of 
MkV findings, materials, and activities.
 3 Strengthen ASRH programming and implementation within non-governmental 
organizations and other civil society organizations through their involvement and 
partnership in networks and capacity-building activities.
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